<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230002763</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>579</s160></s100><s200><s210>1</s210><s211>202001</s211><s212>DNA</s212><s213>Homo sapien</s213></s200><s400> 1gcccagcagg tgtcagcctc attttacccc gcccctattc aagatgaagt tgttctggtt     60ccaacgcctc tgacatatta gctgcatcat tttacatttc tttttttttt ttccttttaa    120atggggtctt gctctgtcac ccaggctgga gtgctgtggt atgatctcgg ctcactgcaa    180tctccacctc cgaggttcca gcgattctct tgcctcagcc tcccgagtag ctgggactac    240aggcacccac catcatactg ggctaatttt tgtgttttta gtagagatgg ggtttcccca    300tgttgcccag gctgatctca aactcctggg cttaagcaat acagccgcgt tggcctccca    360aagtgttggg attacaagca tgagctaccc cacccagctc attttacatt tccacttgtt    420aaactgaaaa ctggcccgag aaagcttctg tactgccatc cttgcgtcct tgcagatgaa    480tcgtaaccta gcatagtagg taggcagact gaaaacctaa cttagcagta ggcttctgta    540acaacagctg tgtctcagcc agttcctgca gccagacttc aaccactcac aggccgcaaa    600ctgttcaaac tgtgttcgga gaaggcgaat tcatctggct gttaacgtgc ctcacttctg    660ctttctgtgg ccactttccc ttttctgtcc ataaatttgc tttgaccaca cagcatccct    720agagtctccc tgaatctgct gtgattctgg gacctgcacc atttgtgaat tgtttttttt    780ttccttgatc agctaaactc tgttcaattc aatttgttgg aagtttttaa cataccaatg    840gtgcaccaag gttccaattt ctccacttcc tcataaataa gtcattttaa atggcttttc    900agtattccaa tatttggaag tattaatgtt tctaccaatt ttctattttt ggacattgag    960gttgtttcat tttttttttc tttttttgag acagagtctc gctccgtcac ccaggctgga   1020gtgcagtggc ctgatcccgg cccactgcaa cctccacctc cctcctcagc ctcctgagta   1080gctgggatta caggtgcatg caccaccaca cccagctaat ttttgtattt ttagtagaga   1140tggggtttca ccatgttggt caggctggtc tcaaactcct gacctcaggt ggtccacctg   1200ccttggcctc ccaaaatgct gggattacag gcctgagcca ctgcgcctgg cctcatcttc   1260ttgatattaa tgttgcttta acatctttgt ccctgtgttt tttgtttttt tttttgagac   1320ggagtctcat tcattctgtc acccaggctg gagttcagtg gcgtgatctc agctcactgc   1380aacctctgtc tcctgggttc cagtgattct cctgcgtcgg tctcctgagt agctgtgttc   1440ctgggtcttt cgatggttat ttaatacttc cctacagtaa tgccctgtgc gtacatgcta   1500agtgtgatga aatggttggc acagttaaat cttttgaaag acattgccaa gtcactcttc   1560agaaaagtga taggaggtca tagcaatttt aagaagtcct catttctaca tttccttact   1620aatctcggtt ggtgtctctt caatctttcc tcacactttt cttgggtttt tcctgaatca   1680tgagtctact acatttacac attttaaagc atctttagaa acaggatctc attttgttgc   1740ccaggctaga gtttggtggc atgattatag ctcctcatac tcctgggctc aagtgatcct   1800tccacctctg aaaccccaaa atttgagaaa ggtctcattt aatttagaaa gtttattttg   1860ccaaggttga gggtgcacac ctgtgatgat atacgagtta aaaagaaatt atttaggcag   1920atactgaggg taagaaagtc ctcggtaagg ttttcttttc aatgaaaagc agcccccaag   1980cattttcttt tctaacaaag agcagcctgt aaaatcgagc tgcagacata cacaagcaag   2040ctggaagctt gcacaggtga atgctggcag ctgtgccaat aagaaaaggc tacctggggc   2100caggcagatc caacatggcg gctccatctt ccctttcctt gtcaaccatg tgcacagtaa   2160ggagcaggca acatagtgtc ccccgagtag agaccaattt gcataataaa aggtgagggt   2220agggtgggca gcttctttgc atgctatgta aacattatgc ctggtccaac caatctttgg   2280gccctgtgta aattagacac cacctcctca agcctgtcta taaaaccctg tccattctgc   2340cgcaggctgg aagacccact ggggcacccc tctctctcta taggagacag ctattcattt   2400ttctctttct ttcacctatt aaagctccac tcttaacccc actccgtgtg tatctatgtt   2460cttgatttcc ttggcatgag gcaatgaacc ttgggtatta ccccagaacc ttgggtatta   2520tgccacttca gtgacacagc ctcaggaaat cctgatgaca tgttcccaag atggtcgggg   2580cacagcttgg ttttatacat tttagggaga catgagacgt caattcatat atgtaagaag   2640tacattggtt ccgtccagaa aggcggggac aacttgaggc agggagagag cttctaggtc   2700acaggtagac aaatggttgc attcttttga atctccgata agcctttcca aaggaggcaa   2760tcagaatatg cgtctattga ctgggcgcag tggctcatgc ctgtaatgcc agcactttgg   2820gaggcggagg tgggtggatc acctgaggtc aggagtttga gagcagcccg gccaacatgg   2880tgaaaccctg tctctactaa aaatacaaaa aattagctgg gcgtggtggc gggcgcctgt   2940aatcccagct actcgggagg ctgaggcagg agaatagctt gaacccagaa ggaagaggtt   3000gcagtgagct gagatggtgc cattgcactc cagcctgggc aacaagagtg aaactccatc   3060tcagaaaaaa aaaaaaaagg cctgggcaaa gtggctcacg cctgtaatcc cagcactttg   3120ggaagccgag gcgggcaggt cacaaagtca ggagattgag accatcctgg ctaacatgat   3180gaaaccccat ctctactaaa aaatacaaaa aactagctgg gtgtggtggc gagcacctgt   3240agtcccagct actcggcagg ctgaggcagg agaatggcgt gaaccgggga ggcggagctt   3300gcagtgagcc gagatcacac cactgcactc cagcccggac gacagggcaa gactctatct   3360caaattaaaa aaaaaaaaaa aaaaaaaaaa aaagagagag agaatatgca tctatctcag   3420tgagcagaag gatgactttg aatggaatgg gagcagttcc tagcttgaac ttccccttta   3480gcttcagtga tttgggggct caaggtatgt tcctttcaca tacctcagcc tcccaagtag   3540ctgggaccac aagtgcatgc caccacacgt ggctaatgtt ttattttttt tgtaggaata   3600gggtctcact atgtgtccag gctggtctaa aacccctgag ctcaaatggt cctcccgcct   3660cagcctcccg aaatgctggg attacaggca tgagccagca tgcccggcct agtctacatt   3720tttataaatt gctaattcaa agttccctct ccaaaacctc atggttttcc ctgttctcat   3780cccctgcacc ctcccttccc ctggagtact cacctggcct tggaggtctg gtgtgagccc   3840ggacttcgat tctaggcaca gcatgtgatg agcgccccca ggtcaaacac ctcccctctg   3900cggcctgtgc ttcaccgcct tgacagtgag aaaggtctcc cttcggctca ttctcgaagt   3960ctcaaacttc acttctcctg tgcgctgatt ctgaattcag cccccgtcca aggtcctggc   4020ccctttctct tctgcttggc gtgttgttca tcaccactgt gcactgctga gggtaagtgc   4080ggttctctgg acctctgctt tatcattaga acagactctt gcggtttccc acgacattcc   4140tttcacttct cacttggaag atgagccgtg aggaaatcct gtgttgtgtg gtatgtgggc   4200tgtgcttctg cttgacttga gggccaagca gcattgcaag ccatggtttt aaataagaaa   4260gaacatttct aaccttcatc ttctagtaag gaaacaagtg ggctttagag ttcttgctca   4320ggaaagacct atgtcccagt ccaaccggac cttttactaa agagatcttc ctgatcctcc   4380tccccaggcc aggggagggg tcctccctgg ggttggagcc tttagtaggg ggtcggagac   4440acgacgtagc cttcatgaca ttcatagtct agttacacga tccctgtaag ggtcagttga   4500agtaagtgct acaaaggaag ggaggtgctc agtggagagg gctctctttt atgtattata   4560tttctttcat ggggagggat atggatcagg gatcagcaga ggtgtttcag tcccgaggga   4620aagaaagtca gcgtggcttg ggagttggga gcagcaagac agtggctcaa gatatcttaa   4680gactagtgga gtacaccttg catgttaaaa gccttgctca gggctgcctg gttcttgtag   4740gacgacagag atggcctagc tctgcatact gcacccccag gggctcagaa cagtgcaaat   4800gtcagtctat ctgtcagtgg cagagccagc cttggagcag gggtgcaagg aggtctctgc   4860actggccagg catgcagaac attctgttca gtagcactgg acagaaggcc ccatctagat   4920gagacagagc tggtggggca ggacaaagac tcctggcagc tcaaacggcc tggcagatgc   4980ttggagagag ggggcttctt gagacagcac catttctggg aagagagtca cctgggaggg   5040atgaggccac gctccggctt ggaggtgaag agaggggctg ctgcaagaaa gaattagaga   5100catgccagcc tttgctgtgt tgcccaggct ggtcatgaac tcttggcctc aagcaatctt   5160cccacctcag cctccccaag cgctgggatt atagacatga gcccccatgc tggccaataa   5220aagatgattt tatggagggg atggtggtga aggttgtggg tggtatgaaa tagtaagaaa   5280tatatattgg tctgcaccca gttcctgcca cagagctcct aaaatcctga gaacttcctg   5340ggtgagcatc ttttgttcta atgaggtgac tcttggtggc tcctggatag gagtgaatca   5400ccagaaagat caagccagag ttagaagcag aaagtgctgg ctataacaca ggaaagctgt   5460aacacaaata ataaagtttt tttttttttt tttgagatgg agcctcactc tgttgcccag   5520gctggagtgc aatggtgcaa tctcagctca ctacaagctc tgcctcccag gttcaagtga   5580ttctcctgcc tcagcctcct gagcagttgg gactacaggt gtgtgccacc acatctggct   5640aatttttgta tttttagcag agacggggtt tcaccatatt aaccaggctg gcctcaaact   5700ccttaccttg tgatccgcct gcctcagcct cccaaagtgc tgggattaca ggcatgagcc   5760accgtgcctg gccaaaagac attgttctta aaagaatcaa ctaactaacc aaataaataa   5820aaatctaacc taattaagaa actaaaaata cacaaaaatt aatttcaagg ggagaaaaat   5880catgtaaaga gagaaagata atgaatactt tgcagaaatt tatgaacata aacataaaac   5940ttggatgaaa tgcatttcta ggaaaacata atttatcaaa actaaccaca agtaaaatag   6000aagcctaaat aggatatttt caagagaaga agtaaagttg tcaaagtgct acccttcaaa   6060aaaacaccag gctcaaacaa tctgacatgg gaatgttagc acaccttaga gagcaaataa   6120aactttgaat gggcttgaaa tattccagac tctagaaaaa caaaacttcc caattctttt   6180tataaagcaa gtataaattg ataccaaaat cttataaaga ccttatacaa aacttcatac   6240caatctcttt tatgaataca aaacccttaa taaagtatta ccagacagaa cccaacaata   6300cataaaaatg tcacatcata acatagtggg gtttatttca ataatgcatg gatggttcaa   6360tacaaggaaa ttcagtaaca caatataata gatcatgtga atatacccaa agaaaaaata   6420gattattttc atagatgctg taaaggcatt tgaccaaatt caacacctac tttttaggtg   6480gtcaataaaa taaattagtt actccttctt tagcatgata aaatatattt atcagcccag   6540aaggcatcat tttacccgat aagggcacac gctggaggga ataatgttaa aattaggaat   6600aagaggatag ctagtttctt tcttcttttt tttttttgag acggagtctt gctctgttgc   6660caggctggag tgcagtggtg caatgttggc tcactgcacg ccccccgcct cccaggttca   6720agcgattctc ctgcctcagc ctcccgagta gctgggacta caggcgcgca ccaccatgcc   6780cggctaattt ttttttgtat tttagtagag atggggtttc accatgttgg tcaggctggt   6840cttgaactcc caacctcacg tactgggatt accggtgtga gccaccacgc cagcccaact   6900actttcaaca ttatccttaa tactgatgct tattgactta ctatggggtt acctctagat   6960aaatccataa taagttgaaa atataagtaa aaaatgccct taatacacct aacctaccaa   7020acatcatagc tgagcccagc ctgccttagc tatgctcaga cactgacgtc agcctacaat   7080tggcaaaatc acacagcagc acagtctact gcagagcatc tgctgtttgc ccttgtgact   7140gcgtggctgc ctgggagctt cccagcttca caagacagta ttacgtagca catcactagc   7200ctggggaaag atcaaagttg aaaatttgaa gtgtggtttc cattgaatgt gtactgcttt   7260tgcaccatca tcaagtcaaa aaattttagt tgaaccagcc taagtttggg accatcttta   7320ttttcaggag gaacttccat gtacattgat gacggacgat agaatccgtt tctatcatcc   7380taatgaacat aatgaataaa tccagacaaa cataaacatt aacagagtaa gcagctttcg   7440gggctggaag ccagaagagg gtgggagcgc agagagagag gccaaacacc agggctgctt   7500ctgctttgcg ggtatttgct gatctggaca aggtatctgg aaggctgagc taagcctcct   7560ttttttttga ggtggcgtct cactctgttg ccaggctgga gtgcaatggt gcgatctcag   7620ctcactgcaa cctccacctc cctggttcaa gcgattctcc tgcctcagcc tcccgagtag   7680ctgggattac aggctcccgc cactacaccc agctgatttt tgtaatttta gtagagacgg   7740ggtttcacca tgttggccag gatggtctcg atctcttgac gtcatgatct gtccacctcg   7800gcctcccaaa gtgctgggat tataggcgtg acccaccgtg ccccgtctga gctaagcctc   7860ttgagcatag gggactaaaa atgaaatcta gcgcatgcca agtttagggt cccaggcaat   7920tcctttccac tttggggtcc actttggggt ccaccccacc caagaagaag gatgacttgg   7980aagtaaacca gctctgaaat atggatggtc ctctgggacc ataccaatcc cttcatatca   8040accacatcca gttcctcaaa actggaactt ggattaagat ggcctaggac ttctagtgtc   8100ccaggagcct ggcattgcaa acaaaaatcc tctccggaag aagataatac cttaagcttc   8160aaatgactct ctaataaatt tcaaatacaa tgtccagcac acaaacacaa attaccagga   8220acgtgatatg aggcctgatg gatgggaatt agcagaaact tcaggcatga gaaacatacc   8280ctcagaggcc tagaatctat ctagtgtcta gataatggag atatgaaata cagacactta   8340aacaactatg tttcccatgt tcaaagagga aatttgcaaa acttgaaagt gttggcagga   8400aatcagaaac tataaaatgt gacaacagca tactttagag tcagtataaa ttacggtccc   8460gaaaactgca gaattccaga acttaatggt aaagcaaggg tttaacagca gaatagaaat   8520agccagagag aactaggaag taagtcagat gacactaccc agaataaggc actgagaggc   8580caaggaatgg aaaatgcaga agaaaggata tggtgagagg atctaatata catttatttg   8640gagtaccagg gagagagaga aggagaagaa cagaagccgt gtttcaagga cggtgactga   8700gaggcttcga aactgatgaa agccatcagt tcacaaattc aaagcccagt gaattccaag   8760gagaaaaaaa gaaatccata ctgtgaaagc aagtccagac aatgacaaac accatcaaca   8820atacacagga caggcataag atgcatttaa tggggacact cagaggcaga gggttatcag   8880aaggaggcac ttctctccca agttctcatc atcccagggc cagggacagc tggtcacacc   8940ttagggagtt cactaggaga gggatctggc ttcttgtcat tctgggtatt tgtagggaaa   9000ttggaaggga accgagagca cctagccaat cgcatagcaa tgggagattt caggctgtgg   9060ggaatgtctt tgctggtgaa aagaacatcc tgaccttaga aatctttcac cgagggggat   9120ctgcgttcca gaacttctgg agctggtata ggtaaggctt tgagctttcc tactgagcca   9180gcctgttgct aggttaccaa aggggacctc gagggccatc tggccaacaa gcagacttgt   9240ctctccttac acccccagac gtatcactgc aaaactacag aaaaccaaag acagagaaaa   9300tcttaaaagc agccagattt aaaaaatggc atattagttt caaagcagca gccatgaaat   9360tgacagctga tgtctcaaca gcaagaatga aaagtggaag acaggccagg tgtggtggct   9420caggcctgta atcccagcac tttgggaggc cgaggcgggt ggatcacgag gtcaggagac   9480caagaccatc ctggctaaca tggtgaaacc ccgtctctac taaaaataca aaaaaattag   9540tcgggcatgg tggtgggtgc ctgtagtccc agctactcgg gaggctgagg caggagaatg   9600gcgtgaaccc gggaggcgga gcttgcagtg agccgagatt gtgccactgc actccagcct   9660gggtgacaga gcaagactct gtctcaaaaa aaaaaaaaaa aaaaaaaaaa aaagggtgac   9720gaagcttcaa tctcctgaaa ggaagcaact gccgcctttg attcgatacc caccaaaatc   9780cgtgaagaag gaaggcaaaa taaaaacact tcctgattga actggaaaga tttccgcaat   9840agaagaccca ctgtccaagg aattctaaag gatgctttcc aggcagaaga aaatgacccc   9900agaggaagat cagagattca ggaaagaaat ggagagtgat aaaaatggaa aattcggggg   9960ccaatttaaa caaaagctga ctgctctaca actgttgtgt ctctatcttt tgtaacatat  10020atgtgtgtgt agcttttttt tttttttttg tcaagatgga ttctcactct gtcgcccagg  10080ctacagtgaa atggcacggt ctcggctcac tgcaacctct gccccttggg ctcaaatgat  10140tctcttgcct cagcctcctg agtagctgag attacaggtg cctggcacaa tgcctggcta  10200atttttgtat ttttactaga gatgggattt ctccatgttg gccaggctgg tcttgaacac  10260ctgacctcag gtgatccacc tgcctgggcc tcccaaagtg ctaggattac aggcgcgagc  10320cactgcatct ggcctatgtg tgtgtttata tggaattaaa acacatggca ataataccct  10380ccaaattggg agaaaccaaa aatagcattt aaatgttgta agctccctgc ataatcaaga  10440agagaataga tttacgttag attttgatac ctggaggatg aatgttgtaa tttctagggt  10500gaccatgaaa agaggagaca acggtgtatg tttttttttt tttgagatgg agtctcactt  10560tgtcacccag gctggagtgt tgtggtgtga tcttggctca ctgcaacctc ctcctcttgg  10620gttcaggcca tcctcccacc taggcctcca gagtaggtgg gatcacaggc acctgccacc  10680acacctggct aatttttttt tttttttaaa tatttagtag agatggggtt tcaccatgtt  10740ggccaggctg gtcttgaact cctgacctca ggcgatctgc ctacctctgc ctctcaaagt  10800gctgggatta caggtgtgag ccatcgcgcc cggccaacag tgatcacttt caaactaaca  10860gaggttcaaa aataaaatca gacttaacca aaaaccaggt aacagagctg gtaggatata  10920cagaaagact gacctcacgt atatcaacga ttacagttaa tattaatgaa ggaaatgctc  10980tagtttaaaa acgagggttg tcaaagaccc cacataagaa gctccttacc agcggtgcac  11040ctagaaccta aggaaacagg acagatgaag gaggacgcgc ccccgccgct gtcctgcgcc  11100tcagccatcc tatgagacgg gaaaggtttc tgtctgcagc tgggcccgtg ctctttacca  11160gctcctggct ttcttctctg gaaggttcct gcctgttttg ccctcacacc tgctcctctc  11220tcagccctct caggggtggg gctggaggcc accaaagagc ctcctctgct ctccagttgc  11280tcgactgctc ctcatttccc cctggggtct gcgtcagggt ttccttcttt tccagcccca  11340ccccgcgtgc atcccacctg gtctcgggtc ggggctgctc ccgcttactg ccccctgccc  11400aggctggtgt gcaccccctc tggctgcttt caaggcctct tctctcttct cggcaggaca  11460ggcacaggca ggtggccagg tgtcatgctt agctccccgc ccagtgagat tctttcattt  11520aacaatcttc ccctgaatag ttcatgttca ttgctgaaaa tttgaaaaat atggaaaagc  11580acaaagatta agatataaac cgccctcaat tcccctgccc agagagagtc actgctatga  11640cttggtgact aggaacctta tttctctctc gctctttttt ttttttttga gacagagtct  11700tgctctgtca cccaggctgg agtgcagtgg ctcgatctca gctcactgca acctccgcct  11760cctgggttca agcgattctc ctgcctcagc ctcttgagta gctgggatta caggcacctg  11820ccaccatgcc cggctaattt ttgtattttt agttgagaga gggtttcatc ttgttggtca  11880ggcggacttg aactcctgac ctcaggtgat cagcccacct cggcctccca aagtgctggg  11940attacaggtg tgagccactg cgccttcatc tctcttctgt gtatgtgtac gctgtttttt  12000ctttagaatg ggggacgtta tcaggctcta catggtgtgt agtcggctag catgttgtaa  12060gcctttccct gtgtcacaag tgctcatctg gaacaggatt ctaatgactg cctgtggcta  12120tgttgggatt cctttaactc agctccttct gcccagcatc tatctttttt ccatcttttg  12180tcctaagtgt tgctataata aatcattgat cacacatgcc tgactgtttg cataggataa  12240attacgggaa atgtttttgc tgttcaggga ctgtgcccat ttttaggcct cagagacacc  12300atgccagact gcccagtatt gatctttact ctttttagat gatgccaaac ttttctgtga  12360actttaaaaa cctgtgtctt gacagtccat ttctgtaagt ctttcacatt agatttcctg  12420tcaggatgat agtcaattct aggcagatga tgttttctca gccatggctg aagcagttgt  12480gatttgttgt ggccatgtaa agtcccgatg atccattgcc tccctggatg ggttggaata  12540atttggtttg ggagcatata acagaatgac ctggagtcac agcagctcag acggaagtgt  12600atttctccct tacagatgaa agaattccag gccaggctgg aatgacaact gcacacagtc  12660atctgggccc cctccttcca gctcccatca ccccaggatg tggcttttat gcagatgatc  12720caaaatggct gctcaagtcc cagccaacac atcccattcc agggagcagg aaaaaggtgt  12780gtctttccct tcattttatg tgattccttt ctagaagtac tactcattac ttctgcttgc  12840atctccctgg ctagcactta cttagttata tggccatagc tagctgaagg aaggacaggg  12900actgtcatac actagctaag aggcaaactg cttagataaa aaggtctcta aagaaggtca  12960gagcggctgc tagggtgcaa ctctattact tattgttatg ggacgaactg tgtccctcat  13020tcaggttgat gtcctaagcc ccagaacctc agaatgggat tgtatttgga gacaggttct  13080ttaaggaggt aaggaggcta aaatgagatc attagggtgg gccataatcc gactgatgtc  13140ttacaagaag agattaggac acggacatgc tcagagggac ggccacgtga ggacaccaag  13200aaaggcagct gtctgcaagt caaggacagg gctcagggga aaccaacctt gccaacacct  13260tcatctcgga cttctagcct ctaggaccat gagaagatac atttctgttg tttaagctgc  13320ccggtctgtg gtactttgtt atggcagccc aagtaaacaa atacagtcat ctgctgctgg  13380aacaaatcac cccagcactg tggcttggca gcacacatgt ctagtcatag agttatatgt  13440agttacgtgt agagccatat gtatcgtcac acgttctgtg ggtcaggaat ttggacccag  13500cttaaccagc tccacttctc gccagggttc agtcaaatac cagctgcctc ccacctgaga  13560gctcagccgg ggaagggtcc ctttccaatc tcacgtggtg ttggcaggat ccagttcctc  13620atggcctgct ggactgagaa cctcagttct cactgcctgt tggccagagg ccgcctttat  13680gtcctcgcca tgtgggcctc tccaacatgg cagctgactt catcagagca tccatgccaa  13740gaaggcaaca gagagggcca gggagactga agtcataccc ttttgcgacc tagtcatggg  13800gtgacattcc atcacctttg cccattggtt agaagcaggc caccaggtac agcccaagct  13860cacggggagg ggtcatacaa gggtgtcaat accaggaggt gaggggtgct ggggccatct  13920tatgagtctg cccactgagg taactaacaa ccttgaggcc tgacacagtg gacaaaggcc  13980cttattaaca gcagagaact gggaacttta tttatttatt tatttttgag acagagtctc  14040actcttgtca cccaggctgg agtgcaatgg catgatcttg gctcactgca acctccacct  14100cccaggttca agcaattctg cctcagcctc cggaatagct gggactacag gcatgcacca  14160ctacacccgg ctaatttttg tatttttagt agagacaggg tttcgccatg ttggccaggc  14220tggtctcgaa ctcctgacct ctggtgatct gcctgccttg gcctcccaaa gtgctgggat  14280tacaggcgtg agccaccgca cctcgctgga acttaatttt tttagagaca gtgtcgctct  14340atcacccaag ctggagtgca gtggtgcaat cctagctcac ttgcagcctc aaattcctgg  14400gttcaggtga tcctcccaca tcagcctccc aagaactggg aactaacagc tgtttctctg  14460ctgtccttct caagaaaagg gaggctactg ctaccccact ggggacaatg ctgggtttcc  14520ctttaggaca ggctctgaga caaggcggag gtgctgtttg tggccacaga gcaggggact  14580ctgggttgca ggtgtggcct ggctaaagta ggctttactg ggctcctctc tgcctgcatc  14640accccccggc tgggcggttg tctctgaggc caaccttact ccctgctggg caggctggac  14700agctgccctc tccgtttgcc cctctaccac ccaaaaggca ggaggctctg gagaccagga  14760ccctgcccgc cacggcctgt gtcccaggcg tgagggggtg ccccacagac ctctgctgag  14820ctgctgctga atgacgcccc ttgggggtcc tgccggaagg tcagagcagg ggtgcactcc  14880cataaagaaa cgcccccagg tcgggactca ttcctgtggg cggcatcttg tggccatagc  14940tgcttctcgc tgcactaatc acagtgcctc tgtgggcagc aggcgctgac cacccaggcc  15000tgccccagac cctctcctcc cttccggggc gctgcgctgg gaccgatggg gggcgccagg  15060cctgtggaca ccgccctgca ggggcctctc cagctcactg ggggtggggt gggggtcaca  15120cttggggtcc tcaggtcgtg ccgaccacgc gcattctctg cgctctgcgc aggagctcgc  15180ccaccctctc cccgtgcaga gagccccgca gctggctccc cgcagggctg tccgggtgag  15240tatggctctg gccacgggcc agtgtggcgg gagggcaaac cccaaggcca cctcggctca  15300gagtccacgg ccggctgtcg ccccgctcca ggcgtcggcg ggggatcctt tccgcatggg  15360cctgcgcccg cgctcggcgc cccctccacg gccccgcccc gtccatggcc ccgtccttca  15420tgggcgagcc cctccatggc cctgcccctc cgcgccccac ccctccctcg ccccacctct  15480caccttcctg ccccgccccc agcctcccca cccctcaccg gccagtcccc tcccctatcc  15540cgctccgccc ctcagccgcc ccgcccctca gccggcctgc ctaatgtccc cgtccccagc  15600atcgccccgc cccgcccccg tctcgccccg cccctcaggc ggcctccctg ctgtgccccg  15660ccccggcctc gccacgcccc tacctcacca cgccccccgc atcgccacgc cccccgcatc  15720gccacgcctc ccttaccatg cagtcccgcc ccgtcccttc ctcgtcccgc ctcgccgcga  15780cacttcacac acagcttcgc ctcaccccat tacagtctca ccacgccccg tcccctctcc  15840gttgagcccc gcgccttcgc ccgggtgggg cgctgcgctg tcagcggcct tgctgtgtga  15900ggcagaacct gcgggggcag gggcgggctg gttccctggc cagccattgg cagagtccgc  15960aggctagggc tgtcaatcat gctggccggc gtggccccgc ctccgccggc gcggccccgc  16020ctccgccggc gcagcgtctg ggacgcaagg cgccgtgggg gctgccggga cgggtccaag  16080atggacggcc gctcaggttc tgcttttacc tgcggcccag agccccattc attgccccgg  16140tgctgagcgg cgccgcgagt cggcccgagg cctccgggga ctgccgtgcc gggcgggaga  16200ccgccatggc gaccctggaa aagctgatga aggccttcga gtccctcaag tccttccagc  16260agcagcagca gcagcagcag cagcagcagc agcagcagca gcagcagcag cagcaacagc  16320cgccaccgcc gccgccgccg ccgccgcctc ctcagcttcc tcagccgccg ccgcaggcac  16380agccgctgct gcctcagccg cagccgcccc cgccgccgcc cccgccgcca cccggcccgg  16440ctgtggctga ggagccgctg caccgaccgt gagtttgggc ccgctgcagc tccctgtccc  16500ggcgggtccc aggctacggc ggggatggcg gtaaccctgc agcctgcggg ccggcgacac  16560gaacccccgg ccccgcagag acagagtgac ccagcaaccc agagcccatg agggacaccc  16620gccccctcct ggggcgaggc cttcccccac ttcagccccg ctccctcact tgggtcttcc  16680cttgtcctct cgcgagggga ggcagagcct tgttggggcc tgtcctgaat tcaccgaggg  16740gagtcacggc ctcagccctc tcgcccttcg caggatgcga agagttgggg cgagaacttg  16800tttcttttta tttgcgagaa accagggcgg gggttctttt aactgcgttg tgaagagaac  16860ttggaggagc cgagatttgc tcagtgccac ttccctcttc tagtctgaga gggaagaggg  16920ctgggggcgc gggacacttc gagaggaggc ggggtttgga gctggagaga tgtgggggca  16980gtggatgaca taatgctttt aggacgcctc ggcgggagtg gcggggcagg gggggggcgg  17040ggagtgaggg cgcgtccaat gggagatttc ttttcctagt ggcacttaaa acagcctgag  17100atttgaggct cttcctacat tgtcaggaca tttcatttag ttcatgatca cggtggtagt  17160aacacgattt taagcaccac ctaagagatc tgctcatcta agcctaagtt ggtctgcagg  17220cgtttgaatg agttgtggtt gccaagtaaa gtggtgaact tacgtggtga ttaatgaaat  17280tatcttaaat attaggaaga gttgattgaa gttttttgcc tatgtgtgtt gggaataaaa  17340ccaacacgtt gctgatgggg aggttaattg ccgagggatg aatgaggtgt acattttacc  17400agtattccag tcaggcttgc cagaatacgg ggggtccgca gactccgtgg gcatctcaga  17460tgtgccagtg aaagggtttc tgtttgcttc attgctgaca gcttgttact ttttggaagc  17520taggggtttc tgttgcttgt tcttggggag aatttttgaa acaggaaaag agagaccatt  17580aaaacatcta gcggaacccc aggactttcc ctggaagtct gtgtgtcgag tgtacagtag  17640gagttaggaa gtactctggt gcagttcagg cctttctctt acctctcagt attctatttc  17700cgatctggat gtgtcccaga tggcatttgg taagaatatc tctgttaaga ctgattaatt  17760tttagtaata tttcttgttc tttgtttctg ttatgatcct tgtctcgtct tcaaagttta  17820attagaaaat gattcggaga gcagtgttag cttatttgtt ggaataaaat ttaggaataa  17880attattctaa aggatggaaa aactttttgg atatttggag aaattttaaa acaatttggc  17940ttatctcttc agtaagtaat ttctcatcca gaaatttact gtagtgcttt tctaggaggt  18000aggtgtcata aaagttcaca cattgcatgt atcttgtgta aacactaaac agggctcctg  18060atgggaagga agacctttct gctgggctgc ttcagacact tgatcattct aaaaatatgc  18120cttctctttc ttatgctgat ttgacagaac ctgcatttgc ttatcttcaa aatatgggta  18180tcaagaaatt tcctttgctg ccttgacaaa ggagatagat tttgtttcat tactttaagg  18240taatatatga ttaccttatt taaaaaattt aatcaggact ggcaaggtgg cttacacctt  18300taatccgagc actttgggag gcctaggtgg acgaatcacc tgaggtcagg agtttgagac  18360cagcctggct aacatggtga aaccctgtct ctactaaaaa tacaaaaatt agctggtcat  18420ggtggcacgt gcctgtaatc caagctacct gggaggctga ggcaggaaaa tcgcttgaac  18480ccgggaggca gagtctgcag tgagttgaga tcacgccact gcactccagc ctgggtgaca  18540gagcgagact ctatctcaaa aaaaattttt tttaatgtat tatttttgca taagtaatac  18600attgacatga tacaaattct gtaattacaa aagggcaata attaaaatat cttccttcca  18660cccctttcct ctgagtacct aactttgtcc ccaagaacaa gcactatttc agttcctcat  18720gtatcctgcc agatataacc tgttcatatt gtaagataga tttaaaatgc tctaaaaaca  18780aaagtagttt agaataatat atatctatat attttttgag atgtagtctc acattgtcac  18840ccaggctgga gtgcagtgat acaatctcgg ctcactgcag tctctgcctc ccaggttcaa  18900atgcttctcc tgcctcagcc ttctgagtag ctgggattac aggcgcccac caccatgtcc  18960agctaatttt tgtattttta gtagagatgg ggtttcacca tgttggccag gctggtcttg  19020aactcctgac cttgtgatct gtccacctcg gcctcccaaa gtgctgggat tacaggtgtg  19080agccaccatg cctggctaga ataataactt ttaaaggttc ttagcatgct ctgaaatcaa  19140ctgcattagg tttatttata gttttatagt tattttaaat aaaatgcata tttgtcatat  19200ttctctgtat tttgctgttg agaaaggagg tattcactaa ttttgagtaa caaacactgc  19260tcacaaagtt tggattttgg cagttctgtt cacgtgcttc agccaaaaaa tcctcttctc  19320aaagtaagat tgatgaaagc aatttagaaa gtatctgttc tgtttttatg gctcttgctc  19380tttggtgtgg aactgtggtg tcacgccatg catgggcctc agtttatgag tgtttgtgct  19440ctgctcagca tacaggatgc aggagttcct tatggggctg gctgcaggct cagcaaatct  19500agcatgcttg ggagggtcct cacagtaatt aggaggcaat taatacttgc ttctggcagt  19560ttcttattct ccttcagatt cctatctggt gtttccctga ctttattcat tcatcagtaa  19620atatttacta aacatgtact atgtgcctgg cactgttata ggtgcagggc tcagcagtga  19680gcagacaaag ctctgccctc gtgaagcttt cattctaatg aaggacatag acagtaagca  19740agatagataa gtaaaatata cagtacgtta atacgtggag gaacttcaaa gcagggaagg  19800ggatagggaa atgtcagggt taatcgagtg ttaacttatt tttattttta aaaaaattgt  19860taagggcttt ccagcaaaac ccagaaagcc tgctagacaa attccaaaag agctgtagca  19920ctaagtgttg acatttttat tttattttgt tttgttttgt tttttttgag acagttcttg  19980ctctatcagc caggctggag tgcactagtg tgatcttggc tcactgcaac ctctgcctct  20040tgggttcaag tgattctcat gcctcagcct cctgtttagc tgggattata gacatgcact  20100gccatgcctg ggtaattttt tttttttccc ccgagacgga gtcttgctct gtcgcccagg  20160ctggagtgca gtggcgcgat ctcagctcac tgcaagctcc gcttcccgag ttcacgccat  20220tctcctgcct cagtctccca agtagctggg actacaggcg cctgccacca cgtccagcta  20280atttttttgt atttttaata gagacggggt ttcaccgtgt tagccaggat gatcttgatc  20340tcctgacctc gtcatccgcc gaccttgtga tccgcccacc tcggcctccc aaagtgctgg  20400gattacaggc atgagccact gtgcccggcc acgcctgggt aatttttgta tttttagtag  20460agatggggtt ttgccatgat gagcaggctg gtctcgaact cccggcctca tgtgatctgc  20520ctgccttggc ctcccaaagt gctaggatta caggcatgag ccaccatacc tggccagtgt  20580tgatatttta aatacggtgt tcagggaagg tccactgaga agacagcttt tttttttttt  20640ttttttgggg ttggggggca aggtcttgct ctttaaccca ggctggaatg cagtatcact  20700atcgtagctc acttcagcct tgaactcctg ggctcaagtg atcctcccac ctcaacctca  20760caatgtgttg ggactatagg tgtgagccat cacacctggc cagatgatgg cttttgagta  20820aagacctcaa gcgagttaag agtctagtgt aagggtgtat gaagtagtgg tattccagat  20880ggggggaaca ggtccaaaat cttcctgttt caggaatagc aaggatgtca ttttagttgg  20940gtgaattgag tgagggggac atttgtagta agaagtaagg tccaagaggt caagggagtg  21000ccatatcaga ccaatactac ttgccttgta gatggaataa agatattggc atttatgtga  21060gtgagatggg atgtcactgg aggattagag cagaggagta gcatgatctg aatttcaatc  21120ttaagtgaac tctggctgac aacagagtga aggggaacac cggcaaaagc agaaaccagt  21180taggaagcca ctgcagtgct cagataagca tggtgggttc tgtcagggta ccggctgtcg  21240gctgtgggca gtgtgaggaa tgactgactg gattttgaat gcggaaccaa ctgcacttgt  21300tgaactctgc taagtataac aatttagcag tagcttgcgt tatcaggttt gtattcagct  21360gcaagtaaca gaaaatcctg ctgcaatagc ttaaactggt aacaagcaag agcttatcag  21420aagacaaaaa taagtctggg gaaattcaac aataagttaa ggaacccagg ctctttcttt  21480tttttttttt tgaaacggag tttcgctctt gtcacccggg ctggagtgca atgatgtgat  21540ctcagctcac taaaacctct acctcctggg ttcaagtgat tcttctgcct cagcctccca  21600agtaactggg attacaggcg tataccacca tgcccagcta atttttgtgt ttttagtaga  21660gatggggttt caccatgttg gccaggctgg tctcgaactt ctgacctcag gtgatccact  21720cgcctcagcc tgccaaagtg ctgggattac aggtttgggc cactgcaccc ggtcagaacc  21780caggctcttt cttatactta ccttgcaaac ccttgttctc attttttccc tttgtatttt  21840tattgttgaa ttgtaatagt tctttatata ttctggatac tggattctta tcagatagat  21900gatttgtaaa aactctccct tcctttggat tgtcttttta ctttcttgat agtgtctttt  21960gaagtgtaaa agtttttaat tttgatgaag tcgagtttat ctattttgtc tttggttgct  22020gtgcttcaag tgtcatatct aagaaatcat tgtctaatcc aaagtcaaaa aggtttactc  22080ctatgttttc ttctaagaat tttagagttt tacatttaag tctgatccat tttgagttaa  22140tttttatata tggttcaggt agaagtccaa ctttattctt ttccatgtgg ttattcagtt  22200gtcccagcac tgtttgttga agagactatt ctttccccat ggaattatct tagtaccctt  22260gttgaaaatt aatcgtcctt aattgtataa atttatttct agactgtcag ttctacctgt  22320tggtctttat gtcgatcctg tgccagtacc atacagtctt gattactgaa gtttgtgtca  22380cagtttaaat tcatgaaatg tgagttctcc aactttgttc cttttcaaga ttgatttggc  22440catgctgggt cccttgcatt tccgtacgaa ttgtaggatc agcttgtcag tttcaacaaa  22500gaagccaagt aggattctga gagggattgt gttgaatctg tagatcaact tggggagtat  22560tcgcatctta acaatattgt cttccaccta tgaacatggg caaactttgt gtaaatggtc  22620agattgtaag tatttcgggc tgtgtgggca cagtgtctct gtcacagcta cgcggctctg  22680ccattgtagc atgaaagtag ccataagcaa tatgtatgag tgtctgtgtt ccaatagaat  22740tttattaatg acaaggaagt ttgaatttca tataattttc acctgtcatg agatagtatt  22800tgattatttt ggtcaaccat ttaaaaatgt aaaaacattt cttagcttgt gaactagcca  22860aaaatatgca ggttatagtt ttcccactcc taggttaaaa tatgatagga ccacatttgg  22920aaagcatttc tttttttttt tttttttttt tttttgagac ggagtttcac tcttgttgcc  22980caggctggag tgcagtggcg cgatctcggc tcactgcaac ctctgcctcc caggttcaag  23040acattctcct gcacggcctc cctagtagct gggattacag gcatgcgcca ccacacccag  23100ctaattttgt atttttagta gagacggggt ttctccatgt tggtcaggct ggtcttgaac  23160tcctgacctc aggtgatcca cccgcctcag cctcccaaag tgctgggatt acagggtgtg  23220agccaccaca ccctgctgga aagcatttct tttttggctg tttttgtttt ttttttaaac  23280tagttttgaa aattataaaa gttacacata tacattataa aaatatcttc aagcagcaca  23340gatgaaaaac aaagcccttc ttgcaagtct gtcatctttg tctaacttcc taagaacaaa  23400agtgtttctt gtgtcttctt cccagatttt aatatgcata tacaagcatt taaatgtgtc  23460attttttgtt tgcttgactg agatcacatt acatatgtat ttttttactt aacaatgtgt  23520catagatatt gttccatagc agtacctgta attcttatta attgctatgt aatattttag  23580aatttctttt taaaagagga cttttggaga tgtaaaggca aaggtctcac atttttgtgg  23640ctgtagaatg tgctggtgac atattctctc taccttgaga agtccccatc cccatcacct  23700ccatttcctg taaataagtc aaccacttga taaactacct ttgaatggat ccacactcaa  23760aacatttagt cttattcaga caacaaggag gaaaaataaa ataccttata aagcactgtt  23820taatattgta ttaaattgga tcaatttggg ggctagaatg tatgttagag acatgatatg  23880tccataggtc cttgctatca cagtgaggtc tcagggacag tcgtttggta tcatttggga  23940tctcataagc agactctctc tgcttgacct gacaaatcag agtctgtgtt ttaacaggtt  24000cagtgagtga cttacatgca cattggagtt tgggaagctc cactgtaggt gcttagacct  24060tacctttgtt gttgctaata acaatgcaag catttgggag gaagacctgt gttgctcata  24120tgtgtccagg tgtagctgag gtggccttgc ttatctgctg tagggccgtt gagcatttct  24180gtagctgtga tgagtgagct gaggtgagcc tgcggagagc tcccagccat tggtagtggg  24240actcgcttag atgaactgga aggacccttt catctgagca gccactatgg agaaaaacaa  24300ccgaatgagg ggagagacaa tgtgcaattt tatttagggc acaaaggaga gctgtggtta  24360gaaggtgaca tttgagtgga aagggggcaa gccatgtgta tagcgggaga agagaggtcc  24420aggcagagtt aacagaaggc agaaatgctt tccatgtttg agaaccagta aggaggccag  24480tggctgaagt aaggtgaagg gcagaaataa ggatgaggct gcgagagatg agaggttaga  24540gacgagcgtc ttgtgcacca agataagctt gtgtggtcaa aacaagtagt ttaatttatg  24600tttttaaaag atcattttgg ctgggcacaa tggttcatgc ctgtaatacc agtagtttga  24660gacggtgtgg tgggaggatt gcctgaggcc agacgaccag catagccaac atagcagcac  24720ctataaggtc tctacaaaaa actttaaaaa attagctggg catagtggtg tgtgcctgta  24780gtcccagcta ctcaggaggc tgaggaggct ggaggattgc ttgagtccag gagtttgagg  24840ctgcagtgag ctatgattat gccactacac tacaacctgg gcaagagagt gagaccctgt  24900ctctaaatat acacacacac acacacacac acacacacac acacacacac acacacacac  24960acacacatat atatgtatat atatgcattt agatgaaaag atcactttga caataccaca  25020tgctggtgag gatttagaaa aactaggtca cttattgctg gtgggaatat aatatagtac  25080ggccactctg gaaaacagtt tggcagtttg tcataaaact gaacataccg ttagtataca  25140gcccagcagc aactacaatc ctgggcatta atcctagaga aatgaaacct taatgttcac  25200ataaaaacct atactcaagt atgcatagca gctttaccca taatatctaa gaactggaat  25260cagctcagat gtccttcaac aggtgaatgg ttaaactact cagtaataaa aaggaatgag  25320ctactgatag catgcaacag tttaggtgaa gttatgctaa tgaaaaaagc caatcccaaa  25380aggttataca tactgtatga ttctatgttt ttttgcaatg gcacagtttt agggatggag  25440aatagattag tggttgcctg gggttagaga tggggtagta gagtaggtta gtggtggcag  25500aggagagaaa agagagggag gtgaatgtgg ttataaaagg acaacacagg ggaatacttg  25560taatggaaat gctttgtctt tttttttttt tttttttttt tggcgacaga gtcttgctct  25620gttgcccagg ctggagtgca gtggcatgat cttttctcac tgcaacctct gcctcctggg  25680ttcaagtgat acttgtgtct cagtctccca tgttcagagt gaaacaaacc agaggtaatg  25740ttcatccaaa taatccaaca cacatgacat taaaacatca agatcaggtc ggacgtggtg  25800gctcatgcct gtaatcccag cacttttggg aggccaaggt gggcagatca cttgaggtca  25860ggagttcgag accagccggg ccaacatgat gaaaccccat cttgactaaa aatacaaaaa  25920ttagccgggc atggtggtgt gcacctgtag tcccagctac ttgggaggct gaggcaagag  25980aactgcttga acccgagggg cagaggttgc agtgagctga gagtgcgcca ttgcacttca  26040gcctgtgtga cagagtaaga ctccatctcc aaaaaaaaaa aaccaagatc aattaaaata  26100cagcattact gggccgggtg tggtggctca cacctgtaat cccagcactt tgggaggccg  26160agatgggcag atcacgaggt caggagatcc agaccatccc ggctaacacg gtgaaacccc  26220gtctctacta aaaaatacaa aaaattagcc gggtatagtg gtgggtgcct gtagtcccag  26280ctacttggga ggctgaagca ggagaatggt gtgaacccgg gaggcagagc tggcagtgag  26340ctgagatcgc gccactgcac tccagcctgg gcgacagagc aagactccgt ctcgggggaa  26400aaaaaaaaat aaataaatag aatgctgtag tgtccttgag tttacatgcc cctccttacg  26460cttgtgtgcc cgtgcagatt gcttgattac acaattagag gaggctggcg gaggattgtt  26520ttaatttttt tttttttgag acagtctggc tctgttcccc aggctagagt gcaatggcgc  26580aatcttggtg cactgcaacc tctgcctcct gggttcaagc agttcttctg ccgcagcctc  26640ccgagtagct gggattatag gcgcccgcca ccacgcccaa ctattttttg tatttttagt  26700agagcagcgt ttcaccatgc tggccaggct ggtctcgaac tcctgacctc agatgatctg  26760ctgccccagc ctcccaaagt gctgggatta caggcgtgag ccacacctgg ccgtttgttt  26820taattttgaa ggtgaagtga aagtgactac atttaccaaa agtgattgaa aagccaggac  26880tgttcttacc ctgtttttcc agttcttgct cagagcaagg tggtttcttt ttcacttaat  26940caccatactt acttttcatg tagaacaagt cagtttgagt tatcagttca tcatcttaac  27000taaattccat gggggaagga attagtttta gtttcttaaa cttccaggtt tgcttattgg  27060acaaaatgag atagcaaggc agtgttttta agttagattt tttatttctt tggtaataca  27120attttctcag aaacttagta gtcttttagt ttagttgttt ttagttggtc ctatgttttg  27180gatcacccct ctctacttta ttttgatagt gccaactgtg aagacatctg aagccatagg  27240tttggatggg aaggaggcat ctttagcctg atcatcttcg ccaggctgtt tatctccttt  27300tgcttggctg agaagtctta ataggaggct tattcccagc tatttgggga catagaagca  27360gttagccatt gcttatattt tactgaggtc tgtgtggtat gttgattgta gtcagttaac  27420gattttgaga actgaaggca gcctggtata tatagagtag gtattagact gtgtttcttc  27480taattgaatt tcccatctct tgtaatctat gccatcatct tctgtactgc tgagaaagaa  27540agaaagtttc taatcaaact ataccactgg ttgtaagatg cagtttggct ttagtgatgt  27600taacacatga ttcaaacgtg aaattgattg agtattggtg aaatacagag gagatttaaa  27660gccagaagac ctgggtttaa atgctggctg tatgacttca tatctgtgtg atcttgggca  27720tgtcatggtt ggcacttcaa tttcttctct ctataatggg ggaagtgagg ccagtcatgg  27780tggctcatac ctataatccc agtgctttgg gaggccaaga tgggaagatc gcttgaggcc  27840aggagtttga gcaattgggc aacatcgtga ggccccgtct ctacaaaata ttttgaaaaa  27900attagccagg cccagtggtg cgtgcctgtg gtccgcgcca ctcaggaggc tgagacggga  27960ggatcctttc agcctaggag tttaaggcta aagtgagcca tgattgtgct atcgtactcc  28020agcctgggca gcagagcaag atcctgactc taaaaaaaag taaaataaag taaaatgggg  28080gaaatgaact gctttagtaa catcatctgt tttttctgtg agcagcgtag cttgacagcc  28140attggtgaac tcgtgccctg tgcttccctg tccagatccc cattctgccc gcaacatgga  28200gtataacggt ttattcatag tagtcgagaa acactcactg aatgaatgaa tgaggtgtag  28260aactaagtgg agtgggtaat tcaacacata ttaatttcct tctttttttt atttttagaa  28320agaaagaact ttcagctacc aagaaagacc gtgtgaatca ttgtctgaca atatgtgaaa  28380acatagtggc acagtctgtc aggtaattgc actttgaact gtctagagaa aataagaact  28440ttgtatattt tcagtcttaa tgggctagaa tattctttgt gtcccagcta ttttaaatgg  28500attcagaaat ccatttaaga tgaagaagga cccttttccc atatttctgg ctatatacaa  28560ggatatccag acactgaaat gaataatgtt ccctttttgt aatcttttat gcaaaaatta  28620aaaccattat ggtaattgaa caacatgttt atgtttagtt aacaccctta gcaactatag  28680ttattttaaa accatctatg gtttgatatt tttgcatttg ttgcaatagt aggaacagca  28740caagacagtt cagtttgtct ctcttatttg ctttttcttg gcagtttgct gtcctattgt  28800acctctgctc ctagcagtgg ctggagccca ctcctctgtg cttcgggatt agtggggatc  28860gtggggcatt gactgtaggt cagctttcct tgcttgatct ttctcactgg gatgaactag  28920cagcaccttc ttttgtagct gctttgcttt tgactatctt tctgaccgtt gttcctagta  28980gctgtagatg gtaaatatat ttaggcctgt ttccaatggc tcagtaggag acatattcac  29040ctatgatatc tgaattctgt tacccacatg ggcatgcgtg aaatagttgc cttgccttac  29100tttcccttgg aataaataat tcatgttatt ctcctggtag aagctagaaa aagcctttat  29160agtcagtcag aaaaaaattt ttagacaaat aatcttgatt ttagtactga caaaaacgtg  29220tggtgattct ttttttaatt tttttttgag acggagtttc actcttgttg cccaggctgg  29280agtgcaatgg cgtgatctcg gctcactgca acctctgcct cctgggttca agtgattctc  29340ctgcctcagc ctcccaagta gctggagtta caggcatgtg ctactgtgcc cagctaattt  29400tgtattttta gtagagatgt tggtcaggct gatctcgaac tcccaacctt aggtgatctg  29460cccgcctcag cctcccaaag tgctgggatt acaggcgtga gccagggcgc ccggtgattc  29520atttgttttt tcaaaaaatt tcctcttggc cattgctttt cacttttgtt tttttttttt  29580ttttgagacg gagtcacgat ctgtcaccca ggctggagtg cagtggcatg atcttggctt  29640actgcaagct ctgcctccca ggttcacgcc attctcctgc ttcagcctgg cgagtagctg  29700ggactacagg tgctcgccac cacacccggc taattttttg tatttttagt agagatgggg  29760tttcaccgtg gtcttgatct cctgacctca tgacccgctc aactcagcct cccaaagtgc  29820tgggattaca ggcgtgagcc accgcgcccg gccctctctt gtctttttat tgtggtaaaa  29880tgcacataaa attgactgtc ttaaccattt ttaggggtac agttcagtat atatattcgt  29940aatgttgtac agccatcact gccatctact tcataagttt ttcttctgtc aaaactgaac  30000atctgtcttc attaaactcc ctatcatcca ttctttcctg tagtcccttt ctactttctg  30060tctgtatgag tgtaactgct ctggagacct catgtaagtg gattcctaca ggatttgtgt  30120tttttttttg gtgatctgct tatttttaat gcctctgtgc atttgtatta tatactttca  30180aagtgatttc acaaaaccgt ttcattttag gttaactcat ttctgttgtt tgtgaaatac  30240tgtgtatgat tctgttctgt ttctgtctaa tttgtggaaa tgttgtggga agaaaatgaa  30300ataacaaatg agcatatgtc ctgaaaataa aaatataaaa attctaagtt agcatgctat  30360tgtagaatac aacgctatga taaaagtagg aaaaaaaaag gtttgaattc tatctctgct  30420acctgtgtaa gctgggtgac tttagataag ctgtaacgtg tttgagcctt actggctcat  30480ttttgaaatg taatccctag ttacacagtt cttgtgggat cagatggtac atgtgaaaca  30540ctgtgaaaaa gcaactgcat agatatgttc attagccacc tgagcgggaa gcgtatccca  30600ttgcgatgcc catcatccaa agctatatgt tatctttact tttttttttt tgagacagag  30660tcttgctctg ttgcccaggc tagagtgcag tggtgcaatc tcagctcact gcaagctcca  30720cctcccgggt tcacgctatt ctcctgcccc agcctcccaa gtagctggga ctacaggcac  30780ccgccaccat gcctggctaa atttttgtat ttttagtaga gatggggttt caccgtgtta  30840gccaggatgg tcttgatctc ctgacctcgt gatccgcccg cctcggcctc ccaaagtgct  30900gggattacag gcgtgagcca ctgcccctgg ccatctttac tttttttgtg aaatgacttt  30960aaatacttgg caaacatttg gtcattgttc atctgatctc caccatccag gtctcagaga  31020acataatttc tctctgaaag cttattgacc caggaaataa gatctctttc aatctgagtg  31080cgtcaggctt tattcttgtc attttgtctt ttgataattt tcaaatggaa ttcatggaat  31140gttggcttat attcatatat tagtaaagta tgttgagaca tcttaagatt gatttgtggt  31200tctatatgcc atattaaatc aaaataatag ctgttaatgg ttttcacatt agtctgtctc  31260ttgtttttat ggagtaatgc tgagagttca ttatgcttgt tctacagaag agcatgttaa  31320aaggagtttt tggagtcaga gaggttattc ttggtttcat aggatacact ctatactttt  31380tagggatttc agagtatata gctgaaggtg atattttatg taaatatgtt ttatggaaac  31440ttattgctca tcgctgtttc ctgttaactc tcctaaaata taattaaact tttggaactt  31500ttttatagct tttgtgctag actaattttt gtctctaatg aggttatata aatggcagct  31560tctgacgttt tcaatgtagg aagtcattta aaacttcatg tatattgtga aaatgtagtc  31620tgctttaagc tctctaaagt ggtctaagtt actggttcct aagtatggat gagcatcaaa  31680atcatctgga aaatttgtta aaaatacagt aatgaaggca cctcactgtc ctttttccca  31740aacatacttc tgcattctgt ttgagtaggt agggactaca catttttcac aagtatcctc  31800ttgggaatac ccaggaatgc ttacttgagc aacctcttac taatatgtac cttgataagg  31860tggctaggta aacataaata tacaaaaatc catagatctc ccatatatta gcataaatca  31920gctagaaaat ataacgttta aagatctagt tcacagtagc accaatatat cgaactctaa  31980ggaatcgata aatatgcaaa aactttataa aaacttctgt taatgtttct gaaagatata  32040ggtgaccact ttctagatag gaagatttta tattactaag ttgaattttc tctaaattaa  32100cacagaaatt taaaataatc ttgatcaaaa ttctagtaga ggtatttttg aacttgttca  32160ctgcaagaat aaatacataa ttgcaaagaa tatctcaaaa tcatcaccag gcctggtgtg  32220gtggcccatg cctgtaatcc cagcactttg ggaggctgag gcaggcagat cacctgaggt  32280caagagtttg agaccagctg gaccagtgcg gtgaaacact gcctctacta aaaatacaaa  32340aattagctgg gtgtggtggt gcatgcctgt agtcccagct acttgggagg ctgaggcagg  32400agaattgctt gaacccagga ggtacaggtt gcggtgagcc tagatcgcac cactgcattc  32460cagcctgggc gacaagagca aaattctgtc tcaagaaaaa agagaaaaaa gaaaaagaaa  32520tcaacactaa tatggtgaga cttaatgtat gtgacattaa aatagtgatt ggatgttaaa  32580acaggtatag aacagaaaga agagtgtatg tgtgtatctg tatgaattta tgatgggtgt  32640aacatatatg tattagggaa atgagggaaa tgatacattt ctctgacttt gggagaacat  32700tatatctcta cctcatattg caaacaaaca taaagttcag attaattacc taaatgtgaa  32760aaaatgaaat aatttcttta aaaaatgtaa tcttagtttg aggaaggtta acattataaa  32820ggaaaaaact gttttgagtg gaatatagtt caatatgtca aaatccacct tcaacaaaat  32880tgaaagtaaa ttgaacttgg ggaaagtatt gacagcatat agatcaaagg ttactagcct  32940gtgtaaagag cagttataaa tatcgttaag aaaaacactg tcgacctgtc ggcaccttgt  33000tctccgactc ccagcctcca gaactgtgac gagtaagtgc ttattgttta aaccacccag  33060tctgtatgtg gtattttgtt atagaaactc aagctgatta ggacactagt aatcagtaga  33120ctgaaactga aacaaaaata agaacctttt ttacctgtca aattggcaaa cattaagaat  33180attcagattt ttgtcagagg tgatacaacc ttctaagaag gcaatttggg aaaatataaa  33240gctttagatt attatatgtc tgacctagca gttttacctc tagggtgctt acccctagga  33300aagtgtgtaa tgatattggt gcagtgccct tcatcccatt agaaaattaa aaataacctt  33360aatggcctac cactaaaagg ggattgaaaa tttaagatat atttatttat gtgtttattg  33420agatggagtc ttgcactgtc cgcctgggcc agagtgcaat ggtgcgatct cggctcactg  33480caacctctgc ttcccgggtt catgtgattc tcctgcctca gcctcctgag tagctgggat  33540tacaggctca caccaccgca cccggctaat tttttgtatt tttagtagag atggggtttc  33600actgtgttgg ccagactggt ctcgaactcc tgacctcatg atccgcgccc ctcggcctcc  33660cagtgttggg attacaggtg tgagccactg cgcctggcca gatacattta tacaagagaa  33720tgttagttaa cattcataga tatttatatt ttgtttactt tttattaaaa aaattttttt  33780tagagacagg atcttactct gtcacccagg caggatgcag ttgcacaatc atagcccact  33840gcagcctgaa ctcctgggct taagtgatcc ttctgcctca gccttttgag tacctggggg  33900actttaggca gtgctactat acctggctaa tttttaaatg ttttatagat gagatcttgc  33960tgtattgccc aggctggtct agaattcctg ggcccaagtg atcctcccac cttggcctcc  34020caaagcgctg agattacagg catgagccac cacttctgac caatagatat ttatatttgt  34080gactggaaaa tatattaaca atgtgttaaa aaattcagtt aaaaaataat gaaagatttt  34140tgcttctggc taagatagaa taacaaggac agcatttatc ttcttgcctt gaaatagttg  34200aaaacggaag aaatatatgt aacagtggtt ttcaagttat tgggcatcag gcaaagaaga  34260atagttatcc caggaaaatg aatgtggaga gccctacaat ttccttacat tactgcctgg  34320tcatggcaag aggaaaaact gagaggagac tgaggctgag ccagtggttt gctgggttga  34380ggaggcagag ctgggagtgc agagatgcaa ggtggtgaga gcccatatgg aagaatacca  34440gggaagagag ctgcagaggg agctccggag acctgcaccc tgccctctca gtaccctgtc  34500atgtgtgtag ctgagtactg acgagcactt gcttgtgcgg aaatgaccca gggctggagg  34560tagagccacc tgaaaggatt agaaggaaca gttgctgaaa gtcacacagg gccaggaaga  34620atttctaatc acaccagttg gagtggaaaa cctcagctct catagagcag gtagggtact  34680cagaagggtt tgcccaccta gccccagact aagtttcgtt actctgaccc tacctaatat  34740taaaaagaga ttaattaaat tgttcgcaac aaaaataata tatttcagtg tttgtaacac  34800gtagaagtga attgtatgac aatagcataa aggctggaag agcagaaatt gacatgtatt  34860tgcgctgggc agaataatgc tcccctcttt ccccaaaaga tatcaagtcc taatccctgg  34920agcctgtaaa tattacttta tatggaaaat tgttttatga tgtgattaaa ttcaggatct  34980tgagatgagg gggctatctt ggatgatctg ggtaggcact aaatgcaatc acatatatat  35040aaaaaggagg cagagggaga ttttacacac agagagaagg ccctgtgaag atggaacaga  35100aagatttgaa ggtgctggcc ttgaaaattg gagtgatgaa gctataagcc aaggaatgca  35160gcagccacca aagctggaag aggcacggag cagttctcat ttagagccta ctccagaggg  35220aatgtggtgc tgccaattcc tttttttttt ttttttttaa gatatcattt acccctttaa  35280gttggttttt tttttttttt ttttttttta gtatttattg atcattcttg ggtgtttctt  35340ggagaggggg atttggcagg gtcataggac aatagtggag ggaaggtcag cagataaaca  35400tgtaaacaaa ggtctctggt tttcctaggc agagggccct gccacgttct gcagtgtttg  35460tgtccctggg tacttgagat tagggagtgg tgatgactct taacgagtat gctgccttca  35520agcatctgtt taacaaagca catcttgcac cgcccttaat ccatttaacc cttagtggac  35580acagcacatg tttcagagag cacggggttg ggggtaaggt tatagattaa cagcatccca  35640aggcagaaga atttttctta gtacagaaca aaatggagtg tcctatgtct acttctttct  35700acgcagacac agtaacaatc tgatctctct ttcttttccc acatttcctc cttttctatt  35760cgacaaaact gccaccgtca tcatggactg ttctcaatga gctattgggt acacctccca  35820gatggggtgg cggccgggca gaggggctcc tcacttccca gatggggcgg ccgggcagag  35880gcgcccccca acctcccaga cggggcggcg gctgggcggg ggctgccccc cacctcccgg  35940acggggcggg tggccgggcg ggggctgccc accacctccc ggacggggcg gctggccggg  36000cgggggctgc cccccacctc ccggacgggg cgggtggccg ggcgggggct gccccccacc  36060tcccggacgg ggcggctggc cgggcggggg ctgcccccca cctcccggac ggagcggctg  36120ccgggcggag gggctcctca cttcccggac ggggcggctg ctgggcggag gggctcctca  36180cttctcagac ggggcggctg gtcagagacg ctcctcacct cccagacggg gtggcagtgg  36240ggcagagaca ttcttaagtt cccagacgga gtcacggccg ggcagaggtg ctcttcacat  36300ctcagacggg gcggcggggc agaggtgctc cccacttccc agacgatggg cggccgggca  36360gagatgctcc tcacttccta gatgggatga cagccgggaa gaggcgctcc tcacttccca  36420gactgggcag ccaggcagag gggctcctca catcccagac gatgggcggc caggcagaaa  36480cgctcctcac ttcctagacg gggtggcggc tgggcagagg ccgcaatctt ggcactttgg  36540gaggccaagg caggcggctg ggaggtgaag gttgtagtga cccgagatca cgccactgca  36600ctccagcctg ggcaacactg agcactgagt gagcgagact ccgtctgcaa tcccggcacc  36660tcgggaggcc gaggctggca gatcacttgc agtcaggagc tggagaccag cccggccaac  36720acggcgaaac cccgtctcca ccaaaaaaca cgaaaaccag tcagacatgg cggtgcgtgc  36780ctgcaatccc aggcacttgg caggctgagg caggagaatc aggtagggag gttgcagtga  36840gtagagatgg tggcagtaca gtccagcctt ggctcggcat cagagggaga ctgtgcgagg  36900gcgagggcga gggcgaggga attccttaat ttcagtttag tgatactaat tttggactct  36960ggcctctaaa actgtgaaag aaaaaatttt ttgtttgttt gtttctttta agccacatag  37020tttgtggtaa tttgttacag cagctgcagg aaactaattt atgctgcatg tgaaatggtg  37080taataaggta gattgtgatg aagatacata gtataaacaa ttaagcaaca actaaaagca  37140caacaaggaa ttatagctaa tgaaccaaaa aaggagatta gaataataaa aatggtgaat  37200cccaaagaag ccagaaatag gggaagaggc aaataaagga aagaaagagc ttgatggtag  37260atttcaacct aactatgtca aaaaggacat tacatgtaaa aggcagcgat ttttcagatt  37320gaatggaaaa gtaagactcg gtatatgctg ctgcctgcaa gaaacacatt ctaaatataa  37380aggcaaaaat aacctacagg taacagaacg gaaagaagtt cactgtgctt acaagaatta  37440gatgcaagct agactggttc tgttaatatc agacaaagtg gatttcaaag caaaggctct  37500tgcccaggat gagatggtca tttcataatg atgaagggga ttcgttcatc agcctggcat  37560agcaagctga aatgtttatg caccggacta cagagctaaa atacatgaag caaagcctga  37620cagaactaca agtagaaaca gacaaatcca cagtgataga gatttcagta gccgctctca  37680atgatttgta gaacacgtag ccataatatc tggatctaga acacttgacc aacactgtcc  37740cctgtgcaac ctcattggca tttacaggac actccaccca gcaccagcag aagagacact  37800ctctcaagtg ctcacagaat gtttgccaag atagagcaga tgctgggcca taaaacaagt  37860ctctaaatta aaagcattca aattattcag agtatgtttt ctgacctcag tatcattaag  37920ttggaatata ttataggaag ataacctgga aaagcctcag atatgtggaa aaacccattt  37980ccacatggcc catgggtcag aagtgaagtc aaaagggaaa tttgaaagtc ttttggattg  38040actgatataa aaacaataga tttctaaact tgtggggtgc tgttacagca tagtaaatgg  38100aaatttctag cattaaatgc ctgttttagg aaagaaagat ttcaaatcaa tgacctcagc  38160ttctaccttt ggaaacttga aaatgacaag caaatggaat ccagagttac cagaagggcc  38220aggtacggtg gcttatgcct gcagttctgc cactttggga ggccgaggca ggtggattgt  38280ttgagactgg cagttgaaga ccagcctggg cagcctaggg agaccccata tctacaaaaa  38340acaaaaaaat tagccaggtg tggtggcatg tgcctgtagt cccagctaac caggagtcta  38400aggtgggagg attgcttgag tctgggaggt tgaggctgca gtgaactgtg attgtgccac  38460tgtgttccat cctgggcaac agaatgagac cctgtctcaa aaacaaaaac agttactaga  38520agaatggaca tcataaagat aggagcagaa gtcagtaaaa tagaaaacaa aaatacatag  38580gaaatcaata aaaccaaaag ctggttcatc aagaacatca ataaattggt aaagctgata  38640ggaaaaacag tgaagtcaca aattagcaat atcaggaatg agggagatga cagtagtata  38700gattatatag atattaaaag gactgtatga ggcaggtgtg gtggttcacg cctgtaatcc  38760cagcaccttg ggaggccgag gtggacagat cacctgaggt caggagtttg ggaccagcct  38820ggccaacatg gtgaaactct gtctctacta aaaatacaaa aattagttgg tcgtggtgct  38880gtgtgcctgt aatcccagct acttgggagg ctgaggcagg agaattgctt gaacctggga  38940ggcggaggtt gcagtgagct gagattgtgc cgttgcactc cagcctgggt gacagagcaa  39000gactccatct caaaacaaat aaataaataa aaaggactat atggtaatat tatgaacaac  39060tttatgccaa taaatttgac aacttataga tgaaatggat gagttccttg aaagacacag  39120aaactattaa agctctctca agaagatata gataagctga ttagccctat atctatttta  39180ttgaatttaa atgtaaaaat caatatttag ttactggaaa acttttaagt gtggttggaa  39240atggtatacg aactttttca actgaatttt atgaagtcta atcacaggta aaggttttct  39300gatgaaaatt tagtgtctga attgagatat actgtaaaaa atgttatata tcttaattat  39360ttcttcacat taattacatg ttgaaataat actttgggtg tattgggtta aattaaatat  39420tatgaaaatc ttgcctgttt tctttttact tttgatgcgt cagctaggaa atataaaagt  39480gtagctcaca ttctgtttct gttgacagta ctgctttgga gcacagtgtt tgaatgatct  39540atcatttcaa agacctttcc tcagttcgtt attcatggct gtctgtattc cacatagata  39600aggtctgaaa tactgctaag tggcatgttt tgttttatgc ttttataagt ttgttgatca  39660ttactgatgt ggacttttgg tgcctcttag gctcattgct atcttccaac cattgtttgc  39720aatttttacc tagagataaa gagaaagaga catttggttt cagagtagtt agattgggat  39780catgaaagag caacctcatt ttgatgcttc aaaaatagca catcccccgt attactggga  39840tttgctattc ttgggattac ttcaagaaca tccttgtgtt actggtttgg atgcttctga  39900atgctgtgaa gtcagtttca tgtacatggc tcatcagttt agctctctct tggctttgtt  39960tagacagttg gagcatgatg gcctaaacag cttctttcaa ttaaacattt taaaatagtt  40020tacaaatagt aaacaaactc cagtttttgt gactctttgt ctcgcacaac aaaaacacaa  40080tctgaccatg atcatctggc atcttagggt gaaatatggt tatactttgg cccataccga  40140aagcaagatt aaaaaggggc aggagagata gactgctgaa ctgattttca aggttccaag  40200aatattgtag gttaagagta aaagtaaact tttggtagaa agcagtgggt tgtctaggat  40260tgaagtatct gaagttttta aacgaaaatt taaaaagaaa aatgagaatt gccttacaag  40320tacaatctct tcttttttaa aaaataaact ttattttgaa atagttttag atttatagaa  40380aaaaattaga tagggtagga agttttcata taccctacat ccagttaccc cagttattat  40440catcctaatt tagtgtgaga cattttcatg tttaatgaat caatattgat atgctattaa  40500cttaagtcca gactttattc agattttctt aatttctatg taatgtcctt tttctgttcc  40560agaattccat gcaggacacc ggatacctca ttacatttca ttgtcatgtc accttaggct  40620cctcttgaca gtttctcttc tttttttgct tagaaattct ccagaatttc agaaacttct  40680gggcatcgct atggaacttt ttctgctgtg cagtgatgac gcagagtcag atgtcaggat  40740ggtggctgac gaatgcctca acaaagttat caaagtaaga accgtgtgga tgatgttctc  40800ctcagagcta tcattgttgt aggctgagag aagaagcgat cattgagtgt tcttctgttt  40860tgagtccctg aggatgtctg cacttttttc ctttctgatg tatggtttgg aggtgctctg  40920ttgtatggtt tggaggtgct ctgttgtatg gtttggaggt gctctattgt atggtttgga  40980ggtgctctgt tgtatggttt ggaggtgctc ttgtatggtt tggaggtgct cttgtatggt  41040ttggaggtgc tctgttgtat ggtttggagg tggtcttgta tggtttgcag gtgctctatt  41100gcatggtttg caggtgctct attgtatggt ttggaagtgc tcttgtatgg tttggaggtg  41160ctcttgtatg gtttggagat gctctattgt atggtttgca ggtgctctat tgtatggttt  41220ggaagtgctc ttgtatggtt tggaggtgct cttgtatggt ttggaggtgc tctgttgtat  41280ggtttggagg tgctctgttg tatggtttgg aggtgctctt gtatggtttg gaggtgctct  41340attgtatggt ttggagatgc tctggtatct gcctgcattg cttgccacac ctgcccggtc  41400agaaggcgct atgttgacaa ttgtgcctgc acggtgccta ggtcaatgaa gggaaccgat  41460ggtagccact ggatgctcct gggaaaatgt cactacaggc accagagaag ccagagctat  41520gcccaaattt ctatgagtct cagttttctt aaccataaaa tgggatcaat gtttttgtgg  41580catgtgtatg agtgtgtgtc tgtgtatgtg tgaggattaa attgtgtatg tgtgaggact  41640aattgccact actggatcct caaagtggta agaagtgttc ttattaataa tgacatcctt  41700acactcttac ccagcaagat tgatgggtgt ggcactgctt ctctttttcc atcacatggt  41760ttccatggta tccttttgcc cagggaatct ttgctttgtg gctagcactt tgttgtttgg  41820ctaatcacgc tttctgtggt caggacgctg gcttctctgg agccatggga ttctagctcc  41880ctgtcttgtc cctagagtgg tcactgtctt ctctctccgc ttgcaattcc tgctttgctc  41940gcatctcact tatgcagtga cgtatatcag tttcaccttg ttctccgtgc ctgctgatca  42000ttggcaccac ttgcatggtg ccatttaggg cctgcttcca gttaagcttg cttctccaca  42060ggcctaaata tccttgcttg cttcttttat tctcactggc aggaccaggg cggtctgtct  42120ttgcatgaga cagggtctcg ctcagtcacc caggctggag tgcagtggct gatcacggct  42180cattgcagcc ttgagctacc gggctcaagc tatcctcctg gcttggcccc ttgagtagct  42240gggactacag gcgtgcacca ccatgcccag ctaattttta aaattatttg tagagatggg  42300atctcgccag gttgcccagg ctggtcttga acgcctgggc tcaagtgatc ctccctcctt  42360ggtttcccaa agtgctggga tcacaggtgt gagccactgt gcctggccct tgatgtttca  42420gttcttgata tttgatcctc agagtcagaa aatctaaaaa gagggctatc ccaggttgcc  42480ttggttcatg gcaaatggga cgttaagagg gcagagagaa tatgaacaga aactgttcta  42540atattggtca tttaatgtgt aagtattgtt cttttttaaa cctccttcat tttttttcca  42600ggaattgctg gacacagtgg cttggtgtgt gtctgaggac tgtaggccat ggccctaggt  42660tgtggtttta ggtctcaggt gctcttcctg gctgtctcct tgcttctttc ccatgtcctc  42720ttctttgttt ccagccattt ctcccttatg cttaagtttg gtgcagcagg gtttggctgc  42780tctcagattc ctgcttcctc agatgctgta gttgtcaggc ccagcgggct ggcagcggga  42840tcaggatctg gctaggtttg ctctcactgt ggcagagtag ggggaggcgt gggagagcac  42900gtgtgacccc aggccagctg tagggagcat aggcatggtc acgtagcctt caggtcctag  42960actttgtctt ctcatgagta tggctgtgtg tgtatggtga aaactaggtt ctacttagcc  43020caagaaaatg ggcacatttt gcatgtggtt tctgtagaga aatgcactgg gtatctgaca  43080tagcctggca gcatgcctcc ctcaggtagg ttagtctcag gcggtgaagc acgtgtgtcc  43140agcaagaact tcatatgtgg cataaagtct ccgttctgtg aggtgctggc aaatcaccac  43200caccgtcaag aggctgaagt gatttttgtc tagggaggca ggaaaggctt cctggagtca  43260gcagccagta ggtgaaagag tagattggag accttcttaa tcatcaccgc ctcttgtctc  43320aaggggtgcc aggaagctgt ggaggctgaa cccatcttat gctgccagag agtgggacac  43380catgagggtc aggtcaaggg gttgtacctt gtttggtaga gaattagggg ctcttgaaga  43440ctttggatgt ggtcagggga gtgtatcatt taggaagagt gacccggtga ggacgtgggg  43500tagaggagga caggtgggag ggagtccagg tgggagtgag tagacccagc aggagtgcag  43560ggcctcgagc caggatggtg gcagggctgt gaggagaggc agccacctgt gtgtctgcgg  43620aagcaggggc aagagggaag aggccagcag cgtgctgcca tcacccagcg actggcgtag  43680attgtgagag accattccct gctcttagga ggggctgagt tttagttttc tcttgttata  43740caataagctt ggtatttgtt tacaaaacat ttgtaaagct aaatcaaggt ttgataaggc  43800ttctagtttt atttaagaag taatgttgaa ataaatgttt gtccaattcg ctttgctcat  43860ttaaggactt tcagtacaaa ctgcaacaac aggattagga tttaaacgtt tctgagatgt  43920ttttactcct cagaatttcc cagaatgtga tctggttttg attttcaagc ttgctgaccc  43980aataggttaa cccacaagtt ttacgaagac catctcagtc cacttacatc aactgcccat  44040gccacggtta aagagatcat cgactgatgt ttggcacagc ttcctccctc ttgggtgggc  44100aagcatttgg aagagaaggc tcctatgggt gagagtgggg caccaaagtc ttccctgtcc  44160catcccctag cttgagaagc ccttctctaa tgtggacttt gtgccgttag catcgttact  44220agcttgaagt tgaccatctg gacgtacttt ctggtttagc ctcacaagtg agcaaggagg  44280gttgagagat gtgctgtgag gaatgtgggg ccccagctgg cagcaggctc tgggtcaggg  44340gggcagggac cacgggcata cctgacagtg aggaggggcc acacctgcag aaaaggatgc  44400aggactccgc cttgggaagt gttctaggcc agagcgaggg tctgtggttt ataagtacac  44460ccacagtgct cgggaccctg cagatgtcca gggtgccgtc tgagcccgta tcatccaaca  44520gaatgttctg ctagtgaaga ttaaagattt actccagggg ctttaggatt tattatatat  44580atataaatcc tatatatata attttttttt tttttttttt tgagatggag tttcgctctt  44640gttgcccagg ctggagtgca atggcgtgat cttggctcac tgcaacctcc gcctcccggg  44700ttcaaactat tctcctgcct cagcctctcg agtagctggg attacaggcg cccaccacca  44760cacccggcta atttttgtat tttttagtag agacggagtt tctccatgtt ggtcaggctg  44820gtcttgaact cctgacctca ggtgatctgc ccgccttggc ctcccaaagt gctgggatta  44880caggcatgag ccaccccacc tggccaggat ttattgtatt tgaaccatct accattttaa  44940ttttgatgtt atgtagtatt tgatgataat gaaagttaaa ttgtttttct ttccattttt  45000ctgtttaagt gaatgacctg tatctagttt attcagtaac ttcctgcata tatttgtttc  45060tttcattctt aatgaatata ttcttaattt agttgctatt atgttttgct ttgccccaaa  45120attgaaatct tagtttcctt ttagctcgtt ttagaactag tgatgggatg tgtcttccat  45180aaatctcttg tgatttgttg taggctttga tggattctaa tcttccaagg ttacagctcg  45240agctctataa ggaaattaaa aaggtgggcc ttgcttttct tttttaaaaa tgttttaaat  45300tttaaatttt tataggtaca cgtattttgt aggtacatgt aaatgtatat atttatgggg  45360tacatgagat attttgatac aggtatacaa tacataataa tcacaccatg gaaagttgga  45420tatccatgcc ctcaagcatt tatcctttgt gttacaaaca atccagttac atgctttact  45480tattttattt tatttttgag acagagtctt gctttcaccc atgctagagt acagtggcat  45540gaccttggct cactgcaacc tccgcctccc gggttcaacc gaactttggg ctggtctcaa  45600actcctgacc tcaggtgatc cgcccgcctc ggcctcccaa agtgttggga ttacaggcgt  45660gagccactgt gccgggcctg attgtacatt ttaaaataac taaaacagtc agggcacagt  45720ggctcatgcc tgtaatccca gcattttggg aggctgaggc aggtgatcac ctgagatcag  45780gagttcgaga ccagcctggc caacatggag aaaccctgtc tctactaaaa atacaaaaat  45840tagccaagtg tggtggcggg cgcctgtaat cctggctact cgggaggctg aggtagggga  45900atcgcttgaa cctgggggtg gaggttgcag tgagccgaga tcacgccact gcattccagc  45960ctgagcgaca gagtgagact ttgtctcaaa aaataaaaat gaaataaaat tgggccgggt  46020gtggtggctc acaccttagt cccagcactt tgggaacctg aggcaggtgg atgcttgaga  46080ccaggagttt gagaccagca tgggcaacat ggcaaaacgc tgtctgtaca gaaattagct  46140gggtgtggtg gtgcacaact atagtctcag ctacttggga gattgaggtg ggaggattaa  46200ttgagcctgg aaggttgaat ctataggtag ctgagattgt gccactgccc ttcagcctgg  46260gcgaccaagt gagaccctgt ctcaaaagaa aaacaaaaaa acaaaaaaca aaccactatt  46320atcgactata tattattgtc tatgatccct ctgctgtgct gtcgaatacc aggtcttggg  46380cccttatttc catcactgag caaacttcac tctgttaagc agcaggtgtg ggatttcatc  46440gttattcagt aattcacaat gttagaagga aatgctgttt ggtagacgat tgctttactt  46500ttcttcaaaa ggttactctt tattagatga gatgagaatt aaaaatggta acttacttta  46560tatctttata attgaagccc actagacctt aaagtagtta ccagatgttt tatgcattta  46620aatggccttt tctctaaaat tagaaagtaa caaggaaaga aaatgcttcg tttctatgca  46680accctcttgg tgactagtat gtgactctta atgcaaccct cattgcaccc cctcagaatg  46740gtgcccctcg gagtttgcgt gctgccctgt ggaggtttgc tgagctggct cacctggttc  46800ggcctcagaa atgcaggtaa gttgtacact ctggatgttg gtttttgtcg ggggccagct  46860gctactgatc ctttatgtct cagctcagat gtcatttcaa aagtctgctc tgccctctcc  46920aaattgcagt cgaccttgcc ctgtttatgt ttccctcata gcactaatcc atgtcagaaa  46980ttgtcacgta cagtctatct gtgtgcttgt ttattttcta tcccaccctt ccgcaagaga  47040cttatgggat gtgtgcccca ggacagcagg ggtcttactg tcttatgctc tgttgcagcc  47100cagcagcgat aacagtgtct gcacatagta cttgcttaaa agatacttgc caaattgttg  47160aaggttgagg taccaatttc attattgctg actataggag ttatagcaaa atatccattt  47220gtctgttaca tgagttaaaa atatggttgt tgcactgtga atagtttggt ttagtcaaaa  47280cagttgtatc ttaacggatt gagaaacaaa agcaggacca cttttcatca gctccctcct  47340tctccttaac cagcaataca tgctgatgct gatatcccat agaccctcag ctccatcctg  47400agtcactggg aatgtggtct aaaccctcac tattaatatg aactgagttt caataagaat  47460cttatatggg tcgggcatag tggctcatac ctttgatccc agcacttcag gaggccaagg  47520caggtggatt gcttgaccca gactaggcaa catggtgaaa cgccgcctct acaaaaaata  47580caaaacttag ccaggcatgg tggtgcgtgc ctgtggtcac agccactcga gaggctgagg  47640tgggaggatc acttgagcct gggaggtgga ggtcgtgttg agccaagatc gcaccactgc  47700actccagcct gggcaacaga gtgagacctg tctcaaaaaa accaaaatcc agaaaagaac  47760ttatatggct gcagaggtat aatcactaag gaaatttcct tttgtataat cttttttctt  47820ttactatcat ttaaaaaaat gtgttatatt tctgaagcaa cacatccagg ttctgcacat  47880agcagccaaa gtgaccttaa agaatataac tgggtcttgt cattccctta tttaaactct  47940tgtacccatt tcccagtgcc gtttagatag agattccaga ctcgtcaatg gctctgtcac  48000ctcagacacc ctgcattgac tcattagtct gattagagtc aggtttttct tcctcctgat  48060ggtttttttt tcccccttag ttctcagcgg aacagtcact tccttaggga ggtttcccca  48120gccaccctct gaggccgtgc ttgttgccag actctgccac tagagggcag ggctgcacca  48180ctcctggcac ctcgcacccg gcctgccctg tcactctgtg tgttgggtga attcctgtga  48240tctgtgactc actgctctgt gtcctacaca ttcggctttt cttctctccc cacaacccca  48300ttttataatt ctcctttttc aggaaagctt tattcccatt taaaaatttt tgtttttaaa  48360atggtatttt cttacactta ttttctaatt aaaaatgagt gttttaagaa gtattatgat  48420ttactgcaaa taatttttaa acccagcctt ttagatcctc tgtgatcata agagaaatga  48480aggatgtctc ccaacacttg agcttcatcc acatttcatc ctcctgttct ttcagctgag  48540ttttccccat cccattaggg actgttggaa tataaaactg gcttttccct aacagggaat  48600gaattgcttc tgtttctcct gaaggagagc tggaagaatg acttgcgttc ttttgcatac  48660acaggcctta cctggtgaac cttctgccgt gcctgactcg aacaagcaag agacccgaag  48720aatcagtcca ggagaccttg gctgcagctg ttcccaaaat tatggcttct tttggcaatt  48780ttgcaaatga caatgaaatt aaggtatgat tgttgcctca ggtcacaaac atgcgagtga  48840tgctgtgagt gagtctgtgg agggtgaggg cttctgaaca gggagtcctg tgggagtgct  48900tcttggggta tgttgtatgt cgtaatttag actaccatca tttgtgttat ttttgaggca  48960cctaaggact tctttccact tctcatttct tactgtgggg tgaagagttg aattgggaga  49020tggtttctag atgcaaattg aaaaggcatt tttccagagc agatttgttt tcggcgtact  49080agagtgactc tttaacctag ctgcgggaag atgactgtgc caagactgca ggtaggagaa  49140agctcactga cgaggccttg tgggtctgaa cgtcctgcag ctatcagagc ctgttggctt  49200cctgttgtgc attccaacaa atcatcttca aacccacttt agtgttttgt ttataatgtc  49260cagaaatagt gaccctgtca catgctctac agattacagg attcttagcc tcttcctttt  49320tggtaggtca gtcctgggtt tgagcccaag tgaccctcct gggaggtgat gatacacact  49380gggtagagtg gaatcagatg gacttggatt agaattctgt cctctttact agttattttc  49440ctctaggcaa actgcccaac agctctaagc tatttccttc gtattctgaa aaataagcct  49500taatgggacc catatagggc aactctgaga gtaaaataaa ggaatatgtg ttagagtgta  49560gcatagtcac ccacgggaag ggcttagatg ttagctgcta ctgctcttat tagctgaatg  49620atttggaata aactgttagc ctctctcatg ttttttctct tgagcttcga agttttcttg  49680ttaatactaa ggagatattc aaactagtca tggggttttg gaatgacgaa gggagatgat  49740gaatctaaag aatttagtgt aatatttctt catgctcagt aaatggtagt ttctgctgct  49800gttattttta ttaccatctc tttggaatgg gagtaggtgc tcctttgtgg tcagaggctg  49860tgagagctcc acagcgccag tttgcccatc tgtacactgg ggtctgttga aggcagtccc  49920ctctgtgata tctctggctg tcagagctca gatgatagat ggtatttttg tactcttagt  49980tctcatcatt ttcatgattt cgatcaccat ttgagtatga tgatgctaac actttgttga  50040acgtagaatc cgttaattac ttccttcctg aacctttggc attaaaaaaa atctattctg  50100ctacctctct gctcatttat ggttattcaa atttattatc aagagcctgg tacagtggct  50160tgtgcctata attgtagcta cttgggaggc tgaggtagga ggattgcttg aggccaggag  50220tttgagacca gcctgggcaa gatagtgaga ccctatctct aaaaaaactg aaaaaaaatt  50280agctggacat gatggcatgt gcctgtggtc ctagctactc aggaggctga gacaggaggc  50340tcggttgagc ccaggagttg gagttcgagg ctacactgag ctgtgattgt gccaccacac  50400tccagcatgg gtggtaaaac aagatgccat ttcttaaaaa aaaaaaatat atatatatat  50460attatcaatg aaattcagta gtaccaacag gattataaac aaagatagta gttcccttcc  50520tactttttct cttaatcctt gtgtctcaca ggcaaacata actcttagta tttcttccaa  50580tatttacttt catgtttctt tctttctttc tttttttttc tttgagatgg agttttgctc  50640ttgttgccaa ggctggagtg caatgacgca atcttggctc accacaacct ctgtctcccg  50700ggttcaagcg attctcctgc ctcagcctcc tagtagctgg gattacaggc atgcatcacc  50760acgctcggct aattttgtac ttttagtaga gatggggttt ctccgggttg gtcaggctgg  50820tctcgaactc ctgacctcag gtgatcctcc cacctcagcc tcccaaagtg ctgggattac  50880aggcgtgagc cactgcgccc agcaacttcc acatttctaa ataacatgct tctactgcta  50940tttttttttt caattttaga cattttttta ctttcactat agttctatca gaattcagtg  51000tgtacgttat tatgcctaag taaatagtca tggttgctta cgtattatat ttctttgatt  51060gtgtttctta tttgatgaga aagctgtgtt ttttgctctg ggttgaaact ggagagagga  51120cctggggagg aggaggagga cagatgaagt tggtgactgt accttcatgg ccatagctgg  51180gttctcagca cccggggatc tgctgatcac ctactcatag gccaggcccc tatcgaagtt  51240ctaggtgacc cagtgctggg gacggggggg ccacctgcaa ggtctaatca tggaggtggg  51300ggctacagtg ttggcttgtg ctggggccag catccttagg aaggcatctt ggaggtggag  51360gagacagccg cccacttctt gattggggcc ttcagcagca ccagcttctt gggcaggctg  51420gtgctggctt tcatcaccat gtcgtgttca atcttcttcc agatcctgac ttctaggttc  51480agctttcctc agaccctggt tcctttcaga ggccattgct gctgccttgc tctttgctgg  51540cttgtgcctt gattatatgt ctttgtacaa ctttttgttt tcctggagtt aatcttcaca  51600tctgttttct tggagttaat cgttacctct atatcgcttg cttattattc tttggccttt  51660ttgtcttctc acaccttcca acttctttgt aatatgtgtt tagtacaatt tttcatgaca  51720ggtagtttac tgaatcagtt tttccccagt gtggtcatcc aacttgagtt atccagctct  51780ctgccccagt ctgggcaggt tgatcttcag gtctgtagta cacttgtatc ctaggacttc  51840tctttgccat tagcctggaa tttcctttgc agttctcccg ttggatgccc agttcctaga  51900tgccatatgt ttttctatcg tctagtagct tcctgagaga agatgaatgg gagggaaatt  51960gtatgaggtt ttgcattcat aaaaatgcca ttttttttcc tgtacacttg gctgggtatg  52020gtgttctggg gtagaaatca ttttccctca gaaatgcaaa gtctttgccc tgttgtctta  52080aaatctccaa cgtgacccga ttccttaacc tatgaatgta cttttctttg gaagctttcc  52140atttttgggg aggtgaagtg ctaggtactt agtaggcctt ttaatttgga aacttacatc  52200ccttcagttc tgggaaaatt ttcttaacat ttctctgaga agttcttgcc ttttattttc  52260tgtgttctct cctgaaattg gttagttgga tgttggtcct cctagattga ctcacatctt  52320acctttttct tttctttttc tggtactttt tagatatcca tctcaaactc ttctattcat  52380tgttatgttt ttaacttctt tcttttcttt gtctcttgat ggggtcttgc cctgttgccc  52440aggttgtggt gcagtggtgc gatcatagct cactgcagcc tcaaattcct gggctcaagc  52500agctgttctg cctcaccctc ccaagtagtt gggactacag gtatgcacca ccacgtccag  52560ctattttctt tacttttttt tttttttttt tgagatggag tcctactctg tcgcccaggc  52620tagagtgcgg tggtgggatt ttggctcact taagcctctg cctcccaggt tcaagcagtt  52680ctcctgcctc agcctctcaa gtagctggga ttacaggtgt gcaccaccat gcccggctaa  52740tttttgtatt tttagtagag ccagagtttc accatgttgg ccaggctggt ctcgaacgcc  52800tgacctcagg tgatccgcct gccttggcct ccgaaagtgc cgggattaca ggcgtgagcc  52860catcattaga tctttaaata ccagtatcta taagtctttt cctcttgagt cagctagtat  52920ccctggaagg aaattactca ttttcctgct tggaggctat aagcttggct atgtttatcc  52980tgcaaccggg gactggaagg gaggggactg acagtgttgc tggtcagggt gccctcttac  53040tttttgtttt ctgtgtgcat ctcacgtctg tcctcagcct atgtaaacac ctcttgagat  53100tatccctctc aatctttgcc ggaggtgggg gaggggctgc ttcctgggct gccttggatt  53160ggagggaaga cctcaggtga gtgggtggga atttgcccaa ggagccatga gaccagccac  53220tatttcaccc tctccatccc tccactttca gatgtatgtg gcgcctccaa agcccgagct  53280cttcttggcg tctgtggctt caataagctt gctttttgct ggtatccctc ctaccctccc  53340ctgtccccag caaagcttgc atttgaactt cttcctacgg gctaacaaat cagtcagtta  53400tgtagctctt gttacttttt agcttccgaa gttttgttga cacccgtagt ctgctaatgt  53460ccctgttctg ttctttctgt tcgtgtaaat atatgcttta tacaacttct ttacatgatt  53520tttgtggggt ttctgggtag cagagcttca caagttcaat ccagcgtgtt ggattagaaa  53580tctcccaccc tctggtttat tcttattctc aaaattacct gccaaacact gatactccct  53640tgtttttcct tttcctgaca ggaaatgtac ataccataca ggacagaaat cattagtgta  53700tcccttggtg aataaccaca aagtgaactt aacccttgta accgccaccc aggtcaagac  53760agaatattac caagcactca gaagcctctc ccctattccc ccgtcactgc tcctgccttc  53820ctccccaagg tcatgactgc tggcttctaa ttccagagtc tgtttttaaa ttctgtgtac  53880atagaccatg gattaagtgt tctttttgtc tggtttattt tggtcgacat taagttcatg  53940agagtcttct atattatcgt gtgtattagt attcctgtag ttttaggagc ttcatagcat  54000tccattgtag ggatatacca cagtttattc attgtattat cactgggttg tttctagttc  54060ttggctattg cgagcagtgc tactgtgacc actcttaggt gtgtcttttg gagtacatgt  54120gcaggtttcc atcttgcaca gctagaggtg gagttgttgg gtgatagggt gtgtgcatct  54180cagctgcagt agaaactgcc aaatagcttt ccttgagtgc ttgtaccagc tcaccctttt  54240gccactgtgt atggggattc caggagctct ggtcctcgct agcacttgga attgctgatg  54300cttttactct tagccttcct gatgggtgtt ttctggaatc acattatgat tttaatttcc  54360attccttaaa gtacccttgg ctctgaagtt taatgattca tgcatctctt cccttttgaa  54420gtactcttac aggtatgttg tgcatgtgtt gaaaagtggc actatctatt ctaaaataca  54480gtatgcctcc tctgtgtttg aacagttgta gcgtggcctt ggggcctcct gttagctggc  54540ttggagaagg gattcttggg attgtagaga ttagacctga ggaggcccct tggagctctc  54600tgactaaatt ttattcttta ttattccaaa ctatttaagc tcaccgtgtg ctgactcatc  54660ataataatga gtagctctca ttgtgcttgt ctatttggac tcatacaatg attttttttt  54720tttctttgag acagagtctt gctctgttgc ctaggctgga gtgcagtggc acaatctcgg  54780ctcactgcag cctccacctc ccaggttcaa gtgattcttg tgcctcagct tctcaagtag  54840ctgagactgc aggtgcgtac caccatgcct ggctaatgtt tgtattttta gtagagacgg  54900ggtttcacca tgttggccag gttggtctca aactcctgac ctcaagtgat ctgccttctt  54960cagcctccca aagtgctggg attacaggtg tgagccactg agcttggcca aagtagtttt  55020ttaagatgtt agtatctttt cttgcagcta aaaaagtttg tcagagatga ttctactttg  55080ttctccaggt gttttctcag ggagaaattg gaggcagtaa gccactgggg gagtcctgtg  55140gctggggggt ggggtagtcc tgtggctcct tgtcagggag tcctgtggct ggcaaggaga  55200gaagtcctgt ggctgggttg ggagggagtc ctgtggctgg ggtctcatcc tgtgcctaac  55260agtgtccaga ggtgccgaga ccagctcagt cggggagacc ctaacccagc agcgctagag  55320gaattaaaga cacacacaca gaaatataga ggtgtgaagt gggaaatcag gggtctcaca  55380gcctttagag ctgagagccc tgaacagaga tttacccaca tatttattaa tagcaaacca  55440gtcattagca ttgtttctat agatgttaaa ttaactaaaa gtatccctta tgggaaacga  55500ggggatgggc cgaattaaaa gaagaggttg ggctagttaa ccgcagcagg agcatgtcct  55560taaggcacag atcgctcatg ctattgtttg tggcttaaga atgcctttaa gcggttttcc  55620accctgggtg ggccaggtgt tccttgccct cattcctgtc aacccacaac cttccagtgt  55680gggcattagg gccattatga acatgttaca gtgcttcaga gattttgttt atggccagtt  55740ttggggccag tttatggcca gattttgggg ggcctgctcc caatacagag gtctcgtgta  55800aattccctgg gaggcgataa gcctctgaga aacagactat gctaaccacg ccatgaaaga  55860gaaacttatt tataaatcag atgccagtta ctagtttact gcttatttgc ccaggcgtag  55920ctctgacaga gtccccgact catagtgctt gctcagtgca tgctgaacaa tgattggaat  55980caagtcatgg ctcagagcat agttttgaat aatgggaaat ggatgttctt aagtaacata  56040gtcaccaaga taatgcgact agctgggtca ccccttttca attttaggat atttttatca  56100agatttaaat ggccatcatt agagttatag cactttctcc tttggattgt cctagaggcc  56160catgagaaag tattccctaa tttcttagga gaacagtttg tgggtagtat gcggtcatgt  56220ccagttaaat tgcagatatt tccgatcgaa gatgttccag tcctgagaac ttcgtgacat  56280tagcaggact tctacaagcc atctcttagg gtggggcatt tactgcagtt ggctagtact  56340cttttctcct taactttgtc atttgttgat ttttttttaa ctgtccccaa atactgtggg  56400cagagtgtat ctagaattga ggcctccacc attgcggaga ggacatggat gctgagcagt  56460cccctgagtg aaggttataa agaagcaaat agactacaca tgtctgtaaa ctgctcttga  56520gtgtcccaaa tttggggtac ttcagttcag ctgtaggaaa agcctcaaac tgtttatact  56580ttgcaagaat tggaaacttc taattcacgt taagttttat gtaatacatg ataagcttca  56640taggagcttc atcttttatc tacttggact tttgcttccg taggttttgt taaaggcctt  56700catagcgaac ctgaagtcaa gctcccccac cattcggcgg acagcggctg gatcagcagt  56760gagcatctgc cagcactcaa gaaggacaca atatttctat agttggctac taaatgtgct  56820cttaggtaag gtggaggcat atgagtggaa gagtctccag catgtactca agatagacct  56880ttgaaataaa taaaaccaga tgatccctca gcttctagac caggctattt ggcactggtt  56940gattgaatgt gaactgcact ggggctgctg tgagcccgca tgggtctctg tgaccctgca  57000gatgcagccg tgcccaggga ctgggcagtg ggtgtgggct ggtgtgagcc ctgtctgcca  57060cccagggcct ggccctctgt ctgtgtcggc catgactatg gtgagtcttg taggcttgag  57120actgtgcctc gggttcctgc gggttctctg taggtcagtt gacagtttct cctgttgttt  57180gggtaactgt ggaaacgaac actggcaagt gctgaagcga gcatgtggac gtgcgatatg  57240aaataacgac ctggctttca aaggcagtga ggctctctgg aaaggacctt gctgagctag  57300ggatgtgggt gtgtagccat tcccagtggg cctcatggcg tactcgttca tgatcatgtt  57360tgtgccatct tgatctctca ggatctcttc ttttttaaca gattaagccg ggaatctcca  57420aacagtgagt cagatgttaa gatgtcttgc ttccaccccc acaggcttac tcgttcctgt  57480cgaggatgaa cactccactc tgctgattct tggcgtgctg ctcaccctga ggtatttggt  57540gcccttgctg cagcagcagg tcaaggacac aagcctgaaa ggcagcttcg gagtgacaag  57600gaaagaaatg gaagtctctc cttctgcaga gcagcttgtc caggtaggag cacagggttt  57660actctaggcc ctgcatgtga atgactgaca ttcaaagaac cgattaattt ggaagagaag  57720cggcagaacc gagagttaga ggtgtggact ctggagctgc gctgctcgtt tccaacccta  57780ggtgctgacc tctagctgtc ttccctctgt atgtccctgt caccgtgagt caaatgcggg  57840tgatgcctcc tcaggtgccg tgttacctaa gcctctcaga gaccactgct accctgtttc  57900taaaaccaga ggtcacgata tgtgttcatc cacccagtaa atactgattg agcacccact  57960gtgtgctagg ctctgggata ggggctgggt atacaatggt gagtatttca gctgcagctt  58020ctgccccgtg gaggctgtgg cctagcacac tggtctaggc acggtggtat atgctcactc  58080aaggagatag ggacgtggtc gtttggggtg tcggaacaaa atgtcggaac ttctctttcc  58140aatgcagaga aaccttgcag taattctaat gtactgtgat tggcagttga cttcagttct  58200ttgtagcacg cttactcagg ttatttcact aactatgtaa ccatgcagcc tcattttaag  58260caattggatt ttttgaactt tacttaaaat gttatgtcag ggtttttatt gtgcttaatg  58320tgtgccattt agctaagttt tgtaggatac gaaattgtaa gtggcttaaa atgattctta  58380atagaatcat gaattgaaga taatgctaat aatttaagca ctgagttagg tagtgtttgt  58440aaaatgctta gaatgcttcc tggcacatgt taaggccatg taagtgctgc gtgttgataa  58500acagctgagc aaaagtggac tcttaagaaa gtattggggc tgagagttct gttccaacca  58560gctgcccttt ggttattttt cagaataaaa gcagagtctc atgggatatg acatttatat  58620ttccttcaca aaaaacactg ctgagtgttt tgttgagtaa aaagggtgta gccatggtaa  58680taatacattt aaaatatagt ttatttcatc tttaccttgc cttgtttttt ttttaagcta  58740gctttttatt gagaattcca cacatacaaa agtatcaact catgaccagt tatatttcat  58800ttataatcct acttctccct ttttttatta tttgaaagca aaccccaatt atcctcttat  58860ttcatctata agtatttcag tatctctata gatgaggact cttctttatt tttaaaactt  58920tatttttaaa atgatggtca gatgcagtgt tcatgcctgt aatcccagaa ctttgggagg  58980ccaagctggg cggatcactt gaacctggga gtttgagacc agcccgggaa acatggcgaa  59040accccatgtc ttaaagaaaa aaatcagcca agtgtggtga tgcatgcctg tagtcccagc  59100tacttgggag gctgagatgg gagggtcaca tgagcctgga agatcaaggc tgcagtgatc  59160catgattgta ccactgcact ccatcctggg tgatggagca agattctgtc tcaaaaaaac  59220aaaactgcaa aacaacgtca caaaacagtg ccattgttag acctgaaaat attaaacatt  59280tcctacatca aatacccacc aactcattat caatttttct ctctactctt ttggaatcag  59340catctaaata aaattggtcg ataaggattg taaatctctt tgatgaactg gttcccctcc  59400atcccagttt ttttccctta gagttcattt attgagaaac cagattgttt gtcttctaag  59460ttttcctgtg gtctgatata ctgcttccat ctccactgtg taaattaaca cctttttctc  59520ttctctgtat ttcctgtaaa tcaataattg gaggaaaagc cttgtcagat ttagtgtata  59580ttttatatct gagtccagta tttcttatat aatattttaa gataagtgta ctcttttaaa  59640aagtattgaa actatatgct caattttttt taactgatgc ttttaagaag gctgcttgat  59700cataaaagtt tagagatcat tggtctgatg ggaaaagcaa ataattacta aaccgtttag  59760caaggttgag gtgcacatgg tggggcctgg agaagttcag tcatgagccg tcacttatgg  59820gcacgtggaa tctgacccgg cacagagttg ggagaagaca ggagctttat agacagaaaa  59880tgtggtcttt gctaagtccc aggagtgaaa gggtgagaca gtgctcacag cacacgagtg  59940tgggtgcgta gacagagcaa gggtgggtcc tgaaaaggcc tgcaggcttt ctcatagatt  60000agcaagagtg ctggttacgg aggtttctaa catttgtgaa cagatcgaaa ctgtgttaaa  60060ttgggattgc agtaatcctg gaaggacagg gatagagggt gaaggggaaa aaagggtatg  60120gatgtgagac ttaattgctg attttcttaa gacctttctc caaagtaaat aaatgatgtg  60180gcacattttt gaactggcaa attctaaact ctagatatga ttatctctat aacatatctt  60240actccatctt cttttgacta aaaactgttc ttaattaaat taccatgaga cgttcaattc  60300agcaaatgta gtttggctaa ccatatttaa ttagaattta atataatcct aggcctggcc  60360aaactattaa gcaagtgtgg gcaaaatatt gataatttta gatatgcagg aacttagttt  60420gctttccatg tgtgcttttc gaaaaaggaa taaattgaaa aatagaggaa gccctgaaat  60480ccaagaagca aactctctca cctaggcatg cagtaaaagc aattctagga tgattgctgt  60540ttggcgcgta gttcgtatta gaaaccattc ttcttgaata aatagtatgt ttaagaagct  60600gggcagaggg aaggcatatg catatattat caacaaggag ggagaaaaag gcaattagta  60660accatccata ggagggtcag caagatttat aaaggaaatt tgtgatccaa gtatgaagca  60720aaataaggtg cagaataaat tttaagcaag taatagatta gagtaagaga acccatttga  60780ccattaacct tgggacattc tctttcaaat gacatggagt agtactgaaa tctttctttc  60840tttctgagtc taggttattg tgactggact cagaaagaaa tatttcatta ttgcagtgaa  60900taacatttgt gaacattatt gttcataaat tatgcagtga ataacattta tgaacacgtg  60960atgtgtaaga tacatactgt ttatttttag ttaagttttt tggctcaact tctaggcaga  61020gaacattaaa tgtaaatagt gttacctagg agcatgtaaa tggaaatctc catagtatga  61080aagcagtgct gttgctaaca gaatttagga gggggcagat gaggtgaagg aaatgtgggt  61140gctgatttcc ttattacatt gagaggagcc aggagattct ttgttcaaaa tggatggctt  61200aagaagtcaa agtataagct gattacgtag agcaggtacc caaaaatgtt ttgtgtaagg  61260ggccagatag taaatatttt cagtcttgca ggccatccca agtctgtggc agctactcaa  61320cactaccttt gtagcatgaa agcagccaca ggcagcccat aaatgtggct ctgttccggt  61380gaaactttag gtacaaaagc aggtgcaggc cagacctgac ctgtgcactg tggtttgctg  61440acctgggatt caggggtata gaagttacca tcagaagagc taaaagtgag actttttact  61500ttatactctt ctacactgtc tgattttgaa aaaaagaaac atgtatttta taatattaaa  61560gatagggttg gcaaatagca aataaaaata cagaatacca gtgaaatttg aacttcagat  61620acattatgag taattttatg gtgtaagtat attccaaatc atgtgggaca tacttacact  61680acaaaattat ttgttgtttg tttacagttt aaatttgagt gccttgtatt ttatctggca  61740actgtaatta aagggaaaaa gaataaattc attatgttca tataatgtga tatagcaggg  61800gtccccaacc cccaggctgc agagtggtac tggtccatgg gtccccaacc cccaggctgc  61860agagcggtat tggtccatgg cctgttagga accaggctgc ccagcaggaa gtgagcagca  61920ggtgagctgg cattcccacc tgagcaccgc ctcctgtcag atcagtggca gcattagatt  61980cccataggag tgcaaaccct attgtgaact gcacatgtga ggggtctagg ttgtgcgctc  62040cttatgagaa tctaatgcct gatgatctga ggtggaacag tctcgtcttg aaaccatccc  62100ctggccctgt ggaaaaattg tctcccatga aaccagtctc tggtgccaga aaggttgggt  62160agcactgtga tatagtatta aaagtgctaa taaatatggc atactgcctt taaaatgtct  62220ggtagctctt tctcagtggc actcataata gtgttttttg atttttaaat gtgtgtcaag  62280ctgactctcc cctccgtgta tgctgggctt tattttccct ttcctagtca ccagttttgg  62340gaaatagaga tcttcattct catgctgctc ctctagtgca agtgctccat ttatttttaa  62400ggaattaata taacaaaaaa tcatgggaat ttagaaaaca acatggaagc taatgatcac  62460attggtggaa gtgataggga aatatttagg gggagaagtt aaggtataaa ctttgtcaat  62520gaagtcctat taaaaacaac aaaaaagtga agcttaggat gcattttata aactctgacc  62580agaacacctg tgtttctctg tttctaggtt tatgaactga cgttacatca tacacagcac  62640caagaccaca atgttgtgac cggagccctg gagctgttgc agcagctctt cagaacgcct  62700ccacccgagc ttctgcaaac cctgaccgca gtcgggggca ttgggcagct caccgctgct  62760aaggaggagt ctggtggccg aagccgtagt gggagtattg tggaacttat aggcaagtta  62820ttagcaaggt ctactcttac aattaacttt gcagtaatac tagttacact ctattgatta  62880tgggcctgcc ctgtgctaag cagtctgcat tccatcttcc ttgccaaaac ttataataca  62940aatttcatct ttattttata aataggggag ttgggctggg tgtggtggct cacgcctgta  63000atttcagcac tttggaagga tcgcttcagc ccaggagttt gagacaacct ggccaagtga  63060gaccctgtct ctacaaaaaa aaaaaaaaaa aaaaaattag ctgggcatgg tggcacatgc  63120ctgtagtccc agctgctttg gaggctgagg tggtaggatt gcttaagccc aagaggttga  63180ggctgcagtg aatcttgatg gcagctgcac tgagcctggt gacagagcaa gatgctgtct  63240caaaataaat ttaaaaataa aataagagaa ttaaagttta gcaggttggg tggcaaaatg  63300aggccacaca tttaaagccc ctcctcctga ttcttttctc tgccttggct gcctcctgtg  63360gcattttagg tgctgagaaa tgaaaacagt agggaaaata gttccaggat cctcatgtta  63420atttgccaga aatggcatct tcaagtcgtc agagggatct gagagttcct tcctggcctg  63480acttgagaaa atccgtctgt ccccagctct gcgtctgcct ccactgccca gtcacctcct  63540ctccatgctc ttggggctgg gccctacccc accatgcagt gctgccctgg agcagtgagc  63600ttggtgggtc ctgtctggca tgagagctgc ctttgggagc tggatcccag cctctaccac  63660tgggtctggt gcctagcagg ctatggataa acttctgctg actccggcct ctcctaagcc  63720actgcaacgt ggtcggtgta gtgcacagtg tgtgtgcagc gtggccttac tcacagcctc  63780cacattagag agaatctgac tgaagtctta ctgctgcctc gtgtgaacat aaatgtttgc  63840cagaaccatg agcaggaaat gttaatctgc cttgtttcct gtcctttaca cggaagaatt  63900tttttctgta tggaatgcgt gccttacaaa taatgagtgg aaatacccat cgctaatgaa  63960aagttatact tgactgttag tcagctaaat aatctgagat ttctaatact tttaatttgg  64020cttttacaat gcaatttatc ttagcttttt tgatttctta ggtcatatct ttagaactat  64080atatttgaat gttaatgtaa ttttcatatt gaaattaaaa tgttgaactg cgatgttaag  64140tgtttcctgt ggaaaaacgt tcacattttc tctagtttta aagttgaatc aagctgtttg  64200aagattttca catttcttct agattttatc agcttgttac tttatctgtc actttctgtg  64260atttgcagct ggagggggtt cctcatgcag ccctgtcctt tcaagaaaac aaaaaggtga  64320ttatttcaga aatcagagtc ttgtgttgaa tcttactgat tttcttgtat ttctgtaatg  64380taatgtatct tgtatttctt gtaatactgt attggactct gtgtatatct cttctcagat  64440gagtgattat atgtgtgaat gttgctggaa tctgataacc aggcctgaat agttttgtag  64500ggtggctttt aaaaattact ttcatatcag aattgctttg tcataaattt tgaacgcatc  64560ataaatttct aatgttcggg gtcagcagac tttttttgta aagggacaga gtgtaaacat  64620cttagcttta tgggccatat ggtctctttt gcaacattca gctctgccct gtgacaggaa  64680tgcagttgta aagacatgag ctactggcca gctatgttcc agtagaactt tacttacaga  64740aacagacagg ctgtagtttg ccaatacctg ccttagggaa tgtgttgtta tattttgtga  64800gttaccttct cagtaaattt tatttagtat tagtcaggaa tattattaag tagcttcttt  64860tccagcctgg tcaacatagt gagacccggt ctctaccaaa acaaaacaaa acaaaaaaac  64920agccacgcat gtggcatgtg cctgtagcct cagctgctgc tcagggggct gaggcaagag  64980gattgtttga gcccaggagt ttgaggtcac agtgagctgt agtcatgcca ctgcactcca  65040gcctaggcaa cagaatgaga ccttgtgtct taaaaaaaaa aagtttcctt tgttgggtta  65100ttttaatttg gacctggtta tcatttttca gccatattta actttgtaca tatcagaatg  65160ttctgataaa acttaacttt tattaaagtg tttgtgatat aatctgctag ttttggtaca  65220cattatcttt tgcaatgcca gttattttct tttccagtgt gggtttgcat aggaaaagaa  65280ttgctgtcac tttctatttt gaaatcttaa aagactgatc cttttttgtg tcatgatttg  65340agtatttaat tgagagccta atgcctaata ttatttgcag tattaaatgg gatcttaaca  65400ggaatagcat tctagccttc attgaattaa gtaaacattt cttaagagaa cttggaatct  65460ataatatttg cgtcatcata gtatgagata cttaatcaag tttgagattt tagtgaaaca  65520ttgtttagaa gccaaaagga ttctaggaaa aattaatgtc tatattcttg aattaggaga  65580gattttggga cgtgtgacta agttacgctg acacttgttt gtttcttagt cgctttttcc  65640agtggcggtg agaacgaaga tgactgattc acattgctca gatgagttta tcctcttctg  65700gctgggacat gggatatatc ctgtctcttt taagcctttt tggtattttt cccccattga  65760gagctgtgtc ttcaaactct tctgttatag ctggaaaatc ctttttaagt gaaatctgcc  65820caaattataa gacagatgaa ggtagagttg tgttggatat aggattaggg tgaaagtagt  65880gggggtgtcc tggagcctct cttctggtgg cagcctagct cttgtgcctt tgaggaaatt  65940accctgggga cggctctgtg gaacatattt gcaaaccact gatttggaag atagagatgg  66000cttttgttaa gatctgaatt cacctttttg gcattttatt tgatttctca aggtaaagaa  66060cttattttgt aataaagttt cctattattt agtagatagg ccaagttgct gtgttaattc  66120catgtagatt ttgggtttcc tttgctcatt ttttcactct taatctcaca tcattgtaag  66180tttatggaag ttatcatact tctgactttt tctttgaaga gcagaaatta gaaattccca  66240ataattattt tgatagtgtc atttaatgac actcacatgt gatgtagcca caaagattta  66300atgagttcag ttttaaatca tattaagact gttggtttca tttgttctca ttaatgtaat  66360tctgaagatg aacaataaaa tgtattttta gaactttcaa atgaaatatt atttcatcct  66420tccagatcat ataatgctta agttctgatt gttaatcata aagtctagaa aattaaaaga  66480taataaaatg aaagtgactt ttaggtatta gagttttatt ataaattctg gtgtgtcatt  66540ggagctatga catgaatatt tcaaaggcca atagcattgg atctttacag ttataactta  66600ccatttttaa gtttaagtag taatatagat tatttaataa tcaaaatcaa taaatattaa  66660ttattaaaat gttttgtggt atagtttgag aatcattgct tttaactttt tccatatagg  66720tttattgact ttaatagcat tctaaacata acatctctac attctttgtg tttaatactg  66780tggaggtata aaaatactta tatatgatga taaactatat tagagtaaat taaatattct  66840tatgagtttc attttagagt gcatttactt aattttgaag tccttatttt tagcaaacta  66900aaaggaatgt tggtacatta tttactaggc aaagtgctct taggagaaga agaagccttg  66960gaggatgact ctgaatcgag atcggatgtc agcagctctg ccttaacagg tagttctcac  67020tagttagccg ctggtgtgga ccttcactgt ctgccttcca ccccttgccc ttcctgctcg  67080tccccctgca cctggtggac agcacgactg ggggcagcag tggagccagg ttgcttaaat  67140ggggcatatt cgggcttctt ttataatact tactctgaag cttgtgtgtc tgtggtgttt  67200gcatcatata tttgttgttt tccatggttt aggctgtttt aaaattaggt ttatggcttg  67260agcatagggc tttgtgagta ggggatggca ggtcgaaaca tctcatgagt tggatgggtt  67320atgctggggg ttgggaaatg ggatgaaaaa ttatgggatg aaaaattgcc tatggatagt  67380ttaacttgaa agaatctgcc tttgtttaca gatagttatc ttttttcttt tttgagatag  67440agtctcacac tgtcacccag tgcagatacc cagtgtcact ggagtgcagt ggtgtgctct  67500tggtgcactg cagcctccgc cttctgggtt ccagcgattc tcctgcctca gcctcccaag  67560tagctgggac tacaggtgcc cgccaccacg cttggctaat ttttgtattt ttttgtggag  67620acgggttttt gccatgttgg tcaggctggt cttgaactcc tgacctcaag tgatctgcct  67680gcctcagcct cccacagtgc cgggattaca ggagtgagcc actgtgcccg gccagttaca  67740gatacttatc taatgaaatt ctctgtgtac tttataaaag atgaggatta actgaaggta  67800ctaataactg gattatatga gggtggtttt ggttgtataa tcctatctaa aagaatattt  67860tagctataac tgaaagtaag acttaaatat ttagagagga aaatctgaat aattctagta  67920gtaattattt atttacaaaa taaaaataga tttttttttg attacacaaa ttaaacaaca  67980ataaaacatc acagcaatcc ggatactata aagctcacat gcttaccgac ccaactgccc  68040caggagtgac cactgccaac agcttcatgt cgaccttttt gccataattt ttatatagcc  68100ttttttgttt ttaaatggta atttagaaag tcaactagga aaatgtgtta caggtttatc  68160ttccaggaga ataggactgg agtcgagatc ttgaatgtgg cttggaagaa ggcaagccca  68220ccccagagag atgagttgac agttgtttct gaccactgct tgcttagagg gcctgcgtgt  68280ctgtgaccgc ctagctttgc gcccctgact aggctgcccc ttaattacaa atgtctttat  68340atattgctcc agctaaggct tggagtagtc ggttaagaac ttgaacttcg gtttttgcag  68400tgaaacagca tttgagaata tcaccttctg ataagcctta ttttataagg tgggtactgt  68460agtgggaggc agtgtgagag atgcttgaag gatgcactgc tgtcctgcat ttcagcatct  68520tcaggatgct gtgcagctga aacatttgat aacggtggaa ctgttcgtta ttttgcaagc  68580ctgtgattcc ctattgaatg ttttctctcg ccatttgaca aatgagtgtt tctctgtctt  68640cagcctcagt gaaggatgag atcagtggag agctggctgc ttcttcaggg gtttccactc  68700cagggtcagc aggtcatgac atcatcacag aacagccacg gtcacagcac acactgcagg  68760cggactcagt ggatctggcc agctgtgact tgacaagctc tgccactgat ggggatgagg  68820aggatatctt gagccacagc tccagccagg tcagcgccgt cccatctgac cctgccatgg  68880acctgaatga tgggacccag gcctcgtcgc ccatcagcga cagctcccag accaccaccg  68940aagggcctga ttcagctgtt accccttcag acagttctga aattgtaagt gggcagaggg  69000gcctgacatc ttttttttta ttttttattt gagacagagt ctcactccat agtgcagtgg  69060aggccgggca caggggctca tgcctgtaat cccagcactt tgggagactg aggcaggcgg  69120atcacttgag gtcaggagtt cgagaccagc ctggccaaca tggtgaaacc ctgtctctac  69180taaaaataca aaaattagtt gggcgtggtg gcacatgtct gtagtcccag ctgttaggga  69240ggctgaggca ggagaattgc ttgagcctgg gaggcagagg ttgcaatgag ccgagatcgt  69300gacactgcac tccagcccgg gcaacagagc aagactccat ttcaaaaaaa ataaaaaaat  69360aaagtgcagt ggctcgttct cagcccactg caacttctgc ctcccaggct cgagcgattc  69420tcccgcctca gcctcctgag taggtgggat tacaggtggg caccaccaca ctcagctaat  69480gtttgtattt tcagtagaga cagggtttca ccatgttggc caggctggtc tcaaactcct  69540gaccttagat gatccaccca ccttggcctc ctaaagtatt gggattatag ttgtgagcca  69600ccatgcccgg ccctgccacc tgccatcttt tgagttcttc cctggagacc tagacctgaa  69660ccctcctgct tgttctcttg ttatctaata cccctattga cagcgcagct tagatcatta  69720atggagagct tgacctcatc tgataccttc actgaaggaa acaacttagt gtcttttgtg  69780ttgaacactg aggtaaaaaa ttggaatagt tgattatatg aactctgcta aaattgagtg  69840cattttacat tttttaaggc cttgttgggc cctggttaaa taattatttt taaaaatcct  69900taaggagcct attataaaca gatctgtggt cttaatgaaa tgtgattaat actgtgcatt  69960attttaagaa cttttgactt ttcaaaaaac ttttacaaca tttcccattt gatagcggca  70020taggtttaag cacttctcat ctctaagtta gtggacaaaa aaccctcatg gatagtctaa  70080taatgtttgc tacaagtcca tgttgagttt tatactccat tttattttca gttttaaaaa  70140ctgtggttaa atatgtgtaa cataaaattt atgttcttaa ccattttttg cgtatacagt  70200tcgctggtat taaatacatt taaataatgt catggaatca ttgctaccac ccatctctgt  70260aaccttttga tcatgtaaca ctgaagctct gttcccattg aactctattc ctcctttccc  70320gccaagtccc tggcaaccac gattcttctt tctgtcttct gaatttgact actttgggtt  70380ctcatatact ttaggagtca cacagtattt gttttactta gcataatgtc cccaaagctc  70440atgcatgttg tagcctatgt tagaacttcc taatgtttca ggccaaatac tattccattg  70500tatggatagg ccacattttg cttttccatt cctctgtcca tggacacttg tattgcttca  70560tgttttagcc attgtgaatc atgctgttat gaacgtgggt gtacagatag ctcctggaga  70620ctctgctttc catttttttg gctaaatacc cagaaatgga gttgctttta cattccaatt  70680ttaatttaaa acattcatat cattgagtgt tttacttaat agtatagtag ttaacaaact  70740taataaaata gtattttggt aataatttgc tggtagtcca ttgttcagtt tttttaggta  70800aattacacag gacatttcaa gtggacatga aacatcttgt gatgtggaat catgccccaa  70860gctgatggct aaacatatga aataccatac cctaaattta gtagatttag tctttgcaat  70920ttaggagata acctgttata ttgttaggtt tttgtcgaaa agctttgtcc tcatatttcc  70980aacttgctgt aaaatttgtt tgtgaagaca aatatttttg tatgggtttt ttctttttca  71040tattaaaaag aaatgtccac attggaattt ttttggagtt tttagagcta atagagcttt  71100tcataatgta gtgggaatga gtgatcagta agctcttagc agtttccatg cgtgcatttc  71160tgtgccttga aataaatgac agatgagtac atttgtgttc tgtgtgtaaa atgtgctctt  71220tcctcattgc acttccatgt tggagggctt gtctcttggt gatcacactt caaaattctc  71280acagcccccc ttgaaccgtt taggtgttag acggtaccga caaccagtat ttgggcctgc  71340agattggaca gccccaggat gaagatgagg aagccacagg tattcttcct gatgaagcct  71400cggaggcctt caggaactct tccatgggta tgtggactac aggtgatgcg ctacaaagtg  71460gtttgtattc agacctggac atcttaatta tatctttgct tccaagaaga agtcctttga  71520tactgttttc tgagttctga atagctgatg aaaatgacca attgaggaat aatcatactt  71580tttcttgatc taaatcttat acttttgagt tatcttagca taaatgtata attgtatttt  71640aagtggaaat ttgtcactta atcttgattt ctctgttttt aaagcccttc aacaggcaca  71700tttattgaaa aacatgagtc actgcaggca gccttctgac agcagtgttg ataaatttgt  71760gttgagagat gaagctactg aaccgggtga tcaagaaaac aaggtgaggg acataggctt  71820gagacgactt ggtgtttctg agcttgtgtg aggatttaaa atcgccctgg ctactgtcta  71880ctttattgct ttcccatccc tgggccttta aatttcccct ttaaatacca gctcttccca  71940ggcctgttgt tttctgcctt tccaggtact acccacagcc ttgagaattg cctgagttct  72000gcctcctttg agagtgtgcc ccagacaaat ctattctgta ctgaatgttt ccttgtctga  72060tttcttggat cattcatttg atggttgcgt atggcctgca acgtttcttg ttttggttct  72120actgaactgt tctaaaagtc tctcttcata ttatcttttt acatgtaaat gtaactgtct  72180tcacttttaa ttcctcaagg acaaggaata gcgtttcaca gttcgtccca tcaatcagaa  72240ttatagcctt tggcatctcc ctatctacca ggcccacttc ctcttagatt tgggcttccc  72300caggctgttg cctttcccca agtagcttct gcttgtcctg tagaagacct ttcatgcttt  72360gcttctgcag cagccgttcc tgaatgccta gtgtcaactg ccttcttacc acgcccaccc  72420tccctgcatg ctgcatttat cccctgccac agccctgtga ccctgtgtcc tgctgcctct  72480gacttgtctg tttctgcttg gccatggtct ctgtgaggtc aggtgtgcat atgggcacaa  72540accagggcat ctctttatcc ccagcacctg gcttaagtgc tgctctggaa ctatctgttg  72600aatgaactaa tgcatgaatg tattgttgag tatgagacaa acaagtgtca ttgtctcctt  72660tctagccttg ccgcatcaaa ggtgacattg gacagtccac tgatgatgac tctgcacctc  72720ttgtccattg tgtccgcctt ttatctgctt cgtttttgct aacaggggga aaaaatggtg  72780agtacaaaag gggatgtgca cagttgaagg aaataactag gtttcagagg tcagcttggt  72840ggcctgtttt tgccttgcgt gcagcagagg aagtagaatc tgaggatgag tttggttttc  72900actagccgag gggagggagg aaatgatggg agcaggtagg ttattgggtc tggttttgtt  72960catttgaaaa caatctgttg tttgaggctg aaggtggctt gggtgatttc ttggcagtgc  73020tggttccgga cagggatgtg agggtcagcg tgaaggccct ggccctcagc tgtgtgggag  73080cagctgtggc cctccacccg gaatctttct tcagcaaact ctataaagtt cctcttgaca  73140ccacggaata ccctggtatg ttaaaagttc acatcttatt ttctcagatt taatcattat  73200tgtaaaaact atttcagtat tgactatttt agttttagag cagtaagtgt tttgagttca  73260tttgggatat ttgacctgcg ttgtagctct tcagaaaaca catgaatagt gaagttcttt  73320gtttcatggg ttccctttag atgaaaccca tagaggagaa aagtagaaac ctcagcacgt  73380aagagccaac atatatacac atcggattta aacctaaagc acaaattgtg cctggtcgca  73440gtggcgctga gtcgcactca gccaggccag gcattcacac tcagggtgag tgggaaccag  73500gactggctga ggcagcagtg gacccaagtc tccatcgcgc ccatgcttac tatggagcct  73560tctcgttctc tctttttctt tgggtgagag ggtacacttg tgtttttgaa tttatatgag  73620gtaagtgtgt aatagggttt tttctaatct tttttaagtg gaatctggaa ttttaatcag  73680atttattatc tgacaaccta gaattataat ccagaaagtc tgtggtattg aggacatatt  73740ggcaatatga tgaatctcta attcttaaat cctgaaactt tttttttttt aatcacttag  73800ggttattata gtgaagtcat ttctgaattt ggatcttctc ttcacacctc tttttctctt  73860tcctgagaat taagcttttg tttcgagtta gaaagttgat agtagggaat tgttccatgg  73920ctgagcaatt tatctccaca gaggaacagt atgtctcaga catcttgaac tacatcgatc  73980atggagaccc acaggttcga ggagccactg ccattctctg tgggaccctc atctgctcca  74040tcctcagcag gtcccgcttc cacgtgggag attggatggg caccattaga accctcacag  74100gtaacggcca gtttttcagc tgtgtttttt ctagttatgc ttactaaggt ttaagtttag  74160atgatgatgt ttgttgcttg ttcttctggt taggaaatac attttctttg gcggattgca  74220ttcctttgct gcggaaaaca ctgaaggatg agtcttctgt tacttgcaag ttagcttgta  74280cagctgtgag ggtgagcata atcttctgtg gaaccatttc ttcacttagt ggacatttta  74340tcattgctac aattaaaatt ggagcttaat aggaaatatt tccatgcact ctaaagctgt  74400aaccagtaat acccaccatg tatccatctc tcagctttag aaagaaaacg ttgccagtaa  74460agttaatgct tcataaactt cagtttaagt tctaattctc agaatatttg tttgaaatag  74520acctcttcct aaaggatata tttagaaata acctatcatt aagtgtaaag tctgttgaat  74580atgctgggca cggtgactca cacctgtaat ctgaccactt tgggaggcca aggtggaagg  74640attgcttgag cccaggagtt caagactatg ggcaacatag ttgaccctgt ccctacagaa  74700aattaaaaaa aaaaaaaaaa aaagtagctg ggtatggtgg tgcatacctg tagtctcagc  74760tactcgggaa gctgaggtgg aggggggatt gcttgagccc cagagatcaa ggctgcagta  74820aggcgtggtt acaccactgc cctctagcct gggcaacaga gtgagactgt ctcaaaaata  74880atagtaataa taatcagttg aattaaaaaa aaaaaaaaaa aaaccactgt gctaggccca  74940tagtatggta agagttaaag tgagccttag ggattattta ctcaacctct gtttctgtat  75000aaagtggaat aggctcaatt ctttaagtga tagcatgttg aacctttcca taccaactgg  75060ctcataagtc acaactggcc agtcaacaag agtaaaaatt aactggtaaa aatcaaagca  75120aaaaacctac aattgtcaaa tttgtgggat aactccccct tttaaaatgt catgcctgac  75180agtaatttct ctctagtttc caggttttca gtcagttgtg tcttttttga gcagaaggaa  75240gcatgctaag agctcaatct tgtggctagc tgggggtctt tgtgtcagcc atgcatgtga  75300tggtgcccct gggtgcttgg ggctgcaggg gaggggtaca gcagtagggg cctgttctgt  75360tctctcgtgc tgtggagtac atagtgacat agtggggtgg tccttggtgt aggtcccttg  75420ttcctacccc tgggtctgag atttatttag aagtggtgtt ggggctgtgc ggcaggcccc  75480tctgtaactg atcaatgttt gtgaagttgc tgtttgagag ttgaaaccat gacataagca  75540gaaatggaag gaagaaagaa ccagttatgt gaaagggaca catttacttt taagcttgta  75600tttactgaga taaagtattc ttaatcaatg ttcttgagag gtgtgggaaa aatgcaacat  75660cctggttgca gttaaaccca gaacattgtg tgttgaagag tgacggttct caaaccgtca  75720agacgcgggt actgagtggg actaacctgc tgtcctcttg ccttggacct tgtgttccag  75780aactgtgtca tgagtctctg cagcagcagc tacagtgagt taggactgca gctgatcatc  75840gatgtgctga ctctgaggaa cagttcctat tggctggtga ggacagagct tctggaaacc  75900cttgcagaga ttgacttcag gtaagtgagt cacatccatt agatttcatg aactaagctc  75960aattgaaagt tctgggatca cttgatgcaa ggaatgatgt tatcaagtac cctgtccatc  76020agaaatccga gtggtttagg tagatgacag tgattttctc ctcccagtgg ctttttgctg  76080aactttgccc tatgcttgga attttatttt attttattat ttatttagag acaagatctt  76140gctctgtcgc ccaggcttga atgcagtagc acaatcatag ctcactgaag ctttgaactc  76200taggactcaa gtggtcctcc tgcctcagcc tcccgattag ctaggagaat aggtgtgtgc  76260cgtcacactg gctaatattt tttgtagaaa tggggtcttg ctatgttgcc caggctggtc  76320tcaaactcct gggcttgatt gatcctccat cttggcctcc caaagtgctg ggattacagg  76380catgagccac tgtgcctggc ctagaatttt aaaatataag tagaagagta gatttttttt  76440tttggtagtc ctcgtcattt aagtattctg gatagtggga ataaaagagc ttagaatttt  76500tcatctttgt cttaaacttt taaaaaaatg tagcttatat taattctgct tgtttaaaaa  76560gaatatactc ttcattatac tgaacctagg taagacagct ggtttatatt ttgttgcaat  76620taaaaaacgt gagctgtggt tgcagtgagc caagattgtg gccattgcac ttcagcctgg  76680caacagagtg agacttggcc tcaaaaaaaa aaaaataaca tgagctgtgt tggcactttc  76740attttctaag agtagttttg gctggagaag ttttctttca gtactttctt ttagaaggga  76800aattttcctt tataatttag ggtttgtttt ttttttttcc aagccacctt ttatagagcc  76860cttgtgggtt atttcattta atccttagaa tgtttataaa tctgggcttg ttctcggctc  76920cacccacaga tagggacgct gagcgtgcat gagtgggcag caagatagca ggttatggag  76980ggcccagctc accccttctg tggcttgagc caattttata gggcacttac agagtctttt  77040gaaatagtat ttattttgaa gaaaaagaaa aacagtttac tgagtactgt cttattgagt  77100ctggaattgt gagaggaatg ccacctctat ttatttaaag ccattggcct tttttgttgt  77160tttgagtaag tgctgcccaa ggtccttcca gggcacctgg atgagcctgc tctggagcaa  77220gctggcggta agtgtttact gagtaactaa atgatttcat tgttaaatgt gctcttttgt  77280taggctggtg agctttttgg aggcaaaagc agaaaactta cacagagggg ctcatcatta  77340tacaggggta agcggtttat ttttgtgaga tgctgtttta ccttcaagaa ggtgaaagtg  77400aggctttcct tgtggaattt ctctaaatgc attcgtcatg ttttagatgt ttatttcaca  77460gtttatatca tgaaagttat aatcttgtca tatggattta agtctagtaa tgttgagttc  77520tttctcacta gctttccaaa atatcttacc taaaatttag tcaaatacaa gattatgttt  77580atttttatta tccttctctc taaagctttt aaaactgcaa gaacgagtgc tcaataatgt  77640tgtcatccat ttgcttggag atgaagaccc cagggtgcga catgttgccg cagcatcact  77700aattaggtat ttaccaatat tttatctctt ttcctttttt ggttgaagta ctaaaagata  77760cgagaatgga aagagaggga agaattcaaa ggatgtagag cagtattcct gaatctgagc  77820tcatttcagc cattctattc ttaaactata atgaaaaaaa aatccaaaaa agtctaaaat  77880tataattaaa aaaacaacaa aatactaact gtccattgta aaaagtaatg cactttcatt  77940gtaaaaattt tggactatag agaatagtac taagaagaaa aaaaaaatca ccttcaattc  78000tgctgccacc tggaggtaat cactgttaat attttgctat atactctatg agtttcttgt  78060tcaaaatcag gtcaaaatta catgcaattt tgtaatctga caatttccac ttaatatttt  78120attagcattt tcctgttatg aaacagtaat tttagttatg ggtcgttgtt ttgctatgcg  78180gttgggataa aattttatat actttttttg gcaattactt attatacata aatgtttgtg  78240tatagttttc tttttctgag aattcctgga agttgagtta ccaggcccgg ctttgaattt  78300ttttttttat tttttttttg agacagagtc ctgctctatt gtccaggtgc tatctcggct  78360cactgcaacc tctgtctccc tggttcaagc gattctcctg cctcagcctc ccgagtagct  78420gggattacag gggcacacca ccacgcccaa ttaatttttg tatttttagt agagacaggg  78480tttcacgata ttggccaggc tggtctcgaa cttctgaccc cgtgatccac ctgcattggc  78540ctcccaaagt gctgggatta caggcgtgag ccatggcgcc tggccaggct ttaaatttaa  78600aacaaatctt ctaatagctt tatggaggtt ataatttaca tttcttgaaa tgtactcact  78660ttgagtgtat agtaaactcc aattttatca catttctgtc accccaaatg tatccttgtg  78720cccatttgct gtaacctccg gttcctgccc caactcctag gcagccactc atctattttc  78780tgtcccttaa gatttgtgtt ttcgccaggc gctcatgcct gtaatcccag cactttggga  78840ggccgaggtt ggtggatcac ttgaggtcag gagttcgaga ccagcctggc caacatggtg  78900aaaccttgtc tctactaaaa atacaaaaat tagtcggatg tggtggcaca cgcctgtaat  78960cccagctact cgggaggctg aggcaggaga atcacttgaa cctgggaggc ggaggttgca  79020gtgagcagag atcgcgccac tgccttccaa cctgggcaac agagagagac tgtctcaaaa  79080caaacaaaga tttgtatttt ctggacattt tatagtactg gggtcatagt atagatggac  79140ttttgcattt ggcttctttt acttaattgt gagattggtt cttgttgtag catgtatcag  79200tagtttgttc atttttattg gcgaaagtat tctattatat gaataatacc atattttatc  79260tatccatcag atggatatta tagagttcat gttttggcta atttatgaat tatggtactg  79320tgaacatttg cctgcaagat tttgtgtaga catgtcttca tttctcttga gtagatcacc  79380tagaagtgga tttttaaata attttggtac ttactgtgaa actgctcttc aaaaacatac  79440cattgttcct tccttccttc cttccttcct tccttccttc tttccttcct cccttcctcc  79500ctcccttccc tacttccctc tccctttccc tttcccttcc ccttttccct tccccttccc  79560gcctgcctgc ctgcctgcct tccttccttc cttccttcgt ttctttctac atatacacat  79620ttttttaaat ttcaatggtt tttggggtac aagtggtttt tggttacatg gctgaatttt  79680ggttacatgg tgaagtctga gattttagta cacctgtcac ccgagtagtg taccttgtac  79740ccaatatgta gttttttgtc cctcaccttc cagccttccg ccttgtgagt ctccaatgtc  79800cattatacca cactgtatgc ccttgcgtac ccacagctca gctcccactt ctgagaacat  79860atagcagaaa catgccaaag tatactccca ctaccagaat gtgattgtgc ctgattcttc  79920tcaccagtac aaatatttca aaaaaagtta aatatgtatc agttttttgg gcagaagttg  79980atacttctct ttatttattt attttttttg agatagggtc tcattctatg atgcccaggc  80040tggagtgtgg tggtgcgatc tcggctcact gcagtctctg cctcccaggt tcaagtgatt  80100cccacgtcag cctcccagga agctggaatt acaggcgagg gccaccactg ccagctaatt  80160tttgtatttt ttggtagaga tggggtttca ccatgttggc cagactggtc tcaagctcct  80220gacctcaagt gatccacctg ccttggcctt ccaaagtgct gggattacag gcgtgagcta  80280ccacacccgg ctgatatttc tttttaaaat aacttacctt cttttgaaag taatacatgt  80340ttaatgaaca gaatttaagg aaaatataaa aaaacgaaat aatctttgta atcaaactac  80400tgaaaagaaa accaaagtta cattttggtg catattcttt ttcattttca tcattgtaat  80460ttgcatttct ttgattactt gtgagacact cctttcattt acttaatagg tttatatgac  80520ttgcctattc agagattttg cagctttacc attttctgca aatgatagca acttcttttt  80580gtttgtttgt ttgtggagac agagtctcgc tctgtcactc aggcaggaat gcagtggtgg  80640aatcttggct cattgcaact attgcctcct gggttcaagc gattttcctg cctcagcctc  80700ccaagtagct gggattacag gagtgtgcca ccatgcccgg ctaatttttg tatctttagt  80760agagatgggg ttttgccatg ttggccgggc tgatcttgaa ctcctggcct caagcggtcc  80820ccctgtctcg gcctcccaaa gtgctgggat tacaggcgtg agccaccgta cccagccagt  80880agttacttct tatattctag aaaaaattct actcatgatc aagtctccat gaggaaagag  80940actttaattg aagatcatgg ggcttgcaga ccaatatgat aaaatagttc attgtttcta  81000aaagtattac tgagtgttga tggcagatat gaaccctttt gtttttgtag gaaaatgtta  81060cccgtattct ccatttgaat tcagtttaga tttgttagga atcgcagctt aagctttgcc  81120atctgggagt gtttgggaca gttttgcaga caaaattgca aaagtgccta aggaatgcag  81180ctggcattca gacctgctct gtgctcagta ctctgtggac agacactgtt cagcacttgt  81240tgatcagaag gtttagaaag agaactttca aagttggttt ttaattaaag catttaatag  81300tgtaaataga aagggattaa attttatgac agacaaaaga aagtacagca cccagctggg  81360cgtgggggct cacgcctgta atccagcact atggggggct gaggtgggtg gatcacgagg  81420tcaggagttc aagagttcaa gaacagcctg gccaaggtga tgaaaccctg tctctactaa  81480aactacaaaa attagccggg cgcggtggca ggcgcctgta atcccagcta ctcaggaggc  81540tgaggcagga gaatcacttg aacctggacg gcagaggttg cagtgagcca agattgcacc  81600attgtactcc ggcctgggcc acagagtgac attctgtctc aaaaaaaaaa aaaaaagaaa  81660aaaagaaagt acagcaccca gttatgtccg agtgggtgca tgagagtgac cctgagattg  81720gagacaacgc tgtcacgtgc ttgaagaacg ccacctgaga aagggggcga gaagtggtgt  81780ccgctggtaa ccagaggtgt tggcttagcc atctgcaggg aggagggtgg tctatcacag  81840gtgagtttca tctactttct taagcaaatt aaccttactt ttgtgttagg cttgtcccaa  81900agctgtttta taaatgtgac caaggacaag ctgatccagt agtggccgtg gcaagagatc  81960aaagcagtgt ttacctgaaa cttctcatgc atgagacgca gcctccatct catttctccg  82020tcagcacaat aaccaggtat gctgacccag tggcatcttc acattgtcgg gaaaatgccc  82080tttcctgatg cctttcttta ggctttaatt gaaaacattt tattttctag aaaaaagctt  82140cagctcagga tgtttgagtg taggtcagtc ctttgatagg atattatcat tttgaggatt  82200gaccacacca cctctgtatt taagctctgc cacaatcact cagctgtgac actgtaaatc  82260tcttaatagt ttattacatt ccatgtgctg acagttgtat ttttgtttgt gacacttacg  82320tattatctgt taaaacattt tcactttagt tgtgttacct ttaaagagga ttgtattcta  82380tcatgcctgt tgattttttg gtgagcgggc tattaaagtc agtgttattt agggttatcc  82440actagttcag tgatttgcga gattatcatt cacatttatt gtggagcttt tgaatatcgt  82500gtcaaatggc cacatatatc ccattcttat ctgcttctta ggtgagtggg acacagtgct  82560ttaatgaagc tataatcttc agaattctag cttgcagaga agattgcaga agtgataaga  82620cttgtgcttt ttaattttgt cttttaaatg ttattttaaa aattggcttt atatgatact  82680ctttttttct gctgagtaac agtgttttac aaaacttgga ctaaatgact tctaagctta  82740aatgatcact tgatgctttt tttctgaatt aggaactcag cttatcaaat atcaaagtca  82800taattcctga ataaataacg tcttttttca tgtaaagact gctttaaaaa acacatggaa  82860ggctgggtgc ggtggctcac gcctgtaatc ctaacacttt gggaggccca ggtgggcagg  82920tcgcttgagc tcaggggttc aagaccaccc agggcaacat ggcaaaaccc acctctactc  82980aaatacaaaa aattagccag gcgtggtggc gggcccctgt aatcccagct actcgggagg  83040ctgagggatg agaatcactt gagccccgga ggcagaggtt gcagtgagcc aagattgtgc  83100cattgcactc ccagcttggg ctacagagtg agactctgtc tcaaaaaaag acacacacac  83160aaacaaaaaa aacatggaga catttttttg gccaccttaa tatttcccct cagataattt  83220cctttgttta aactcagaac tggcattttc tctcttggag aagattcagg acaaatactc  83280ctttaagata agtagaagca gtgaaagagg atttgattat caggaatttg ataagcttag  83340aataaattgt tgcttcttaa tgtcatttca gaagatgaat atttattaat agatgccaac  83400tgagatatca ttaaaattga ttactaacta ctacttggaa aagtctccca gttccaaact  83460tcagcaggcc tcttgacaat tcagctgtgg tcaattgggt cttgcgtgat agatacaatg  83520accaattgtg cagcagagtg tgctgcttag ctgcctattc tgttagcatt catgtgttaa  83580cttaaaatca taatctcctt agttttgttg agtgtctccg tggacaagac actgtgaggg  83640atacaaaatc agattggctt tattcaaacc actggggtat tataattcat ttataattta  83700ttttattttt tgcctttttt ccatgtgttc taaaggaatt agagtttgta tataactata  83760atgggggata gaaattgaca tgtgccatga agggaatgca aaaaagtgcc gtgggagatg  83820agaagtggag aaaggaattt cttttttctt ggaagcagga ataacttcat gaagcatgta  83880tttcaactta aacagatagt aggcaacgct gtaaggggag tatggctgca gcaaaagtgt  83940tcggggcaga ctgggaggaa gggagggaat aaattcagcc attgttatgg aataatgatc  84000aaaatttatt ttcagcccgt ttcacttaaa agttgagact gcttaacttt ttttaatctt  84060taatcttaaa cttttaaatg ccatttgatc tttaaaaata tatgttttaa tagtgtattt  84120taagtctcta tatttttgtt attagaatat atagaggcta taacctacta ccaagcataa  84180cagacgtcac tatggaaaat aacctttcaa gagttattgc agcagtttct catgaactaa  84240tcacatcaac caccagagca ctcacagtaa gtctctttct tgatcggtct tactgacatt  84300gtaatagttt ttggtagctt gtatggccag ttagttgtat ggtcatctta cggtgaggtg  84360cttgtcttac agctcttact tatccatgag gcttgctaag aaattgtgct tctgtgaaaa  84420gaatctcagc ttactccagg aatgtaaatg actatgtttt ttctgattat taaagtaata  84480cacgcccaaa ataaaaaaat tcagccaatt taggaagaca caacaattaa aataagccag  84540gcatggtggc tcatgcctgt aatcccagca ctttgggagg ccaaggttgg gggctcactt  84600gaggtcagga gtcggatacc agcctggcca acgtggtgaa accccatctc tactaaaaat  84660acaaaaatta gctgggcgtg gtggcgggcg cctgtaatcc cagctactca ggaggctgag  84720gcaggagaat cgcttgaacc tgggaggtag aggttgcagt gagctgaggt caagccactg  84780cactccagcc tgtgcaatag agcgagactc tgtctcaaaa aaaaaaaaaa aaaaagaaaa  84840gaaaaaagta aactactgtc acctgcattg gtaatgtatc agaagtttaa aatgtctaga  84900ttataattaa ctcagtgacc tggtaatata tactaaggga aaaatattta taatttacat  84960ttttacattt ttattttttt aattttatta tttttttttt gagacagagt tttgctcttg  85020ttgcccaggc tggagtgcaa tggcatgatc tcagctcacc acaacctcca cctcccgggt  85080tcaagcaatt ctcctgcctc agcctcctga gtagctggga ttacaggcat gcaccaccat  85140gcccggctaa ttttgtattt ttagtagaga cagggtttct ccatgttggt caggctggtc  85200tcaaactccc aacctcaggt gatccgccct cctcgacccc ccaaagtgct gggattacag  85260gtgtgagcca ccatgcctgg ccttacattt ttataataag aatttatgtt gctgacatta  85320gaaaagaacc ataatatcca agaatccaag aataattaaa ttatgtacat atgctagtat  85380atagtgtgat gctttggaga atttttaaca atatggagat gtataatctg gattgtaata  85440ttgagtgaaa aaaggcagaa tacaaacctg gtgggggtat agtcggattt cagttaagaa  85500aaataatatt tacatatata catttctcac actggcagat aatcaccaag ataaattttg  85560ggattgtgga tgattttttt cttctttata tttttcagat attctcaaat tttctaaaat  85620gagcaagtat aacttttgtt atcagaaaaa aataatatac aaaagtaatg ttaatttgct  85680ggtgaccagg ttaaaccttt ttatttttat tttttgagat ggaatctcac tctgttgccc  85740aggctagagc acagtggcat gatcttggct cactgcagcc tccgcttcct gggttcaaat  85800gattctctgg ccccagcctc ctgagtggct ggaattacag gcgtgtggca ccacacctgg  85860ctaatttttg tatttttagt agaggtaggg tttcaccagg ttggtcaggc tggtctcgaa  85920ctcctgacct cgtgatccac ccacctcggc ctcccaaagt gctgggatta caggcgtgag  85980ctactgcgcc cagccagacc tttttatttt atttgacaaa agaaatactt ccatgttata  86040gaagactaaa tattgtttgg gctgtctgca gtatggtctt cccttgattt gttcaaaata  86100tcgtaaactt tgcttattta tttttattgt ggccgactgt gtcgggcact gttgtaggct  86160tgggatggaa aaacaggatt cctgccctta gggtttctgc aggctggtca gggagacgat  86220gtggtaagct ggagctcagc tcctaaggat gtgcaggggc agttgagagg cggaagggtg  86280ggagatcatt ccagggtgtg ggcagcacag gaacctctct tcattgggat ataattgcca  86340ttctgataac acgtgtttga ggtgtctaaa gtaggaagtt gtaccatggt gggacagata  86400tcctgtggtt atcatacaca gatctcagtt ttcttctcat tgtttgtact ttttataaag  86460ggtaacagga gatataattc aataaacctt tgtggtgttt gggtgtgatt ttattgtttc  86520tttcttctca gtttggatgc tgtgaagctt tgtgtcttct ttccactgcc ttcccagttt  86580gcatttggag tttaggttgg cactgtgggt atgtattttc ctcagtatat attaatagtt  86640gtctacaaca gtatgacata aacatagtta ttaggatgcc ctttttcttt ctttttaagt  86700cttttatcaa tttggctttt tggaaaaata tctgatggaa tacttgtttc tgctatatta  86760gctgtgtgag actagtgaca ggagctgtgg gaaatgaatg ccaaatgttc ttaggcattg  86820atgggaattt cagggtgtgg tcttcaagtt catttaaggg aattttcata tgctggcaaa  86880aggcttttct cattagcttg actctttcca aaattatttg ctgtgaatta gaagtttagg  86940aacctttttt cacttaattg tgacctagca tacgaaatgg tgatgattta ggaactactg  87000ttcttgtatt aacagctttt atttaaaaat gattttcctc cagtagatgg ccctactagc  87060atctgggaaa taatttcaag tcttctccag cattcaggaa taggctttca ttttgtgtat  87120caattactga gaatgatttt ggtgactcac atcacatttg agaagtaaac ctgcagattt  87180cttgtgtgtg tcagcaaatg accaactgat atttgcttga agtggattac attatctgct  87240ctagaatgat tgctttccca ccttcctcac atacagactg agcagctacg gtttctaatc  87300ataggtctgg cactagactt cacttctggg caactttggc attggagtaa aatgtattaa  87360tttaaagaaa gttaaaaatc cgttcaagta aacatacagt tctaatactt tttacaattt  87420aaaatataga tttaaatgat aaaataaaaa agaaaatatg ggtagacacc ataatcctcg  87480tttctgcatc tgttcacaag gggttgatat ttatgagttc tattctccat atccattcta  87540tgttctctta atgctcagtc agcacctcag gtggttggag ttcaatgctt ggtagtttga  87600cttacactgt cttttctagg ggattgagcc ctgggtagtc ctgcttattt gaggttgcaa  87660tttgtctttc aataactttt actacaagat atggcgtgtt aaaggatacc attggggaac  87720caacataata atatcaggaa aactaaccac gtcagacctg ccccattgtg tatcaagtac  87780actatttttc catagtaata aagagttcac cccagccaat tctcttttat tttgtgcctg  87840tttactcaat ggcattaaca tgcccaaatg tctgggtagc tgtctcatct ccagttcagc  87900agaaccattg tcatatgccc tagtaaaagc attccttcat tggacactta ggccccaata  87960ctttcattca gatctactac ctgatttcat ttctcaaatg atttttatgg agctctgatt  88020tataggaaag atgttagttg attaaaaata aaacaatttc tgagctggta taaaatgtat  88080tgtgacatgc cttcctcttg gaattgcaag agaaaggaag actgttgttt gcttaaaaat  88140tgtctataat ttgactttgc aaatgtctgc ttccagagtg cctccactga gtgcctcaga  88200tgagtctagg aagagctgta ccgttgggat ggccacaatg attctgaccc tgctctcgtc  88260agcttggttc ccattggatc tctcagccca tcaagatgct ttgattttgg ccggaaactt  88320gcttgcaggt actggtactg agttgaaaca gggactccag gacttggatt ttgatttcct  88380tagggggaat gggggtggtg agcatatgag gggaaaatac tataaggtca ttgccagtga  88440tggcttgtcc ctttagtcaa atttcagatg ttacctatat gcataaacac atgcagttgg  88500cagctgttct gtgctgagta ttttaaagta gcctcttccc aatatagccc ctcagttaac  88560tacaagtaaa ctcattttga atttcatttt aatgggcacc atatgccagt actccctcgg  88620gcactgggat gttaagaaag tataatgtat ggacttcatt ctcaagttag ttttagatta  88680gagggggata cacgtaaaca aaagtgcagt ggtcacacag agtggcccta atcactctcc  88740ttgggcagat ttatgggctg gtaggaaaga gcacaacacg gagagggtgt agcaccttgg  88800cgatgataat ggaggatgtg gccagcaagg aagacggagt ccattgaaat tgattttggg  88860agaagttgcc aatctccatg aaagaattgg ggcctgtgct atttgcttca gggggctata  88920ggagagtttc gtgaaaggga ctaaaagatg agtattttaa taagatcatt catccaactt  88980gaacatgggc tggaggagaa ggtagggaga ctcaggagat taatgttgat gctaaggcaa  89040gataatggct ttgggactgt agggaagaca ctgattgtaa gagaatgaag gaggcagaat  89100tgccaggcct ggttcaccaa ctgaacttcg gttgtgaaga caaagaaacc tgggatgact  89160tcacatcctg ggcaggtgtg tggtggtgac agtcatggaa attgggaaca cagatttgtg  89220cgggaaacat cagtttcagt ttgagtttgg cttatcagtt gaatatcagg cacagatgtc  89280tggccaactc tcaacatagg gtcttaaatg acttcagttc cccaagcaat ttgtccttcc  89340catgctattg gggtggagag gtaatgtctg tgcccatatc acagccagtg ctcccaaatc  89400tctgagaagt tcatgggcct ctgaagaaga agccaaccca gcagccacca agcaagagga  89460ggtctggcca gccctggggg accgggccct ggtgcccatg gtggagcagc tcttctctca  89520cctgctgaag gtgattaaca tttgtgccca cgtcctggat gacgtggctc ctggacccgc  89580aataaaggta atgtcccact tgggtgctgg attcatacag ccttaatgac tatgggtttc  89640cagactacct ttgtttagta atctgtccct tctttattct ctttttgctt taaatgaaca  89700aaattgctca gattgtgaca ctaaatttaa catcaaaatg tgaccatgtg gatgggtgca  89760gtggctcgtg cctgttattc cagcactttg ggagactgag gcaagtggat cacttgaggc  89820caagagttcg agaccagcct gggcaacatc acgaaacccc ctctctacta aaaatacaaa  89880aaattagatg ggttgggccg ggcgtggtgg ctcaagcctg taatcccagc actttgggag  89940gccgaggtgg gcggatcacg aggtcaagag atcaagacca tcctggctaa cacagtgaaa  90000ccccgtctct actaaaaata caaaaaaatt atctgagcat ggtggcgggc gcctgtagtc  90060ccagctgctc gggaggctga ggcaggagaa tggcgtgaat ccgggaggcg gagcttgcag  90120tgagccgaga tcgtgccact gcactccagc ctgggtgaca gagcgagact ccgtctcaaa  90180aaaaaaatta gatgggcatg gtggtgcgtg cctgtaatcc cagctacttg ggaggctgag  90240gcaagagagt tgcttgaacc tgggaggcgg agtttgcagt aagccttgat tgtgccgctg  90300cactccagcc tgggtgacag agtcagactc tttccaaaag aagaaaaaaa tgtgaccatg  90360tgttttatag ctcttttagt atcatcagtc actgttatcc ctaagaggga aatacctagc  90420tttagtttta ggtttccagc attagccaag aaagctcaga attgatgttc ctggccaagt  90480acctcattgc tgtctcctta aatcttggtt aatggctact gtcctggcta gcatagttat  90540ggagcatttc catggttgta gaatgttctg ccaatctcag ggacagtttt gcttttctgt  90600gaagcaataa aatcaacttc aaaacaaatg ttaactattt gtacaatgga tttaagatag  90660accagttcac atactttttt tttttttttt ttttgagatg gagtttcatt cttgttgcct  90720gggctggagt gcaatggtgt gatctcagct cactgcaact tctgcctcct gggttcaaac  90780gattcttctg cctcagcctc tcgaggcaga ttacagctgg gattacaggc atgcaccacc  90840acacccagct aatttttttg tagttttagt agagacgggg tttcaccatg ttggtcaggt  90900tggtctcaaa ctcctgacct gaagtgatct atccgcttcg gcctcccaaa gtgttgggat  90960tacgggcatg agccaccacg cccagcctaa gatagaccag ttcacttact gtttatatct  91020gattactctc tctttgcctt gtcttctacc tttaaaaatc tccctactaa cttcccattc  91080tcctttagct gccatcagtc ttctcccttc tctgcaaaca tctctggaga gtcccagcct  91140cagcccacag agcttcccac tgctctgagg tggaccttgt ttgcaaggct tctttggctc  91200tcttggcctg gaccctgtct actacttcag ccatccttcc ttaacccctg ctggtggttt  91260ctgttgccac actccatagc agcgtttccc gcccagatca tgtctttaca tctctgggca  91320ctgctctggt cctgcctgcc tttccctctt tgtatcctgc aggctgctac ccccatcttg  91380agtgtcctct tcagttggct ttcagagggc ctcctgggtg ttcccttacc cacttgccac  91440tccccagtca ctgggttcag tccttcctgc ccaccagcac atgctttcta ggctctgtcc  91500taggccgtct tctctctttg tagtctctgg gccagtgctg ttctagagag tggcagaatt  91560ttctataacc atggcagtgc tccatagcta tgccaggcaa gacagtagcc actaaacaca  91620tatagctgtt gagcccttga aatgcagcta gtgtgactga agaactgaac cccgattcgg  91680tttaattttc attaaattta aatttaaata accttatgtg ggtagtggct ccagtattgg  91740gcagggcagc ctgagagtcg gggctgttct cctgtcttca gtgtctagat gagggacctc  91800agaggacctg tctctggagc tgcagttcaa tgtagccagc tgccccgtga cacttacata  91860tagctgattt gtggatatgt cagacacggt gtgatgagct cagctttctg tcctcctccc  91920cacatctgcc cctgccccat ttaccccact ttgtgtctta tcaagctaga aacaggtcac  91980cacaagtctt catttccact caccaagtct tttgtttccc ctactaaata ttttgcgaga  92040agaaagtgtg tacctttgta ttcacataca tgtacatgca catatacatg cacatatgca  92100ggggtcccca acctctgtta aaaaccggac tgcaggccgt gcgtggtggc tcacgcctgt  92160aattccagaa ctttgggagg ccgagaccag tgcatcacaa ggtcaggaga tcgagaccat  92220tccggctcac acggtgaaac cccgtctcta ctaaaaatac aaaaaaaaat tagccgggtg  92280tggtggcggg cgcccatagt cccagctacc tgggaggctg atgcaggaga acggcgtgaa  92340cctgggaggc ggagcttgca gtgagccgag attgtgccat tgcactccag cctgggcgac  92400agagcgagac tctgtctcaa aaacaaaaca aaacaaaaaa aaaaaaaacc aggctgcaca  92460ggaagaagtg agcaagcatt accatctgag ctctatctcc tctcaggcca gtggtggcat  92520tagattctca taggagcgtg tatgagttcg ttctcacact tctgtaaaga catacctgag  92580acatataaag aaaagaggtt taattggctc acagttctgc aggctgtaca ggcttctgtt  92640tctgggaagg cctcaggaaa cttgcagtca tggcagaagg tgaaggggaa gtaggcacat  92700cttcacatgg cccacaggaa aaagagagaa ggagagagag agagagacag agagagagag  92760agaaaaagaa agattgagag ggagagagga gggagaaagg agagtgcctg tagggggagt  92820tgctacacaa aggagcacca gggggatggt gctcaaccat tagaaactac ccccatgatc  92880caatcacctc ccaccaggcc ccacctccga cactggagat tacaattcag catgagattt  92940gggtggggac acagagccaa accatatcag agcatgaacc ctattgtgaa ctgcacattt  93000gagggatcta ggttgcatgc tccttatgag aatctaatgc ctgatgatga tttgaggtgg  93060aacagtttca tcccgaaacc atcccccgcc aaccctggtt tgtggaaaaa ttgtcttcca  93120cagaaccggt ccctggtgcc aaaaagtttg gggacctctg cacatatgca tgcacctgta  93180catggacaca taatacatgt acatatgcat actttatatt ctctgccact tctggtccag  93240actgatatac tatctcattt ggattactgc actagccttt tgttttggaa acagcatttt  93300ttaaaaaatt taatttaatt tttttgagat agggtgtcat tctgttgccc agcttggagt  93360gcagtgtcat gatcatagct cactgcggcc tcgatctccc aggctcaagt gatccttctg  93420cctcagcctt ctcagtagtt gggactacag gcatacccac catgcccagc taattttttg  93480attttttttt ttttttgaga cagagtctca gcctgtcgcc caggctggag tgggttggcg  93540cgatctcagc tcactgcaac ttctgcctcc caggttcaag tgattctcct gcctcagcct  93600cccgagtagt tgggattaca ggcgcctgcc accacaccca gctaactttt tgtattttta  93660gtagagacgg ggtttcacca tgttggccag gctggtctcg aacttgtgac ctcgtgatta  93720gcccgcctcg gcctcccaaa gtgctgggat tacaggcgtg agctaccgct cccagccagg  93780aaacagcatt cttgagataa ttcatataat tcacccattt aaagtatata attcattctc  93840tttagtatgc ccacagagtt gtacagccat caccagaatc agttttagaa cccataaagg  93900aactctgtac tctttaccca aaacctccat gcctccagct gcaggcagcc actaacctgc  93960cttctgtctc tgtgactcta cgtcttctgg acattactgt ggatgggctc atacagtcag  94020tgagcttgtg actggtgcct tctaccaagc agggttttca gtgtagcagc ctctctgttt  94080ttcttttttt tttaaattgt gacggaactt ctgcctcccg ggttcaagcg attctcctgc  94140ctcagcctcc cgagtggctg ggactacagg cccatgtcac catgcctggc taattttttt  94200tttttttttt tttagtagag atgggtttca acatgttagc cagggtggtc tcgatctcct  94260gacttcatga tccgcctgcc tcggcctccc aaagtgctgg gattacaggc gtgagccacc  94320atgcccggct aacctttcat ttactgtctg catttcttcc ctgatgcctt ccagtccatg  94380cacccgattg tagccattca tcctattatg gtttaaggtg actgtcttag tcagcatggg  94440ttgccataac aaaataccat agcctgggtg gcttcaacaa cagaatttac ttctcacact  94500tctggaggtt gggaagtcca agatccagga ctttcgcctt gccctcatgt ggtgaggggg  94560tgaggaagct ctgtggggcc tcttatatat ggatgctaat ctcattcatg aggggtctgc  94620cctcatgacc cagtcacctc ccaaaggccc cacctcctaa taccatcacc ctggtaatta  94680agtttcagtg tataaatttg ggggactata gacattgaaa ccataacaag cacttttcta  94740agatcaggga gtgagtaagt agcagagcta ggacctcaat tccacatgtc agtcatcttg  94800ccttcactct gctccatgat ggctgcctcc tagagcattg ggagtctcga tgttctatat  94860gctctcatgt gttgtgtatt ggagatagtt gaggctttat gaatacatct ggatttgttg  94920acttctagct ttgctggtaa ccagctgtga ccttgaataa gttacttcat ctctgagcct  94980gtttcctctt ttagaaacag gagtttaaaa tgctgctttg ggttgggcac ggtggctcat  95040gcctgtaatt ccagcacttt gggaggctga gatgggagga tcactggagc ttggagttcg  95100agaccagcct gggcatcata gtgtgagatc ctgtctcctc aagaaattaa aaaattagct  95160gggtgatgtg gcgtgtgcct gtggtcccat ctactctgga ggctgaggtg ggaggattgc  95220ttgagcccag gaggttgagg ctacaatgaa atatgattgc accccatcct gggtgacgag  95280tgagaccctg tctcaaaaaa gaaaaaaaaa atgctgcttt gtaccccttt catgtcatgg  95340cgtcatggcc aacatagaat gccctggttg tttgctgttg gagggcatgg gcctgggggc  95400tccctgaggg ctccttccat cttcaactca ttctctgtgc acctgttagg aagttgtggg  95460ccagtcccta ccatgtatca ttgtgtgggt aaaagtaaat aaaatgtgta cagtgtctga  95520actgtacata tcagggtcca agaacaaaat gagtgacatg ggttagctct ttttaataaa  95580tggtaaaacc aaatattcta attttcagtt ttgttatact tccatcacat gtttttgttt  95640ttttgttttt tgtttttgtt tttctatttt aggcagcctt gccttctcta acaaaccccc  95700cttctctaag tcccatccga cgaaagggga aggagaaaga accaggagaa caagcatctg  95760taccgttgag tcccaagaaa ggcagtgagg ccagtgcagg taggaaacag cgtggggaag  95820ggagggacat gagtgcagca tctgtcatgt agaaacatag gatttaagta acttggtgtt  95880ttagagaaat aaatataata cacatcagta aagtgagaga aagtttctcc aggtgcggtt  95940caagatatta gaaactaatg actgatgtac acagaccacc ttttggtctg aagcatttct  96000aagtgccact ggctgacatg cagcccctac agcctccagg cttccagccc tagcatggag  96060catcactctc ctatgcttcc ctggttgcag gtgatggctg gagaggcctc ctgattttca  96120gtaagggaag tggtgtagat gcttaggaat agatgtagtg agtgaaaaaa ctgattctga  96180tatgtcaaaa attctgattg gaaatggaat atttacattt ggaagagcta aaggcgagag  96240aaagtgggga taaagtcatc tgagttggag gagcttaaac cattcacaag tttggaggac  96300ctttttttac ccatgaaaag gtcagaacag aaggggctag gatttaggtg tgactgcagt  96360ttattgaatt cccatccata ctgctctcgg tgggcagtgg caggggcagg agaggagcct  96420ggcaaagcat gaagtgactg ctgctgcctc tgctatctgg gacgcctggc cacctgtctg  96480tacagtctcc ctccagaccc attctcacgc tgtctcttgg cacccagggg ccagtgatgg  96540ttctcccatt tgttttgtgt atatagcatt tatatcaagg ctatttattt atttatttat  96600tttatttatt tatttttttg agacagagtc tcactctgtc acccaggctg gagtgcagtg  96660gtgcaatctc ggctcagtgc aagctctgcc tcctgggttc aagcaattct cctgcctcag  96720cctcctgagt agctgggact acaggtgtgc accaccacac ctggctaatt ttttgtattt  96780tttattagtg gagacggggt ttcaccttgt tggccaggat ggtcttgatc tcctgacctc  96840gtgatccgtc cacctcagcc tctcaaagtg ctgggattac aggcatgagt cactgtaccc  96900ggcctattta tttattttta attgacaaaa ttgtatatat ctgtaatata caacatgatg  96960tttgaaatat gtgtacattg gccaggcgtg gtggctcaca cctgtaatcc cagcactttg  97020ggaggctgag gtgggcggat cacgaggtcg ggagttcaag accaaactgg ccagcatggt  97080gaaatcctgt ctctactaaa aataccacaa aaaaaaaaaa aaaaaaaaaa agccgggcat  97140ggtggctcgc gccagtcgtc ccagctactt gggaggctga ggcaggagaa ttgcttgaat  97200ctggcaggtg gaggttgcag tgagctgagt tcatgccact gcactctagc ctgggcgata  97260gagcgagact ccgtctcaaa aaaaaaaaaa aaagaagaaa tacatatgca ttgtggaatg  97320gctaattaac ctgtgcatca cctcacgtat cattgttttg tggtgagaac acttaaaatc  97380tactctttca gtgattttct tgcatatggt acattgctat taactgcagt caccatgcta  97440tacagtagat ctcttgaact cattcctcct gtctataaat gaaattttgt atccttgacc  97500aacacattca aggttttttt tgagatggag tcttcttcac ccaggctgga gtaccatggc  97560acgatctcat ctcactgcaa cctccgcctc ccaggttcaa gcaattctcc tgcctcagcc  97620tcctgagtag ctgggattac aggcacatgc tactgcacct ggctaatttt tgtattttta  97680gtagaagtgg agtttcacca tgttggccag gctggtctcg aactcctgac ctcaagtgat  97740ccgcctgcct tggcctgcca aagtgctggg attacaggtg tgagccactg cacccggcct  97800caagcgtttt aaaagatgct cttttctaag gattgactgt agtacaggag gaagattgac  97860ctgttgaaaa gcctcagcct ttacaagtgt aaaattatca gtatattact atcatctttc  97920tgatgaatta aataaactaa ggactccaag tcaaaagtct tcaaactgaa gtagaatagt  97980tgtatatagt gcttggcact ttaatattta gtatcggttt aatgataatg tttgtgcctt  98040tgccgtcttt aaaacatttt tacatcatcc ctgtttgatt acttggtgtg ctcatgaagt  98100tgttggccac taaggaatct taggctcaga gaggttctgg aattggccag tggtccttga  98160atcagctgct cctatgattc tctaactgat ttctcacaaa gcaaacaagc aatcataaca  98220aaacaactgt gcacactgct cttcttattt tgttatttaa aaagtactta ggctctactt  98280atgtttgtta gtcaatttct cattacttct agttaatcaa aaggtcagag gaaatacttg  98340aatattttca tactagaata ctttaaaaaa tcatgatttc cagtaatctc tttaaaactt  98400ggcaagttat tttgatctaa aagtttatct tttgtgtgca tatttttaaa gcttctagac  98460aatctgatac ctcaggtcct gttacaacaa gtaaatcctc atcactgggg agtttctatc  98520atcttccttc atacctcaaa ctgcatgatg tcctgaaagc tacacacgct aactacaagg  98580tatgggcctc tgcatctttt aaaaatatat atgcacacat acttacgtct aatggatagt  98640tgatgttttt cttatgattt gtaggatgta taagcccttt gagatatgag ttacatttag  98700ttttttcaag tttgtttgtc tttcagcttt gtttatgata gcttctatca tacaggtgtt  98760ttggattttc atattgtttg tactcacagc taagattgat tacagtgaca gagctaggat  98820gtgcagccag gttatagggg gaagtggccc tggtggagtc tggagggatc cgtgtacagg  98880cttccttccc tcccgtgagg ctcacacaaa aatacagcaa catgctggtc ctgcaggtac  98940cctctgccta acatgagcca caattccaga ctcacagaag aaaagcaggt gttcggcata  99000aaccatgtgt ttcaaatagt ctgggcatgg tgagccactt gttatcagct agggaaagtt  99060tatgtcagcg taagaaactg ttcaccagat acccccaaga gccagccttt ctgtctaggg  99120atgttttagt tttttagttc attttttttt ttaactttaa aattttctgt tcatctgcaa  99180tttgttagat atgaagtatg tgtctaattt aatttttgtt tttggttgtc cccaataatg  99240tttacagaag aatttttctg cactaattgg cttgagttac ttacattctc atagttctct  99300agtttcagta gtttcattta ttattttgtt atatcaatct atctgtctgc tcatctatta  99360gaagcatcct tgtttttttt ttttcttttt tagacagagt cttgctctgt ccccaggttg  99420gagtgcagtg gtgcaaccat gcctccctgc agtctcaggg ctcaagtgat cctcccacct  99480cagctcctga gtacctggga ctaccggcat gtgccaccac acccagctaa tttttacatt  99540ttttgtagag acagggtctc cctaagttgc ctgggctggt ctcaagctcc tggcttaagt  99600aatcctccct ccttggcctc ccaaagtgct gggattacag gtgtgagcaa ctgcacccgg  99660ctacaagtat acttcttaat tattgtagct taatggtatt tatgagggga tcagttcccc  99720tgttgttctt tagaattttc tggatattct tctttattga ttttgggatg tgaacaatag  99780aatcaacttc tacttgtaga ttgatttagg gagaacttat acctcagatg ttaagtcacc  99840ctgtccagaa tgtgggatgc tttcctattt gttcagaact ttttaaatta cctcagaagc  99900acatgaaatt taaaggattt taaaaaaaac ttaaagatta tttcacatag ctcttgcaca  99960tttcttgata aatgaatcct caggtattcc tctgtttttg ttactaatag ttacttctta 100020tgggtttttt ttcccctgaa aatcatttat caaacgtatg tggcttattt tctgaaggat 100080gtttgataat tttggaagat atgaaagtct tcatatttta caaggtttga ggtctcttta 100140agctgcatgg ttctcatgtc agctcccaaa gcagaagacg gcatgttgaa aaatgccgta 100200gagaagatac ttcttttcca cctgttttca actcatatca tcttgaattt cagggcacct 100260ttccatgctc ctagtgcttg ctatctgttt attattttcc ttcctgaata ccctgaactc 100320cagcatgttc tgctgtaatt ctggcctccc tggcatcttg gactcctgtt tcctttgctc 100380tgtcatcccc gcggtcagct cctgctgcgc agcttctcag ctgaagtgcg tttggagtgc 100440ctggcgtgtc ttgctggatc tttgagtatt gcctctggtt tccttggttc cttctgctga 100500gttgctcagc gtctccactc cccatttctt gtgtggccct tcctgcactc ctctgattcc 100560ttttgtcttc cctggtttct tgctttggtt tcgagtctcc acagaacttt tgcagctctt 100620ctgaagacct ggaagctttt tcatcttaat tctcatctca tgacctcttt tcccttcttt 100680gagagctaga acttcccatg gtgaacttct ctttccagaa ttccatgcct tcttttccct 100740cccacttacc tgttgtccag gagaggtcag attgctgtgc atattggagg agaacccttt 100800cttccctggg ctcttcatct cacatgacat caccacatca cctcgttcct tggaccctca 100860gtggtgtcac tgctggattt ttctttcctt tggctggcct tagggcacac ccaggttgac 100920tagcgtagtc atggtattta gatccactca cattttcagt ttctgtgtct gtctcttgcc 100980tgcttctgac ttcgcccaga gaaagcttct ctttcacaag ggttcttaga tttatgttca 101040ctgagcacct tcttttctga ggcagtgttt taccaatatt tattttccta gtcagtctcg 101100ccttaccttt cttgttatgc atgtctttgg tcctgaccca ttctctgagt ctgtaaaata 101160gaattgctgt ataatttaat tacatgaaat cctttagaat cttaacacat cttacacctg 101220atttaatatt ttattgtatc caaattgaac caaccctatg tgaatttgac agtgatttct 101280cccagggatc ctagtgtata aggaatagga cttagtattt tctatttttt gatataccac 101340ataccagata ctgattatga tggacattta accctttttt ctcattatga aagaaagtta 101400ggaattattt cttccagtag cgccagtgta acctgaaagc ctttgaaaga gtagtttttg 101460tatagctatc tgaaaggaat ttctttccaa aatatttttc cagtgctgac aacaaacacg 101520cagacacacc ctgcaaggtg agtgtacggc gccgcacagt ggaggcatct gctgcagccg 101580tcgatgtttg tgtctttggt tgtacattat gagatcgtga cagggccagt aaccgtgtgt 101640tctctccttc accttcccaa ggtcacgctg gatcttcaga acagcacgga aaagtttgga 101700gggtttctcc gctcagcctt ggatgttctt tctcagatac tagagctggc cacactgcag 101760gacattggga aggtttgtgt cttgtttttt ctccttgggt tgtggctggc acacttgatg 101820tgcgtcttct gggctgagtt catctaggat ggagcctggt tctccagggt gcctccggga 101880gactcctccc tgccccacgt gcttgcgtca caggacccaa gtctgactct gccttagcca 101940tgaagtttag ggggaagttt ctatttgtat tctatttttg tctgttatca tgtattagct 102000tagacccagt ttagtttgga aaatcagtgg gtttcaaaat gtgtttgtag agtcctttat 102060ttcttaactt gaccttttca agtggaaagg ggcaaaacag acgggtaagg gggcggggcg 102120ggaggtgtga cttgctcttt tgtgcctgag gaagtaacag agctggggtt gacagtcata 102180ttctctgaca cagatagtct ctgacttatc tcacagaaag tcagcggcag agcctgagtt 102240aaaagtctcg tagattttct ttttcttttt tttggtggct aatttcagtt ttatttatat 102300ttgtttattt atttattata ctttaagttc tgggttacat gtgcagaatg tgcagttttg 102360ttacataggt atacacgtgc catgatggtt tgctgcaccc atcaacccat cacctacatt 102420aggtatttct cctaatgtta tccctccccc agtcccctca ctccccatgg gccccggtgt 102480gtgatgttct cctccctgtg cccatgtgtt ctcattgttc aatttccact tgtgagtgag 102540aacatgcggt gtttggtttt ctgatcttgt gatagtttgc tgagaatgat ggtttccagc 102600atcatccatg tgcctgcaaa ggacatgaac tcatcctttt ttatggctgt atagtattcc 102660atggtgtata tgtgccacat tttcttaatc cagtctatca ttgatggaca ttcgggttgg 102720ttccaagtct ttgctattgt gactagtgcc acaataaaca tacatgtgca tgtgtcttta 102780tcgtagaatg atttataatc ctttgggtat atgcccagta atgggattgc tgggtcaaat 102840ggtatttcta gttctagacc tttgaggaat cgccagactg tcttccacaa tagttgaact 102900aatttacact cccaccaaca gtgtaaaagt gttcctattt ttccacaacc tctccagcat 102960ctgttgtttc gtgacttttt aacgatcgcc atcctaactg gcgtgagatg gtatctcatt 103020gtgattttga tctgcatttc tctaatgacc agtggtgatg agcatttttt cgtatgtctg 103080ttggctgcat aaatgtcttc ttttgcgaag tgtctgttca tatcctttgt ccattttttg 103140atggggttgt ttgctttttt ttcgtaaatt tgtttaagtt ctttgtagat tctggatgtt 103200aatcttttgt cagatgggta gattgcaaaa attttatccc attctgtagg ttgcctgttc 103260actctgatga tagtttcttt tgctatgcag aagctcttta gtttaattag atcccgtttg 103320tcaattttgg cttttgttgc cattgctttt ggtgttttag acatgaagtc tttgcctatg 103380cctatgtcct gaatgttatg gcccaggttt tcttctagga tttttatggt cctaggtctt 103440atgtttaagt ctttgatcca tcttgagttg atttttgtgt aaggtataag gaaggggtcc 103500agtttcagtt ttctgcatgt ggctagccag ttttcccaac accatttatt aaatagggaa 103560tcttttcccc attgcttatg tgtgtcaggt ttgtcaaaga tcagatgatt gtagatgtgt 103620ggtggtattt ctgaggcctc tgttctgttc cattggtcta tatatctgtt ttggtaccag 103680taccatgcag ttttggttac tgtagtgttg tagtatagtt tgaagtcagg tagtgtgatg 103740cctccagctt tgttcttcta gcccaggatt gtcttggcta tgcaggctct tttttggttc 103800catatgaagt ttaaaatagt tttttccaat tctgtgaaga aagtcagtga tagcttgatg 103860gggggatagc attgaatcta taaattactt tgggcagcaa ggccattttc acgatattga 103920ttcgtcctat ccatgaacat ggaatgtttt tctatttgtt tgtgtcctct cttatttcct 103980tgagcagtgg tttgtagttc tccttgaaga ggtccttcac atcccttgta agttgtcttc 104040ctaggtgttt cattccctta gtagcatttg tgaatgggag ttcactcatg atttggctct 104100ctgtttgtct gttattggtg tataggaatg cttgtgattt ttgcacattg attttgtatc 104160ctgagacttt gctgaagttg ctaatcagct taaggagatt ttgagctgaa ccaatagggt 104220tttctaaata tacaatcatg tcatctgcaa acagggacag ttttacttcc tctcttccta 104280tttgaatacc ctttattgct ttctcttgcc tgattgcgct ggccagaact tccaatacta 104340tgttgaatag gagtggtgag agagggcatc cttgtcttgt gccggttttc gaagggaatg 104400cttccagttt ttgcccattc agtatgatat tagctgtggg tttgtcataa atagctctta 104460ctatgttgag atacgttcca tcgataccta gtttattgag agtttttagc atgaaaggct 104520gttgaatttt gtcaaaggcc ttttctgcat ctgttgagat aatcatatgg tttttgttgt 104580tggttctgtt tatgtgatgg attacgttta ttgatttgcg tatgttgaac cagccttgca 104640ttccagggat gaagctgact tgattgtggt ggataagctt tttgatgtgc tgctggattc 104700agtttgccag tattttattg aggattttca catcgatgtt catcagggat attggcctaa 104760aattctcttt ttttgttgtg tctctgccag gctttggtat caggatgatg ctggcctcat 104820aaaatgagtt agggaggatt ctctcttttt ctattgattg gaatagtttc agaaggaatg 104880gtaccatctc ctctttgtac ctctggtaga attcggctgt gaatccatcc tggacttttt 104940ttggttagta ggctattaac tattgcctca agtttagaac ctgttatcag tctattcaga 105000gattcagctt ttttctggtt tagtcttggg agggtgtatg tgtccaggaa tttatccatt 105060tcttctagat tttctagttt atttgggtag agatgtttat agtattctct gatggtagtt 105120tgtatttctg tgggatcggt ggtgatatcc cctttatcgt ttttattgag tctatttgat 105180tcttctctct tttcttcttt attagtcttg ctagcggtct acctatttta ttgatctttt 105240caaaaaacca gcacctggat tcattgattt tttttggagg gttttttttc gtgtctctat 105300ctccttcagt tctgctctga tcttagttat tttttgtctt ctgctagctt ttgaatttgt 105360ttgctcttgc ttttctagtt cttttaattg tgatgttagg gtgttaattt tagatctttt 105420ctgctttctc ttgtgggcat ttagtgctat aaatttccct ctacacactg ctttaaatgt 105480gtcccagaga ttctggtatg ttgtgtcttc gttctcattg gtttccaaga aaatttttat 105540ttctgccttc atttcgttat ttacccagta gtcattcaag agcaggttgt tcagtttcca 105600tgtagttgtg tggttttgag tgagattctc aatcctgagt tctaatttga ttgcactgtg 105660gtctgacaga cagtttgttg tgatttctgt tcttttacat ttgctgagga gtgttttact 105720tccaactatg tggtcagttt tagaataagt gcaatgtggt gctgagaaga atgtatgttc 105780tgttgatttg gggtgcagag ttctgtagat gtctattagg tccgcttggt ccagtgctga 105840gttcaagtcc tggatatcct tgttaatttt ctggctcatt gatctgccta atattgacag 105900tggggtgtta aagtctccca ctattaccgg gtgggagtct ctttgtaggt ctctaagaac 105960ttgcttcatg aatctgggtg ctcctgtatt gggggcgtgt atatttagga tagttagctc 106020ttcttgttga attgatccct ttaccattat gtaatggcct tctttgtctc ctttgaactt 106080tgttgattta aagtctgttt tatcagagac taggattgca atccctgctt tttttttgct 106140ttccatttgc ttgttagatc ttcctccatc cctttatttt gagccaatga gtgtctttgc 106200atgtgagatg ggtctcctga atacagcaca ccaatgggtc ttgactcttt atccaatttg 106260ccagtctgtg tcttttaatt ggggcattta gcccatttac atttaaggtt aatattgcta 106320tgtgtgaatt tgatcctgtc attatgatcc tagttggtta ttttgcccgt taactgatgc 106380agtttcttca tagcgtcagt agtctttaca atttggcatg tttttgcagt ggctggtact 106440ggttgttcct ttccatgttt agtgcttcct tcaggagctc ttgtaaggca ggcctggtgg 106500tgacaaaatc tctgcatttg cttgtctgta aaggatttta tttctcgttc acttatgaag 106560cttagtttgg ctggatatga aattctgggt tgaaaatact ttttttaaag aatgttgaat 106620attggctccc actcttttct ggcttgtagg atttctgcag agagatctgc tgttagtctg 106680atgggcttcc ctttgtgggt aacccgacct ttctctctgg ctgccctttc cttcatttca 106740atcttggtgg atctgatgat tatgtgtctt ggggttgctc ttctcgagga gtatctttgt 106800ggtgttctct gtatttcctg aatttgaatg ttggtctgcc ttgctaggtt ggggaagttc 106860tcctggataa tatcctgaag agtgttttct aacttggttc tattctcccc atcactttca 106920ggtacaccaa tcaaacgtag atttggtctt ttcacatagt cccatatttc ttggaggctt 106980ggttcatttc ttttcactct tttttctcta atcttgtctt ctcgctttat ttcattaatt 107040tgatcttcaa tcactgatat cctttcttct gcttgattga atcggctgtc gaagcttgtg 107100tatacttcac aaaattctcg ttctgtggtt tttagctcca tcaggtcatt taagctcttc 107160tctacactgg ttattctagc cattagtcta acattttttt caaggttttt agcttccttg 107220tgatgggtta gaacatgctc ctttagctcg gagaagtttg ttattaccga ccttctgaag 107280cctacttctg tcaattcatc aaactcattc tccatccagt tttgttccct tgctggtgag 107340gagttgtgat cctttggagg agaagaggtg ttctggtttt tggaattttc agcctttctg 107400ctatggtttc tccccatcat tgtggtttta tctacctttg gtctttgatg ttggtgacct 107460acggatgggg ttttggtgtg ggtgtccttt ttgttgatgt tgatgctatt cctttctgtt 107520tgttagtttt ccttctaaca gacaggcccc tcagctgcag gtctgttgga gtttgctgga 107580ggtccactcc aggccctgtt tgcctgggca tcaccagcag aggctgcaga acagcaaata 107640ttgctgcctg atccttcctc tggaaacatc gtcccagagc acgaaggtgt ctgcctgtat 107700gaggtgtttg ttggccccta ctgggaggtg tctcccagtc aggctacatg ggggtcaggg 107760acccacttga ggcagtctgt tcattatcgg agcttgaatg ccgtaccggg agaaccactg 107820ctctcttcag agctgtcagg cacgtatgtt taaatctgga gaagctgtct gctgcctttt 107880gttcagatgt gcccttcccc cagaggtgga atctagagag gcagtaggcc ttgctgagct 107940gcagtgggct ctgcccagtt cgagcttccc tgctgctttg tttacactgt gagcatagaa 108000ccacctactc tagcctcagc agtggtggac acccctcccc cagccaagct cctgcatccc 108060aggtcgattt cagagtgctg cgctagcagt gagcaaggcc ccatgggcgt gggacccgct 108120gagccaggca caggagagaa tctcctggtc tgctggttgt gaagactgtg ggaaaagtgc 108180agtatttggg caggagtgta ctgctccttc aggtacagtc actcatggct tcctttggct 108240tggaaaggga agtcccccga ccccttgtgc ttcccaggtg aggcaacacc ccgccctgct 108300tcggcttgcc ctccgtgggc tgcacccact gtccagcaag tcccagtgag atgaactagg 108360tacctcagtt ggaaatgcag aaatcacctg tcttctgtgt cgatctcact gggagctgta 108420gactggagct gttcctattc ggccattttg gaagcatccc ttgttttttg aggtggagtc 108480ttgctctgtc gcccaggctg acgtgcatcg gcacaatctc ggcccactgc aacctttgcc 108540tcctggtttc aagcgattct cctacctcag cctccggagt agctgggatt acaggcacct 108600gccaccatgc ctggctaatt ttttgtattt ttagtggaga tggggtttca ccacattggc 108660caggctagtc tcgaactcct gaccttgtga tccacccacc tcagcctcct agagtgctgg 108720gatcacaggt gtcagccacc acgcccagcc atattttcag atctccctct ctttgcccta 108780aaccactgtg cttaataagt agtttttagt ggccagcagt ctccatgtat aacacatttt 108840agcaaaatgg aaaatactat atgttttaaa tttgaacgtg agattatact gaaataaaaa 108900tcatctaact gggattcttt aaatagtaag attttctttt ttgtatgtgg gttttttttt 108960aaccttatta ttatgactgt catatataga aatggctgtt tttcagttac agtcagtgaa 109020tgtatcaaat gctgccttat ccaaataata aaagtaaatt attaataagt cacaatttaa 109080tgaagattga tgttagttga tctttatatt cttgaaatca gccatatggt tgtgtgtgta 109140tgtatatatt tttaaaggta cataaagata ataagctcat ctctgaaaat ttttacattt 109200ggcataagaa taactggata attaagcatc ttattctctg gcctgtgtct ttacagttaa 109260aggtagattt actcacctct ccttttttgt ttttctaagt tcatcttttt tgctgtttca 109320agacagaggc ccattttagc tttctcgcat atccttttgt ttgtactttg gaagcctcac 109380ctgcttaatt gttgagtttt tatccgtggt cttttagagg gggatatgta gggtagaagc 109440tttcacaggt tcttgtttgc acttggcccc tgactgtttt gaggaatctc cctcactgac 109500tcacagcatg gcaaggtttc agatctcttt ctgccacaca gcagttctga ggcagctgga 109560aagatatcca gatgcttaga ttgtcaggcc aggcttgaga tatacaaact attgagcctt 109620atctgtgacc ttgcttaggt gaaggcatca gagcccctgc accaacatgc ataggcctct 109680gcatgtgtgc ggggctgggt gttgaggtct gagcacaagt gtagctggag aggtgagctt 109740gatgtggcga cgggtatgag caggttttct tcagacttct gtgagtttac ctagttccag 109800gatttaaagg cacagagact ttagaattaa aatagaatca ttttcttttt ctaaatagca 109860acactaggaa taaaaaataa taattccaca ttcttgacag gtaatgtttt ttcttgtctt 109920ctaatcctta tttattccat actcattttt atacataatt gaaatgtatt atgcattgga 109980tttttctttt gcattatatt atagacgatt tttcatgtaa ctccttactg ttccatttta 110040tatgttttgt ctggtttaag actttatctg caaaccggga aactgtctct acaaaaagaa 110100aaacaaaaat agttggccgc agtggcatgc gtctgtggtc ccagctactc ggggctgagg 110160tgggaggatt gcttgagcct tgggaggttg aggctgcaaa gagccatgat catgccattg 110220cactccagca tgggtgacag actttatact gtctgttttg ggtgatttga taatgatatg 110280ccctgatgta gtttttttat atcttgtgtt tcttgtgcct gggtttattg aggttgggtc 110340tgtggcttca tagtattttt aaagtttgga aaattttagg ccattctttc tttctttctt 110400tctttttttt ttttttgaga cagtgtctcg ctctgtcgcc tgcgttggag tgcagtgaca 110460ctatcttggc tcactgcaag ctctgcctcc tgggttcacg ccattctcct gcctcagcct 110520cctgagtagc tgggactaca ggcgcctgcc accacgcctg gctaattttt tgtattttta 110580gtagagacga ggtttcactg tgttagccag gatggtctca atctcctgac ctcgtgatct 110640gcccgcctgg gcctcccaaa gtgctgggat tacaggcgtg agccactgca cccagctagg 110700ccattatttc ttcaaagatt ttttttctgc cctgcctccc tccttttttc cctctcttaa 110760aggggctgtg atttcctgaa tgattgctta gtgttgtccc atagcttact gatgctcttt 110820tcagtgtttg attgttttat gtgttttctg ttttgtatag tttctattat tgtgttttca 110880agttctctga tcttttcttc tacagtgtct actctgttgt taatctgtta atctgttgtt 110940aatcctgtcc agcgtatttt tttttttgtt tttgaaacag tctcactctg ttgcccaggc 111000tggagtttag tggtgcgata tcagctcact gcaacctcca cctcccaggc tcaagcaatt 111060cttctgcctc agcctcccga gtagctggga ctataggcac gtgccaccac acctggctaa 111120tttgtgtatt tttattagag atggggtttc accatgttgg ccaaactggc cttgaactcc 111180tgacctcagg tgattcatcc gcctcggtct cccaaagtgt tgggattata ggcatgagcc 111240accgtgtctg gcccctgttc agtgtatatc actaattttg tttttatctc tagaagtttg 111300atttaggtct tttaaaaatg tctccctgtg tttctgttta gctttgtgaa cacaattgta 111360ataactgttt taatatcctt ctctgctagt tctaagatct tctaataact tcccagttct 111420tggtgtttct cattggttga ttgatactcc tcgttttggg ttgtattttc ctgcctcttt 111480gtatggctgc caatttttta ttggatgccc aaccttgtga attttacttt gttggatgct 111540atatattttt gtgttcccat agatcttctt gagctttgtt ctgaggttag ttgagttaca 111600tatagatggt ttactctttt gggtcttgct ttataatttg tcagatgggt tggagcagtg 111660cttagtttag gactaatttt ttttttggac taattattcc tctttaggaa taattaggta 111720ccatgcttag gaggcaagac catcctgagt actctaccta atgaaccaga aagtttgggt 111780tttccagtcc gcctgctgag aacagtgact ttctagccct gtgtgagcgc tgagctctgc 111840tccttctaat cctttccaat gcttctttcc ctggcctcag ggagttttct cacacacata 111900tctctgctga gtactcgaga gggaccttcc ccagatctcc agagctctct ctgtcttgtt 111960ttctcttctc tggtgctctg tcttatgaac tgtggctgtc ttggtctcct tagattctca 112020gcacctcttc aattcagagg gttgcctgtc cctcctcctt gtgccacagc ctaggaactc 112080tctcaaagca gcgagttggg gcagccatag ggctgactta gtctctcgtc tcccagggat 112140cactgtcctt cattgctcat gtccagtgtc ttgaggactc tgggttttgt ctgttttgtt 112200ttttggtttg ctttggttgt ctcaggcagg agggtaaacc cagtccctca ccctcattgt 112260gctcagtagt ggaagtctca ctctattaca ttagatatta gtatttgtag cagagccctg 112320gttccctggt acttggggag ctcttgaaag gccagaaaca gcatgctttc tcaccttttc 112380cagggcttca gtttctggtg cacatcaagc attccataca catttgttaa agtcctttgt 112440tagacaagta gtgattcaca ggttctattt gtaatttttt cagttaacat gtattgggta 112500tctgctggga gctagtaaaa acaaaaagtg gtgtgtgaca aattcaattc tgacaagaac 112560aaccttaaac acttagaata tactttgagc atatcagaat tttaaaaatg tgtggccctt 112620gagtatttga aaccaacaag aatctattgc ttattagtag aggatatttt gttaaacaag 112680tggagagaga ggcattttca gtctaattgg tgttggcttt tagcagctga tggaaaccag 112740ttcgtgatta gccaggcagt ggtgaaacag gctgtgcatt ctgaatgcct aggtatctag 112800gcattcagaa tggtggcgct ctttgagtta gcatcttctt ctttcttgat tctttttttt 112860ttttttttga gatggacttt cgctcttgtt gcccaggtaa caactccagt gcaatggcgc 112920catctcggct cactgtaacc tctgcctccc tggttcaagc gattctcctg cctcagcctc 112980tcaagtagct gggattacag gtgtgcgcca ccacgcctgg ctaattttgt atttttggta 113040gagatggggt ttcactatat tggtcaggct ggtcttgaac tcctgacctc aagtgatgca 113100cctgcctcga tctcccaaaa tgctgggatt acaggcgtga gccaccactc ccagcccctt 113160cttgattctt gaaaaggaca ttgggtgctg tacatctcgt tatagatgtt gataaaaatg 113220cttgtgagaa gagtaacatt aaggtagtta tttggtcatt tttgcagatt attttaagac 113280aattctagga ctgatttgtg gtaaatcaca cattgctgta tcatagttgt gttcactgaa 113340catattcagg ggctctacag atgcagggct cttagctgct ttgcacactt ctgaattcct 113400gccctgcgaa caggactgga tacctaatag acaacaggta cttgataaca gtttattgaa 113460ttaatgagtg aatgaacaga tacataaatg catgaaagaa tggttgtaat gtatataact 113520tggatttcaa gactttttac tgactgttca aaataagaaa ttgaaaactt tcctctgatt 113580ttcctctact atttacacaa tttaaatgga agttatcttg taccttcaat ttctgtctag 113640gattcgtaca ataacgggtc atctctgagt cgcttaatgt ctcacttgtc tttctacagt 113700gtgttgaaga gatcctagga tacctgaaat cctgctttag tcgagaacca atgatggcaa 113760ctgtttgtgt tcaacaagta agagcttcat tcttttcctc ttctgttaag acgttcgggt 113820atgacagcaa aacgctgcta ctccttaaga ggcaggcgct gttggcataa tcagctggga 113880ggattgtggg gtccagcgca gcactttttg gctcagtcca tgattgagcc aagaggccat 113940ccttcccttc actccccagg aggacgaggt ctgtcactgt ggagggcaga ggacaccaga 114000agctcctctg caacctcgct agttaacttc cagtccctcg gagtttctgt ttagaatgct 114060caatctcatt tagaattgca aggaaaccca aaacgcctat ttaaggtaca aacagcactt 114120catacaatat ctcatgaggt attaatagtg attcacagga agaatttcac gctgtgagtc 114180tttgctaaca tatccagtta tttacagatg gatttgatat ttgtgtggga gattcttaaa 114240agtgttgttc acgccacatt gttgatgcct catttttttc actgtagttg ttgaagactc 114300tctttggcac aaacttggcc tcccagtttg atggcttatc ttccaacccc agcaagtcac 114360aaggccgagc acagcgcctt ggctcctcca gtgtgaggcc aggcttgtac cactactgct 114420tcatggcccc gtacacccac ttcacccagg ccctcgctga cgccagcctg aggaacatgg 114480tgcaggcgga gcaggagaac gacacctcgg ggtaacagtt gtggcaagaa tgctgtcgtt 114540ggtggaagca cgaaagagca agcaggaaat actttgtaaa agaataaaaa cgaaaaatgt 114600tagcgaacat cttctaatag tctgctgtat tcagagaact ctaggagata tatatggttg 114660atgcaaagat gatttaaggc atagcccggc cttccaagaa gtgtgtggcc agtgagtgag 114720atgggcttgg gacttacaca tctcagaggt gggggtagag gaggaggaac actgagtggg 114780ctgagaagca gccagctctc attgccaaag tgtgtcagca aaccagaatg cagttcataa 114840tgtccccacc cattcaaagc acaggacctg tagagtggtg tggcatgtgt tggtggcact 114900tttcaggcct gtaacaagga tgaaagaaca gcttcatagc agcacagtag tgctggtgtt 114960cagaggtgtg tgaaggccat agaagcatct tggatatatt accttgtgtt ttgtcagctt 115020tatgactaga agtctctttt cacttaaatt tgtttttttt ttttttgaga cggagtcttg 115080ctctgtcgcc caggctggag tgcagtggtg caatctcagc tcactgcaag ctctgcatcc 115140tgggttcatg ccattctcct gcctcagcct cccgagtagc tgggactaca ggcgcctgcc 115200atcacgcctg gctaactttt ttttgtattt ttagtagaga cggggtttca ccatgttagc 115260caggatggtc tcgatctcct gacctcgtga tctgcccgtc ccggcctccc aaagtgctgg 115320gattacaggc gtgagccacc gcgcccggcc tcttttcact taaatttatg tttgtgtttt 115380taatgcctag tatacaggac ttcttaaatt gccttaagta tgaacaggta tttgagttgc 115440taatctgtat agtagcaata atagaatccc ttgtttttcc ttttataaat ttagcgatta 115500aatagctaca attaaaacac tagagtcagg agtcaaggaa aatacccatg ttccaggctg 115560tatgttagtg atgtacttac tatatattgg agtttcagga gtaagtctgt ttcaatgctt 115620tctgtaacca tttggggtat taataagcat gtgagtgtgt gcatgtttgg gttaatttca 115680tatatgtttc ttagaaggga tatcattgat gtaaatattt taaaggcttg tcctccaaaa 115740aaatcatgta atttcttcta aattactgat cttttaaatg accttcacct ttctctcaaa 115800tctcacttaa gactgggctg agtagtcagt ttcctgtagc agaaaaaagc tcagacttga 115860gtagccttct gcgagtgagg agacttgatg gctgtcaggc agctgtaaac tctaaataga 115920gtgtcattat ctgaagaggg cgatgctgcc acactgagtg gcctttcaag ttgtttctca 115980atctgacacg ttctgatcgt gtgaatgtga aattggtttg agcaggagta tatctgagtg 116040cagaggagat tatttaaaga tattctcatt ctctgcttcc cttttattcc catttggcag 116100atggtttgat gtcctccaga aagtgtctac ccagttgaag acaaacctca cgagtgtcac 116160aaagaaccgt gcagataagg taaatggtgc cgtttgtggc atgtgaactc aggcgtgtca 116220gtgctagaga ggaaactgga gctgagactt tccaggtatt ttgcttgaag cttttagttg 116280aaggcttact tatggattct ttctttcttt ttttcttttt tatagaatgc tattcataat 116340cacattcgtt tgtttgaacc tcttgttata aaagctttaa aacagtacac gactacaaca 116400tgtgtgcagt tacagaagca ggttttagat ttgctggcgc agctggttca gttacgggtt 116460aattactgtc ttctggattc agatcaggtt tgtcactttt atctttcatc catcatacct 116520gttcctaatt tagtacaaat taccctaaaa gacactgaaa tctactttaa agaaatgtgg 116580tctgcatgtt tccctcatca gttgctgctg cttatctttt tcatgcacct agctggtgca 116640gaaggcctgg ggcatagcca gcctcagcaa gtcagcatcc ttgccccagc tccctggact 116700caaggctaac ctggggttgg ctgttaggga tttccaaagg tttgtcccat ccacttgcct 116760cccctccaaa ataagtttga atttaaattg tgagatacaa ttaagattta ttgtttgggg 116820aacatttttg caaaatctag agttagttta aacagattat caattattac cataattgat 116880catctgcagt ttcaagctat ctaacaggtt cacttacctc tttaaaaagg aatggaattt 116940agcaggacag taactgagac ccgtgctcct ggagtccatg tgggagctgt gtggctctgc 117000acaagcattt gcacgcttcc cctcttgact gcattacctt cctcctatag ttgctgtggg 117060caccagattc tggctagtcc tgtcccttca tgatgcacat tttcctcaag attcgtccca 117120gttaaatcac tgcagatgaa actgcctttt catcgtcaaa atttaactgt catttttgag 117180ccgtgatctt gggctacttt cttatgtggg gtaggaatat ttgtgagtta gaaatattac 117240acttctctat ttccttctag acgtaaatct gttaatcctg tcagcactgt tactcacctg 117300aaagggtctg tttccctagg agaactgagg gcactcggtc aacactgatt ttccacagtg 117360ggtattgggg tggtatctgc ttgttttttt tgttgttgtt gtttgttttt ttttgttttt 117420tttttgagat ggagtctcgc tctgtcaccc aggctggagt gcaggggtgc gatctcggct 117480cactgccagc tccgcctcag aggttcacgc cattctcctg cctcagcctc ccgagtagct 117540gggactacag gcacccacca ctacgccagg ctaatttttt gtatttttag tagagacgag 117600gtttcactgt gttagccagg atggtctcca tctcctgacc tcgtgatctg cccgcctcgg 117660cctcccaaag tgctgggatg acaggcgtga gccaccgcgc ccggcctggg gtctgctttt 117720aatgaaggag gcatcaaggg gtgggctttg cgttggcctg atgctttcat ctttctttca 117780caaaacctgt ccgaagaaaa tccgtctaaa tgggccattg ctctcctcag gaaatagtca 117840ttgggaactt cttttccttt cctttgacac taggaggctg actggggaga agccctggtc 117900tatggctgtg ggcagcaggg gctgagagga gcaggctctc aggggggcac gggtacccca 117960agggaagcca gagccctgat ttgttccatt ctagtaagaa caaagactgc tctggtttca 118020tgtttgttct gattgccttt catcaaccgg tcccctttct cccagttctt aagattcagt 118080acagtgacag ttttatgaac aagaatagaa cactagaaca gacaaaccat tgaactctat 118140gctgataaag atttattgag ctcctgctgt atgtttgcat tctgcccaga ggctctgaga 118200aaaccaggcc atatgctcca tgctttatcc atggaagctc cccgtcaggt tgggaaagct 118260gacagctgca gggaatacag tgtgacacaa aactggctcc catgcagccc ttacgtgtcg 118320cctctcagat ggttggggga cgaaggtcga ctcctttggg tatcttatta ctaaaccagt 118380ttcagggaat ctgtgccacc ctatctgcca ttaacgtgaa cagatgagtc cccaaggtgt 118440aattttgggt attgtctgat gtctcttgga atttattatt tgtttttcca atgagatttc 118500acctcagggt atagtaaagt tgttgagggg attcctggat gtgttctgca attatctagg 118560ctgatttcag aatagagtta tgcttatagt caaatttatc agctgtcaag aattttattt 118620aaaatttatg cagataagca ggaggaaaag aagcctggtt tttacatttt aatcctatta 118680ttgatgtgaa attttatttt ccttcctgta ggtgtttatt ggctttgtat tgaaacagtt 118740tgaatacatt gaagtgggcc agttcaggta atagcatttt attattttag atttttttct 118800tcttcttgtg tacttacatg taatttaggt tattaagtga atgtttaaac tactgttagg 118860catttttgct gttttcttta aatggaaatc tgactaacat actgtgcatt tttgcttctc 118920ttaaaaatta atgtatatct caagacttgt ttggaagtag ttatgtatct gaaaattcca 118980tatgttgtca gtattcattg cacatttcaa agcatttaat tgtgttgaca gatggtggaa 119040tgaaatcttg tggtggagca ctagttttta aatcttctta gagaaagcag ttttatataa 119100tgttgtcttt agtaattatt atgcatttgt attctctgca gctttttctt gctagatgtt 119160gaggttttaa tacttcttgc tagtccatta caggtttata attattaaaa gttaaaattc 119220ttttagtacc taaaatgctt aataaacatt gtaattagga aaatttagtg cagaaggaaa 119280gtgttcccag attccctggg gtctggaaac atagtgttta ttctaattac atgacacctc 119340cactgtgttt tggggcaagt tactgtttct cttttgagtt tcaatttctt caagagcaaa 119400gaggcagagg agagctagga agatcgtagc tgctgtgccc ctgtgccgtc gggtgccttc 119460tacctgctgc ctccgaacct ttacacatgt ccctgctctg cgcgagggca cagatgggat 119520gcactgtggc aggggtgggg ttagagtaga tcacggacac ctgttagctt gatgtgtgct 119580tgctgtcaag gttgaatcat gaattatttt atgttgctta tattgatatg tatcttaatt 119640ttaaaagaaa ggtctaaatg gatgtttttg tttttaggga atcagaggca atcattccaa 119700acatcttttt cttcttggta ttactatctt atgaacgcta tcattcaaaa cagatcattg 119760gaattcctaa aatcattcag ctctgtgatg gcatcatggc cagtggaagg aaggctgtga 119820cacatggtaa cgggacacac ctttcactgt cgtcttcggt gtcgtgatgt gcttggcagt 119880gttcgttttc atatacccac tttgaacgtt gtcagtggca gccatgtgct tctcaggctc 119940tgcatgtgtg tctgtgtatg tgaaggtact ggttagagac gtttcaaaag agaagagagc 120000atattcttta ctctcagcaa tttgtaatct tctcagggaa aaaaattcaa gaaacagtaa 120060gataacctaa ggtacagata gattctgaat ataaagttcc tgttcattca catgaaacgc 120120taaaagttct tcacttgatc ttagccaaaa ggccaagaag cgatgcaaca ctaaaaattc 120180ttaaatcgaa cttgccgtga attaaatttt gatctctcat ccagtggtat tggagatata 120240gtttgacttg ggttcagggc tttctgtttt gcctgatgat tttgctggag cttaaataag 120300gaacccagga gatggccagc tgtgcaagcc cccagcctgt ggaaggagct agtgtggttt 120360tatgaatgag ttgcaaatct ttctttgagc tttttgaact gatcttccag cattgcccta 120420ttgacccctc cctgactcct ttgctggaat ctgtaggctt ttgaactttg acagggacac 120480atcctaagac ccttgcaaac tcccagatgt gagaatggca ctactactta gagtcttttc 120540gactcagcgt gtgtgcagaa gagcatcaac cgggctgtgt tgcgaggcag ggccttggct 120600gacctctcag tgtttacata gctaagccag ttagtgtttg ccacggcctc acaagggctt 120660cagattcaca cagccaaagt atagattatt aaaggcatag gtgtttggtt tcctggactt 120720ggagggtctt tggacagaaa atcagtaggc aaccacaccc agtactttgt gctgggaagc 120780ttggtcatct gtgagagggt cagagagtat acccatgcgt gcatgccacc gaagggtcag 120840tgagtattcc tgtgtgtgca tgtctcaggg ccggagagag tatgtgtcac tgagaggtca 120900gagtgtttgt gtgtgtgtca aagagggttg cattgtgccc ttcactgagg ggtcagaggg 120960tgcctcgcgt gtgtgtgtgt gtacgtgtgt gtgtgtcact gaggggtcag agtgtgcctg 121020tgtgtgtgct tgtgtgtgcg tacatgtcac tgaggggtca gagtgtgcct ctgtgtgtgt 121080gctcatgtgt gtgcatacgt gtcactgagg ggtcagagtg tgcctctgtg tgtgctcatt 121140tgtgagcgta tgtgtcactg agggggtcag agtgtgcctc tgtgtgtgtg ctcatgtgtg 121200agcgtatgtg tcactgaggg ggtcagagtg tgcctctgtg tgtgtgctca tgtgtgagcg 121260tatgtgtcac tgaggggtca gtgttcctat gtgctcatga cattgagggt cagagtgtgc 121320ctgtgtgcca atgaaaggca tttcttatat ttttttatat gtggtcatag tagaccagtt 121380aatttatttt gactcctgtg ttagaccaaa ataagacttg ggggaaagtc ccttatctat 121440ctaatgacag agtgagttta cttaaaaaag cataataatc cagtggcttt gactaaatgt 121500attatgtgga agtctttatt gtcttttcag atgaatcaag tagattattc ttgagaccag 121560gaatgttgct gttttggtta tttggaaagt tttatcattt tcaaattgac ttttgaattt 121620gagtcacctt ttttcagaag tggtgttaaa ttataggagc cctaggtttt ttttcttttt 121680ttagaagtca tcacaaaatg atcagtgttc agaggaagag ctttgacctt ccacatggta 121740taatgattga taaccttaat tcatctctta ccataaacca agtatgtgta agggttttct 121800ttatttcttg aaagcatttt gtagatgttg agagcagttt tccaaatgta atttccatga 121860aatgcctgat aagggtaccc ttttgtcccc acagccatac cggctctgca gcccatagtc 121920cacgacctct ttgtattaag aggaacaaat aaagctgatg caggaaaaga gcttgaaacc 121980caaaaagagg tggtggtgtc aatgttactg agactcatcc agtaccatca ggtaagagga 122040atgtatgttg gaactgtcgt ggatacttta ttgacccgtg cagatggaag gaagtgccat 122100gtggtaacgc tcactgttaa ctgtgttact ttgaaccagg tttgggcttt ctggggcctg 122160ggtagatgcc ggtgcagggg gatggggagg gaggcggggg gtgggggggt gtggtggagt 122220tggggaggtg cagtggcagg aggtgttgtt ggtgtgtatc cttttttttt ttttgagatg 122280gagtctctct ccgtcgccca ggctggagtg tggtggcacg atcttggctc attgcaagct 122340ccacctcccg ggtttaagca attctcctgc ctccacctcc cgagtagctg ggattacagg 122400catgcaccac catgcccagc aaattttttt ttttgtattt ttagtagaga tggggtttca 122460ccatgatggc caagctgttt cgaactcctg acctcaagtg atcctcctgc cttggcctcc 122520caaagtgcta ggattacagg cgtgagccac catgcccagc ctggtgttta tctttaaagt 122580gggcacagcc acaggagttc acctgactcc tggtctgaga gtcacgagat cgttcaagat 122640agtgaggccc tcttttccaa aacgaggacc aaaaatcaat tgacagtgtt ggtcaagatg 122700gtagaaacct taaaatgata gaaatctcaa ctctgaaata aaaactttat ttgtatattt 122760atttaccact attttgacat agggctaagg tctttttctt tgagctgatt tctggttttg 122820ttttcttaaa gtggcataag aattcaaaga cattttgagg aaggctgagt gcagaaatct 122880ctctttttaa atgacttctc ctttctttta acttgcactg ttgtctagcc ctcacttatt 122940ttgtcaattc tttttagctg tttgtctttg aatcttcata aagccatagc ttttctcata 123000agaagcagca ctttctttgt tcattcatat tttaatgaac ccctgtagta tttaattaaa 123060tacttaatgc ctaattaaat cacataattg caatgcaaaa gtacatgtat cataaagagg 123120tctgaaaatg agcaactggc aagcaggtgg tggcaggcag agctgcttgg gtgggtgggt 123180gtcatggaga ggagttcatc agccacatgt tcagtgagct ctggatatgt ctgtttagaa 123240atgatcacta ataaacttgt gctcaaccat gtatacctct gggaagcagg tgctcttcag 123300tagattgcct ctgcagagaa cacagaattg aagtgaatgt ccacaaaggc aatgagccac 123360ctgcagaata gtttagtcaa ggctgtgttt gaagtttgcc aaagattaat atacatttga 123420ttttcatgtt gtgccttttc tctgattgtg aaatattaca aattctatac aaataacaat 123480gatggcaaat cctcctgagc aaagtgtgca ccttgtatgt gccctagagg aacttgtgtt 123540tcgttctgat tcccctacat ttctcatgtc atagagtggg ggttgcatta gtgtccccct 123600gtcctcgctg ggatcacatc tgtttggatc ctagagtctt ccagctgaac tgggacaagt 123660ataacagacg gacacgtagg ggtggaaagg cgtctcttgg cagcagactt tctaattgtg 123720cacgctctta taggtgttgg agatgttcat tcttgtcctg cagcagtgcc acaaggagaa 123780tgaagacaag tggaagcgac tgtctcgaca gatagctgac atcatcctcc caatgttagc 123840caaacagcag gtttgtcccc gcagccttgg cttgttgttg catagtgatg gtagcttaag 123900gtccttgtga aaggtgggtg gctggaatca gctcttcctt cagtcctaat ctgtgccttg 123960atagcagttc tccgtgctag tcatgggaca gctgacttca tttcttctca caatgccatc 124020tcaggttggt attgcccacc tactttacag gggggatccc acagctccga gaggttatgg 124080aggtgatcag gcagcacaca gctttagagt gctggggtga gggcgggcca aggctaactc 124140taaagcccga acccttacct cctacactgc ctcctgcatt ctggtcaacc cagtgtttta 124200tttggtggtt agatttttgt ttttgttacc ttactgcttg taatttagca gttttccttt 124260cctttccctt cctttccttt ccgacagggt ctcactctgt cacccaggct agagtgcagt 124320cgtgtaatct cactgcaaca acctctgcct cccaggttca accaattctc ccacctcagc 124380ctcctgagta gcaaggacca caggtgtgca ccactacgcc tggctagttt tttgtatttt 124440tagtagagat gaggtctcgc tgtgttgccc aggctggttt taaactcctg ggcgcaagtg 124500atccaccaac cttggcctgc caaagtgctg gcattacagg tgtgagccac ctcgcctggc 124560ctattcatca ctaatcagaa tttctatgat caaatgacat gaatcattgt ttccacaact 124620gcagtggaag gaaatggcct ggcagtgcca gtttcagaag cagcctgccc ccagtcaggc 124680acaggccact gtgcccccag tgtagcagca cctctgtagc tcacagagaa gggtggtggg 124740gacctccttg aggcagctct gccagaaaat ctcatgagct gcctggcaca gcttgaggtt 124800gccttttaag tggactcagc aaatacatgt ttgttcatct tgattataca caataaacaa 124860ctactctgta tagtacgagt agtccgtggt ttttggcatt tgatttaaac ttagaggcat 124920gtgatattga tgttactgcc ttcatgactg cacccccatt ctgatttcat aatggaatgt 124980tatcttgaga ccagttagac aacaggacag ggatcttggc ttctggtgag attgacagca 125040gttttagtgt ggtcagggtc tccctgccta cagatggttt tagaatggtg ccctggaagc 125100tttatcccat tcttttctgt gcgtaatctg agtagagtgg agatcgaagg cctgaataca 125160tagtaaatac ctgacttaat atctgccgca atggaaattg tgtgatacaa catttatgaa 125220acgcttagtg cagcacctgc caggtagctc accacaggtg catgttgcat tcagaagtag 125280tgctagatac tatcctgtta ctggcagtgc atacatcagt gatcaaagca gattaaagaa 125340agaccccctg ccttcttgga gtgaagattt tgttgggatg cgggtaaggg gacagacaat 125400agaaaagcaa gtgagtgaag tctataccat ggcggctgat caggaacacc gtacagaaga 125460atccaggagg gaagagagtt aggtggtgtc tgcggtggga gtggcattgt tcagctggtg 125520atgagaagaa gctttggtga tctggtgaca tttgagtgaa tttgcagaaa ggaaagatac 125580aagcctagga gatacctggg gaaggaacat tccaggcaga gcaaatagca gtgcaaaggc 125640cctggcgggg ggcggacatg ctgttagggt acaagcaatg agggtggagg agtggggcag 125700ccatggggag ggaagggagt gaggcctggt ggggtgaggc cagtgtggag gagccttgag 125760agggtttgcg ctgatgtggt gtaggtttta gcaggatcat tcttattcct gagttgagaa 125820tagccttgag ggggaggtga gggcagagca gggccaccca tgtgagaccc ggcactggag 125880tggaatggcc caagtcagca tcccttggca gcatgaaagc aaaaccagca aggtttgctg 125940gtggcttaga tgtggcatgt gagagagagc agggctttgg gggtgatttc agggtgagga 126000cagggtggct gtggacaagg tagggcagac attgggggca gcaggaggtc agagcctgtc 126060tggatgtagc agttgagacc ccataggtgc ctaatgaggt gaggccagca tcaggtgtat 126120gagcctggag ttgtcgagag actgtggggc agggggtcag catctgagat gtccactcac 126180agtggaccca gactggctgg agaggaggag gagcttgaat accgagcctg ctgagtccca 126240gctccaaggt caggtaggtg aggggagcca gtgctggggc agggggagta ggcaggtgtg 126300gggttcctaa agccaagatt ttttttaagg cattttgtgc aggagggcga catctgctgt 126360cagcaccttg ggaacttggc ccaggtttgg cagcaccgag ggcactgatg agtgcttttg 126420gaggagcaaa gggagccaaa ccctaatggg aatgtgttcc tgaaaggaca ggagagagac 126480ttgggaaaag gttttacttg aagagggaac ggagaaatag ggcagtagcc agaggaggag 126540aggagtcggc aatgggttaa gttggcagaa atgaaggcct gtttacgcac tgagggcaga 126600agcaacaggg aggatcagtt catgacacag gagacacaaa tcgccgttgt ggtgttcaca 126660gacatgggtt aggattggct gcatggatga cagagcactg tgggttctcc cagagttgct 126720ggggaggagg cagagttggt gagcacaggc gagggtccag gatgcaggaa tcctggagct 126780caagtcagtt gttcccttgt tgtaagatgt ggccagtgtt gtgagcttca catctgtgcc 126840ttgaaaaaca ccacatctgt ttgcagagtt gtttactatg tatacacact cagtagaaac 126900aaaaattgga aacagtcagt gcccaccatc aataagtaat ggttgaacac actgtggtat 126960aagcttagac tattttagct tgggctattt tgcatgatta aaaatgttct ggccaggtgt 127020ggtggctcat gcctgtaatc ccagcacttt gggaggccaa ggcaggcaga ttgcttgagc 127080tcaggagttt gagaccagcc tgggcaacat ggtgaaaccc tgtctctact agaaatacaa 127140aaagtagctg ggtgtggtgg tgtgcgcctg tagtcctggc taactcagga ggctgaggtg 127200ggaggatcac ttgagcccat tcgtgcgcca ctgcactcct ggggcacaga gtgagactct 127260gttagaaaga gagagagaga aagaagagag agggagggag gaaggaagga aggaaataaa 127320tggaagaaat ggaagggagg aaggggaggg aggaaggaag aaaggaagtt cagccagttg 127380ccttgggagt tctccattgc actgggttaa gtgagaagag cagagacgtt tatgattttt 127440caaaacaact aaaacaaaac ctctgtgggt gagggggcaa ggatatggct ataggaacat 127500ggggcagatt aagaaaggga tatacacaca ccacttagca tttgttacaa ctgttgtggg 127560agggatggag tgcagaaaaa gaaaaaaaaa agtgcacacc atcccatgta tgtgtataca 127620aagggacgct tggaagactg gtccccaaaa tgttggtaat gattgtgtca gggtgctgca 127680gtgctagttg attttttttc acacttttgt atatttgagt cttttacaga aagcatttat 127740tatttatgta ataaaaatct aaatgacaag atttctgtta tgggaaaaat gtagctatac 127800agtgttgttg taaaaatgtt tgcttggttc accactgaac ttaaaatgct tttaaatgag 127860ggaaggtgac gatgagatga ttatgatgat ttgcccttga gttacatagc tggtgtacag 127920gaagctgtcg tttcttttgg cttacgtaga aatgtttgtg gtgtctaatt ccacagatgc 127980acattgactc tcatgaagcc cttggagtgt taaatacatt atttgagatt ttggcccctt 128040cctccctccg tccggtagac atgcttttac ggagtatgtt cgtcactcca aacacaatgg 128100tgagtctctc gcctggctca gcagatgaat ctggacggct tgttcaggct ctgattactg 128160ggaccacccc cagaatgtct gagtcagtca gtttgggtag ggcttcttga gagtttgctt 128220tttttttttt tttttttttt ggtgtggggg tggtgcggaa cagagtctca ctctgtcgcc 128280caggctggag tacagtgtca tgatctcggc tcactgcaag ctctgccttc cagcttcaca 128340ccattctcct gcctcagcct cccgagttgc tgggactaca agcgcccacc accacgcccg 128400gctaattttt ttgtattttt agtagagatg gggtttcacc gtgttagcca ggatggtctt 128460gatctcctga cctcgtgacc cgcccatctc agcctcccaa agtgctggga ttacaggcgt 128520gagccaccgc acccggcctt tttatttttt ttggagatgg agccttgctc tgtcacccag 128580gctggagtac agtggcgcta cctcgactca ctgcaacctc cgcctcccgg gttcaagcaa 128640ttttcctgcc tcagcctccc gagtagctgg gactacaggt gcgtgccact gtgcccggct 128700aattttttgt atttttagta gagacggggt ttcactgtgt tagccaggat ggtcgcgatc 128760tcctgacctt gtgatccgcc cgcctcggcc tcccaaagtg ttgggattac aggtggctct 128820cgcaccaagc caagagtttg catttttagc aaattcccag gtgaaactaa tgcctgcttt 128880tctgggagca cactttggga ctcagtgata gagaggttta ttggtaggat agtaaaatag 128940gagttatttt ctttcacaaa attggcaatt gggggaaatt taatcttcct tttttcttca 129000gctgtgactt atgtattatg tttattttag gcgtccgtga gcactgttca actgtggata 129060tcgggaattc tggccatttt gagggttctg atttcccagt caactgaaga tattgttctt 129120tctcgtattc aggagctctc cttctctccg tatttaatct cctgtacagt aattaatagg 129180ttaagagatg gggacagtac ttcaacgcta gaagaacaca gtgaagggaa acaaataaag 129240aatttgccag aagaaacatt ttcaaggtat gctttctatc tgagcctata actaacccat 129300gccttttggg aagtcacgtg atgtttcaca gtcagtaagt ctggaataat acctggtctt 129360gcttcacttc tgagttgggt aaagaagtct gtatcagtgt aattttctaa tccgtcctgc 129420attatctatg gctcttggtt catacctgtc ttgaagttct gtcatgttct gtctcttgtc 129480ctcagtagag atgctacagc agtggctcgc ctcaggcagg gcagggcagt ggggtggctg 129540tcctgggggc aggcagtagg ggcacgctga cgtcagggaa gttgaaaccc aagagaagcc 129600agtaaaagtg agtctcagat tgtcaccatg tgctggcagt tttacacgct gtcagtaata 129660aaagtcttct ccctgcaggg cagcctgcct ccaataaata cgtgtagtat caaatcctgt 129720cttccctcat aaattgtttg gaagctcccc aaggacagtg atgaggcact cgtaagtgct 129780tgctgcctag atgggtccct ctccaccttt gctagattct gagcattcac tgagttagag 129840ctgcttctgc aaatgtgctg cttctgctaa gtggctgtga cttcatgcag ccttcacttg 129900gtttgtcatc agtggagatg ccctgtgttg tcgaaggaga taagcccagt aagcctgctg 129960ggcacctttt ggtttgcagg ttcagcaggc agcccatggc tttccctgtg tcgcattgaa 130020gcagctggct aaaattgatg atacattaaa ttcctgtgac agatgatcag cttgtatttg 130080tgtaatggtg tacagttcac aaagcttaaa aaaatgctac ctgccatttc atcctcagtg 130140aggaaggtga tacacagaga gaccaagtga ctgtgtccac ggcgacggcg ctctgcattt 130200cactttagcg gttaatgtac tctacctata tttttacttt atatttacca tatatctttt 130260catgtatact tggcgtaagt gctttatagt agtcacctaa ttcactgtca tcttttttgt 130320ttcttggaag gtttctatta caactggttg gtattctttt agaagacatt gttacaaaac 130380agctgaaggt ggaaatgagt gagcagcaac atactttcta ttgccaggaa ctaggcacac 130440tgctaatgtg tctgatccac atcttcaagt ctggtaggtg aatcacatta gtcttcctgg 130500agtgtctcgt tccccattct gcactataca ctctcagagt gtaggagctg tgctgcccgg 130560tagaaactct gccttgccca gtgtgccagt tgaaaatatt tgttgctgta agagtacacc 130620tgataccatg tgacccagca gttccactct tgggtatata cccaaaagaa tggaaagcag 130680ggtggtgaaa agatatttgc atgccagcat tcatagcagc attattcacg atagctaaaa 130740tgtggaacca actgaagtgt ccctcgatgg atgaatggat aagcaaaatc tggtgtatat 130800ttacagtgga atattattca gccttaaaaa aaggacattc tgacacatgc tacaacatgg 130860gtgaccctta aggacattat gctaaatgaa ataagccagt cacaaaagga caaatactat 130920gtgattccac ttacatgagg gacctggagt agttaattca tagatataga aagtagaatg 130980gtggttgcca ggggctgcag gggaggggag ttatttttac aagatgaaga gagttattct 131040agaaatgaat ggtggtgatg gttgtataac attatgaatg tacttaatgc tactgaactg 131100tacagttaaa aatagttaag aggaccaggt gtcatggctc atgcctgaaa tccaagcact 131160ttgagaggcc aaggcaggag gattgcttga gccaaggagt ttgagaccag cctcagcaac 131220atggtaggac cccatctgta caaacaaact agccggggat agtggtgtgc atgtggtccc 131280agctactcag gagactgagg ctggaggatc gcttgagccc aggaggttaa gtctctagtg 131340agatgtgttc atgccactgc actccagcct cggctataga gtaagaccct gcctcaaaaa 131400aacaaaacaa aacaagacaa gagccaaaaa tggttaagat gggccaatca cagtggctta 131460tgcctgtaat cccaacactt tgggaggtca aggtaaaagg atcacttgaa gccaggagct 131520tgggaccagc ctgagcaaca tatcgagacc cctatctcta caaagaaaat caaaaactag 131580ctagatatgg tgggcacatg cctgtagtcc cagctacttg ggaggctgag gtgggaggat 131640ctcttgagct caggagttcg aggctgcagg gagctattat tgcactccag cctgggctac 131700agaatgatac cctgcctctt attaaaaaaa aatccaaaaa aaaaaaaaag taaacctgag 131760agcttcctcc tcctgtgtta aatttggagg ccaagatgtt tttgttactt ttacaaatga 131820tcaaggacgg tgaaggttgg gcatggtagc tcacacctga aatcccagca ctttgggagg 131880ctgaggcggg gtgatcgctt gagcttgaga ccagcctgga caacatagca agagacccca 131940tctccacaaa aataaaaaaa taaaaaaaaa tagccaggag tagtggcatg agcctgagcc 132000caggaggtca agctgtagtg agccatgatc atgccactgc actccagcct gggcgagatc 132060gagaccatgt ctctagagaa agaaaatgac aaggacagtg aacccaagaa agtcataaga 132120tgccagctgt gcagcaagca tggaaagcag ccagtccaaa ttaggacagt gtgttttcca 132180agaagaacga tcgtttgtaa tgagaatgct ttgctttaaa taaatgacta aatagctaga 132240agcctagttc taggggatag gcacgtcttt cttctctcaa gaaaatagaa aggcaattct 132300aatttctagt aacagcaaac agcattaagt catggtccaa atatgaggca aaccaaaatg 132360tggcttgatt gttcagcagt tgatctgttg gaagcccttg atattaaaaa ggttctcctt 132420taagcggctt aggagtcacg atcaaagacc tatagaaaga gatgccatcc ttctaggatc 132480cttggctctc ttgggaacta gattcagata gtcataatgt aaatactgct tgagctttct 132540ttctttcttt ctttctttct tttttttttt gagacagagt ttcactcttg ttgcccatcc 132600tggagtgcaa tggtgccatc tcggctcacc gcaacctctg cctcccaggt tcaagcaatt 132660ctcctgcctc agcctcccga gtagctggga ttacgggcat gcaccaccac gcctggctaa 132720ttttttgtat ttttagtaga gacagggttt ctccatgttg aggctggtct cgaactcctg 132780acctcaggtg atccacccgc ctcggcctcc caaagtgctg ggattacagg tgtgagccac 132840cgcacccggc ccgagctttc atttttgaaa tcaatgtatg actgaaacac tgaagactta 132900ctgacttaat tatggtttca gaacagaatg aaaatgtctt cggttctgat gaatataaaa 132960ggaaaactaa ccaagttaat ttggcaagta gatggtagag atagaggtgg ggagtggaag 133020gggaactaaa atcttcacct agcattgttg ggattatatg gttacatcat ctgaagttga 133080cagaccaaaa tatagaggct tcagaggtct ccaaatagaa ctaaacatgt aattcagatt 133140gttaggaggt agtataaatg agctaaatct catctttatt acggtagagt taatgggtga 133200tgtctaaagt tgtctgaagt ctataaatca tgacaaatta tgatgtggtg attgtattca 133260acagtctttc agttgcaggg ataaaacccc agtttaaact agagtaagag aaagaatgtg 133320ttggtttaag ctcctggaaa gtgcaggcaa gggtagttgg taggactgca tctagtgttg 133380taattctgtg gtctgcattg tatatttatg catctcagct ctgctttctt cttttcattt 133440atataatttt taaattttat tttaaagata gggtctcact ttgtcgccta ggctgaagtg 133500cagtggcatg aagtgcagtg cgaggctcac tctagcctcg aactcctggg ctctagagtt 133560cttcctgcct cagccttcta agtagctgag acaataggca tgtaccaaca tgcctggata 133620ggttttaaaa tttttttgta gaaatggaag tcttgctgtg ttgcccaggc gggtctttaa 133680ctcttagctt caggcgatcc tcctgcctct gcctcccaaa atgctgaggt tataggtgtc 133740acccaccacg cccagtctca tctctgcttc ctgtgttagt tttgttctct ggtgggctgt 133800tttcacatga ccgaagatga cctctagcag gctgtgttct cagcccctca agtaggccta 133860tgtgattggc cttgcatgag taatatgggt gaccataaac ccctgaatgc tctggtccac 133920atgggccaaa tgggagactg gacagcattc cattgatgag gaggtggggc tggtctccgg 133980gagtaaggga gaggagcaca tgcagtaact gatggtctgc tgcaagggat agcagcacag 134040cagttagaat tttggaggta actaccagaa ctgaaaacag aaatgataac aagtagttgc 134100cttaaaaagg gatgggagca gggtgctttt gtgatcaaag ctcctttctc ttactggatt 134160tttgtacaca ttttgcatac atatcttaga gtaaaagata gcattttcag ccttggtcca 134220tttgaggata ctcttggcgt ggcccgcctc catgctagca ggctctggtt gtgccaagtt 134280cagttgagca tcctggctct tgcctgcacg gaacttccag tcagtgcgtc agtatcacaa 134340gtcttgatat ttcctatgaa gaagaacagt agtgcagtga cagacgaaat gggtgggcag 134400gcagaggcag gatttctgag ggagagaagt agctagcttt ttgcagagaa gagttccggc 134460acccaagaga gcagctgaga gtacaggcag gcaggcagga tgccggtagg gcccggccgc 134520acggcgccac agaatcctgg agaaaggggc ctcttcatgg cctctgcatt cagctgctgt 134580caccctccgc acaggccatg gccaaaattt aattttcata gtggactcta gtttttgagc 134640cttacttgct attattgaaa taattttctt gtttcttttt aaagatcttc ggattatgct 134700tcactgacca ctgtaataag tttaaagttg agaaaatatg gcttgttaat gaatgatagg 134760tcaattttag tatgttggtc attttaatat tttgccacca gttggtttgg atttgatgcc 134820aggaggagac agcctcattt ctaaggacta gtcttgcctt tgtgggataa gggtggtgtg 134880ttctgtgtcc ttctacatgt ccgagcgatc tctgtgcagc tcaaatgtgg tcactgtctt 134940attgcgctga tttcctctcc ttccatctca caattgaggc aaaatattgt tactgttgaa 135000gtgttgtcca ataggacttc cagcagagac aggatgtctg cactgtctaa tttagttgcc 135060tttagccaca tgtggtgttc tgtacctgaa atgtggctgg tctgattgga tagcttaatt 135120tataatttta tttaatttta attaacttaa atttaaacag ctctgtgtgg atagtggctc 135180ctgtatgaga cagtgcaggt ctgttgagaa gcagctttac tggtgggagt ggagggcttg 135240gagagggcac gtgggtttcc tgctggtatc ttttgacctt atttaatctg cccaacattt 135300gcaagtaagt tgtgtgtgtg tgtatatata aatgtgtgtt tctgtcttct tgtttccttt 135360gactgcattt atttgaaaga cactaggtgg cagaattact gtatttgatt ggtttcaaga 135420taagagttga aataattcat ctcgtgtttt tatataagta aggtgtgttt agcatgtaaa 135480attggtaata tgtattcacg tactgcttaa acaaaggcta tgaattccac ccataaaccg 135540aaaatgaaga cctttaaatt tgtccatttc aggcgtgggt acttcttaaa taatacctgg 135600ttcaggaact agtcagaatg gcacccttga ctttttgttt cctgcttttc ctcttgttgg 135660gagaggaggg tattcatccc aaagtggttt gcctatttca cattccatct aggataagca 135720gaatagccaa gaaagatagc tgtcctcctg tttacaacat ttggggtaac cagcatccct 135780ctcttttggt ccaagataga ctggtttaga aacagatgat ggcaccagag gcccaggagg 135840tggaaacatc agctttgttt gttgtccatg tggctgaatt agagctgtct ggccttgtag 135900cctcaacacg gccttccagc tttgctcacc gtgattttca aggacacatc ttgtgctctt 135960ccctgcctgc catccagact atacccagtc agggtggcag gagctgctgc cccttcctcc 136020ctgagtcctg gtcgtgggtg gtggagatgt gccatgacgc tcacggaggc atgctcaccc 136080cttcctctgt ggcagagggg atggctgcac gacagctctt ccctgtcctt tccaaagcgt 136140ctgtggttcc actttttggg gcaaagcagg aatactggaa gagagagaaa gtggtccttt 136200ctatagtaat aaagttgaca ttgattcaag ttcatgcttg gggaaaggac agggctacta 136260acaattataa tgctgggagc aatggaattt tctcatgggt atgtggtagg tttaatttta 136320attatcccag ttaattctta gaactgctct gtgaagtatt tcccgctttg tgcttaagtt 136380ctaaaagatc ctgtgccaaa accaagaatg aaaacccaag cattctttct tgcccatcga 136440tctttctctc atcaggccac ttcttgggtt gatagtggtg agtgtagccg ctgccacttt 136500cagaataccc accatgggcc ccagtcactg tgtggcgtgg agaagagatg gttctctctg 136560tgtcatagct gaacaagccc agcccagaga ggtttctgcc ctaggagctc tcgatggtgg 136620aattgggatg cgatcccaca tcctgcctgt tttgaaaaca gcattcttta tttccaattc 136680ctgcttccat tgttcctttt aatatttctt tgtttagctc acaaaaacac ggcttgcgga 136740gctgctgcgt gcagctgtag ctgtttctct gggtgcagcc tgcatccgcc ttcctgcccg 136800cctcctttcc tgcactgcca tcgtggtctc cgggcacttg gtccctttct cttcccctga 136860gtccctttgg ctcccctgtg ccacccttgt gatccacagg ctctgccttc tttctgtctc 136920agactgctgc tcatcactac tcgggaccct aggaagggag gttccaccga gaagcatctt 136980ctcatctcag ccacgttctc agtgccactg ttgtctttgt taggtaatgg tagctactgt 137040aacaaataaa ccaacatttc catggcttca caccagagaa ggttgtttct tggttttatg 137100acaatgtatt gagggtgttc ttggttcacg gatggttttc ctccatgtgg gaattcgggg 137160acccaggctc ctttccttct tttggttctg ttctccaggc cttcacatcc tctgtgtctg 137220gttggggaca aggagaggga aggtaaagaa ggctttgtgg ccttggataa gtgacaggca 137280tgcctttgct ggtgttctct cgtggtgaca ggtcacagcc ccaccctgta aaaggggact 137340gagagacgtc gtcctgctgc ttcccagcag cagcactgtg gtctctgatg tgttttctgt 137400gaggataaaa acaggtgatt ccaggatgag gaaagtcagg gaaacccttg gaaggagggg 137460accaggcggg tgtcaccatg ggattagtgg tggcttcaga atgagctgca gcgagtgcca 137520tgccttctaa agcttttgct attctgatat gcccacacca tgcccagcag gtgtctgcct 137580tgctctccgc agagagagtg atgaatcctt ctcatgagcc tctgtccagt tgttcctccc 137640tccacctgga agggaccctg ggttcctcat aacatcccag cggaacaggg gaccttctat 137700cctgtcccca agttcatcct catcctcctg ccggcttcct ggcccctctt atgtctgctt 137760cctgacgcca catccttctg gattctctgg aattgaattt tgcctttgat gcttatttaa 137820aaatatccat tgcaggccag gtgtggtggc tcacacctgt aatcctgtgc actttgggaa 137880gccaaggtgg gcagattgct tgagcccagg agtttgagat tagcctgagc aacatgttga 137940aatcctgttt ctatagaaaa tacaaaaatt agctgggcat ggtggcgcac acctatactc 138000ccagctactc aggaacctga gacaggagga tcaattgagc cccggaggcc aaagctacag 138060tgggctgtga tcgtgccact gtactccagt ctggtcaaac agagtgagac cctgtctgaa 138120aaaaaaaaaa aaatccattg catacttcac cgtagcgaaa catgtatgtc ttacctttcc 138180tttcctgcct gtagctgctc ttttacactt aacagccaca ctaagccagc cttaaatgaa 138240aaacaaacca gcacttcctg tgccctcctg cttccttcat gaggggtccc tccctctgtg 138300tacactccat tctcattgcc catggtggtt tgtttccctc ttgtttctca agccatggca 138360gcctgcctct tgccctcttt actaaaaagg cctttgcaga ggctgcctgt gttctttctt 138420tctaggtctc tctcatccta ggccctccag cttgattctg tggagctgcc ctcttgtcac 138480tcagtagctt gtggggtctt ctctgtctag ccacttaatt gattgtgttc ctcgagttgc 138540tgtccatggt ctctcgttac tgttttctct gtgtttctgc ctctctcctt ggccttggta 138600ggtccatccc ctttgtgacc ttggctgttg ctctcatgga caactttctc ttgctggtcc 138660ttgtagtcct ggcatccagc ttctcgacac gggacttgtc ctgccagtac ctcagacttg 138720cacttaaaat tgaactagca ccactgtcac tctccagggc ctcttcttgt taattagatc 138780attagggatg ttcagaatcc cagcatcata gtatgttcct cctcccgcta ccccaggaac 138840cctaacctta cctcctcctc tctatctact aggaggtggc cctcagagtc cgtctcatct 138900tccacctgaa cttccctaat aggctccagc agctgccacc ccgggggctg agtacttcct 138960ccatgccttg tgcagtgctg agccctttac ctgggttctc ctgtttgctc cttattacag 139020ccctgcgaac agatactgct cttaattcca tcttacacct aaggaagctg aggccccagg 139080taaggtgcat ccaaggtcac ccaggtagta gacagtagag ccacgatctg aaccaggcag 139140tctgattcag agcctgtgtt gacactcagc cacctagaac acagcttgga ttgtgggttt 139200ctattacctg ttcaaaaccc ctacatcccg ggtctgtccc tgcacgtgct ctgtggcctg 139260gctgcatctt ccttgaaggc agtgcatgcc tcttcactca gggggcccat gcaggaacag 139320agggccccac agaaggatga ggccagtgca gaatgggctg gaggggacaa tgctgaccag 139380gaagcaagtg tagagaaatc ccaggaaacc tggaggagcc agagacaagg cattagaact 139440cctcgtcgtg acctggtctg cattctctga gtgtgctgct tctgttagct cgcttccttg 139500gtctcaggtt atagtttaag gcattgtgga gccctaaaaa gcctgtactc tgtttttacc 139560tgttttagga ccctttcact ttggggatgt gttgattttt tttttttttt tttttttttt 139620tttgagatag agtctcgctc cattgcccag gctagagtgc agtggcacga tcttggccac 139680tgctgcccct gcctcctggg ttcaagcaat tcttgtgctc ccgcctccca aatacctggg 139740attacaggca cccgccacca cactcggcca atttttgtat ttttagtgga gacagggttt 139800taccatgttg gtcaggctgg tctcgaactc ctgacctcaa gtgatctgcc caccttggcc 139860tcccaaagtg ctgtgattat aggcgtgagc caccacaccc ggcctgaaat ttaaatcaga 139920aataaaattt tgatcccaac agtgatgcca ggcagcccag atctggggga gagggtggcc 139980ttggccagct gggcctttct ctgtttccca agtcttgctg cctctccctg ctgggctttg 140040cagcctgtgc atgtctctgt gcctttgacc ttgtttatcc aaaggagagg atagaatgaa 140100gtcatgattc ctggagccct gagaaggatg ctgtggagaa atttgccggt agaatctagc 140160tgagtgtgtt gctgaggtgc cagcattgtg tgtggggagg ctgaccgctt ggcctgccta 140220ggcccaggat gctccatggc cgggcacaga ggccacttgg ctgtcaggtg tcaggagcct 140280gcagagggca cacagagcct ggaccgcagg ggggtcctgc tttctcacct ggcctccttc 140340agcatttctg tccctcagtc cttagcaagc ccaggagctg ttgagtttgg caggtgccga 140400gtgctgttcc tgcctgtgta gctgtggctc agtcctgtgg gggccccgct gtggcccgag 140460tgcagtgatt cgaggcgctg agtgttccct gactccttct ccaggagctg tgttcagact 140520ttcgcagctc ttggcttgga gctcctggag ggcttggcat tgccgaccaa tgtggaggtc 140580gacagtgaga gaggaggaat gctagctttc ttgaccagtc cattaaataa gtgggatatt 140640ggccaggcac ggcggctcac gccttaatcc cagcactttg ggaggctgag gcgggtggat 140700cacgagctca ggagttcaag accagcctgg ccaacatggt gaaaccccct ctatactaaa 140760aatacaaata ttagctgggc gtggtggcag gcgcctgtaa tcctagctac ttgggaggct 140820gaggcaggag aacagcttga aaccggaagg tggagtttgc agtgagccaa gattgcgcca 140880ctgcactcca acctgggcaa caagagcaaa actctatctc aaaaaaaaaa aaaaaagtag 140940gatatctgtt tctgcttaga aaaatcagaa ttttctaaat gccaggtgtt ctgaatacgt 141000aagtatggga gacgactcag cctgtttcat ttttatgtaa aatcttcgcg tagccatgtg 141060gcactggacc gagatgaaag caaagacatt tctccttaac tttgtttcta ggaatgttcc 141120ggagaatcac agcagctgcc actaggctgt tccgcagtga tggctgtggc ggcagtttct 141180acaccctgga cagcttgaac ttgcgggctc gttccatgat caccacccac ccggccctgg 141240tgctgctctg gtgtcagata ctgctgcttg tcaaccacac cgactaccgc tggtgggcag 141300aagtgcagca gaccccgaag taggttcata atgccccaca gcccagggcg ccagcccagc 141360accctgtcct gagactccca gtaacctgag ctttggccac cgttaaagca ttttcatttt 141420ccattttttg tgagggcttg tgaaatttct gctgcatatt aatattcctt tcatggacag 141480catattattg ggacaaacat gcggtccagc taaaggcatt caaaatagca gttgctttct 141540aaatgcgatt ttctttggca ggttctttga caccattgca tcttgtggga tatgcttgtc 141600atgctctgtg gctcctacta agttctagtc cttaaattgg ttccatagcc agacatgttg 141660caatgtctta acctcattat aaagtaaatg tggttctggt tatccttaga taatgaagta 141720acagtgtagc aaatttcaaa acctcttgga aatgttattt taccattcaa aaaggcttac 141780taaggttctc gttatgggtg gccctctttt tgcaaaaggt tttcaggctt aagctccatt 141840tctaggtgct ccaacactcc attatttgta tatgtatgga aataaaagct gtgaccaccc 141900ccaaccctgg cccccgccca gctgaatcct cagcacagta tttctggaag gctcaagatc 141960ccacgctggg gaaaagaagt tctggagaca aaagagggca ggtgctgccg tgcctctctg 142020ctcagtatgg atactggacc ttgtgctgcc agggctccca gtagggccag ttcatggcac 142080tcagctggaa agtccactgt tgggaggcat tcttaaccat ccactctgtg ccgtatgtag 142140tggggtctgg tcattctgtt ggaggagaca gaccagtgac gacatttgaa atgcttggtg 142200gatgtcttag gcctgttacg atgactgagc actgtggggg caggagacag aaagtcagtg 142260tctcctagtt ctgtgctgct ttaacgtgca tagaaatcag ctgcggattc agcagatcac 142320tccttttctg acagatgggc ctgcttactc tgatgttata tcagaaagct ctgaatctgg 142380gaattgtgtc ccctgaattg gagtaacaga aatgcttaga tgatgagtgt ttaaaagaaa 142440taaaccaaag gtaaatttag tttggaattc agcaagcgtc ttcattcagc cctctgaggg 142500caaactacag ctttttgtaa atgtaggtaa attctgtgac tgtttcgtga ccccctctga 142560tccagttttc ctttataacc ttctgtattg ttccttctat tatcctgaaa taacattaat 142620agattaggct gggcgtggtg gctcatgcct ataatcccag caccttggga agccaaggcg 142680ggcagatcac ctgaggccag gacttcgaga ccagcctggc caacatgatg aaatgctgtc 142740tctactgaaa ataacaaaaa ttagccgagc atggtgacag gtgcctgtag tccctgctac 142800tcagaaggct gaggcgggag aatcgcttga acctaggagg aaaaggttgc agtgagctga 142860gatcgcgcca ctgcactcta gcctgggtga cagagtgaga ctccatctca aaaaaaaaaa 142920aaaaaaaaaa aaattaatgg atcaatggat ttttaaccta ataattaaat ttcaaaaaat 142980atcgttcttt aatggtaatg taaaggtaaa attaagataa tatgtaacaa gcatgtgagt 143040gtctaaggtg tccccgtggt ggaaggaaaa aataaatccc cataagtgtc caagatgccc 143100atagagagca gagctgttct ggtttaaacc cctgctctta gcactgtgtt tttccagctg 143160tgggtggtgg gggatgagta tctttttatt tccatgagat gagaaaaatg aattactaga 143220agtgtgaaat acaaaacaca gctgctcttt ttttagccat agactcagca gccataaaat 143280tgctgtatcc agttgcagaa attcctgctg cttactcttg accctctctc ggtttgtgtg 143340catctcctct caggctggct cccagatggg agctggctcc aggcgacact gggtgctctg 143400ctccaggagg tccttatgtg ggtcctgccc tagcctagcc cctctcttat ggactctgtc 143460actgtgggtt tatgattcac tctcaatctg tcttacctct tggtgaactg ttagagtcct 143520gcctatactt tggcgcttgt gggtgtgttg tggtacacat gatgtgttgg tcacttccca 143580gctcatcttg ttctgagtca ccctagattt gggacattca ttcgccacca gtaccgggcg 143640gtgtatggcc tgagatttgg gggggcttgt gctgctacaa attggggctg aatttgagtt 143700gacagtggac cttctttatg tctactgctc atatttgaat tgcaaatact gcctcttctc 143760tttcagaggc tcattaccct atagctgtat tattgcaaag tgcacaatta cagcttgagt 143820gtaagtcaca ctgcgctggc aggacggccc actgagaaag ggcacgtttc ctgttcgtta 143880gttttcacat tgacacataa tttacaatac agtaaaatgt acttttctat caactgtagt 143940cagtaacagc ccccctcccc caaccacatc aagatataga ggagtgctgt cacttcaaac 144000agttccctct tcctctgcca catcctgccc ctccccaggt ctaaccacca atccgtgctc 144060tgtccctctg ttcagcccat tgcagaaggc catagaaata gaatctatag gctaggtgtg 144120gtggctcatg cctgtaatcc cagtattttg agaggctgaa gtgggaggat gacttgaggc 144180tgggagttca agactagcct gggctgccta gcaagacccc atctccagaa aaaaaaaatt 144240taaaaattac aatcacgtcc ctgtagttca gctgcttggg aggctgaggc aggaggatca 144300cttgagctca ggagttagag gttacagtga gctatgatcg tgccactgtg ctccagccta 144360ggtgacacag caagacgttg tctctgggga aaaaagaaag aaacggaacc acgcggtgtg 144420cagccttctg agtctggccc ctttcggtga gcagtgtcta aagttctgtc gcgtgttgcc 144480cacgcgtcgg tggctcgctc cttgcaactg ctgagcattg tatggctagg ctgtagtttg 144540ttttcacttc accagttggg aaacagagaa aaggcacttt ttaaaaagtt taaatctgta 144600gaattttggt ttttaccagt tctcttctaa atcctgaggg attacaggaa aagttgttgt 144660atttcagaat attcttagct tgatgtgacc tctgtccccg ttaaggccct ttgccgcaat 144720gggaaggacg tcgctcggtc agaccctgaa ggtcagaggg gcagtttggg agtgtgtcaa 144780cattttaact gtatggacta gagccaagag tctcaaggtt tataattccc acgtattcaa 144840aaagaaaaaa acaataaagt gagaagtcag tgtagagtga aataacctgt gttagtgggg 144900aagaagtgtt tttaaacagg atttccataa cgtataacat caacatgttt agagtggtga 144960tgtttcattg ggaaacgaac agtaaaacat gaaagcaggg aggttttcat tctggcagtt 145020ggcaactttc acggcagatg gagaatttca aaagcaattg ctcaattatc aaacatagcc 145080agtgtgagtt ctgaaataaa ggtgctgatt gaatgtgcag ctttatggtg gattttgcta 145140ttcaggcaag cattttaatt ttctgcctgt taaattctgt tttctttagt ttttcatatg 145200tggtttattg tagcttagga atagataact gagagtatat attacacata caacattctg 145260atatggcaat atttaaaaca acttgtctgt tttagaacta gaattaaaca taatcatctt 145320cagtattttg caaataagct cactgccatc cagaaacatt gtcaatgcat ctgttgctcc 145380ttctagaaga cacagtctgt ccagcacaaa gttacttagt ccccagatgt ctggagaaga 145440ggaggattct gacttggcag ccaaacttgg aatgtgcaat agagaaatag tacgaagagg 145500ggctctcatt ctcttctgtg attatgtcgt aagtttgaaa tgcctgtaaa cggggttgag 145560ggaggtgggg accaggagaa catcctgtgt agatgacact tgcatggacc ctctggaacc 145620cagaccgccc ggtgtcctgc caagctccat cgaaactaaa tctagaatga atgtttactt 145680ctgctgtgac atataattgg agaccaggcc tggccttcca gtcactggat tctaagttgg 145740actgtgagag tttttgcagc tgactcattt atcaaatgcc cggctattgg ctcacgccta 145800catgatgctg ggtatgtttg ttaatttgag ggaagcaatg gaataataat aactaatgat 145860ttaaaaaaca aagtaagtgc attgactgta gtggggttct gattttaaat ttttttaaaa 145920attaatacca ggagcagtgg cttatgccta aattccagca actcgagagg ctgaggtagg 145980aagatcactt gagcccagga gtttgagaca agcctgggct atggtgtgag acacccatct 146040ctaaaaaaat aaaaaataaa aaattatcca agtgtggtgg ctcgtgcctg taatcacagc 146100tctttgagaa gctgagggcg gaggatggct tgagcctggg agttcgagac cagcctggca 146160acacagagaa accctgcctc taccaaaaaa agaaagagag gaagaaagaa aaattagcct 146220ggcgtggtgg tgcatgcctg tggtcccagc cacctgagag actgagaagg gaggattgct 146280tgagcccaga agtttgaggc tgcagtgagc tgtgactgtg tcactgcact ccggcctggg 146340tgacaaggcg agacccctgc tctaaaataa tttttttaag ttaatttgta gaaaaggtgt 146400tagatgttct ttgtcacatt ttatgatgga ttcctgttta aatgccgttc tctttaaaga 146460aaaaaaaata acttgtggga gtttttaacc ataaaactag catcacatat ttaccatgga 146520gaatttacaa aaaaacaaat aaacggagga aaataaaacc tcctgtaatc atactactca 146580gagataactt gctgttagat tttggtctag atttaatact ttttctatat ttatattaaa 146640aatatttaaa acatatgcat ttctttgtca caaacatggt atcttataga tactactgtc 146700acatagcaaa acagtgttaa atattctgaa tcagaaaagg aagccgactc tccaactgaa 146760agaggtgtta tcctagagac tttttctggt gatgacaatt tattaatagt cactttttgc 146820tttactttct ctattgaagt agtttttcta ttttgttcta cttttaagga taatataatt 146880tataatgctg tttttcacag aaatataaga aaaaagatac taattttata agttaataaa 146940gtttgatcat cccaaatcca aaaatctgaa atccaaaatg ctccaaattc tgaagctttt 147000tgagtgctga cattatgttc aaaggaaatg ttcattggaa ggtttcagat tttcggattt 147060agggagctca acaaataagt ataatgcaca tatttcaaaa cctgaaaaaa atcctaaatt 147120cagaatactt ctgatcccaa acatttcaga taagggttat tcaacctgta ctgtcagatg 147180atcccaaatg aaaaatatta atcgttaacc aaatatcaag gaattgatca cattttacag 147240tttctgccta ggattatgaa tcaagatgaa aaggctctgc atgtttaaaa atatatattt 147300ttattttctt ataaatctta aatatctaca cttaagattt atttgatatg tgggatccat 147360tcatattttg gattcaacag ttctgtcaaa actgtggcag tgatagggga ttcttttttt 147420cccactgaac tatcacaaaa ttggaaaaag agtaattgga gaaccccact ggcttagccg 147480gcccgaagcc cgggagaggg caggcagtgc tgtggatggg gtcatcccag cgcaacgctg 147540cccctgctac ctgcggatct cgctgaggcc tgcctttgtc ctttgaccct tggccatttg 147600ttagtgtctc tgagagctgg actgctgtac cctacttccc cagggggcct aacttcacac 147660agcctctgcc gcagtgcgtg gttggaggtg acggccttgg taaatcgagt ttcctacctc 147720ctcaattatt tgtgctcata cactgtatat ttttagtgag gtttatattt gggatgtgtt 147780ttctccttct taccctttct ggcctttcta tggcattaat acctggtctc ttcttgtgta 147840cttgaaaatg aatctctcat catatttttc cttagtgtca gaacctccat gactccgagc 147900acttaacgtg gctcattgta aatcacattc aagatctgat cagcctttcc cacgagcctc 147960cagtacagga cttcatcagt gccgttcatc ggaactctgc tgccagcggc ctgttcatcc 148020aggcaattca gtctcgttgt gaaaaccttt caactgtacg tcttcatcct gccgactatt 148080gccagttgca gttttccctg ccttaaaaat ggagtattga aatttttaac tttaatttct 148140gatttgcaaa atagtcatct tttgttcttt tccttcttgc tgttagccaa ccatgctgaa 148200gaaaactctt cagtgcttgg aggggatcca tctcagccag tcgggagctg tgctcacgct 148260gtatgtggac aggcttctgt gcaccccttt ccgtgtgctg gctcgcatgg tcgacatcct 148320tgcttgtcgc cgggtagaaa tgcttctggc tgcaaattta caggtattgg gaagagaaac 148380cctgatattg atttatattg aaaatttagc aggccaagca aaacaggtgg ctggcttttt 148440cctccgtaag tatggtcttg acatggtcac cgatagaaac atggaaacat ctgcaaactt 148500gccgttactc gtgtgtccga tctgactgtt tcttgtattt ttttctagtc tgcccttact 148560aggatgaact gtacacatca gttcatcctt tttaaatgag catgaggtta ttttgggttg 148620ttaggtgtta caaacacact aatgtgtttt tgtctattag agcagcatgg cccagttgcc 148680aatggaagaa ctcaacagaa tccaggaata ccttcagagc agcgggctcg ctcagaggta 148740atgctggaaa cacaggtcgt ccttgtgtta ggacaaccca ggatataaag gatatagatt 148800tgtacgggaa taaattcaca ggacaagaaa tcgatgtgcc ttataggtgg gtttactgca 148860gaagtgccat aatagaacct tcctactttt aaaacaacca gatctcactt tctaaagagt 148920aaaggatgac cggcaggatc acgtctgtga cgtgagtgga ggcagtttgc actcctggtg 148980gctgtttgag aggtagcatt tagaatgcct gtattcactg tcctgtgatg agtgggaaaa 149040taggttatca ggtttatctt agcaaaatca aagcatgtca tctaattgct aaacaagagt 149100tggcaaatct gagagacatt actcaatcct tggcatgcag gacttacatc tgcatcctgt 149160tgccatttta tgtcttcaaa gcatttaatc atttagttgt gtttgcaaag tctttgagaa 149220gcctttgtca gaaatcccta catctcctat gtgagtgtat ttccatgact gcagaataag 149280ttaaactttt acctttttcc ttcccttgcg gggcggggtg gggggcaggg attgtgtgtg 149340tgagagggag agagagacag cagagaagga gaatataatt atcatgctgt gtactttgag 149400ctgaaactgc aaaaaaggaa aaacacacaa aaattattat gcttttcagt ctttagagta 149460ccttgtctat tatgcttttc agtctttaga gtaccttgtt gatggtgttt ttaaatggga 149520ttgggcacaa ttaggtggac agtttgggat gatttttcag tctgtagggc caagctcttt 149580tgtaatttgc attatgaagt tgtcactctc atagcagatg gcgggagata aactattatt 149640actttttgac cctagactta gtcttcagtc cagatgaggg agattaaaag attataaata 149700tcttgtgcca gatgaggtga ttttattttg aaatgaccat gaattcctat cagttgtctt 149760actgggatat ttgatagtgg aatttgtgca tttgagtctt agatgatctg ttttacattt 149820attaagaaag cctttattag cttttatact gtgtattgcc tgttgcagtg tttgagtata 149880aatgaaattt ctggaaaata ttaatggagt acaaactgtg atacttaaaa gtaaactagg 149940gcctgcattt gtatcatgac ctgtttgagt attgatgaga agatagctgt gaagaaaaag 150000gtttaaacaa gtgtattttc ctttaagaag ccactaatag tgcatctcct tagagtgtat 150060atttctagaa tcctagtgtg cagagtttag actaagacta aaaaaaaaaa aaaacaaatt 150120atactgtaat ttcattttta tttgtatttt agacaccaaa ggctctattc cctgctggac 150180aggtttcgtc tctccaccat gcaagactca cttagtccct ctcctccagt ctcttcccac 150240ccgctggacg gggatgggca cgtgtcactg gaaacagtga gtccggacaa agtaagtgtc 150300cagcgtgtct gcatgggagg cacagggcgc tgagtgcctc tgtcacctgt ggcagataca 150360gagagtgcag aggaggtgcc gtggacccaa ggagttctgg cgctcggctc ggctcagtga 150420agctgtggtt agagacgtgg ggggccatca aggtctgagg gagccaagca gtgctgatgt 150480gggacccttt tggtaggagt gtggggtgag tagttagtgg gtgaatcaag gaatagtcgg 150540ccgtggcctg caggcccctg actgcacagg ccttcaagca catgtcaatg ccgttagcct 150600ccctccatct cctcatacct tctggccacc tgtgagttgc actgccactg ccagccattc 150660tggtatgttg tcagcacctc cactgctcat acctcatggt tagggaccac ctggagcctt 150720ggtagagcct tggtagagcc ttggtactct actttcctgg acaaagttca gcttatgaat 150780atgaatttag atttcaaaaa ccagcagccc aagtataaga aagcgaaggt tcagtcctgc 150840cttcttaggc tctattcgct aagcacctgc cctgccctgg ttgctgggga gagatgagta 150900aagcagacaa cccaggagag gatggcaaag gggccgctaa cccttagtgg tttagctata 150960tttggaaggc ctattggaag ttcaccaggt gaagggggag gctgtgaggg tgcccaggca 151020ggtaacagaa gtccaaaggg gaaaacctgt ggtgtggtga gccgtatagc cacagcctgc 151080cggccggcag ccctctcagc ctagtgcggt gttcccaagc actggcctag gcctgtagct 151140ccagggatgt gaagtcccct tgaacgccgc ccatcatgtt ccccttatcc atttttttct 151200tcccaggact ggtacgttca tcttgtcaaa tcccagtgtt ggaccaggtc agattctgca 151260ctgctggaag gtgcagagct ggtgaatcgg attcctgctg aagatatgaa tgccttcatg 151320atgaactcgg tacgggggga gcagtggagg caaggaatcc tcagcttttc ttgtgacttc 151380caagtgggat ttgtctcatc atcatgtgac ccacttgttg acaacacatg ttggggactc 151440cagtctgggc agggacggga tgtcggagag actccactct gaatggggcc gggaagtggg 151500gaggactcca tttcagatgg ggtcgggaca tgggggttat gctgatcgag acagaaaagc 151560acattgtttc agccacatta gaatccacgg aggtgttgtt ttgaaatcca gctggcccca 151620aggctgggtg tatggtttgg gatgagaact atctggcctc cactggagga acaaacacag 151680gatgttatca tctaagctcc atggccaaga cagaatggaa gtcaaggttg cgtatttgcc 151740gtagacttca acacagtgtc gtaatgcgtg acgtcaataa cttgtttcta gtgtcttgga 151800agttgatctt tagtcgtaaa agagaccctt ggatgcagcg agatttcctc tactcacacc 151860tctgttagat gtagtgaggt tcttcacccc ccaaccccag atgtcagagg gcaccctgcg 151920cagagctagg aggccatgca aagccttggt gtccctgtcc ctcacccgtg ggcaggtcct 151980gtgagcagtg ggggggccac ctcttgggta tggtgcagcc atggcccaag cagggcttct 152040tctcagacct actaggacgg gagaaacctc ctggtgcttt agccctgcgt tgatatgcag 152100caaatgggag ggaagtgggc acctgggagg acaaatgcct gtagaggccg ggagtgacgg 152160caggtgttca tgaaaagaga ccttgtgggg agggcaacac aacagtgtgt tctgatgtac 152220tgaagagctc aactgaaaac aacaggagaa ttagcccaaa atccatttac taaaattgtt 152280tatctttttt tttttttttg agacaaagtc tcgctgttgt cccccaggct ggagtgcaat 152340ggcgctatct tggctcactg caacctccgc ctcctgggtt catacgattc tcctgcctca 152400gcctcccaaa tagctggtat taacaggcat gcaccaccac gcccggctaa tttttgtatt 152460tttagtagag acgggatttc accatgttgg ccaggctggt ctcaaactcc tgacctcagg 152520tgatccgccc acctcggcct cccaaagtgc tgggattata ggcctgagcc accacgcccg 152580gcctaaaatt gtttatctta agattcatgc agtgaaagct aacttactga gtgataaatt 152640tgcttagtga tctgtttatt aggttttcca aatttgctaa ttgggctttg aacagctgta 152700aaagttctga ctgtaaaaga aagcttcaac ttttggcatt catgatgctt ttctgagtat 152760taaactaaga tagatgtttt acctgaagga tcggccacca atctttaaat ggctaaacaa 152820aagggttgct aaaacataat ccaaattgac ataagaaata ccatttttcc aaccaaaatt 152880ttggcattca tatggctact tttacgtatt tcagctgcat ttgaacatct ttttcaaact 152940ttagggtggt tggtgtatca ctgaggtctt ggatgacact ttagctttga ttttgttttt 153000atgaattaaa attgtcatac caaaattttt atttcaagca aatccaagag cataaaaaat 153060taaaatatta cttaaaatac taagagagaa cagatatata ttttactaag catatgttga 153120atgaaattgt tcaaatattt ataacaggca tagagtagaa ttttcttaaa aatatttttg 153180atggtatacc aatttgtatt ttctcagaaa catttgcctt attctttttt ctgttgtgtt 153240tttcttacct gattgaaagc tcataatctg ttgttattgt ttgttaacct ttaatgctct 153300gatttcagga gttcaaccta agcctgctag ctccatgctt aagcctaggg atgagtgaaa 153360tttctggtgg ccagaagagt gccctttttg aagcagcccg tgaggtgact ctggcccgtg 153420tgagcggcac cgtgcagcag ctccctgctg tccatcatgt cttccagccc gagctgcctg 153480cagagccggc ggcctactgg agcaagttga atgatctgtt tggtaattaa aattaaaatt 153540tatcttattt ttaaaaagca ttccagggcc agtatagtac tttgcaccaa gtaaatgtac 153600aataaaggca gtggatctaa tacattgaaa gcgtttacag aggtagctaa agagcagcac 153660gggtgtcctc ggctcagaat ttcttcctgt gtgtttgcca ctttgccatt cattgacatg 153720gtcatggaca tagggctcta agcccttgag gaaggctggg ccagacctca ggggagatgc 153780agccccaaac cacgtgcagt cctgtggacg gatgtgtaga tgtgccactg aggaacaatg 153840tcttgagctt tcatcagatt ctcagagaat tgcttgactg cctttcgaag ttgatgcatc 153900tgtgctcacg tttgcaccca cccacgaggt ccttctgttt caggggatgc tgcactgtat 153960cagtccctgc ccactctggc ccgggccctg gcacagtacc tggtggtggt ctccaaactg 154020cccagtcatt tgcaccttcc tcctgagaaa gagaaggaca ttgtgaaatt cgtggtggca 154080acccttgagg taagaggcag ctcgggagct cagtgttgct gtggggaggg ggcatggggc 154140tgacactgaa gagggtaaag cagttttatt tgaaaagcaa gatctctgac cagtccagtc 154200acttttccat ctcagcctgg cagtaagtct tgtcaccgtc aagttattgt agccatcctt 154260caccctcacc tcgccactcc tcatggtggc ctgtgaggtc agccaggtcc ccttctcatc 154320tgcacctacc atgttaggtg gatcctaatt ttagagacat gaaaaataat catctggaag 154380tactttatgt cttaagttgg cctggacatg tcagccaagg aatacttact tggtttgtgt 154440tagtgcttgt aattcgcccc cagaatgtgt acacgttctg gatgcattaa agtctggcct 154500gtatccttaa agggccatcg ctgtgctgcc tgccctcagc aaggacacac tttgcagacc 154560cacagaggct ccgcctccac ctcacaccaa agaaagggag gagtccaaag ggcatcagtg 154620ccattactca caaaatgata aatacaccct tattctgaac cacgtggagt catatggttt 154680gtgatccctg tccttcaggt ttcagcttag tggggaagtg ggaaagtcag cgtgtgatca 154740cagcacaggg tgattgctgc tgattatatt atgtgcctgc tgtatgcagg atgaaatact 154800ttatatgcgt catcttattt gactctcaca accccctgtg agataggctc tgttactccc 154860atttgacagg tgaggaaagc aaggcttaga gaatttcagt gacttgccca ggtcctctga 154920gctaggaagt agccattctg gcatttgaac ccaaggcctg ctatccctag aacccacgct 154980ctcaaattca acctatgaca gaggcaagcc ctggtgctgt gggagcccca aggaagagcc 155040tctggcctgg tggccacgta gcccaggaga gatttctaca ggagcccaca gcgctgaagg 155100agagagaggc agcagagtaa gggggctttg tggcagagag gggactggca ctttggggaa 155160taggtgggtc aggactgaat gtaatggagc catgtcagag ctgtccttct ggaagggcaa 155220gggcacctgg acgcgctgcc cctcagtgct ttggacggtt ccacaactgt gattcacacg 155280gcttccccaa acgaaggtac acgagtgggc attctgtgac tcggtacttc cctttaggcc 155340ctgtcctggc atttgatcca tgagcagatc ccgctgagtc tggatctcca ggcagggctg 155400gactgctgct gcctggccct gcagctgcct ggcctctgga gcgtggtctc ctccacagag 155460tttgtgaccc acgcctgctc cctcatctac tgtgtgcact tcatcctgga ggccggtgag 155520tccccgtcca tgaacggtgg gttcctatca tagttcctgt ctgcttcacc atgtttttat 155580tttgtgctgc ctgtttgcca ggtactaagc taggaattgg ggatggagag gtagataaaa 155640tatgcatcag gaagggctgg gccccatctc ttactctcca atatattgga gtctacactg 155700gaatttaact ggaatttgct tttttagtca ttttatttag attttgaagt ttcagctttc 155760atcaaaaata cctctaaact ttatgtctct gtgatctttg gtcttagctg ttttatgtat 155820ttagtcttat atgatcataa gattaataac attacattca gaagattatt tgttttctgt 155880cagagttaaa atgtttgttt ttatactgca ttgtaatatt aacgtactgt aaaataaaag 155940tggcttgttc ttttcaagga acagtatcct caacaagggt cattagccac aatttttaaa 156000aaattggacg tcatagttta catgttagag ggcgttttga agctttgtat ttttaaatta 156060aatgttatag agtgatgttt tcatgtttca taattgtttt catctgtgca tttgtagcca 156120acttgaaaac aaagatccag ggattactac ttaaaagcca gacttcttgg aggttatagt 156180gatgattttg atagtatctt gagccgtctc ataataacct cagggtgaga gatggccaac 156240aggagacagt cgagggactt agaaatctga atgaaatctg aagttcaaat cttcagacat 156300ataccactaa ccaagagatt ggtacctcag tctagtattg tctgtttgtc taaaattggt 156360tctaaggaat ctaggctagt ctgtctatcc ctttcaactt ttgtgaggct gcacaaatgt 156420aaaatgttga ataaaaagca ctgatggaag tgtgtagaaa ttcttctctt tgttctgttg 156480taattttagt tgcagtgcag cctggagagc agcttcttag tccagaaaga aggacaaata 156540ccccaaaagc catcagcgag gaggaggagg aagtagatcc aaacacacag agtaagtctc 156600aggacccatt tttttcttac atgttgttcc tccaggactt aaaaatcatt cacagagacg 156660tgcaccgcgg tgagtgtgga ctcctggaag cgcaccgtag ctccgctgtg tcctgctgct 156720cctccctagc tgtcagggag gctgtagtcc attgctttgc cagctctttt gtttccgagt 156780gaacacctta tccgtacaca tgcggctgtc tctgacccta cagaccagct gggatgccac 156840tgggggagcg ctcccttccc cccgcacttc ccacactctg cagttattct gagatccttg 156900agggcaggga acaggtttgt cttctttgtg ttctcagaaa ttaatgctcg gcctctggtc 156960agcaagcaac aaccttttgt tgagtgataa tgaataaata aatgtttccc acatgagtat 157020tcagtaacct cagtgtcagg ttcagccatc tgttttggtg gatatttaaa agaaaattcc 157080gcttttccta cagaaaaaaa aaaaaatcca aatcccagtg atttaagcca gttatagact 157140tagacatata ctacggcttt tcatgcactt tcctcccaat tctagagtag gtattttact 157200aggaaaatgg tggcagtgcc tgttgggagg aagattcttt ggccaagtgt cttttgttct 157260tgccagggcc cctaggctgc tggggtgctt cagcttcttt agcccagtgt ctggtgggga 157320atggcccctg ttgcctgtcc cacagaggtg ggggtgcctc acctggagcc tgtccacaca 157380ttttacacag cacgcttacc tggagcatca ggcatctttt ccatgctctg tggctcagga 157440aacacgcctt ttcaatcatg agtgcaccag tgcttttggg ctttttctcc ccgcttttgt 157500gcaatcctgg ttgtggatgg agttttcctg tctttagtct tctgcatagt acttttctct 157560tctggttccc ggttcaaggt tttgtaatta gagaatgacc cagaagcaat ggcattttaa 157620tgcacagcca aggacttctc tgaatttgta tctcaaacct ctgtgggtcc ttcaggcttc 157680agtttgtgat ttcatgattt cttgttgcta cctaaggaat atgaaaacac ccacctccct 157740actctgcatc ttccagccga gtggcacctc aggctgtgga tcctgtgctt ctgtggtgag 157800gataagaata gtgccaaccg tgtggattga aatcaatcag ttaatccctc catgtaaagc 157860acctggaacg gatgacagtc ttgttatgaa tactcaacaa atgctatcat gatttttagt 157920tagatttcca ttgctttaaa acagttgaga catcttggcg gtttgagtta gagcaacggg 157980ccctgaagtg ggttctgttt gggtgaagat gattatgctt attccccatg gccctcttta 158040ggcaagagtg ggaagctttc tttgtttttt taatcacctc gataggacgt tacttcttaa 158100aggtcatcca ataaatatta ataggccggg cgcggtggct cacgcctgta atcccagcac 158160tttgggaggc cgaggcgggc ggatcacgag gtcaggagat cgagaccatc ccagctaaaa 158220cggtgaaacc ccgtctctac taaaaataca aaaaattagc cgggcgtagt ggcgggcgcc 158280tgtagtccca gctacttggg aggctgaggc aggagaatgg cgtgaacccg ggaggcggag 158340cttgcagtga gccgagatcc cgccactgca ctccagcctg ggcgacagag caagactccg 158400tctcaaaaaa aaaaaaaaat attaataaag ccaactcgtt agcgtggggc ttaattgctt 158460aagtccaatg agaagtcctt ctctatccta ggaagttgcc caaactgtag aatctcgtgg 158520cctgtgggta atagccacgt aatacacact cactgcctca acaaatcata ttttagtagg 158580tatgatattc tagactcaag acaccattct gtggatcttc ccaagggtgt gaagtgtcca 158640cagcgtctgc cttgggagtt tccatgccca ccagaaccat gccccaagcc cctcaagcac 158700tctgacctag gaaagccagt gaagcaagga tgacaacatg gccctttgat actagctgag 158760ggacagacac aggtcctggg agaccagaga aagacgaggg gcagaggagg tgtcctaaag 158820gaagtctgag gctgaggagc cacaggatgg cttccagctg tcacaggctg ctgctggcct 158880tatcacagag agtgggccag agggctggga accaaggcca gagctcaggt tcaggaccat 158940tccagcaatc ccagcagaaa atggggagaa ttgtatggta taggcggata tgaaggtaga 159000atctgcaggc cttcagtggc caactcagag tctaagtgga ttccacagtt acagcttgag 159060cagctggttg taggtcatgc tttctacact gggcatatag gatgtgtttt ttaaaaagtc 159120ctctcttaac cgttgcttgt ttagatccta agtatatcac tgcagcctgt gagatggtgg 159180cagaaatggt ggagtctctg cagtcggtgt tggccttggg tcataaaagg aatagcggcg 159240tgccggcgtt tctcacgcca ttgctaagga acatcatcat cagcctggcc cgcctgcccc 159300ttgtcaacag ctacacacgt gtgcccccac tggtgagtct gctcgttcct tgcagaagac 159360caagtacggt gaaaggcacc ggtaggccct gggctgggca cacgtgagag ggcgggacag 159420aatccccgca gcccagaggc tgcctgctgt ggttctggtg cccactgtgg ttctggtgcc 159480aggctgcttt cctcaggcac cacgtgtgga ggtcgctagt agaaatactg ggttttctaa 159540aatgaactga ggccctacat ccctaagaga ttagtgttag acctgattct agagcaacta 159600gaccactttg cttaatagca gaccagaaac cacaccccct cgagtgagtg agattttcct 159660ttggagataa ttcatgtttt tctacacagt tttgcagttg tcttcagaat tggtttaaag 159720taggtgttat tgccaggcgc agtagctcat gcctgtaatc ccagcacttt gggaagccaa 159780ggtgggcgga tcacttgagg tcaggatttc gagaccagcc tggccaacat ggtgaaaccc 159840catctctact aaaaatataa aaattagcca ggtgtggtgg tgtacgcctg taatcccagc 159900tactcaggag actgagacag gagaatcgct tgaacccagg aggcgaaggt tgcagtaagc 159960cgagatcgcg ccactgcact ctagcctggg caacagagca agactccgtc tcaaaaaaaa 160020aaaaggtagg tgttattgat cagaaccctt gtttcagata acatgaggag cttagcttga 160080ggagagtgag ggttgatgga gggggactga cttctgccca gtgaaatggc atcatctccc 160140accagcccgc tgaaataaga tgatggggcc tgttccttag ggcctgcagc atcctcaggc 160200aggaaagaaa ggccgacctg gcagggtgtg agccagcagg tgtaggtcag ggagaatgga 160260gccaggtccc agggaagagg cttgtggctg cctgagaagg gtgcgtgcct gcctgtgtgt 160320gtgtgtgcac gtgtgtgtat gtatgctgga gagtctaggg aggcttgctc caaggacgca 160380gtattgtttg atcctgagag ataaggattc tgccgcaggg aatgaaggta ttccagatgg 160440cgggcttatt ccgaagaaga ggccagtgcc tggcggtgct ggaagcagtt gcagaacagg 160500gagttgtagg ctttcctggg aagagagcag caggggtgct ggagaagcag gccacacttg 160560ctgcatgggg ttgctctcgg ccccactctt ggtgcacagc gagtcactgt gggttcatta 160620gcatctggtt atgagacagt aactgctcct ttggaggggc tcgtggagac catgcaggag 160680ggcacggtct tgaggtcatg ccgtccagag cacacctgag gataggccag gacgggctgc 160740acgctgtagg taaaattcct ccagcaagct cttcactggc attgaggagt tccctgagtg 160800cggtcatctg gaaggcagct gtaacaggca ctgcagtctc tccctgggtg ggtaccagag 160860aggagcatag gggagcataa ccgatttaaa gagagggctt tcctgtggtg aggtaagaga 160920ttagctggtc attatcatag agccccctct gcctttgtgc agatgggctg tgggaatcct 160980ggggttccgt tgggtccttt gtcacctcac tgaaggcatg taagctgagc tggccagacc 161040gtgagctgat cctgccactt gaacagcatc aagcctgcct ctggattctt ctgtgcatgg 161100cacttgtctg agcacctcac gcacagagaa ctggacttca gagtttacag aaataagctg 161160tatggttcat tttcatgcct gcttgccaat aaacatatct gagctgaacc tcattgaacg 161220cctgccttta ttctagcaca gcacctgctg tttgtgggcg aggggtgctg tctctaactc 161280ctgcctgctt ctcccagcac tccctgagtg gggtgtgcca gcagcctcag gatgaggaca 161340ggaagtggga gggcagagca gatttgggag ggccacttga tggggaagga agtcccagga 161400agcagttgga gctgttttct gggggagaag gtgccagctc tgggacagtg ttggggtagt 161460gaggagggag cccagtggag agaagtcggg cttcctgctt cctcacagta tgtctgtcct 161520gactcaactc ggatgatgtc acttcctttt catcttctca ggtgtggaag cttggatggt 161580cacccaaacc gggaggggat tttggcacag cattccctga gatccccgtg gagttcctcc 161640aggaaaagga agtctttaag gagttcatct accgcatcaa cacactaggt actcttgggg 161700cctctccttc aggtcaccat tgtcggacat ctaccgggag gaaatccaga gcccccagta 161760ctgggatctt ctcatttgac tccagaaaag atttaagcat gataataata caaacctatg 161820tgaatacatt ttgcagtgtt ggcaaaactc cttttatact gagaaaatag atcccagttc 161880ctgtgttttg tggcttgaat cccagctttg tgtattccgg gcttgtttga agtcaggaaa 161940ggttcatgtg tagtggacaa cgtgagacca aattctgcct tagattttgc atttaggcta 162000aacagtggca gcacttgtct cagaatgttt tcttgtgttc accagtctga tcctgttgtg 162060tctcagtggt ccattttctc atatgggaac aagcagacgg gagcagatgg agtcaggttt 162120cttggcactc gccttcccca gagcctagag gcagcatggg gagaaagcag gcttggggct 162180cagacagtcc tggtctgctt ccagccctcc tacctgagca gcgcagggca agtccgtcta 162240acctctagag accctcagtt ttgtcatatg taaaatgggg gtcgtgtcta tttcatagaa 162300ttgttgcaga tttagaaatt acatttctaa acaaatgtta ccccttattt ctaaataagt 162360gtctaaatga ataagtcacc acttttgccc ctatttgatg gcaagaggtg tgatcttgtg 162420gtgggactgt aatcagtcag ttctcagtga ctgtgccctg ctgtggtgtt tcctggaatg 162480ttcctgtctt gtcctagaaa gtctggcagg ggcaccctga ctccactgtc cagtcctctc 162540cccagtccct cgggcttctg cagatttgag gcttgtttgg atcccagaag gttgtggcag 162600gagacacctt gcctctactt tcccctttat aattcaatgt ccaaagagag ccctgagcag 162660gtacctcacg ccagctgcct cacggagctc ctcctcttcc tggctgtgag gatcggtatc 162720agtggcctcc tgctctctcc cccttgccta acacgagcac ctttgcttac ttgggtgccc 162780ttgctcttga actgcccatc ggacgtgcgt gacccaagac tgtgccgcag tccttgcctt 162840gtctgtgctc attttctttg ttcatttttt tccctgtaac gtaaattgtt atatttgtct 162900gtatctgtgt ctgaatcagt cctgcacgct ctccttctct ctgtctcttg ttctttcttt 162960accccgttta tcacggggac cccgatgtcc attgctctag ttctcctgtc ctaagcaccc 163020catcccgtct ctctggcctt accacaagtg gcgtggctgc ctcagacatc atgatgggga 163080catgaagcac agctgtcaga aacaactgtt cgttagatac actcgaatgc agctcatcaa 163140tagggatgga gggtctgtcg gatgtatttt cactgaatcc ccgttcctac cttgatacac 163200tctttttaat ctattcttct agacaggtca gaggaaccat tactttgact tttaaatttt 163260tagcagcttt attgaggtag aattcacata ctacagattt cacccactct aagcggacag 163320cttggtggcc attagtttta tccacagagt tgtgcagcca gctgcacagt ctcagggctg 163380gactccaggg aagattttag cccatttagt gagtggggca gaagtggccc tggccctgca 163440cgaggttgcc tgcatgggcg tccctgccct gtccctgtgt ctgctccact gggggttgac 163500caggctgcca gggccgactt gggcctgtgc cacctgcctc tcatgtgtct cggacagtgc 163560agccgatgtc tatacttcgg tttcctcaat gatgaaatgg aggggatagt gttccccgca 163620tcatagaact gtgtgaggtt taagggactc actgcccttg gcgtggagcc ttctccaggg 163680gccgtgctgt gtcggcgtag ctgtcagctc tccgttacag gcttgagaag ggttgacact 163740ctctcatgta acatttatat ttctaggctg gaccagtcgt actcagtttg aagaaacttg 163800ggccaccctc cttggtgtcc tggtgacgca gcccctcgtg atggagcagg aggagagccc 163860accagaagta aggccacacc ctgtgctggt tggcacatgg gcagttatgg ccgcttgcag 163920gcctttggtg gggaataaaa taaggcagca agctggtgtt ctttttttct cttaccttat 163980ttttgaaaga gtagctgaat ggtgtcttga ctgatattcc agagcaggga caaagcctgc 164040tgaggtctgg gggctgcgat taccaatggc tggaatgcat tttattacgg tgcattccat 164100gttaaggatc aatacgattg tgccctttct ggaaaatatc ttttagttta tcaatattca 164160gaggagtgta ggttgaatta aaatgaaaag gcactttata aaggccatga gtagtacctg 164220gtttcatttt tctaatgtct tgcagagatt ttatcaggct tcttgaagtg ttcacgtaca 164280ttacgctaac acgatattaa taataactgt gctctggtac agcggagcca gcagaatggg 164340aagttgtgga atgcaggccc ttgattctga tagaaggtgt ggtttgaact cacagaaatg 164400acagtttgga gggtagacat atgtcacaag tcatcaagat tgtctttaaa ttcatgcata 164460gaagctaaca gggtgtcata agcaaggcct gtaaaatgta tgagggaatt caaagataat 164520ttattaaaaa gtaattcatg tttggagttt tgtgcccaaa ggagtccttg atttgaaaaa 164580tgggcttttg cccatcagat tgtttcaggg cccgtgtgtg cggaggccct gccttgtgcc 164640ccgtgagctc agcctgacag aaatcctttg gtagcactta aggctcctct tcctcccatt 164700gaggcaggga agactctggg ttctgcaggc agaggtggtt gtgggtgtct tgctgctctt 164760gttgacatgt gggctctcct tccaggaaga cacagagagg acccagatca acgtcctggc 164820cgtgcaggcc atcacctcac tggtgctcag tgcaatgact gtgcctgtgg ccggcaaccc 164880agctgtaagc tgcttggagc agcagccccg gaacaagcct ctgaaagctc tcgacaccag 164940gtttgcttga gttcccacgt gtctctggga catagcaggt gctggggaca gtgggttccc 165000cgctgaagcg tccagcagct tcaaccaggc cgttttcctt cattgctaga attgaaaaca 165060ccgtccgtgt ggcctgtgca ggagatgcag acccaaaggt ggcctcctgg tcagtgagaa 165120gctggaaacg tgacaggaac tgacgtgggg ttattgagca tttaggggaa gacgttagca 165180gagcaggaat gagcaggcaa ctagtagaac acccacttaa gggctcacgg acaggtgctc 165240acttaggaag tgagtttcat ttggtattac accaggttcc tttaggcaaa gcggagggaa 165300agttctggtg tttttcactt gtaagatttt gaaggaaaca aaacactctt tacctttttt 165360ctaaaatgta ggtttgggag gaagctgagc attatcagag ggattgtgga gcaagagatt 165420caagcaatgg tttcaaagag agagaatatt gccacccatc atttatatca ggcatgggat 165480cctgtccctt ctctgtctcc ggctactaca ggtacctgag ggaaagggtg cgggggagcg 165540gttgtacttg ggctagaatg agagaagact ggcatgctca ccacaccagt gatgcgggaa 165600gacctgagtg tggtctgagt tggaggctgt ggtgctaaat acgctgcccc tttcataagc 165660aggagtctta gtcaggccca gggaggaagt aaaatctgga aatgaatgag aagcattctc 165720tcctgccagt caagaaatga gaagcgaaag aattctcacg ggctgtaaga ccagcaggat 165780ttaaaagttg aattagttgc ttatgttaag aactcaacca agttcatcta cacaagctga 165840atctccagct tttcctaaga aaccatgtgt ggcagtggct gcagggcagg gcacagctgg 165900gcctgagcac cccgctccct gcacctctcc cctccctggg ccctgcctgt cactgcccac 165960tctcccacca agccttccgg ttgtgtgcct gccctatcac aggcatcgga gcttgtcacc 166020tggtttaaaa gaagagagtt gtgtggggat ttgggatgca cgtttttcac tcaaaagtat 166080tttagcgtag agctctgtga ttccgtagct atttaggagt ttaagcacct tgaaggcttt 166140aattgcagaa agttctatgt ggacgtgcaa tgtgttatac gcagtgtcta tgagactcaa 166200atgtttatta gggcgttgaa gtaaactgag cacttggagg gccatggatc cagccttcaa 166260ggagctcata agtcaggagg acccaggagc aatgacctgt catagaaggc agaaaagagg 166320ggcacagagg tgggtgggag gcatacacag gcagctcctg gagctccaag gggagcaagt 166380gcttccaggg aagggggcgt ggaggcccct ttggaggagg caagttgatc tggggtctgg 166440cagagggtta gctggggaca tttagcggga ggctggtgcc cgggaattgg ggggatgccc 166500agcagaaaga catgaggagg ctggcctggg gcgtgggggg gtgtgaaagg ttaagtgggg 166560gcattatcct gctcccgctc ctgccggctg tatctggtca gcctgggcac cgaggtgggg 166620ttctggaagg cactgttcac caaaatgctt atctgggtcc cccagagagc ttgcctgcct 166680ggactgtcgg ctcgcctgca actgctgact cctaagcttt tgcagctcag cccacaacca 166740gttcctattc acagaggtgg gagctgaggg gtgacaagtg actgctgcag tcttatttgt 166800catagagaaa aagtgacaga gtccagcttg cccactggcc ctgccagctt aactggttat 166860aaagtgacaa atccccaaga cccacagggc tctgcacaac ctgggccctc ctgccagtgg 166920cggcgagggc aggtggctca cggctgggtg cctgtctggg caggagctgg gctggtatgg 166980ggtgggcctg cggccctgcc cccctgtgca gatcaagact cagggtgctg gtgttcacag 167040gtgccctcat cagccacgag aagctgctgc tacagatcaa ccccgagcgg gagctgggga 167100gcatgagcta caaactcggc caggtcagtc tcgcgccccc gccgcctggc ctctgtccgt 167160ttctgtcctc agactttggc gcttgacaca cccaggagaa aagctcagtg cactttttaa 167220atgaaaggaa gttttccttt tttttaaaaa aaaatttaat gttcattgtt tttatctgtt 167280ttattcctag gtcccgcaag cagaggaagc attagttttg tttttattta tgttctgtat 167340tccagaaagt agttaagaga cctcacatgt agcgatagag atgtgtgtaa gagacagtga 167400gagggcgtga cttggactta agcaaggacc gtgagacaca aaaagggggg tgaggacaga 167460gtggagtcag ctgaaatgct caggaggaag tagacgccat gaagggccat ggtatggggg 167520gccgcaggcg tggccgtgag tgtccctggg gccagctctt ggggggctcc ctgagtgtcc 167580ctgtccctgt ggccagttct gggtgggagc cccgtgtgca ggcagacagc tcggccactt 167640cctagcaggt cacattggtc tgtgcttctg tttcctcctc agataagtga agggattcaa 167700gggtctgggt gtggtggcta acacctgtaa tctataacat tttaggaggc tgaggcagga 167760ggcttacctg agctcaggag gttgaggctg cagtgagcca tgattgcacc actgcactcc 167820agcctgggca acagaccagt actctgtccc ttaaaaaaaa atgtaaacag aaacgtaggg 167880ccatttgcat atgatggcac atggcgtgga gccctacagg tgtatgctgg gcggggcccg 167940gctgtgctgg ccgacttgca cctttccctc caccccggtg ctgtgtcttt cgctcaccgg 168000gttcctgatt tagtgaaagc agttgtgcag gacagttctc tttgtagctt ttgtttctgt 168060ggaaatgggt cagaatatgg tgtttagaaa cacttatgag ctctgagagt ttcctcttct 168120gagttcctgg cctgcagcct tcacagcaga aaccctgtga tgtcacaagc ctgtttctgt 168180tccctgctct ctgcctgtac tgtcctgttt tgtgcctgcc ggtttcagtg acaggaagca 168240gggagctact ggaccagcct gtatttttct agacatagtt ggaaaaagaa gtcccactct 168300tctgtccttt cacctttgac agatgtttcc accccaagat aagtgaaaat gaccaatagg 168360atgcactgta tttttcatga aagtgtttct gaagggcagg ctgagagtga gaggcctggg 168420gctcactggg tgcctctggc cttgtcctgg gcccagggac actggtctgt gcccgaggta 168480ttccctatcc ccccaacccc gctgcatttg gccacatcct tcaatgtttg cgttgtgtcc 168540agcgtccgca aaccaactgt catgggatca tactggggct gaagtacggt cccacccctg 168600ccctgtctgg ggctgaagta cagtgccacc cctgccctgt ctggggctga aggacagtgc 168660cacccctgcc ctgtctgggg ctgaagtaca gtgccacccc tgccctgtct ggggctgaag 168720gacagtgcca ccccttccct gtctggggct gaaggacagt gccacccctg ccctgtctgg 168780ggctgaagga cagtgccacc cctgccctgt ctggggctga aggacagtgc cacccctgcc 168840ctgtctgggg ctgaaggaca gtgccacccc tgccctgtct ggggctgaag gacagtgcca 168900cccctgccct gtctggggct gaaggacagt gccacccctg ccctgtctgg ggctgaagga 168960cagtgccacc cctgccctgt ctggggctga aggacagtgc cacccctgcc ctgtctgggg 169020ctgaaggaca gtgccacccc tgccctgtct ggggctgaag gacagtgcca cccctgccct 169080gtctggggct gaaggacagt gccacccctg ccctgtctgg ggctgaagga cagtgccacc 169140cctgccctgt ctggggctga aggacagtgc cacccctgcc ctgtctgggg ctgaaggaca 169200gtgccacccc tgccctgtct gggatgttta gcccctagat gccactggac tgagccgcta 169260cttgcttttg ggaaagaggg gtgggggtta ggggtctggg cgaggggagt gcaggggctc 169320ctccttggcc tgagagctgt tcatacagac tcctcgccca ctccctgcag ggtgctgggt 169380cccagggggg aaatggccct tggtgccaag aacgtgagtt ggggctagtg ccagtgatga 169440tggagaacag ctttttatgg gcacacagcc cacagcactg tgccaagtgc tcgaggcttc 169500ccgagaacca ggcagaaagg aggacagtcg aggtgtgctg actgcgtggt ggctgcgtga 169560tctagagcgc gggtcacaaa ggcgcgaggg agctctggcc ttgggtttac cgcaatgact 169620gccagtgcgg gagactggaa aaggaatctc acgtattggt tccgtgtttt ggggactcca 169680ttcagatgtc acttaggagt gaaagcatcc cttcgtagag cctctttctg tgtcaccctc 169740ctcagctgct cctggggttg actggcccct gattcatgcc tttagcatgt gctggagctt 169800cccagcagct gtccagcccc tgccccaccc tctctgtggg ctcccttgcc cgtaacctgg 169860ggtgtctgaa cgacccttgc taaggggcag actgttagac ggtaggcatg tgctgagtcc 169920cagtggccac acccacccac caggagcctg gcactgtggc cgcagcactg agcagtgccc 169980cgtttctgtg gcaggtgtcc atacactccg tgtggctggg gaacagcatc acacccctga 170040gggaggagga atgggacgag gaagaggagg aggaggccga cgcccctgca ccttcgtcac 170100cacccacgtc tccagtcaac tccaggtttt ccaatggcct ttttcttttt aacagaaatt 170160tgaaatttct tatcagtcat ttgatttgtt tgaggtgctt cttgaaatga gcctctcatc 170220tcatgtactt ggaaaatacc catctcgcat attccacagg aaacaccggg ctggagttga 170280catccactcc tgttcgcagt ttttgcttga gttgtacagc cgctggatcc tgccgtccag 170340ctcagccagg aggaccccgg ccatcctgat cagtgaggtg gtcagatccg taagtgagcc 170400ttcccattcc cctcacacct gcacgtgcca cacgcaccac acacgccaca caccccacac 170460acacacaccg cccacacaca tgccacttgc acacacaccc ctcatgcatg caacacacac 170520acaggccaca cgcaccatag acaccacaca cacatgccac atgcacacac atacacggca 170580tgcaccatac acacaacaca cacagcacac atgccacaca cacacgccac accacatgca 170640ccacacacat gccacatgca cacacactcc acatgcatgc accacacaca cacacacaca 170700ccacacacac cacatgcacc acaccacaca ggttacatgc acacaacaca cacatgccac 170760gtgcacacac cccacacacc acatgtatgt gccacacaca gcacacaacc acacacatgc 170820accacacaca tgccacatgt gcatgcacca gacacatggc acacactaca cacacgccac 170880gtgcacacac cccacacaca tgtacgcacc acacacatgc cacacacaca tgcaccacac 170940acatgccaca tgtacacaca tgtatataca caccccacac cacacacaca ccacttgcac 171000accacgcaca cacaccacat gcgcacacac acaccacata cgccacatgt acacaccata 171060cacacaccat acatgcacca cgtgtaccac gcacccacac agacacagca cacgcataca 171120ccacacacac acgcacacat gcgtcccgca cagtaatgtc tcttgggtgt aagaacacga 171180cttgccagta gtagcgttct ggatgcgttg cctggattct aacagcgcga ttctcccctt 171240gccctcctgg ttttccacat ctccagcttc tagtggtctc agacttgttc accgagcgca 171300accagtttga gctgatgtat gtgacgctga cagaactgcg aagggtgcac ccttcagaag 171360acgagatcct cgctcagtac ctggtgcctg ccacctgcaa ggcagctgcc gtccttggga 171420tggtaagtga caggtggcac agaggtttct gtgctgaagc cacgggggcc catctgcctt 171480gggacctggt gttggccaga ggtgccgggt gcggctgcct ccttccaaga gttgacccga 171540accggactcc acggcccacg tgagctgcag tgcttctcag atggaggggg ttcagcgacg 171600gtcagtgcca ttcacaggtc actgtgatgt gggttgtggc ggccaagcca tggtttgggg 171660tcccgtatcc ctgggcttat gacatcattg tagtagccca tccccacaga accacggtgt 171720gtggtggcgc tgaggcatcg tagatggtgg aaatgctact ggcttcccca tgctctgccc 171780tgaggcctga ctgcctcact ccccttctca gttatgttcc aggccccccg agcttcctgg 171840ctggacagct tctctcctgg gggccgtttt gtcacagtga ccctgtgttt ctagtcccaa 171900atctgggtgc tatagtctct ttttagcgtg gtggttgtct tagtcttttt tggctgctac 171960cacaagttac cttagactgg gtaatttata aacagtggaa atttacttct caccgttctg 172020ggggctggaa gttttcatgg tcaaggtgcc agcagatttg gtgtgtgatg agggctgctc 172080tctgcttcat agatggcatc ttctggctgg gtcctcacgg tggaaggagt gaacaagctc 172140cctcaggcct tttagaaggg ccccaatcca caagggctct cccatcatga cctcatcacc 172200tcccaaggcc ccaccttctt gtactgtggc actgcaaatt aggtgtcagt gtaggagttt 172260caggagggat agaaacattc agaccatccc agcggtcaag tgttcatcct cttgagttcc 172320tccttattct gcttctggtt tatcaggatt cagccagtgc agcatggtac ctgtattctg 172380tggcacatca ccacatggta tttgccaagt atccatcacc tgcacacgtg aaatcattgc 172440ccgtgggtcc cgacatctgg cgaagcatat tcaaggatgg cagaactgtc agagctggca 172500cctctggttc cttgtcatgt ggcattacct agtaatccat tttatgatag caatggaaac 172560tcatttcttc aacaaacacc tgagtggctg ccgtgtgcca gccgtctggg gcccttggtg 172620agaatggcat ggtggtgccc atcagggcct gcctagcccg tgctctggac gggctcctgt 172680gtgtcaggaa cgacaatgct gtcatgacgg tgaatgattt ttttttttgc catcactcca 172740gccgctaaca tttgcggagc tcttcctccc gcacccccac ctgacaaggc caagggtgac 172800cttggcccca ccctaggcgg ccaaggtcag aggttagctg gcttgtctgg gtcacacaaa 172860atgcagcaga ggttgaggtg agcacatgtc cgtgacctgg agcctgactc cctctctgcg 172920agtcttgact gctcttgcct agactctgtc ctccccgagc ccaaacgcca gtcatcttcc 172980cttgtgggtg tccttcagcc tggtgccatg ctggtgactc agcagccgtc cagggagtgg 173040aaacaattga gtgtgtgggt tccctgtgtg ggcatctctc ttcacggcga acaccctctg 173100ggtgttgccc acacgatgtc aaagcggctc ttggaagggg tccttctcct ttgtgggaag 173160tttcagctgc tgggctaact tgaattgtaa ctgtggtttt gtgctcaggc ccagatcccc 173220ctaggcaagt gttgtgccat cagtaatcaa atgagaaata atcattttga aaagcagatc 173280ctaaggcagg atggtcatgg acactcactc ccagctcttt gtgcactcat gctttctgga 173340agatggccat cctctgtgaa ggttttcagc gcgtcatgct tggtacccac gtatccagag 173400catgtcgttt tgaggtattt gcccaccgtt gtgaaatccg tgccacccga gagcaggtcc 173460tgatgtgggg ctttcagaag tgggacctgg ggccgtacgc agtccttagg gaggggccgt 173520gtggcgttgt gcgtgtgagg ggatagcaca gggtgaggtg ggggcccaag aaggaagtga 173580cccacaaaga acagcctcct cttttggtcc ttgttcctgg gatggctggg agtggcttct 173640gtgtcgtccg gccatttccc ctgcggagag gctcctacca ctgccgagaa cctcatcatt 173700ccacaaaaac aagaggccgc ctggccatcc agcgctccat gggaattctg tgtccccata 173760gtcttgggct gaaggagggt gacattcctt gctgacttct gcaggggtct cctcactgtt 173820aaagagcaga ttgaaagtga agaacgtggg ctaagtgttt aggtcgatat ttaaccctgc 173880taggttttgg atactaagtg aaattgaggc cattttggtt gaagttgaca gaaaccacta 173940tcagggatcc ccaagactac cccaggcttt tctagaaaga ctctcagcta agatgtgtta 174000tggtaaaagc acacaaaaca aaatcagcaa agaaaattag caagggcaga ggcccatggg 174060gcgatgtccc gaggacacca ggcttgagct tccagaatcc tctcccagcg gggtcgtgca 174120ggacgcactt aactccccgc acagtgagcc gtgacagcgc gtgtgcagtg tcgtcgccag 174180gaaagcacac tagagactcg gtgccagggt ttttactggg ggctgggcac atgggcaccc 174240tctgcctgcc tcgtgcccag actctggact cccggaggga aggcaagttc tcagcaccaa 174300ccctggtgcc cacacaagca gctgagcaca gggagcccct cctcagtgag gatggtgggc 174360accgtcccaa caccagccag gggccagcct tgcacacagg cctctcagga tggtctccgg 174420cctgctgtgt agtctcttct gcacacaagc gtgagggcag cgcccccgcc tcggctgtgg 174480ggaggagcca ctgggacgtg agctctggtg gcatgcagca gcttttgtct gtgtgtgcct 174540aggacaaggc cgtggcggag cctgtcagcc gcctgctgga gagcacgctc aggagcagcc 174600acctgcccag cagggttgga gccctgcacg gcgtcctcta tgtgctggag tgcgacctgc 174660tggacgacac tgccaagcag ctcatcccgg tcatcagcga ctatctcctc tccaacctga 174720aagggatcgc ccagtgagtg ggagcctggc tggggctggg gcgggggtct cagaatgagc 174780tgtgaaggaa gcagcatcac cctctccaag tgcccaggct cctggccaga tggcaggcca 174840ggtatcagtg ggaacccagg tgggtgccat ggctgaggtc agtgagacgc aagagcacag 174900gtgcgtccta gaggcttcct cgggcacctc cagcgagctg gagctctcgc ctctgctgct 174960gtctcatgtg gcgcttagca cactctccca cgtgcccatt cctgactctg ctctcgaggc 175020catcggctct cattctctgc tcccagaacc ctgttattac ccaggctagc ctcctctctg 175080caccttcccc gccctggccc agtacctccc tcttgtttcc actgtgattc cgacctcacc 175140ttatcttaaa gctgctggac ggcaggttct gtacacacgt gtccttgaca aagcacggct 175200ggtgccgcaa cccctcagcg agcaagtcaa gctcttcaca gcgatgtctt acaagcgcag 175260agggctctgt gacaccctgg tctcaccgcc actcttccaa agtcgcagag gctttagcag 175320agatgggccc agcctctctg agtcataggc ttctgcacac gggagctgtc tttagaggga 175380gggtggaatt tcatcagcca cccacatggg ggagttgagg gcaagaatta ggagcaaaga 175440tgggaagggg tctgggagga atggccagtg atcccctttg acaagtgggc aggaaacggg 175500ggctaggtca aagttgagtg gaagacctgg agggagacgg gaaggtctct gtaggcacag 175560ttcagacagg agggaggtgt gagccagggc acatgccggt ggccgtctgg caggatttgg 175620gacatgctgg agcagggaca gcggctcatc aggggccatt gccctcatcc aggccagagt 175680gtcacaagcc cgtggggagg cccttctcgc ctgtcatcct tgctgggcag tgggtgctgt 175740gctagcagga caggcggacg gctggcaact gtctctgcat ccctggagcc tggcataggg 175800ccaagtcaca cggggcacag gcctgcaaat caggcacata tgttggtgca gtgacgtgat 175860tttggggggc agccccagaa caggccccag acacaggcca aagccctgcc tgtgctggtg 175920tgttgggctg ttctatggct cttgctgtgg gcatggagga ctcagggaag gagagttgag 175980gtggtccagg agttgcgttt gggatgcaga gagcttgtgg catccaggta gaaatggtgc 176040gtggggctga cctcagcacc atgggcagag gggccgtgtc acgtgcctcc gaggtggagg 176100tgggaccacg tggtgacaga tatacgcatc actgggcacg tttttgtggg tgttgggggg 176160catcgtattg gctcctctgt tcacagtggc cactcattca gtccctggct accaggtcct 176220cactgtgcca tggggaaggc cggcgctgtc gggggatcac agaaggcagc acgtcatgat 176280ggcatgtgcc atgaaggaaa agcacagggc actcaggaag tagaggggac tggcctgggg 176340tgtgggaatc tagggcctcg ttgagggaca gagagaggaa gtgtgtggtg gccagcatgg 176400aggtggccac aggggaggct gagttaggcc gagagggcag ggcgttgggg aggtagacgg 176460gctcagccac tcagggagtg gtcaagcaga ggctgaaggg tcaggccagg ttgcaggggc 176520ctgggggagc cactcagggt aggcgctccc gggagcccgc ctggcccata gctctacact 176580cccgcgtggg gccggacatg ctgtgaagcc ctctccacgt tggatggggg tggctgagcc 176640tggatgctgt ctcccgtttt cagctgcgtg aacattcaca gccagcagca cgtactggtc 176700atgtgtgcca ctgcgtttta cctcattgag aactatcctc tggacgtagg gccggaattt 176760tcagcatcaa taatacaggt gagtgggccc tggctgtctt cctctgcaca cggggagtgg 176820gcttcccttc tcttttcctt gcaggatcat accagtgggc cagttttgac ttggtcggga 176880ggaggcatga acacctgaga ctgtgcagcg attctttgac acagaggcct ttctccctgt 176940gcagatgtgt ggggtgatgc tgtctggaag tgaggagtcc accccctcca tcatttacca 177000ctgtgccctc agaggcctgg agcgcctcct gctctctgag cagctctccc gcctggatgc 177060agaatcgctg gtcaagctga gtgtggacag agtgaacgtg cacagcccgc accgggccat 177120ggcggctctg ggcctgatgc tcacctgcat gtacacaggt gagcatgtac acggtgccca 177180taaggccagc ccaagtcctg ttcaagggag gcaggagcat gctcactcaa gggacctcga 177240ctaggtgccc tctgatttca cacttctggt gttgccccaa gccggcccca tcaccttgca 177300agaaaggctc tggagccccc agggctggag tacctggtca gggttgaccg tccctgtggt 177360cactcatccc atgtggctga gctgggctgg gtcctgggca agcaaggggc tgatatcacc 177420tgctttcaga tctccaggga ctcactggac ccctgtgtac aaagcactgt ctacagagcc 177480tattgggttg tatagaggta accttcgtac tgaacacttt tgttacagga aaggagaaag 177540tcagtccggg tagaacttca gaccctaatc ctgcagcccc cgacagcgag tcagtgattg 177600ttgctatgga gcgggtatct gttctttttg ataggtaaga agcgaagccc catccctcag 177660ccgttagctt ccctagaact ttggcctgaa gctgtgcttt tgtgtgtgtc tgctgatccc 177720ctggcgctgt tgctggagtc ctgccagtga ttccccacca cagcctgacc atgggctgcc 177780ttggctcagg gttccactgg cgagctggtg gtccttggac cccagcactc aggtgtagcg 177840ttgaccagtt ccaaggttgt cccagtgcct gcccatctct cctgagggct cagggacagt 177900acctggcagt tgggggtgtg gcagggggca ggaatgacca gcctctggga gggtggggca 177960gaagcctgta cagtgaggag gagctggctc agcctggctg cctatcgtga gaggggagcc 178020cacggggctg tgggaggggg gccgtggtgc ctgtgagcag ggtgaggagc agcggcagga 178080ggatgaaggt ggaacccaca catgcatctt tgagacccgt gtggtcagtg gcttctgccc 178140cccaccaccc cccactgctg tgcgtgcata gaattggctt ccctcacctg ctctggaagt 178200gggttaggag cttggtaggg ctttttctca aggacaaggg cccctgattt gctctcaggc 178260ctcagtcctg gcgacatggt ggatctggag ccttgttgca ctgccttgcc tgtgctctcc 178320aatcagggtg gccagtgggg agccatttgg cttttctcaa gagcatactc aggtggacct 178380tgctccactg tttgaccaga tgaggcattc tgaacagcca agcctgtgct ggtctgtttt 178440catgttgatt tttttttttc ttttcttttt gagatggagt ttttcccttg tcacccaggc 178500tggagtgcaa tggtgtgatc tcggctcact gcaacctccg cctcccgggt tcaagtgatt 178560ctcctgcctc agcctcccta gtagctggga ttacaggcac acaccaccat gcccagctaa 178620tttttgtgtt tttagtagag acggggtttc accgtgttgg ctgggctggt ctcgaactcc 178680tgaactcaag tgatccaccc tccttggcct cccaaagtgc tgggattgca ggcgtgagcc 178740actgcgcccg gcccccatgt cgatttttaa atgcacctct gcatcgttct tcagtcccca 178800tatgctcact gagcaccact gcgactggca gacgggcaca gggaggcgcc acgaccagtc 178860ctggccttca aggggcttgt ggtctagtgg gcccaatgct aggtggcgag tgctccaaag 178920agtgtggtgc acgccttccg cttgaccgct ctccagacgc cacagggagg cacctcgcag 178980ctgaccacag atttctctct gtggagcagt gtcttcagag cggctgccat gccactgctg 179040ggcgagggtc tgcgggcggg tagagccagg agcacctgtg aggaagtgca ctgccatttt 179100cgtagctgct tcccgtgtgt ctcagttaca cacggctggc atgtgtgcac tgatgagacg 179160ggaacgtgat ggttgctttt cagcactgaa agggatactg ctcagggggc gtgtttcagg 179220atctggttag ggaagaagca gcgagagcac agatggggcc ctgtgtggta acaagaaaaa 179280agtcctggtt gacaacagtg ccacgaagcg ttagaacaca tagggatgtt tgtggagcat 179340ttgcatgtgg aaagcagcaa aaacataatg ggaacgggtt cttttgttat gatttttaaa 179400aatctctttt gtaacatcct tcccgctgcg ccgtttctgc atattccttt atgtagcttt 179460caaactcctc ttaggagttc tggtccctac agggcgtggg agcccaggct ttacgtagct 179520ttcaaactcc tcttaggagt tctggtccct acagggtgtg ggagcccagg gcctgtgccg 179580agcagcctgc ctccacgagc tagacagagg aagggctggg gttttgcctt tttagtctca 179640aaattcgtac tccagttgct taggctctga ctttccccac ttggaaagtc cctcacggcc 179700gagggtccct cccagccctg atttcacatc ggcattttcc ccagtattag agccaaggcc 179760ctccgcgggc aggtggggca gctgtgggag ctggtgccag tctctgacct gcgtccctcc 179820tcccaggatc aggaaaggct ttccttgtga agccagagtg gtggccagga tcctgcccca 179880gtttctagac gacttcttcc caccccagga catcatgaac aaagtcatcg gagagtttct 179940gtccaaccag cagccatacc cccagttcat ggccaccgtg gtgtataagg tgaggttgca 180000tgtgggatgg ggatggagtg ggaaagcctg gaggtggagt tgcctccgac ttcccagcag 180060attcgccagc agagcccagc tcctccgctt taaagcagca atgcctctgg cccccacccc 180120acccccgcca cccaggcgca gcaggtgctt cccgtccccc cagccctgac actcaggcac 180180ctgcttgctc cttgcaggtg tttcagactc tgcacagcac cgggcagtcg tccatggtcc 180240gggactgggt catgctgtcc ctctccaact tcacgcagag ggccccggtc gccatggcca 180300cgtggagcct ctcctgcttc tttgtcagcg cgtccaccag cccgtgggtc gcggcgatgt 180360atcctctctg ggtccctggt gctggccccg tttcccttgt caacaccgag gctcatgttt 180420catgataagg ttttgaaacc taacctttgc aaaaacccca cagatgccag ggtgacaggc 180480cctcagcccc agggaagtaa aatgctgaca ggggtacaga aaggagcacg tccagacatt 180540tgctgaccag ggcctctcag aggggccggt gtatggcagg agggtcgcag ctgaggggcc 180600tttctgtgga gggcctgggt gaggggagcg agggtgggcg gtggtctctg cagacgtccc 180660gcccactcgc gggctctgtg tggctgggct tctcctgaca ctgcttctca ttagctttgg 180720tcattgtgcc tcgatcgccc tctcggggaa aggcttaagt aaagatccag ttcccacccc 180780cagatgctgg ctgccaggag tttccctttc cacagccctt ccccaagaca gaccacaaga 180840gcctccaagc agcacagttg tcctggtgct gacagcacag ccttgcccgg cgtgcctggc 180900acggctctgc cctcactgca ttggagcagg gctagtggag gccagcggaa gcaccggcca 180960ccagcgctgc acaggagcca ggccaggtga gtgctgccga gtgggtgccc tgcctgcagg 181020gcatccagcc agccaagggt tgcaggaatg gaggtggagg cgctgatgca gctggaggca 181080tccaggtggc ccttccgggg ctctgctcgc tctccaggct ccctggaccc ctttgtagac 181140tgtttcagga gaggaactcc caggtgagga cagggaggca gcattcccct catttgccgg 181200cctttttcct taactcctgc accagcctcc cacatgtcat cagcaggatg ggcaagctgg 181260agcaggtgga cgtgaacctt ttctgcctgg tcgccacaga cttctacaga caccagatag 181320aggaggagct cgaccgcagg gccttccagt ctgtgcttga ggtggttgca gccccaggaa 181380gcccatatca ccggctgctg acttgtttac gaaatgtcca caaggtcacc acctgctgag 181440cgccatggtg ggagagactg tgaggcggca gctggggccg gagcctttgg aagtctgcgc 181500ccttgtgccc tgcctccacc gagccagctt ggtccctatg ggcttccgca catgccgcgg 181560gcggccaggc aacgtgcgtg tctctgccat gtggcagaag tgctctttgt ggcagtggcc 181620aggcagggag tgtctgcagt cctggtgggg ctgagcctga ggccttccag aaagcaggag 181680cagctgtgct gcaccccatg tgggtgacca ggtcctttct cctgatagtc acctgctggt 181740tgttgccagg ttgcagctgc tcttgcatct gggccagaag tcctccctcc tgcaggctgg 181800ctgttggccc ctctgctgtc ctgcagtaga aggtgccgtg agcaggcttt gggaacactg 181860gcctgggtct ccctggtggg gtgtgcatgc cacgccccgt gtctggatgc acagatgcca 181920tggcctgtgc tgggccagtg gctgggggtg ctagacaccc ggcaccattc tcccttctct 181980cttttcttct caggatttaa aatttaatta tatcagtaaa gagattaatt ttaacgtaac 182040tctttctatg cccgtgtaaa gtatgtgaat cgcaaggcct gtgctgcatg cgacagcgtc 182100cggggtggtg gacagggccc ccggccacgc tccctctcct gtagccactg gcatagccct 182160cctgagcacc cgctgacatt tccgttgtac atgttcctgt ttatgcattc acaaggtgac 182220tgggatgtag agaggcgtta gtgggcaggt ggccacagca ggactgagga caggccccca 182280ttatcctagg ggtgcgctca cctgcagccc ctcctcctcg ggcacagacg actgtcgttc 182340tccacccacc agtcagggac agcagcctcc ctgtcactca gctgagaagg ccagccctcc 182400ctggctgtga gcagcctcca ctgtgtccag agacatgggc ctcccactcc tgttccttgc 182460tagccctggg gtggcgtctg cctaggagct ggctggcagg tgttgggacc tgctgctcca 182520tggatgcatg ccctaagagt gtcactgagc tgtgttttgt ctgagcctct ctcggtcaac 182580agcaaagctt ggtgtcttgg cactgttagt gacagagccc agcatccctt ctgcccccgt 182640tccagctgac atcttgcacg gtgacccctt ttagtcagga gagtgcagat ctgtgctcat 182700cggagactgc cccacggccc tgtcagagcc gccactccta tccccaggcc aggtccctgg 182760accagcctcc tgtttgcagg cccagaggag ccaagtcatt aaaatggaag tggattctgg 182820atggccgggc tgctgctgat gtaggagctg gatttgggag ctctgcttgc cgactggctg 182880tgagacgagg caggggctct gcttcctcag ccctagaggc gagccaggca aggttggcga 182940ctgtcatgtg gcttggtttg gtcatgcccg tcgatgtttt gggtattgaa tgtggtaagt 183000ggaggaaatg ttggaactct gtgcaggtgc tgccttgaga cccccaagct tccacctgtc 183060cctctcctat gtggcagctg gggagcagct gagatgtgga cttgtatgct gcccacatac 183120gtgaggggga gctgaaaggg agcccctcct ctgagcagcc tctgccaggc ctgtatgagg 183180cttttcccac cagctcccaa cagaggcctc ccccagccag gaccacctcg tcctcgtggc 183240ggggcagcag gagcggtaga aaggggtccg atgtttgagg aggcccttaa gggaagctac 183300tgaattataa cacgtaagaa aatcaccatt ccgtattggt tgggggctcc tgtttctcat 183360cctagctttt tcctggaaag cccgctagaa ggtttgggaa cgaggggaaa gttctcagaa 183420ctgttggctg ctccccaccc gcctcccgcc tcccccgcag gttatgtcag cagctctgag 183480acagcagtat cacaggccag atgttgttcc tggctagatg tttacatttg taagaaataa 183540cactgtgaat gtaaaacaga gccattccct tggaatgcat atcgctgggc tcaacataga 183600gtttgtcttc ctcttgttta cgacgtgatc taaaccagtc cttagcaagg ggctcagaac 183660accccgctct ggcagtaggt gtcccccacc cccaaagacc tgcctgtgtg ctccggagat 183720gaatatgagc tcattagtaa aaatgacttc acccacgcat atacataaag tatccatgca 183780tgtgcatata gacacatcta taattttaca cacacacctc tcaagacgga gatgcatggc 183840ctctaagagt gcccgtgtcg gttcttcctg gaagttgact ttccttagac ccgccaggtc 183900aagttagccg cgtgacggac atccaggcgt gggacgtggt cagggcaggg ctcattcatt 183960gcccactagg atcccactgg cgaagatggt ctccatatca gctctctgca gaagggagga 184020agactttatc atgttcctaa aaatctgtgg caagcaccca tcgtattatc caaattttgt 184080tgcaaatgtg attaatttgg ttgtcaagtt ttgggggtgg gctgtgggga gattgctttt 184140gttttcctgc tggtaatatc gggaaagatt ttaatgaaac cagggtagaa ttgtttggca 184200atgcactgaa gcgtgtttct ttcccaaaat gtgcctccct tccgctgcgg gcccagctga 184260gtctatgtag gtgatgtttc cagctgccaa gtgctctttg ttactgtcca ccctcatttc 184320tgccagcgca tgtgtccttt caaggggaaa atgtgaagct gaaccccctc cagacaccca 184380gaatgtagca tctgagaagg ccctgtgccc taaaggacac ccctcgcccc catcttcatg 184440gagggggtca tttcagagcc ctcggagcca atgaacagct cctcctcttg gagctgagat 184500gagccccacg tggagctcgg gacggatagt agacagcaat aactcggtgt gtggccgcct 184560ggcaggtgga acttcctccc gttgcggggt ggagtgaggt tagttctgtg tgtctggtgg 184620gtggagtcag gcttctcttg ctacctgtga gcatccttcc cagcagacat cctcatcggg 184680ctttgtccct cccccgcttc ctccctctgc ggggaggacc cgggaccaca gctgctggcc 184740agggtagact tggagctgtc ctccagaggg gtcacgtgta ggagtgagaa gaaggaagat 184800cttgagagct gctgagggac cttggagagc tcaggatggc tcagacgagg acactcgctt 184860gccgggcctg ggcctcctgg gaaggaggga gctgctcaga atgccgcatg acaactgaag 184920gcaacctgga aggttcaggg gccgctcttc ccccatgtgc ctgtcacgct ctggtgcagt 184980caaaggaacg ccttcccctc agttgtttct aagagcagag tctcccgctg caatctgggt 185040ggtaactgcc agccttggag gatcgtggcc aacgtggacc tgcctacgga gggtgggctc 185100tgacccaagt ggggcctcct tgtccaggtc tcactgcttt gcaccgtggt cagagggact 185160gtcagctgag cttgagctcc cctggagcca gcagggctgt gatgggcgag tcccggagcc 185220ccacccagac ctgaatgctt ctgagagcaa agggaaggac tgacgagaga tgtatattta 185280attttttaac tgctgcaaac attgtacatc caaattaaag gaaaaaaatg gaaaccatca 185340gttgttgctg tgtgaggctt gctttgcttc atgagaacct agaccttgct gagctggagt 185400cttaggaagc agtctcctaa gtgcttctcc agcaggggca gaaactgtcc caccagctaa 185460catctggcat tatggagggt cccccaggca gctgccagca gggacaggcc ccgtgttttc 185520tgtagccagg gatgaggaag tggccccagg gcatgggcct ggctgggtgc ttctgcaagg 185580gccttcccaa accacagtac aggtggtctt cctgccctgc agatgggagc tgtgggagct 185640gctggagctg ctggagcctt catggtcaag tgacatcata agcttatatg acatacacaa 185700gcctcaggac ttggcccatg gcactgaagc aggtcatcag gcccagcaca gagactagag 185760ctgtgttctc acagggccca ccacccttcc acctccttgg ccattgacac ctgcgtccct 185820ggcccagctg ctcccaggta acccccaaag cagctggcac atcccacctc tggtgtggcc 185880ggggctgctg tgtgtccgca gggcctgccc cgtctattct agcttgtttg tcctgtctga 185940accagcgcct actccaagaa gcctctgctc agcccagcgg ggatgcttct aagctccgga 186000cgagcctctc ggaagccttg gtgattggtg gtgtagtcat cttgggatgc agatgtctta 186060ccaacctgca agaacaaaaa ccctgtggct tcctctggtg cagggtattt agtcaatgtt 186120tgctgaggtc ccgtctggtt ctggctaatt ggcaggggtc gtccacccat tctttccctg 186180ctctgctgtc tgtgccagga gagacggggg ccagtcggcc aaggggccag ctcctgctgc 186240ctgctcctct tgggcacgtg cgggggcccc ctttctctga gcagggatag ggatcagtct 186300gccggaggga tgtggtggac aggcctaaag catttggggc ggggcatgcc acttgagctc 186360cctaaatctg tctcctcata ggtgacaccg ctccagggcc ccccagtggc ctctcctttc 186420agagctacct aaattctggt cacttcagag aaatggagca cccccttctc cctggtccag 186480gtgtggacag cctggcacac tgagcacacc tggcatggct ggtaatttca gaaagaagag 186540gggccggggt ccagtgggaa gcagcggtga acccctcgtg agtgggcttt gcagtccctc 186600cccatgccac ggcagagctg ccctcaacac agccttcctc ttcctcatcg gagagcacac 186660cctgtcccct tgccgagctg tgccctgtgc cttcggtggt atttgatttt ggctgctact 186720ggctttgttg ggatctggaa gtcgcttccc ctgcgtggtg cgtggagcac tgtaagtcag 186780atgagggaag tagccagggt gaggtgagta ccgggtggag ccgccactga agggactggg 186840taggggggcc ttgcctctac atgatgtgac acagccaacc gaggacagag gaagccccgt 186900tcctgggggt gtggggtgca cccctcaggg aagcctgcag tggggcctga ggaaaggcat 186960cctccgcgag cccacgagtc tggtccatga gcaccgtgac agtgtctgtg ggtagaggtg 187020gacccggcct tgtgtcatca ccaggacctc ttttgggaaa ccatgtggac atcgcttgcg 187080ggtcccccag gctctgcagc cccagcagcc tggctgcctt ttgggcaagt ggcttgagcc 187140acagaggacc cagtcctgtt gcagccacat cctctggggg ggcccgccag tgtggccggc 187200tttctccacc ctacaccagg cctccaggtg tcctggtcgg gggtgtctgg gccctgggtg 187260ggccctgtgg acctgtgagg tcagggtcag ggcatcactg gaggcagagg gctgaagttg 187320tgggtctggg ttccccttgt gtgcacaggc ccctgccctc catgcttggt caggcagcta 187380cccccaaaac tgctaggaca ggctggtcct gaggtggatc ctggcccctg taccctctgg 187440acagcccacc cgcccaacct tctaccctgc cccagcggcg gcagtgttgg ccacatcctt 187500cccctcctgg ccccaattgc tctggggaag tccaggctcc ggagcctgcc caggggcccc 187560ccgtgatttg ggcccaggac tccacgtggt tctctgcctt cacccaagcc ctgaactcct 187620cagctgccaa atccccaccc atctgcacag gctgtgctca ccactgctgc tcctggaagg 187680tgcccctcag tgggacgccc acctcctctc tgggcttctg tgtttgggag ccctgctgcc 187740cccacccttg gtcagtcccc atgtcctgct ggcctgtcag gcagggcaga aaatccaccc 187800agaaatgctg agcaggatga gagtctagtt gggcccagcc tcattattta gaagggatgg 187860aggcctaggg agcatgcttc tagcctgagc ccagcagggc cccgcccatg tcccaggtct 187920gcaccaggga cagctcctgc cgaggcctga cctgcccctt ctccctcagg tgctgctggt 187980tgaccagcct ctggccctag gagaccccgt agcgactgag ggtcccagca ggccatgcag 188040ctttgccaag gtacgagccc ctccccagca ggggacagat gtggggaccc tcccaggcag 188100gagcagctgg gtgcctggtg ctgccatctg ctgcctgcct ggttcttgtc ctcacattgg 188160aggtcagtgt gagggctctg cctcgggaaa ggccatggag cttgccctgt ccagggcctc 188220ccatgtgcac tgagcctggg aagagagggt tggagttgag ccttttaccc tgggaatgct 188280gcctggagga tggtgcgggt gtggggtggc accctgccag gcagggccct gcctccctgc 188340gcccactgga actcgggcag gcaggggtgt aggtgcctcc tctagagccg tccggtgggg 188400gcccccggca gtggtggtgg tgtccactgg ccagcagctg ccccttcagc caggacagta 188460ggcctgacgc tgtccccagc agctccaagg tggatttgtg gaagggggta gagggcacgt 188520agaggcccca tgacctcccc agggttctgg gagggctgtg cccccttagc cagcaccatg 188580ctgggtgata tagtcagatc ctgttacccc tgttgtggag gtgaggaaac aggttagtgg 188640ggaggacatg actaaggtcc atgctgagtc gctagagctg cacccagaac cactgctggg 188700accccatgcc tttctgctta ccccttgtgc cgggagatgc caagagatgc tgggagccag 188760ccccacctct gcccttggag tcatggctac ggaaagggca ttcggaccgg tccctgacct 188820caccggggag ggccgaaccc tgttcctgag gagccagggc ttcctagagg aggtaggcct 188880tctagtcact ccttcatctg caggcactcc acagagctct ctgtgccagc ccccagcacg 188940gagggctgac cttagtcgag tggagatgcc ccagtgccag gcagtaggga tgatgtctcc 189000tgaggcccag atggaaggga ctggactagt ctcatggggc tgatggtggg gccaggcctt 189060gaccagggac ccagtgtagg gggtgcagag acccctctga gttcctcaca catccctggg 189120gccctcccca tacacttcct atcctgactg cgggcaagag ggagccccag ttcgccttcc 189180ctatgctggg cacccacagt ggggctgggc acccccgcca tgcccctgcc ctgtccttcc 189240cctgagagcc tcggtcccac ctccaaggtg cctcagagga cagcaggggc agcgggcaga 189300ggccgagatg cctcctcatt ccaggctcag ctgcccttct tggggcagcc cacacctgag 189360agtctcctgc agttggtcag gcctgaggag ggcagggggg tgcctgctgt ccctctgctg 189420accacagtgg catttagcct gggcaccgcg cccagcacag tccatgctgc acaggtgccg 189480tgggctccac agagccctgc ctgacatgca tgtgttacgt ttcgggtgcc gatgcccttg 189540ggcggcactt ctccgggcag aacccccagg ccaccgctcc ggttccggtt ccgctgcatc 189600tggggctctc ggcaggctgt ggtcctccgg ccagcctggg ggcatctcag tccctcagcc 189660ccacaggggc ctgccccgca gcctgggcct cgagccccgt ctccgcacgc tgtgccgaat 189720ctggctgccc atcagctccc tgcgtaccca gactgtgccc tgccatgccc gtggctcttc 189780ccaggagtgc cctgtggcct ccccctggct tgctgggctg attccctcct gtgtctcaaa 189840cagagctcac ctttgccatc actgctgtcc tcaccggccg gtgccagagg cccgtgtctg 189900tgtaccctgt gtctgcacct ctgggcaggg cctggctctg accaacccgg gcttccagtg 189960tccacagacc taaggcccag ggcgcctggg ggctggagca agagaagcaa aaggagccaa 190020gggtgggggt ttggggttct tgtgagggcc cagccccagg accccaggac caggacaccc 190080aggagcccca gggcccagcc ccagttcaga aggcaggggc cttctgaggg agcttaaggg 190140tcccacagcc caggaccccc accagggcca gtggccagcg ttgggggact cagcctcctc 190200gtcgctcgtc ctctctgttt ctcccacctt ttgccccctt tctccttgcc tgttcccacc 190260cgaggccccc tcttggcctg cgtgagccgg ggcggcactg aactgggggc cgatccgcct 190320gggcggcggt gagaggcagg gccgggagcc gggccgctgg gtttgggcct ggcccgctcg 190380ccgcaatatt gatggcccgt cagtgcagcc ctgattcctg tgctttcagt taaaaggttt 190440ctgttgttgt agcttatgca gttgctctgt tgctatggaa acgtgacatc aaaatgacgt 190500ttcccgttta aaagctttta actaaattcc tgcctgtcag atgtaggccc cattttgagc 190560gtggagctgc cttcgagcga gcgtgagcgg cgcctcccgc ccatggtgcg tggggccggg 190620ccggggccct cgctgagcgc gctctctcac cccacaggcg cctccggcat ggcggcggcc 190680gaggggcccg gctacctcgt gtctccccag gcggagaagc accggcgggc ccgcaactgg 190740acggacgccg agatgcgcgg cctcatgctg gtctgggagg agttcttcga cgagctcaag 190800cagaccaagc gcaacgccaa ggtgtacgag aagatggcca gcaagctctt cgagatgacc 190860ggcgagcgca ggctgggcga ggagatcaag atcaagatca ccaacatgac cttccagtac 190920aggtgggcga gcgggcagtg tgggccccac caggacgggc gggcccgggc gtggcgggcc 190980gctcctgact ttcttggagc tctgagtcgg gacgatgtgt gggtcgtggc ctgcctgtcg 191040gtctcctctg gccgggtatg ggcagaaccc cacggggtga gacggggccc acggaaaccg 191100tgtgtgcagc cttccattgg ggaagtgggg aaactgaggc ccagcaaggg caggaaacca 191160gtctaagagc tgaggggtag caggggtggg gctggtgctg ggcagaggcc aggatggctc 191220ccaggacgta tgggcggtct gggcactgtc cctcggaggc agcaacactc atggtggtgc 191280ccactgacct cacaccctgc tcccccatag ggaggcggcg gctgccagtg ccctccccac 191340caccaagctc ccaagctcag caggggtttc aggggcctac tgcgtcattg gggaaattga 191400gactgcaagt gagaaggagg ctcagtgctc tgcgacttgg agcatccact gagcctctgc 191460catgagccgg tgagccccac tggggctggc cctagggtca cggtggggta tttccagaaa 191520tcaccaggtg aggtgcagga ccagccagcg catgggtggg gcttacggtg cgaagaagaa 191580agaggtggag gcctgccctg gcccaggact cccagcgtgg gggctcccgg cctggcccca 191640cctctgctcc tgctacatgg caggtgggcc cttcctgccc tggcaacctg cagggaaggc 191700cggaggggac cacccagcca gggagatgtt ggcgtctagg aggggacagg tgtggtccca 191760cacacccagc atcttaaagt gcgtgggtcc ccagcccatt aggacagggt cccgggtggg 191820caggggtcat ggtggggtga aggtctcagg cacaggcaag gtcacaggtg cggtgagggt 191880cttgcagggt gtgaaggtca taggtgtgcg gtgaaggtca caggtgtggg gtgatggttt 191940tgggtgtggg gagggtcttg cacggagcga gggtggcagc aagagctgga agctgcaggg 192000ggagaatggc agcagagagc acccggccct gtgggcggcc tggacagggc tgggcctggg 192060gctgccggag agcctgtcag cttccaggat gggagtggcc tcactcagct gctccacctc 192120cgggtcaggc aggtgagcct ggggcagaga ggctgagagc acctgagcca cttgtgggag 192180aggccacccc cactgccccc ctcaggcgag gagccggcct ccagcacagc agaagggaac 192240ccccagtccc cagccctagt gggagtgggg aagaggccca gcaaggcccc ggacagaccg 192300ccagcctgtg aggtctccgc tttcagttgc gttgatttga ttttttctga gccttgaagg 192360aggggtccgg ggcctggccc tgcccaaagg cccctaggca ggccccaaag ccgggaccta 192420gggtgctgag catgacggat gttgggtttg agcggctggc ttgcgacgtg agggctgagg 192480tgtgagcctg ggtatcttca gaggttcggt ggacacaggc agctgcccgc ggccccactg 192540ttcccgtggc ctcctagtcc tgctcaggca cctggtgagg aagggacgca gagggcagtg 192600ggaggtggcc acgactgttc cagcaggctc ccctctgact caggaattca cgggcaccac 192660ctccctggct ggctctggtt ggtgtctggc caggttattc attatttatg ctgaaagcct 192720cttcagagtc ccaggggagg gtttctgtct ccattcctgg aggctgagag atgagggtgc 192780agcagagtgg gggcctccac tccagaccct gcagtctggg ctggccaagg gctgcaccgg 192840tgcactgcac gtcatggctg atgaagcact tccacaccgc agcccctcag agctgccaca 192900gtcagcctta gttcaccgag ggggaagctg aggcccagag catgagaggg acttgcccag 192960ggccacatag tccttagcag aggaagctgt ggctgggtga ctcgatcttt gtcctttttc 193020tttatacccg cagtctcccc atagcagagg cttttctttt ttttttcttt ttcttttttt 193080tttttttaca agaactcttt atatattaag gctgttgggc tgaagaagcc tgagagggtg 193140gctggttctg tggagcatgg tttgttgaag tacagtttgg gggcctccta cactgagaat 193200aggccttttc tcgtttctcc aaagagtggg ctggctcaag tagggcagag agagaagcct 193260ggggcagagg ttagggatgg gcacccagcg cctgccctca cacgctctgt gctggtgtct 193320tcacagccac gtgccaccct gggcagcatc ccctgctcac catctggctg tgcctgtttg 193380ctgggggcac ctcattcaga atccagctta ttgtttccaa cggccaatgg ccacaccctg 193440gcaggtagca agagtaggag agaggagaca cccactccga gcacaggttg ggtttggagc 193500ccggccttgg ggcactctgt cactcaaagg cagagtgggg agtgggcact gggccttagg 193560aggtactggg tccagtgagg cagagatgcc cctgccccac ccccaccttg tggcttcttc 193620cctggcctgg ccagagctgt ctggccgcca tggggccctg tgtctcctgc cttgacctcc 193680cagagggcag ccgaggccca ggggaggcct ggggacttag cctctcaggg caggacctgt 193740ctgcaggagt aggtgggtgc tgggggtccc agtggtaatg aggcatcagg cagtgtggga 193800aggggcccat ccggcccacc ccagggcctc tgggcaggtt gcaggttgta gcgctggatc 193860taggctcctg cccagactgt aggttcaacc aagaatggca tgggagccca gcctgctgtt 193920tgctttatta aatctgccct gtagctgggg gaggggctta ctttgatcat cactatgtca 193980ttgatataaa aatagaggct cagagaggtg aatgaacctg cccaaagtca cacagcaaag 194040tgtggagatg agatactgac tcagggctgt ggacactgaa gcctgtgctc taacgccagt 194100ggctgtcgct ccctgaggca ttctctcccg aacaacacag ttattatatt acaaaatatt 194160atcactatat ttatatatct tataatacct tattattaca ataaaacctt attactctac 194220ctttcaaaat gaattattta aaaagcagta tttgctcatt gcagagagtc tagaaactat 194280agaaaagcaa gggaaaagca ataggaccag ccccaaggtc ccagcatgca cagataacct 194340tagtaatact gggacgtgtg cttccttttt aacatctgag cccgtgtagg tcctgaagcc 194400cagcttcttt ctaagtccat tgtcatcttg accctggagc ctggccgatt ttgctgggga 194460ggcccttgcc agccgagagc ggctcctgcc tgtgccggcg tggcgcgccc ctctgctgag 194520gctgggcagg acaggggctg ggccagctct gtttctcacc cttggctctt gtgtctctcg 194580tttcaggaaa ttaaaatgca tgacagatag cgagtccgcc ccgcccgact ggccctatta 194640cctagccatt gatgggattc tggccaaggt ccccgagtcc tgtgatggca aactgccgga 194700cagccagccg ccggggccct ccacgtccca gaccgaggcg tccctgtcgc cgcccgctaa 194760gtccacccct ctgtacttcc cgtataacca gtgctcctac gaaggccgct tcgaggatga 194820tcgctccgac agctcctcca gcttactgtc ccttaagttc aggtagtgtg tctgcttgtc 194880cttcccctgc cctggggtat ctcagccccc accatttaga gaaagggact gggagtggca 194940aggccggcgg cggcggccac agtggttgca gaggccgtgg ctgcgggcag cgcctccagg 195000gacaggcggc ctcagaccag ggagggcttt agtgtccaca ggcagaccga gtttgtctcc 195060cagctccatc acttttgagc tgcacggaaa gttccttgac ttctctggcc tcagtctccc 195120tcctataaaa tgggggtaaa tcagtacctt tctcagaggg tggctgggag catcacagga 195180gagaagacgc agcatggggc ccggcacacg gagggagacc aagccccaga ccccagaatg 195240cgccccctgg cctcccttag cccacacaga ccccaccctc acaggctagc tgccctctca 195300gcactgggga gggtgtcggg ctgcacctca tcacgtgttg ccgtgggcat gacccgtccc 195360ctctgccatc catcccacac ctcagacccg tcccgtgctg gccacgtgac tgtgcctgca 195420agatgctcac agggcagccg ggagccaggc agcatgcagg acagacacct gcggggtggg 195480cctggggagc ccagagaagg tgcttttgag gaggggacat ttggggtggg ctttcaaggt 195540aaaatagaag ttggccattt ggaggcaaga acaggaagat tgtggatttg agtcacagct 195600tctcccctgc cctggtcttc aagtctttct gacaggaggt gtcagaaaag tatctttagt 195660agagaaggcg tctccgagga gggtccctct catgccgggg gccgctgctt gactcaggat 195720ttctcattga agacctgaga caaaaacgct tttgctggca gctagaagga accagcagga 195780ggcctgagat ttgtggctgt tgttcccgtg gactgagccc agttctcaga ctcagctgcc 195840tggggccttg cacaggactg gggcgtgggg gctgccctcc ctgatcaggc ccaaagcgcg 195900gatctcacgc ccctgaggtt ggctgtaccc tctcagctca gagcagagtg tgggccaggg 195960atgagcaggc actggagcag ggccctgggg tctgtgggtt ttggcagctc cctgcccttc 196020agggaggtct gctgagacca cgggtggccc ctaccccagc agcagagctc tcaggaggcg 196080cccacagggc tggactgcct ttactcacca cctctaccag agctctgagg tcctggggag 196140agagcccagg cctcttgtgg gccccacacc ctctaggtgc ctgtccttct gcctctctac 196200caaggtgtgc cggccccatt tctaggccgc cgggagataa gggggctcac atctcaggcc 196260cttccttctg ggacctcagt ttccccatct gcctaaggcc gggtggggct ggtggtcttg 196320gcttccctac aggggtcctg agtactctgc actacccagc accccccacc cctgccttca 196380tctctccctg ggggtggtct ctccacccct ggcccccaac tggggctgag cccccacctg 196440cccagtttgg tgggtgaagg gtgctccctg gcaggatatg cccctctgca gcccagaaca 196500tcccaccctt tccagaccga aggggtgtgg attgtcctgg gaccctggtc attggggtca 196560tccgctagtc gcaaaggacg gcaatgcctg tggcctctct ttctttcttt ttcttttttt 196620ttttttttga gacggagtct cgctcttgtg cagagagcag tggcgcgatc ttggctcact 196680gcaacctccg cctcgtgggt tcaagcgatt ctcctgcctc agcctcccga gtagctggga 196740ttacaggcac ccgccacaac gcctggctaa tttttgtatt tttagtagag atggggtttc 196800accatgttgg ccaggctggt cttgaactcc tgacctcagg tgatccacct gcctctgcct 196860cccaaagtgc tgggattaca ggcataagcc tccacacccg gccacccctg ttactttctg 196920tcaaaggcgg tgggttctgg cccctccttt gcacatggaa tatgagaccc tgagtaagtg 196980acctgactcc ctggggcctc agtttcccca tttgcccagt aggattgtcg ggagggtccg 197040gtgaggcccc tggtgtgccc aggctctgtg gccagcacgt ccacagccgg cactgtcctt 197100ccaggtcgga ggagcggccg gtgaagaagc gcaaggtgca gagctgccac ctgcagaaga 197160agcagctgcg gctgctggag gccatggtgg aggagcagcg ccggctgagc cgcgccgtgg 197220aggagacctg ccgcgaggtg cgccgcgtgc tggaccagca gcacatcctg caggtgcaga 197280gcctgcagct gcaggagcgc atgatgagtc tgctggagag gatcatcacc aagtccagcg 197340tctaggccag caggcggcgg cggcggcggg gccgggcggc tggtggtact gctcaggcca 197400cccagggcag gccactcagg ccaggcgggc aagggggccg ccccgcgagc ggagaccgcc 197460ttccacctgg cctctggcag gatgtccctt ctgaggggta ttttgaggaa cccccaggcc 197520ctggggaccg tgaggctcca gtctccagca tgaatgccct tcctcggaca caggccaggg 197580cctctggggt tcactccgag taagaacgtc ctagagccac tctccagtgt cgttactatc 197640aatgatactt gacgtggctt tgatattaaa cgtatacttt ttcattcttg cctggaacgc 197700acagtttgct gttgctggct tggtgaggat gccctgattg atggatcccg aaaatgaaag 197760cagatggaaa cgggttgggg caggctggag ctgggggagc tctctcctga agggaaccct 197820gtgtcctccc tcaccaggac ctctgcgtct ctccttaaat ggcctctgac gcctgatgaa 197880aaccccagcg accttccagg aggcttttat tcagctctgt ttggagcatc aggtgtttcc 197940actgcctcct tagcaatgac actaataaaa gtcgtaacac ctgttcacat gcacagccct 198000gttgagtgtt ctgggtgctg gagatatcat ggtggatgac acaaaggccc tggcctcttg 198060gagcttatgc tcccatgcgg ggaagacaca tgggtcagta gagaaatggt tgcaggttgt 198120gataagtgct ggaagggagg ggttggcctg aggacacgga ggcagacata cgtggagctg 198180ggaacagtgg ccacacaggg aacggccagt gcgaaggccc agaggcagag gacactggag 198240caagcccagg agcagctagg aggctggtgg ccagcagcca ggccacggaa gcccgtgcag 198300cccgtgggga ggagtgttca tgcttttcaa gcttagtggg agtcttttgg ccagtgcagc 198360tctgggtctg acatcggtgg gggacagagg ggtggtggag cggccacagc tgcaagctca 198420cctcactgcc ggcccttcca ccagtttcaa actctttcta gaagctccag ctttcccaaa 198480gctgaattct ctatgagcct ccttggccgg gactcgggcg tctggttgcc ctggctgcaa 198540aggaggctgg ggccaggtgt gtttgagtca cctcctggaa ttaggcaagt tgctgcccaa 198600atagaaggtt gttggcaggt gggtcagcag gtgaacagca tggtttgact cagggttcag 198660aaaaatctcc ctctggctgc caagcgagca ggccgtggag acaggtgcag aggcaggtgt 198720ggcagcaggc atcctgccag gcagtgctgc agtcatcctg cgacaagcag cagcagctca 198780tcctaccctc tagggggtct tgaggtcagc caggcaagag agcagcttgg actccactgg 198840gtgtgggacc agcctgtgga ccatggtggt gtggagggtg ccctcggcct gcctgtgtga 198900aggagaggcc ggcgtgttct gtggagccca aaggggagct gggcaagcag gattcacttc 198960actctgaggg tcctggagct cccaccctcc tcagccatct ccccagagcc tgtgtgccga 199020ggactcggcc catgttgctg tgggatgaga ggcagagtgt cgtgagggtg taaggagcgg 199080cggcagtggt gggaggaggg agcagcagcc agcgctacgg tgccagtttc cagctgccag 199140atgacgccgc tgaccctgtg gttgagaaga gatgcacaga gccagctctt gcaagccagt 199200gtggctgcca tagcacctgc cgagaagcag aaggaagggt ggccccagga ggacagagga 199260tgcgggcaca tctgatgcgg gcctgagttt tgggagcttt tgctctagcc agtttccagc 199320tccgggaccc acccgcctcg taggcaagac accacccaag aaatcatttg cttaacaaac 199380acactgggct ccaactggac acctgtgcca ccctagatgc tgggaaccca gccatgacac 199440aggcacctgc ccccagctgc tgaccactga ggctggctag cagctcccat ggggccagtg 199500tggggttccc cagcctccta acagggagcc agtcacaagc cctcgagagg gaagggtgcc 199560cgcggccctg gcaggaaggt taggctggac gctcccacaa gacataacag atggaggttc 199620taaatgatgt agcaacttct tcaccctgaa actgctgtag agtcagccat gacgcaccgg 199680tacttcagta actgccaggc atccgggaca gcacaccgcg agtcgctgct gtgcttgggt 199740tagaagtggt ttggtctgtt ttcttctcgc cctctctaat cagagtcagt gattcatgcc 199800cttccatcac cttagagaag gggcaggcgc tgcccgacct tctccaggct ggagcagcat 199860cgcctcatgt cagcagaact cagctgtaga atatcgtggg gttggtgcct ttcatcagca 199920gcatgtcctt aacaactttc tgatttcttc cttagttgtt ggtccattaa ggagaaaaaa 199980aatgatctca gccattgcta aaatatttga taagattcag caaagcagca tgttaacatt 200040gaaaactaga atcaggagcc aggcagatgt gcttgctttt cacctgtagt atttcatgtt 200100gttttgacgt ttttagctaa tgcattaaga taaataaaca aaagccgggc acggtggttc 200160acgcctgtaa tcccagcact ttgggaggct gaggcgggag gatcctctga ggtcaggagt 200220tcaagaccag cctgaccaac atggagaaac ctcgtcatta ctaaaaatac aaaattagct 200280gggcgtggtg gtgcatgcct gtaatcccag ctacttggga ggctgaggca ggagaatcgc 200340ttgaacccgg gaggcggagg ttgcagtgag ctgagattgc accactgcac tccagcctgg 200400gtgacagtga aactcggtct caaaaaaaaa aaaaaattaa aaaaagataa ataaaataag 200460caggataaga aatgaagaaa gtagagttac ctttgttttc agatttcatt tttgtatacc 200520cagaaagcca aatgtacaaa agactgggag ctctttaaac cagcttaaac ttgttgaaaa 200580tgaggatgaa gaaatatccc attcagagtt ggaatgaatt taacccagaa ggaacaggac 200640ctctactgaa gagaactatg cagtcttact gaaaaatcta aataatacct gagcgctgga 200700gaaacttcgc acactcctga aagctccaaa gtcaatgtca tcattttatt aatgtcattc 200760caaacatagt ctcaataata tcacttcttg gttttgacat ggacgcgatg atgtttaaat 200820tcatatgaaa aaagaacggg gccaaaagtc caaggccagt cagcgtgaga agaccgctcg 200880gcctccctcg gagtcgggga gttggaaccg cagactgaga tcatgtggct gctggaggcc 200940aggacgaacg tcgggaaatg gagactcctg cgttgctggt gggatgtggt gcagccgctt 201000ccaggagcaa tttggtgtcc cgtcctaaag ctgaagaaac gcatttcctc tggtcagtgc 201060cactcctaga caggccaccc tgcggcagcc gtcctcaaac tggtctgagg acccctcaac 201120gctcttaaaa atcattaaaa gtgggccagg tgcggtggct cacacctgta atcccagcac 201180tttgggaggc caagacaggc ggatcacgag gtcaggacat tgagatcatc ctggctaaca 201240cggtgaaacc ccgtctctac taaaaataca aaaaattagc cgggcgtggt ggcgggcgcc 201300tgtagtccca gctacttggg aggctgagcc aggagaatgg cgtgaaccca ggaggtggag 201360cttgcagtga gctgagatca ctccactgca ctccagcctg ggcagcagag cgagactctg 201420tctcaaaaaa aaataataaa taaataaata aaaataaaat aaaataaaat tcattaaaag 201480tgccaaagaa cttttgctta tgtgagttct aatgaccaat attaatacac attagaatat 201540cttattagaa attaaacctg agacctttag aaaacatgta ttcatttcaa aatagcaata 201600aacccatgac atattaacat aaataacaat tgtatgaaaa atatattttc caaaacaaaa 201660agttttcggg agaagtgtgg catagtttta catggtcgta aatctctggc ttaagagaag 201720cccactggcc tctcagcagg ctctgggtcc gtccactttg ggggtgtttt ggttgtgaag 201780tataggagtg aatggagaag ctcattctta cccagatgtg tatttgaaaa gaaaaggaac 201840attttaataa cctttgcaaa taatcggtat attcttccgt gatcctattc caacactgga 201900caggtggtgg tttgtttttt ttttttggag acggagtccc gctctgtcac tcaggctgga 201960gtgcagtggc gcgatttcag ctcactgcaa gctccgcctc c                     202001</s400><s200><s210>2</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 2tcacagctat cttctcatc                                                  19</s400><s200><s210>3</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 3taaattgtca tcacc                                                      15</s400><s200><s210>4</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 4ataaattgtc atcacca                                                    17</s400><s200><s210>5</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 5cacagctatc ttctcat                                                    17</s400><s200><s210>6</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 6cacagctatc ttctcat                                                    17</s400><s200><s210>7</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 7aattgtcatc accag                                                      15</s400><s200><s210>8</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 8ttgtcatcac cagaa                                                      15</s400><s200><s210>9</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 9attgtcatca ccaga                                                      15</s400><s200><s210>10</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 10aattgtcatc accag                                                      15</s400><s200><s210>11</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 11ataaattgtc atcacca                                                    17</s400><s200><s210>12</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 12aataaattgt catcacctt                                                  19</s400><s200><s210>13</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 13taaattgtca tcacc                                                      15</s400><s200><s210>14</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 14taaattgtca tcacc                                                      15</s400><s200><s210>15</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 15taaattgtca tcacc                                                      15</s400><s200><s210>16</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 16taaattgtca tcacc                                                      15</s400><s200><s210>17</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 17ataaattgtc atcacca                                                    17</s400><s200><s210>18</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 18ataaattgtc atcacca                                                    17</s400><s200><s210>19</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 19ataaattgtc atcacca                                                    17</s400><s200><s210>20</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 20ataaattgtc atcacca                                                    17</s400><s200><s210>21</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 21ataaattgtc atcacca                                                    17</s400><s200><s210>22</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 22ataaattgtc atcacca                                                    17</s400><s200><s210>23</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 23taaattgtca tcacca                                                     16</s400><s200><s210>24</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 24ataaattgtc atcacc                                                     16</s400><s200><s210>25</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 25taaattgtca tcacc                                                      15</s400><s200><s210>26</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 26taaattgtca tcacc                                                      15</s400><s200><s210>27</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 27acagctatct tctca                                                      15</s400><s200><s210>28</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 28acagctatct tctca                                                      15</s400><s200><s210>29</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 29cacagctatc ttctcat                                                    17</s400><s200><s210>30</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 30cacagctatc ttctcat                                                    17</s400><s200><s210>31</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 31taaattgtca tcaccag                                                    17</s400><s200><s210>32</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 32taattttcta gacttta                                                    17</s400><s200><s210>33</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 33gaatacgggt aacattt                                                    17</s400><s200><s210>34</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 34aaattgtcat caccaga                                                    17</s400><s200><s210>35</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 35taattttcta gacttta                                                    17</s400><s200><s210>36</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 36aattttctag actttat                                                    17</s400><s200><s210>37</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 37tcaagctagt aacgatg                                                    17</s400><s200><s210>38</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 38cacagctatc ttctcat                                                    17</s400><s200><s210>39</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 39acagctatct tctcatc                                                    17</s400><s200><s210>40</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 40ttgatctgta gcagcag                                                    17</s400><s200><s210>41</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 41tgatctgtag cagcagc                                                    17</s400><s200><s210>42</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 42gaatacgggt aacattt                                                    17</s400><s200><s210>43</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 43aatacgggta acatttt                                                    17</s400><s200><s210>44</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 44taattttcta gacttta                                                    17</s400><s200><s210>45</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 45ttgatctgta gcagcag                                                    17</s400><s200><s210>46</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 46cacagctatc ttctcat                                                    17</s400><s200><s210>47</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 47taaattgtca tcacc                                                      15</s400><s200><s210>48</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 48attgtcatca ccaga                                                      15</s400><s200><s210>49</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 49ataaattgtc atcacca                                                    17</s400><s200><s210>50</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 50ataaattgtc atcacca                                                    17</s400><s200><s210>51</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 51taaattgtca tcaccag                                                    17</s400><s200><s210>52</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 52ataaattgtc atcacca                                                    17</s400><s200><s210>53</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 53ataaattgtc atcacca                                                    17</s400><s200><s210>54</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 54taaattgtca tcacca                                                     16</s400><s200><s210>55</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 55taaattgtca tcacca                                                     16</s400><s200><s210>56</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 56taaattgtca tcacca                                                     16</s400><s200><s210>57</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 57taaattgtca tcacca                                                     16</s400><s200><s210>58</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 58taaattgtca tcacca                                                     16</s400><s200><s210>59</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 59taaattgtca tcacca                                                     16</s400><s200><s210>60</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 60ataaattgtc atcacca                                                    17</s400><s200><s210>61</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 61ataaattgtc atcacca                                                    17</s400><s200><s210>62</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 62ataaattgtc atcacca                                                    17</s400><s200><s210>63</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 63taaattgtca tcaccag                                                    17</s400><s200><s210>64</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 64aaattgtcat caccaga                                                    17</s400><s200><s210>65</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 65aattgtcatc accagaa                                                    17</s400><s200><s210>66</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 66ataaattgtc atcacca                                                    17</s400><s200><s210>67</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 67ataaattgtc atcacca                                                    17</s400><s200><s210>68</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 68ataaattgtc atcacca                                                    17</s400><s200><s210>69</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 69ataaattgtc atcacca                                                    17</s400><s200><s210>70</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 70ataaattgtc atcacc                                                     16</s400><s200><s210>71</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 71ataaattgtc atcacc                                                     16</s400><s200><s210>72</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 72ataaattgtc atcacc                                                     16</s400><s200><s210>73</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 73ataaattgtc atcacc                                                     16</s400><s200><s210>74</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 74ataaattgtc atcacc                                                     16</s400><s200><s210>75</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 75ataaattgtc atcacc                                                     16</s400><s200><s210>76</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 76aataaattgt catcaccag                                                  19</s400><s200><s210>77</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 77ataaattgtc atcaccaga                                                  19</s400><s200><s210>78</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 78taaattgtca tcaccagaa                                                  19</s400><s200><s210>79</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 79aaattgtcat caccagaaa                                                  19</s400><s200><s210>80</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 80aattgtcatc accagaaaa                                                  19</s400><s200><s210>81</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 81attgtcatca ccagaaaaa                                                  19</s400><s200><s210>82</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 82taataaattg tcatcacca                                                  19</s400><s200><s210>83</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 83ttaataaatt gtcatcacc                                                  19</s400><s200><s210>84</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 84taattttcta gacttta                                                    17</s400><s200><s210>85</s210><s211>18</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 85taatttctct agacttta                                                   18</s400><s200><s210>86</s210><s211>18</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 86taatttctct agacttta                                                   18</s400><s200><s210>87</s210><s211>18</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 87aattttctct agatttat                                                   18</s400><s200><s210>88</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 88aatacgggta acatttt                                                    17</s400><s200><s210>89</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 89gaatacgggt aactttt                                                    17</s400><s200><s210>90</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 90aaattgtcat caccaga                                                    17</s400><s200><s210>91</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 91ataaattgtc atcacca                                                    17</s400><s200><s210>92</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 92aattttctag acttta                                                     16</s400><s200><s210>93</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 93taattttcta gacttt                                                     16</s400><s200><s210>94</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 94attttctaga cttta                                                      15</s400><s200><s210>95</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 95aattttctag acttt                                                      15</s400><s200><s210>96</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 96taattttcta gactt                                                      15</s400><s200><s210>97</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 97attttctaga ctttat                                                     16</s400><s200><s210>98</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 98aattttctag acttta                                                     16</s400><s200><s210>99</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 99ttttctagac tttat                                                      15</s400><s200><s210>100</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 100attttctaga cttta                                                      15</s400><s200><s210>101</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 101aattttctag acttt                                                      15</s400><s200><s210>102</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 102caagctagta acgatg                                                     16</s400><s200><s210>103</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 103tcaagctagt aacgat                                                     16</s400><s200><s210>104</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 104aagctagtaa cgatg                                                      15</s400><s200><s210>105</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 105caagctagta acgat                                                      15</s400><s200><s210>106</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 106tcaagctagt aacga                                                      15</s400><s200><s210>107</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 107atacgggtaa catttt                                                     16</s400><s200><s210>108</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 108aatacgggta acattt                                                     16</s400><s200><s210>109</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 109tacgggtaac atttt                                                      15</s400><s200><s210>110</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 110atacgggtaa cattt                                                      15</s400><s200><s210>111</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 111aatacgggta acatt                                                      15</s400><s200><s210>112</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 112aatacgggta acattt                                                     16</s400><s200><s210>113</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 113gaatacgggt aacatt                                                     16</s400><s200><s210>114</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 114atacgggtaa cattt                                                      15</s400><s200><s210>115</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 115aatacgggta acatt                                                      15</s400><s200><s210>116</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 116gaatacgggt aacat                                                      15</s400><s200><s210>117</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 117gatctgtagc agcagc                                                     16</s400><s200><s210>118</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 118tgatctgtag cagcag                                                     16</s400><s200><s210>119</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 119atctgtagca gcagc                                                      15</s400><s200><s210>120</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 120gatctgtagc agcag                                                      15</s400><s200><s210>121</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 121tgatctgtag cagca                                                      15</s400><s200><s210>122</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 122tgatctgtag cagcag                                                     16</s400><s200><s210>123</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 123ttgatctgta gcagca                                                     16</s400><s200><s210>124</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 124gatctgtagc agcag                                                      15</s400><s200><s210>125</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 125tgatctgtag cagca                                                      15</s400><s200><s210>126</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 126ttgatctgta gcagc                                                      15</s400><s200><s210>127</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 127aattttctag acttta                                                     16</s400><s200><s210>128</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 128taattttcta gacttt                                                     16</s400><s200><s210>129</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 129attttctaga cttta                                                      15</s400><s200><s210>130</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 130aattttctag acttt                                                      15</s400><s200><s210>131</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 131taattttcta gactt                                                      15</s400><s200><s210>132</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 132taaattgcca tcacc                                                      15</s400><s200><s210>133</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 133aaattgccat cacca                                                      15</s400><s200><s210>134</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 134aattgccatc accag                                                      15</s400><s200><s210>135</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 135attgccatca ccaga                                                      15</s400><s200><s210>136</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 136taaattgcca tcacc                                                      15</s400><s200><s210>137</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 137aaattgccat cacca                                                      15</s400><s200><s210>138</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 138aattgccatc accag                                                      15</s400><s200><s210>139</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 139attgccatca ccaga                                                      15</s400><s200><s210>140</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 140taaattgcca tcaccag                                                    17</s400><s200><s210>141</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 141aaattgccat caccaga                                                    17</s400><s200><s210>142</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 142aattgccatc accagaa                                                    17</s400><s200><s210>143</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 143attgccatca ccagaaa                                                    17</s400><s200><s210>144</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 144taaattgcca tcaccag                                                    17</s400><s200><s210>145</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 145aaattgccat caccaga                                                    17</s400><s200><s210>146</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 146aattgccatc accagaa                                                    17</s400><s200><s210>147</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 147attgccatca ccagaaa                                                    17</s400><s200><s210>148</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 148gggcacagac ttcca                                                      15</s400><s200><s210>149</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 149agggcacaga cttcc                                                      15</s400><s200><s210>150</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 150aagggcacag acttc                                                      15</s400><s200><s210>151</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 151caagggcaca gactt                                                      15</s400><s200><s210>152</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 152gggcacagac ttccaa                                                     16</s400><s200><s210>153</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 153agggcacaga cttcca                                                     16</s400><s200><s210>154</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 154aagggcacag acttcc                                                     16</s400><s200><s210>155</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 155caagggcaca gacttc                                                     16</s400><s200><s210>156</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 156agagaacaag aaggc                                                      15</s400><s200><s210>157</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 157gagaacaaga aggct                                                      15</s400><s200><s210>158</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 158agaacaagaa ggctc                                                      15</s400><s200><s210>159</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 159gaacaagaag gctcc                                                      15</s400><s200><s210>160</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 160agagaacaag aaggct                                                     16</s400><s200><s210>161</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 161gagaacaaga aggctc                                                     16</s400><s200><s210>162</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 162agaacaagaa ggctcc                                                     16</s400><s200><s210>163</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 163gaacaagaag gctcca                                                     16</s400><s200><s210>164</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 164taaattgcca tcacc                                                      15</s400><s200><s210>165</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 165ataaattgcc atcacca                                                    17</s400><s200><s210>166</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 166ataaattgcc atcacca                                                    17</s400><s200><s210>167</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 167ataaattgcc atcacc                                                     16</s400><s200><s210>168</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 168taaattgcca tcacc                                                      15</s400><s200><s210>169</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 169taaattgcca tcacc                                                      15</s400><s200><s210>170</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 170attgccatca ccaga                                                      15</s400><s200><s210>171</s210><s211>16</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 171taaattgcca tcacca                                                     16</s400><s200><s210>172</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 172ataaattgcc atcacca                                                    17</s400><s200><s210>173</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 173taaattgcca tcaccag                                                    17</s400><s200><s210>174</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 174acacagtaga tgagg                                                      15</s400><s200><s210>175</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 175gcacacagta gatgaggga                                                  19</s400><s200><s210>176</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 176aagggatgct gacttgggc                                                  19</s400><s200><s210>177</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 177cagtgctacc caacc                                                      15</s400><s200><s210>178</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 178acagtgctac ccaacct                                                    17</s400><s200><s210>179</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 179ttcaagctag taacgatgc                                                  19</s400><s200><s210>180</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 180cttcaagcta gtaacga                                                    17</s400><s200><s210>181</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 181acagctatct tctca                                                      15</s400><s200><s210>182</s210><s211>18</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 182ataaattgtc atcaccag                                                   18</s400><s200><s210>183</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 183aataaattgt catcaccag                                                  19</s400><s200><s210>184</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 184ataaattgtc atcacca                                                    17</s400><s200><s210>185</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 185gcacacagta gatgaggga                                                  19</s400><s200><s210>186</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 186gcacacagta gatgaggga                                                  19</s400><s200><s210>187</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 187gcacacagta gatgaggga                                                  19</s400><s200><s210>188</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 188acagtagatg agggagcag                                                  19</s400><s200><s210>189</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 189cacacagtag atgaggg                                                    17</s400><s200><s210>190</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 190aagggatgct gacttgggc                                                  19</s400><s200><s210>191</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 191gggatgctga cttgg                                                      15</s400><s200><s210>192</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 192ataaattgtc atcacca                                                    17</s400><s200><s210>193</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 193ataaattgtc atcacca                                                    17</s400><s200><s210>194</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 194aataaattgt catcaccag                                                  19</s400><s200><s210>195</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 195aataaattgt catcaccag                                                  19</s400><s200><s210>196</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 196aataaattgt catcaccag                                                  19</s400><s200><s210>197</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 197acagtgctac ccaacct                                                    17</s400><s200><s210>198</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 198ttcaagctag taacg                                                      15</s400><s200><s210>199</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 199gagcagctgc aacctggca                                                  19</s400><s200><s210>200</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 200gagcagctgc aacctggca                                                  19</s400><s200><s210>201</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 201gcagctgcaa cctgg                                                      15</s400><s200><s210>202</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 202ttgatctgta gcagcagct                                                  19</s400><s200><s210>203</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 203ccttcctcac tgaggatga                                                  19</s400><s200><s210>204</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 204taacactcga ttaaccctg                                                  19</s400><s200><s210>205</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 205aagaagcctg ataaaatct                                                  19</s400><s200><s210>206</s210><s211>20</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 206tgcttcagag ctgagcagaa                                                 20</s400><s200><s210>207</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 207accacaacgg cgatt                                                      15</s400><s200><s210>208</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 208tacctaagag cacat                                                      15</s400><s200><s210>209</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 209tagttcatcc cagtg                                                      15</s400><s200><s210>210</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 210gaggaggtat actgt                                                      15</s400><s200><s210>211</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 211tggtgccggg tgtct                                                      15</s400><s200><s210>212</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 212aaacggcgca gcggg                                                      15</s400><s200><s210>213</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 213cgcctatacc ataca                                                      15</s400><s200><s210>214</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 214gataatatcc tatca                                                      15</s400><s200><s210>215</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 215agagaacaag aaggc                                                      15</s400><s200><s210>216</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 216aaccactgtg ggatg                                                      15</s400><s200><s210>217</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 217ctaaaactaa cttga                                                      15</s400><s200><s210>218</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 218cgttgaagta ctgtc                                                      15</s400><s200><s210>219</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 219taacactcga ttaac                                                      15</s400><s200><s210>220</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 220cctaaatcaa tctac                                                      15</s400><s200><s210>221</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 221attttctaga cttta                                                      15</s400><s200><s210>222</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 222cttcctcact gagga                                                      15</s400><s200><s210>223</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 223gaaatgggtt tttcc                                                      15</s400><s200><s210>224</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 224taagaaacac aatca                                                      15</s400><s200><s210>225</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 225gaacaaacag aagaa                                                      15</s400><s200><s210>226</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 226tggtgccagg tgtct                                                      15</s400><s200><s210>227</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 227aaacggcaca gcggg                                                      15</s400><s200><s210>228</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 228acttcaagct agtaacgat                                                  19</s400><s200><s210>229</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 229acaccacaac ggcgatttg                                                  19</s400><s200><s210>230</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 230cttacctaag agcacattt                                                  19</s400><s200><s210>231</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 231gctagttcat cccagtgag                                                  19</s400><s200><s210>232</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 232cagaggaggt atactgtat                                                  19</s400><s200><s210>233</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 233aatggtgccg ggtgtctag                                                  19</s400><s200><s210>234</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 234agaaacggcg cagcgggaa                                                  19</s400><s200><s210>235</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 235tccgcctata ccatacaat                                                  19</s400><s200><s210>236</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 236atgataatat cctatcaaa                                                  19</s400><s200><s210>237</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 237agagagaaca agaaggctc                                                  19</s400><s200><s210>238</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 238caaaccactg tgggatgaa                                                  19</s400><s200><s210>239</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 239atctaaaact aacttgaga                                                  19</s400><s200><s210>240</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 240agcgttgaag tactgtccc                                                  19</s400><s200><s210>241</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 241gttaacactc gattaaccc                                                  19</s400><s200><s210>242</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 242tccctaaatc aatctacaa                                                  19</s400><s200><s210>243</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 243taattttcta gactttatg                                                  19</s400><s200><s210>244</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 244accttcctca ctgaggatg                                                  19</s400><s200><s210>245</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 245tggaaatggg tttttccac                                                  19</s400><s200><s210>246</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 246aataagaaac acaatcaaa                                                  19</s400><s200><s210>247</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 247cagaacaaac agaagaatt                                                  19</s400><s200><s210>248</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 248aatggtgcca ggtgtctag                                                  19</s400><s200><s210>249</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 249agaaacggca cagcgggaa                                                  19</s400><s200><s210>250</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 250agaatacggg taaca                                                      15</s400><s200><s210>251</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 251ctgagcggag aaacc                                                      15</s400><s200><s210>252</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 252ttccctaaaa acaaa                                                      15</s400><s200><s210>253</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 253cttttctatt gtctg                                                      15</s400><s200><s210>254</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 254tagaggacgc cgtgc                                                      15</s400><s200><s210>255</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 255ttccctagaa acaaa                                                      15</s400><s200><s210>256</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 256caagggcaca gactt                                                      15</s400><s200><s210>257</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 257taaccgtggc atggg                                                      15</s400><s200><s210>258</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 258gactatagca cccag                                                      15</s400><s200><s210>259</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 259gtgtgtacag aacct                                                      15</s400><s200><s210>260</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 260gaagcctgat aaaat                                                      15</s400><s200><s210>261</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 261ttcagaatgc ctcat                                                      15</s400><s200><s210>262</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 262ggacagggtg tgctc                                                      15</s400><s200><s210>263</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 263agctaggcta aagag                                                      15</s400><s200><s210>264</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 264tgggcagaaa ggact                                                      15</s400><s200><s210>265</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 265tgatctgtag cagca                                                      15</s400><s200><s210>266</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 266cttttccgtg ctgtt                                                      15</s400><s200><s210>267</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 267ggagaatacg ggtaacatt                                                  19</s400><s200><s210>268</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 268ggctgagcgg agaaaccct                                                  19</s400><s200><s210>269</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 269gattccctaa aaacaaaaa                                                  19</s400><s200><s210>270</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 270tgcttttcta ttgtctgtc                                                  19</s400><s200><s210>271</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 271catagaggac gccgtgcag                                                  19</s400><s200><s210>272</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 272gattccctag aaacaaaaa                                                  19</s400><s200><s210>273</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 273cacaagggca cagacttcc                                                  19</s400><s200><s210>274</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 274tttaaccgtg gcatgggca                                                  19</s400><s200><s210>275</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 275gagactatag cacccagat                                                  19</s400><s200><s210>276</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 276acgtgtgtac agaacctgc                                                  19</s400><s200><s210>277</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 277tgttcagaat gcctcatct                                                  19</s400><s200><s210>278</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 278ggggacaggg tgtgctctc                                                  19</s400><s200><s210>279</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 279gcagctaggc taaagagtc                                                  19</s400><s200><s210>280</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 280ggtgggcaga aaggactga                                                  19</s400><s200><s210>281</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 281gttgatctgt agcagcagc                                                  19</s400><s200><s210>282</s210><s211>19</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 282aacttttccg tgctgttct                                                  19</s400><s200><s210>283</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 283aacactcgat taaccct                                                    17</s400><s200><s210>284</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 284taacactcga ttaaccc                                                    17</s400><s200><s210>285</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 285ttaacactcg attaacc                                                    17</s400><s200><s210>286</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 286gttaacactc gattaac                                                    17</s400><s200><s210>287</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 287agttaacact cgattaa                                                    17</s400><s200><s210>288</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 288aacactcgat taaccct                                                    17</s400><s200><s210>289</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 289taacactcga ttaaccc                                                    17</s400><s200><s210>290</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 290ttaacactcg attaacc                                                    17</s400><s200><s210>291</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 291gttaacactc gattaac                                                    17</s400><s200><s210>292</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 292agttaacact cgattaa                                                    17</s400><s200><s210>293</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 293acactcgatt aaccctg                                                    17</s400><s200><s210>294</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 294aacactcgat taaccct                                                    17</s400><s200><s210>295</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 295taacactcga ttaaccc                                                    17</s400><s200><s210>296</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 296ttaacactcg attaacc                                                    17</s400><s200><s210>297</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 297gttaacactc gattaac                                                    17</s400><s200><s210>298</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 298agttaacact cgattaa                                                    17</s400><s200><s210>299</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 299acactcgatt aaccctg                                                    17</s400><s200><s210>300</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 300aacactcgat taaccct                                                    17</s400><s200><s210>301</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 301taacactcga ttaaccc                                                    17</s400><s200><s210>302</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 302ttaacactcg attaacc                                                    17</s400><s200><s210>303</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 303gttaacactc gattaac                                                    17</s400><s200><s210>304</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 304agttaacact cgattaa                                                    17</s400><s200><s210>305</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 305aaattgtcat caccaga                                                    17</s400><s200><s210>306</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 306aataaattgt catcacc                                                    17</s400><s200><s210>307</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 307taataaattg tcatcac                                                    17</s400><s200><s210>308</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 308aaattgtcat caccaga                                                    17</s400><s200><s210>309</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 309taaattgtca tcaccag                                                    17</s400><s200><s210>310</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 310ataaattgtc atcacca                                                    17</s400><s200><s210>311</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 311aataaattgt catcacc                                                    17</s400><s200><s210>312</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 312taataaattg tcatcac                                                    17</s400><s200><s210>313</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 313aattgtcatc accagaa                                                    17</s400><s200><s210>314</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 314taaattgtca tcaccag                                                    17</s400><s200><s210>315</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 315ataaattgtc atcacca                                                    17</s400><s200><s210>316</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 316aataaattgt catcacc                                                    17</s400><s200><s210>317</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 317taataaattg tcatcac                                                    17</s400><s200><s210>318</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 318aattgtcatc accagaa                                                    17</s400><s200><s210>319</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 319aaattgtcat caccaga                                                    17</s400><s200><s210>320</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 320taaattgtca tcaccag                                                    17</s400><s200><s210>321</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 321ataaattgtc atcacca                                                    17</s400><s200><s210>322</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 322aataaattgt catcacc                                                    17</s400><s200><s210>323</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 323taataaattg tcatcac                                                    17</s400><s200><s210>324</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 324tcaagctagt aacgatg                                                    17</s400><s200><s210>325</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 325ttcaagctag taacgat                                                    17</s400><s200><s210>326</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 326cttcaagcta gtaacga                                                    17</s400><s200><s210>327</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 327acttcaagct agtaacg                                                    17</s400><s200><s210>328</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 328aacttcaagc tagtaac                                                    17</s400><s200><s210>329</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 329caagctagta acgatgc                                                    17</s400><s200><s210>330</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 330ttcaagctag taacgat                                                    17</s400><s200><s210>331</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 331cttcaagcta gtaacga                                                    17</s400><s200><s210>332</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 332acttcaagct agtaacg                                                    17</s400><s200><s210>333</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 333aacttcaagc tagtaac                                                    17</s400><s200><s210>334</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 334ttttctagac tttatga                                                    17</s400><s200><s210>335</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 335attttctaga ctttatg                                                    17</s400><s200><s210>336</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 336aattttctag actttat                                                    17</s400><s200><s210>337</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 337ttaattttct agacttt                                                    17</s400><s200><s210>338</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 338ttttctagac tttatga                                                    17</s400><s200><s210>339</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 339attttctaga ctttatg                                                    17</s400><s200><s210>340</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 340aattttctag actttat                                                    17</s400><s200><s210>341</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 341taattttcta gacttta                                                    17</s400><s200><s210>342</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 342ttaattttct agacttt                                                    17</s400><s200><s210>343</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 343tttctagact ttatgat                                                    17</s400><s200><s210>344</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 344ttttctagac tttatga                                                    17</s400><s200><s210>345</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 345attttctaga ctttatg                                                    17</s400><s200><s210>346</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 346ttaattttct agacttt                                                    17</s400><s200><s210>347</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 347tttctagact ttatgat                                                    17</s400><s200><s210>348</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 348ttttctagac tttatga                                                    17</s400><s200><s210>349</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 349attttctaga ctttatg                                                    17</s400><s200><s210>350</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 350aattttctag actttat                                                    17</s400><s200><s210>351</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 351ttaattttct agacttt                                                    17</s400><s200><s210>352</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 352ttcctcactg aggatga                                                    17</s400><s200><s210>353</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 353cttcctcact gaggatg                                                    17</s400><s200><s210>354</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 354ccttcctcac tgaggat                                                    17</s400><s200><s210>355</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 355accttcctca ctgagga                                                    17</s400><s200><s210>356</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 356caccttcctc actgagg                                                    17</s400><s200><s210>357</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 357ttcctcactg aggatga                                                    17</s400><s200><s210>358</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 358cttcctcact gaggatg                                                    17</s400><s200><s210>359</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 359ccttcctcac tgaggat                                                    17</s400><s200><s210>360</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 360accttcctca ctgagga                                                    17</s400><s200><s210>361</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 361caccttcctc actgagg                                                    17</s400><s200><s210>362</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 362tcctcactga ggatgaa                                                    17</s400><s200><s210>363</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 363ttcctcactg aggatga                                                    17</s400><s200><s210>364</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 364cttcctcact gaggatg                                                    17</s400><s200><s210>365</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 365ccttcctcac tgaggat                                                    17</s400><s200><s210>366</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 366accttcctca ctgagga                                                    17</s400><s200><s210>367</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 367caccttcctc actgagg                                                    17</s400><s200><s210>368</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 368tcctcactga ggatgaa                                                    17</s400><s200><s210>369</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 369ttcctcactg aggatga                                                    17</s400><s200><s210>370</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 370cttcctcact gaggatg                                                    17</s400><s200><s210>371</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 371ccttcctcac tgaggat                                                    17</s400><s200><s210>372</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 372accttcctca ctgagga                                                    17</s400><s200><s210>373</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 373caccttcctc actgagg                                                    17</s400><s200><s210>374</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 374accactttgg gatgaat                                                    17</s400><s200><s210>375</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 375aaccactttg ggatgaa                                                    17</s400><s200><s210>376</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 376aaaccacttt gggatga                                                    17</s400><s200><s210>377</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 377caaaccactt tgggatg                                                    17</s400><s200><s210>378</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 378gcaaaccact ttgggat                                                    17</s400><s200><s210>379</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 379ccactttggg atgaata                                                    17</s400><s200><s210>380</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 380accactttgg gatgaat                                                    17</s400><s200><s210>381</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 381aaccactttg ggatgaa                                                    17</s400><s200><s210>382</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 382aaaccacttt gggatga                                                    17</s400><s200><s210>383</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 383caaaccactt tgggatg                                                    17</s400><s200><s210>384</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 384gcaaaccact ttgggat                                                    17</s400><s200><s210>385</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 385agttcatccc agtgaga                                                    17</s400><s200><s210>386</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 386tagttcatcc cagtgag                                                    17</s400><s200><s210>387</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 387ctagttcatc ccagtga                                                    17</s400><s200><s210>388</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 388gctagttcat cccagtg                                                    17</s400><s200><s210>389</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 389tgctagttca tcccagt                                                    17</s400><s200><s210>390</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 390agttcatccc agtgaga                                                    17</s400><s200><s210>391</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 391tagttcatcc cagtgag                                                    17</s400><s200><s210>392</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 392ctagttcatc ccagtga                                                    17</s400><s200><s210>393</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 393gctagttcat cccagtg                                                    17</s400><s200><s210>394</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 394tgctagttca tcccagt                                                    17</s400><s200><s210>395</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 395gttcatccca gtgagaa                                                    17</s400><s200><s210>396</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 396agttcatccc agtgaga                                                    17</s400><s200><s210>397</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 397tagttcatcc cagtgag                                                    17</s400><s200><s210>398</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 398ctagttcatc ccagtga                                                    17</s400><s200><s210>399</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 399gctagttcat cccagtg                                                    17</s400><s200><s210>400</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 400tgctagttca tcccagt                                                    17</s400><s200><s210>401</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 401gttcatccca gtgagaa                                                    17</s400><s200><s210>402</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 402agttcatccc agtgaga                                                    17</s400><s200><s210>403</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 403tagttcatcc cagtgag                                                    17</s400><s200><s210>404</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 404ctagttcatc ccagtga                                                    17</s400><s200><s210>405</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 405gctagttcat cccagtg                                                    17</s400><s200><s210>406</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 406tgctagttca tcccagt                                                    17</s400><s200><s210>407</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 407aggaggcata ctgtatt                                                    17</s400><s200><s210>408</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 408gaggaggcat actgtat                                                    17</s400><s200><s210>409</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 409agaggaggca tactgta                                                    17</s400><s200><s210>410</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 410cagaggaggc atactgt                                                    17</s400><s200><s210>411</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 411acagaggagg catactg                                                    17</s400><s200><s210>412</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 412ggaggcatac tgtattt                                                    17</s400><s200><s210>413</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 413aggaggcata ctgtatt                                                    17</s400><s200><s210>414</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 414gaggaggcat actgtat                                                    17</s400><s200><s210>415</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 415agaggaggca tactgta                                                    17</s400><s200><s210>416</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 416cagaggaggc atactgt                                                    17</s400><s200><s210>417</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 417acagaggagg catactg                                                    17</s400><s200><s210>418</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 418gagaacgaga aggctcc                                                    17</s400><s200><s210>419</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 419agagaacgag aaggctc                                                    17</s400><s200><s210>420</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 420gagagaacga gaaggct                                                    17</s400><s200><s210>421</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 421agagagaacg agaaggc                                                    17</s400><s200><s210>422</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 422aagagagaac gagaagg                                                    17</s400><s200><s210>423</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 423agaacgagaa ggctcca                                                    17</s400><s200><s210>424</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 424gagaacgaga aggctcc                                                    17</s400><s200><s210>425</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 425agagaacgag aaggctc                                                    17</s400><s200><s210>426</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 426gagagaacga gaaggct                                                    17</s400><s200><s210>427</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 427agagagaacg agaaggc                                                    17</s400><s200><s210>428</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 428aagagagaac gagaagg                                                    17</s400><s200><s210>429</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 429gatctgtagc agcagct                                                    17</s400><s200><s210>430</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 430tgatctgtag cagcagc                                                    17</s400><s200><s210>431</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 431ttgatctgta gcagcag                                                    17</s400><s200><s210>432</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 432gttgatctgt agcagca                                                    17</s400><s200><s210>433</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 433ggttgatctg tagcagc                                                    17</s400><s200><s210>434</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 434gatctgtagc agcagct                                                    17</s400><s200><s210>435</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 435tgatctgtag cagcagc                                                    17</s400><s200><s210>436</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 436ttgatctgta gcagcag                                                    17</s400><s200><s210>437</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 437gttgatctgt agcagca                                                    17</s400><s200><s210>438</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 438ggttgatctg tagcagc                                                    17</s400><s200><s210>439</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 439atctgtagca gcagctt                                                    17</s400><s200><s210>440</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 440gatctgtagc agcagct                                                    17</s400><s200><s210>441</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 441gttgatctgt agcagca                                                    17</s400><s200><s210>442</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 442ggttgatctg tagcagc                                                    17</s400><s200><s210>443</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 443atctgtagca gcagctt                                                    17</s400><s200><s210>444</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 444gatctgtagc agcagct                                                    17</s400><s200><s210>445</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 445tgatctgtag cagcagc                                                    17</s400><s200><s210>446</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 446gttgatctgt agcagca                                                    17</s400><s200><s210>447</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 447ggttgatctg tagcagc                                                    17</s400><s200><s210>448</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 448cagctatctt ctcatca                                                    17</s400><s200><s210>449</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 449acagctatct tctcatc                                                    17</s400><s200><s210>450</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 450cacagctatc ttctcat                                                    17</s400><s200><s210>451</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 451tcacagctat cttctca                                                    17</s400><s200><s210>452</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 452ttcacagcta tcttctc                                                    17</s400><s200><s210>453</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 453cagctatctt ctcatca                                                    17</s400><s200><s210>454</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 454acagctatct tctcatc                                                    17</s400><s200><s210>455</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 455cacagctatc ttctcat                                                    17</s400><s200><s210>456</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 456tcacagctat cttctca                                                    17</s400><s200><s210>457</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 457ttcacagcta tcttctc                                                    17</s400><s200><s210>458</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 458agctatcttc tcatcaa                                                    17</s400><s200><s210>459</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 459cagctatctt ctcatca                                                    17</s400><s200><s210>460</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 460tcacagctat cttctca                                                    17</s400><s200><s210>461</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 461ttcacagcta tcttctc                                                    17</s400><s200><s210>462</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 462agctatcttc tcatcaa                                                    17</s400><s200><s210>463</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 463cagctatctt ctcatca                                                    17</s400><s200><s210>464</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 464acagctatct tctcatc                                                    17</s400><s200><s210>465</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 465cacagctatc ttctcat                                                    17</s400><s200><s210>466</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 466tcacagctat cttctca                                                    17</s400><s200><s210>467</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 467ttcacagcta tcttctc                                                    17</s400><s200><s210>468</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 468tgtgtacaga acctgcc                                                    17</s400><s200><s210>469</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 469gtgtgtacag aacctgc                                                    17</s400><s200><s210>470</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 470cgtgtgtaca gaacctg                                                    17</s400><s200><s210>471</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 471acgtgtgtac agaacct                                                    17</s400><s200><s210>472</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 472cacgtgtgta cagaacc                                                    17</s400><s200><s210>473</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 473tgtgtacaga acctgcc                                                    17</s400><s200><s210>474</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 474gtgtgtacag aacctgc                                                    17</s400><s200><s210>475</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 475cgtgtgtaca gaacctg                                                    17</s400><s200><s210>476</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 476acgtgtgtac agaacct                                                    17</s400><s200><s210>477</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 477cacgtgtgta cagaacc                                                    17</s400><s200><s210>478</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 478gtgtacagaa cctgccg                                                    17</s400><s200><s210>479</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 479tgtgtacaga acctgcc                                                    17</s400><s200><s210>480</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 480gtgtgtacag aacctgc                                                    17</s400><s200><s210>481</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 481cgtgtgtaca gaacctg                                                    17</s400><s200><s210>482</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 482acgtgtgtac agaacct                                                    17</s400><s200><s210>483</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 483cacgtgtgta cagaacc                                                    17</s400><s200><s210>484</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 484gtgtacagaa cctgccg                                                    17</s400><s200><s210>485</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 485tgtgtacaga acctgcc                                                    17</s400><s200><s210>486</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 486gtgtgtacag aacctgc                                                    17</s400><s200><s210>487</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 487cgtgtgtaca gaacctg                                                    17</s400><s200><s210>488</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 488acgtgtgtac agaacct                                                    17</s400><s200><s210>489</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 489cacgtgtgta cagaacc                                                    17</s400><s200><s210>490</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 490tgagcggaga aaccctc                                                    17</s400><s200><s210>491</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 491ctgagcggag aaaccct                                                    17</s400><s200><s210>492</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 492gctgagcgga gaaaccc                                                    17</s400><s200><s210>493</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 493ggctgagcgg agaaacc                                                    17</s400><s200><s210>494</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 494aggctgagcg gagaaac                                                    17</s400><s200><s210>495</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 495gagcggagaa accctcc                                                    17</s400><s200><s210>496</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 496tgagcggaga aaccctc                                                    17</s400><s200><s210>497</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 497ctgagcggag aaaccct                                                    17</s400><s200><s210>498</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 498gctgagcgga gaaaccc                                                    17</s400><s200><s210>499</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 499ggctgagcgg agaaacc                                                    17</s400><s200><s210>500</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 500aggctgagcg gagaaac                                                    17</s400><s200><s210>501</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 501agaatacggg taacatt                                                    17</s400><s200><s210>502</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 502gagaatacgg gtaacat                                                    17</s400><s200><s210>503</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 503ggagaatacg ggtaaca                                                    17</s400><s200><s210>504</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 504tggagaatac gggtaac                                                    17</s400><s200><s210>505</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 505agaatacggg taacatt                                                    17</s400><s200><s210>506</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 506gagaatacgg gtaacat                                                    17</s400><s200><s210>507</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 507ggagaatacg ggtaaca                                                    17</s400><s200><s210>508</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 508aaccgtggca tgggcag                                                    17</s400><s200><s210>509</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 509taaccgtggc atgggca                                                    17</s400><s200><s210>510</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 510ttaaccgtgg catgggc                                                    17</s400><s200><s210>511</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 511tttaaccgtg gcatggg                                                    17</s400><s200><s210>512</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 512ctttaaccgt ggcatgg                                                    17</s400><s200><s210>513</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 513accgtggcat gggcagt                                                    17</s400><s200><s210>514</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 514aaccgtggca tgggcag                                                    17</s400><s200><s210>515</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 515taaccgtggc atgggca                                                    17</s400><s200><s210>516</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 516ttaaccgtgg catgggc                                                    17</s400><s200><s210>517</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 517tttaaccgtg gcatggg                                                    17</s400><s200><s210>518</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 518ctttaaccgt ggcatgg                                                    17</s400><s200><s210>519</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 519actatagcac ccagatt                                                    17</s400><s200><s210>520</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 520gactatagca cccagat                                                    17</s400><s200><s210>521</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 521agactatagc acccaga                                                    17</s400><s200><s210>522</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 522gagactatag cacccag                                                    17</s400><s200><s210>523</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 523agagactata gcaccca                                                    17</s400><s200><s210>524</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 524actatagcac ccagatt                                                    17</s400><s200><s210>525</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 525gactatagca cccagat                                                    17</s400><s200><s210>526</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 526agactatagc acccaga                                                    17</s400><s200><s210>527</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 527gagactatag cacccag                                                    17</s400><s200><s210>528</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 528agagactata gcaccca                                                    17</s400><s200><s210>529</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 529ctatagcacc cagattt                                                    17</s400><s200><s210>530</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 530actatagcac ccagatt                                                    17</s400><s200><s210>531</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 531gactatagca cccagat                                                    17</s400><s200><s210>532</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 532agactatagc acccaga                                                    17</s400><s200><s210>533</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 533gagactatag cacccag                                                    17</s400><s200><s210>534</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 534agagactata gcaccca                                                    17</s400><s200><s210>535</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 535ctatagcacc cagattt                                                    17</s400><s200><s210>536</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 536actatagcac ccagatt                                                    17</s400><s200><s210>537</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 537gactatagca cccagat                                                    17</s400><s200><s210>538</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 538agactatagc acccaga                                                    17</s400><s200><s210>539</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 539gagactatag cacccag                                                    17</s400><s200><s210>540</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 540agagactata gcaccca                                                    17</s400><s200><s210>541</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 541ttttctattg tctgtcc                                                    17</s400><s200><s210>542</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 542cttttctatt gtctgtc                                                    17</s400><s200><s210>543</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 543gcttttctat tgtctgt                                                    17</s400><s200><s210>544</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 544tgcttttcta ttgtctg                                                    17</s400><s200><s210>545</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 545ttgcttttct attgtct                                                    17</s400><s200><s210>546</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 546tttctattgt ctgtccc                                                    17</s400><s200><s210>547</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 547ttttctattg tctgtcc                                                    17</s400><s200><s210>548</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 548cttttctatt gtctgtc                                                    17</s400><s200><s210>549</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 549gcttttctat tgtctgt                                                    17</s400><s200><s210>550</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 550tgcttttcta ttgtctg                                                    17</s400><s200><s210>551</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 551ttgcttttct attgtct                                                    17</s400><s200><s210>552</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 552ttttccgtgc tgttctg                                                    17</s400><s200><s210>553</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 553cttttccgtg ctgttct                                                    17</s400><s200><s210>554</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 554acttttccgt gctgttc                                                    17</s400><s200><s210>555</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 555aacttttccg tgctgtt                                                    17</s400><s200><s210>556</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 556aaacttttcc gtgctgt                                                    17</s400><s200><s210>557</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 557ttttccgtgc tgttctg                                                    17</s400><s200><s210>558</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 558cttttccgtg ctgttct                                                    17</s400><s200><s210>559</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 559acttttccgt gctgttc                                                    17</s400><s200><s210>560</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 560aacttttccg tgctgtt                                                    17</s400><s200><s210>561</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 561aaacttttcc gtgctgt                                                    17</s400><s200><s210>562</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 562tttccgtgct gttctga                                                    17</s400><s200><s210>563</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 563ttttccgtgc tgttctg                                                    17</s400><s200><s210>564</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 564cttttccgtg ctgttct                                                    17</s400><s200><s210>565</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 565acttttccgt gctgttc                                                    17</s400><s200><s210>566</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 566aacttttccg tgctgtt                                                    17</s400><s200><s210>567</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 567aaacttttcc gtgctgt                                                    17</s400><s200><s210>568</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 568tttccgtgct gttctga                                                    17</s400><s200><s210>569</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 569ttttccgtgc tgttctg                                                    17</s400><s200><s210>570</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 570cttttccgtg ctgttct                                                    17</s400><s200><s210>571</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 571acttttccgt gctgttc                                                    17</s400><s200><s210>572</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 572aacttttccg tgctgtt                                                    17</s400><s200><s210>573</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 573aaacttttcc gtgctgt                                                    17</s400><s200><s210>574</s210><s211>13481</s211><s212>DNA</s212><s213>Homo sapien</s213><s220><s221>CDS</s221><s222>(146)..(9580)</s222></s220></s200><s400> 574gctgccggga cgggtccaag atggacggcc gctcaggttc tgcttttacc tgcggcccag     60agccccattc attgccccgg tgctgagcgg cgccgcgagt cggcccgagg cctccgggga    120ctgccgtgcc gggcgggaga ccgcc atg gcg acc ctg gaa aag ctg atg aag      172                            Met Ala Thr Leu Glu Lys Leu Met Lys                            1               5gcc ttc gag tcc ctc aag tcc ttc cag cag cag cag cag cag cag cag      220Ala Phe Glu Ser Leu Lys Ser Phe Gln Gln Gln Gln Gln Gln Gln Gln10                  15                  20                  25cag cag cag cag cag cag cag cag cag cag cag cag cag caa cag ccg      268Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Pro                30                  35                  40cca ccg ccg ccg ccg ccg ccg ccg cct cct cag ctt cct cag ccg ccg      316Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Gln Leu Pro Gln Pro Pro            45                  50                  55ccg cag gca cag ccg ctg ctg cct cag ccg cag ccg ccc ccg ccg ccg      364Pro Gln Ala Gln Pro Leu Leu Pro Gln Pro Gln Pro Pro Pro Pro Pro        60                  65                  70ccc ccg ccg cca ccc ggc ccg gct gtg gct gag gag ccg ctg cac cga      412Pro Pro Pro Pro Pro Gly Pro Ala Val Ala Glu Glu Pro Leu His Arg    75                  80                  85cca aag aaa gaa ctt tca gct acc aag aaa gac cgt gtg aat cat tgt      460Pro Lys Lys Glu Leu Ser Ala Thr Lys Lys Asp Arg Val Asn His Cys90                  95                  100                 105ctg aca ata tgt gaa aac ata gtg gca cag tct gtc aga aat tct cca      508Leu Thr Ile Cys Glu Asn Ile Val Ala Gln Ser Val Arg Asn Ser Pro                110                 115                 120gaa ttt cag aaa ctt ctg ggc atc gct atg gaa ctt ttt ctg ctg tgc      556Glu Phe Gln Lys Leu Leu Gly Ile Ala Met Glu Leu Phe Leu Leu Cys            125                 130                 135agt gat gac gca gag tca gat gtc agg atg gtg gct gac gaa tgc ctc      604Ser Asp Asp Ala Glu Ser Asp Val Arg Met Val Ala Asp Glu Cys Leu        140                 145                 150aac aaa gtt atc aaa gct ttg atg gat tct aat ctt cca agg tta cag      652Asn Lys Val Ile Lys Ala Leu Met Asp Ser Asn Leu Pro Arg Leu Gln    155                 160                 165ctc gag ctc tat aag gaa att aaa aag aat ggt gcc cct cgg agt ttg      700Leu Glu Leu Tyr Lys Glu Ile Lys Lys Asn Gly Ala Pro Arg Ser Leu170                 175                 180                 185cgt gct gcc ctg tgg agg ttt gct gag ctg gct cac ctg gtt cgg cct      748Arg Ala Ala Leu Trp Arg Phe Ala Glu Leu Ala His Leu Val Arg Pro                190                 195                 200cag aaa tgc agg cct tac ctg gtg aac ctt ctg ccg tgc ctg act cga      796Gln Lys Cys Arg Pro Tyr Leu Val Asn Leu Leu Pro Cys Leu Thr Arg            205                 210                 215aca agc aag aga ccc gaa gaa tca gtc cag gag acc ttg gct gca gct      844Thr Ser Lys Arg Pro Glu Glu Ser Val Gln Glu Thr Leu Ala Ala Ala        220                 225                 230gtt ccc aaa att atg gct tct ttt ggc aat ttt gca aat gac aat gaa      892Val Pro Lys Ile Met Ala Ser Phe Gly Asn Phe Ala Asn Asp Asn Glu    235                 240                 245att aag gtt ttg tta aag gcc ttc ata gcg aac ctg aag tca agc tcc      940Ile Lys Val Leu Leu Lys Ala Phe Ile Ala Asn Leu Lys Ser Ser Ser250                 255                 260                 265ccc acc att cgg cgg aca gcg gct gga tca gca gtg agc atc tgc cag      988Pro Thr Ile Arg Arg Thr Ala Ala Gly Ser Ala Val Ser Ile Cys Gln                270                 275                 280cac tca aga agg aca caa tat ttc tat agt tgg cta cta aat gtg ctc     1036His Ser Arg Arg Thr Gln Tyr Phe Tyr Ser Trp Leu Leu Asn Val Leu            285                 290                 295tta ggc tta ctc gtt cct gtc gag gat gaa cac tcc act ctg ctg att     1084Leu Gly Leu Leu Val Pro Val Glu Asp Glu His Ser Thr Leu Leu Ile        300                 305                 310ctt ggc gtg ctg ctc acc ctg agg tat ttg gtg ccc ttg ctg cag cag     1132Leu Gly Val Leu Leu Thr Leu Arg Tyr Leu Val Pro Leu Leu Gln Gln    315                 320                 325cag gtc aag gac aca agc ctg aaa ggc agc ttc gga gtg aca agg aaa     1180Gln Val Lys Asp Thr Ser Leu Lys Gly Ser Phe Gly Val Thr Arg Lys330                 335                 340                 345gaa atg gaa gtc tct cct tct gca gag cag ctt gtc cag gtt tat gaa     1228Glu Met Glu Val Ser Pro Ser Ala Glu Gln Leu Val Gln Val Tyr Glu                350                 355                 360ctg acg tta cat cat aca cag cac caa gac cac aat gtt gtg acc gga     1276Leu Thr Leu His His Thr Gln His Gln Asp His Asn Val Val Thr Gly            365                 370                 375gcc ctg gag ctg ttg cag cag ctc ttc aga acg cct cca ccc gag ctt     1324Ala Leu Glu Leu Leu Gln Gln Leu Phe Arg Thr Pro Pro Pro Glu Leu        380                 385                 390ctg caa acc ctg acc gca gtc ggg ggc att ggg cag ctc acc gct gct     1372Leu Gln Thr Leu Thr Ala Val Gly Gly Ile Gly Gln Leu Thr Ala Ala    395                 400                 405aag gag gag tct ggt ggc cga agc cgt agt ggg agt att gtg gaa ctt     1420Lys Glu Glu Ser Gly Gly Arg Ser Arg Ser Gly Ser Ile Val Glu Leu410                 415                 420                 425ata gct gga ggg ggt tcc tca tgc agc cct gtc ctt tca aga aaa caa     1468Ile Ala Gly Gly Gly Ser Ser Cys Ser Pro Val Leu Ser Arg Lys Gln                430                 435                 440aaa ggc aaa gtg ctc tta gga gaa gaa gaa gcc ttg gag gat gac tct     1516Lys Gly Lys Val Leu Leu Gly Glu Glu Glu Ala Leu Glu Asp Asp Ser            445                 450                 455gaa tcg aga tcg gat gtc agc agc tct gcc tta aca gcc tca gtg aag     1564Glu Ser Arg Ser Asp Val Ser Ser Ser Ala Leu Thr Ala Ser Val Lys        460                 465                 470gat gag atc agt gga gag ctg gct gct tct tca ggg gtt tcc act cca     1612Asp Glu Ile Ser Gly Glu Leu Ala Ala Ser Ser Gly Val Ser Thr Pro    475                 480                 485ggg tca gca ggt cat gac atc atc aca gaa cag cca cgg tca cag cac     1660Gly Ser Ala Gly His Asp Ile Ile Thr Glu Gln Pro Arg Ser Gln His490                 495                 500                 505aca ctg cag gcg gac tca gtg gat ctg gcc agc tgt gac ttg aca agc     1708Thr Leu Gln Ala Asp Ser Val Asp Leu Ala Ser Cys Asp Leu Thr Ser                510                 515                 520tct gcc act gat ggg gat gag gag gat atc ttg agc cac agc tcc agc     1756Ser Ala Thr Asp Gly Asp Glu Glu Asp Ile Leu Ser His Ser Ser Ser            525                 530                 535cag gtc agc gcc gtc cca tct gac cct gcc atg gac ctg aat gat ggg     1804Gln Val Ser Ala Val Pro Ser Asp Pro Ala Met Asp Leu Asn Asp Gly        540                 545                 550acc cag gcc tcg tcg ccc atc agc gac agc tcc cag acc acc acc gaa     1852Thr Gln Ala Ser Ser Pro Ile Ser Asp Ser Ser Gln Thr Thr Thr Glu    555                 560                 565ggg cct gat tca gct gtt acc cct tca gac agt tct gaa att gtg tta     1900Gly Pro Asp Ser Ala Val Thr Pro Ser Asp Ser Ser Glu Ile Val Leu570                 575                 580                 585gac ggt acc gac aac cag tat ttg ggc ctg cag att gga cag ccc cag     1948Asp Gly Thr Asp Asn Gln Tyr Leu Gly Leu Gln Ile Gly Gln Pro Gln                590                 595                 600gat gaa gat gag gaa gcc aca ggt att ctt cct gat gaa gcc tcg gag     1996Asp Glu Asp Glu Glu Ala Thr Gly Ile Leu Pro Asp Glu Ala Ser Glu            605                 610                 615gcc ttc agg aac tct tcc atg gcc ctt caa cag gca cat tta ttg aaa     2044Ala Phe Arg Asn Ser Ser Met Ala Leu Gln Gln Ala His Leu Leu Lys        620                 625                 630aac atg agt cac tgc agg cag cct tct gac agc agt gtt gat aaa ttt     2092Asn Met Ser His Cys Arg Gln Pro Ser Asp Ser Ser Val Asp Lys Phe    635                 640                 645gtg ttg aga gat gaa gct act gaa ccg ggt gat caa gaa aac aag cct     2140Val Leu Arg Asp Glu Ala Thr Glu Pro Gly Asp Gln Glu Asn Lys Pro650                 655                 660                 665tgc cgc atc aaa ggt gac att gga cag tcc act gat gat gac tct gca     2188Cys Arg Ile Lys Gly Asp Ile Gly Gln Ser Thr Asp Asp Asp Ser Ala                670                 675                 680cct ctt gtc cat tgt gtc cgc ctt tta tct gct tcg ttt ttg cta aca     2236Pro Leu Val His Cys Val Arg Leu Leu Ser Ala Ser Phe Leu Leu Thr            685                 690                 695ggg gga aaa aat gtg ctg gtt ccg gac agg gat gtg agg gtc agc gtg     2284Gly Gly Lys Asn Val Leu Val Pro Asp Arg Asp Val Arg Val Ser Val        700                 705                 710aag gcc ctg gcc ctc agc tgt gtg gga gca gct gtg gcc ctc cac ccg     2332Lys Ala Leu Ala Leu Ser Cys Val Gly Ala Ala Val Ala Leu His Pro    715                 720                 725gaa tct ttc ttc agc aaa ctc tat aaa gtt cct ctt gac acc acg gaa     2380Glu Ser Phe Phe Ser Lys Leu Tyr Lys Val Pro Leu Asp Thr Thr Glu730                 735                 740                 745tac cct gag gaa cag tat gtc tca gac atc ttg aac tac atc gat cat     2428Tyr Pro Glu Glu Gln Tyr Val Ser Asp Ile Leu Asn Tyr Ile Asp His                750                 755                 760gga gac cca cag gtt cga gga gcc act gcc att ctc tgt ggg acc ctc     2476Gly Asp Pro Gln Val Arg Gly Ala Thr Ala Ile Leu Cys Gly Thr Leu            765                 770                 775atc tgc tcc atc ctc agc agg tcc cgc ttc cac gtg gga gat tgg atg     2524Ile Cys Ser Ile Leu Ser Arg Ser Arg Phe His Val Gly Asp Trp Met        780                 785                 790ggc acc att aga acc ctc aca gga aat aca ttt tct ttg gcg gat tgc     2572Gly Thr Ile Arg Thr Leu Thr Gly Asn Thr Phe Ser Leu Ala Asp Cys    795                 800                 805att cct ttg ctg cgg aaa aca ctg aag gat gag tct tct gtt act tgc     2620Ile Pro Leu Leu Arg Lys Thr Leu Lys Asp Glu Ser Ser Val Thr Cys810                 815                 820                 825aag tta gct tgt aca gct gtg agg aac tgt gtc atg agt ctc tgc agc     2668Lys Leu Ala Cys Thr Ala Val Arg Asn Cys Val Met Ser Leu Cys Ser                830                 835                 840agc agc tac agt gag tta gga ctg cag ctg atc atc gat gtg ctg act     2716Ser Ser Tyr Ser Glu Leu Gly Leu Gln Leu Ile Ile Asp Val Leu Thr            845                 850                 855ctg agg aac agt tcc tat tgg ctg gtg agg aca gag ctt ctg gaa acc     2764Leu Arg Asn Ser Ser Tyr Trp Leu Val Arg Thr Glu Leu Leu Glu Thr        860                 865                 870ctt gca gag att gac ttc agg ctg gtg agc ttt ttg gag gca aaa gca     2812Leu Ala Glu Ile Asp Phe Arg Leu Val Ser Phe Leu Glu Ala Lys Ala    875                 880                 885gaa aac tta cac aga ggg gct cat cat tat aca ggg ctt tta aaa ctg     2860Glu Asn Leu His Arg Gly Ala His His Tyr Thr Gly Leu Leu Lys Leu890                 895                 900                 905caa gaa cga gtg ctc aat aat gtt gtc atc cat ttg ctt gga gat gaa     2908Gln Glu Arg Val Leu Asn Asn Val Val Ile His Leu Leu Gly Asp Glu                910                 915                 920gac ccc agg gtg cga cat gtt gcc gca gca tca cta att agg ctt gtc     2956Asp Pro Arg Val Arg His Val Ala Ala Ala Ser Leu Ile Arg Leu Val            925                 930                 935cca aag ctg ttt tat aaa tgt gac caa gga caa gct gat cca gta gtg     3004Pro Lys Leu Phe Tyr Lys Cys Asp Gln Gly Gln Ala Asp Pro Val Val        940                 945                 950gcc gtg gca aga gat caa agc agt gtt tac ctg aaa ctt ctc atg cat     3052Ala Val Ala Arg Asp Gln Ser Ser Val Tyr Leu Lys Leu Leu Met His    955                 960                 965gag acg cag cct cca tct cat ttc tcc gtc agc aca ata acc aga ata     3100Glu Thr Gln Pro Pro Ser His Phe Ser Val Ser Thr Ile Thr Arg Ile970                 975                 980                 985tat aga ggc tat aac cta cta cca agc ata aca gac gtc act atg  gaa    3148Tyr Arg Gly Tyr Asn Leu Leu Pro Ser Ile Thr Asp Val Thr Met  Glu                990                 995                 1000aat aac ctt tca  aga gtt att gca gca  gtt tct cat gaa cta  atc      3193Asn Asn Leu Ser  Arg Val Ile Ala Ala  Val Ser His Glu Leu  Ile            1005                 1010                 1015aca tca acc acc  aga gca ctc aca ttt  gga tgc tgt gaa gct  ttg      3238Thr Ser Thr Thr  Arg Ala Leu Thr Phe  Gly Cys Cys Glu Ala  Leu            1020                 1025                 1030tgt ctt ctt tcc  act gcc ttc cca gtt  tgc att tgg agt tta  ggt      3283Cys Leu Leu Ser  Thr Ala Phe Pro Val  Cys Ile Trp Ser Leu  Gly            1035                 1040                 1045tgg cac tgt gga  gtg cct cca ctg agt  gcc tca gat gag tct  agg      3328Trp His Cys Gly  Val Pro Pro Leu Ser  Ala Ser Asp Glu Ser  Arg            1050                 1055                 1060aag agc tgt acc  gtt ggg atg gcc aca  atg att ctg acc ctg  ctc      3373Lys Ser Cys Thr  Val Gly Met Ala Thr  Met Ile Leu Thr Leu  Leu            1065                 1070                 1075tcg tca gct tgg  ttc cca ttg gat ctc  tca gcc cat caa gat  gct      3418Ser Ser Ala Trp  Phe Pro Leu Asp Leu  Ser Ala His Gln Asp  Ala            1080                 1085                 1090ttg att ttg gcc  gga aac ttg ctt gca  gcc agt gct ccc aaa  tct      3463Leu Ile Leu Ala  Gly Asn Leu Leu Ala  Ala Ser Ala Pro Lys  Ser            1095                 1100                 1105ctg aga agt tca  tgg gcc tct gaa gaa  gaa gcc aac cca gca  gcc      3508Leu Arg Ser Ser  Trp Ala Ser Glu Glu  Glu Ala Asn Pro Ala  Ala            1110                 1115                 1120acc aag caa gag  gag gtc tgg cca gcc  ctg ggg gac cgg gcc  ctg      3553Thr Lys Gln Glu  Glu Val Trp Pro Ala  Leu Gly Asp Arg Ala  Leu            1125                 1130                 1135gtg ccc atg gtg  gag cag ctc ttc tct  cac ctg ctg aag gtg  att      3598Val Pro Met Val  Glu Gln Leu Phe Ser  His Leu Leu Lys Val  Ile            1140                 1145                 1150aac att tgt gcc  cac gtc ctg gat gac  gtg gct cct gga ccc  gca      3643Asn Ile Cys Ala  His Val Leu Asp Asp  Val Ala Pro Gly Pro  Ala            1155                 1160                 1165ata aag gca gcc  ttg cct tct cta aca  aac ccc cct tct cta  agt      3688Ile Lys Ala Ala  Leu Pro Ser Leu Thr  Asn Pro Pro Ser Leu  Ser            1170                 1175                 1180ccc atc cga cga  aag ggg aag gag aaa  gaa cca gga gaa caa  gca      3733Pro Ile Arg Arg  Lys Gly Lys Glu Lys  Glu Pro Gly Glu Gln  Ala            1185                 1190                 1195tct gta ccg ttg  agt ccc aag aaa ggc  agt gag gcc agt gca  gct      3778Ser Val Pro Leu  Ser Pro Lys Lys Gly  Ser Glu Ala Ser Ala  Ala            1200                 1205                 1210tct aga caa tct  gat acc tca ggt cct  gtt aca aca agt aaa  tcc      3823Ser Arg Gln Ser  Asp Thr Ser Gly Pro  Val Thr Thr Ser Lys  Ser            1215                 1220                 1225tca tca ctg ggg  agt ttc tat cat ctt  cct tca tac ctc aaa  ctg      3868Ser Ser Leu Gly  Ser Phe Tyr His Leu  Pro Ser Tyr Leu Lys  Leu            1230                 1235                 1240cat gat gtc ctg  aaa gct aca cac gct  aac tac aag gtc acg  ctg      3913His Asp Val Leu  Lys Ala Thr His Ala  Asn Tyr Lys Val Thr  Leu            1245                 1250                 1255gat ctt cag aac  agc acg gaa aag ttt  gga ggg ttt ctc cgc  tca      3958Asp Leu Gln Asn  Ser Thr Glu Lys Phe  Gly Gly Phe Leu Arg  Ser            1260                 1265                 1270gcc ttg gat gtt  ctt tct cag ata cta  gag ctg gcc aca ctg  cag      4003Ala Leu Asp Val  Leu Ser Gln Ile Leu  Glu Leu Ala Thr Leu  Gln            1275                 1280                 1285gac att ggg aag  tgt gtt gaa gag atc  cta gga tac ctg aaa  tcc      4048Asp Ile Gly Lys  Cys Val Glu Glu Ile  Leu Gly Tyr Leu Lys  Ser            1290                 1295                 1300tgc ttt agt cga  gaa cca atg atg gca  act gtt tgt gtt caa  caa      4093Cys Phe Ser Arg  Glu Pro Met Met Ala  Thr Val Cys Val Gln  Gln            1305                 1310                 1315ttg ttg aag act  ctc ttt ggc aca aac  ttg gcc tcc cag ttt  gat      4138Leu Leu Lys Thr  Leu Phe Gly Thr Asn  Leu Ala Ser Gln Phe  Asp            1320                 1325                 1330ggc tta tct tcc  aac ccc agc aag tca  caa ggc cga gca cag  cgc      4183Gly Leu Ser Ser  Asn Pro Ser Lys Ser  Gln Gly Arg Ala Gln  Arg            1335                 1340                 1345ctt ggc tcc tcc  agt gtg agg cca ggc  ttg tac cac tac tgc  ttc      4228Leu Gly Ser Ser  Ser Val Arg Pro Gly  Leu Tyr His Tyr Cys  Phe            1350                 1355                 1360atg gcc ccg tac  acc cac ttc acc cag  gcc ctc gct gac gcc  agc      4273Met Ala Pro Tyr  Thr His Phe Thr Gln  Ala Leu Ala Asp Ala  Ser            1365                 1370                 1375ctg agg aac atg  gtg cag gcg gag cag  gag aac gac acc tcg  gga      4318Leu Arg Asn Met  Val Gln Ala Glu Gln  Glu Asn Asp Thr Ser  Gly            1380                 1385                 1390tgg ttt gat gtc  ctc cag aaa gtg tct  acc cag ttg aag aca  aac      4363Trp Phe Asp Val  Leu Gln Lys Val Ser  Thr Gln Leu Lys Thr  Asn            1395                 1400                 1405ctc acg agt gtc  aca aag aac cgt gca  gat aag aat gct att  cat      4408Leu Thr Ser Val  Thr Lys Asn Arg Ala  Asp Lys Asn Ala Ile  His            1410                 1415                 1420aat cac att cgt  ttg ttt gaa cct ctt  gtt ata aaa gct tta  aaa      4453Asn His Ile Arg  Leu Phe Glu Pro Leu  Val Ile Lys Ala Leu  Lys            1425                 1430                 1435cag tac acg act  aca aca tgt gtg cag  tta cag aag cag gtt  tta      4498Gln Tyr Thr Thr  Thr Thr Cys Val Gln  Leu Gln Lys Gln Val  Leu            1440                 1445                 1450gat ttg ctg gcg  cag ctg gtt cag tta  cgg gtt aat tac tgt  ctt      4543Asp Leu Leu Ala  Gln Leu Val Gln Leu  Arg Val Asn Tyr Cys  Leu            1455                 1460                 1465ctg gat tca gat  cag gtg ttt att ggc  ttt gta ttg aaa cag  ttt      4588Leu Asp Ser Asp  Gln Val Phe Ile Gly  Phe Val Leu Lys Gln  Phe            1470                 1475                 1480gaa tac att gaa  gtg ggc cag ttc agg  gaa tca gag gca atc  att      4633Glu Tyr Ile Glu  Val Gly Gln Phe Arg  Glu Ser Glu Ala Ile  Ile            1485                 1490                 1495cca aac atc ttt  ttc ttc ttg gta tta  cta tct tat gaa cgc  tat      4678Pro Asn Ile Phe  Phe Phe Leu Val Leu  Leu Ser Tyr Glu Arg  Tyr            1500                 1505                 1510cat tca aaa cag  atc att gga att cct  aaa atc att cag ctc  tgt      4723His Ser Lys Gln  Ile Ile Gly Ile Pro  Lys Ile Ile Gln Leu  Cys            1515                 1520                 1525gat ggc atc atg  gcc agt gga agg aag  gct gtg aca cat gcc  ata      4768Asp Gly Ile Met  Ala Ser Gly Arg Lys  Ala Val Thr His Ala  Ile            1530                 1535                 1540ccg gct ctg cag  ccc ata gtc cac gac  ctc ttt gta tta aga  gga      4813Pro Ala Leu Gln  Pro Ile Val His Asp  Leu Phe Val Leu Arg  Gly            1545                 1550                 1555aca aat aaa gct  gat gca gga aaa gag  ctt gaa acc caa aaa  gag      4858Thr Asn Lys Ala  Asp Ala Gly Lys Glu  Leu Glu Thr Gln Lys  Glu            1560                 1565                 1570gtg gtg gtg tca  atg tta ctg aga ctc  atc cag tac cat cag  gtg      4903Val Val Val Ser  Met Leu Leu Arg Leu  Ile Gln Tyr His Gln  Val            1575                 1580                 1585ttg gag atg ttc  att ctt gtc ctg cag  cag tgc cac aag gag  aat      4948Leu Glu Met Phe  Ile Leu Val Leu Gln  Gln Cys His Lys Glu  Asn            1590                 1595                 1600gaa gac aag tgg  aag cga ctg tct cga  cag ata gct gac atc  atc      4993Glu Asp Lys Trp  Lys Arg Leu Ser Arg  Gln Ile Ala Asp Ile  Ile            1605                 1610                 1615ctc cca atg tta  gcc aaa cag cag atg  cac att gac tct cat  gaa      5038Leu Pro Met Leu  Ala Lys Gln Gln Met  His Ile Asp Ser His  Glu            1620                 1625                 1630gcc ctt gga gtg  tta aat aca tta ttt  gag att ttg gcc cct  tcc      5083Ala Leu Gly Val  Leu Asn Thr Leu Phe  Glu Ile Leu Ala Pro  Ser            1635                 1640                 1645tcc ctc cgt ccg  gta gac atg ctt tta  cgg agt atg ttc gtc  act      5128Ser Leu Arg Pro  Val Asp Met Leu Leu  Arg Ser Met Phe Val  Thr            1650                 1655                 1660cca aac aca atg  gcg tcc gtg agc act  gtt caa ctg tgg ata  tcg      5173Pro Asn Thr Met  Ala Ser Val Ser Thr  Val Gln Leu Trp Ile  Ser            1665                 1670                 1675gga att ctg gcc  att ttg agg gtt ctg  att tcc cag tca act  gaa      5218Gly Ile Leu Ala  Ile Leu Arg Val Leu  Ile Ser Gln Ser Thr  Glu            1680                 1685                 1690gat att gtt ctt  tct cgt att cag gag  ctc tcc ttc tct ccg  tat      5263Asp Ile Val Leu  Ser Arg Ile Gln Glu  Leu Ser Phe Ser Pro  Tyr            1695                 1700                 1705tta atc tcc tgt  aca gta att aat agg  tta aga gat ggg gac  agt      5308Leu Ile Ser Cys  Thr Val Ile Asn Arg  Leu Arg Asp Gly Asp  Ser            1710                 1715                 1720act tca acg cta  gaa gaa cac agt gaa  ggg aaa caa ata aag  aat      5353Thr Ser Thr Leu  Glu Glu His Ser Glu  Gly Lys Gln Ile Lys  Asn            1725                 1730                 1735ttg cca gaa gaa  aca ttt tca agg ttt  cta tta caa ctg gtt  ggt      5398Leu Pro Glu Glu  Thr Phe Ser Arg Phe  Leu Leu Gln Leu Val  Gly            1740                 1745                 1750att ctt tta gaa  gac att gtt aca aaa  cag ctg aag gtg gaa  atg      5443Ile Leu Leu Glu  Asp Ile Val Thr Lys  Gln Leu Lys Val Glu  Met            1755                 1760                 1765agt gag cag caa  cat act ttc tat tgc  cag gaa cta ggc aca  ctg      5488Ser Glu Gln Gln  His Thr Phe Tyr Cys  Gln Glu Leu Gly Thr  Leu            1770                 1775                 1780cta atg tgt ctg  atc cac atc ttc aag  tct gga atg ttc cgg  aga      5533Leu Met Cys Leu  Ile His Ile Phe Lys  Ser Gly Met Phe Arg  Arg            1785                 1790                 1795atc aca gca gct  gcc act agg ctg ttc  cgc agt gat ggc tgt  ggc      5578Ile Thr Ala Ala  Ala Thr Arg Leu Phe  Arg Ser Asp Gly Cys  Gly            1800                 1805                 1810ggc agt ttc tac  acc ctg gac agc ttg  aac ttg cgg gct cgt  tcc      5623Gly Ser Phe Tyr  Thr Leu Asp Ser Leu  Asn Leu Arg Ala Arg  Ser            1815                 1820                 1825atg atc acc acc  cac ccg gcc ctg gtg  ctg ctc tgg tgt cag  ata      5668Met Ile Thr Thr  His Pro Ala Leu Val  Leu Leu Trp Cys Gln  Ile            1830                 1835                 1840ctg ctg ctt gtc  aac cac acc gac tac  cgc tgg tgg gca gaa  gtg      5713Leu Leu Leu Val  Asn His Thr Asp Tyr  Arg Trp Trp Ala Glu  Val            1845                 1850                 1855cag cag acc ccg  aaa aga cac agt ctg  tcc agc aca aag tta  ctt      5758Gln Gln Thr Pro  Lys Arg His Ser Leu  Ser Ser Thr Lys Leu  Leu            1860                 1865                 1870agt ccc cag atg  tct gga gaa gag gag  gat tct gac ttg gca  gcc      5803Ser Pro Gln Met  Ser Gly Glu Glu Glu  Asp Ser Asp Leu Ala  Ala            1875                 1880                 1885aaa ctt gga atg  tgc aat aga gaa ata  gta cga aga ggg gct  ctc      5848Lys Leu Gly Met  Cys Asn Arg Glu Ile  Val Arg Arg Gly Ala  Leu            1890                 1895                 1900att ctc ttc tgt  gat tat gtc tgt cag  aac ctc cat gac tcc  gag      5893Ile Leu Phe Cys  Asp Tyr Val Cys Gln  Asn Leu His Asp Ser  Glu            1905                 1910                 1915cac tta acg tgg  ctc att gta aat cac  att caa gat ctg atc  agc      5938His Leu Thr Trp  Leu Ile Val Asn His  Ile Gln Asp Leu Ile  Ser            1920                 1925                 1930ctt tcc cac gag  cct cca gta cag gac  ttc atc agt gcc gtt  cat      5983Leu Ser His Glu  Pro Pro Val Gln Asp  Phe Ile Ser Ala Val  His            1935                 1940                 1945cgg aac tct gct  gcc agc ggc ctg ttc  atc cag gca att cag  tct      6028Arg Asn Ser Ala  Ala Ser Gly Leu Phe  Ile Gln Ala Ile Gln  Ser            1950                 1955                 1960cgt tgt gaa aac  ctt tca act cca acc  atg ctg aag aaa act  ctt      6073Arg Cys Glu Asn  Leu Ser Thr Pro Thr  Met Leu Lys Lys Thr  Leu            1965                 1970                 1975cag tgc ttg gag  ggg atc cat ctc agc  cag tcg gga gct gtg  ctc      6118Gln Cys Leu Glu  Gly Ile His Leu Ser  Gln Ser Gly Ala Val  Leu            1980                 1985                 1990acg ctg tat gtg  gac agg ctt ctg tgc  acc cct ttc cgt gtg  ctg      6163Thr Leu Tyr Val  Asp Arg Leu Leu Cys  Thr Pro Phe Arg Val  Leu            1995                 2000                 2005gct cgc atg gtc  gac atc ctt gct tgt  cgc cgg gta gaa atg  ctt      6208Ala Arg Met Val  Asp Ile Leu Ala Cys  Arg Arg Val Glu Met  Leu            2010                 2015                 2020ctg gct gca aat  tta cag agc agc atg  gcc cag ttg cca atg  gaa      6253Leu Ala Ala Asn  Leu Gln Ser Ser Met  Ala Gln Leu Pro Met  Glu            2025                 2030                 2035gaa ctc aac aga  atc cag gaa tac ctt  cag agc agc ggg ctc  gct      6298Glu Leu Asn Arg  Ile Gln Glu Tyr Leu  Gln Ser Ser Gly Leu  Ala            2040                 2045                 2050cag aga cac caa  agg ctc tat tcc ctg  ctg gac agg ttt cgt  ctc      6343Gln Arg His Gln  Arg Leu Tyr Ser Leu  Leu Asp Arg Phe Arg  Leu            2055                 2060                 2065tcc acc atg caa  gac tca ctt agt ccc  tct cct cca gtc tct  tcc      6388Ser Thr Met Gln  Asp Ser Leu Ser Pro  Ser Pro Pro Val Ser  Ser            2070                 2075                 2080cac ccg ctg gac  ggg gat ggg cac gtg  tca ctg gaa aca gtg  agt      6433His Pro Leu Asp  Gly Asp Gly His Val  Ser Leu Glu Thr Val  Ser            2085                 2090                 2095ccg gac aaa gac  tgg tac gtt cat ctt  gtc aaa tcc cag tgt  tgg      6478Pro Asp Lys Asp  Trp Tyr Val His Leu  Val Lys Ser Gln Cys  Trp            2100                 2105                 2110acc agg tca gat  tct gca ctg ctg gaa  ggt gca gag ctg gtg  aat      6523Thr Arg Ser Asp  Ser Ala Leu Leu Glu  Gly Ala Glu Leu Val  Asn            2115                 2120                 2125cgg att cct gct  gaa gat atg aat gcc  ttc atg atg aac tcg  gag      6568Arg Ile Pro Ala  Glu Asp Met Asn Ala  Phe Met Met Asn Ser  Glu            2130                 2135                 2140ttc aac cta agc  ctg cta gct cca tgc  tta agc cta ggg atg  agt      6613Phe Asn Leu Ser  Leu Leu Ala Pro Cys  Leu Ser Leu Gly Met  Ser            2145                 2150                 2155gaa att tct ggt  ggc cag aag agt gcc  ctt ttt gaa gca gcc  cgt      6658Glu Ile Ser Gly  Gly Gln Lys Ser Ala  Leu Phe Glu Ala Ala  Arg            2160                 2165                 2170gag gtg act ctg  gcc cgt gtg agc ggc  acc gtg cag cag ctc  cct      6703Glu Val Thr Leu  Ala Arg Val Ser Gly  Thr Val Gln Gln Leu  Pro            2175                 2180                 2185gct gtc cat cat  gtc ttc cag ccc gag  ctg cct gca gag ccg  gcg      6748Ala Val His His  Val Phe Gln Pro Glu  Leu Pro Ala Glu Pro  Ala            2190                 2195                 2200gcc tac tgg agc  aag ttg aat gat ctg  ttt ggg gat gct gca  ctg      6793Ala Tyr Trp Ser  Lys Leu Asn Asp Leu  Phe Gly Asp Ala Ala  Leu            2205                 2210                 2215tat cag tcc ctg  ccc act ctg gcc cgg  gcc ctg gca cag tac  ctg      6838Tyr Gln Ser Leu  Pro Thr Leu Ala Arg  Ala Leu Ala Gln Tyr  Leu            2220                 2225                 2230gtg gtg gtc tcc  aaa ctg ccc agt cat  ttg cac ctt cct cct  gag      6883Val Val Val Ser  Lys Leu Pro Ser His  Leu His Leu Pro Pro  Glu            2235                 2240                 2245aaa gag aag gac  att gtg aaa ttc gtg  gtg gca acc ctt gag  gcc      6928Lys Glu Lys Asp  Ile Val Lys Phe Val  Val Ala Thr Leu Glu  Ala            2250                 2255                 2260ctg tcc tgg cat  ttg atc cat gag cag  atc ccg ctg agt ctg  gat      6973Leu Ser Trp His  Leu Ile His Glu Gln  Ile Pro Leu Ser Leu  Asp            2265                 2270                 2275ctc cag gca ggg  ctg gac tgc tgc tgc  ctg gcc ctg cag ctg  cct      7018Leu Gln Ala Gly  Leu Asp Cys Cys Cys  Leu Ala Leu Gln Leu  Pro            2280                 2285                 2290ggc ctc tgg agc  gtg gtc tcc tcc aca  gag ttt gtg acc cac  gcc      7063Gly Leu Trp Ser  Val Val Ser Ser Thr  Glu Phe Val Thr His  Ala            2295                 2300                 2305tgc tcc ctc atc  tac tgt gtg cac ttc  atc ctg gag gcc gtt  gca      7108Cys Ser Leu Ile  Tyr Cys Val His Phe  Ile Leu Glu Ala Val  Ala            2310                 2315                 2320gtg cag cct gga  gag cag ctt ctt agt  cca gaa aga agg aca  aat      7153Val Gln Pro Gly  Glu Gln Leu Leu Ser  Pro Glu Arg Arg Thr  Asn            2325                 2330                 2335acc cca aaa gcc  atc agc gag gag gag  gag gaa gta gat cca  aac      7198Thr Pro Lys Ala  Ile Ser Glu Glu Glu  Glu Glu Val Asp Pro  Asn            2340                 2345                 2350aca cag aat cct  aag tat atc act gca  gcc tgt gag atg gtg  gca      7243Thr Gln Asn Pro  Lys Tyr Ile Thr Ala  Ala Cys Glu Met Val  Ala            2355                 2360                 2365gaa atg gtg gag  tct ctg cag tcg gtg  ttg gcc ttg ggt cat  aaa      7288Glu Met Val Glu  Ser Leu Gln Ser Val  Leu Ala Leu Gly His  Lys            2370                 2375                 2380agg aat agc ggc  gtg ccg gcg ttt ctc  acg cca ttg cta agg  aac      7333Arg Asn Ser Gly  Val Pro Ala Phe Leu  Thr Pro Leu Leu Arg  Asn            2385                 2390                 2395atc atc atc agc  ctg gcc cgc ctg ccc  ctt gtc aac agc tac  aca      7378Ile Ile Ile Ser  Leu Ala Arg Leu Pro  Leu Val Asn Ser Tyr  Thr            2400                 2405                 2410cgt gtg ccc cca  ctg gtg tgg aag ctt  gga tgg tca ccc aaa  ccg      7423Arg Val Pro Pro  Leu Val Trp Lys Leu  Gly Trp Ser Pro Lys  Pro            2415                 2420                 2425gga ggg gat ttt  ggc aca gca ttc cct  gag atc ccc gtg gag  ttc      7468Gly Gly Asp Phe  Gly Thr Ala Phe Pro  Glu Ile Pro Val Glu  Phe            2430                 2435                 2440ctc cag gaa aag  gaa gtc ttt aag gag  ttc atc tac cgc atc  aac      7513Leu Gln Glu Lys  Glu Val Phe Lys Glu  Phe Ile Tyr Arg Ile  Asn            2445                 2450                 2455aca cta ggc tgg  acc agt cgt act cag  ttt gaa gaa act tgg  gcc      7558Thr Leu Gly Trp  Thr Ser Arg Thr Gln  Phe Glu Glu Thr Trp  Ala            2460                 2465                 2470acc ctc ctt ggt  gtc ctg gtg acg cag  ccc ctc gtg atg gag  cag      7603Thr Leu Leu Gly  Val Leu Val Thr Gln  Pro Leu Val Met Glu  Gln            2475                 2480                 2485gag gag agc cca  cca gaa gaa gac aca  gag agg acc cag atc  aac      7648Glu Glu Ser Pro  Pro Glu Glu Asp Thr  Glu Arg Thr Gln Ile  Asn            2490                 2495                 2500gtc ctg gcc gtg  cag gcc atc acc tca  ctg gtg ctc agt gca  atg      7693Val Leu Ala Val  Gln Ala Ile Thr Ser  Leu Val Leu Ser Ala  Met            2505                 2510                 2515act gtg cct gtg  gcc ggc aac cca gct  gta agc tgc ttg gag  cag      7738Thr Val Pro Val  Ala Gly Asn Pro Ala  Val Ser Cys Leu Glu  Gln            2520                 2525                 2530cag ccc cgg aac  aag cct ctg aaa gct  ctc gac acc agg ttt  ggg      7783Gln Pro Arg Asn  Lys Pro Leu Lys Ala  Leu Asp Thr Arg Phe  Gly            2535                 2540                 2545agg aag ctg agc  att atc aga ggg att  gtg gag caa gag att  caa      7828Arg Lys Leu Ser  Ile Ile Arg Gly Ile  Val Glu Gln Glu Ile  Gln            2550                 2555                 2560gca atg gtt tca  aag aga gag aat att  gcc acc cat cat tta  tat      7873Ala Met Val Ser  Lys Arg Glu Asn Ile  Ala Thr His His Leu  Tyr            2565                 2570                 2575cag gca tgg gat  cct gtc cct tct ctg  tct ccg gct act aca  ggt      7918Gln Ala Trp Asp  Pro Val Pro Ser Leu  Ser Pro Ala Thr Thr  Gly            2580                 2585                 2590gcc ctc atc agc  cac gag aag ctg ctg  cta cag atc aac ccc  gag      7963Ala Leu Ile Ser  His Glu Lys Leu Leu  Leu Gln Ile Asn Pro  Glu            2595                 2600                 2605cgg gag ctg ggg  agc atg agc tac aaa  ctc ggc cag gtg tcc  ata      8008Arg Glu Leu Gly  Ser Met Ser Tyr Lys  Leu Gly Gln Val Ser  Ile            2610                 2615                 2620cac tcc gtg tgg  ctg ggg aac agc atc  aca ccc ctg agg gag  gag      8053His Ser Val Trp  Leu Gly Asn Ser Ile  Thr Pro Leu Arg Glu  Glu            2625                 2630                 2635gaa tgg gac gag  gaa gag gag gag gag  gcc gac gcc cct gca  cct      8098Glu Trp Asp Glu  Glu Glu Glu Glu Glu  Ala Asp Ala Pro Ala  Pro            2640                 2645                 2650tcg tca cca ccc  acg tct cca gtc aac  tcc agg aaa cac cgg  gct      8143Ser Ser Pro Pro  Thr Ser Pro Val Asn  Ser Arg Lys His Arg  Ala            2655                 2660                 2665gga gtt gac atc  cac tcc tgt tcg cag  ttt ttg ctt gag ttg  tac      8188Gly Val Asp Ile  His Ser Cys Ser Gln  Phe Leu Leu Glu Leu  Tyr            2670                 2675                 2680agc cgc tgg atc  ctg ccg tcc agc tca  gcc agg agg acc ccg  gcc      8233Ser Arg Trp Ile  Leu Pro Ser Ser Ser  Ala Arg Arg Thr Pro  Ala            2685                 2690                 2695atc ctg atc agt  gag gtg gtc aga tcc  ctt cta gtg gtc tca  gac      8278Ile Leu Ile Ser  Glu Val Val Arg Ser  Leu Leu Val Val Ser  Asp            2700                 2705                 2710ttg ttc acc gag  cgc aac cag ttt gag  ctg atg tat gtg acg  ctg      8323Leu Phe Thr Glu  Arg Asn Gln Phe Glu  Leu Met Tyr Val Thr  Leu            2715                 2720                 2725aca gaa ctg cga  agg gtg cac cct tca  gaa gac gag atc ctc  gct      8368Thr Glu Leu Arg  Arg Val His Pro Ser  Glu Asp Glu Ile Leu  Ala            2730                 2735                 2740cag tac ctg gtg  cct gcc acc tgc aag  gca gct gcc gtc ctt  ggg      8413Gln Tyr Leu Val  Pro Ala Thr Cys Lys  Ala Ala Ala Val Leu  Gly            2745                 2750                 2755atg gac aag gcc  gtg gcg gag cct gtc  agc cgc ctg ctg gag  agc      8458Met Asp Lys Ala  Val Ala Glu Pro Val  Ser Arg Leu Leu Glu  Ser            2760                 2765                 2770acg ctc agg agc  agc cac ctg ccc agc  agg gtt gga gcc ctg  cac      8503Thr Leu Arg Ser  Ser His Leu Pro Ser  Arg Val Gly Ala Leu  His            2775                 2780                 2785ggc gtc ctc tat  gtg ctg gag tgc gac  ctg ctg gac gac act  gcc      8548Gly Val Leu Tyr  Val Leu Glu Cys Asp  Leu Leu Asp Asp Thr  Ala            2790                 2795                 2800aag cag ctc atc  ccg gtc atc agc gac  tat ctc ctc tcc aac  ctg      8593Lys Gln Leu Ile  Pro Val Ile Ser Asp  Tyr Leu Leu Ser Asn  Leu            2805                 2810                 2815aaa ggg atc gcc  cac tgc gtg aac att  cac agc cag cag cac  gta      8638Lys Gly Ile Ala  His Cys Val Asn Ile  His Ser Gln Gln His  Val            2820                 2825                 2830ctg gtc atg tgt  gcc act gcg ttt tac  ctc att gag aac tat  cct      8683Leu Val Met Cys  Ala Thr Ala Phe Tyr  Leu Ile Glu Asn Tyr  Pro            2835                 2840                 2845ctg gac gta ggg  ccg gaa ttt tca gca  tca ata ata cag atg  tgt      8728Leu Asp Val Gly  Pro Glu Phe Ser Ala  Ser Ile Ile Gln Met  Cys            2850                 2855                 2860ggg gtg atg ctg  tct gga agt gag gag  tcc acc ccc tcc atc  att      8773Gly Val Met Leu  Ser Gly Ser Glu Glu  Ser Thr Pro Ser Ile  Ile            2865                 2870                 2875tac cac tgt gcc  ctc aga ggc ctg gag  cgc ctc ctg ctc tct  gag      8818Tyr His Cys Ala  Leu Arg Gly Leu Glu  Arg Leu Leu Leu Ser  Glu            2880                 2885                 2890cag ctc tcc cgc  ctg gat gca gaa tcg  ctg gtc aag ctg agt  gtg      8863Gln Leu Ser Arg  Leu Asp Ala Glu Ser  Leu Val Lys Leu Ser  Val            2895                 2900                 2905gac aga gtg aac  gtg cac agc ccg cac  cgg gcc atg gcg gct  ctg      8908Asp Arg Val Asn  Val His Ser Pro His  Arg Ala Met Ala Ala  Leu            2910                 2915                 2920ggc ctg atg ctc  acc tgc atg tac aca  gga aag gag aaa gtc  agt      8953Gly Leu Met Leu  Thr Cys Met Tyr Thr  Gly Lys Glu Lys Val  Ser            2925                 2930                 2935ccg ggt aga act  tca gac cct aat cct  gca gcc ccc gac agc  gag      8998Pro Gly Arg Thr  Ser Asp Pro Asn Pro  Ala Ala Pro Asp Ser  Glu            2940                 2945                 2950tca gtg att gtt  gct atg gag cgg gta  tct gtt ctt ttt gat  agg      9043Ser Val Ile Val  Ala Met Glu Arg Val  Ser Val Leu Phe Asp  Arg            2955                 2960                 2965atc agg aaa ggc  ttt cct tgt gaa gcc  aga gtg gtg gcc agg  atc      9088Ile Arg Lys Gly  Phe Pro Cys Glu Ala  Arg Val Val Ala Arg  Ile            2970                 2975                 2980ctg ccc cag ttt  cta gac gac ttc ttc  cca ccc cag gac atc  atg      9133Leu Pro Gln Phe  Leu Asp Asp Phe Phe  Pro Pro Gln Asp Ile  Met            2985                 2990                 2995aac aaa gtc atc  gga gag ttt ctg tcc  aac cag cag cca tac  ccc      9178Asn Lys Val Ile  Gly Glu Phe Leu Ser  Asn Gln Gln Pro Tyr  Pro            3000                 3005                 3010cag ttc atg gcc  acc gtg gtg tat aag  gtg ttt cag act ctg  cac      9223Gln Phe Met Ala  Thr Val Val Tyr Lys  Val Phe Gln Thr Leu  His            3015                 3020                 3025agc acc ggg cag  tcg tcc atg gtc cgg  gac tgg gtc atg ctg  tcc      9268Ser Thr Gly Gln  Ser Ser Met Val Arg  Asp Trp Val Met Leu  Ser            3030                 3035                 3040ctc tcc aac ttc  acg cag agg gcc ccg  gtc gcc atg gcc acg  tgg      9313Leu Ser Asn Phe  Thr Gln Arg Ala Pro  Val Ala Met Ala Thr  Trp            3045                 3050                 3055agc ctc tcc tgc  ttc ttt gtc agc gcg  tcc acc agc ccg tgg  gtc      9358Ser Leu Ser Cys  Phe Phe Val Ser Ala  Ser Thr Ser Pro Trp  Val            3060                 3065                 3070gcg gcg atc ctc  cca cat gtc atc agc  agg atg ggc aag ctg  gag      9403Ala Ala Ile Leu  Pro His Val Ile Ser  Arg Met Gly Lys Leu  Glu            3075                 3080                 3085cag gtg gac gtg  aac ctt ttc tgc ctg  gtc gcc aca gac ttc  tac      9448Gln Val Asp Val  Asn Leu Phe Cys Leu  Val Ala Thr Asp Phe  Tyr            3090                 3095                 3100aga cac cag ata  gag gag gag ctc gac  cgc agg gcc ttc cag  tct      9493Arg His Gln Ile  Glu Glu Glu Leu Asp  Arg Arg Ala Phe Gln  Ser            3105                 3110                 3115gtg ctt gag gtg  gtt gca gcc cca gga  agc cca tat cac cgg  ctg      9538Val Leu Glu Val  Val Ala Ala Pro Gly  Ser Pro Tyr His Arg  Leu            3120                 3125                 3130ctg act tgt tta  cga aat gtc cac aag  gtc acc acc tgc tga           9580Leu Thr Cys Leu  Arg Asn Val His Lys  Val Thr Thr Cys            3135                 3140gcgccatggt gggagagact gtgaggcggc agctggggcc ggagcctttg gaagtctgcg   9640cccttgtgcc ctgcctccac cgagccagct tggtccctat gggcttccgc acatgccgcg   9700ggcggccagg caacgtgcgt gtctctgcca tgtggcagaa gtgctctttg tggcagtggc   9760caggcaggga gtgtctgcag tcctggtggg gctgagcctg aggccttcca gaaagcagga   9820gcagctgtgc tgcaccccat gtgggtgacc aggtcctttc tcctgatagt cacctgctgg   9880ttgttgccag gttgcagctg ctcttgcatc tgggccagaa gtcctccctc ctgcaggctg   9940gctgttggcc cctctgctgt cctgcagtag aaggtgccgt gagcaggctt tgggaacact  10000ggcctgggtc tccctggtgg ggtgtgcatg ccacgccccg tgtctggatg cacagatgcc  10060atggcctgtg ctgggccagt ggctgggggt gctagacacc cggcaccatt ctcccttctc  10120tcttttcttc tcaggattta aaatttaatt atatcagtaa agagattaat tttaacgtaa  10180ctctttctat gcccgtgtaa agtatgtgaa tcgcaaggcc tgtgctgcat gcgacagcgt  10240ccggggtggt ggacagggcc cccggccacg ctccctctcc tgtagccact ggcatagccc  10300tcctgagcac ccgctgacat ttccgttgta catgttcctg tttatgcatt cacaaggtga  10360ctgggatgta gagaggcgtt agtgggcagg tggccacagc aggactgagg acaggccccc  10420attatcctag gggtgcgctc acctgcagcc cctcctcctc gggcacagac gactgtcgtt  10480ctccacccac cagtcaggga cagcagcctc cctgtcactc agctgagaag gccagccctc  10540cctggctgtg agcagcctcc actgtgtcca gagacatggg cctcccactc ctgttccttg  10600ctagccctgg ggtggcgtct gcctaggagc tggctggcag gtgttgggac ctgctgctcc  10660atggatgcat gccctaagag tgtcactgag ctgtgttttg tctgagcctc tctcggtcaa  10720cagcaaagct tggtgtcttg gcactgttag tgacagagcc cagcatccct tctgcccccg  10780ttccagctga catcttgcac ggtgacccct tttagtcagg agagtgcaga tctgtgctca  10840tcggagactg ccccacggcc ctgtcagagc cgccactcct atccccaggc caggtccctg  10900gaccagcctc ctgtttgcag gcccagagga gccaagtcat taaaatggaa gtggattctg  10960gatggccggg ctgctgctga tgtaggagct ggatttggga gctctgcttg ccgactggct  11020gtgagacgag gcaggggctc tgcttcctca gccctagagg cgagccaggc aaggttggcg  11080actgtcatgt ggcttggttt ggtcatgccc gtcgatgttt tgggtattga atgtggtaag  11140tggaggaaat gttggaactc tgtgcaggtg ctgccttgag acccccaagc ttccacctgt  11200ccctctccta tgtggcagct ggggagcagc tgagatgtgg acttgtatgc tgcccacata  11260cgtgaggggg agctgaaagg gagcccctcc tctgagcagc ctctgccagg cctgtatgag  11320gcttttccca ccagctccca acagaggcct cccccagcca ggaccacctc gtcctcgtgg  11380cggggcagca ggagcggtag aaaggggtcc gatgtttgag gaggccctta agggaagcta  11440ctgaattata acacgtaaga aaatcaccat tccgtattgg ttgggggctc ctgtttctca  11500tcctagcttt ttcctggaaa gcccgctaga aggtttggga acgaggggaa agttctcaga  11560actgttggct gctccccacc cgcctcccgc ctcccccgca ggttatgtca gcagctctga  11620gacagcagta tcacaggcca gatgttgttc ctggctagat gtttacattt gtaagaaata  11680acactgtgaa tgtaaaacag agccattccc ttggaatgca tatcgctggg ctcaacatag  11740agtttgtctt cctcttgttt acgacgtgat ctaaaccagt ccttagcaag gggctcagaa  11800caccccgctc tggcagtagg tgtcccccac ccccaaagac ctgcctgtgt gctccggaga  11860tgaatatgag ctcattagta aaaatgactt cacccacgca tatacataaa gtatccatgc  11920atgtgcatat agacacatct ataattttac acacacacct ctcaagacgg agatgcatgg  11980cctctaagag tgcccgtgtc ggttcttcct ggaagttgac tttccttaga cccgccaggt  12040caagttagcc gcgtgacgga catccaggcg tgggacgtgg tcagggcagg gctcattcat  12100tgcccactag gatcccactg gcgaagatgg tctccatatc agctctctgc agaagggagg  12160aagactttat catgttccta aaaatctgtg gcaagcaccc atcgtattat ccaaattttg  12220ttgcaaatgt gattaatttg gttgtcaagt tttgggggtg ggctgtgggg agattgcttt  12280tgttttcctg ctggtaatat cgggaaagat tttaatgaaa ccagggtaga attgtttggc  12340aatgcactga agcgtgtttc tttcccaaaa tgtgcctccc ttccgctgcg ggcccagctg  12400agtctatgta ggtgatgttt ccagctgcca agtgctcttt gttactgtcc accctcattt  12460ctgccagcgc atgtgtcctt tcaaggggaa aatgtgaagc tgaaccccct ccagacaccc  12520agaatgtagc atctgagaag gccctgtgcc ctaaaggaca cccctcgccc ccatcttcat  12580ggagggggtc atttcagagc cctcggagcc aatgaacagc tcctcctctt ggagctgaga  12640tgagccccac gtggagctcg ggacggatag tagacagcaa taactcggtg tgtggccgcc  12700tggcaggtgg aacttcctcc cgttgcgggg tggagtgagg ttagttctgt gtgtctggtg  12760ggtggagtca ggcttctctt gctacctgtg agcatccttc ccagcagaca tcctcatcgg  12820gctttgtccc tcccccgctt cctccctctg cggggaggac ccgggaccac agctgctggc  12880cagggtagac ttggagctgt cctccagagg ggtcacgtgt aggagtgaga agaaggaaga  12940tcttgagagc tgctgaggga ccttggagag ctcaggatgg ctcagacgag gacactcgct  13000tgccgggcct gggcctcctg ggaaggaggg agctgctcag aatgccgcat gacaactgaa  13060ggcaacctgg aaggttcagg ggccgctctt cccccatgtg cctgtcacgc tctggtgcag  13120tcaaaggaac gccttcccct cagttgtttc taagagcaga gtctcccgct gcaatctggg  13180tggtaactgc cagccttgga ggatcgtggc caacgtggac ctgcctacgg agggtgggct  13240ctgacccaag tggggcctcc ttgtccaggt ctcactgctt tgcaccgtgg tcagagggac  13300tgtcagctga gcttgagctc ccctggagcc agcagggctg tgatgggcga gtcccggagc  13360cccacccaga cctgaatgct tctgagagca aagggaagga ctgacgagag atgtatattt  13420aattttttaa ctgctgcaaa cattgtacat ccaaattaaa ggaaaaaaat ggaaaccatc  13480a                                                                  13481</s400><s200><s210>575</s210><s211>20</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 575ccttccctga aggttcctcc                                                 20</s400><s200><s210>576</s210><s211>20</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220></s200><s400> 576tctctattgc acattccaag                                                 20</s400><s200><s210>577</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220><s220><s221>misc_feature</s221><s222>(5)..(5)</s222><s223>bases at these positions are RNA</s223></s220></s200><s400> 577taaautgtca tcacc                                                      15</s400><s200><s210>578</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220><s220><s221>misc_feature</s221><s222>(6)..(6)</s222><s223>bases at these positions are RNA</s223></s220></s200><s400> 578taaatugtca tcacc                                                      15</s400><s200><s210>579</s210><s211>15</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic oligonucleotide</s223></s220><s220><s221>misc_feature</s221><s222>(11)..(11)</s222><s223>Bases at these positions are RNA</s223></s220></s200><s400> 579taaattgtca ucacc                                                      15</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230002764A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221220" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230002764</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17635284</doc-number><date>20200814</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>113</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>P</subclass><main-group>35</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>P</subclass><main-group>11</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>113</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20180101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>P</subclass><main-group>35</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20180101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>P</subclass><main-group>11</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2310</main-group><subgroup>341</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2310</main-group><subgroup>11</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2320</main-group><subgroup>32</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e43">EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA</invention-title><us-related-documents><us-provisional-application><document-id><country>US</country><doc-number>63035357</doc-number><date>20200605</date></document-id></us-provisional-application><us-provisional-application><document-id><country>US</country><doc-number>63023065</doc-number><date>20200511</date></document-id></us-provisional-application><us-provisional-application><document-id><country>US</country><doc-number>62989540</doc-number><date>20200313</date></document-id></us-provisional-application><us-provisional-application><document-id><country>US</country><doc-number>62944204</doc-number><date>20191205</date></document-id></us-provisional-application><us-provisional-application><document-id><country>US</country><doc-number>62936220</doc-number><date>20191115</date></document-id></us-provisional-application><us-provisional-application><document-id><country>US</country><doc-number>62900136</doc-number><date>20190913</date></document-id></us-provisional-application><us-provisional-application><document-id><country>US</country><doc-number>62886930</doc-number><date>20190814</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>Codiak BioSciences, Inc.</orgname><address><city>Cambridge</city><state>MA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>BURZYN</last-name><first-name>Dalia</first-name><address><city>Newton</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>KAMERKAR</last-name><first-name>Sushrut</first-name><address><city>Cambridge</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>BOUTIN</last-name><first-name>Adam T.</first-name><address><city>Cambridge</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>BROOM</last-name><first-name>Wendy</first-name><address><city>Arlington</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="04" designation="us-only"><addressbook><last-name>SATHYANARAYANAN</last-name><first-name>Sriram</first-name><address><city>Lexington</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="05" designation="us-only"><addressbook><last-name>VERMA</last-name><first-name>Ajay</first-name><address><city>Wayland</city><state>MA</state><country>US</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>Codiak BioSciences, Inc.</orgname><role>02</role><address><city>Cambridge</city><state>MA</state><country>US</country></address></addressbook></assignee></assignees><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/US2020/046563</doc-number><date>20200814</date></document-id><us-371c12-date><date>20220214</date></us-371c12-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">The present disclosure relates to extracellular vesicles, e.g., exosomes, comprising an antisense oligonucleotide (ASO), wherein the ASO comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within a CEBP/transcript. Also provided herein are methods for producing the exosomes and methods for using the exosomes to treat and/or prevent diseases or disorders.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00000" num="00000"><img id="EMI-D00000" he="155.19mm" wi="136.99mm" file="US20230002764A1-20230105-D00000.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="241.81mm" wi="164.00mm" orientation="landscape" file="US20230002764A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="242.40mm" wi="170.18mm" orientation="landscape" file="US20230002764A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="242.40mm" wi="170.94mm" orientation="landscape" file="US20230002764A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00004" num="00004"><img id="EMI-D00004" he="242.40mm" wi="171.70mm" orientation="landscape" file="US20230002764A1-20230105-D00004.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00005" num="00005"><img id="EMI-D00005" he="242.40mm" wi="171.20mm" orientation="landscape" file="US20230002764A1-20230105-D00005.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00006" num="00006"><img id="EMI-D00006" he="242.40mm" wi="170.69mm" orientation="landscape" file="US20230002764A1-20230105-D00006.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00007" num="00007"><img id="EMI-D00007" he="238.84mm" wi="147.57mm" orientation="landscape" file="US20230002764A1-20230105-D00007.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00008" num="00008"><img id="EMI-D00008" he="134.03mm" wi="89.15mm" orientation="landscape" file="US20230002764A1-20230105-D00008.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00009" num="00009"><img id="EMI-D00009" he="243.76mm" wi="123.27mm" orientation="landscape" file="US20230002764A1-20230105-D00009.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00010" num="00010"><img id="EMI-D00010" he="177.29mm" wi="151.81mm" file="US20230002764A1-20230105-D00010.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00011" num="00011"><img id="EMI-D00011" he="110.41mm" wi="104.73mm" file="US20230002764A1-20230105-D00011.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00012" num="00012"><img id="EMI-D00012" he="224.62mm" wi="137.92mm" file="US20230002764A1-20230105-D00012.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00013" num="00013"><img id="EMI-D00013" he="236.22mm" wi="149.61mm" file="US20230002764A1-20230105-D00013.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00014" num="00014"><img id="EMI-D00014" he="238.93mm" wi="144.53mm" file="US20230002764A1-20230105-D00014.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00015" num="00015"><img id="EMI-D00015" he="206.59mm" wi="175.85mm" file="US20230002764A1-20230105-D00015.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00016" num="00016"><img id="EMI-D00016" he="118.03mm" wi="100.50mm" file="US20230002764A1-20230105-D00016.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00017" num="00017"><img id="EMI-D00017" he="227.50mm" wi="164.42mm" file="US20230002764A1-20230105-D00017.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00018" num="00018"><img id="EMI-D00018" he="104.22mm" wi="83.06mm" file="US20230002764A1-20230105-D00018.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00019" num="00019"><img id="EMI-D00019" he="242.49mm" wi="144.19mm" orientation="landscape" file="US20230002764A1-20230105-D00019.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00020" num="00020"><img id="EMI-D00020" he="236.90mm" wi="164.68mm" file="US20230002764A1-20230105-D00020.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00021" num="00021"><img id="EMI-D00021" he="239.10mm" wi="162.64mm" file="US20230002764A1-20230105-D00021.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00022" num="00022"><img id="EMI-D00022" he="228.26mm" wi="170.94mm" orientation="landscape" file="US20230002764A1-20230105-D00022.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00023" num="00023"><img id="EMI-D00023" he="224.11mm" wi="125.98mm" file="US20230002764A1-20230105-D00023.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00024" num="00024"><img id="EMI-D00024" he="120.23mm" wi="100.75mm" file="US20230002764A1-20230105-D00024.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00025" num="00025"><img id="EMI-D00025" he="242.15mm" wi="110.24mm" orientation="landscape" file="US20230002764A1-20230105-D00025.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00026" num="00026"><img id="EMI-D00026" he="242.15mm" wi="142.41mm" orientation="landscape" file="US20230002764A1-20230105-D00026.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00027" num="00027"><img id="EMI-D00027" he="191.35mm" wi="84.75mm" file="US20230002764A1-20230105-D00027.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00028" num="00028"><img id="EMI-D00028" he="155.53mm" wi="166.29mm" orientation="landscape" file="US20230002764A1-20230105-D00028.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00029" num="00029"><img id="EMI-D00029" he="176.11mm" wi="155.02mm" file="US20230002764A1-20230105-D00029.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00030" num="00030"><img id="EMI-D00030" he="170.77mm" wi="147.49mm" orientation="landscape" file="US20230002764A1-20230105-D00030.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00031" num="00031"><img id="EMI-D00031" he="188.72mm" wi="147.15mm" orientation="landscape" file="US20230002764A1-20230105-D00031.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00032" num="00032"><img id="EMI-D00032" he="160.44mm" wi="154.77mm" file="US20230002764A1-20230105-D00032.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00033" num="00033"><img id="EMI-D00033" he="139.11mm" wi="136.57mm" file="US20230002764A1-20230105-D00033.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00034" num="00034"><img id="EMI-D00034" he="193.12mm" wi="176.61mm" file="US20230002764A1-20230105-D00034.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00035" num="00035"><img id="EMI-D00035" he="156.04mm" wi="110.15mm" file="US20230002764A1-20230105-D00035.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00036" num="00036"><img id="EMI-D00036" he="222.17mm" wi="171.70mm" orientation="landscape" file="US20230002764A1-20230105-D00036.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00037" num="00037"><img id="EMI-D00037" he="137.92mm" wi="118.28mm" file="US20230002764A1-20230105-D00037.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00038" num="00038"><img id="EMI-D00038" he="176.95mm" wi="115.15mm" orientation="landscape" file="US20230002764A1-20230105-D00038.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00039" num="00039"><img id="EMI-D00039" he="211.33mm" wi="185.17mm" file="US20230002764A1-20230105-D00039.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00040" num="00040"><img id="EMI-D00040" he="195.50mm" wi="174.58mm" file="US20230002764A1-20230105-D00040.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00041" num="00041"><img id="EMI-D00041" he="148.59mm" wi="104.22mm" orientation="landscape" file="US20230002764A1-20230105-D00041.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00042" num="00042"><img id="EMI-D00042" he="175.77mm" wi="139.02mm" file="US20230002764A1-20230105-D00042.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00043" num="00043"><img id="EMI-D00043" he="195.33mm" wi="110.32mm" orientation="landscape" file="US20230002764A1-20230105-D00043.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0001" level="1">REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY VIA EFS-WEB</heading><p id="p-0002" num="0001">The content of the electronically submitted sequence listing in ASCII text file (Name: 4000_058PC07_Seqlisting_ST25.txt; Size: 280,024 bytes; and Date of Creation: Aug. 13, 2020), filed with the application, is incorporated herein by reference in its entirety.</p><heading id="h-0002" level="1">CROSS REFERENCE TO RELATED APPLICATIONS</heading><p id="p-0003" num="0002">This PCT application claims the priority benefit of U.S. Provisional Application Nos. 62/886,930 filed Aug. 14, 2019; 62/900,136 filed Sep. 13, 2019; 62/936,220 filed Nov. 15, 2019; 62/944,204 filed Dec. 5, 2019; 62/989,540 filed Mar. 13, 2020; 63/023,065 filed May 11, 2020; 63/035,357 filed Jun. 5, 2020; each of which is incorporated herein by reference in its entirety.</p><heading id="h-0003" level="1">FIELD OF DISCLOSURE</heading><p id="p-0004" num="0003">The present disclosure relates to extracellular vesicles (EVs), e.g., exosomes, comprising an antisense oligonucleotide (ASO), wherein the ASO comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within a CEBP/&#x3b2; transcript. In certain aspects of the disclosure, the extracellular vesicle further comprises a scaffold protein.</p><heading id="h-0004" level="1">BACKGROUND</heading><p id="p-0005" num="0004">Exosomes are small extracellular vesicles that are naturally produced by every eukaryotic cell. Exosomes comprise a membrane that encloses an internal space (i.e., lumen). As drug delivery vehicles, EVs, e.g., exosomes, offer many advantages over traditional drug delivery methods as a new treatment modality in many therapeutic areas. In particular, exosomes have intrinsically low immunogenicity, even when administered to a different species.</p><p id="p-0006" num="0005">Antisense oligonucleotides have emerged as a powerful means of regulating target gene expression in vitro or in vivo. However, there remains a need to improve the stability and targeting of ASOs in vivo. Accordingly, new and more effective engineered-EVs (e.g., exosomes), particularly those that can be used to deliver therapeutic agents that can reduce the expression of a gene associated with a disease (e.g., N for cancer), are necessary to better enable therapeutic use and other applications of EV-based technologies.</p><heading id="h-0005" level="1">SUMMARY OF DISCLOSURE</heading><p id="p-0007" num="0006">Certain aspects of the present disclosure are directed to an extracellular vesicle comprising an antisense oligonucleotide (ASO) which comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within a CEBP/&#x3b2; transcript (SEQ ID NO: 11 or SEQ ID NO: 13). In some aspects, the ASO is not TGGATITAAAGGCAGGCGGC (SEQ ID NO: 90).</p><p id="p-0008" num="0007">In some aspects, the extracellular vesicle targets a cell selected from the group consisting of a macrophage, a myeloid-derived suppressor cell (MDSC), a monocyte, a basophil, a neutrophil, an eosinophil, and any combination thereof.</p><p id="p-0009" num="0008">In some aspects, the ASO comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 1 to 518 of a CEBP/&#x3b2; transcript corresponding to a nucleotide sequence as set forth in SEQ ID NO: 13, or nucleotides 521 to 2113 of a CEBP/&#x3b2; transcript corresponding to a nucleotide sequence as set forth in SEQ ID NO: 13. In some aspects, the contiguous nucleotide sequence is at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% complementary to the nucleic acid sequence within the CEBP/&#x3b2; transcript. In some aspects, the ASO is capable of reducing CEBP/P protein expression in a human cell (e.g., an immune cell), wherein the human cell expresses the CEBP/P protein. In some aspects, the CEBP/&#x3b2; protein expression is reduced by at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% compared to CEBP/P protein expression in a human cell that is not exposed to the ASO.</p><p id="p-0010" num="0009">In some aspects, the ASO is capable of reducing a level of CEBP/&#x3b2; mRNA in a human cell (e.g., an immune cell), wherein the human cell expresses the CEBP/&#x3b2; mRNA. In some aspects, the level of CEBP/&#x3b2; mRNA is reduced by at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% compared to the level of the CEBP/&#x3b2; mRNA in a human cell that is not exposed to the ASO.</p><p id="p-0011" num="0010">In some aspects, the ASO is a gapmer, a mixmer, or a totalmer. In some aspects, the ASO comprises one or more nucleoside analogs. In some aspects, one or more of the nucleoside analogs comprises a 2&#x2032;-O-alkyl-RNA; 2&#x2032;-O-methyl RNA (2&#x2032;-OMe); 2&#x2032;-alkoxy-RNA; 2&#x2032;-O-methoxyethyl-RNA (2&#x2032;-MOE); 2&#x2032;-amino-DNA; 2&#x2032;-fluoro-RNA; 2&#x2032;-fluoro-DNA; arabino nucleic acid (ANA); 2&#x2032;-fluoro-ANA; or bicyclic nucleoside analog. In some aspects, one or more of the nucleoside analogs is a sugar modified nucleoside. In some aspects, the sugar-modified nucleoside is an affinity enhancing 2&#x2032; sugar modified nucleoside. In some aspects, one or more of the nucleoside analogs comprises a nucleoside comprising a bicyclic sugar. In some aspects, one or more of the nucleoside analogs comprises an LNA.</p><p id="p-0012" num="0011">In some aspects, one or more of the nucleotide analogs is selected from the group consisting of constrained ethyl nucleoside (cEt), 2&#x2032;,4&#x2032;-constrained 2&#x2032;-O-methoxyethyl (cMOE), &#x3b1;-L-LNA, &#x3b2;-D-LNA, 2&#x2032;-O,4&#x2032;-C-ethylene-bridged nucleic acids (ENA), amino-LNA, oxy-LNA, thio-LNA, and any combination thereof. In some aspects, the ASO comprises one or more 5&#x2032;-methyl-cytosine nucleobases.</p><p id="p-0013" num="0012">In some aspects, the contiguous nucleotide sequence is complementary to a nucleic acid sequence within (i) a 5&#x2032; untranslated region (UTR); (ii) a coding region; or (iii) a 3&#x2032; UTR of the CEBP/&#x3b2; transcript. In some aspects, the contiguous nucleotide sequence is complementary to a nucleic acid sequence comprising (i) nucleotides 1-600 of SEQ ID NO: 13; (ii) nucleotides 100-600 of SEQ ID NO: 13; (iii) nucleotides 200-600 of SEQ ID NO: 13; (iv) nucleotides 300-600 of SEQ ID NO: 13; (v) 400-600 of SEQ ID NO: 13, (vi) nucleotides 500-1000 of SEQ ID NO: 13; (vii) nucleotides 900-1200 of SEQ ID NO: 13; (viii) nucleotides 1000-1300 of SEQ ID NO: 13; (ix) nucleotides 1300-1500 of SEQ ID NO: 13; (x) 489-649 of SEQ ID NO: 13; (xi) nucleotides 594-728 of SEQ ID NO: 13; (xii) nucleotides 765-700 of SEQ ID NO: 13; (xiii) nucleotides 936-1076 of SEQ ID NO: 13; (xiv) nucleotides 999-2068 of SEQ ID NO: 13; (xv) 1203-1357 of SEQ ID NO: 13; (xvi) nucleotides 1355-1487 of SEQ ID NO: 13 (xvii) 529-609 of SEQ ID NO: 13; (xviii) nucleotides 634-688 of SEQ ID NO: 13; (xix) nucleotides 805-700 of SEQ ID NO: 13; (xx) nucleotides 976-1036 of SEQ ID NO: 13; (xxi) nucleotides 1039-2028 of SEQ ID NO: 13; (xxii) 1243-1317 of SEQ ID NO: 13; or (xxiii) nucleotides 1395-1447 of SEQ ID NO: 13. In some aspects, the contiguous nucleotide sequence is complementary to a nucleic acid sequence within (i) 539-599 of SEQ ID NO: 13; (ii) nucleotides 644-678 of SEQ ID NO: 13; (iii) nucleotides 815-690 of SEQ ID NO: 13; (iv) nucleotides 986-1026 of SEQ ID NO: 13; (v) nucleotides 1049-2018 of SEQ ID NO: 13; (vi) 1253-1307 of SEQ ID NO: 13; or (vii) nucleotides 1405-1437 of SEQ ID NO: 13.</p><p id="p-0014" num="0013">In some aspects, the contiguous nucleotide sequence comprises a nucleotide sequence complementary to a sequence selected from the sequences in <figref idref="DRAWINGS">FIG. <b>1</b></figref>.</p><p id="p-0015" num="0014">In some aspects, the continuous nucleotide sequence is fully complementary to a nucleotide sequence within the CEBP/&#x3b2; transcript. In some aspects, the ASO comprises a nucleotide sequence selected from SEQ ID NOs: 194-296, with one or two mismatches. In some aspects, the ASO has a design selected from the group consisting of the designs in <figref idref="DRAWINGS">FIG. <b>1</b></figref>, wherein the upper letter is a sugar-modified nucleoside and the lower case letter is DNA. In some aspects, the ASO is from 14 to 20 nucleotides in length.</p><p id="p-0016" num="0015">In some aspects, the contiguous nucleotide sequence comprises one or more modified internucleoside linkages. In some aspects, the one or more modified internucleoside linkages is a phosphorothioate linkage. In some aspects, at least 75/6, at least 80%, at least 85%, at least 90%, at least 95%, or 100% of internucleoside linkages are modified. In some aspects, each of the internucleoside linkages in the ASO is a phosphorothioate linkage.</p><p id="p-0017" num="0016">In some aspects, the extracellular vesicle further comprises an anchoring moiety. In some aspects, the ASO is linked to the anchoring moiety. In some aspects, the extracellular vesicle further comprises an exogenous targeting moiety. In some aspects, the exogenous targeting moiety comprises a peptide, an antibody or an antigen-binding fragment thereof, a chemical compound, an RNA aptamer, or any combination thereof. In some aspects, the exogenous targeting moiety comprises a peptide. In some aspects, the exogenous targeting moiety comprises a microprotein, a designed ankyrin repeat protein (darpin), an anticalin, an adnectin, an aptamer, a peptide mimetic molecule, a natural ligand for a receptor, a camelid nanobody, or any combination thereof.</p><p id="p-0018" num="0017">In some aspects, the exogenous targeting moiety comprises a full-length antibody, a single domain antibody, a heavy chain only antibody (VHH), a single chain antibody, a shark heavy chain only antibody (VNAR), an scFv, a Fv, a Fab, a Fab&#x2032;, a F(ab&#x2032;)2, or any combination thereof.</p><p id="p-0019" num="0018">In some aspects, the antibody is a single chain antibody.</p><p id="p-0020" num="0019">In some aspects, the exogenous targeting moiety targets the exosome to the liver, heart, lungs, brain, kidneys, central nervous system, peripheral nervous system, muscle, bone, joint, skin, intestine, bladder, pancreas, lymph nodes, spleen, blood, bone marrow, or any combination thereof. In some aspects, the exogenous targeting moiety targets the exosome to a tumor cell, dendritic cell, T cell, B cell, macrophage, neuron, hepatocyte, Kupffer cell, myeloid-lineage cell (e.g., a neutrophils, monocytes, macrophages, hematopoietic stem cell, an MDSC (e.g., a monocytic MDSC or a granulocytic MDSC)), or any combination thereof.</p><p id="p-0021" num="0020">In some aspects, the EV comprises a scaffold moiety linking the exogenous targeting moiety to the EV. In some aspects, the anchoring moiety and/or the scaffold moiety is a Scaffold X. In some aspects, the anchoring moiety and/or the scaffold moiety is a Scaffold Y.</p><p id="p-0022" num="0021">In some aspects, the Scaffold X is a scaffold protein that is capable of anchoring the ASO on the luminal surface of the EV and/or on the exterior surface of the EV.</p><p id="p-0023" num="0022">In some aspects, the Scaffold Y is a scaffold protein that is capable of anchoring the ASO on the luminal surface of the EV and/or on the exterior surface of the EV.</p><p id="p-0024" num="0023">In some aspects, the ASO is linked to the anchoring moiety and/or the scaffold moiety on the exterior surface of the EV. In some aspects, the ASO is linked to the anchoring moiety and/or the scaffold moiety on the luminal surface of the EV. In some aspects, the anchoring moiety comprises sterol, GM1, a lipid, a vitamin, a small molecule, a peptide, or a combination thereof. In some aspects, the anchoring moiety comprises cholesterol. In some aspects, the anchoring moiety comprises a phospholipid, a lysophospholipid, a fatty acid, a vitamin (e.g., vitamin D and/or vitamin E), or any combination thereof. In some aspects, the ASO is linked to the anchoring moiety and/or the scaffold moiety by a linker.</p><p id="p-0025" num="0024">In some aspects, the ASO is linked to the EV by a linker. In some aspects, the linker is a polypeptide. In some aspects, the linker is a non-polypeptide moiety. In some aspects, the linker comprise ethylene glycol. In some aspects, the linker comprises HEG, TEG, PEG, or any combination thereof.</p><p id="p-0026" num="0025">In some aspects, the linker comprises acrylic phosphoramidite (e.g., ACRYDITE&#x2122;), adenylation, azide (NHS Ester), digoxigenin (NHS Ester), cholesterol-TEG, I-LINKER&#x2122;, an amino modifier (e.g., amino modifier C6, amino modifier C12, amino modifier C6 dT, or Uni-Link&#x2122; amino modifier), alkyne, 5&#x2032; Hexynyl, 5-Octadiynyl dU, biotinylation (e.g., biotin, biotin (Azide), biotin dT, biotin-TEG, dual biotin, PC biotin, or desthiobiotin), thiol modification (thiol modifier C3 S&#x2014;S, dithiol or thiol modifier C6 S&#x2014;S), or any combination thereof. In some aspects, the linker is a cleavable linker. In some aspects, the linker comprises valine-alanine-p-aminobenzylcarbamate or valine-citrulline-p-aminobenzylcarbamate. In some aspects, the linker comprises (i) a maleimide moiety and (ii) valine-alanine-p-aminobenzylcarbamate or valine-citrulline-p-aminobenzylcarbamate.</p><p id="p-0027" num="0026">In some aspects, the EV is an exosome.</p><p id="p-0028" num="0027">Certain aspects of the present disclosure are directed to an antisense oligonucleotide (ASO) comprising comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within a CEBP/&#x3b2; transcript (SEQ ID NO: 11 or SEQ ID NO: 13). In some aspects, the ASO is not or TGGATITAAAGGCAGGCGGC (SEQ ID NO: 90). In some aspects, the ASO comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 1 to 518 of a CEBP/&#x3b2; transcript corresponding to a nucleotide sequence as set forth in SEQ ID NO: 13, or nucleotides 521 to 2113 of a CEBP/&#x3b2; transcript corresponding to a nucleotide sequence as set forth in SEQ ID NO: 13. In some aspects, the contiguous nucleotide sequence thereof is at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% complementary to the nucleic acid sequence within the CEBP/&#x3b2; transcript. In some aspects, the ASO is capable of reducing CEBP/&#x3b2; protein expression in a human cell (e.g., an immune cell), wherein the human cell expresses the CEBP/&#x3b2; protein. In some aspects, the CEBP/&#x3b2; protein expression is reduced by at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% compared to CEBP/&#x3b2; protein expression in a human cell that is not exposed to the ASO. In some aspects, the ASO is capable of reducing a level of CEBP/&#x3b2; mRNA in a human cell (e.g., an immune cell), wherein the human cell expresses the CEBP/&#x3b2; mRNA. In some aspects, the level of CEBP/&#x3b2; mRNA is reduced by at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% compared to the level of the CEBP/&#x3b2; mRNA in a human cell that is not exposed to the ASO.</p><p id="p-0029" num="0028">In some aspects, the ASO is a gapmer, a mixmer, or a totalmer. In some aspects, the ASO comprises one or more nucleoside analogs. In some aspects, one or more of the nucleoside analogs comprises a 2&#x2032;-O-alkyl-RNA; 2&#x2032;-O-methyl RNA (2&#x2032;-OMe); 2&#x2032;-alkoxy-RNA; 2&#x2032;-O-methoxyethyl-RNA (2&#x2032;-MOE); 2&#x2032;-amino-DNA; 2&#x2032;-fluoro-RNA; 2&#x2032;-fluoro-DNA; arabino nucleic acid (ANA); 2&#x2032;-fluoro-ANA; or bicyclic nucleoside analog (LNA). In some aspects, one or more of the nucleoside analogs is a sugar modified nucleoside. In some aspects, the sugar modified nucleoside is an affinity enhancing 2&#x2032; sugar modified nucleoside. In some aspects, one or more of the nucleoside analogs comprises a nucleoside comprising a bicyclic sugar. In some aspects, one or more of the nucleoside analogs comprises an LNA. In some aspects, the LNA is selected from the group consisting of constrained ethyl nucleoside (cEt), 2&#x2032;,4&#x2032;-constrained 2&#x2032;-O-methoxyethyl (cMOE), &#x3b1;-L-LNA, &#x3b2;-D-LNA, 2&#x2032;-O,4&#x2032;-C-ethylene-bridged nucleic acids (ENA), amino-LNA, oxy-LNA, thio-LNA, and any combination thereof. In some aspects, the ASO comprises one or more 5&#x2032;-methyl-cytosine nucleobases.</p><p id="p-0030" num="0029">In some aspects, the ASO comprises any one of SEQ ID NO: 194 to SEQ ID NO: 296. In some aspects, the ASO has a design selected from the group consisting of the designs in <figref idref="DRAWINGS">FIG. <b>1</b></figref>, wherein the upper letter is a sugar modified nucleoside and the lower case letter is DNA. In some aspects, the ASO is from 14 to 20 nucleotides in length.</p><p id="p-0031" num="0030">In some aspects, the contiguous nucleotide sequence comprises one or more modified internucleoside linkages. In some aspects, the one or more modified internucleoside linkages is a phosphorothioate linkage. In some aspects, at least 75/6, at least 80%, at least 85%, at least 90%, at least 95%, or 100% of internucleoside linkages are modified. In some aspects, each of the internucleoside linkages in the ASO is a phosphorothioate linkage.</p><p id="p-0032" num="0031">Certain aspects of the present disclosure are directed to a conjugate comprising an ASO described herein covalently attached to at least one non-nucleotide or non-polynucleotide moiety. In some aspects, the non-nucleotide or non-polynucleotide moiety comprises a protein, a fatty acid chain, a sugar residue, a glycoprotein, a polymer, or any combinations thereof.</p><p id="p-0033" num="0032">Certain aspects of the present disclosure are directed to an extracellular vesicle comprising an ASO disclosed herein or a conjugate disclosed herein.</p><p id="p-0034" num="0033">Certain aspects of the present disclosure are directed to a pharmaceutical composition comprising an extracellular vesicle disclosed herein, an ASO disclosed herein, or a conjugate disclosed herein, and a pharmaceutically acceptable diluent, carrier, salt, or adjuvant.</p><p id="p-0035" num="0034">In some aspects, the pharmaceutically acceptable salt comprises a sodium salt, a potassium salt, an ammonium salt, or any combination thereof. In some aspects, the pharmaceutical composition further comprises at least one additional therapeutic agent.</p><p id="p-0036" num="0035">In some aspects, the additional therapeutic agent is an CEBP/&#x3b2; antagonist. In some aspects, the CEBP/&#x3b2; antagonist is a chemical compound, an siRNA, an shRNA, an antisense oligonucleotide, a protein, or any combination thereof. In some aspects, the CEBP/&#x3b2; antagonist is an anti-CEBP/&#x3b2; antibody, or a fragment thereof. In some aspects, the CEBP/&#x3b2; antagonist comprises an antisense oligonucleotide (ASO).</p><p id="p-0037" num="0036">Certain aspects of the present disclosure are directed to a kit comprising an extracellular vesicle disclosed herein, an ASO disclosed herein, a conjugate disclosed herein, or a pharmaceutical composition disclosed herein, and instructions for use.</p><p id="p-0038" num="0037">Certain aspects of the present disclosure are directed to a diagnostic kit comprising an extracellular vesicle disclosed herein, an ASO disclosed herein, a conjugate disclosed herein, or a pharmaceutical composition disclosed herein, and instructions for use.</p><p id="p-0039" num="0038">Certain aspects of the present disclosure are directed to a method of inhibiting or reducing CEBP/&#x3b2; protein expression in a cell, comprising administering an extracellular vesicle disclosed herein, an ASO disclosed herein, a conjugate disclosed herein, or a pharmaceutical composition disclosed hereinto the cell expressing CEBP/&#x3b2; protein, wherein the CEBP/&#x3b2; protein expression in the cell is inhibited or reduced after the administration.</p><p id="p-0040" num="0039">Certain aspects of the present disclosure are directed to a method of treating a cancer in a subject in need thereof, comprising administering an effective amount of an extracellular vesicle disclosed herein, an ASO disclosed herein, a conjugate disclosed herein, or a pharmaceutical composition disclosed hereinto the subject.</p><p id="p-0041" num="0040">Certain aspects of the present disclosure are directed to a use of an extracellular vesicle disclosed herein, an ASO disclosed herein, a conjugate disclosed herein, or a pharmaceutical composition disclosed herein in the manufacture of a medicament for the treatment of a cancer in a subject in need thereof.</p><p id="p-0042" num="0041">Certain aspects of the present disclosure are directed to a method of treating a disease or disorder in a subject in need thereof, comprising administering an effective amount of an extracellular vesicle disclosed herein, an ASO disclosed herein, a conjugate disclosed herein, or a pharmaceutical composition disclosed herein to the subject, wherein the disease or disorder is selected from a fibrosis, an inflammation, a neurodegenerative disease, a metabolic disorder/CVD, and any combination thereof.</p><p id="p-0043" num="0042">Certain aspects of the present disclosure are directed to a use of an extracellular vesicle disclosed herein, an ASO disclosed herein, a conjugate disclosed herein, or a pharmaceutical composition disclosed herein in the manufacture of a medicament for the treatment of a disease or disorder in a subject in need thereof, wherein the disease or disorder is selected from a fibrosis, an inflammation, a neurodegenerative disease, a metabolic disorder/CVD, and any combination thereof.</p><p id="p-0044" num="0043">In some aspects, the ASO inhibits or reduces expression of CEBP/&#x3b2; mRNA in the cell after the administration. In some aspects, a level of CEBP/&#x3b2; mRNA is reduced by at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% after the administration compared to the level of CEBP/&#x3b2; mRNA in a cell not exposed to the ASO. In some aspects, the expression of CEBP/&#x3b2; protein is reduced by at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% after the administration compared to the expression of CEBP/&#x3b2; protein in a cell not exposed to the ASO.</p><p id="p-0045" num="0044">In some aspects, the extracellular vesicle, the ASO, the conjugate, or the pharmaceutical composition is administered intracardially, orally, parenterally, intrathecally, intra-cerebroventricularly, pulmorarily, topically, or intraventricularly.</p><p id="p-0046" num="0045">In some aspects, the cancer is selected from the group consisting of fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell cancer, squamous cell cancer of the head and neck cancer, colorectal cancer, lymphoma, leukemia, liver cancer, glioblastoma, melanoma, myeloma basal cell cancer, adenocarcinoma, sweat gland cancer, sebaceous gland cancer, papillary cancer, papillary adenocarcinomas, cystadenocarcinoma, medullary cancer, bronchogenic cancer, renal cell cancer, hepatoma, bile duct cancer, choriocarcinoma, seminoma, embryonal cancer, Wilms' tumor, cervical cancer, testicular cancer, lung cancer, small cell lung cancer, bladder cancer, epithelial cancer, glioma, glioblastoma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, follicular lymphoma, Hodgkin's lymphoma, B cell lymphoma, and any combination thereof.</p><p id="p-0047" num="0046">In some aspects, the disease or disorder comprises a fibrosis. In some aspects, the disease or disorder comprises a fibrosis selected from the group consisting of liver fibrosis (NASH), cirrhosis, pulmonary fibrosis, cystic fibrosis, chronic ulcerative colitis/IBD, bladder fibrosis, kidney fibrosis, CAPS (Muckle-Wells syndrome), atrial fibrosis, endomyocardial fibrosis, old myocardial infarction, glial scar, arterial stiffness, arthrofibrosis, Crohn's disease, Dupuytren's contracture, keloid fibrosis, mediastinal fibrosis, myelofibrosis, Peyronie's disease, nephrogenic systemic fibrosis, progressive massive fibrosis, retroperitoneal fibrosis, scleroderma/systemic sclerosis, adhesive capsulitis, and any combination thereof.</p><p id="p-0048" num="0047">Certain aspects of the present disclosure are directed to a method of activating meningeal macrophages, treating a cancer of the central nervous system, inducing M1 polarization of meningeal macrophages, or inducing meningeal macrophage infiltration in a subject in need thereof, comprising administering an extracellular vesicle described herein, an ASO described herein, a conjugate described herein, or a pharmaceutical composition described herein.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0006" level="1">BRIEF DESCRIPTION OF FIGURES</heading><p id="p-0049" num="0048"><figref idref="DRAWINGS">FIG. <b>1</b></figref> is a table listing various ASO sequences that target the CEBP/&#x3b2; transcript. The tables include the following information (from left to right): (i) description of the ASO, (ii) the ASO sequence without any particular design or chemical structure, (iii) SEQ ID number designated for the ASO sequence only, (iv) the ASO length, (v) the ASO sequence with a chemical structure, and (vi) the target start and end positions on the target transcript sequence (SEQ ID: 13, as indicated). The ASOs are from 5&#x2032; to 3&#x2032;. The symbols in the chemical structures are as follows: Nb means LNA; dN means DNA; 5MdC means 5-Methyl-dC; Nm means MOE; and s means phosphorothioate.</p><p id="p-0050" num="0049"><figref idref="DRAWINGS">FIGS. <b>2</b>A-<b>2</b>E</figref> are graphical representations of Cy5 levels, as detected by fluorescence (MFI) and normalized to PBS controls. Cy5 is used as a marker of uptake of exosomes comprising ASOs (&#x201c;Exo ASO&#x201d;; left) or free ASOs (right), as indicated, in various cell types isolated from the blood (<figref idref="DRAWINGS">FIG. <b>2</b>A</figref>), liver (<figref idref="DRAWINGS">FIG. <b>2</b>B</figref>), spleen (<figref idref="DRAWINGS">FIG. <b>2</b>C</figref>), and a tumor (CT26; <figref idref="DRAWINGS">FIGS. <b>2</b>D-<b>2</b>E</figref>). Horizontal lines indicate the average MR.</p><p id="p-0051" num="0050"><figref idref="DRAWINGS">FIGS. <b>2</b>F-<b>2</b>K</figref> are fluorescent images of bone marrow tissue samples taken from two mice each, showing uptake of exosomes comprising ASOs (<figref idref="DRAWINGS">FIGS. <b>2</b>F-<b>2</b>G</figref>) or free ASO (<figref idref="DRAWINGS">FIGS. <b>2</b>H-<b>2</b>I</figref>), as compared to PBS negative controls (<figref idref="DRAWINGS">FIGS. <b>2</b>J-<b>2</b>K</figref>).</p><p id="p-0052" num="0051"><figref idref="DRAWINGS">FIG. <b>2</b>L</figref> is a graphical representation of the results of flow cytometry to quantify the number of Cy5 labeled tumor cells and macrophages after intratumoral administration of fluorescently labeled exoASO.</p><p id="p-0053" num="0052"><figref idref="DRAWINGS">FIG. <b>2</b>M</figref> is a graphical representation of the results of flow cytometry to quantify the number of Cy5 labeled myeloid-derived suppressor cells, macrophages, and dendritic cells after intratumoral administration of fluorescently labeled exoASO. MDSC=myeloid-derived suppressor cells; mMDSC=monocytic MDSC; gMDSC=granulocytic MDSC; cDC1=type 1 conventional dendritic cells; cDC2=type 2 conventional dendritic cells.</p><p id="p-0054" num="0053"><figref idref="DRAWINGS">FIG. <b>2</b>N</figref> is graphical representation of the expression level of PTGFRN cognate receptors in glioblastoma (GBM) in various cell types across five targets.</p><p id="p-0055" num="0054"><figref idref="DRAWINGS">FIGS. <b>3</b>A-<b>3</b>B</figref> are graphical representations of the normalized gene expression (%) of CEBP/&#x3b2; (<figref idref="DRAWINGS">FIG. <b>3</b>A</figref>) and CD163 (<figref idref="DRAWINGS">FIG. <b>3</b>B</figref>) in polarized macrophages following treatment with CEBP/&#x3b2;-Exo-ASO, CEBP/&#x3b2; free ASO, or a scrambled Exo ASO (negative control), as indicated (<figref idref="DRAWINGS">FIGS. <b>3</b>A-<b>3</b>B</figref>).</p><p id="p-0056" num="0055"><figref idref="DRAWINGS">FIGS. <b>4</b>A-<b>4</b>N</figref> are graphical representations of the expression of TGF&#x3b2;1 (<figref idref="DRAWINGS">FIG. <b>4</b>A</figref>), CD163 (<figref idref="DRAWINGS">FIG. <b>4</b>B</figref>), STAT5b (<figref idref="DRAWINGS">FIG. <b>4</b>C</figref>), STAT6 (<figref idref="DRAWINGS">FIG. <b>4</b>D</figref>), CEBP/&#x3b2; (<figref idref="DRAWINGS">FIG. <b>4</b>E</figref>), IL12p8 (<figref idref="DRAWINGS">FIG. <b>4</b>F</figref>), AIFJ (<figref idref="DRAWINGS">FIG. <b>4</b>G</figref>), MYC (<figref idref="DRAWINGS">FIG. <b>4</b>H</figref>), HL DQA (<figref idref="DRAWINGS">FIG. <b>4</b>I</figref>), CD74 (MHF) (<figref idref="DRAWINGS">FIG. <b>4</b>J</figref>), TNF-&#x3b1; (<figref idref="DRAWINGS">FIG. <b>4</b>K</figref>), IL12p40 (<figref idref="DRAWINGS">FIG. <b>4</b>L</figref>), IL-10 (<figref idref="DRAWINGS">FIG. <b>4</b>M</figref>), TARC/CCL17 (<figref idref="DRAWINGS">FIG. <b>4</b>N</figref>), and CD206 (<figref idref="DRAWINGS">FIG. <b>4</b>O</figref>) in primary human macrophages untreated or treated with scramble Exo ASO, CEBP/&#x3b2;-Exo-ASO, or CEBP/&#x3b2; free ASO, as indicated. ***=p&#x3c;0.001; and ****=P&#x3c;0.0001.</p><p id="p-0057" num="0056"><figref idref="DRAWINGS">FIGS. <b>5</b>A-<b>5</b>F</figref> are graphical representations of the results of flow cytometry to isolate CD11b<sup>+</sup> cells. <figref idref="DRAWINGS">FIGS. <b>5</b>A-<b>5</b>C</figref> show CD45 expression pre-treatment (<figref idref="DRAWINGS">FIG. <b>5</b>A</figref>), following treatment with a negative control (scramble Exo ASO; <figref idref="DRAWINGS">FIG. <b>5</b>B</figref>), or post-treatment with an Exo-ASO (<figref idref="DRAWINGS">FIG. <b>5</b>C</figref>). <figref idref="DRAWINGS">FIGS. <b>5</b>D-<b>5</b>F</figref> show CD11b expression pre-treatment (<figref idref="DRAWINGS">FIG. <b>5</b>D</figref>), following treatment with a negative control (scramble Exo ASO; <figref idref="DRAWINGS">FIG. <b>5</b>E</figref>), or post-treatment with an Exo-ASO (<figref idref="DRAWINGS">FIG. <b>5</b>F</figref>). <figref idref="DRAWINGS">FIG. <b>5</b>G</figref> is a graphical representation of tumor volume in mice following treatment with a negative control (scramble Exo ASO), or post-treatment with an Exo-ASO.</p><p id="p-0058" num="0057"><figref idref="DRAWINGS">FIGS. <b>6</b>A-<b>6</b>B</figref> are graphical representations of the expression of CEBP/&#x3b2; (<figref idref="DRAWINGS">FIG. <b>6</b>A</figref>) and ARG1 (<figref idref="DRAWINGS">FIG. <b>6</b>C</figref>) in CD11b-enriched cells as compared to non-enriched cells following exposure to scramble Exo-ASO (<figref idref="DRAWINGS">FIGS. <b>6</b>A-<b>6</b>B</figref>), CEBP/&#x3b2; free ASO (<figref idref="DRAWINGS">FIG. <b>6</b>A</figref>), or CEBP/&#x3b2;-Exo-ASO (<figref idref="DRAWINGS">FIGS. <b>6</b>A-<b>6</b>B</figref>).</p><p id="p-0059" num="0058"><figref idref="DRAWINGS">FIGS. <b>7</b>A-<b>7</b>V</figref> are graphical representations of the expression of STAT6 (<figref idref="DRAWINGS">FIG. <b>7</b>A</figref>), CEBP/&#x3b2; (<figref idref="DRAWINGS">FIG. <b>7</b>B</figref>), TGFB81 (<figref idref="DRAWINGS">FIG. <b>7</b>C</figref>), STAT3 (<figref idref="DRAWINGS">FIG. <b>7</b>D</figref>), SIRP-&#x3b1; (<figref idref="DRAWINGS">FIG. <b>7</b>E</figref>), CD47 (<figref idref="DRAWINGS">FIG. <b>7</b>F</figref>), NOS2 (<figref idref="DRAWINGS">FIG. <b>7</b>G</figref>), ARG1 (<figref idref="DRAWINGS">FIG. <b>7</b>H</figref>), CD206 (<figref idref="DRAWINGS">FIG. <b>7</b>I</figref>), CD274 (<figref idref="DRAWINGS">FIG. <b>7</b>J</figref>), NLRP3 (<figref idref="DRAWINGS">FIG. <b>7</b>K</figref>), CSFIR (<figref idref="DRAWINGS">FIG. <b>7</b>L</figref>), CD36 (<figref idref="DRAWINGS">FIG. <b>7</b>M</figref>), STAB1 (<figref idref="DRAWINGS">FIG. <b>7</b>N</figref>), IL13 (<figref idref="DRAWINGS">FIG. <b>7</b>O</figref>), P13KG (<figref idref="DRAWINGS">FIG. <b>7</b>P</figref>), LY6C (<figref idref="DRAWINGS">FIG. <b>7</b>Q</figref>), LY6G (<figref idref="DRAWINGS">FIG. <b>7</b>R</figref>), IFN&#x3b2;1 (<figref idref="DRAWINGS">FIG. <b>7</b>S</figref>), IFN&#x3b3; (<figref idref="DRAWINGS">FIG. <b>7</b>T</figref>), IFN&#x3b1;1 (<figref idref="DRAWINGS">FIG. <b>7</b>U</figref>), and IL6R&#x3b1; (<figref idref="DRAWINGS">FIG. <b>7</b>V</figref>) in CD11b-enriched cells treated with scramble Exo ASO or CEBP/&#x3b2;-Exo-ASO, as indicated.</p><p id="p-0060" num="0059"><figref idref="DRAWINGS">FIG. <b>7</b>W</figref> is an image of a hierarchical clustering of gene expression in CD11b-enriched tumor associated myeloid cells, performed by Nanostring using the nCounter Human Myeloid Innate Immunity Panel v2.</p><p id="p-0061" num="0060"><figref idref="DRAWINGS">FIGS. <b>8</b>A and <b>8</b>B</figref> are graphical representations of the normalized gene expression (%) of CEBP/&#x3b2; (<figref idref="DRAWINGS">FIG. <b>8</b>A</figref>) and TGF&#x3b2;1 (<figref idref="DRAWINGS">FIG. <b>8</b>B</figref>) in primary human M2 macrophages were polarized with IL-13/TGF&#x3b2; treatment subsequently treated with CEBP/&#x3b2; Exo ASO, CEBP/&#x3b2; free ASO, or a scrambled Exo ASO (negative control), as indicated.</p><p id="p-0062" num="0061"><figref idref="DRAWINGS">FIG. <b>9</b></figref> is a graphical representation of exosome uptake, as evidenced by Cy5 levels, in Lung TD2 following nasal administration of a negative control (&#x2014;C) or Exo-ASO-Cy5 (&#x201c;IN&#x201d;) to na&#xef;ve mice or mice were treated with bleomycin to induce pulmonary fibrosis (&#x201c;bleo&#x201d;).</p><p id="p-0063" num="0062"><figref idref="DRAWINGS">FIGS. <b>10</b>A-<b>10</b>H</figref> are images of fluorescent in situ hybridization to detect exosome uptake by normal and induced fibrotic lung tissue.</p><p id="p-0064" num="0063"><figref idref="DRAWINGS">FIGS. <b>11</b>A-<b>11</b>H</figref> are images of in situ hybridization to detect exosome uptake by normal and induced fibrotic lung tissue.</p><p id="p-0065" num="0064"><figref idref="DRAWINGS">FIGS. <b>12</b>A-<b>12</b>B</figref> are images of fluorescent in situ hybridization to detect exosome uptake by lung tissue in Hepa1-6 mice.</p><p id="p-0066" num="0065"><figref idref="DRAWINGS">FIGS. <b>13</b>A-<b>13</b>H</figref> show the anti-tumor activity of exoASO-CEBP/&#x3b2; compared to free CEBP/&#x3b2; ASO, anti-PD1 antibodies, and anti-CSF1R antibodies. <figref idref="DRAWINGS">FIG. <b>13</b>A</figref> shows the timeline of exoASO-CEBP/s, free CEBP/&#x3b2; ASO, anti-PD1 antibody, and anti-CSFIR antibody administration. <figref idref="DRAWINGS">FIG. <b>13</b>B</figref> shows that average tumor growth in mice treated with either exo-ASO-CEBP/s, ASO-CEBP/3, anti-PD1 antibodies, or anti-CSF1R antibodies (n=10 per group). <figref idref="DRAWINGS">FIGS. <b>13</b>C-<b>13</b>H</figref> show individual tumor growth in mice treated with either exo-ASO-CEBP/&#x3b2; (<figref idref="DRAWINGS">FIG. <b>13</b>G</figref>), ASO-CEBP/&#x3b2; (<figref idref="DRAWINGS">FIG. <b>13</b>H</figref>), PBS negative control (<figref idref="DRAWINGS">FIG. <b>13</b>C</figref>), an anti-PD1 antibody (<figref idref="DRAWINGS">FIG. <b>13</b>D</figref>), an anti-CSFIR antibody, and an exoASO-Scramble negative control (<figref idref="DRAWINGS">FIG. <b>13</b>F</figref>), as indicated. CR=number of complete responders.</p><p id="p-0067" num="0066"><figref idref="DRAWINGS">FIG. <b>14</b>A</figref> shows that average tumor growth in mice treated with either exo-ASO-CEBP/s, ASO-CEBP/1, anti-PD-1 antibodies, or anti-CSFIR antibodies. <figref idref="DRAWINGS">FIG. <b>14</b>B</figref> shows the timeline of exoASO-CEBP/s, free CEBP/&#x3b2; ASO, anti-PD-1 antibody, and anti-CSFIR antibody administration.</p><p id="p-0068" num="0067"><figref idref="DRAWINGS">FIGS. <b>15</b>A-<b>15</b>H</figref> show the anti-tumor activity of exoASO-CEBP/&#x3b2; compared to free CEBP/&#x3b2; ASO, anti-PD-1 antibodies, and anti-CSFIR antibodies. <figref idref="DRAWINGS">FIGS. <b>15</b>B-<b>15</b>F</figref> show individual tumor growth in mice treated with either exo-ASO-CEBP/&#x3b2; (<figref idref="DRAWINGS">FIG. <b>15</b>C</figref>), ASO-CEBP/&#x3b2; (<figref idref="DRAWINGS">FIG. <b>15</b>D</figref>), PBS negative control (<figref idref="DRAWINGS">FIG. <b>15</b>A</figref>), an anti-PD-1 antibody (<figref idref="DRAWINGS">FIG. <b>15</b>F</figref>), an anti-CSFIR antibody (<figref idref="DRAWINGS">FIG. <b>15</b>E</figref>), and an exoASO-Scramble negative control (<figref idref="DRAWINGS">FIG. <b>15</b>B</figref>), as indicated. CR=number of complete responders.</p><p id="p-0069" num="0068"><figref idref="DRAWINGS">FIG. <b>16</b></figref> shows the percent survival of the animals post tumor implantation with various treatment groups.</p><p id="p-0070" num="0069"><figref idref="DRAWINGS">FIG. <b>17</b></figref> shows measured tumor volume post tumor implantation for complete responders (CR) upon rechallenge with various treatment groups.</p><p id="p-0071" num="0070"><figref idref="DRAWINGS">FIG. <b>18</b>A</figref> shows CEBP/&#x3b2; and DAPI staining in Hepa 1-6 tumors. <figref idref="DRAWINGS">FIGS. <b>18</b>B-<b>18</b>H</figref> show liver samples of Hepa 1-6 tumors after no treatment (<figref idref="DRAWINGS">FIG. <b>18</b>B</figref>) and treatment with a vehicle control (<figref idref="DRAWINGS">FIG. <b>18</b>F</figref>), CEBP/&#x3b2; Free ASO (<figref idref="DRAWINGS">FIG. <b>18</b>C</figref>), exo-CEBP/&#x3b2; ASO (<figref idref="DRAWINGS">FIGS. <b>18</b>D and <b>18</b>G</figref>), and exo-CEBP/&#x3b2; ASO plus anti-PD-1 antibody (<figref idref="DRAWINGS">FIG. <b>18</b>H</figref>).</p><p id="p-0072" num="0071"><figref idref="DRAWINGS">FIGS. <b>19</b>A-<b>19</b>B</figref> show percent scored lesions after treatment with an anti-PD-1 antibody (<figref idref="DRAWINGS">FIGS. <b>19</b>A and <b>19</b>B</figref>), exo-ASO scramble plus an anti-PD-1 antibody (<figref idref="DRAWINGS">FIG. <b>19</b>B</figref>), exo-CEBP/&#x3b2; ASO (<figref idref="DRAWINGS">FIGS. <b>19</b>A and <b>19</b>B</figref>), exo-CEBP/&#x3b2; ASO plus an anti-PD-1 antibody (<figref idref="DRAWINGS">FIG. <b>19</b>B</figref>), CEBP/&#x3b2;1 Free ASO (<figref idref="DRAWINGS">FIGS. <b>19</b>A and <b>19</b>B</figref>), anti-CSFIR (<figref idref="DRAWINGS">FIGS. <b>19</b>A and <b>19</b>B</figref>), a vehicle control (<figref idref="DRAWINGS">FIG. <b>19</b>B</figref>), and an untreated group (<figref idref="DRAWINGS">FIG. <b>19</b>A</figref>).</p><p id="p-0073" num="0072"><figref idref="DRAWINGS">FIG. <b>19</b>C</figref> shows the normalized expression of mCEBP/&#x3b2;1 following treatment with an anti-PD-1 antibody, exo-ASO scramble plus an anti-PD-1 antibody, exo-CEBP/&#x3b2; ASO, exo-CEBP/&#x3b2; ASO plus an anti-PD-1 antibody, CEBP/&#x3b2; Free ASO, and a vehicle control. <figref idref="DRAWINGS">FIGS. <b>19</b>D and <b>19</b>E</figref> are histology images of tumo tissue following treatment with a vehicle control (<figref idref="DRAWINGS">FIG. <b>19</b>D</figref>) or exo-CEBP/&#x3b2; ASO (<figref idref="DRAWINGS">FIG. <b>19</b>E</figref>).</p><p id="p-0074" num="0073"><figref idref="DRAWINGS">FIG. <b>20</b></figref> shows the ratio of liver weight to body weight as compared to percent scored lesions after treatment with anti-PD-1, exo-CEBP/&#x3b2; ASO, CEBP/&#x3b2;1 Free ASO, anti-CSF1R, and an untreated group.</p><p id="p-0075" num="0074"><figref idref="DRAWINGS">FIGS. <b>21</b>A-<b>21</b>L</figref> are images showing expression of pro-inflammatory M1 markers TNF&#x3b1; (<figref idref="DRAWINGS">FIGS. <b>21</b>A, <b>21</b>E, and <b>21</b>I</figref>), CD11b (<figref idref="DRAWINGS">FIGS. <b>21</b>B, <b>21</b>F, and <b>21</b>J</figref>), INOS (<figref idref="DRAWINGS">FIGS. <b>21</b>C, <b>21</b>G, and <b>21</b>K</figref>), and F4/80 (<figref idref="DRAWINGS">FIGS. <b>21</b>D, <b>21</b>H, and <b>21</b>L</figref>) following injection of exoASO Scramble (<figref idref="DRAWINGS">FIGS. <b>21</b>A-<b>21</b>D</figref>), free CEBP/&#x3b2; ASO (<figref idref="DRAWINGS">FIGS. <b>21</b>E-<b>21</b>H</figref>), or exo-CEBP/&#x3b2; ASO (<figref idref="DRAWINGS">FIGS. <b>21</b>I-<b>21</b>L</figref>).</p><p id="p-0076" num="0075"><figref idref="DRAWINGS">FIGS. <b>22</b>A-<b>22</b>D</figref> are schematic drawings of exemplary CD47-Scaffold X fusion constructs that can be expressed on the extracellular vesicles described herein, along within an ASO targeting a CEBP/&#x3b2; transcript. <figref idref="DRAWINGS">FIG. <b>22</b>A</figref> shows constructs comprising the extracellular domain of wild-type CD47 (with a C15S substitution) fused to either a flag-tagged (1083 and 1084) or non-flag-tagged (1085 and 1086) full length Scaffold X (1083 and 1086) or a truncated Scaffold X (1084 and 1085). <figref idref="DRAWINGS">FIG. <b>22</b>B</figref> shows constructs comprising the extracellular domain of Velcro-CD47 fused to either a flag-tagged (1087 and 1088) or non-flag-tagged (1089 and 1090) full length Scaffold X (1087 and 1090) or a truncated Scaffold X (1088 and 1089). <figref idref="DRAWINGS">FIG. <b>22</b>C</figref> shows constructs wherein the first transmembrane domain of wild-type CD47 (with a C15S substitution; 1127 and 1128) or Velcro-CD47 (1129 and 1130) is replaced with a fragment of Scaffold X, comprising the transmembrane domain and the first extracellular motif of Scaffold X. <figref idref="DRAWINGS">FIG. <b>22</b>D</figref> shows various constructs comprising a minimal &#x201c;self&#x201d; peptide (GNYTCEVTELTREGETIIELK; SEQ ID NO: 628) fused to either a flag-tagged (1158 and 1159) or non-flag-tagged (1160 and 1161) full length Scaffold X (1158 and 1161) or a truncated Scaffold X (1159 and 1160).</p><p id="p-0077" num="0076"><figref idref="DRAWINGS">FIG. <b>23</b></figref> shows the expression of exemplary mouse CD47-Scaffold X fusion constructs that can be expressed on the surface of modified exosomes, along with an ASO targeting a CEBP/&#x3b2; transcript. The constructs comprises the extracellular domain of wild-type murine CD47 (with a C15S substitution) fused to either a flag-tagged (1923 and 1925) or non-flag-tagged (1924 and 1922) full length Scaffold X (1923 and 1922) or a truncated Scaffold X (1925 and 1924).</p><p id="p-0078" num="0077"><figref idref="DRAWINGS">FIG. <b>24</b>A</figref> shows a schematic diagram of exemplary extracellular vesicle (e.g., exosome) targeting Trks using neurotrophin-Scaffold X fusion construct that can be expressed along with an ASO targeting a CEBP/&#x3b2; transcript. Neurotrophins bind to Trk receptors as a homo dimer and allow the EV to target a sensory neuron.</p><p id="p-0079" num="0078"><figref idref="DRAWINGS">FIG. <b>24</b>B</figref> shows a schematic diagram of exemplary extracellular vesicle (e.g., exosome) having (i) neuro-tropism as well as (ii) an anti-phagocytic signal, e.g., CD47 and/or CD24, on the exterior surface of the EV that can be expressed along with (iii) an ASO targeting a CEBP/&#x3b2; transcript.</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0007" level="1">DETAILED DESCRIPTION OF DISCLOSURE</heading><p id="p-0080" num="0079">Certain aspects of the present disclosure are directed to an extracellular vesicle (EV), e.g., an exosome, comprising an antisense oligonucleotide (ASO), wherein the ASO comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within a CEBP/&#x3b2; transcript.</p><heading id="h-0008" level="1">I. Definitions</heading><p id="p-0081" num="0080">In order that the present description can be more readily understood, certain terms are first defined. Additional definitions are set forth throughout the detailed description.</p><p id="p-0082" num="0081">It is to be noted that the term &#x201c;a&#x201d; or &#x201c;an&#x201d; entity refers to one or more of that entity; for example, &#x201c;a nucleotide sequence,&#x201d; is understood to represent one or more nucleotide sequences. As such, the terms &#x201c;a&#x201d; (or &#x201c;an&#x201d;), &#x201c;one or more,&#x201d; and &#x201c;at least one&#x201d; can be used interchangeably herein.</p><p id="p-0083" num="0082">Furthermore, &#x201c;and/or&#x201d; where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. Thus, the term &#x201c;and/or&#x201d; as used in a phrase such as &#x201c;A and/or B&#x201d; herein is intended to include &#x201c;A and B,&#x201d; &#x201c;A or B,&#x201d; &#x201c;A&#x201d; (alone), and &#x201c;B&#x201d; (alone). Likewise, the term &#x201c;and/or&#x201d; as used in a phrase such as &#x201c;A, B, and/or C&#x201d; is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).</p><p id="p-0084" num="0083">It is understood that wherever aspects are described herein with the language &#x201c;comprising,&#x201d; otherwise analogous aspects described in terms of &#x201c;consisting of&#x201d; and/or &#x201c;consisting essentially of&#x201d; are also provided.</p><p id="p-0085" num="0084">Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure is related. For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and the Oxford Dictionary Of Biochemistry And Molecular Biology, Revised, 2000, Oxford University Press, provide one of skill with a general dictionary of many of the terms used in this disclosure.</p><p id="p-0086" num="0085">Units, prefixes, and symbols are denoted in their Systeme International de Unites (SI) accepted form. Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, nucleotide sequences are written left to right in 5&#x2032; to 3&#x2032; orientation. Amino acid sequences are written left to right in amino to carboxy orientation. The headings provided herein are not limitations of the various aspects of the disclosure, which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification in its entirety.</p><p id="p-0087" num="0086">The term &#x201c;about&#x201d; is used herein to mean approximately, roughly, around, or in the regions of. When the term &#x201c;about&#x201d; is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term &#x201c;about&#x201d; can modify a numerical value above and below the stated value by a variance of, e.g., 10 percent, up or down (higher or lower). For example, if it is stated that &#x201c;the ASO reduces expression of CEBP/&#x3b2; protein in a cell following administration of the ASO by at least about 60%,&#x201d; it is implied that the CEBP/&#x3b2; levels are reduced by a range of 50% to 70%.</p><p id="p-0088" num="0087">The term &#x201c;antisense oligonucleotide&#x201d; (ASO) refers to an oligomer or polymer of nucleosides, such as naturally-occurring nucleosides or modified forms thereof, that are covalently linked to each other through intemucleotide linkages. The ASO useful for the disclosure includes at least one non-naturally occurring nucleoside. An ASO is at least partially complementary to a target nucleic acid, such that the ASO hybridizes to the target nucleic acid sequence.</p><p id="p-0089" num="0088">The term &#x201c;nucleic acids&#x201d; or &#x201c;nucleotides&#x201d; is intended to encompass plural nucleic acids. In some aspects, the term &#x201c;nucleic acids&#x201d; or &#x201c;nucleotides&#x201d; refers to a target sequence, e.g., pre-mRNAs, mRNAs, or DNAs in vivo or in vitro. When the term refers to the nucleic acids or nucleotides in a target sequence, the nucleic acids or nucleotides can be naturally occurring sequences within a cell. In other aspects, &#x201c;nucleic acids&#x201d; or &#x201c;nucleotides&#x201d; refer to a sequence in the ASOs of the disclosure. When the term refers to a sequence in the ASOs, the nucleic acids or nucleotides can be non-naturally occurring, i.e., chemically synthesized, enzymatically produced, recombinantly produced, or any combination thereof. In some aspects, the nucleic acids or nucleotides in the ASOs are produced synthetically or recombinantly, but are not a naturally occurring sequence or a fragment thereof. In some aspects, the nucleic acids or nucleotides in the ASOs are not naturally occurring because they contain at least one nucleoside analog that is not naturally occurring in nature.</p><p id="p-0090" num="0089">The term &#x201c;nucleotide&#x201d; as used herein, refers to a glycoside comprising a sugar moiety, a base moiety and a covalently linked group (linkage group), such as a phosphate or phosphorothioate intemucleotide linkage group, and covers both naturally occurring nucleotides, such as DNA or RNA, and non-naturally occurring nucleotides comprising modified sugar and/or base moieties, which are also referred to as &#x201c;nucleotide analogs&#x201d; herein. Herein, a single nucleotide can be referred to as a monomer or unit. In certain aspects, the term &#x201c;nucleotide analogs&#x201d; refers to nucleotides having modified sugar moieties. Non-limiting examples of the nucleotides having modified sugar moieties (e.g., LNA) are disclosed elsewhere herein. In other aspects, the term &#x201c;nucleotide analogs&#x201d; refers to nucleotides having modified nucleobase moieties. The nucleotides having modified nucleobase moieties include, but are not limited to, 5-methyl-cytosine, isocytosine, pseudoisocytosine, 5-bromouracil, 5-propynyluracil, 6-aminopurine, 2-aminopurine, inosine, diaminopurine, and 2-chloro-6-aminopurine. In some aspects, the terms &#x201c;nucleotide&#x201d;, &#x201c;unit&#x201d; and &#x201c;monomer&#x201d; are used interchangeably. It will be recognized that when referring to a sequence of nucleotides or monomers, what is referred to is the sequence of bases, such as A, T, G, C or U, and analogs thereof.</p><p id="p-0091" num="0090">The term &#x201c;nucleoside&#x201d; as used herein is used to refer to a glycoside comprising a sugar moiety and a base moiety, and can therefore be used when referring to the nucleotide units, which are covalently linked by the internucleotide linkages between the nucleotides of the ASO. In the field of biotechnology, the term &#x201c;nucleotide&#x201d; is often used to refer to a nucleic acid monomer or unit. In the context of an ASO, the term &#x201c;nucleotide&#x201d; can refer to the base alone, i.e., a nucleobase sequence comprising cytosine (DNA and RNA), guanine (DNA and RNA), adenine (DNA and RNA), thymine (DNA) and uracil (RNA), in which the presence of the sugar backbone and internucleotide linkages are implicit. Likewise, particularly in the case of oligonucleotides where one or more of the internucleotide linkage groups are modified, the term &#x201c;nucleotide&#x201d; can refer to a &#x201c;nucleoside.&#x201d; For example the term &#x201c;nucleotide&#x201d; can be used, even when specifying the presence or nature of the linkages between the nucleosides.</p><p id="p-0092" num="0091">The term &#x201c;nucleotide length&#x201d; as used herein means the total number of the nucleotides (monomers) in a given sequence. For example, the sequence of ASO-CEBP/&#x3b2;-540 (SEQ ID NO: 194) has 15 nucleotides; thus the nucleotide length of the sequence is 15. The term &#x201c;nucleotide length&#x201d; is therefore used herein interchangeably with &#x201c;nucleotide number.&#x201d;</p><p id="p-0093" num="0092">As one of ordinary skill in the art would recognize, the 5&#x2032; terminal nucleotide of an oligonucleotide does not comprise a 5&#x2032; intemucleotide linkage group, although it can comprise a 5&#x2032; terminal group.</p><p id="p-0094" num="0093">The compounds described herein can contain several asymmetric centers and can be present in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates. In some aspects, the asymmetric center can be an asymmetric carbon atom. The term &#x201c;asymmetric carbon atom&#x201d; means a carbon atom with four different substituents. According to the Cahn-Ingold-Prelog Convention an asymmetric carbon atom can be of the &#x201c;R&#x201d; or &#x201c;S&#x201d; configuration.</p><p id="p-0095" num="0094">As used herein, the term &#x201c;bicyclic sugar&#x201d; refers to a modified sugar moiety comprising a 4 to 7 membered ring comprising a bridge connecting two atoms of the 4 to 7 membered ring to form a second ring, resulting in a bicyclic structure. In some aspects, the bridge connects the C2 and C4&#x2032; of the ribose sugar ring of a nucleoside (i.e., 2&#x2032;-4&#x2032; bridge), as observed in LNA nucleosides.</p><p id="p-0096" num="0095">As used herein, a &#x201c;coding region&#x201d; or &#x201c;coding sequence&#x201d; is a portion of polynucleotide which consists of codons translatable into amino acids. Although a &#x201c;stop codon&#x201d; (TAG, TGA, or TAA) is typically not translated into an amino acid, it can be considered to be part of a coding region, but any flanking sequences, for example promoters, ribosome binding sites, transcriptional terminators, introns, untranslated regions (&#x201c;UTRs&#x201d;), and the like, are not part of a coding region. The boundaries of a coding region are typically determined by a start codon at the 5&#x2032; terminus, encoding the amino terminus of the resultant polypeptide, and a translation stop codon at the 3&#x2032; terminus, encoding the carboxyl terminus of the resulting polypeptide.</p><p id="p-0097" num="0096">The term &#x201c;non-coding region&#x201d; as used herein means a nucleotide sequence that is not a coding region. Examples of non-coding regions include, but are not limited to, promoters, ribosome binding sites, transcriptional terminators, introns, untranslated regions (&#x201c;UTRs&#x201d;), non-coding exons and the like. Some of the exons can be wholly or part of the 5&#x2032; untranslated region (5&#x2032; UTR) or the 3&#x2032; untranslated region (3&#x2032; UTR) of each transcript. The untranslated regions are important for efficient translation of the transcript and for controlling the rate of translation and half-life of the transcript.</p><p id="p-0098" num="0097">The term &#x201c;region&#x201d; when used in the context of a nucleotide sequence refers to a section of that sequence. For example, the phrase &#x201c;region within a nucleotide sequence&#x201d; or &#x201c;region within the complement of a nucleotide sequence&#x201d; refers to a sequence shorter than the nucleotide sequence, but longer than at least 10 nucleotides located within the particular nucleotide sequence or the complement of the nucleotides sequence, respectively. The term &#x201c;sub-sequence&#x201d; or &#x201c;subsequence&#x201d; can also refer to a region of a nucleotide sequence.</p><p id="p-0099" num="0098">The term &#x201c;downstream,&#x201d; when referring to a nucleotide sequence, means that a nucleic acid or a nucleotide sequence is located 3&#x2032; to a reference nucleotide sequence. In certain aspects, downstream nucleotide sequences relate to sequences that follow the starting point of transcription. For example, the translation initiation codon of a gene is located downstream of the start site of transcription.</p><p id="p-0100" num="0099">The term &#x201c;upstream&#x201d; refers to a nucleotide sequence that is located 5&#x2032; to a reference nucleotide sequence.</p><p id="p-0101" num="0100">As used herein, the term &#x201c;regulatory region&#x201d; refers to nucleotide sequences located upstream (5&#x2032; non-coding sequences), within, or downstream (3&#x2032; non-coding sequences) of a coding region, and which influence the transcription, RNA processing, stability, or translation of the associated coding region. Regulatory regions can include promoters, translation leader sequences, introns, polyadenylation recognition sequences, RNA processing sites, effector binding sites, UTRs, and stem-loop structures. If a coding region is intended for expression in a eukaryotic cell, a polyadenylation signal and transcription termination sequence will usually be located 3&#x2032; to the coding sequence.</p><p id="p-0102" num="0101">The term &#x201c;transcript&#x201d; as used herein can refer to a primary transcript that is synthesized by transcription of DNA and becomes a messenger RNA (mRNA) after processing, i.e., a precursor messenger RNA (pre-mRNA), and the processed mRNA itself. The term &#x201c;transcript&#x201d; can be interchangeably used with &#x201c;pre-mRNA&#x201d; and &#x201c;mRNA.&#x201d; After DNA strands are transcribed to primary transcripts, the newly synthesized primary transcripts are modified in several ways to be converted to their mature, functional forms to produce different proteins and RNAs, such as mRNA, tRNA, rRNA, lncRNA, miRNA and others. Thus, the term &#x201c;transcript&#x201d; can include exons, introns, 5&#x2032; UTRs, and 3&#x2032; UTRs.</p><p id="p-0103" num="0102">The term &#x201c;expression&#x201d; as used herein refers to a process by which a polynucleotide produces a gene product, for example, a RNA or a polypeptide. It includes, without limitation, transcription of the polynucleotide into messenger RNA (mRNA) and the translation of an mRNA into a polypeptide. Expression produces a &#x201c;gene product.&#x201d; As used herein, a gene product can be either a nucleic acid, e.g., a messenger RNA produced by transcription of a gene, or a polypeptide which is translated from a transcript. Gene products described herein further include nucleic acids with post transcriptional modifications, e.g., polyadenylation or splicing, or polypeptides with post translational modifications, e.g., methylation, glycosylation, the addition of lipids, association with other protein subunits, or proteolytic cleavage.</p><p id="p-0104" num="0103">The terms &#x201c;identical&#x201d; or percent &#x201c;identity&#x201d; in the context of two or more nucleic acids refer to two or more sequences that are the same or have a specified percentage of nucleotides or amino acid residues that are the same, when compared and aligned (introducing gaps, if necessary) for maximum correspondence, not considering any conservative amino acid substitutions as part of the sequence identity. The percent identity can be measured using sequence comparison software or algorithms or by visual inspection. Various algorithms and software are known in the art that can be used to obtain alignments of amino acid or nucleotide sequences.</p><p id="p-0105" num="0104">One such non-limiting example of a sequence alignment algorithm is the algorithm described in Karlin et al., 1990<i>, Proc. Natl. Acad. Sci., </i>87:2264-2268, as modified in Karlin et al., 1993<i>, Proc. Natl. Acad. Sci., </i>90:5873-5877, and incorporated into the NBLAST and XBLAST programs (Altschul et al., 1991<i>, Nucleic Acids Res., </i>25:3389-3402). In certain aspects, Gapped BLAST can be used as described in Altschul et al., 1997<i>, Nucleic Acids Res. </i>25:3389-3402. BLAST-2, WU-BLAST-2 (Altschul et al., 1996<i>, Methods in Enzymology, </i>266:460-480), ALIGN, ALIGN-2 (Genentech, South San Francisco, Calif.) or Megalign (DNASTAR) are additional publicly available software programs that can be used to align sequences. In certain aspects, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (e.g., using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 90 and a length weight of 1, 2, 3, 4, 5, or 6). In certain alternative aspects, the GAP program in the GCG software package, which incorporates the algorithm of Needleman and Wunsch (<i>J. Mol. Biol</i>. (48):444-453 (1970)) can be used to determine the percent identity between two amino acid sequences (e.g., using either a BLOSUM 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5). Alternatively, in certain aspects, the percent identity between nucleotide or amino acid sequences is determined using the algorithm of Myers and Miller (CABIOS, 4:11-17 (1989)). For example, the percent identity can be determined using the ALIGN program (version 2.0) and using a PAM120 with residue table, a gap length penalty of 12 and a gap penalty of 4. One skilled in the art can determine appropriate parameters for maximal alignment by particular alignment software. In certain aspects, the default parameters of the alignment software are used.</p><p id="p-0106" num="0105">In certain aspects, the percentage identity &#x201c;X&#x201d; of a first nucleotide sequence to a second nucleotide sequence is calculated as 100&#xd7;(Y/Z), where Y is the number of amino acid residues scored as identical matches in the alignment of the first and second sequences (as aligned by visual inspection or a particular sequence alignment program) and Z is the total number of residues in the second sequence. If the length of a first sequence is longer than the second sequence, the percent identity of the first sequence to the second sequence will be higher than the percent identity of the second sequence to the first sequence.</p><p id="p-0107" num="0106">Different regions within a single polynucleotide target sequence that align with a polynucleotide reference sequence can each have their own percent sequence identity. It is noted that the percent sequence identity value is rounded to the nearest tenth. For example, 80.11, 80.12, 80.13, and 80.14 are rounded down to 80.1, while 80.15, 80.16, 80.17, 80.18, and 80.19 are rounded up to 80.2. It also is noted that the length value will always be an integer.</p><p id="p-0108" num="0107">As used herein, the terms &#x201c;homologous&#x201d; and &#x201c;homology&#x201d; are interchangeable with the terms &#x201c;identity&#x201d; and &#x201c;identical.&#x201d;</p><p id="p-0109" num="0108">The term &#x201c;naturally occurring variant thereof&#x201d; refers to variants of the CEBP/&#x3b2; polypeptide sequence or CEBP/&#x3b2; nucleic acid sequence (e.g., transcript) which exist naturally within the defined taxonomic group, such as mammalian, such as mouse, monkey, and human. Typically, when referring to &#x201c;naturally occurring variants&#x201d; of a polynucleotide the term also can encompass any allelic variant of the CEBP/&#x3b2;-encoding genomic DNA which is found at Chromosomal position 1q44 at 247,416,156-247,449,108 (i.e., nucleotides 247,416,156-247,449,108 of GenBank Accession No. NC_000001.11) by chromosomal translocation or duplication, and the RNA, such as mRNA derived therefrom. &#x201c;Naturally occurring variants&#x201d; can also include variants derived from alternative splicing of the CEBP/&#x3b2; mRNA. When referenced to a specific polypeptide sequence, e.g., the term also includes naturally occurring forms of the protein, which can therefore be processed, e.g., by co- or post-translational modifications, such as signal peptide cleavage, proteolytic cleavage, glycosylation, etc.</p><p id="p-0110" num="0109">In determining the degree of &#x201c;complementarity&#x201d; between the ASOs of the disclosure (or regions thereof) and the target region of the nucleic acid which encodes mammalian CEBP/&#x3b2; (e.g., the CEBP/&#x3b2; gene), such as those disclosed herein, the degree of &#x201c;complementarity&#x201d; (also, &#x201c;homology&#x201d; or &#x201c;identity&#x201d;) is expressed as the percentage identity (or percentage homology) between the sequence of the ASO (or region thereof) and the sequence of the target region (or the reverse complement of the target region) that best aligns therewith. The percentage is calculated by counting the number of aligned bases that are identical between the two sequences, dividing by the total number of contiguous monomers in the ASO, and multiplying by 100. In such a comparison, if gaps exist, it is preferable that such gaps are merely mismatches rather than areas where the number of monomers within the gap differs between the ASO of the disclosure and the target region.</p><p id="p-0111" num="0110">The term &#x201c;complement&#x201d; as used herein indicates a sequence that is complementary to a reference sequence. It is well known that complementarity is the base principle of DNA replication and transcription as it is a property shared between two DNA or RNA sequences, such that when they are aligned antiparallel to each other, the nucleotide bases at each position in the sequences will be complementary, much like looking in the mirror and seeing the reverse of things. Therefore, for example, the complement of a sequence of 5&#x2032;&#x2033;ATGC&#x2033;3&#x2032; can be written as 3&#x2032;&#x2033;TACG&#x2033;5&#x2032; or 5&#x2032;&#x2033;GCAT&#x2033;3&#x2032;. The terms &#x201c;reverse complement&#x201d;, &#x201c;reverse complementary&#x201d;, and &#x201c;reverse complementarity&#x201d; as used herein are interchangeable with the terms &#x201c;complement&#x201d;, &#x201c;complementary&#x201d;, and &#x201c;complementarity.&#x201d; In some aspects, the term &#x201c;complementary&#x201d; refers to 100% match or complementarity (i.e., fully complementary) to a contiguous nucleic acid sequence within a CEBP/&#x3b2; transcript. In some aspects, the term &#x201c;complementary&#x201d; refers to at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% match or complementarity to a contiguous nucleic acid sequence within a CEBP/&#x3b2; transcript.</p><p id="p-0112" num="0111">The terms &#x201c;corresponding to&#x201d; and &#x201c;corresponds to,&#x201d; when referencing two separate nucleic acid or nucleotide sequences can be used to clarify regions of the sequences that correspond or are similar to each other based on homology and/or functionality, although the nucleotides of the specific sequences can be numbered differently. For example, different isoforms of a gene transcript can have similar or conserved portions of nucleotide sequences whose numbering can differ in the respective isoforms based on alternative splicing and/or other modifications. In addition, it is recognized that different numbering systems can be employed when characterizing a nucleic acid or nucleotide sequence (e.g., a gene transcript and whether to begin numbering the sequence from the translation start codon or to include the 5&#x2032;UTR). Further, it is recognized that the nucleic acid or nucleotide sequence of different variants of a gene or gene transcript can vary. As used herein, however, the regions of the variants that share nucleic acid or nucleotide sequence homology and/or functionality are deemed to &#x201c;correspond&#x201d; to one another. For example, a nucleotide sequence of a CEBP/&#x3b2; transcript corresponding to nucleotides X to Y of SEQ ID NO: 1 (&#x201c;reference sequence&#x201d;) refers to an CEBP/&#x3b2; transcript sequence (e.g., CEBP/&#x3b2; pre-mRNA or mRNA) that has an identical sequence or a similar sequence to nucleotides X to Y of SEQ ID NO: 1, wherein X is the start site and Y is the end site (as shown in <figref idref="DRAWINGS">FIG. <b>1</b></figref>). A person of ordinary skill in the art can identify the corresponding X and Y residues in the CEBP/&#x3b2; transcript sequence by aligning the CEBP/&#x3b2; transcript sequence with SEQ ID NO: 1.</p><p id="p-0113" num="0112">The terms &#x201c;corresponding nucleotide analog&#x201d; and &#x201c;corresponding nucleotide&#x201d; are intended to indicate that the nucleobase in the nucleotide analog and the naturally occurring nucleotide have the same pairing, or hybridizing, ability. For example, when the 2-deoxyribose unit of the nucleotide is linked to an adenine, the &#x201c;corresponding nucleotide analog&#x201d; contains a pentose unit (different from 2-deoxyribose) linked to an adenine.</p><p id="p-0114" num="0113">The annotation of ASO chemistry is as follows Beta-D-oxy LNA nucleotides are designated by OxyB where B designates a nucleotide base such as thymine (T), uridine (U), cytosine (C), 5-methylcytosine (MC), adenine (A) or guanine (G), and thus include OxyA, OxyT, OxyMC, OxyC and OxyG. DNA nucleotides are designated by DNAb, where the lower case b designates a nucleotide base such as thymine (T), uridine (U), cytosine (C), 5-methylcytosine (Mc), adenine (A) or guanine (G), and thus include DNAa, DNAt, DNA and DNAg. The letter M before C or c indicates 5-methylcytosine. The letter &#x201c;s&#x201d; indicates a phosphorothioate intemucleotide linkage.</p><p id="p-0115" num="0114">The term &#x201c;ASO Number&#x201d; or &#x201c;ASO No.&#x201d; as used herein refers to a unique number given to a nucleotide sequence having the detailed chemical structure of the components, e.g., nucleosides (e.g., DNA), nucleoside analogs (e.g., beta-D-oxy-LNA), nucleobase (e.g., A, T, G, C, U, or MC), and backbone structure (e.g., phosphorothioate or phosphorodiester). For example, ASO-CEBP/&#x3b2;-540 can refer to CEBP/&#x3b2;-540 (SEQ ID NO: 194).</p><p id="p-0116" num="0115">&#x201c;Potency&#x201d; is normally expressed as an IC<sub>50 </sub>or EC<sub>50 </sub>value, in &#x3bc;M, nM or pM unless otherwise stated. Potency can also be expressed in terms of percent inhibition. IC<sub>50 </sub>is the median inhibitory concentration of a therapeutic molecule. EC<sub>50 </sub>is the median effective concentration of a therapeutic molecule relative to a vehicle or control (e.g., saline). In functional assays, IC<sub>50 </sub>is the concentration of a therapeutic molecule that reduces a biological response, e.g., transcription of mRNA or protein expression, by 50% of the biological response that is achieved by the therapeutic molecule. In functional assays, ECs is the concentration of a therapeutic molecule that produces 50% of the biological response, e.g., transcription of mRNA or protein expression. IC<sub>50 </sub>or EC<sub>50 </sub>can be calculated by any number of means known in the art.</p><p id="p-0117" num="0116">As used herein, the term &#x201c;inhibiting,&#x201d; e.g., the expression of CEBP/&#x3b2; gene transcript and/or CEBP/&#x3b2; protein refers to the ASO reducing the expression of the CEBP/&#x3b2; gene transcript and/or CEBP/&#x3b2; protein in a cell or a tissue. In some aspects, the term &#x201c;inhibiting&#x201d; refers to complete inhibition (100% inhibition or non-detectable level) of CEBP/&#x3b2; gene transcript or CEBP/&#x3b2; protein. In other aspects, the term &#x201c;inhibiting&#x201d; refers to at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or at least 99% inhibition of CEBP/&#x3b2; gene transcript and/or CEBP/&#x3b2; protein expression in a cell or a tissue.</p><p id="p-0118" num="0117">As used herein, the term &#x201c;extracellular vesicle&#x201d; or &#x201c;EV&#x201d; refers to a cell-derived vesicle comprising a membrane that encloses an internal space. Extracellular vesicles comprise all membrane-bound vesicles (e.g., exosomes, nanovesicles) that have a smaller diameter than the cell from which they are derived. In some aspects, extracellular vesicles range in diameter from 20 nm to 1000 nm, and can comprise various macromolecular payload either within the internal space (i.e., lumen), displayed on the external surface of the extracellular vesicle, and/or spanning the membrane. In some aspects, the payload can comprise nucleic acids, proteins, carbohydrates, lipids, small molecules, and/or combinations thereof. In certain aspects, an extracellular vehicle comprises a scaffold moiety. By way of example and without limitation, extracellular vesicles include apoptotic bodies, fragments of cells, vesicles derived from cells by direct or indirect manipulation (e.g., by serial extrusion or treatment with alkaline solutions), vesiculated organelles, and vesicles produced by living cells (e.g., by direct plasma membrane budding or fusion of the late endosome with the plasma membrane). Extracellular vesicles can be derived from a living or dead organism, explanted tissues or organs, prokaryotic or eukaryotic cells, and/or cultured cells. In some aspects, the extracellular vesicles are produced by cells that express one or more transgene products.</p><p id="p-0119" num="0118">As used herein, the term &#x201c;exosome&#x201d; refers to an extracellular vesicle with a diameter between 20-300 nm (e.g., between 40-200 nm). Exosomes comprise a membrane that encloses an internal space (i.e., lumen), and, in some aspects, can be generated from a cell (e.g., producer cell) by direct plasma membrane budding or by fusion of the late endosome with the plasma membrane. In certain aspects, an exosome comprises a scaffold moiety. As described infra, exosome can be derived from a producer cell, and isolated from the producer cell based on its size, density, biochemical parameters, or a combination thereof. In some aspects, the EVs, e.g., exosomes, of the present disclosure are produced by cells that express one or more transgene products.</p><p id="p-0120" num="0119">As used herein, the term &#x201c;nanovesicle&#x201d; refers to an extracellular vesicle with a diameter between 20-250 nm (e.g., between 30-150 nm) and is generated from a cell (e.g., producer cell) by direct or indirect manipulation such that the nanovesicle would not be produced by the cell without the manipulation. Appropriate manipulations of the cell to produce the nanovesicles include but are not limited to serial extrusion, treatment with alkaline solutions, sonication, or combinations thereof. In some aspects, production of nanovesicles can result in the destruction of the producer cell. In some aspects, population of nanovesicles described herein are substantially free of vesicles that are derived from cells by way of direct budding from the plasma membrane or fusion of the late endosome with the plasma membrane. In certain aspects, a nanovesicle comprises a scaffold moiety. Nanovesicles, once derived from a producer cell, can be isolated from the producer cell based on its size, density, biochemical parameters, or a combination thereof.</p><p id="p-0121" num="0120">As used herein the term &#x201c;surface-engineered EVs, e.g., exosomes&#x201d; (e.g., Scaffold X-engineered EVs, e.g., exosomes) refers to an EV, e.g., exosome, with the membrane or the surface of the EV, e.g., exosome, modified in its composition so that the surface of the engineered EV, e.g., exosome, is different from that of the EV, e.g., exosome, prior to the modification or of the naturally occurring EV, e.g., exosome. The engineering can be on the surface of the EV, e.g., exosome, or in the membrane of the EV, e.g., exosome, so that the surface of the EV, e.g., exosome, is changed. For example, the membrane is modified in its composition of a protein, a lipid, a small molecule, a carbohydrate, etc. The composition can be changed by a chemical, a physical, or a biological method or by being produced from a cell previously or concurrently modified by a chemical, a physical, or a biological method. Specifically, the composition can be changed by a genetic engineering or by being produced from a cell previously modified by genetic engineering. In some aspects, a surface-engineered EV, e.g., exosome, comprises an exogenous protein (i.e., a protein that the EV, e.g., exosome, does not naturally express) or a fragment or variant thereof that can be exposed to the surface of the EV, e.g., exosome, or can be an anchoring point (attachment) for a moiety exposed on the surface of the EV, e.g., exosome. In other aspects, a surface-engineered EV, e.g., exosome, comprises a higher expression (e.g., higher number) of a natural exosome protein (e.g., Scaffold X) or a fragment or variant thereof that can be exposed to the surface of the EV, e.g., exosome, or can be an anchoring point (attachment) for a moiety exposed on the surface of the EV, e.g., exosome.</p><p id="p-0122" num="0121">As used herein the term &#x201c;lumen-engineered exosome&#x201d; (e.g., Scaffold Y-engineered exosome) refers to an EV, e.g., exosome, with the membrane or the lumen of the EV, e.g., exosome, modified in its composition so that the lumen of the engineered EV, e.g., exosome, is different from that of the EV, e.g., exosome, prior to the modification or of the naturally occurring EV, e.g., exosome. The engineering can be directly in the lumen or in the membrane of the EV, e.g., exosome so that the lumen of the EV, e.g., exosome is changed. For example, the membrane is modified in its composition of a protein, a lipid, a small molecule, a carbohydrate, etc. so that the lumen of the EV, e.g., exosome is modified. The composition can be changed by a chemical, a physical, or a biological method or by being produced from a cell previously modified by a chemical, a physical, or a biological method. Specifically, the composition can be changed by a genetic engineering or by being produced from a cell previously modified by genetic engineering. In some aspects, a lumen-engineered exosome comprises an exogenous protein (i.e., a protein that the EV, e.g., exosome does not naturally express) or a fragment or variant thereof that can be exposed in the lumen of the EV, e.g., exosome or can be an anchoring point (attachment) for a moiety exposed on the inner layer of the EV, e.g., exosome. In other aspects, a lumen-engineered EV, e.g., exosome, comprises a higher expression of a natural exosome protein (e.g., Scaffold X or Scaffold Y) or a fragment or variant thereof that can be exposed to the lumen of the exosome or can be an anchoring point (attachment) for a moiety exposed in the lumen of the exosome.</p><p id="p-0123" num="0122">The term &#x201c;modified,&#x201d; when used in the context of EVs, e.g., exosomes described herein, refers to an alteration or engineering of an EV, e.g., exosome and/or its producer cell, such that the modified EV, e.g., exosome is different from a naturally-occurring EV, e.g., exosome. In some aspects, a modified EV, e.g., exosome described herein comprises a membrane that differs in composition of a protein, a lipid, a small molecular, a carbohydrate, etc. compared to the membrane of a naturally-occurring EV, e.g., exosome (e.g., membrane comprises higher density or number of natural exosome proteins and/or membrane comprises proteins that are not naturally found in exosomes (e.g., an ASO). In certain aspects, such modifications to the membrane changes the exterior surface of the EV, e.g., exosome (e.g., surface-engineered EVs, e.g., exosomes described herein). In certain aspects, such modifications to the membrane changes the lumen of the EV, e.g., exosome (e.g., lumen-engineered EVs, e.g., exosomes described herein).</p><p id="p-0124" num="0123">As used herein, the term &#x201c;scaffold moiety&#x201d; refers to a molecule that can be used to anchor a payload or any other compound of interest (e.g., an ASO) to the EV, e.g., exosome either on the luminal surface or on the exterior surface of the EV, e.g., exosome. In certain aspects, a scaffold moiety comprises a synthetic molecule. In some aspects, a scaffold moiety comprises a non-polypeptide moiety. In other aspects, a scaffold moiety comprises a lipid, carbohydrate, or protein that naturally exists in the EV, e.g., exosome. In some aspects, a scaffold moiety comprises a lipid, carbohydrate, or protein that does not naturally exist in the EV, e.g., exosome. In certain aspects, a scaffold moiety is Scaffold X. In some aspects, a scaffold moiety is Scaffold Y. In further aspects, a scaffold moiety comprises both Scaffold X and Scaffold Y. Non-limiting examples of other scaffold moieties that can be used with the present disclosure include: aminopeptidase N (CD13); Neprilysin, AKA membrane metalloendopeptidase (MME); ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1); Neuropilin-1 (NRP1); CD9, CD63, CD81, PDGFR, GPI anchor proteins, lactadherin (MFGE8), LAMP2, and LAMP2B.</p><p id="p-0125" num="0124">As used herein, the term &#x201c;Scaffold X&#x201d; refers to exosome proteins that have recently been identified on the surface of exosomes. See, e.g., U.S. Pat. No. 10,195,290, which is incorporated herein by reference in its entirety. Non-limiting examples of Scaffold X proteins include: prostaglandin F2 receptor negative regulator (&#x201c;the PTGFRN protein&#x201d;); basigin (&#x201c;the BSG protein&#x201d;); immunoglobulin superfamily member 2 (&#x201c;the IGSF2 protein&#x201d;); immunoglobulin superfamily member 3 (&#x201c;the IGSF3 protein&#x201d;); immunoglobulin superfamily member 8 (&#x201c;the IGSF8 protein&#x201d;); integrin beta-1 (&#x201c;the ITGB1 protein); integrin alpha-4 (&#x201c;the ITGA4 protein&#x201d;); 4F2 cell-surface antigen heavy chain (&#x201c;the SLC3A2 protein&#x201d;); a class of ATP transporter proteins (&#x201c;the ATP1A1 protein,&#x201d; &#x201c;the ATP1A2 protein,&#x201d; &#x201c;the ATP1A3 protein,&#x201d; &#x201c;the ATP1A4 protein,&#x201d; &#x201c;the ATP1B3 protein,&#x201d; &#x201c;the ATP2B1 protein,&#x201d; &#x201c;the ATP2B2 protein,&#x201d; &#x201c;the ATP2B3 protein,&#x201d; &#x201c;the ATP2B protein&#x201d;); and a functional fragment thereof. In some aspects, a Scaffold X protein can be a whole protein or a fragment thereof (e.g., functional fragment, e.g., the smallest fragment that is capable of anchoring another moiety on the exterior surface or on the luminal surface of the EV, e.g., exosome). In some aspects, a Scaffold X can anchor a moiety (e.g., an ASO) to the external surface or the luminal surface of the exosome.</p><p id="p-0126" num="0125">As used herein, the term &#x201c;Scaffold Y&#x201d; refers to exosome proteins that were newly identified within the lumen of exosomes. See, e.g., International Publ. No. WO/2019/099942, which is incorporated herein by reference in its entirety. Non-limiting examples of Scaffold Y proteins include: myristoylated alanine rich Protein Kinase C substrate (&#x201c;the MARCKS protein&#x201d;); myristoylated alanine rich Protein Kinase C substrate like 1 (&#x201c;the MARCKSL1 protein&#x201d;); and brain acid soluble protein 1 (&#x201c;the BASP1 protein&#x201d;). In some aspects, a Scaffold Y protein can be a whole protein or a fragment thereof (e.g., functional fragment, e.g., the smallest fragment that is capable of anchoring a moiety to the luminal surface of the exosome). In some aspects, a Scaffold Y can anchor a moiety (e.g., an ASO) to the luminal surface of the EV, e.g., exosome. In some aspects, a Scaffold Y can anchor a moiety (e.g., an ASO) to the exterior surface of the EV, e.g., exosome.</p><p id="p-0127" num="0126">As used herein, the term &#x201c;fragment&#x201d; of a protein (e.g., therapeutic protein, Scaffold X, or Scaffold Y) refers to an amino acid sequence of a protein that is shorter than the naturally-occurring sequence, N- and/or C-terminally deleted or any part of the protein deleted in comparison to the naturally occurring protein. As used herein, the term &#x201c;functional fragment&#x201d; refers to a protein fragment that retains protein function. Accordingly, in some aspects, a functional fragment of a Scaffold X protein retains the ability to anchor a moiety on the luminal surface or on the exterior surface of the EV, e.g., exosome. Similarly, in certain aspects, a functional fragment of a Scaffold Y protein retains the ability to anchor a moiety on the luminal surface or exterior surface of the EV, e.g., exosome. Whether a fragment is a functional fragment can be assessed by any art known methods to determine the protein content of EVs, e.g., exosomes including Western Blots, FACS analysis and fusions of the fragments with autofluorescent proteins like, e.g., GFP. In certain aspects, a functional fragment of a Scaffold X protein retains at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 100% of the ability, e.g., an ability to anchor a moiety, of the naturally occurring Scaffold X protein. In some aspects, a functional fragment of a Scaffold Y protein retains at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 100% of the ability, e.g., an ability to anchor another molecule, of the naturally occurring Scaffold Y protein.</p><p id="p-0128" num="0127">As used herein, the term &#x201c;variant&#x201d; of a molecule (e.g., functional molecule, antigen, Scaffold X and/or Scaffold Y) refers to a molecule that shares certain structural and functional identities with another molecule upon comparison by a method known in the art. For example, a variant of a protein can include a substitution, insertion, deletion, frameshift or rearrangement in another protein.</p><p id="p-0129" num="0128">In some aspects, a variant of a Scaffold X comprises a variant having at least about 70% identity to the full-length, mature PTGFRN, BSG, IGSF2, IGSF3, IGSF8, ITGB1, ITGA4, SLC3A2, or ATP transporter proteins or a fragment (e.g., functional fragment) of the PTGFRN, BSG, IGSF2, IGSF3, IGSF8, ITGB1, ITGA4, SLC3A2, or ATP transporter proteins. In some aspects, variants or variants of fragments of PTGFRN share at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with PTGFRN according to SEQ ID NO: 301 or with a functional fragment thereof. In some aspects variants or variants of fragments of BSG share at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with BSG according to SEQ ID NO: 303 or with a functional fragment thereof. In some aspects variants or variants of fragments of IGSF2 share at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with IGSF2 according to SEQ ID NO: 308 or with a functional fragment thereof. In some aspects variants or variants of fragments of IGSF3 share at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with IGSF3 according to SEQ ID NO: 309 or with a functional fragment thereof. In some aspects variants or variants of fragments of IGSF8 share at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with IGSF8 according to SEQ ID NO: 304 or with a functional fragment thereof. In some aspects variants or variants of fragments of ITGB1 share at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with ITGB1 according to SEQ ID NO: 305 or with a functional fragment thereof. In some aspects variants or variants of fragments of ITGA4 share at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with ITGA4 according to SEQ ID NO: 306 or with a functional fragment thereof. In some aspects variants or variants of fragments of SLC3A2 share at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with SLC3A2 according to SEQ ID NO: 307 or with a functional fragment thereof. In some aspects variants or variants of fragments of ATP1A1 share at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with ATP1A1 according to SEQ ID NO: 310 or with a functional fragment thereof. In some aspects variants or variants of fragments of ATP1A2 share at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with ATP1A2 according to SEQ ID NO: 311 or with a functional fragment thereof. In some aspects variants or variants of fragments of ATP1A3 share at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with ATP1A3 according to SEQ ID NO: 312 or with a functional fragment thereof. In some aspects variants or variants of fragments of ATP1A4 share at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with ATP1A4 according to SEQ ID NO: 313 or with a functional fragment thereof. In some aspects variants or variants of fragments of ATP1B3 share at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with ATP1B3 according to SEQ ID NO: 314 or with a functional fragment thereof. In some aspects variants or variants of fragments of ATP2B1 share at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with ATP2B1 according to SEQ ID NO: 315 or with a functional fragment thereof. In some aspects variants or variants of fragments of ATP2B2 share at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with ATP2B2 according to SEQ ID NO: 316 or with a functional fragment thereof. In some aspects variants or variants of fragments of ATP2B3 share at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with ATP2B3 according to SEQ ID NO: 317 or with a functional fragment thereof. In some aspects variants or variants of fragments of ATP2B4 share at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with ATP2B4 according to SEQ ID NO: 318 or with a functional fragment thereof. In some aspects, the variant or variant of a fragment of Scaffold X protein disclosed herein retains the ability to be specifically targeted to EVs, e.g., exosomes. In some aspects, the Scaffold X includes one or more mutations, for example, conservative amino acid substitutions.</p><p id="p-0130" num="0129">In some aspects, a variant of a Scaffold Y comprises a variant having at least 70% identity to MARCKS, MARCKSL1, BASP1, or a fragment of MARCKS, MARCKSL1, or BASP1. In some aspects variants or variants of fragments of MARCKS share at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with MARCKS according to SEQ ID NO: 401 or with a functional fragment thereof. In some aspects variants or variants of fragments of MARCKSL1 share at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with MARCKSL1 according to SEQ ID NO: 402 or with a functional fragment thereof. In some aspects variants or variants of fragments of BASP1 share at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with BASP1 according to SEQ ID NO: 403 or with a functional fragment thereof. In some aspects, the variant or variant of a fragment of Scaffold Y protein retains the ability to be specifically targeted to the luminal surface of EVs, e.g., exosomes. In some aspects, the Scaffold Y includes one or more mutations, e.g., conservative amino acid substitutions.</p><p id="p-0131" num="0130">A &#x201c;conservative amino acid substitution&#x201d; is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, if an amino acid in a polypeptide is replaced with another amino acid from the same side chain family, the substitution is considered to be conservative. In another aspect, a string of amino acids can be conservatively replaced with a structurally similar string that differs in order and/or composition of side chain family members.</p><p id="p-0132" num="0131">The term &#x201c;percent sequence identity&#x201d; or &#x201c;percent identity&#x201d; between two polynucleotide or polypeptide sequences refers to the number of identical matched positions shared by the sequences over a comparison window, taking into account additions or deletions (i.e., gaps) that must be introduced for optimal alignment of the two sequences. A matched position is any position where an identical nucleotide or amino acid is presented in both the target and reference sequence. Gaps presented in the target sequence are not counted since gaps are not nucleotides or amino acids. Likewise, gaps presented in the reference sequence are not counted since target sequence nucleotides or amino acids are counted, not nucleotides or amino acids from the reference sequence.</p><p id="p-0133" num="0132">The percentage of sequence identity is calculated by determining the number of positions at which the identical amino-acid residue or nucleic acid base occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. The comparison of sequences and determination of percent sequence identity between two sequences may be accomplished using readily available software both for online use and for download. Suitable software programs are available from various sources, and for alignment of both protein and nucleotide sequences. One suitable program to determine percent sequence identity is bl2seq, part of the BLAST suite of programs available from the U.S. government's National Center for Biotechnology Information BLAST web site (blast.ncbi.nlm.nih.gov). Bl2seq performs a comparison between two sequences using either the BLASTN or BLASTP algorithm. BLASTN is used to compare nucleic acid sequences, while BLASTP is used to compare amino acid sequences. Other suitable programs are, e.g., Needle, Stretcher, Water, or Matcher, part of the EMBOSS suite of bioinformatics programs and also available from the European Bioinformatics Institute (EBI) at www.ebi.ac.uk/fools/psa.</p><p id="p-0134" num="0133">Different regions within a single polynucleotide or polypeptide target sequence that aligns with a polynucleotide or polypeptide reference sequence can each have their own percent sequence identity. It is noted that the percent sequence identity value is rounded to the nearest tenth. For example, 80.11, 80.12, 80.13, and 80.14 are rounded down to 80.1, while 80.15, 80.16, 80.17, 80.18, and 80.19 are rounded up to 80.2. It also is noted that the length value will always be an integer.</p><p id="p-0135" num="0134">One skilled in the art will appreciate that the generation of a sequence alignment for the calculation of a percent sequence identity is not limited to binary sequence-sequence comparisons exclusively driven by primary sequence data. Sequence alignments can be derived from multiple sequence alignments. One suitable program to generate multiple sequence alignments is ClustalW2, available from www.clustal.org. Another suitable program is MUSCLE, available from www.drive5.com/muscle/. ClustalW2 and MUSCLE are alternatively available, e.g., from the EBI.</p><p id="p-0136" num="0135">It will also be appreciated that sequence alignments can be generated by integrating sequence data with data from heterogeneous sources such as structural data (e.g., crystallographic protein structures), functional data (e.g., location of mutations), or phylogenetic data. A suitable program that integrates heterogeneous data to generate a multiple sequence alignment is T-Coffee, available at www.tcoffee.org, and alternatively available, e.g., from the EBI. It will also be appreciated that the final alignment used to calculate percent sequence identity may be curated either automatically or manually.</p><p id="p-0137" num="0136">The polynucleotide variants can contain alterations in the coding regions, non-coding regions, or both. In one aspect, the polynucleotide variants contain alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. In another aspect, nucleotide variants are produced by silent substitutions due to the degeneracy of the genetic code. In other aspects, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to others, e.g., a bacterial host such as <i>E. coli</i>).</p><p id="p-0138" num="0137">Naturally occurring variants are called &#x201c;allelic variants,&#x201d; and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism (Genes II, Lewin, B., ed., John Wiley &#x26; Sons, New York (1985)). These allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present disclosure. Alternatively, non-naturally occurring variants can be produced by mutagenesis techniques or by direct synthesis.</p><p id="p-0139" num="0138">Using known methods of protein engineering and recombinant DNA technology, variants can be generated to improve or alter the characteristics of the polypeptides. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. Ron et al., <i>J. Biol. Chem. </i>268: 2984-2988 (1993), incorporated herein by reference in its entirety, reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., <i>J. Biotechnology </i>7:199-216 (1988), incorporated herein by reference in its entirety.)</p><p id="p-0140" num="0139">Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem 268:22105-22111 (1993), incorporated herein by reference in its entirety) conducted extensive mutational analysis of human cytokine IL-la. They used random mutagenesis to generate over 3,500 individual IL-la mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that &#x201c;[m]ost of the molecule could be altered with little effect on either [binding or biological activity].&#x201d; (See Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.</p><p id="p-0141" num="0140">As stated above, polypeptide variants include, e.g., modified polypeptides. Modifications include, e.g., acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation (Mei et al., <i>Blood </i>116:270-79 (2010), which is incorporated herein by reference in its entirety), proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. In some aspects, Scaffold X and/or Scaffold Y is modified at any convenient location.</p><p id="p-0142" num="0141">As used herein the term &#x201c;linked to&#x201d; or &#x201c;conjugated to&#x201d; are used interchangeably and refer to a covalent or non-covalent bond formed between a first moiety and a second moiety, e.g., Scaffold X and an ASO, respectively, e.g., a scaffold moiety expressed in or on the extracellular vesicle and an ASO, e.g., Scaffold X (e.g., a PTGFRN protein), respectively, in the luminal surface of or on the external surface of the extracellular vesicle.</p><p id="p-0143" num="0142">The term &#x201c;encapsulated&#x201d;, or grammatically different forms of the term (e.g., encapsulation, or encapsulating) refers to a status or process of having a first moiety (e.g., an ASO) inside a second moiety (e.g., an EV, e.g., exosome) without chemically or physically linking the two moieties. In some aspects, the term &#x201c;encapsulated&#x201d; can be used interchangeably with &#x201c;in the lumen of.&#x201d; Non-limiting examples of encapsulating a first moiety (e.g., an ASO) into a second moiety (e.g., EVs, e.g., exosomes) are disclosed elsewhere herein.</p><p id="p-0144" num="0143">As used herein, the term &#x201c;producer cell&#x201d; refers to a cell used for generating an EV, e.g., exosome. A producer cell can be a cell cultured in vitro, or a cell in vivo. A producer cell includes, but not limited to, a cell known to be effective in generating EVs, e.g., exosomes, e.g., HEK293 cells, Chinese hamster ovary (CHO) cells, mesenchymal stem cells (MSCs), BJ human foreskin fibroblast cells, fHDF fibroblast cells, AGE.HN&#xae; neuronal precursor cells, CAP&#xae; amniocyte cells, adipose mesenchymal stem cells, RPTEC/fERT1 cells. In certain aspects, a producer cell is not an antigen-presenting cell. In some aspects, a producer cell is not a dendritic cell, a B cell, a mast cell, a macrophage, a neutrophil, Kupffer-Browicz cell, cell derived from any of these cells, or any combination thereof. In some aspects, the EVs, e.g., exosomes useful in the present disclosure do not carry an antigen on MHC class I or class II molecule exposed on the surface of the EV, e.g., exosome, but instead can carry an antigen in the lumen of the EV, e.g., exosome or on the surface of the EV, e.g., exosome by attachment to Scaffold X and/or Scaffold Y.</p><p id="p-0145" num="0144">As used herein, the terms &#x201c;isolate,&#x201d; &#x201c;isolated,&#x201d; and &#x201c;isolating&#x201d; or &#x201c;purify,&#x201d; &#x201c;purified,&#x201d; and &#x201c;purifying&#x201d; as well as &#x201c;extracted&#x201d; and &#x201c;extracting&#x201d; are used interchangeably and refer to the state of a preparation (e.g., a plurality of known or unknown amount and/or concentration) of desired EVs, that have undergone one or more processes of purification, e.g., a selection or an enrichment of the desired EV preparation. In some aspects, isolating or purifying as used herein is the process of removing, partially removing (e.g., a fraction) of the EVs from a sample containing producer cells. In some aspects, an isolated EV composition has no detectable undesired activity or, alternatively, the level or amount of the undesired activity is at or below an acceptable level or amount. In other aspects, an isolated EV composition has an amount and/or concentration of desired EVs at or above an acceptable amount and/or concentration. In other aspects, the isolated EV composition is enriched as compared to the starting material (e.g., producer cell preparations) from which the composition is obtained. This enrichment can be by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, 99.99%, 99.999%, 99.9999%, or greater than 99.9999% as compared to the starting material. In some aspects, isolated EV preparations are substantially free of residual biological products. In some aspects, the isolated EV preparations are 100% free, 99% free, 98% free, 97% free, 96% free, 95% free, 94% free, 93% free, 92% free, 91% free, or 90% free of any contaminating biological matter. Residual biological products can include abiotic materials (including chemicals) or unwanted nucleic acids, proteins, lipids, or metabolites. Substantially free of residual biological products can also mean that the EV composition contains no detectable producer cells and that only EVs are detectable.</p><p id="p-0146" num="0145">As used herein, the term &#x201c;payload&#x201d; refers to an agent that acts on a target (e.g., a target cell) that is contacted with the EV. A non-limiting examples of payload that can be included on the EV, e.g., exosome, is an ASO. Payloads that can be introduced into an EV, e.g., exosome, and/or a producer cell include agents such as, nucleotides (e.g., nucleotides comprising a detectable moiety or a toxin or that disrupt transcription), nucleic acids (e.g., DNA or mRNA molecules that encode a polypeptide such as an enzyme, or RNA molecules that have regulatory function such as miRNA, dsDNA, lncRNA, and siRNA), amino acids (e.g., amino acids comprising a detectable moiety or a toxin or that disrupt translation), polypeptides (e.g., enzymes), lipids, carbohydrates, and small molecules (e.g., small molecule drugs and toxins). In certain aspects, a payload comprises an ASO. As used herein, the term &#x201c;antibody&#x201d; encompasses an immunoglobulin whether natural or partly or wholly synthetically produced, and fragments thereof. The term also covers any protein having a binding domain that is homologous to an immunoglobulin binding domain. &#x201c;Antibody&#x201d; further includes a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. As used herein, the term &#x201c;antigen&#x201d; refers to any agent that when introduced into a subject elicits an immune response (cellular or humoral) to itself. Use of the term antibody is meant to include whole antibodies, polyclonal, monoclonal and recombinant antibodies, fragments thereof, and further includes single-chain antibodies, humanized antibodies, murine antibodies, chimeric, mouse-human, mouse-primate, primate-human monoclonal antibodies, anti-idiotype antibodies, antibody fragments, such as, e.g., scFv, (scFv)<sub>2</sub>, Fab, Fab&#x2032;, and F(ab&#x2032;)<sub>2</sub>, F(ab1)<sub>2</sub>, Fv, dAb, and Fd fragments, diabodies, and antibody-related polypeptides. Antibody includes bispecific antibodies and multispecific antibodies so long as they exhibit the desired biological activity or function.</p><p id="p-0147" num="0146">The terms &#x201c;individual,&#x201d; &#x201c;subject,&#x201d; &#x201c;host,&#x201d; and &#x201c;patient,&#x201d; are used interchangeably herein and refer to any mammalian subject for whom diagnosis, treatment, or therapy is desired, particularly humans. The compositions and methods described herein are applicable to both human therapy and veterinary applications. In some aspects, the subject is a mammal, and in other aspects the subject is a human. As used herein, a &#x201c;mammalian subject&#x201d; includes all mammals, including without limitation, humans, domestic animals (e.g., dogs, cats and the like), farm animals (e.g., cows, sheep, pigs, horses and the like) and laboratory animals (e.g., monkey, rats, mice, rabbits, guinea pigs and the like).</p><p id="p-0148" num="0147">The term &#x201c;pharmaceutical composition&#x201d; refers to a preparation which is in such form as to permit the biological activity of the active ingredient to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the composition would be administered. Such composition can be sterile.</p><p id="p-0149" num="0148">As used herein, the term &#x201c;substantially free&#x201d; means that the sample comprising EVs, e.g., exosomes, comprise less than 10% of macromolecules by mass/volume (m/v) percentage concentration. Some fractions may contain less than 0.001%, less than 0.01%, less than 0.05%, less than 0.1%, less than 0.2%, less than 0.3%, less than 0.4%, less than 0.5%, less than 0.6%, less than 0.7%, less than 0.8%, less than 0.9%, less than 1%, less than 2%, less than 3%, less than 4%, less than 5%, less than 6%, less than 7%, less than 8%, less than 9%, or less than 10% (m/v) of macromolecules.</p><p id="p-0150" num="0149">As used herein, the term &#x201c;macromolecule&#x201d; means nucleic acids, contaminant proteins, lipids, carbohydrates, metabolites, or a combination thereof.</p><p id="p-0151" num="0150">As used herein, the term &#x201c;conventional exosome protein&#x201d; means a protein previously known to be enriched in exosomes, including but is not limited to CD9, CD63, CD81, PDGFR, GPI anchor proteins, lactadherin (MFGE8), LAMP2, and LAMP2B, a fragment thereof, or a peptide that binds thereto.</p><p id="p-0152" num="0151">&#x201c;Administering,&#x201d; as used herein, means to give a composition comprising an EV, e.g., exosome, disclosed herein to a subject via a pharmaceutically acceptable route. Routes of administration can be intravenous, e.g., intravenous injection and intravenous infusion. Additional routes of administration include, e.g., subcutaneous, intramuscular, oral, nasal, and pulmonary administration. EVs, e.g., exosomes can be administered as part of a pharmaceutical composition comprising at least one excipient.</p><p id="p-0153" num="0152">An &#x201c;effective amount&#x201d; of, e.g., an ASO or an extracellular vesicle as disclosed herein, is an amount sufficient to carry out a specifically stated purpose. An &#x201c;effective amount&#x201d; can be determined empirically and in a routine manner, in relation to the stated purpose.</p><p id="p-0154" num="0153">&#x201c;Treat,&#x201d; &#x201c;treatment,&#x201d; or &#x201c;treating,&#x201d; as used herein refers to, e.g., the reduction in severity of a disease or condition; the reduction in the duration of a disease course; the amelioration or elimination of one or more symptoms associated with a disease or condition; the provision of beneficial effects to a subject with a disease or condition, without necessarily curing the disease or condition. The term also includes prophylaxis or prevention of a disease or condition or its symptoms thereof. In one aspect, the &#x201c;treating&#x201d; or &#x201c;treatment&#x201d; includes inducing hematopoiesis in a subject in need thereof. In some aspects, the disease or condition is associated with a hematopoiesis or a deficiency thereof. In certain aspects, the disease or condition is a cancer. In some aspects, the treating enhances hematopoiesis in a subject having a cancer, wherein the enhanced hematopoiesis comprises increased proliferation and/or differentiation of one or more immune cell in the subject</p><p id="p-0155" num="0154">&#x201c;Prevent&#x201d; or &#x201c;preventing,&#x201d; as used herein, refers to decreasing or reducing the occurrence or severity of a particular outcome. In some aspects, preventing an outcome is achieved through prophylactic treatment. In some aspects, an EV, e.g., an exosome, comprising an ASO, described herein, is administered to a subject prophylactically. In some aspects, the subject is at risk of developing cancer. In some aspects, the subject is at risk of developing a hematopoietic disorder.</p><heading id="h-0009" level="1">II. Antisense Oligonucleotides (ASOs)</heading><p id="p-0156" num="0155">The present disclosure employs antisense oligonucleotides (ASOs) for use in modulating the function of nucleic acid molecules encoding mammalian CEBP/0, such as the CEBP/&#x3b2; nucleic acid, e.g., CEBP/&#x3b2; transcript, including CEBP/&#x3b2; pre-mRNA, and CEBP/&#x3b2; mRNA, or naturally occurring variants of such nucleic acid molecules encoding mammalian CEBP/P. The term &#x201c;ASO&#x201d; in the context of the present disclosure, refers to a molecule formed by covalent linkage of two or more nucleotides (i.e., an oligonucleotide).</p><p id="p-0157" num="0156">The ASO comprises a contiguous nucleotide sequence of from about 10 to about 30, such as 10-20, 14-20, 16-20, or 15-25, nucleotides in length. In certain aspects, the ASO is 20 nucleotides in length. In certain aspects, the ASO is 18 nucleotides in length. In certain aspects, the ASO is 19 nucleotides in length. In certain aspects, the ASO is 17 nucleotides in length. In certain aspects, the ASO is 16 nucleotides in length. In certain aspects, the ASO is 15 nucleotides in length. The terms &#x201c;antisense ASO,&#x201d; &#x201c;antisense oligonucleotide,&#x201d; and &#x201c;oligomer&#x201d; as used herein are interchangeable with the term &#x201c;ASO.&#x201d; The ASOs useful for the present disclosure are not naturally occurring and cannot be found in nature. In some aspects, the ASOs are chemically modified.</p><p id="p-0158" num="0157">A reference to a SEQ ID number includes a particular nucleobase sequence, but does not include any design or full chemical structure. Furthermore, the ASOs disclosed in the figures herein show a representative design, but are not limited to the specific design shown in the figures unless otherwise indicated. For example, when a claim (or this specification) refers to SEQ ID NO: 101, it includes the nucleotide sequence of SEQ ID NO: 101 only. The design of any ASO disclosed herein can be written as SEQ ID NO: XX, wherein each of the first nucleotide, the second nucleotide, the third nucleotide, the first nucleotide, the second nucleotide, and the Nth nucleotide from the 5&#x2032; end is a modified nucleotide, e.g., LNA, and each of the other nucleotides is a non-modified nucleotide (e.g., DNA).</p><p id="p-0159" num="0158">In various aspects, the ASO of the disclosure does not comprise RNA (units). In some aspects, the ASO comprises one or more DNA units. In one aspect, the ASO according to the disclosure is a linear molecule or is synthesized as a linear molecule. In some aspects, the ASO is a single stranded molecule, and does not comprise short regions of, for example, at least 3, 4 or 5 contiguous nucleotides, which are complementary to equivalent regions within the same ASO (i.e, duplexes)&#x2014;in this regard, the ASO is not (essentially) double stranded. In some aspects, the ASO is essentially not double stranded. In some aspects, the ASO is not a siRNA. In various aspects, the ASO of the disclosure can consist entirely of the contiguous nucleotide region. Thus, in some aspects the ASO is not substantially self-complementary.</p><p id="p-0160" num="0159">In other aspects, the present disclosure includes fragments of ASOs. For example, the disclosure includes at least one nucleotide, at least two contiguous nucleotides, at least three contiguous nucleotides, at least four contiguous nucleotides, at least five contiguous nucleotides, at least six contiguous nucleotides, at least seven contiguous nucleotides, at least eight contiguous nucleotides, or at least nine contiguous nucleotides of the ASOs disclosed herein. Fragments of any of the sequences disclosed herein are contemplated as part of the disclosure.</p><p id="p-0161" num="0160">In some aspects, the ASOs for the present disclosure include a phosphorodiamidate Morpholino oligomer (PMO) or a peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO).</p><heading id="h-0010" level="1">II.A. The Target</heading><p id="p-0162" num="0161">Suitably the ASO of the disclosure is capable of down-regulating (e.g., reducing or removing) expression of the CEBP/&#x3b2; mRNA or CEBP/&#x3b2; protein. In this regard, the ASO of the disclosure can promote differentiation of M2 macrophages and/or decrease the differentiation of M1 macrophages. In particular, the present disclosure is directed to ASOs that target one or more regions of the CEBP/&#x3b2;pre-mRNA (e.g., intron regions, exon regions, and/or exon-intron junction regions).</p><p id="p-0163" num="0162">Unless indicated otherwise, the term &#x201c;CEBP/3,&#x201d; as used herein, can refer to CEBP/&#x3b2; from one or more species (e.g., humans, non-human primates, dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, and bears).</p><p id="p-0164" num="0163">CEBP/&#x3b2; (CEBP/&#x3b2;) is also known as CCAAT/enhancer-binding protein beta. Synonyms of CEBP/&#x3b2;/CEBP/&#x3b2; are known and include C/EBP beta; &#x2022;Liver activator protein; LAP; Liver-enriched inhibitory protein; LIP; Nuclear factor NF-IL6; transcription factor 5; TCF-5; CEBPB; CEBP&#x3b2;; CEBP&#x3b2;; CEBP/B; and TCF5. The sequence for the human CEBP/B8 gene can be found under publicly available GenBank Accession Number NC_000020.11 (50190583 . . . 50192690). The human CEBP/&#x3b2; gene is found at chromosome location 20q13.13 at 50190583-50192690.</p><p id="p-0165" num="0164">The sequence for the human CEBP/&#x3b2; pre-mRNA transcript (SEQ ID NO: 11) corresponds to the reverse complement of residues 50190583-50192690 of chromosome 20q13.13. The CEBP/&#x3b2; mRNA sequence (GenBank Accession No. NM_001285878.1) is provided in SEQ ID NO: 13 (Table 1), except that the nucleotide &#x201c;t&#x201d; in SEQ ID NO: 13 is shown as &#x201c;u&#x201d; in the mRNA. The sequence for human CEBP/&#x3b2; protein can be found under publicly available Accession Numbers: P17676, (canonical sequence, SEQ ID NO: 12), P17676-2 (SEQ ID NO: 14), and P17676-3 (SEQ ID NO: 15), each of which is incorporated by reference herein in its entirety.</p><p id="p-0166" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;1</entry></row><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>CEBP/p&#x2003;mRNA&#x2003;and&#x2003;Protein&#x2003;Sequences</entry></row><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="offset" colwidth="35pt" align="left"/><colspec colname="1" colwidth="182pt" align="left"/><tbody valign="top"><row><entry/><entry>CEBP/&#x3b2;&#x2003;mRNA&#x2003;Sequence</entry></row><row><entry/><entry>TCCCAATCCCGGGGCGGCCGGGCGGGGGTGGGCAG</entry></row><row><entry/><entry>GGGGCGTGAGGCCGCCCCTGCGTCCCGGGGGCCCC</entry></row><row><entry/><entry>CCGAAAACGCGCTCCGGGTGCCCGGTCCCTCCGCT</entry></row><row><entry/><entry>GCGCCCTGCCGCCGTCCTCCCGGGGGTCTCGGGCG</entry></row><row><entry/><entry>GCCGCGGCCGTGTCCTTCGCGTCCCGGCGGCGCGG</entry></row><row><entry/><entry>CGGGAGGGGCCGGCGTGACGCAGCGGTTGCTACGG</entry></row><row><entry/><entry>GCCGCCCTTATAAATAACCGGGCTCAGGAGAAACT</entry></row><row><entry/><entry>TTAGCGAGTCAGAGCCGCGCACGGGACTGGGAAGG</entry></row><row><entry/><entry>GGACCCACCCGAGGGTCCAGCCACCAGCCCCCTCA</entry></row><row><entry/><entry>CTAATAGCGGCCACCCCGGCAGCGGCGGCAGCAGC</entry></row><row><entry/><entry>AGCAGCGACGCAGCGGCGACAGCTCAGAGCAGGGA</entry></row><row><entry/><entry>GGCCGCGCCACCTGCGGGCCGGCCGGAGCGGGCAG</entry></row><row><entry/><entry>CCCCAGGCCCCCTCCCCGGGCACCCGCGTTCATGC</entry></row><row><entry/><entry>AACGCCTGGTGGCCTGGGACCCAGCATGTCTCCCC</entry></row><row><entry/><entry>CTGCCGCCGCCGCCGCCTGCCTTTAAATCCATGGA</entry></row><row><entry/><entry>AGTGGCCAACTTCTACTACGAGGCGGACTGCTTGG</entry></row><row><entry/><entry>CTGCTGCGTACGGCGGCAAGGCGGCCCCCGCGGCG</entry></row><row><entry/><entry>CCCCCCGCGGCCAGACCCGGGCCGCGCCCCCCCGC</entry></row><row><entry/><entry>CGGCGAGCTGGGCAGCATCGGCGACCACGAGCGCG</entry></row><row><entry/><entry>CCATCGACTTCAGCCCGTACCTGGAGCCGCTGGGC</entry></row><row><entry/><entry>GCGCCGCAGGCCCCGGCGCCCGCCACGGCCACGGA</entry></row><row><entry/><entry>CACCTTCGAGGCGGCTCCGCCCGCGCCCGCCCCCG</entry></row><row><entry/><entry>CGCCCGCCTCCTCCGGGCAGCACCACGACTTCCTC</entry></row><row><entry/><entry>TCCGACCTCTTCTCCGACGACTACGGGGGCAAGAA</entry></row><row><entry/><entry>CTGCAAGAAGCCGGCCGAGTACGGCTACGTGAGCC</entry></row><row><entry/><entry>TGGGGCGCCTGGGGGCCGCCAAGGGCGCGCTGCAC</entry></row><row><entry/><entry>CCCGGCTGCTTCGCGCCCCTGCACCCACCGCCCCC</entry></row><row><entry/><entry>GCCGCCGCCGCCGCCCGCCGAGCTCAAGGCGGAGC</entry></row><row><entry/><entry>CGGGCTTCGAGCCCGCGGACTGCAAGCGGAAGGAG</entry></row><row><entry/><entry>GAGGCCGGGGCGCCGGGCGGCGGCGCAGGCATGGC</entry></row><row><entry/><entry>GGCGGGCTTCCCGTACGCGCTGCGCGCTTACCTCG</entry></row><row><entry/><entry>GCTACCAGGCGGTGCCGAGCGGCAGCAGCGGGAGC</entry></row><row><entry/><entry>CTCTCCACGTCCTCCTCGTCCAGCCCGCCCGGCAC</entry></row><row><entry/><entry>GCCGAGCCCCGCTGACGCCAAGGCGCCCCCGACCG</entry></row><row><entry/><entry>CCTGCTACGCGGGGGCCGCGCCGGCGCCCTCGCAG</entry></row><row><entry/><entry>GTCAAGAGCAAGGCCAAGAAGACCGTGGACAAGCA</entry></row><row><entry/><entry>CAGCGACGAGTACAAGATCCGGCGCGAGCGCAACA</entry></row><row><entry/><entry>ACATCGCCGTGCGCAAGAGCCGCGACAAGGCCAAG</entry></row><row><entry/><entry>ATGCGCAACCTGGAGACGCAGCACAAGGTCCTGGA</entry></row><row><entry/><entry>GCTCACGGCCGAGAACGAGCGGCTGCAGAAGAAGG</entry></row><row><entry/><entry>TGGAGCAGCTGTCGCGCGAGCTCAGCACCCTGCGG</entry></row><row><entry/><entry>AACTTGTTCAAGCAGCTGCCCGAGCCCCTGCTCGC</entry></row><row><entry/><entry>CTCCTCCGGCCACTGCTAGCGCGGCCCCCGCGCGC</entry></row><row><entry/><entry>GTCCCCCTGCCGGCCGGGGCTGAGACTCCGGGGAG</entry></row><row><entry/><entry>CGCCCGCGCCCGCGCCCTCGCCCCCGCCCCCGGCG</entry></row><row><entry/><entry>GCGCCGGCAAAACTTTGGCACTGGGGCACTTGGCA</entry></row><row><entry/><entry>GCGCGGGGAGCCCGTCGGTAATTTTAATATTTTAT</entry></row><row><entry/><entry>TATATATATATATCTATATTTTTGTCCAAACCAAC</entry></row><row><entry/><entry>CGCACATGCAGATGGGGCTCCCGCCCGTGGTGTTA</entry></row><row><entry/><entry>TTTAAAGAAGAAACGTCTATGTGTACAGATGAATG</entry></row><row><entry/><entry>ATAAACTCTCTGCTTCTCCCTCTGCCCCTCTCCAG</entry></row><row><entry/><entry>GCGCCGGCGGGCGGGCCGGTTTCGAAGTTGATGCA</entry></row><row><entry/><entry>ATCGGTTTAAACATGGCTGAACGCGTGTGTACACG</entry></row><row><entry/><entry>GGACTGACGCAACCCACGTGTAACTGTCAGCCGGG</entry></row><row><entry/><entry>CCCTGAGTAATCGCTTAAAGATGTTCCTACGGGCT</entry></row><row><entry/><entry>TGTTGCTGTTGATGTTTTGTTTTGTTTTGTTTTTT</entry></row><row><entry/><entry>GGTCTTTTTTTGTATTATAAAAAATAATCTATTTC</entry></row><row><entry/><entry>TATGAGAAAAGAGGCGTCTGTATATTTTGGGAATC</entry></row><row><entry/><entry>TTTTCCGTTTCAAGCATTAAGAACACTTTTAATAA</entry></row><row><entry/><entry>ACTTTTTTTTGAGAATGGTTACAAAGCCTTTTGGG</entry></row><row><entry/><entry>GGCAGTAAAAAAA&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;11)</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>CEBP/&#x3b2;&#x2003;Protein&#x2003;Sequence</entry></row><row><entry/><entry>MQRLVAWDPACLPLPPPPPAFKSMEVANFYYEADC</entry></row><row><entry/><entry>LAAAYGGKAAPAAPPAARPGPRPPAGELGSIGDHE</entry></row><row><entry/><entry>RAIDFSPYLEPLGAPQAPAPATATDTFEAAPPAPA</entry></row><row><entry/><entry>PAPASSGQHHDFLSDLFSDDYGGKNCKKPAEYGYV</entry></row><row><entry/><entry>SLGRLGAAKGALHPGCFAPLHPPPPPPPPPAELKA</entry></row><row><entry/><entry>EPGFEPADCKRKEEAGAPGGGAGMAAGFPYALRAY</entry></row><row><entry/><entry>LGYQAVPSGSSGSLSTSSSSSPPGTPSPADAKAPP</entry></row><row><entry/><entry>TACYAGAAPAPSQVKSKAKKTVDKHSDEYKIRRER</entry></row><row><entry/><entry>NNIAVRKSRDKAKMRNLETQHKVLELTAENERLQK</entry></row><row><entry/><entry>KVEQLSRELSTLRNLFKQLPEPLLASSGHC</entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;12)</entry></row><row><entry/><entry namest="offset" nameend="1" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0167" num="0165">Natural variants of the human CEBP/&#x3b2; gene product are known. For example, natural variants of human CEBP/&#x3b2; protein can contain one or more amino acid substitutions selected from: A241P, A253G, G195S, and any combination thereof. Additional variants of human CEBP/&#x3b2; protein resulting from alternative splicing are also known in the art. CEBP/&#x3b2; Isoform 2 (identifier: P17676-2 at UniProt) differs from the canonical sequence (SEQ ID NO: 13) as follows: deletion of residues 1-23 relative to SEQ ID NO: 13. The sequence of CEBP/&#x3b2; Isoform 3 (identifier: P17676-3) differs from the canonical sequence (SEQ ID NO: 13) as follows: deletion of residues 1-198 relative to SEQ ID NO: 13. Therefore, the ASOs of the present disclosure can be designed to reduce or inhibit expression of the natural variants of the protein.</p><p id="p-0168" num="0166">An example of a target nucleic acid sequence of the ASOs is CEBP/&#x3b2; pre-mRNA. SEQ ID NO: 11 represents a human CEBP/&#x3b2; genomic sequence (i.e., reverse complement of nucleotides 50190583-50192690 of chromosome 20q13.13). SEQ ID NO: 11 is identical to a CEBP/&#x3b2; pre-mRNA sequence except that nucleotide &#x201c;t&#x201d; in SEQ ID NO: 11 is shown as &#x201c;u&#x201d; in pre-mRNA. In certain aspects, the &#x201c;target nucleic acid&#x201d; comprises an intron of a CEBP/&#x3b2; protein-encoding nucleic acids or naturally occurring variants thereof, and RNA nucleic acids derived therefrom, e.g., pre-mRNA. In other aspects, the target nucleic acid comprises an exon region of a CEBP/&#x3b2; protein-encoding nucleic acids or naturally occurring variants thereof, and RNA nucleic acids derived therefrom, e.g., pre-mRNA. In yet other aspects, the target nucleic acid comprises an exon-intron junction of a CEBP/&#x3b2; protein-encoding nucleic acids or naturally occurring variants thereof, and RNA nucleic acids derived therefrom, e.g., pre-mRNA. In some aspects, for example when used in research or diagnostics the &#x201c;target nucleic acid&#x201d; can be a cDNA or a synthetic oligonucleotide derived from the above DNA or RNA nucleic acid targets. The human CEBP/&#x3b2; protein sequence encoded by the CEBP/&#x3b2; pre-mRNA is shown as SEQ ID NO: 13. In other aspects, the target nucleic acid comprises an untranslated region of a CEBP/&#x3b2; protein-encoding nucleic acids or naturally occurring variants thereof, e.g., 5&#x2032; UTR, 3&#x2032; UTR, or both.</p><p id="p-0169" num="0167">In some aspects, an ASO of the disclosure hybridizes to a region within the introns of a CEBP/&#x3b2; transcript, e.g., SEQ ID NO: 11. In certain aspects, an ASO of the disclosure hybridizes to a region within the exons of a CEBP/&#x3b2; transcript, e.g., SEQ ID NO: 11. In other aspects, an ASO of the disclosure hybridizes to a region within the exon-intron junction of a CEBP/&#x3b2;, transcript, e.g., SEQ ID NO: 11. In some aspects, an ASO of the disclosure hybridizes to a region within a CEBP/&#x3b2; transcript (e.g., an intron, exon, or exon-intron junction), e.g., SEQ ID NO: 11, wherein the ASO has a design according to formula: 5&#x2032; A-B-C 3&#x2032; as described elsewhere herein.</p><p id="p-0170" num="0168">In some aspects, the ASO targets a mRNA encoding a particular isoform of CEBP/&#x3b2; protein (e.g., Isoform 1). In some aspects, the ASO targets all isoforms of CEBP/&#x3b2; protein. In other aspects, the ASO targets two isoforms (e.g., Isoform 1 and Isoform 2, Isoform 1 and Isoform 3, or Isoform 2 and Isoform 3) of CEBP/&#x3b2; protein.</p><p id="p-0171" num="0169">In some aspects, the ASO comprises a contiguous nucleotide sequence (e.g., 10 to 30 nucleotides in length, e.g., 20 nucleotides in length) that are complementary to a nucleic acid sequence within a CEBP/&#x3b2; transcript, e.g., a region corresponding to SEQ ID NO: 11 or SEQ ID NO: 13. In some aspects, the ASO comprises a contiguous nucleotide sequence that hybridizes to a nucleic acid sequence, or a region within the sequence, of a CEBP/&#x3b2; transcript (&#x201c;target region&#x201d;), wherein the nucleic acid sequence corresponds (i) nucleotides 1-600 of SEQ ID NO: 13; (ii) nucleotides 100-600 of SEQ ID NO: 13; (iii) nucleotides 200-600 of SEQ ID NO: 13; (iv) nucleotides 300-600 of SEQ ID NO: 13; (v) 400-600 of SEQ ID NO: 13, (vi) nucleotides 500-1000 of SEQ ID NO: 13; (vii) nucleotides 900-1200 of SEQ ID NO: 13; (viii) nucleotides 1000-1300 of SEQ ID NO: 13; (ix) nucleotides 1300-1500 of SEQ ID NO: 13, and wherein, optionally, the ASO has one of the designs described herein or a chemical structure shown elsewhere herein.</p><p id="p-0172" num="0170">In some aspects, the ASO comprises a contiguous nucleotide sequence that hybridizes to a nucleic acid sequence, or a region within the sequence, of a CEBP/&#x3b2; transcript (&#x201c;target region&#x201d;), wherein the nucleic acid sequence corresponds to (i) 439-699 of SEQ ID NO: 13; (ii) nucleotides 544-778 of SEQ ID NO: 13; (iii) nucleotides 715-750 of SEQ ID NO: 13; (iv) nucleotides 886-1126 of SEQ ID NO: 13; (v) nucleotides 949-2118 of SEQ ID NO: 13; (vi) or 1153-1407 of SEQ ID NO: 13 and wherein, optionally, the ASO has one of the designs described herein or a chemical structure shown elsewhere herein.</p><p id="p-0173" num="0171">In some aspects, the ASO comprises a contiguous nucleotide sequence that hybridizes to a nucleic acid sequence, or a region within the sequence, of a CEBP/&#x3b2; transcript (&#x201c;target region&#x201d;), wherein the nucleic acid sequence corresponds to (i) 489-649 of SEQ ID NO: 13; (ii) nucleotides 594-728 of SEQ ID NO: 13; (iii) nucleotides 765-700 of SEQ ID NO: 13; (iv) nucleotides 936-1076 of SEQ ID NO: 13; (v) nucleotides 999-2068 of SEQ ID NO: 13; (vi) or 1203-1357 of SEQ ID NO: 13 and wherein, optionally, the ASO has one of the designs described herein or a chemical structure shown elsewhere herein.</p><p id="p-0174" num="0172">In some aspects, the ASO comprises a contiguous nucleotide sequence that hybridizes to a nucleic acid sequence, or a region within the sequence, of a CEBP/&#x3b2; transcript (&#x201c;target region&#x201d;), wherein the nucleic acid sequence corresponds to (i) nucleotides 1355-1487 of SEQ ID NO: 13 (ii) 529-609 of SEQ ID NO: 13; (iii) nucleotides 634-688 of SEQ ID NO: 13; (iv) nucleotides 805-700 of SEQ ID NO: 13; (v) nucleotides 976-1036 of SEQ ID NO: 13; (vi) nucleotides 1039-2028 of SEQ ID NO: 13; (vii) 1243-1317 of SEQ ID NO: 13; or (viii) nucleotides 1395-1447 of SEQ ID NO: 13 and wherein, optionally, the ASO has one of the designs described herein or a chemical structure shown elsewhere herein.</p><p id="p-0175" num="0173">In some aspects, the target region corresponds to nucleotides 540-554 of SEQ ID NO: 13 (e.g., ASO-CEBPb-540; SEQ ID NO: 194). In some aspects, the target region corresponds to nucleotides 565-579 of SEQ ID NO: 13 (e.g., ASO-CEBPb-565; SEQ ID NO: 195). In some aspects, the target region corresponds to nucleotides 569-583 of SEQ ID NO: 13 (e.g., ASO-CEBPb-569; SEQ ID NO: 196). In some aspects, the target region corresponds to nucleotides 648-662 of SEQ ID NO: 13 (e.g., ASO-CEBPb-648; SEQ ID NO: 197). In some aspects, the target region corresponds to nucleotides 816-830 of SEQ ID NO: 13 (e.g., ASO-CEBPb-816; SEQ ID NO: 198). In some aspects, the target region corresponds to nucleotides 817-831 of SEQ ID NO: 13 (e.g., ASO-CEBPb-817; SEQ ID NO: 199). In some aspects, the target region corresponds to nucleotides 818-832 of SEQ ID NO: 13 (e.g., ASO-CEBPb-818; SEQ ID NO: 200). In some aspects, the target region corresponds to nucleotides 819-833 of SEQ ID NO: 13 (e.g., ASO-CEBPb-819; SEQ ID NO: 201). In some aspects, the target region corresponds to nucleotides 820-834 of SEQ ID NO: 13 (e.g., ASO-CEBPb-820; SEQ ID NO: 202). In some aspects, the target region corresponds to nucleotides 851-865 of SEQ ID NO: 13 (e.g., ASO-CEBPb-851; SEQ ID NO: 203). In some aspects, the target region corresponds to nucleotides 853-867 of SEQ ID NO: 13 (e.g., ASO-CEBPb-853; SEQ ID NO: 204). In some aspects, the target region corresponds to nucleotides 856-870 of SEQ ID NO: 13 (e.g., ASO-CEBPb-856; SEQ ID NO: 205). In some aspects, the target region corresponds to nucleotides 858-872 of SEQ ID NO: 13 (e.g., ASO-CEBPb-858; SEQ ID NO: 206). In some aspects, the target region corresponds to nucleotides 987-1001 of SEQ ID NO: 13 (e.g., ASO-CEBPb-987; SEQ ID NO: 207). In some aspects, the target region corresponds to nucleotides 1056-1070 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1056; SEQ ID NO: 208). In some aspects, the target region corresponds to nucleotides 1064-1078 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1064; SEQ ID NO: 209). In some aspects, the target region corresponds to nucleotides 1065-1079 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1065; SEQ ID NO: 210). In some aspects, the target region corresponds to nucleotides 1066-1080 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1066; SEQ ID NO: 211). In some aspects, the target region corresponds to nucleotides 1071-1085 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1071; SEQ ID NO: 212). In some aspects, the target region corresponds to nucleotides 1270-1284 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1270; SEQ ID NO: 213). In some aspects, the target region corresponds to nucleotides 1273-1287 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1273; SEQ ID NO: 214). In some aspects, the target region corresponds to nucleotides 1274-1288 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1274; SEQ ID NO: 215). In some aspects, the target region corresponds to nucleotides 1405-1419 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1405; SEQ ID NO: 216). In some aspects, the target region corresponds to nucleotides 1407-1421 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1407; SEQ ID NO: 217). In some aspects, the target region corresponds to nucleotides 539-554 of SEQ ID NO: 13 (e.g., ASO-CEBPb-539; SEQ ID NO: 218). In some aspects, the target region corresponds to nucleotides 540-555 of SEQ ID NO: 13 (e.g., ASO-CEBPb-540; SEQ ID NO: 219). In some aspects, the target region corresponds to nucleotides 563-578 of SEQ ID NO: 13 (e.g., ASO-CEBPb-563; SEQ ID NO: 220). In some aspects, the target region corresponds to nucleotides 564-579 of SEQ ID NO: 13 (e.g., ASO-CEBPb-564; SEQ ID NO: 221). In some aspects, the target region corresponds to nucleotides 565-580 of SEQ ID NO: 13 (e.g., ASO-CEBPb-565; SEQ ID NO: 222). In some aspects, the target region corresponds to nucleotides 568-583 of SEQ ID NO: 13 (e.g., ASO-CEBPb-568; SEQ ID NO: 223). In some aspects, the target region corresponds to nucleotides 644-659 of SEQ ID NO: 13 (e.g., ASO-CEBPb-644; SEQ ID NO: 224). In some aspects, the target region corresponds to nucleotides 645-660 of SEQ ID NO: 13 (e.g., ASO-CEBPb-645; SEQ ID NO: 225). In some aspects, the target region corresponds to nucleotides 648-663 of SEQ ID NO: 13 (e.g., ASO-CEBPb-648; SEQ ID NO: 226). In some aspects, the target region corresponds to nucleotides 819-834 of SEQ ID NO: 13 (e.g., ASO-CEBPb-819; SEQ ID NO: 227). In some aspects, the target region corresponds to nucleotides 855-870 of SEQ ID NO: 13 (e.g., ASO-CEBPb-855; SEQ ID NO: 228). In some aspects, the target region corresponds to nucleotides 860-875 of SEQ ID NO: 13 (e.g., ASO-CEBPb-860; SEQ ID NO: 229). In some aspects, the target region corresponds to nucleotides 986-1001 of SEQ ID NO: 13 (e.g., ASO-CEBPb-986; SEQ ID NO: 230). In some aspects, the target region corresponds to nucleotides 987-1002 of SEQ ID NO: 13 (e.g., ASO-CEBPb-987; SEQ ID NO: 231). In some aspects, the target region corresponds to nucleotides 996-1011 of SEQ ID NO: 13 (e.g., ASO-CEBPb-996; SEQ ID NO: 232). In some aspects, the target region corresponds to nucleotides 1049-1064 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1049; SEQ ID NO: 233). In some aspects, the target region corresponds to nucleotides 1050-1065 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1050; SEQ ID NO: 234). In some aspects, the target region corresponds to nucleotides 1064-1079 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1064; SEQ ID NO: 235). In some aspects, the target region corresponds to nucleotides 1065-1080 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1065; SEQ ID NO: 236). In some aspects, the target region corresponds to nucleotides 1066-1081 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1066; SEQ ID NO: 237). In some aspects, the target region corresponds to nucleotides 1083-1098 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1083; SEQ ID NO: 238). In some aspects, the target region corresponds to nucleotides 1088-1103 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1088; SEQ ID NO: 239). In some aspects, the target region corresponds to nucleotides 1253-1268 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1253; SEQ ID NO: 240). In some aspects, the target region corresponds to nucleotides 1269-1284 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1269; SEQ ID NO: 241). In some aspects, the target region corresponds to nucleotides 1272-1287 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1272; SEQ ID NO: 242). In some aspects, the target region corresponds to nucleotides 1274-1289 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1274; SEQ ID NO: 243). In some aspects, the target region corresponds to nucleotides 539-555 of SEQ ID NO: 13 (e.g., ASO-CEBPb-539; SEQ ID NO: 244). In some aspects, the target region corresponds to nucleotides 564-580 of SEQ ID NO: 13 (e.g., ASO-CEBPb-564; SEQ ID NO: 245). In some aspects, the target region corresponds to nucleotides 565-581 of SEQ ID NO: 13 (e.g., ASO-CEBPb-565; SEQ ID NO: 246). In some aspects, the target region corresponds to nucleotides 567-583 of SEQ ID NO: 13 (e.g., ASO-CEBPb-567; SEQ ID NO: 247). In some aspects, the target region corresponds to nucleotides 647-663 of SEQ ID NO: 13 (e.g., ASO-CEBPb-647; SEQ ID NO: 248). In some aspects, the target region corresponds to nucleotides 648-664 of SEQ ID NO: 13 (e.g., ASO-CEBPb-648; SEQ ID NO: 249). In some aspects, the target region corresponds to nucleotides 815-831 of SEQ ID NO: 13 (e.g., ASO-CEBPb-815; SEQ ID NO: 250). In some aspects, the target region corresponds to nucleotides 818-834 of SEQ ID NO: 13 (e.g., ASO-CEBPb-818; SEQ ID NO: 251). In some aspects, the target region corresponds to nucleotides 820-836 of SEQ ID NO: 13 (e.g., ASO-CEBPb-820; SEQ ID NO: 252). In some aspects, the target region corresponds to nucleotides 854-870 of SEQ ID NO: 13 (e.g., ASO-CEBPb-854; SEQ ID NO: 253). In some aspects, the target region corresponds to nucleotides 855-871 of SEQ ID NO: 13 (e.g., ASO-CEBPb-855; SEQ ID NO: 254). In some aspects, the target region corresponds to nucleotides 859-875 of SEQ ID NO: 13 (e.g., ASO-CEBPb-859; SEQ ID NO: 255). In some aspects, the target region corresponds to nucleotides 1050-1066 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1050; SEQ ID NO: 256). In some aspects, the target region corresponds to nucleotides 1053-1069 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1053; SEQ ID NO: 257). In some aspects, the target region corresponds to nucleotides 1062-1078 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1062; SEQ ID NO: 258). In some aspects, the target region corresponds to nucleotides 1063-1079 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1063; SEQ ID NO: 259). In some aspects, the target region corresponds to nucleotides 1064-1080 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1064; SEQ ID NO: 260). In some aspects, the target region corresponds to nucleotides 1065-1081 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1065; SEQ ID NO: 261). In some aspects, the target region corresponds to nucleotides 1265-1281 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1265; SEQ ID NO: 262). In some aspects, the target region corresponds to nucleotides 1270-1286 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1270; SEQ ID NO: 263). In some aspects, the target region corresponds to nucleotides 1271-1287 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1271; SEQ ID NO: 264). In some aspects, the target region corresponds to nucleotides 1272-1288 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1272; SEQ ID NO: 265). In some aspects, the target region corresponds to nucleotides 1274-1290 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1274; SEQ ID NO: 266). In some aspects, the target region corresponds to nucleotides 1277-1293 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1277; SEQ ID NO: 267). In some aspects, the target region corresponds to nucleotides 564-583 of SEQ ID NO: 13 (e.g., ASO-CEBPb-564; SEQ ID NO: 268). In some aspects, the target region corresponds to nucleotides 565-584 of SEQ ID NO: 13 (e.g., ASO-CEBPb-565; SEQ ID NO: 269). In some aspects, the target region corresponds to nucleotides 818-837 of SEQ ID NO: 13 (e.g., ASO-CEBPb-818; SEQ ID NO: 270). In some aspects, the target region corresponds to nucleotides 1061-1080 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1061; SEQ ID NO: 271). In some aspects, the target region corresponds to nucleotides 1062-1081 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1062; SEQ ID NO: 272). In some aspects, the target region corresponds to nucleotides 1064-1083 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1064; SEQ ID NO: 273). In some aspects, the target region corresponds to nucleotides 1267-1286 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1267; SEQ ID NO: 274). In some aspects, the target region corresponds to nucleotides 1272-1291 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1272; SEQ ID NO: 275). In some aspects, the target region corresponds to nucleotides 645-664 of SEQ ID NO: 13 (e.g., ASO-CEBPb-645; SEQ ID NO: 276). In some aspects, the target region corresponds to nucleotides 848-867 of SEQ ID NO: 13 (e.g., ASO-CEBPb-848; SEQ ID NO: 277). In some aspects, the target region corresponds to nucleotides 849-868 of SEQ ID NO: 13 (e.g., ASO-CEBPb-849; SEQ ID NO: 278). In some aspects, the target region corresponds to nucleotides 850-869 of SEQ ID NO: 13 (e.g., ASO-CEBPb-850; SEQ ID NO: 279). In some aspects, the target region corresponds to nucleotides 1063-1082 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1063; SEQ ID NO: 280). In some aspects, the target region corresponds to nucleotides 1070-1089 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1070; SEQ ID NO: 281). In some aspects, the target region corresponds to nucleotides 1071-1090 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1071; SEQ ID NO: 282). In some aspects, the target region corresponds to nucleotides 1262-1281 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1262; SEQ ID NO: 283). In some aspects, the target region corresponds to nucleotides 1274-1293 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1274; SEQ ID NO: 284). In some aspects, the target region corresponds to nucleotides 1275-1294 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1275; SEQ ID NO: 285). In some aspects, the target region corresponds to nucleotides 644-663 of SEQ ID NO: 13 (e.g., ASO-CEBPb-644; SEQ ID NO: 286). In some aspects, the target region corresponds to nucleotides 647-666 of SEQ ID NO: 13 (e.g., ASO-CEBPb-647; SEQ ID NO: 287). In some aspects, the target region corresponds to nucleotides 851-870 of SEQ ID NO: 13 (e.g., ASO-CEBPb-851; SEQ ID NO: 288). In some aspects, the target region corresponds to nucleotides 1266-1285 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1266; SEQ ID NO: 289). In some aspects, the target region corresponds to nucleotides 1268-1287 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1268; SEQ ID NO: 290). In some aspects, the target region corresponds to nucleotides 1270-1289 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1270; SEQ ID NO: 291). In some aspects, the target region corresponds to nucleotides 646-665 of SEQ ID NO: 13 (e.g., ASO-CEBPb-646; SEQ ID NO: 292). In some aspects, the target region corresponds to nucleotides 1060-1079 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1060; SEQ ID NO: 293). In some aspects, the target region corresponds to nucleotides 1263-1282 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1263; SEQ ID NO: 294). In some aspects, the target region corresponds to nucleotides 1269-1288 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1269; SEQ ID NO: 295). In some aspects, the target region corresponds to nucleotides 1271-1290 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1271; SEQ ID NO: 296).</p><p id="p-0176" num="0174">In some aspects, the target region corresponds to nucleotides 540-554 of SEQ ID NO: 13 (e.g., ASO-CEBPb-540; SEQ ID NO: 194) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the Y end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 565-579 of SEQ ID NO: 13 (e.g., ASO-CEBPb-565; SEQ ID NO: 195) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 569-583 of SEQ ID NO: 13 (e.g., ASO-CEBPb-569; SEQ ID NO: 196) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 648-662 of SEQ ID NO: 13 (e.g., ASO-CEBPb-648; SEQ ID NO: 197) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 816-830 of SEQ ID NO: 13 (e.g., ASO-CEBPb-816; SEQ ID NO: 198) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 817-831 of SEQ ID NO: 13 (e.g., ASO-CEBPb-817; SEQ ID NO: 199) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 818-832 of SEQ ID NO: 13 (e.g., ASO-CEBPb-818; SEQ ID NO: 200) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 819-833 of SEQ ID NO: 13 (e.g., ASO-CEBPb-819; SEQ ID NO: 201) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 820-834 of SEQ ID NO: 13 (e.g., ASO-CEBPb-820; SEQ ID NO: 202) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 851-865 of SEQ ID NO: 13 (e.g., ASO-CEBPb-851; SEQ ID NO: 203) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 853-867 of SEQ ID NO: 13 (e.g., ASO-CEBPb-853; SEQ ID NO: 204) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 856-870 of SEQ ID NO: 13 (e.g., ASO-CEBPb-856; SEQ ID NO: 205) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 858-872 of SEQ ID NO: 13 (e.g., ASO-CEBPb-858; SEQ ID NO: 206) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 987-1001 of SEQ ID NO: 13 (e.g., ASO-CEBPb-987; SEQ ID NO: 207) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1056-1070 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1056; SEQ ID NO: 208) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1064-1078 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1064; SEQ ID NO: 209) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1065-1079 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1065; SEQ ID NO: 210) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1066-1080 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1066; SEQ ID NO: 211) f 10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1071-1085 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1071; SEQ ID NO: 212) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1270-1284 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1270; SEQ ID NO: 213) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1273-1287 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1273; SEQ ID NO: 214) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1274-1288 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1274; SEQ ID NO: 215) f 10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1405-1419 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1405; SEQ ID NO: 216) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1407-1421 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1407; SEQ ID NO: 217) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 539-554 of SEQ ID NO: 13 (e.g., ASO-CEBPb-539; SEQ ID NO: 218) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 540-555 of SEQ ID NO: 13 (e.g., ASO-CEBPb-540; SEQ ID NO: 219) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 563-578 of SEQ ID NO: 13 (e.g., ASO-CEBPb-563; SEQ ID NO: 220) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 564-579 of SEQ ID NO: 13 (e.g., ASO-CEBPb-564; SEQ ID NO: 221) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 565-580 of SEQ ID NO: 13 (e.g., ASO-CEBPb-565; SEQ ID NO: 222) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 568-583 of SEQ ID NO: 13 (e.g., ASO-CEBPb-568; SEQ ID NO: 223) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 644-659 of SEQ ID NO: 13 (e.g., ASO-CEBPb-644; SEQ ID NO: 224) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 645-660 of SEQ ID NO: 13 (e.g., ASO-CEBPb-645; SEQ ID NO: 225) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 648-663 of SEQ ID NO: 13 (e.g., ASO-CEBPb-648; SEQ ID NO: 226) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 819-834 of SEQ ID NO: 13 (e.g., ASO-CEBPb-819; SEQ ID NO: 227) &#xb1;10, 20, 30, 40, 50, 60, 70, 80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 855-870 of SEQ ID NO: 13 (e.g., ASO-CEBPb-855; SEQ ID NO: 228) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 860-875 of SEQ ID NO: 13 (e.g., ASO-CEBPb-860; SEQ ID NO: 229) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 986-1001 of SEQ ID NO: 13 (e.g., ASO-CEBPb-986; SEQ ID NO: 230) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 987-1002 of SEQ ID NO: 13 (e.g., ASO-CEBPb-987; SEQ ID NO: 231) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 996-1011 of SEQ ID NO: 13 (e.g., ASO-CEBPb-996; SEQ ID NO: 232) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1049-1064 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1049; SEQ ID NO: 233) f 10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1050-1065 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1050; SEQ ID NO: 234) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1064-1079 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1064; SEQ ID NO: 235) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1065-1080 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1065; SEQ ID NO: 236) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1066-1081 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1066; SEQ ID NO: 237) f 10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1083-1098 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1083; SEQ ID NO: 238) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1088-1103 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1088; SEQ ID NO: 239) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1253-1268 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1253; SEQ ID NO: 240) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1269-1284 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1269; SEQ ID NO: 241) f 10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1272-1287 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1272; SEQ ID NO: 242) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1274-1289 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1274; SEQ ID NO: 243) &#xb1;10, 20, 30, 40, 50, 60, 70, 80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 539-555 of SEQ ID NO: 13 (e.g., ASO-CEBPb-539; SEQ ID NO: 244) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 564-580 of SEQ ID NO: 13 (e.g., ASO-CEBPb-564; SEQ ID NO: 245) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 565-581 of SEQ ID NO: 13 (e.g., ASO-CEBPb-565; SEQ ID NO: 246) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 567-583 of SEQ ID NO: 13 (e.g., ASO-CEBPb-567; SEQ ID NO: 247) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 647-663 of SEQ ID NO: 13 (e.g., ASO-CEBPb-647; SEQ ID NO: 248) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 648-664 of SEQ ID NO: 13 (e.g., ASO-CEBPb-648; SEQ ID NO: 249) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 815-831 of SEQ ID NO: 13 (e.g., ASO-CEBPb-815; SEQ ID NO: 250) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 818-834 of SEQ ID NO: 13 (e.g., ASO-CEBPb-818; SEQ ID NO: 251) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 820-836 of SEQ ID NO: 13 (e.g., ASO-CEBPb-820; SEQ ID NO: 252) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 854-870 of SEQ ID NO: 13 (e.g., ASO-CEBPb-854; SEQ ID NO: 253) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 855-871 of SEQ ID NO: 13 (e.g., ASO-CEBPb-855; SEQ ID NO: 254) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 859-875 of SEQ ID NO: 13 (e.g., ASO-CEBPb-859; SEQ ID NO: 255) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1050-1066 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1050; SEQ ID NO: 256) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1053-1069 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1053; SEQ ID NO: 257) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1062-1078 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1062; SEQ ID NO: 258) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1063-1079 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1063; SEQ ID NO: 259) f 10, 20, 30, 40, 50, 60, 70, 80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1064-1080 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1064; SEQ ID NO: 260) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1065-1081 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1065; SEQ ID NO: 261) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1265-1281 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1265; SEQ ID NO: 262) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1270-1286 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1270; SEQ ID NO: 263) f 10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1271-1287 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1271; SEQ ID NO: 264) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1272-1288 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1272; SEQ ID NO: 265) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1274-1290 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1274; SEQ ID NO: 266) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1277-1293 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1277; SEQ ID NO: 267) f 10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 564-583 of SEQ ID NO: 13 (e.g., ASO-CEBPb-564; SEQ ID NO: 268) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 565-584 of SEQ ID NO: 13 (e.g., ASO-CEBPb-565; SEQ ID NO: 269) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 818-837 of SEQ ID NO: 13 (e.g., ASO-CEBPb-818; SEQ ID NO: 270) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1061-1080 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1061; SEQ ID NO: 271) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1062-1081 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1062; SEQ ID NO: 272) f 10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1064-1083 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1064; SEQ ID NO: 273) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1267-1286 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1267; SEQ ID NO: 274) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1272-1291 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1272; SEQ ID NO: 275) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, 70, 80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 645-664 of SEQ ID NO: 13 (e.g., ASO-CEBPb-645; SEQ ID NO: 276) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 848-867 of SEQ ID NO: 13 (e.g., ASO-CEBPb-848; SEQ ID NO: 277) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 849-868 of SEQ ID NO: 13 (e.g., ASO-CEBPb-849; SEQ ID NO: 278) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 850-869 of SEQ ID NO: 13 (e.g., ASO-CEBPb-850; SEQ ID NO: 279) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1063-1082 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1063; SEQ ID NO: 280) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1070-1089 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1070; SEQ ID NO: 281) f 10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1071-1090 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1071; SEQ ID NO: 282) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1262-1281 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1262; SEQ ID NO: 283) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1274-1293 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1274; SEQ ID NO: 284) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1275-1294 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1275; SEQ ID NO: 285) f 10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 644-663 of SEQ ID NO: 13 (e.g., ASO-CEBPb-644; SEQ ID NO: 286) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 647-666 of SEQ ID NO: 13 (e.g., ASO-CEBPb-647; SEQ ID NO: 287) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 851-870 of SEQ ID NO: 13 (e.g., ASO-CEBPb-851; SEQ ID NO: 288) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1266-1285 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1266; SEQ ID NO: 289) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1268-1287 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1268; SEQ ID NO: 290) f 10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1270-1289 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1270; SEQ ID NO: 291) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 646-665 of SEQ ID NO: 13 (e.g., ASO-CEBPb-646; SEQ ID NO: 292) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1060-1079 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1060; SEQ ID NO: 293) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1263-1282 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1263; SEQ ID NO: 294) f 10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1269-1288 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1269; SEQ ID NO: 295) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or 90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end. In some aspects, the target region corresponds to nucleotides 1271-1290 of SEQ ID NO: 13 (e.g., ASO-CEBPb-1271; SEQ ID NO: 296) &#xb1;10, &#xb1;20, &#xb1;30, &#xb1;40, &#xb1;50, &#xb1;60, &#xb1;70, &#xb1;80, or &#xb1;90 nucleotides at the 3&#x2032; end and/or the 5&#x2032; end.</p><p id="p-0177" num="0175">In some aspects, the ASO is not TGGATITAAAGGCAGGCGGC (SEQ ID NO: 90). In some aspects, the target region comprises. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 1-518 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 1-517 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 1-516 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 1-515 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 1-514 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 1-513 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 1-512 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 1-511 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 1-510 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 1-509 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 1-508 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 1-507 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 1-506 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 1-505 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 1-504 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 1-503 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 1-502 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 1-501 of SEQ ID NO: 13.</p><p id="p-0178" num="0176">In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 504-2113 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 505-2113 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 506-2113 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 507-2113 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 508-2113 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 509-2113 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 510-2113 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 511-2113 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 512-2113 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 513-2113 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 514-2113 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 515-2113 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 516-2113 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 517-2113 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 518-2113 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 519-2113 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 520-2113 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 521-2113 of SEQ ID NO: 13. In some aspects, the target region corresponds to a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within nucleotides 522-2113 of SEQ ID NO: 13.</p><p id="p-0179" num="0177">In some aspects, the ASO of the present disclosure hybridizes to multiple target regions within the CEBP/&#x3b2; transcript (e.g., genomic sequence, SEQ ID NO: 1 or SEQ ID NO: 11, respectively). In some aspects, the ASO hybridizes to two different target regions within the CEBP/&#x3b2; transcript. In some aspects, the ASO hybridizes to three different target regions within the CEBP/&#x3b2; transcript. The sequences of exemplary ASOs that hybridizes to multiple target regions, and the start/end sites of the different target regions are provided in <figref idref="DRAWINGS">FIG. <b>1</b></figref>. In some aspects, the ASOs that hybridizes to multiple regions within the CEBP/&#x3b2; transcript (e.g., genomic sequence, SEQ ID NO: 1 or SEQ ID NO: 11, respectively) are more potent (e.g., having lower EC50) at reducing CEBP/&#x3b2; expression compared to ASOs that hybridizes to a single region within the CEBP/&#x3b2; transcript (e.g., genomic sequence, SEQ ID NO: 1 or SEQ ID NO: 11, respectively).</p><p id="p-0180" num="0178">In some aspects, the ASO of the disclosure is capable of hybridizing to the target nucleic acid (e.g., CEBP/&#x3b2; transcript) under physiological condition, i.e., in vivo condition. In some aspects, the ASO of the disclosure is capable of hybridizing to the target nucleic acid (e.g., CEBP/&#x3b2; transcript) in vitro. In some aspects, the ASO of the disclosure is capable of hybridizing to the target nucleic acid (e.g., CEBP/&#x3b2; transcript) in vitro under stringent conditions. Stringency conditions for hybridization in vitro are dependent on, inter alia, productive cell uptake, RNA accessibility, temperature, free energy of association, salt concentration, and time (see, e.g., Stanley T Crooke, Antisense Drug Technology: Principles, Strategies and Applications, 2<sup>nd </sup>Edition, CRC Press (2007)). Generally, conditions of high to moderate stringency are used for in vitro hybridization to enable hybridization between substantially similar nucleic acids, but not between dissimilar nucleic acids. An example of stringent hybridization conditions includes hybridization in 5&#xd7; saline-sodium citrate (SSC) buffer (0.75 M sodium chloride/0.075 M sodium citrate) for 1 hour at 40&#xb0; C., followed by washing the sample 10 times in 1&#xd7;SSC at 40&#xb0; C., and 5 times in 1&#xd7;SSC buffer at room temperature. In vivo hybridization conditions consist of intracellular conditions (e.g., physiological pH and intracellular ionic conditions) that govern the hybridization of antisense oligonucleotides with target sequences. In vivo conditions can be mimicked in vitro by relatively low stringency conditions. For example, hybridization can be carried out in vitro in 2&#xd7;SSC (0.3 M sodium chloride/0.03 M sodium citrate), 0.1% SDS at 37&#xb0; C. A wash solution containing 4&#xd7;SSC, 0.1% SDS can be used at 37&#xb0; C., with a final wash in 1&#xd7;SSC at 45&#xb0; C.</p><p id="p-0181" num="0179">In some aspects, the ASO of the present disclosure is capable of targeting a CEBP/&#x3b2; transcript from one or more species (e.g., humans, non-human primates, dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, and bears). In certain aspects, the ASO disclosed herein is capable of targeting both human and rodent (e.g., mice or rats) CEBP/&#x3b2; transcript. Accordingly, in some aspects, the ASO is capable of down-regulating (e.g., reducing or removing) expression of the CEBP/&#x3b2; mRNA or protein both in humans and in rodents (e.g., mice or rats). In some aspects, any ASO described herein is part of a conjugate, comprising the ASO covalently linked to at least one non-nucleotide or non-polynucleotide.</p><p id="p-0182" num="0180">Certain aspects of the present disclosure are directed to a conjugate comprising an ASO described herein. In certain aspects, the conjugate comprises an ASO covalently attached to at least one non-nucleotide. In certain aspects, the conjugate comprises an ASO covalently attached to at least non-polynucleotide moiety. In some aspects, the non-nucleotide or non-polynucleotide moiety comprises a protein, a fatty acid chain, a sugar residue, a glycoprotein, a polymer, or any combinations thereof.</p><heading id="h-0011" level="1">II.B. ASO Sequences</heading><p id="p-0183" num="0181">The ASOs of the disclosure comprise a contiguous nucleotide sequence which corresponds to the complement of a region of CEBP/&#x3b2; transcript, e.g., a nucleotide sequence corresponding to SEQ ID NO: 11 or SEQ ID NO: 13.</p><p id="p-0184" num="0182">In certain aspects, the disclosure provides an ASO from 10-30, such as 10-15 nucleotides, 10-20 nucleotides, 10-25 nucleotides in length, or about 20 nucleotides in length, wherein the contiguous nucleotide sequence has at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity to a region within the complement of a CEBP/&#x3b2; transcript, such as SEQ ID NO: 11 or SEQ ID NO: 13 or naturally occurring variant thereof. Thus, for example, the ASO hybridizes to a single stranded nucleic acid molecule having the sequence of SEQ ID NO: 11 or SEQ ID NO: 13 or a portion thereof.</p><p id="p-0185" num="0183">The ASO can comprise a contiguous nucleotide sequence which is fully complementary (perfectly complementary) to the equivalent region of a nucleic acid which encodes a mammalian CEBP/&#x3b2; protein (e.g., SEQ ID NO: 11 or SEQ ID NO: 13). The ASO can comprise a contiguous nucleotide sequence which is fully complementary (perfectly complementary) to a nucleic acid sequence, or a region within the sequence, corresponding to nucleotides X-Y of SEQ ID NO: 11 or SEQ ID NO: 13, wherein X and Y are the start site and the end site, respectively, as shown in <figref idref="DRAWINGS">FIG. <b>1</b>B</figref>.</p><p id="p-0186" num="0184">The ASO can comprise a contiguous nucleotide sequence which is fully complementary (perfectly complementary) to the equivalent region of a mRNA which encodes a mammalian CEBP/&#x3b2; protein (e.g., SEQ ID NO: 13). The ASO can comprise a contiguous nucleotide sequence which is fully complementary (perfectly complementary) to a mRNA sequence, or a region within the sequence, corresponding to nucleotides X-Y of SEQ ID NO: 13, wherein X and Y are the start site and the end site, respectively.</p><p id="p-0187" num="0185">In some aspects, the nucleotide sequence of the ASOs of the disclosure or the contiguous nucleotide sequence has at least about 80% sequence identity to a sequence selected from SEQ ID NOs: 194 to 296 (i.e., the sequences in <figref idref="DRAWINGS">FIG. <b>1</b>B</figref>), such as at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96% sequence identity, at least about 97% sequence identity, at least about 98% sequence identity, at least about 99% sequence identity, such as about 100% sequence identity (homologous). In some aspects, the ASO has a design described elsewhere herein or a chemical structure shown elsewhere herein (e.g., <figref idref="DRAWINGS">FIG. <b>1</b>B</figref>).</p><p id="p-0188" num="0186">In some aspects the ASO (or contiguous nucleotide portion thereof) is selected from, or comprises, one of the sequences selected from the group consisting of SEQ ID NOs: 194 to 296 or a region of at least 10 contiguous nucleotides thereof, wherein the ASO (or contiguous nucleotide portion thereof) can optionally comprise one, two, three, or four mismatches when compared to the corresponding CEBP/&#x3b2; transcript.</p><p id="p-0189" num="0187">In some aspects, the ASO comprises a sequence selected from the group consisting of SEQ ID NO: 194 (e.g., ASO-CEBPb-540), SEQ ID NO: 195 (e.g., ASO-CEBPb-565), SEQ ID NO: 196 (e.g., ASO-CEBPb-569), SEQ ID NO: 197 (e.g., ASO-CEBPb-648), SEQ ID NO: 198 (e.g., ASO-CEBPb-816), SEQ ID NO: 199 (e.g., ASO-CEBPb-817), SEQ ID NO: 200 (e.g., ASO-CEBPb-818), SEQ ID NO: 201 (e.g., ASO-CEBPb-819), SEQ ID NO: 202 (e.g., ASO-CEBPb-820), SEQ ID NO: 203 (e.g., ASO-CEBPb-851), SEQ ID NO: 204 (e.g., ASO-CEBPb-853), SEQ ID NO: 205 (e.g., ASO-CEBPb-856), SEQ ID NO: 206 (e.g., ASO-CEBPb-858), SEQ ID NO: 207 (e.g., ASO-CEBPb-987), SEQ ID NO: 208 (e.g., ASO-CEBPb-1056), SEQ ID NO: 209 (e.g., ASO-CEBPb-1064), SEQ ID NO: 210 (e.g., ASO-CEBPb-1065), SEQ ID NO: 211 (e.g., ASO-CEBPb-1066), SEQ ID NO: 212 (e.g., ASO-CEBPb-1071), SEQ ID NO: 213 (e.g., ASO-CEBPb-1270), SEQ ID NO: 214 (e.g., ASO-CEBPb-1273), SEQ ID NO: 215 (e.g., ASO-CEBPb-1274), SEQ ID NO: 216 (e.g., ASO-CEBPb-1405), SEQ ID NO: 217 (e.g., ASO-CEBPb-1407), SEQ ID NO: 218 (e.g., ASO-CEBPb-539), SEQ ID NO: 219 (e.g., ASO-CEBPb-540), SEQ ID NO: 220 (e.g., ASO-CEBPb-563), SEQ ID NO: 221 (e.g., ASO-CEBPb-564), SEQ ID NO: 222 (e.g., ASO-CEBPb-565), SEQ ID NO: 223 (e.g., ASO-CEBPb-568), SEQ ID NO: 224 (e.g., ASO-CEBPb-644), SEQ ID NO: 225 (e.g., ASO-CEBPb-645), SEQ ID NO: 226 (e.g., ASO-CEBPb-648), SEQ ID NO: 227 (e.g., ASO-CEBPb-819), SEQ ID NO: 228 (e.g., ASO-CEBPb-855), SEQ ID NO: 229 (e.g., ASO-CEBPb-860), SEQ ID NO: 230 (e.g., ASO-CEBPb-986), SEQ ID NO: 231 (e.g., ASO-CEBPb-987), SEQ ID NO: 232 (e.g., ASO-CEBPb-996), SEQ ID NO: 233 (e.g., ASO-CEBPb-1049), SEQ ID NO: 234 (e.g., ASO-CEBPb-1050), SEQ ID NO: 235 (e.g., ASO-CEBPb-1064), SEQ ID NO: 236 (e.g., ASO-CEBPb-1065), SEQ ID NO: 237 (e.g., ASO-CEBPb-1066), SEQ ID NO: 238 (e.g., ASO-CEBPb-1083), SEQ ID NO: 239 (e.g., ASO-CEBPb-1088), SEQ ID NO: 240 (e.g., ASO-CEBPb-1253), SEQ ID NO: 241 (e.g., ASO-CEBPb-1269), SEQ ID NO: 242 (e.g., ASO-CEBPb-1272), SEQ ID NO: 243 (e.g., ASO-CEBPb-1274), SEQ ID NO: 244 (e.g., ASO-CEBPb-539), SEQ ID NO: 245 (e.g., ASO-CEBPb-564), SEQ ID NO: 246 (e.g., ASO-CEBPb-565), SEQ ID NO: 247 (e.g., ASO-CEBPb-567), SEQ ID NO: 248 (e.g., ASO-CEBPb-647), SEQ ID NO: 249 (e.g., ASO-CEBPb-648), SEQ ID NO: 250 (e.g., ASO-CEBPb-815), SEQ ID NO: 251 (e.g., ASO-CEBPb-818), SEQ ID NO: 252 (e.g., ASO-CEBPb-820), SEQ ID NO: 253 (e.g., ASO-CEBPb-854), SEQ ID NO: 254 (e.g., ASO-CEBPb-855), SEQ ID NO: 255 (e.g., ASO-CEBPb-859), SEQ ID NO: 256 (e.g., ASO-CEBPb-1050), SEQ ID NO: 257 (e.g., ASO-CEBPb-1053), SEQ ID NO: 258 (e.g., ASO-CEBPb-1062), SEQ ID NO: 259 (e.g., ASO-CEBPb-1063), SEQ ID NO: 260 (e.g., ASO-CEBPb-1064), SEQ ID NO: 261 (e.g., ASO-CEBPb-1065), SEQ ID NO: 262 (e.g., ASO-CEBPb-1265), SEQ ID NO: 263 (e.g., ASO-CEBPb-1270), SEQ ID NO: 264 (e.g., ASO-CEBPb-1271), SEQ ID NO: 265 (e.g., ASO-CEBPb-1272), SEQ ID NO: 266 (e.g., ASO-CEBPb-1274), SEQ ID NO: 267 (e.g., ASO-CEBPb-1277), SEQ ID NO: 268 (e.g., ASO-CEBPb-564), SEQ ID NO: 269 (e.g., ASO-CEBPb-565), SEQ ID NO: 270 (e.g., ASO-CEBPb-818), SEQ ID NO: 271 (e.g., ASO-CEBPb-1061), SEQ ID NO: 272 (e.g., ASO-CEBPb-1062), SEQ ID NO: 273 (e.g., ASO-CEBPb-1064), SEQ ID NO: 274 (e.g., ASO-CEBPb-1267), SEQ ID NO: 275 (e.g., ASO-CEBPb-1272), SEQ ID NO: 276 (e.g., ASO-CEBPb-645), SEQ ID NO: 277 (e.g., ASO-CEBPb-848), SEQ ID NO: 278 (e.g., ASO-CEBPb-849), SEQ ID NO: 279 (e.g., ASO-CEBPb-850), SEQ ID NO: 280 (e.g., ASO-CEBPb-1063), SEQ ID NO: 281 (e.g., ASO-CEBPb-1070), SEQ ID NO: 282 (e.g., ASO-CEBPb-1071), SEQ ID NO: 283 (e.g., ASO-CEBPb-1262), SEQ ID NO: 284 (e.g., ASO-CEBPb-1274), SEQ ID NO: 285 (e.g., ASO-CEBPb-1275), SEQ ID NO: 286 (e.g., ASO-CEBPb-644), SEQ ID NO: 287 (e.g., ASO-CEBPb-647), SEQ ID NO: 288 (e.g., ASO-CEBPb-851), SEQ ID NO: 289 (e.g., ASO-CEBPb-1266), SEQ ID NO: 290 (e.g., ASO-CEBPb-1268), SEQ ID NO: 291 (e.g., ASO-CEBPb-1270), SEQ ID NO: 292 (e.g., ASO-CEBPb-646), SEQ ID NO: 293 (e.g., ASO-CEBPb-1060), SEQ ID NO: 294 (e.g., ASO-CEBPb-1263), SEQ ID NO: 295 (e.g., ASO-CEBPb-1269), and SEQ ID NO: 296 (e.g., ASO-CEBPb-1271).</p><p id="p-0190" num="0188">In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 194 (e.g., ASO-CEBPb-540). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 195 (e.g., ASO-CEBPb-565). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 196 (e.g., ASO-CEBPb-569). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 197 (e.g., ASO-CEBPb-648). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 198 (e.g., ASO-CEBPb-816). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 199 (e.g., ASO-CEBPb-817). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 200 (e.g., ASO-CEBPb-818). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 201 (e.g., ASO-CEBPb-819). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 202 (e.g., ASO-CEBPb-820). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 203 (e.g., ASO-CEBPb-851). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 204 (e.g., ASO-CEBPb-853). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 205 (e.g., ASO-CEBPb-856). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 206 (e.g., ASO-CEBPb-858). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 207 (e.g., ASO-CEBPb-987). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 208 (e.g., ASO-CEBPb-1056). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 209 (e.g., ASO-CEBPb-1064). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 210 (e.g., ASO-CEBPb-1065). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 211 (e.g., ASO-CEBPb-1066). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 212 (e.g., ASO-CEBPb-1071). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 213 (e.g., ASO-CEBPb-1270). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 214 (e.g., ASO-CEBPb-1273). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 215 (e.g., ASO-CEBPb-1274). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 216 (e.g., ASO-CEBPb-1405). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 217 (e.g., ASO-CEBPb-1407). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 218 (e.g., ASO-CEBPb-539). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 219 (e.g., ASO-CEBPb-540). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 220 (e.g., ASO-CEBPb-563). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 221 (e.g., ASO-CEBPb-564). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 222 (e.g., ASO-CEBPb-565). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 223 (e.g., ASO-CEBPb-568). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 224 (e.g., ASO-CEBPb-644). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 225 (e.g., ASO-CEBPb-645). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 226 (e.g., ASO-CEBPb-648). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 227 (e.g., ASO-CEBPb-819). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 228 (e.g., ASO-CEBPb-855). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 229 (e.g., ASO-CEBPb-860). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 230 (e.g., ASO-CEBPb-986). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 231 (e.g., ASO-CEBPb-987). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 232 (e.g., ASO-CEBPb-996). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 233 (e.g., ASO-CEBPb-1049). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 234 (e.g., ASO-CEBPb-1050). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 235 (e.g., ASO-CEBPb-1064). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 236 (e.g., ASO-CEBPb-1065). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 237 (e.g., ASO-CEBPb-1066). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 238 (e.g., ASO-CEBPb-1083). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 239 (e.g., ASO-CEBPb-1088). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 240 (e.g., ASO-CEBPb-1253). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 241 (e.g., ASO-CEBPb-1269). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 242 (e.g., ASO-CEBPb-1272). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 243 (e.g., ASO-CEBPb-1274). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 244 (e.g., ASO-CEBPb-539). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 245 (e.g., ASO-CEBPb-564). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 246 (e.g., ASO-CEBPb-565). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 247 (e.g., ASO-CEBPb-567). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 248 (e.g., ASO-CEBPb-647). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 249 (e.g., ASO-CEBPb-648). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 250 (e.g., ASO-CEBPb-815). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 251 (e.g., ASO-CEBPb-818). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 252 (e.g., ASO-CEBPb-820). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 253 (e.g., ASO-CEBPb-854). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 254 (e.g., ASO-CEBPb-855). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 255 (e.g., ASO-CEBPb-859). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 256 (e.g., ASO-CEBPb-1050). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 257 (e.g., ASO-CEBPb-1053). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 258 (e.g., ASO-CEBPb-1062). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 259 (e.g., ASO-CEBPb-1063). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 260 (e.g., ASO-CEBPb-1064). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 261 (e.g., ASO-CEBPb-1065). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 262 (e.g., ASO-CEBPb-1265). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 263 (e.g., ASO-CEBPb-1270). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 264 (e.g., ASO-CEBPb-1271). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 265 (e.g., ASO-CEBPb-1272). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 266 (e.g., ASO-CEBPb-1274). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 267 (e.g., ASO-CEBPb-1277). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 268 (e.g., ASO-CEBPb-564). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 269 (e.g., ASO-CEBPb-565). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 270 (e.g., ASO-CEBPb-818). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 271 (e.g., ASO-CEBPb-1061). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 272 (e.g., ASO-CEBPb-1062). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 273 (e.g., ASO-CEBPb-1064). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 274 (e.g., ASO-CEBPb-1267). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 275 (e.g., ASO-CEBPb-1272). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 276 (e.g., ASO-CEBPb-645). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 277 (e.g., ASO-CEBPb-848). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 278 (e.g., ASO-CEBPb-849). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 279 (e.g., ASO-CEBPb-850). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 280 (e.g., ASO-CEBPb-1063). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 281 (e.g., ASO-CEBPb-1070). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 282 (e.g., ASO-CEBPb-1071). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 283 (e.g., ASO-CEBPb-1262). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 284 (e.g., ASO-CEBPb-1274). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 285 (e.g., ASO-CEBPb-1275). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 286 (e.g., ASO-CEBPb-644). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 287 (e.g., ASO-CEBPb-647). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 288 (e.g., ASO-CEBPb-851). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 289 (e.g., ASO-CEBPb-1266). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 290 (e.g., ASO-CEBPb-1268). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 291 (e.g., ASO-CEBPb-1270). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 292 (e.g., ASO-CEBPb-646). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 293 (e.g., ASO-CEBPb-1060). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 294 (e.g., ASO-CEBPb-1263). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 295 (e.g., ASO-CEBPb-1269). In some aspects, the ASO comprises the sequence as set forth in SEQ ID NO: 296 (e.g., ASO-CEBPb-1271).</p><p id="p-0191" num="0189">In some aspects, the ASOs of the disclosure bind to the target nucleic acid sequence (e.g., CEBP/&#x3b2; transcript) and are capable of inhibiting or reducing expression of the CEBP/&#x3b2; transcript by at least 10% or 20% compared to the normal (i.e., control) expression level in the cell, e.g., at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% compared to the normal expression level (e.g., expression level in cells that have not been exposed to the ASO).</p><p id="p-0192" num="0190">In some aspects, the ASOs of the disclosure are capable of reducing expression of CEBP/&#x3b2; mRNA in vitro by at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% in target cells when the cells are in contact with the ASO compared to cells that are not in contact with the ASO (e.g., contact with saline).</p><p id="p-0193" num="0191">In some aspects, the ASO can tolerate 1, 2, 3, or 4 (or more) mismatches, when hybridizing to the target sequence and still sufficiently bind to the target to show the desired effect, i.e., down-regulation of the target mRNA and/or protein. Mismatches can, for example, be compensated by increased length of the ASO nucleotide sequence and/or an increased number of nucleotide analogs, which are disclosed elsewhere herein.</p><p id="p-0194" num="0192">In some aspects, the ASO of the disclosure comprises no more than three mismatches when hybridizing to the target sequence. In other aspects, the contiguous nucleotide sequence comprises no more than two mismatches when hybridizing to the target sequence. In other aspects, the contiguous nucleotide sequence comprises no more than one mismatch when hybridizing to the target sequence.</p><heading id="h-0012" level="1">II.C. ASO Length</heading><p id="p-0195" num="0193">The ASOs can comprise a contiguous nucleotide sequence of a total of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 contiguous nucleotides in length. It should be understood that when a range is given for an ASO, or contiguous nucleotide sequence length, the range includes the lower and upper lengths provided in the range, for example from (or between) 10-30, includes both 10 and 30.</p><p id="p-0196" num="0194">In some aspects, the ASOs comprise a contiguous nucleotide sequence of a total of about 14-20, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleotides in length. In certain aspects, the ASOs comprise a contiguous nucleotide sequence of a total of about 20 contiguous nucleotides in length. In certain aspects, ASOs of the present disclosure are 14 nucleotides in length. In certain aspects, ASOs of the present disclosure are 15 nucleotides in length. In certain aspects, ASOs of the present disclosure are 16 nucleotides in length. In certain aspects, ASOs of the present disclosure are 17 nucleotides in length. In certain aspects, ASOs of the present disclosure are 18 nucleotides in length. In certain aspects, ASOs of the present disclosure are 19 nucleotides in length.</p><heading id="h-0013" level="1">II.D. Nucleosides and Nucleoside Analogs</heading><p id="p-0197" num="0195">In one aspect of the disclosure, the ASOs comprise one or more non-naturally occurring nucleoside analogs. &#x201c;Nucleoside analogs&#x201d; as used herein are variants of natural nucleosides, such as DNA or RNA nucleosides, by virtue of modifications in the sugar and/or base moieties. Analogs could in principle be merely &#x201c;silent&#x201d; or &#x201c;equivalent&#x201d; to the natural nucleosides in the context of the oligonucleotide, i.e. have no functional effect on the way the oligonucleotide works to inhibit target gene expression. Such &#x201c;equivalent&#x201d; analogs can nevertheless be useful if, for example, they are easier or cheaper to manufacture, or are more stable to storage or manufacturing conditions, or represent a tag or label. In some aspects, however, the analogs will have a functional effect on the way in which the ASO works to inhibit expression; for example by producing increased binding affinity to the target and/or increased resistance to intracellular nucleases and/or increased ease of transport into the cell. Specific examples of nucleoside analogs are described by e.g. Freier &#x26; Altmann; <i>Nucl. Acid Res., </i>1997, 25, 4429-4443 and Uhlmann; <i>Curr. Opinion in Drug Development, </i>2000, 3(2), 293-213, and in Scheme 1. The ASOs of the present disclosure can contain more than one, more than two, more than three, more than four, more than five, more than six, more than seven, more than eight, more than nine, more than 10, more than 11, more than 12, more than 13, more than 14, more than 15, more than 16, more than 18, more than 19, or more than 20 nucleoside analogs. In some aspects, the nucleoside analogs in the ASOs are the same. In other aspects, the nucleoside analogs in the ASOs are different. The nucleotide analogs in the ASOs can be any one of or combination of the following nucleoside analogs.</p><p id="p-0198" num="0196">In some aspects, the nucleoside analog comprises a 2&#x2032;-O-alkyl-RNA; 2&#x2032;-O-methyl RNA (2&#x2032;-OMe); 2&#x2032;-alkoxy-RNA; 2&#x2032;-O-methoxyethyl-RNA (2&#x2032;-MOE); 2&#x2032;-amino-DNA; 2&#x2032;-fluoro-RNA; 2&#x2032;-fluoro-DNA; arabino nucleic acid (ANA); 2&#x2032;-fluoro-ANA; bicyclic nucleoside analog; or any combination thereof. In some aspects, the nucleoside analog comprises a sugar modified nucleoside. In some aspects, the nucleoside analog comprises a nucleoside comprising a bicyclic sugar. In some aspects, the nucleoside analog comprises an LNA.</p><p id="p-0199" num="0197">In some aspects, the nucleoside analog is selected from the group consisting of constrained ethyl nucleoside (cEt), 2&#x2032;,4&#x2032;-constrained 2&#x2032;-O-methoxyethyl (cMOE), &#x3b1;-L-LNA, S-D-LNA, 2&#x2032;-O,4&#x2032;-C-ethylene-bridged nucleic acids (ENA), amino-LNA, oxy-LNA, thio-LNA, and any combination thereof. In some aspects, the ASO comprises one or more 5&#x2032;-methyl-cytosine nucleobases.</p><heading id="h-0014" level="1">II.D.1. Nucleobase</heading><p id="p-0200" num="0198">The term nucleobase includes the purine (e.g., adenine and guanine) and pyrimidine (e.g., uracil, thymine and cytosine) moiety present in nucleosides and nucleotides which form hydrogen bonds in nucleic acid hybridization. In the context of the present disclosure, the term nucleobase also encompasses modified nucleobases which may differ from naturally occurring nucleobases, but are functional during nucleic acid hybridization. In some aspects, the nucleobase moiety is modified by modifying or replacing the nucleobase. In this context, &#x201c;nucleobase&#x201d; refers to both naturally occurring nucleobases such as adenine, guanine, cytosine, thymidine, uracil, xanthine and hypoxanthine, as well as non-naturally occurring variants. Such variants are for example described in Hirao et al., (2012) <i>Accounts of Chemical Research vol </i>45 page 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl. 37 1.4.1.</p><p id="p-0201" num="0199">In a some aspects, the nucleobase moiety is modified by changing the purine or pyrimidine into a modified purine or pyrimidine, such as substituted purine or substituted pyrimidine, such as a nucleobase selected from isocytosine, pseudoisocytosine, 5-methyl-cytosine, 5-thiozolo-cytosine, 5-propynyl-cytosine, 5-propynyl-uracil, 5-bromouracil, 5-thiazolo-uracil, 2-thio-uracil, 2&#x2032;thio-thymine, inosine, diaminopurine, 6-aminopurine, 2-aminopurine, 2,6-diaminopurine, and 2-chloro-6-aminopurine.</p><p id="p-0202" num="0200">The nucleobase moieties may be indicated by the letter code for each corresponding nucleobase, e.g., A, T, G, C, or U, wherein each letter may optionally include modified nucleobases of equivalent function. For example, in the exemplified oligonucleotides, the nucleobase moieties are selected from A, T, G, C, and 5-methyl-cytosine. Optionally, for LNA gapmers, 5-methyl-cytosine LNA nucleosides may be used.</p><heading id="h-0015" level="1">II.D.2. Sugar Modification</heading><p id="p-0203" num="0201">The ASO of the disclosure can comprise one or more nucleosides which have a modified sugar moiety, i.e, a modification of the sugar moiety when compared to the ribose sugar moiety found in DNA and RNA. Numerous nucleosides with modification of the ribose sugar moiety have been made, primarily with the aim of improving certain properties of oligonucleotides, such as affinity and/or nuclease resistance.</p><p id="p-0204" num="0202">Such modifications include those where the ribose ring structure is modified, e.g. by replacement with a hexose ring (HNA), or a bicyclic ring, which typically have a biradical bridge between the C2 and C4&#x2032; carbons on the ribose ring (LNA), or an unlinked ribose ring which typically lacks a bond between the C2 and C3&#x2032; carbons (e.g., UNA). Other sugar modified nucleosides include, for example, bicyclohexose nucleic acids (WO2011/017521) or tricyclic nucleic acids (WO2013/154798). Modified nucleosides also include nucleosides where the sugar moiety is replaced with a non-sugar moiety, for example in the case of peptide nucleic acids (PNA), or morpholino nucleic acids.</p><p id="p-0205" num="0203">Sugar modifications also include modifications made via altering the substituent groups on the ribose ring to groups other than hydrogen, or the 2&#x2032;-OH group naturally found in RNA nucleosides. Substituents may, for example be introduced at the 2&#x2032;, 3&#x2032;, 4&#x2032;, or 5&#x2032; positions. Nucleosides with modified sugar moieties also include 2&#x2032; modified nucleosides, such as 2&#x2032; substituted nucleosides. Indeed, much focus has been spent on developing 2&#x2032; substituted nucleosides, and numerous 2&#x2032; substituted nucleosides have been found to have beneficial properties when incorporated into oligonucleotides, such as enhanced nucleoside resistance and enhanced affinity.</p><heading id="h-0016" level="1">II.D.2.a. 2&#x2032; Modified Nucleosides</heading><p id="p-0206" num="0204">A 2&#x2032; sugar modified nucleoside is a nucleoside which has a substituent other than H or &#x2014;OH at the 2&#x2032; position (2&#x2032; substituted nucleoside) or comprises a 2&#x2032; linked biradical, and includes 2&#x2032; substituted nucleosides and LNA (2&#x2032;-4&#x2032; biradical bridged) nucleosides. For example, the 2&#x2032; modified sugar may provide enhanced binding affinity (e.g., affinity enhancing 2&#x2032; sugar modified nucleoside) and/or increased nuclease resistance to the oligonucleotide. Examples of 2&#x2032; substituted modified nucleosides are 2&#x2032;-O-alkyl-RNA, 2&#x2032;-O-methyl-RNA, 2&#x2032;-alkoxy-RNA, 2&#x2032;-O-methoxyethyl-RNA (MOE), 2&#x2032;-amino-DNA, 2&#x2032;-Fluoro-RNA, 2&#x2032;-Fluro-DNA, arabino nucleic acids (ANA), and 2&#x2032;-Fluoro-ANA nucleoside. For further examples, please see, e.g., Freier &#x26; Altmann; <i>Nucl. Acid Res., </i>1997, 25, 4429-4443; Uhlmann, <i>Curr. Opinion in Drug Development, </i>2000, 3(2), 293-213; and Deleavey and Damha, Chemistry and Biology 2012, 19, 937. Below are illustrations of some 2&#x2032; substituted modified nucleosides.</p><p id="p-0207" num="0000"><chemistry id="CHEM-US-00001" num="00001"><img id="EMI-C00001" he="143.68mm" wi="75.27mm" file="US20230002764A1-20230105-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><heading id="h-0017" level="1">II.D.2.b. Locked Nucleic Acid Nucleosides (LNA)</heading><p id="p-0208" num="0205">LNA nucleosides are modified nucleosides which comprise a linker group (referred to as a biradical or a bridge) between C2 and C4&#x2032; of the ribose sugar ring of a nucleoside (i.e., 2&#x2032;-4&#x2032; bridge), which restricts or locks the conformation of the ribose ring. These nucleosides are also termed bridged nucleic acid or bicyclic nucleic acid (BNA) in the literature. The locking of the conformation of the ribose is associated with an enhanced affinity of hybridization (duplex stabilization) when the LNA is incorporated into an oligonucleotide for a complementary RNA or DNA molecule. This can be routinely determined by measuring the melting temperature of the oligonucleotide/complement duplex.</p><p id="p-0209" num="0206">Non limiting, exemplary LNA nucleosides are disclosed in WO 99/014226, WO 00/66604, WO 98/039352, WO 2004/046160, WO 00/047599, WO 2007/134181, WO 2010/077578, WO 2010/036698, WO 2007/090071, WO 2009/006478, WO 2011/156202, WO 2008/154401, WO 2009/067647, WO 2008/150729, Morita et al., <i>Bioorganic </i>&#x26; <i>Med.Chem. Lett. </i>12, 73-76, Seth et al., <i>J. Org. Chem. </i>2010, Vol 75(5) pp. 1569-81, and Mitsuoka et al., <i>Nucleic Acids Research </i>2009, 37(4), 1225-1238.</p><p id="p-0210" num="0207">In some aspects, the modified nucleoside or the LNA nucleosides of the ASO of the disclosure has a general structure of the formula I or II:</p><p id="p-0211" num="0000"><chemistry id="CHEM-US-00002" num="00002"><img id="EMI-C00002" he="85.26mm" wi="69.85mm" file="US20230002764A1-20230105-C00002.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0212" num="0000">wherein<br/>W is selected from &#x2014;O&#x2014;, &#x2014;S&#x2014;, &#x2014;N(R<sup>a</sup>)&#x2014;, &#x2014;C(R<sup>a</sup>R<sup>b</sup>)&#x2014;, in particular &#x2014;O&#x2014;;<br/>B is a nucleobase or a modified nucleobase moiety;<br/>Z is an internucleoside linkage to an adjacent nucleoside or a 5&#x2032;-terminal group;<br/>Z* is an internucleoside linkage to an adjacent nucleoside or a 3&#x2032;-terminal group;<br/>R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5 </sup>and R<sup>5* </sup>are independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, alkoxyalkyl, alkenyloxy, carboxyl, alkoxycarbonyl, alkylcarbonyl, formyl, azide, heterocycle and aryl; and<br/>X, Y, R<sup>a </sup>and R<sup>b </sup>are as defined herein.</p><p id="p-0213" num="0208">In some aspects, &#x2014;X&#x2014;Y&#x2014;, R<sup>a </sup>is hydrogen or alkyl, in particular hydrogen or methyl. In some aspects of &#x2014;X&#x2014;Y&#x2014;, R<sup>b </sup>is hydrogen or alkyl, in particular hydrogen or methyl. In other aspects of &#x2014;X&#x2014;Y&#x2014;, one or both of R<sup>a </sup>and R<sup>b </sup>are hydrogen. In further aspects of &#x2014;X&#x2014;Y&#x2014;, only one of R<sup>a </sup>and R<sup>b </sup>is hydrogen. In some aspects of &#x2014;X&#x2014;Y&#x2014;, one of R<sup>a </sup>and R<sup>b </sup>is methyl and the other one is hydrogen. In certain aspects of &#x2014;X&#x2014;Y&#x2014;, R<sup>a </sup>and R<sup>b </sup>are both methyl at the same time.</p><p id="p-0214" num="0209">In some aspects, &#x2014;X&#x2014;, R<sup>a </sup>is hydrogen or alkyl, in particular hydrogen or methyl. In some aspects of &#x2014;X&#x2014;, R<sup>b </sup>is hydrogen or alkyl, in particular hydrogen or methyl. In other aspects of &#x2014;X&#x2014;, one or both of R<sup>a </sup>and R<sup>b </sup>are hydrogen. In certain aspects of &#x2014;X&#x2014;, only one of R<sup>a </sup>and R<sup>b </sup>is hydrogen. In certain aspects of &#x2014;X&#x2014;, one of R<sup>a </sup>and R<sup>b </sup>is methyl and the other one is hydrogen. In other aspects of &#x2014;X&#x2014;, R<sup>a </sup>and R<sup>b </sup>are both methyl at the same time.</p><p id="p-0215" num="0210">In some aspects, &#x2014;Y&#x2014;, R<sup>a </sup>is hydrogen or alkyl, in particular hydrogen or methyl. In certain aspects of &#x2014;Y&#x2014;, R<sup>b </sup>is hydrogen or alkyl, in particular hydrogen or methyl. In other aspects of &#x2014;Y&#x2014;, one or both of R<sup>a </sup>and R<sup>b </sup>are hydrogen. In some aspects of &#x2014;Y&#x2014;, only one of R<sup>a </sup>and R<sup>b </sup>is hydrogen. In other aspects of &#x2014;Y&#x2014;, one of R<sup>a </sup>and R<sup>b </sup>is methyl and the other one is hydrogen. In some aspects of &#x2014;Y&#x2014;, R<sup>a </sup>and R<sup>b </sup>are both methyl at the same time.</p><p id="p-0216" num="0211">In some aspects, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5 </sup>and R<sup>5* </sup>are independently selected from hydrogen and alkyl, in particular hydrogen and methyl.</p><p id="p-0217" num="0212">In some aspects, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5 </sup>and R<sup>5* </sup>are all hydrogen at the same time.</p><p id="p-0218" num="0213">In some aspects, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, are all hydrogen at the same time, one of R<sup>5 </sup>and R<sup>5* </sup>is hydrogen and the other one is as defined above, in particular alkyl, more particularly methyl.</p><p id="p-0219" num="0214">In some aspects, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, are all hydrogen at the same time, one of R and R<sup>5* </sup>is hydrogen and the other one is azide.</p><p id="p-0220" num="0215">In some aspects, &#x2014;X&#x2014;Y&#x2014; is &#x2014;O&#x2014;CH<sub>2</sub>&#x2014;, W is oxygen and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5 </sup>and R<sup>5* </sup>are all hydrogen at the same time. Such LNA nucleosides are disclosed in WO 99/014226, WO 00/66604, WO 98/039352 and WO 2004/046160, which are all hereby incorporated by reference, and include what are commonly known in the art as beta-D-oxy LNA and alpha-L-oxy LNA nucleosides.</p><p id="p-0221" num="0216">In some aspects, &#x2014;X&#x2014;Y&#x2014; is &#x2014;S&#x2014;CH<sub>2</sub>&#x2014;, W is oxygen and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5 </sup>and R<sup>5* </sup>are all hydrogen at the same time. Such thio LNA nucleosides are disclosed in WO 99/014226 and WO 2004/046160 which are hereby incorporated by reference.</p><p id="p-0222" num="0217">In some aspects, &#x2014;X&#x2014;Y&#x2014; is &#x2014;NH&#x2014;CH<sub>2</sub>&#x2014;, W is oxygen and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5 </sup>and R<sup>5* </sup>are all hydrogen at the same time. Such amino LNA nucleosides are disclosed in WO 99/014226 and WO 2004/046160, which are hereby incorporated by reference.</p><p id="p-0223" num="0218">In some aspects, &#x2014;X&#x2014;Y&#x2014; is &#x2014;O&#x2014;CH<sub>2</sub>CH<sub>2</sub>&#x2014; or &#x2014;OCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>&#x2014;, W is oxygen, and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5 </sup>and R<sup>5* </sup>are all hydrogen at the same time. Such LNA nucleosides are disclosed in WO 00/047599 and Morita et al., <i>Bioorganic </i>&#x26; <i>Med.Chem. Lett. </i>12, 73-76, which are hereby incorporated by reference, and include what are commonly known in the art as 2&#x2032;-O-4&#x2032;C-ethylene bridged nucleic acids (ENA).</p><p id="p-0224" num="0219">In some aspects, &#x2014;X&#x2014;Y&#x2014; is &#x2014;O&#x2014;CH<sub>2</sub>&#x2014;, W is oxygen, R<sup>1</sup>, R<sup>2</sup>, R<sup>3 </sup>are all hydrogen at the same time, one of R<sup>5 </sup>and R<sup>5* </sup>is hydrogen and the other one is not hydrogen, such as alkyl, for example methyl. Such 5&#x2032; substituted LNA nucleosides are disclosed in WO 2007/134181, which is hereby incorporated by reference.</p><p id="p-0225" num="0220">In some aspects, &#x2014;X&#x2014;Y&#x2014; is &#x2014;O&#x2014;CR<sup>a</sup>R<sup>b</sup>&#x2014;, wherein one or both of R<sup>a </sup>and R<sup>b </sup>are not hydrogen, in particular alkyl such as methyl, W is oxygen, R<sup>1</sup>, R<sup>2</sup>, R<sup>3 </sup>are all hydrogen at the same time, one of R<sup>5 </sup>and R<sup>5* </sup>is hydrogen and the other one is not hydrogen, in particular alkyl, for example methyl. Such bis modified LNA nucleosides are disclosed in WO 2010/077578, which is hereby incorporated by reference.</p><p id="p-0226" num="0221">In some aspects, &#x2014;X&#x2014;Y&#x2014; is &#x2014;O&#x2014;CH(CH<sub>2</sub>&#x2014;O&#x2014;CH<sub>3</sub>)&#x2014; (&#x201c;2&#x2032; O-methoxyethyl bicyclic nucleic acid&#x201d;, Seth et al., <i>J. Org. Chem. </i>2010, Vol 75(5) pp. 1569-81).</p><p id="p-0227" num="0222">In some aspects, &#x2014;X&#x2014;Y&#x2014; is &#x2014;O&#x2014;CHR<sup>a</sup>&#x2014;, W is oxygen and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5 </sup>and R<sup>5* </sup>are all hydrogen at the same time. Such 6&#x2032;-substituted LNA nucleosides are disclosed in WO 2010/036698 and WO 2007/090071, which are both hereby incorporated by reference. In such 6&#x2032;-substituted LNA nucleosides, R<sup>a </sup>is in particular C1-C6 alkyl, such as methyl.</p><p id="p-0228" num="0223">In some aspects, &#x2014;X&#x2014;Y&#x2014; is &#x2014;O&#x2014;CH(CH<sub>2</sub>&#x2014;O&#x2014;CH<sub>3</sub>)&#x2014;, W is oxygen and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5 </sup>and R<sup>5* </sup>are all hydrogen at the same time. Such LNA nucleosides are also known in the art as cyclic MOEs (cMOE) and are disclosed in WO 2007/090071.</p><p id="p-0229" num="0224">In some aspects, &#x2014;X&#x2014;Y&#x2014; is &#x2014;O&#x2014;CH(CH<sub>3</sub>)&#x2014;.</p><p id="p-0230" num="0225">In some aspects, &#x2014;X&#x2014;Y&#x2014; is &#x2014;O&#x2014;CH<sub>2&#x2212;</sub>O&#x2014;CH<sub>2</sub>&#x2014; (Seth et al., <i>J. Org. Chem </i>2010 op. cit.)</p><p id="p-0231" num="0226">In some aspects, &#x2014;X&#x2014;Y&#x2014; is &#x2014;O&#x2014;CH(CH<sub>3</sub>)&#x2014;, W is oxygen and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5 </sup>and R<sup>5* </sup>are all hydrogen at the same time. Such 6&#x2032;-methyl LNA nucleosides are also known in the art as cET nucleosides, and may be either (S)-cET or (R)-cET diastereoisomers, as disclosed in WO 2007/090071 (beta-D) and WO 2010/036698 (alpha-L) which are both hereby incorporated by reference.</p><p id="p-0232" num="0227">In some aspects, &#x2014;X&#x2014;Y&#x2014; is &#x2014;O&#x2014;CR<sup>a</sup>R<sup>b</sup>&#x2014;, wherein neither R<sup>a </sup>nor R<sup>b </sup>is hydrogen, W is oxygen, and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5 </sup>and R<sup>5* </sup>are all hydrogen at the same time. In certain aspects, R<sup>a </sup>and R<sup>b </sup>are both alkyl at the same time, in particular both methyl at the same time. Such 6&#x2032;-di-substituted LNA nucleosides are disclosed in WO 2009/006478 which is hereby incorporated by reference.</p><p id="p-0233" num="0228">In some aspects, &#x2014;X&#x2014;Y&#x2014; is &#x2014;S&#x2014;CHR<sup>a</sup>&#x2014;, W is oxygen, and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5 </sup>and R<sup>5* </sup>are all hydrogen at the same time. Such 6&#x2032;-substituted thio LNA nucleosides are disclosed in WO 2011/156202, which is hereby incorporated by reference. In certain aspects of such 6&#x2032;-substituted thio LNA, R<sup>a </sup>is alkyl, in particular methyl.</p><p id="p-0234" num="0229">In some aspects, &#x2014;X&#x2014;Y&#x2014; is &#x2014;C(&#x2550;CH<sub>2</sub>)C(R<sup>a</sup>R<sup>b</sup>)&#x2014;, such as, W is oxygen, and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5 </sup>and R<sup>5* </sup>are all hydrogen at the same time. Such vinyl carbo LNA nucleosides are disclosed in WO 2008/154401 and WO 2009/067647, which are both hereby incorporated by reference.</p><p id="p-0235" num="0230">In some aspects, &#x2014;X&#x2014;Y&#x2014; is &#x2014;N(OR<sup>a</sup>)&#x2014;CH<sub>2</sub>&#x2014;, W is oxygen and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5 </sup>and R<sup>5* </sup>are all hydrogen at the same time. In some aspects, R<sup>a </sup>is alkyl such as methyl. Such LNA nucleosides are also known as N substituted LNAs and are disclosed in WO 2008/150729, which is hereby incorporated by reference.</p><p id="p-0236" num="0231">In some aspects, &#x2014;X&#x2014;Y&#x2014; is &#x2014;O&#x2014;NCH<sub>3</sub>&#x2014; (Seth et al., <i>J. Org. Chem </i>2010 op. cit.).</p><p id="p-0237" num="0232">In some aspects, &#x2014;X&#x2014;Y&#x2014; is ON(R<sup>a</sup>)&#x2014; &#x2014;N(R<sup>a</sup>)&#x2014;O&#x2014;, &#x2014;NR<sup>a</sup>&#x2014;CR<sup>a</sup>R<sup>b</sup>&#x2014;CR<sup>a</sup>R<sup>b</sup>&#x2014;, or &#x2014;NR<sup>a</sup>&#x2014;CR<sup>a</sup>R<sup>b</sup>&#x2014;, W is oxygen, and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5 </sup>and R<sup>5* </sup>are all hydrogen at the same time. In certain aspects, R<sup>a </sup>is alkyl, such as methyl. (Seth et al., <i>J. Org. Chem </i>2010 op. cit.).</p><p id="p-0238" num="0233">In some aspects, R<sup>5 </sup>and R<sup>5* </sup>are both hydrogen at the same time. In other aspects, one of R<sup>5 </sup>and R<sup>5* </sup>is hydrogen and the other one is alkyl, such as methyl. In such aspects, R<sup>1</sup>, R<sup>2 </sup>and R<sup>3 </sup>can be in particular hydrogen and &#x2014;X&#x2014;Y&#x2014; can be in particular &#x2014;O&#x2014;CH<sub>2</sub>&#x2014; or &#x2014;O&#x2014;CHC(R<sup>a</sup>)<sub>3</sub>&#x2014;, such as &#x2014;O&#x2014;CH(CH<sub>3</sub>)&#x2014;.</p><p id="p-0239" num="0234">In some aspects, &#x2014;X&#x2014;Y&#x2014; is &#x2014;CR<sup>a</sup>R<sup>b</sup>&#x2014;O&#x2014;CR<sup>a</sup>R<sup>b</sup>&#x2014;, such as &#x2014;CH<sub>2</sub>&#x2014;O&#x2014;CH<sub>2</sub>&#x2014;, W is oxygen and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5 </sup>and R<sup>5* </sup>are all hydrogen at the same time. In such aspects, R<sup>a </sup>can be in particular alkyl such as methyl. Such LNA nucleosides are also known as conformationally restricted nucleotides (CRNs) and are disclosed in WO 2013/036868, which is hereby incorporated by reference.</p><p id="p-0240" num="0235">In some aspects, &#x2014;X&#x2014;Y&#x2014; is &#x2014;O&#x2014;CR<sup>a</sup>R<sup>b</sup>&#x2014;O&#x2014;CR<sup>a</sup>R<sup>b</sup>&#x2014;, such as &#x2014;O&#x2014;CH<sub>2</sub>&#x2014;O&#x2014;CH<sub>2</sub>&#x2014;, W is oxygen and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5 </sup>and R<sup>5* </sup>are all hydrogen at the same time. In certain aspects, R<sup>a </sup>can be in particular alkyl such as methyl. Such LNA nucleosides are also known as COC nucleotides and are disclosed in Mitsuoka et al., <i>Nucleic Acids Research </i>2009, 37(4), 1225-1238, which is hereby incorporated by reference.</p><p id="p-0241" num="0236">It will be recognized than, unless specified, the LNA nucleosides may be in the beta-D or alpha-L stereoisoform.</p><p id="p-0242" num="0237">Certain examples of LNA nucleosides are presented in Scheme 1.</p><p id="p-0243" num="0000"><chemistry id="CHEM-US-00003" num="00003"><img id="EMI-C00003" he="246.63mm" wi="67.48mm" file="US20230002764A1-20230105-C00003.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0244" num="0238">As illustrated elsewhere, in some aspects of the disclosure the LNA nucleosides in the oligonucleotides are beta-D-oxy-LNA nucleosides.</p><heading id="h-0018" level="1">III.E. Nuclease Mediated Degradation</heading><p id="p-0245" num="0239">Nuclease mediated degradation refers to an oligonucleotide capable of mediating degradation of a complementary nucleotide sequence when forming a duplex with such a sequence.</p><p id="p-0246" num="0240">In some aspects, the oligonucleotide may function via nuclease mediated degradation of the target nucleic acid, where the oligonucleotides of the disclosure are capable of recruiting a nuclease, particularly and endonuclease, preferably endoribonuclease (RNase), such as RNase H. Examples of oligonucleotide designs which operate via nuclease mediated mechanisms are oligonucleotides which typically comprise a region of at least 5 or 6 DNA nucleosides and are flanked on one side or both sides by affinity enhancing nucleosides, for example gapmers.</p><heading id="h-0019" level="1">II.F. RNase H Activity and Recruitment</heading><p id="p-0247" num="0241">The RNase H activity of an antisense oligonucleotide refers to its ability to recruit RNase H when in a duplex with a complementary RNA molecule and induce degradation of the complementary RNA molecule. WO01/23613 provides in vitro methods for determining RNaseH activity, which may be used to determine the ability to recruit RNaseH. Typically, an oligonucleotide is deemed capable of recruiting RNase H if, when provided with a complementary target nucleic acid sequence, it has an initial rate, as measured in pmol/l/min, of at least 5%, such as at least 10% or more than 20% of the of the initial rate determined when using a oligonucleotide having the same base sequence as the modified oligonucleotide being tested, but containing only DNA monomers, with phosphorothioate linkages between all monomers in the oligonucleotide, and using the methodology provided by Example 91-95 of WO01/23613.</p><p id="p-0248" num="0242">In some aspects, an oligonucleotide is deemed essentially incapable of recruiting RNaseH if, when provided with the complementary target nucleic acid, the RNaseH initial rate, as measured in pmol/min, is less than 20%, such as less than 10%,such as less than 5% of the initial rate determined when using a oligonucleotide having the same base sequence as the oligonucleotide being tested, but containing only DNA monomers, with no 2&#x2032; substitutions, with phosphorothioate linkages between all monomers in the oligonucleotide, and using the methodology provided by Example 91-95 of WO01/23613.</p><heading id="h-0020" level="1">II.G. ASO Design</heading><p id="p-0249" num="0243">The ASO of the disclosure can comprise a nucleotide sequence which comprises both nucleosides and nucleoside analogs, and can be in the form of a gapmer. Examples of configurations of a gapmer that can be used with the ASO of the disclosure are described in U.S. Patent Appl. Publ. No. 2012/0322851.</p><p id="p-0250" num="0244">The term &#x201c;gapmer&#x201d; as used herein refers to an antisense oligonucleotide which comprises a region of RNase H recruiting oligonucleotides (gap) which is flanked 5&#x2032; and 3&#x2032; by one or more affinity enhancing modified nucleosides (flanks). The term &#x201c;LNA gapmer&#x201d; is a gapmer oligonucleotide wherein at least one of the affinity enhancing modified nucleosides is an LNA nucleoside. The term &#x201c;mixed wing gapmer&#x201d; refers to an LNA gapmer wherein the flank regions comprise at least one LNA nucleoside and at least one DNA nucleoside or non-LNA modified nucleoside, such as at least one 2&#x2032; substituted modified nucleoside, such as, for example, 2&#x2032;-O-alkyl-RNA, 2&#x2032;-O-methyl-RNA, 2&#x2032;-alkoxy-RNA, 2&#x2032;-O-methoxyethyl-RNA (MOE), 2&#x2032;-amino-DNA, 2&#x2032;-Fluoro-RNA, 2&#x2032;-Fluro-DNA, arabino nucleic acid (ANA), and 2&#x2032;-Fluoro-ANA nucleoside(s).</p><p id="p-0251" num="0245">In some aspects, the ASO of the disclosure can be in the form of a mixmer. In some aspects, the ASO of the disclosure can be in the form of a totalmer. In some aspects, in addition to enhancing affinity of the ASO for the target region, some nucleoside analogs also mediate RNase (e.g., RNaseH) binding and cleavage. Since &#x3b1;-L-LNA monomers recruit RNaseH activity to a certain extent, in some aspects, gap regions (e.g., region B as referred to herein) of ASOs containing &#x3b1;-L-LNA monomers consist of fewer monomers recognizable and cleavable by the RNaseH, and more flexibility in the mixmer construction is introduced.</p><heading id="h-0021" level="1">II.G.1. Gapmer Design</heading><p id="p-0252" num="0246">In some aspects, the ASO of the disclosure is a gapmer and comprises a contiguous stretch of nucleotides (e.g., one or more DNA) which is capable of recruiting an RNase, such as RNaseH, referred to herein in as region B (B), wherein region B is flanked at both 5&#x2032; and 3&#x2032; by regions of nucleoside analogs 5&#x2032; and 3&#x2032; to the contiguous stretch of nucleotides of region B&#x2014; these regions are referred to as regions A (A) and C (C), respectively. In some aspects, the nucleoside analogs are sugar modified nucleosides (e.g., high affinity sugar modified nucleosides). In certain aspects, the sugar modified nucleosides of regions A and C enhance the affinity of the ASO for the target nucleic acid (i.e., affinity enhancing 2&#x2032; sugar modified nucleosides). In some aspects, the sugar modified nucleosides are 2&#x2032; sugar modified nucleosides, such as high affinity 2&#x2032; sugar modifications, such as LNA and/or 2&#x2032;-MOE.</p><p id="p-0253" num="0247">In a gapmer, the 5&#x2032; and 3&#x2032; most nucleosides of region B are DNA nucleosides, and are positioned adjacent to nucleoside analogs (e.g., high affinity sugar modified nucleosides) of regions A and C, respectively. In some aspects, regions A and C can be further defined by having nucleoside analogs at the end most distant from region B (i.e., at the 5&#x2032; end of region A and at the 3&#x2032; end of region C).</p><p id="p-0254" num="0248">In some aspects, the ASOs of the present disclosure comprise a nucleotide sequence of formula (5&#x2032; to 3&#x2032;) A-B-C, wherein: (A) (5&#x2032; region or a first wing sequence) comprises at least one nucleoside analog (e.g., 3-5 LNA units); (B) comprises at least four consecutive nucleosides (e.g., 4-24 DNA units), which are capable of recruiting RNase (when formed in a duplex with a complementary RNA molecule, such as the pre-mRNA or mRNA target); and (C) (3&#x2032; region or a second wing sequence) comprises at least one nucleoside analog (e.g., 3-5 LNA units).</p><p id="p-0255" num="0249">In some aspects, region A comprises 3-5 nucleoside analogs, such as LNA, region B consists of 6-24 (e.g., 6, 7, 8, 9, 10, 11, 12, 13, or 14) DNA units, and region C consists of 3 or 4 nucleoside analogs, such as LNA. Such designs include (A-B-C) 3-14-3, 3-11-3, 3-12-3, 3-13-3, 4-9-4, 4-10-4, 4-11-4, 4-12-4, and 5-10-5. In some aspects, the ASO has a design of LLLD<sub>n</sub>LLL, LLLLD<sub>n</sub>LLLL, or LLLLLD<sub>n</sub>LLLLL, wherein the L is a nucleoside analog, the D is DNA, and n can be any integer between 4 and 24. In some aspects, n can be any integer between 6 and 14. In some aspects, n can be any integer between 8 and 12. In some aspects, the ASO has a design of LLLMMDnMMLLL, LLLMDnMLLL, LLLLMMDnMMLLLL, LLLLMDnMLLLL, LLLLLLMMDnMMLLLLL, or LLLLLLMDnMLLLLL, wherein the D is DNA, n can be any integer between 3 and 15, the L is LNA, and the M is 2&#x2032;MOE.</p><p id="p-0256" num="0250">Further gapmer designs are disclosed in WO2004/046160, WO 2007/146511, and WO2008/113832, each of which is hereby incorporated by reference in its entirety.</p><heading id="h-0022" level="1">II.H. Internucleotide Linkages</heading><p id="p-0257" num="0251">The monomers of the ASOs described herein are coupled together via linkage groups. Suitably, each monomer is linked to the 3&#x2032; adjacent monomer via a linkage group.</p><p id="p-0258" num="0252">The person having ordinary skill in the art would understand that, in the context of the present disclosure, the 5&#x2032; monomer at the end of an ASO does not comprise a 5&#x2032; linkage group, although it may or may not comprise a 5&#x2032; terminal group.</p><p id="p-0259" num="0253">In some aspects, the contiguous nucleotide sequence comprises one or more modified internucleoside linkages. The terms &#x201c;linkage group&#x201d; or &#x201c;internucleoside linkage&#x201d; are intended to mean a group capable of covalently coupling together two nucleosides. Non-limiting examples include phosphate groups and phosphorothioate groups.</p><p id="p-0260" num="0254">The nucleosides of the ASO of the disclosure or contiguous nucleosides sequence thereof are coupled together via linkage groups. Suitably, each nucleoside is linked to the 3&#x2032; adjacent nucleoside via a linkage group.</p><p id="p-0261" num="0255">In some aspects, the internucleoside linkage is modified from its normal phosphodiester to one that is more resistant to nuclease attack, such as phosphorothioate, which is cleavable by RNaseH, also allows that route of antisense inhibition in reducing the expression of the target gene. In some aspects, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of internucleoside linkages are modified.</p><heading id="h-0023" level="1">III. Extracellular Vesicles, e.g., Exosomes</heading><p id="p-0262" num="0256">Disclosed herein are EVs, e.g., exosomes, comprising an ASO. The ASO can be any ASO described herein or a functional fragment thereof. In certain aspects, the ASO reduces the level of an CEBP/&#x3b2; mRNA or an CEBP/&#x3b2; protein in a target cell.</p><p id="p-0263" num="0257">In some aspects, the EV, e.g., the exosome, comprises at least one ASO. In some aspects, the EV, e.g., the exosome, comprises at least two ASOs, e.g., a first ASO comprising a first nucleotide sequence and a second ASO comprising a second nucleotide sequence. In some aspects, the EV, e.g., the exosome, comprises at least three ASOs, at least four ASOs, at least five ASOs, at least six ASOs, or more than six ASOs. In some aspects, each of the first ASO, the second ASO, the third ASO, the fourth ASO, the fifth ASO, the sixth ASO, and/or the ninth ASO is different.</p><p id="p-0264" num="0258">In some aspects, the EV, e.g, the exosome, comprises a first ASO and a second ASO, wherein the first ASO comprises a first nucleotide sequence that is complimentary to a first target sequence in a first transcript, and wherein the second ASO comprises a second nucleotide sequence that is complimentary to a second target sequence in the first transcript. In some aspects, the first target sequence does not overlap with the second target sequence. In some aspects, the first target sequence comprises at least one nucleotide that is within the 5&#x2032;UTR of the transcript, and the second target sequence does not comprise a nucleotide that is within the 5&#x2032;UTR. In some aspects, the first target sequence comprises at least one nucleotide that is within the 3&#x2032;UTR of the transcript, and the second target sequence does not comprise a nucleotide that is within the 3&#x2032;UTR. In some aspects, the first target sequence comprises at least one nucleotide that is within the 5&#x2032;UTR of the transcript, and the second target sequence comprises at least one nucleotide that is within the 3&#x2032;UTR.</p><p id="p-0265" num="0259">In some aspects, the first ASO targets a sequence within an exon-intron junction, and the second ASO targets a sequence within an exon-intron junction. In some aspects, the first ASO targets a sequence within an exon-intron junction, and the second ASO targets a sequence within an exon. In some aspects, the first ASO targets a sequence within an exon-intron junction, and the second ASO targets a sequence within an intron. In some aspects, the first ASO targets a sequence within an exon, and the second ASO targets a sequence within an exon. In some aspects, the first ASO targets a sequence within an intron, and the second ASO targets a sequence within an exon. In some aspects, the first ASO targets a sequence within an intron, and the second ASO targets a sequence within an intron.</p><p id="p-0266" num="0260">In some aspects, the EV, e.g, the exosome, comprises a first ASO and a second ASO, wherein the first ASO comprises a first nucleotide sequence that is complimentary to a first target sequence in a first transcript, and wherein the second ASO comprises a second nucleotide sequence that is complimentary to a second target sequence in a second transcript, wherein the first transcript is not the product of the same gene as the second transcript.</p><p id="p-0267" num="0261">In some aspects, the EV, e.g., the exosome, targets a tumor cell, dendritic cell, T cell, B cell, macrophage, monocyte, neuron, hepatocyte, Kupffer cell, myeloid-lineage cell (e.g., a neutrophil, myeloid-derived suppressor cell (MDSC, e.g., a monocytic MDSC or a granulocytic MDSC), monocyte, macrophage, hematopoietic stem cell, basophil, neutrophil, or eosinophil), or any combination thereof. In some aspects, the EV, e.g., the exosome, targets a myeloid-lineage cell. In some aspects, the EV, e.g., the exosome, targets a macrophage. In certain aspects, the EV, e.g., the exosome, targets the liver, heart, lungs, brain, kidneys, central nervous system, peripheral nervous system, muscle, bone, joint, skin, intestine, bladder, pancreas, lymph nodes, spleen, blood, bone marrow, or any combination thereof.</p><p id="p-0268" num="0262">In some aspects, the EV, e.g., the exosome, reduces the expression of one or more gene that is upregulated by the CEBP/s. In some aspects, the EV, e.g., the exosome, promotes differentiation of M2 macrophages. In some aspects, the EV, e.g., the exosome, reduces differentiation of M1 macrophages.</p><p id="p-0269" num="0263">In some aspects, the EV, e.g., the exosome, treats a cancer in a subject in need thereof. In some aspects, the cancer is selected from the group consisting of fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell cancer, squamous cell cancer of the head and neck cancer, colorectal cancer, lymphoma, leukemia, liver cancer, glioblastoma, melanoma, myeloma basal cell cancer, adenocarcinoma, sweat gland cancer, sebaceous gland cancer, papillary cancer, papillary adenocarcinomas, cystadenocarcinoma, medullary cancer, bronchogenic cancer, renal cell cancer, hepatoma, bile duct cancer, choriocarcinoma, seminoma, embryonal cancer, Wilms' tumor, cervical cancer, testicular cancer, lung cancer, small cell lung cancer, bladder cancer, epithelial cancer, glioma, glioblastoma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, and any combination thereof. In some aspects, the EV, e.g., the exosome, increases immune cell, e.g., macrophage, infiltration of a tumor.</p><p id="p-0270" num="0264">In some aspects, the EV, e.g., the exosome, treats a tumor of the central nervous system in a subject. In some aspects, the EV, e.g., the exosome, treats a brain tumor in a subject. In some aspects, the EV, e.g., the exosome, treats a glioblastoma in a subject. In some aspects, the glioblastoma is a glioblastoma multiforme (GBM). In some aspects, the EV, e.g., the exosome, treats a leptomeningeal cancer disease in a subject. In some aspects, the EV, e.g., the exosome, comprising the ASO activates macrophages within the central nervous system. In some aspects, the EV, e.g., the exosome, comprising the ASO induces M1 polarization of macrophages within the central nervous system. In some aspects, the EV, e.g., the exosome, comprising the ASO activates meningeal macrophages. In some aspects, the EV, e.g., the exosome, comprising the ASO induces M1 polarization of meningeal macrophages. In some aspects, the EV, e.g., the exosome, comprising the ASO induces tumor infiltration of meningeal macrophages.</p><p id="p-0271" num="0265">In some aspects, the EV, e.g., the exosome, treats a fibrosis in a subject in need thereof. Excessive M2 macrophage activation leads to the continuous production of TGF&#x3b2; and growth factors that promote proliferation of myofibroblasts, activation of EMT/EndoMT, and extracellular matrix deposition. M2 macrophages represent a break point between wound healing and exacerbation of pro-fibrotic process. In some aspects, the fibrosis is selected from liver fibrosis (NASH), cirrhosis, pulmonary fibrosis, cystic fibrosis, chronic ulcerative colitis/IBD, bladder fibrosis, kidney fibrosis, CAPS (Muckle-Wells syndrome), atrial fibrosis, endomyocardial fibrosis, old myocardial infarction, glial scar, arterial stiffness, arthrofibrosis, Crohn's disease, Dupuytren's contracture, keloid fibrosis, mediastinal fibrosis, myelofibrosis, Peyronie's disease, nephrogenic systemic fibrosis, progressive massive fibrosis, retroperitoneal fibrosis, scleroderma/systemic sclerosis, adhesive capsulitis, and any combination thereof. In some aspects, the EV, e.g., the exosome, treats liver fibrosis (NASH). In some aspects, the EV, e.g., the exosome, treats CAPS (Muckle-Wells syndrome).</p><p id="p-0272" num="0266">In some aspects, the EV, e.g., the exosome, treats a neurodegenerative disease. In some aspects, the neurodegenerative disease is selected from Alzheimer's disease, Parkinson's disease, prion disease, motor neuron disease, Huntington's disease, spinocerebellar ataxia, spinal muscular atrophy, and any combination thereof.</p><p id="p-0273" num="0267">In some aspects, the EV, e.g., the exosome, treats a metabolic disorder/CVD. In some aspects, the metabolic disorder/CVD is selected from an acid-base imbalance, metabolic brain disease, disorder of calcium metabolism, DNA repair-deficiency disorder, glucose metabolism disorder, hyperlactatemia, iron metabolism disorder, lipid metabolism disorder, malabsorption syndrome, metabolic syndrome X, inborn error of metabolism, mitochondrial disease, phosphorus metabolism disorder, porphyrias, proteostasis deficiency, metabolic skin disease, wasting syndrome, water-electrolyte imbalance, and any combination thereof.</p><p id="p-0274" num="0268">As described supra, EVs, e.g., exosomes, described herein are extracellular vesicles with a diameter between about 20-300 nm. The size of the EV, e.g., exosome, described herein can be measured according to methods described, infra.</p><p id="p-0275" num="0269">In some aspects, an EV, e.g., exosome, of the present disclosure comprises a bi-lipid membrane (&#x201c;EV, e.g., exosome, membrane&#x201d;), comprising an interior (luminal) surface and an exterior surface. In certain aspects, the interior (luminal) surface faces the inner core (i.e., lumen) of the EV, e.g., exosome. In certain aspects, the exterior surface can be in contact with the endosome, the multivesicular bodies, or the membrane/cytoplasm of a producer cell or a target cell</p><p id="p-0276" num="0270">In some aspects, the EV, e.g., exosome, membrane comprises lipids and fatty acids. In some aspects, the EV, e.g., exosome, membrane comprises phospholipids, glycolipids, fatty acids, sphingolipids, phosphoglycerides, sterols, cholesterols, and phosphatidylserines.</p><p id="p-0277" num="0271">In some aspects, the EV, e.g., exosome, membrane comprises an inner leaflet and an outer leaflet. The composition of the inner and outer leaflet can be determined by transbilayer distribution assays known in the art, see, e.g., Kuypers et al., <i>Biohim Biophys Acta </i>1985 819:170. In some aspects, the composition of the outer leaflet is between approximately 70-90% choline phospholipids, between approximately 0-15% acidic phospholipids, and between approximately 5-30% phosphatidylethanolamine. In some aspects, the composition of the inner leaflet is between approximately 15-40% choline phospholipids, between approximately 10-50% acidic phospholipids, and between approximately 30-60% phosphatidylethanolamine.</p><p id="p-0278" num="0272">In some aspects, the EV, e.g., exosome, membrane comprises one or more polysaccharide, such as glycan.</p><p id="p-0279" num="0273">In some aspects, the EV, e.g., exosome, of the present disclosure comprises an ASO, wherein the ASO is linked to the EV via a scaffold moiety, either on the exterior surface of the EV or on the luminal surface of the EV.</p><p id="p-0280" num="0274">In some aspects, the EV, e.g., exosome, comprising an ASO comprises an anchoring moiety, which optionally comprising a linker, between the ASO and the exosome membrane. Non-limiting examples of the linkers are disclosed elsewhere herein.</p><heading id="h-0024" level="1">III.A. Anchoring Moieties (AM)</heading><p id="p-0281" num="0275">One or more anchoring moieties (AMs) can be used to anchor an ASO to the EV of the present disclosure. In some aspects, the ASO is linked directly to the anchoring moiety or via a linker. In some aspects, the ASO can be attached to an anchoring moiety or linker combination via reaction between a &#x201c;reactive group&#x201d; (RG; e.g., amine, thiol, hydroxy, carboxylic acid, or azide) with a &#x201c;reactive moiety&#x201d; (RM; e.g., maleimide, succinate, NHS). Several potential synthetic routes are envisioned, for example:</p><p id="p-0282" num="0000">[AM]&#x2212;/Reactive moiety/+/Reactive group/&#x2212;[ASO]<br/>[AM]&#x2212;[Linker]n&#x2212;/Reactive moiety/+/Reactive group/&#x2212;[ASO]<br/>[AM]&#x2212;/Reactive moiety/+/Reactive group/&#x2212;[Linker]n&#x2212;[ASO]<br/>[AM]&#x2212;[Linker]n&#x2212;/Reactive moiety/+/Reactive group/&#x2212;[Linker]n&#x2212;[ASO]</p><p id="p-0283" num="0276">The anchoring moiety can insert into the lipid bilayer of an EV, e.g., an exosome, allowing the loading of the exosome with an ASO. Currently, a predominant obstacle to the commercialization of exosomes as a delivery vehicle for polar ASOs, is highly inefficient loading. This obstacle can be overcome by modifying polar ASOs, prior to loading them into exosomes. Thus, as described herein, modification of ASOs facilitates their loading into exosomes.</p><p id="p-0284" num="0277">The methods of loading exosomes with modified polar ASOs set forth herein significantly improve loading efficiency as compared to the loading efficiency previously reported for introducing unmodified ASOs into exosomes by, for example, electroporation or cationic lipid transfection.</p><p id="p-0285" num="0278">In some aspects, the modifications increase the hydrophobicity of the an ASO by at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, or at least about 10 fold relative to native (non-modified) ASO. In some aspects, the modifications increase the hydrophobicity of the ASO by at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, or at least about 10 orders of magnitude relative to native (non-modified) ASO.</p><p id="p-0286" num="0279">In some aspects, the modifications increase the hydrophobicity of the ASO by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 125%, at least about 150%, at least about 175%, at least about 200%, at least about 250%, at least about 300%, at least about 350%, at least about 400%, at least about 450%, at least about 500%, at least about 600%, at least about 700%, at least about 800%, at least about 900%, or at least about 1000% relative to native (non-modified) ASO, e.g., the corresponding unmodified ASO. Increases in hydrophobicity can be assessed using any suitable method. For example, hydrophobicity can be determined by measuring the percentage solubility in an organic solvent, such as octanol, as compared to solubility in an aqueous solvent, such as water.</p><p id="p-0287" num="0280">In some aspect, an anchoring moiety can be chemically conjugated to an ASO to enhance its hydrophobic character. In exemplary aspects, the anchoring moiety is a sterol (e.g., cholesterol), GM1, a lipid, a vitamin, a small molecule, a peptide, or a combination thereof. In some aspects, the moiety is a lipid. In some aspects, the anchoring moiety is a sterol, e.g., cholesterol. Additional hydrophobic moieties include, for example, phospholipids, lysophospholipids, fatty acids, or vitamins (e.g., vitamin D or vitamin E).</p><p id="p-0288" num="0281">In some aspects, the anchoring moiety is conjugated at the termini of the ASO either directly or via one or more linkers (i.e., &#x201c;terminal modification&#x201d;). In other aspects, the anchoring moiety is conjugated to other portions of the ASO.</p><p id="p-0289" num="0282">In some aspects, the ASO can include a detectable label. Exemplary labels include fluorescent labels and/or radioactive labels. In some aspects, where ASOs are fluorescently labeled, the detectable label can be, for example, Cy3. Adding a detectable label to ASOs can be used as a way of labeling exosomes, and following their biodistribution. In other aspects, a detectable label can be attached to exosomes directly, for example, by way of labeling an exosomal lipid and/or an exosomal peptide.</p><p id="p-0290" num="0283">The different components of an ASO (i.e., anchoring moieties, linkers and linker combinations, and ASOs) can be linked by amide, ester, ether, thioether, disulfide, phosphoramidate, phosphotriester, phosphorodithioate, methyl phosphonate, phosphodiester, or phosphorothioate linkages or, alternatively any or other linkage.</p><p id="p-0291" num="0284">In some aspects, the different components of an ASO can be linker using bifunctional linkers (i.e., linkers containing two functional groups), such as N-succinimidyl-3-(2-pyridyldithio)propionate, N-4-maleimide butyric acid, S-(2-pyridyldithio)cysteamine, iodoacetoxysuccinimide, N-(4-maleimide butyloxy) succinimide, N-[5-(3&#x2032;-maleimide propylamide)-1-carboxypenyl]iminodiacetic acid, N-(5-aminopentyl)-iminodiacetic acid, and the like.</p><heading id="h-0025" level="1">III.A.1. Anchoring Moieties</heading><p id="p-0292" num="0285">Suitable anchoring moieties capable of anchoring an ASO to the surface of an EV, e.g., an exosome, comprise for example sterols (e.g., cholesterol), lipids, lysophospholipids, fatty acids, or fat-soluble vitamins, as described in detail below.</p><p id="p-0293" num="0286">In some aspects, the anchoring moiety can be a lipid. A lipid anchoring moiety can be any lipid known in the art, e.g., palmitic acid or glycosylphosphatidylinositols. In some aspects, the lipid, is a fatty acid, phosphatide, phospholipid (e.g., phosphatidyl choline, phosphatidyl serine, or phosphatidyl ethanolamine), or analogue thereof (e.g, phophatidylcholine, lecithin, phosphatidylethanolamine, cephalm, or phosphatidylserine or analogue or portion thereof, such as a partially hydrolyzed portion thereof).</p><p id="p-0294" num="0287">Generally, anchoring moieties are chemically attached. However, an anchoring moiety can be attached to an ASO enzymatically. In some aspects, in the possible to attach an anchoring moiety to an ASO via modification of cell culture conditions. For example, by using a culture medium where myristic acid is limiting, some other fatty acids including shorter-chain and unsaturated, can be attached to an N-terminal glycine. For example, in BK channels, myristate has been reported to be attached posttranslationally to internal serine/threonine or tyrosine residues via a hydroxyester linkage.</p><p id="p-0295" num="0288">The anchoring moiety can be conjugated to an ASO directly or indirectly via a linker combination, at any chemically feasible location, e.g., at the 5&#x2032; and/or 3&#x2032; end of the ASO. In one aspect, the anchoring moiety is conjugated only to the 3&#x2032; end of the ASO. In one aspect, the anchoring moiety is conjugated only to the 5&#x2032; end of the ASO. In one aspect, the anchoring moiety is conjugated at a location which is not the 3&#x2032; end or 5&#x2032; end of the ASO.</p><p id="p-0296" num="0289">Some types of membrane anchors that can be used to practice the methods of the present disclosure presented in the following table:</p><p id="p-0297" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="238pt" align="center"/><thead><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row><row><entry>Modification</entry><entry>Modifying Group</entry></row><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>S-Palmitoylation</entry><entry><chemistry id="CHEM-US-00004" num="00004"><img id="EMI-C00004" he="10.24mm" wi="83.23mm" file="US20230002764A1-20230105-C00004.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry> </entry></row><row><entry>N-Palmitoylation</entry><entry><chemistry id="CHEM-US-00005" num="00005"><img id="EMI-C00005" he="12.11mm" wi="83.23mm" file="US20230002764A1-20230105-C00005.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry> </entry></row><row><entry>N-Myristoylation</entry><entry><chemistry id="CHEM-US-00006" num="00006"><img id="EMI-C00006" he="12.11mm" wi="73.49mm" file="US20230002764A1-20230105-C00006.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry> </entry></row><row><entry>O-Acylation</entry><entry><chemistry id="CHEM-US-00007" num="00007"><img id="EMI-C00007" he="34.88mm" wi="68.58mm" file="US20230002764A1-20230105-C00007.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry> </entry></row><row><entry>Farnesylation</entry><entry><chemistry id="CHEM-US-00008" num="00008"><img id="EMI-C00008" he="8.64mm" wi="63.67mm" file="US20230002764A1-20230105-C00008.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry> </entry></row><row><entry>Geranylgeranylation</entry><entry><chemistry id="CHEM-US-00009" num="00009"><img id="EMI-C00009" he="8.64mm" wi="83.23mm" file="US20230002764A1-20230105-C00009.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry> </entry></row><row><entry>Cholesterol</entry><entry><chemistry id="CHEM-US-00010" num="00010"><img id="EMI-C00010" he="29.80mm" wi="75.69mm" file="US20230002764A1-20230105-C00010.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0298" num="0290">In some aspects, an anchoring moiety of the present disclosure can comprise two or more types of anchoring moieties disclosed herein. For example, in some aspects, an anchoring moiety can comprise two lipids, e.g., a phospholipids and a fatty acid, or two phospholipids, or two fatty acids, or a lipid and a vitamin, or cholesterol and a vitamin, etc. which taken together have 6-80 carbon atoms (i.e., an equivalent carbon number (ECN) of 6-80).</p><p id="p-0299" num="0291">In some aspects, the combination of anchoring moieties, e.g., a combination of the lipids (e.g., fatty acids) has an ECN of 6-80, 8-80, 10-80, 12-80, 14-80, 16-80, 18-80, 20-80, 22-80, 24-80, 26-80, 28-80, 30-80, 4-76, 6-76, 8-76, 10-76, 12-76, 14-76, 16-76, 18-76, 20-76, 22-76, 24-76, 26-76, 28-76, 30-76, 6-72, 8-72, 10-72, 12-72, 14-72, 16-72, 18-72, 20-72, 22-72, 24-72, 26-72, 28-72, 30-72, 6-68, 8-68, 10-68, 12-68, 14-68, 16-68, 18-68, 20-68, 22-68, 24-68, 26-68, 28-68, 30-68, 6-64, 8-64, 10-64, 12-64, 14-64, 16-64, 18-64, 20-64, 22-64, 24-64, 26-64, 28-64, 30-64, 6-60, 8-60, 10-60, 12-56, 14-56, 16-56, 18-56, 20-56, 22-56, 24-56, 26-56, 28-56, 30-56, 6-52, 8-52, 10-52, 12-52, 14-52, 16-52, 18-52, 20-52, 22-52, 24-52, 26-52, 28-52, 30-52, 6-48, 8-48, 10-48, 12-48, 14-48, 16-48, 18-48, 20-48, 22-48, 24-48, 26-48, 28-48, 30-48, 6-44, 8-44, 10-44, 12-44, 14-44, 16-44, 18-44, 20-44, 22-44, 24-44, 26-44, 28-44, 30-44, 6-40, 8-40, 10-40, 12-40, 14-40, 16-40, 18-40, 20-40, 22-40, 24-40, 26-40, 28-40, 30-40, 6-36, 8-36, 10-36, 12-36, 14-36, 16-36, 18-36, 20-36, 22-36, 24-36, 26-36, 28-36, 30-36, 6-32, 8-32, 10-32, 12-32, 14-32, 16-32, 18-32, 20-32, 22-32, 24-32, 26-32, 28-32, or 30-32.</p><heading id="h-0026" level="1">III.A.1.a. Cholesterol and Other Sterols</heading><p id="p-0300" num="0292">In some aspects, the anchoring moiety comprises a sterol, steroid, hopanoid, hydroxysteroid, secosteroid, or analog thereof with lipophilic properties. In some aspects, the anchoring moiety comprises a sterol, such as a phytosterol, mycosterol, or zoosterol. Exemplary zoosterols include cholesterol and 24S-hydroxycholesterol; exemplary phytosterols include ergosterol (mycosterol), campesterol, sitosterol, and stigmasterol. In some aspects, the sterol is selected from ergosterol, 7-dehydrocholesterol, cholesterol, 24S-hydroxycholesterol, lanosterol, cycloartenol, fucosterol, saringosterol, campesterol, &#x3b2;-sitosterol, sitostanol, coprostanol, avenasterol, or stigmasterol. Sterols may be found either as free sterols, acylated (sterol esters), alkylated (steryl alkyl ethers), sulfated (sterol sulfate), or linked to a glycoside moiety (steryl glycosides), which can be itself acylated (acylated sterol glycosides).</p><p id="p-0301" num="0293">In some aspects, the anchoring moiety comprises a steroid. In some aspects, the steroid is selected from dihydrotestosterone, uvaol, hecigenin, diosgenin, progesterone, or cortisol.</p><p id="p-0302" num="0294">For example, sterols may be conjugated to the ASO directly or via a linker combination at the available &#x2014;OH group of the sterol. Exemplary sterols have the general skeleton shown below:</p><p id="p-0303" num="0000"><chemistry id="CHEM-US-00011" num="00011"><img id="EMI-C00011" he="20.74mm" wi="40.81mm" file="US20230002764A1-20230105-C00011.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0304" num="0295">As a further example ergosterol has the structure below:</p><p id="p-0305" num="0000"><chemistry id="CHEM-US-00012" num="00012"><img id="EMI-C00012" he="33.02mm" wi="64.69mm" file="US20230002764A1-20230105-C00012.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0306" num="0296">Cholesterol has the structure below:</p><p id="p-0307" num="0000"><chemistry id="CHEM-US-00013" num="00013"><img id="EMI-C00013" he="39.20mm" wi="62.82mm" file="US20230002764A1-20230105-C00013.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0308" num="0297">Accordingly, in some embodiments, the free &#x2014;OH group of a sterol or steroid is used to conjugate the ASO directly or via a linker combination, to the sterol (e.g., cholesterol) or steroid.</p><heading id="h-0027" level="1">III.A.1.b. Fatty Acids</heading><p id="p-0309" num="0298">In some aspects, the anchoring moiety is a fatty acid. In some aspects, the fatty acid is a short-chain, medium-chain, or long-chain fatty acid. In some aspects, the fatty acid is a saturated fatty acid. In some aspects, the fatty acid is an unsaturated fatty acid. In some aspects, the fatty acid is a monounsaturated fatty acid. In some aspects, the fatty acid is a polyunsaturated fatty acid, such as an &#x3c9;-3 (omega-3) or &#x3c9;-6 (omega-6) fatty acid.</p><p id="p-0310" num="0299">In some aspects, the lipid, e.g., fatty acid, has a C<sub>2</sub>-C<sub>60 </sub>chain. In some embodiments, the lipid, e.g., fatty acid, has a C<sub>2</sub>-C<sub>28 </sub>chain. In some aspects, the fatty acid, has a C<sub>2</sub>-C<sub>40 </sub>chain. In some aspects, the fatty acid, has a C<sub>2</sub>-C<sub>12 </sub>or C<sub>4</sub>-C<sub>12 </sub>chain. In some aspects, the fatty acid, has a C<sub>4</sub>-C<sub>40 </sub>chain. In some aspects, the fatty acid, has a C<sub>4</sub>-C<sub>40</sub>, C<sub>2</sub>-C<sub>38</sub>, C<sub>2</sub>-C<sub>36</sub>, C<sub>2</sub>-C<sub>34</sub>, C<sub>2</sub>-C<sub>32</sub>, C<sub>2</sub>-C<sub>30</sub>, C<sub>4</sub>-C<sub>30</sub>, C<sub>2</sub>-C<sub>28</sub>, C<sub>4</sub>-C<sub>28</sub>, C<sub>2</sub>- C<sub>26</sub>, C<sub>4</sub>-C<sub>26</sub>, C<sub>2</sub>-C<sub>24</sub>, C<sub>4</sub>-C<sub>24</sub>, C<sub>6</sub>-C<sub>24</sub>, C<sub>8</sub>-C<sub>24</sub>, C<sub>10</sub>-C<sub>24</sub>, C<sub>2</sub>-C<sub>22</sub>, C<sub>4</sub>-C<sub>22</sub>, C<sub>6</sub>-C<sub>22</sub>, C<sub>8</sub>-C<sub>22</sub>, C<sub>10</sub>-C<sub>22</sub>, C<sub>2</sub>-C<sub>20</sub>, C<sub>4</sub>-C<sub>20</sub>, C<sub>4</sub>-C<sub>20</sub>, C<sub>8</sub>-C<sub>20</sub>, C<sub>10</sub>-C<sub>20</sub>, C<sub>2</sub>-C<sub>18</sub>, C<sub>4</sub>-C<sub>18</sub>, C<sub>6</sub>-C<sub>18</sub>, C<sub>8</sub>-C<sub>18</sub>, C<sub>10</sub>-C<sub>18</sub>, C<sub>12</sub>-C<sub>18</sub>, C<sub>14</sub>-C<sub>18</sub>, C<sub>16</sub>-C<sub>18</sub>, C<sub>2</sub>- C<sub>16</sub>, C<sub>4</sub>-C<sub>16</sub>, C<sub>6</sub>-C<sub>16</sub>, C<sub>8</sub>-C<sub>16</sub>, C<sub>10</sub>-C<sub>16</sub>, C<sub>12</sub>-C<sub>16</sub>, C<sub>14</sub>-C<sub>16</sub>, C<sub>2</sub>-C<sub>15</sub>, C<sub>4</sub>-C<sub>15</sub>, C<sub>6</sub>-C<sub>15</sub>, C<sub>8</sub>-C<sub>15</sub>, C<sub>9</sub>-C<sub>15</sub>, C<sub>10</sub>-C<sub>15</sub>, C<sub>11</sub>- C<sub>15</sub>, C<sub>12</sub>-C<sub>15</sub>, C<sub>13</sub>-C<sub>15</sub>, C<sub>2</sub>-C<sub>14</sub>, C<sub>4</sub>-C<sub>14</sub>, C<sub>6</sub>-C<sub>14</sub>, C<sub>8</sub>-C<sub>14</sub>, C<sub>9</sub>-C<sub>14</sub>, C<sub>10</sub>-C<sub>14</sub>, C<sub>11</sub>-C<sub>14</sub>, C<sub>12</sub>-C<sub>14</sub>, C<sub>2</sub>-C<sub>13</sub>, C<sub>6</sub>-C<sub>13</sub>, C<sub>7</sub>-C<sub>13</sub>, C<sub>8</sub>-C<sub>13</sub>, C<sub>8</sub>-C<sub>13</sub>, C<sub>9</sub>-C<sub>13</sub>, C<sub>10</sub>-C<sub>13</sub>, C<sub>10</sub>-C<sub>13</sub>, C<sub>11</sub>-C<sub>13</sub>, C<sub>2</sub>-C<sub>12</sub>, C<sub>4</sub>-C<sub>12</sub>, C<sub>6</sub>-C<sub>12</sub>, C<sub>7</sub>-C<sub>12</sub>, C<sub>8</sub>-C<sub>12</sub>, C<sub>9</sub>-C<sub>12</sub>, C<sub>10</sub>-C<sub>12</sub>, C<sub>2</sub>-C<sub>11</sub>, C<sub>4</sub>-C<sub>11</sub>, C<sub>6</sub>-C<sub>11</sub>, C<sub>7</sub>-C<sub>11</sub>, C<sub>8</sub>-C<sub>11</sub>, C<sub>9</sub>-C<sub>11</sub>, C<sub>2</sub>-C<sub>10</sub>, C<sub>4</sub>-C<sub>10</sub>, C<sub>2</sub>-C<sub>9</sub>, C<sub>4</sub>-C<sub>9</sub>, C<sub>2</sub>-C<sub>8</sub>, C<sub>2</sub>-C<sub>7</sub>, C<sub>4</sub>- C<sub>7</sub>, C<sub>2</sub>-C<sub>6</sub>, or C<sub>4</sub>-C<sub>6</sub>, chain. In some aspects, the fatty acid, has a C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub>, C<sub>5</sub>, C<sub>6</sub>, C<sub>7</sub>, C<sub>8</sub>, C<sub>9</sub>, C<sub>10</sub>, C<sub>11</sub>, C<sub>12</sub>, C<sub>13</sub>, C<sub>14</sub>, C<sub>15</sub>, C<sub>16</sub>, C<sub>17</sub>, C<sub>18</sub>, C<sub>19</sub>, C<sub>20</sub>, C<sub>21</sub>, C<sub>22</sub>, C<sub>23</sub>, C<sub>24</sub>, C<sub>25</sub>, C<sub>26</sub>, C<sub>27</sub>, C<sub>28</sub>, C<sub>29</sub>, C<sub>30</sub>, C<sub>31</sub>, C<sub>32</sub>, C<sub>33</sub>, C<sub>34</sub>, C<sub>35</sub>, C<sub>36</sub>, C<sub>37</sub>, C<sub>38</sub>, C<sub>39</sub>, C<sub>40</sub>, C<sub>41</sub>, C<sub>42</sub>, C<sub>43</sub>, C<sub>44</sub>, C<sub>45</sub>, C<sub>46</sub>, C<sub>47</sub>, C<sub>48</sub>, C<sub>49</sub>, C<sub>50</sub>, C<sub>51</sub>, C<sub>52</sub>, C<sub>53</sub>, C<sub>54</sub>, C<sub>55</sub>, C<sub>56</sub>, C<sub>57</sub>, C<sub>58</sub>, C<sub>59</sub>, or C<sub>60 </sub>chain.</p><p id="p-0311" num="0300">In some aspects, the anchoring moiety comprises two fatty acids, each of which is independently selected from a fatty acid having a chain with any one of the foregoing ranges or numbers of carbon atoms. In some aspects, one of the fatty acids is independently a fatty acid with a C6-C21 chain and one is independently a fatty acid with a C12-C36 chain. In some embodiments, each fatty acid independently has a chain of 11, 12, 13, 14, 15, 16, or 17 carbon atoms.</p><p id="p-0312" num="0301">Suitable fatty acids include saturated straight-chain fatty acids, saturated branched fatty acids, unsaturated fatty acids, hydroxy fatty acids, and polycarboxylic acids. In some aspects, such fatty acids have up to 32 carbon atoms.</p><p id="p-0313" num="0302">Examples of useful saturated straight-chain fatty acids include those having an even number of carbon atoms, such as butyric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachic acid, behenic acid, lignoceric acid, hexacosanoic acid, octacosanoic acid, triacontanoic acid and n-dotriacontanoic acid, and those having an odd number of carbon atoms, such as propionic acid, n-valeric acid, enanthic acid, pelargonic acid, hendecanoic acid, tridecanoic acid, pentadecanoic acid, heptadecanoic acid, nonadecanoic acid, heneicosanoic acid, tricosanoic acid, pentacosanoic acid, and heptacosanoic acid.</p><p id="p-0314" num="0303">Examples of suitable saturated branched fatty acids include isobutyric acid, isocaproic acid, isocaprylic acid, isocapric acid, isolauric acid, 11-methyldodecanoic acid, isomyristic acid, 13-methyl-tetradecanoic acid, isopalmitic acid, 15-methyl-hexadecanoic acid, isostearic acid, 17-methyloctadecanoic acid, isoarachic acid, 19-methyl-eicosanoic acid, &#x3b1;-ethyl-hexanoic acid, &#x3b1;-hexyldecanoic acid, &#x3b1;-heptylundecanoic acid, 2-decyltetradecanoic acid, 2-undecyltetradecanoic acid, 2-decylpentadecanoic acid, 2-undecylpentadecanoic acid, and Fine oxocol 1800 acid (product of Nissan Chemical Industries, Ltd.). Suitable saturated odd-carbon branched fatty acids include anteiso fatty acids terminating with an isobutyl group, such as 6-methyl-octanoic acid, 8-methyl-decanoic acid, 10-methyl-dodecanoic acid, 12-methyl-tetradecanoic acid, 14-methyl-hexadecanoic acid, 16-methyl-octadecanoic acid, 18-methyl-eicosanoic acid, 20-methyl-docosanoic acid, 22-methyl-tetracosanoic acid, 24-methyl-hexacosanoic acid, and 26-methyloctacosanoic acid.</p><p id="p-0315" num="0304">Examples of suitable unsaturated fatty acids include 4-decenoic acid, caproleic acid, 4-dodecenoic acid, 5-dodecenoic acid, lauroleic acid, 4-tetradecenoic acid, 5-tetradecenoic acid, 9-tetradecenoic acid, palmitoleic acid, 6-octadecenoic acid, oleic acid, 9-octadecenoic acid, 11-octadecenoic acid, 9-eicosenoic acid, cis-11-eicosenoic acid, cetoleic acid, 13-docosenoic acid, 15-tetracosenoic acid, 17-hexacosenoic acid, 6,9,12,15-hexadecatetraenoic acid, linoleic acid, linolenic acid, &#x3b1;-eleostearic acid, &#x3b2;-eleostearic acid, punicic acid, 6,9,12,15-octadecatetraenoic acid, parinaric acid, 5,8,11,14-eicosatetraenoic acid, 5,8,11,14,17-eicosapentaenoic acid, 7,10,13,16,19-docosapentaenoic acid, 4,7,10,13,16,19-docosahexaenoic acid, and the like.</p><p id="p-0316" num="0305">Examples of suitable hydroxy fatty acids include &#x3b1;-hydroxylauric acid, &#x3b1;-hydroxymyristic acid, &#x3b1;-hydroxypalmitic acid, &#x3b1;-hydroxystearic acid, &#x3c9;-hydroxylauric acid, &#x3b1;-hydroxyarachic acid, 9-hydroxy-12-octadecenoic acid, ricinoleic acid, &#x3b1;-hydroxybehenic acid, 9-hydroxy-trans-10,12-octadecadienic acid, kamolenic acid, ipurolic acid, 9,10-dihydroxystearic acid, 12-hydroxystearic acid and the like.</p><p id="p-0317" num="0306">Examples of suitable polycarboxylic acids include oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, D,L-malic acid, and the like.</p><p id="p-0318" num="0307">In some aspects, each fatty acid is independently selected from propionic acid, butyric acid, valeric acid, caproic acid, enanthic acid, caprylic acid, pelargonic acid, capric acid, undecylic acid, lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, stearic acid, nonadecylic acid, arachidic acid, heneicosylic acid, behenic acid, tricosylic acid, lignoceric acid, pentacosylic acid, cerotic acid, heptacosylic acid, montanic acid, nonacosylic acid, melissic acid, henatriacontylic acid, lacceroic acid, psyllic acid, geddic acid, ceroplastic acid, hexatriacontylic acid, heptatriacontanoic acid, or octatriacontanoic acid.</p><p id="p-0319" num="0308">In some aspects, each fatty acid is independently selected from &#x3b1;-linolenic acid, steandonic acid, eicosapentaenoic acid, docosahexaenoic acid, linoleic acid, gamma-linoleic acid, dihomo-gamma-linoleic acid, arachidonic acid, docosatetraenoic acid, palmitoleic acid, vaccenic acid, paullinic acid, oleic acid, elaidic acid, gondoic acid, erucic acid, nervonic acid, mead acid, adrenic acid, bosseopentaenoic acid, ozubondo acid, sardine acid, herring acid, docosahexaenoic acid, or tetracosanolpentaenoic acid, or another monounsaturated or polyunsaturated fatty acid.</p><p id="p-0320" num="0309">In some aspects, one or both of the fatty acids is an essential fatty acid. In view of the beneficial health effects of certain essential fatty acids, the therapeutic benefits of disclosed therapeutic-loaded exosomes may be increased by including such fatty acids in the therapeutic agent. In some aspects, the essential fatty acid is an n-6 or n-3 essential fatty acid selected from the group consisting of linolenic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid, arachidonic acid, adrenic acid, docosapentaenoic n-6 acid, alpha-linolenic acid, stearidonic acid, the 20:4n-3 acid, eicosapentaenoic acid, docosapentaenoic n-3 acid, or docosahexaenoic acid.</p><p id="p-0321" num="0310">In some aspects, each fatty acid is independently selected from all-cis-7,10,13-hexadecatrienoic acid, &#x3b1;-linolenic acid, stearidonic acid, eicosatnenoic acid, eicosatetraenoic acid, eicosapentaenoic acid (EPA), docosapentaenoic acid, docosahexaenoic acid (DHA), tetracosapentaenoic acid, tetracosahexaenoic acid, or lipoic acid. In other aspects, the fatty acid is selected from cicosapentaenoic acid, docosahexaenoic acid, or lipoic acid. Other examples of fatty acids include all-cis-7,10,13-hexadecatrienoic acid, &#x3b1;-linolenic acid (ALA or all-cis-9,12,15-octadecatrienoic acid), stearidonic acid (STD or all-cis-6,9,12,15-octadecatetracnoic acid), eicosatrienoic acid (ETE or all-cis-11,14,17-eicosatrienoic acid), eicosatetraenoic acid (ETA or all-cis-8,11,14,17-eicosatetraenoic acid), cicosapentaenoic acid (EPA), docosapentaenoic acid (DPA, clupanodonic acid or all-cis-7,10,13,16,19-docosapentaenoic acid), docosahexaenoic acid (DHA or all-cis-4,7,10,13,16,19-docosahexaenoic acid), tetracosapentaenoic acid (all-cis-9,12,15,18,21-docosahexaenoic acid), ortetracosahexaenoic acid (nisinic acid or all-cis-6,9,12,15,18,21-tetracosenoic acid). In some aspects, the fatty acid is a medium-chain fatty acid such as lipoic acid.</p><p id="p-0322" num="0311">Fatty acid chains differ greatly in the length of their chains and may be categorized according to chain length, e.g as short to very long. Short-chain fatty acids (SCFA) are fatty acids with chains of about five or less carbons (e.g. butyric acid). In some aspects, the fatty acid is a SCFA. Medium-chain fatty acids (MCFA) include fatty acids with chains of about 6-12 carbons, which can form medium-chain triglycerides. In some aspects, the fatty acid is a MCFA. Long-chain fatty acids (LCFA) include fatty acids with chains of 13-21 carbons. In some aspects, the fatty acid is a LCFA. In some aspects, the fatty acid is a LCFA Very long chain fatty acids (VLCFA) include fatty acids with chains of 22 or more carbons, such as 22-60, 22-50, or 22-40 carbons. In some aspects, the fatty acid is a VLCFA.</p><heading id="h-0028" level="1">III.A.1.c. Phospholipids</heading><p id="p-0323" num="0312">In some aspects, the anchoring moiety comprises a phospholipid. Phospholipids are a class of lipids that are a major component of all cell membranes. They can form lipid bilayers because of their amphiphilic characteristic. The structure of the phospholipid molecule generally consists of two hydrophobic fatty acid &#x201c;tails&#x201d; and a hydrophilic &#x201c;head&#x201d; consisting of a phosphate group. For example, a phospholipid can be a lipid according to the following formula:</p><p id="p-0324" num="0000"><chemistry id="CHEM-US-00014" num="00014"><img id="EMI-C00014" he="24.30mm" wi="44.79mm" file="US20230002764A1-20230105-C00014.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0325" num="0000">in which R<sub>p </sub>represents a phospholipid moiety and R<sub>1 </sub>and R<sub>2 </sub>represent fatty acid moieties with or without unsaturation that may be the same or different.</p><p id="p-0326" num="0313">A phospholipid moiety may be selected, for example, from the non-limiting group consisting of phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl glycerol, phosphatidyl serine, phosphatidic acid, 2 lysophosphatidyl choline, and a sphingomyelin</p><p id="p-0327" num="0314">Particular phospholipids may facilitate fusion to a lipid bilayer, e.g., the lipid bilayer of an exosomal membrane. For example, a cationic phospholipid may interact with one or more negatively charged phospholipids of a membrane. Fusion of a phospholipid to a membrane may allow one or more elements of a lipid-containing composition to bind to the membrane or to pass through the membrane.</p><p id="p-0328" num="0315">A fatty acid moiety may be selected, for example, from the non-limiting group consisting of lauric acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, alpha-linolenic acid, erucic acid, phytanoic acid, arachidic acid, arachidonic acid, eicosapentaenoic acid, behenic acid, docosapentaenoic acid, and docosahexanoic acid.</p><p id="p-0329" num="0316">The phospholipids using as anchoring moieties in the present disclosure can be natural or non-natural phospholipids. Non-natural phospholipid species including natural species with modifications and substitutions including branching, oxidation, cyclization, and alkynes are also contemplated. For example, a phospholipid may be functionalized with or cross-linked to one or more alkynes (e.g., an alkenyl group in which one or more double bonds is replaced with a triple bond). Under appropriate reaction conditions, an alkyne group may undergo a copper-catalyzed cycloaddition upon exposure to an azide.</p><p id="p-0330" num="0317">Phospholipids include, but are not limited to, glycerophospholipids such as phosphatidylcholines, phosphatidylethanolamines, phosphatidylserines, phosphatidylinositols, phosphatidy glycerols, and phosphatidic acids.</p><p id="p-0331" num="0318">Examples of phospholipids that can be used in the anchoring moieties disclosed herein include<ul id="ul0001" list-style="none">    <li id="ul0001-0001" num="0000">    <ul id="ul0002" list-style="none">        <li id="ul0002-0001" num="0319">Phosphatidylethanolamines: E.g., dilauroylphosphatidyl ethanolamine, dimyristoylphosphatidyl ethanolamine, dipalmitoylphosphatidyl ethanolamine, distearoylphosphatidyl ethanolamine, diolcoylphosphatidyl ethanolamine, 1-palmitoyl-2-oleylphosphatidyl ethanolamnne, 1-oleyl-2-palmitoylphosphatidyl ethanolamine, and dierucoylphosphatidyl ethanolamine:</li>        <li id="ul0002-0002" num="0320">Phosphatidyl glycerols: E.g., dilauroylphosphatidyl glycerol, dimyristoylphosphatidyl glycerol, dipalmitoylphosphatidyl glycerol, distearoylphosphatidyl glycerol, dioleoylphosphatidyl glycerol, 1-palmitoyl-2-oleyl-phosphatidyl glycerol, 1-oleyl-2-palmitoyl-phosphatidyl glycerol, and dierucoylphosphatidyl glycerol;</li>        <li id="ul0002-0003" num="0321">Phosphatidyl serines. E.g., such as dilauroylphosphatidyl serine, dimyristoylphosphatidyl serine, dipalmitoylphosphatidyl serine, distearoylphosphatidyl serine, dioleoylphosphatidyl serine. 1-palmitoyl-2-oleyl-phosphatidyl serine, 1-oleyl-2-palmitoyl-phosphatidyl serine, and dierucoylphosphatidyl serine;</li>        <li id="ul0002-0004" num="0322">Phosphatidic acids: E.g, dilauroylphosphatidic acid, dimyristoylphosphatidic acid, dipalmitoylphosphatidic acid, distearoylphosphatidic acid, dioleoylphosphatidic acid, 1-palmitoyl-2-olcylphosphatidic acid, 1-oleyl-2-palmitoyl-phosphatidic acid, and dicrucoylphosphatidic acid, and,</li>        <li id="ul0002-0005" num="0323">Phosphatidyl inositols: E.g., dilauroylphosphatidyl inositol, dimyristoylphosphatidyl inositol, dipalmitoylphosphatidyl inositol, distearoylphosphatidyl inositol, dioleoylphosphatidyl inositol, 1-palmitoyl-2-olcyl-phosphatidyl inositol, 1-oleyl-2-palmitoyl-phosphatidyl inositol, and dierucoylphosphatidyl inositol.</li>    </ul>    </li></ul></p><p id="p-0332" num="0324">Phospholipids may be of a symmetric or an asymmetric type. As used herein, the term &#x201c;symmetric phospholipid&#x201d; includes glycerophospholipids having matching fatty acid moieties and sphingolipids in which the variable fatty acid moiety and the hydrocarbon chain of the sphingosine backbone include a comparable number of carbon atoms. As used herein, the term &#x201c;asymmetric phospholipid&#x201d; includes lysolipids, glycerophospholipids having different fatty acid moieties (e.g., fatty acid moieties with different numbers of carbon atoms and/or unsaturations (e.g., double bonds)), and sphingolipids in which the variable fatty acid moiety and the hydrocarbon chain of the sphingosine backbone include a dissimilar number of carbon atoms (e.g., the variable fatty acid moiety include at least two more carbon atoms than the hydrocarbon chain or at least two fewer carbon atoms than the hydrocarbon chain).</p><p id="p-0333" num="0325">In some aspects, the anchoring moiety comprises at least one symmetric phospholipid. Symmetric phospholipids may be selected from the non-limiting group consisting of<ul id="ul0003" list-style="none">    <li id="ul0003-0001" num="0326">1,2-dipropionyl-sn-glycero-3-phosphocholine (03:0 PC),</li>    <li id="ul0003-0002" num="0327">1,2-dibutyryl-sn-glycero-3-phosphocholine (04:0 PC),</li>    <li id="ul0003-0003" num="0328">1,2-dipentanoyl-sn-glycero-3-phosphocholine (05:0 PC),</li>    <li id="ul0003-0004" num="0329">1,2-dihexanoyl-sn-glycero-3-phosphocholine (06:0 PC),</li>    <li id="ul0003-0005" num="0330">1,2-diheptanoyl-sn-glycero-3-phosphocholine (07:0 PC),</li>    <li id="ul0003-0006" num="0331">1,2-dioctanoyl-sn-glycero-3-phosphocholine (08:0 PC),</li>    <li id="ul0003-0007" num="0332">1,2-dinonanoyl-sn-glycero-3-phosphocholine (09:0 PC),</li>    <li id="ul0003-0008" num="0333">1,2-didecanoyl-sn-glycero-3-phosphocholine (10:0 PC),</li>    <li id="ul0003-0009" num="0334">1,2-diundecanoyl-sn-glycero-3-phosphocholine (11:0 PC, DUPC),</li>    <li id="ul0003-0010" num="0335">1,2-dilauroyl-sn-glycero-3-phosphocholine (12:0 PC),</li>    <li id="ul0003-0011" num="0336">1,2-ditridecanoyl-sn-glycero-3-phosphocholine (13:0 PC),</li>    <li id="ul0003-0012" num="0337">1,2-dimyristoyl-sn-glycero-3-phosphocholine (14:0 PC, DMPC),</li>    <li id="ul0003-0013" num="0338">1,2-dipentadecanoyl-sn-glycero-3-phosphocholine (15:0 PC),</li>    <li id="ul0003-0014" num="0339">1,2-dipalmitoyl-sn-glycero-3-phosphocholine (16:0 PC, DPPC),</li>    <li id="ul0003-0015" num="0340">1,2-diphytanoyl-sn-glycero-3-phosphocholine (4ME 16:0 PC),</li>    <li id="ul0003-0016" num="0341">1,2-diheptadecanoyl-sn-glycero-3-phosphocholine (17:0 PC),</li>    <li id="ul0003-0017" num="0342">1,2-distearoyl-sn-glycero-3-phosphocholine (18:0 PC, DSPC),</li>    <li id="ul0003-0018" num="0343">1,2-dinonadecanoyl-sn-glycero-3-phosphocholine (19:0 PC),</li>    <li id="ul0003-0019" num="0344">1,2-diarachidoyl-sn-glycero-3-phosphocholine (20:0 PC),</li>    <li id="ul0003-0020" num="0345">1,2-dihenarachidoyl-sn-glycero-3-phosphocholine (21:0 PC),</li>    <li id="ul0003-0021" num="0346">1,2-dibehenoyl-sn-glycero-3-phosphocholine (22:0 PC),</li>    <li id="ul0003-0022" num="0347">1,2-ditricosanoyl-sn-glycero-3-phosphocholine (23:0 PC),</li>    <li id="ul0003-0023" num="0348">1,2-dilignoceroyl-sn-glycero-3-phosphocholine (24:0 PC),</li>    <li id="ul0003-0024" num="0349">1,2-dimyristoleoyl-sn-glycero-3-phosphocholine (14:1 (&#x394;9-Cis) PC),</li>    <li id="ul0003-0025" num="0350">1,2-dimyristelaidoyl-sn-glycero-3-phosphocholine (14:1 (&#x394;9-Trans) PC),</li>    <li id="ul0003-0026" num="0351">1,2-dipalmitoleoyl-sn-glycero-3-phosphocholine (16:1 (&#x394;9-Cis) PC),</li>    <li id="ul0003-0027" num="0352">1,2-dipalmitelaidoyl-sn-glycero-3-phosphocholine (16:1 (&#x394;9-Trans) PC),</li>    <li id="ul0003-0028" num="0353">1,2-dipetroselenoyl-sn-glycero-3-phosphocholine (18:1 (&#x394;6-Cis) PC),</li>    <li id="ul0003-0029" num="0354">1,2-dioleoyl-sn-glycero-3-phosphocholine (18:1 (&#x394;9-Cis) PC, DOPC),</li>    <li id="ul0003-0030" num="0355">1,2-dielaidoyl-sn-glycero-3-phosphocholine (18:1 (&#x394;9-Trans) PC),</li>    <li id="ul0003-0031" num="0356">1,2-dilinoleoyl-sn-glycero-3-phosphocholine (18:2 (Cis) PC, DLPC),</li>    <li id="ul0003-0032" num="0357">1,2-dilinolenoyl-sn-glycero-3-phosphocholine (18:3 (Cis) PC, DLnPC),</li>    <li id="ul0003-0033" num="0358">1,2-dieicosenoyl-sn-glycero-3-phosphocholine (20:1 (Cis) PC),</li>    <li id="ul0003-0034" num="0359">1,2-diarachidonoyl-sn-glycero-3-phosphocholine (20:4 (Cis) PC, DAPC),</li>    <li id="ul0003-0035" num="0360">1,2-dierucoyl-sn-glycero-3-phosphocholine (22:1 (Cis) PC),</li>    <li id="ul0003-0036" num="0361">1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine (22:6 (Cis) PC, DHAPC),</li>    <li id="ul0003-0037" num="0362">1,2-dinervonoyl-sn-glycero-3-phosphocholine (24:1 (Cis) PC),</li>    <li id="ul0003-0038" num="0363">1,2-dihexanoyl-sn-glycero-3-phosphoethanolamine (06:0 PE),</li>    <li id="ul0003-0039" num="0364">1,2-dioctanoyl-sn-glycero-3-phosphoethanolamine (08:0 PE),</li>    <li id="ul0003-0040" num="0365">1,2-didecanoyl-sn-glycero-3-phosphoethanolamine (10:0 PE),</li>    <li id="ul0003-0041" num="0366">1,2-dilauroyl-sn-glycero-3-phosphoethanolamine (12:0 PE),</li>    <li id="ul0003-0042" num="0367">1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (14:0 PE),</li>    <li id="ul0003-0043" num="0368">1,2-dipentadecanoyl-sn-glycero-3-phosphoethanolamine (15:0 PE),</li>    <li id="ul0003-0044" num="0369">1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (16:0 PE),</li>    <li id="ul0003-0045" num="0370">1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (4ME 16:0 PE),</li>    <li id="ul0003-0046" num="0371">1,2-diheptadecanoyl-sn-glycero-3-phosphoethanolamine (17:0 PE),</li>    <li id="ul0003-0047" num="0372">1,2-distearoyl-sn-glycero-3-phosphoethanolamine (18:0 PE, DSPE),</li>    <li id="ul0003-0048" num="0373">1,2-dipalmitoleoyl-sn-glycero-3-phosphoethanolamine (16:1 PE),</li>    <li id="ul0003-0049" num="0374">1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (18:1 (&#x394;9-Cis) PE, DOPE),</li>    <li id="ul0003-0050" num="0375">1,2-dielaidoyl-sn-glycero-3-phosphoethanolamine (18:1 (&#x394;9-Trans) PE),</li>    <li id="ul0003-0051" num="0376">1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine (18:2 PE, DLPE),</li>    <li id="ul0003-0052" num="0377">1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine (18:3 PE, DLnPE),</li>    <li id="ul0003-0053" num="0378">1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine (20:4 PE, DAPE),</li>    <li id="ul0003-0054" num="0379">1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine (22:6 PE, DHAPE),</li>    <li id="ul0003-0055" num="0380">1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC),</li>    <li id="ul0003-0056" num="0381">1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), and any combination thereof.</li></ul></p><p id="p-0334" num="0382">In some aspects, the anchoring moiety comprises at least one symmetric phospholipid selected from the non-limiting group consisting of DLPC, DMPC, DOPC, DPPC, DSPC, DUPC, 18:0 Diether PC, DLnPC, DAPC, DHAPC, DOPE, 4ME 16:0 PE, DSPE, DLPE, DLZPE, DAPE, DHAPE, DOPG, and any combination thereof.</p><p id="p-0335" num="0383">In some aspects, the anchoring moiety comprises at least one asymmetric phospholipid.</p><p id="p-0336" num="0384">Asymmetric phospholipids may be selected from the non-limiting group consisting of<ul id="ul0004" list-style="none">    <li id="ul0004-0001" num="0385">1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine (14:0-16:0 PC, MPPC),</li>    <li id="ul0004-0002" num="0386">1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine (14:0-18:0 PC, MSPC),</li>    <li id="ul0004-0003" num="0387">1-palmitoyl-2-acetyl-sn-glycero-3-phosphocholine (16:0-02:0 PC),</li>    <li id="ul0004-0004" num="0388">1-palmitoyl-2-myristoyl-sn-glycero-3-phosphocholine (16:0-14:0 PC, PMPC),</li>    <li id="ul0004-0005" num="0389">1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine (16:0-18:0 PC, PSPC),</li>    <li id="ul0004-0006" num="0390">1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (16:0-18:1 PC, POPC),</li>    <li id="ul0004-0007" num="0391">1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine (16:0-18:2 PC, PLPC),</li>    <li id="ul0004-0008" num="0392">1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (16:0-20:4 PC),</li>    <li id="ul0004-0009" num="0393">1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine (14:0-22:6 PC),</li>    <li id="ul0004-0010" num="0394">1-stearoyl-2-myristoyl-sn-glycero-3-phosphocholine (18:0-14:0 PC, SMPC),</li>    <li id="ul0004-0011" num="0395">1-stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine (18:0-16:0 PC, SPPC),</li>    <li id="ul0004-0012" num="0396">1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (18:0-18:1 PC, SOPC),</li>    <li id="ul0004-0013" num="0397">1-stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine (18:0-18:2 PC),</li>    <li id="ul0004-0014" num="0398">1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (18:0-20:4 PC),</li>    <li id="ul0004-0015" num="0399">1-stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine (18:0-22:6 PC),</li>    <li id="ul0004-0016" num="0400">1-oleoyl-2-myristoyl-sn-glycero-3-phosphocholine (18:1-14:0 PC, OMPC),</li>    <li id="ul0004-0017" num="0401">1-oleoyl-2-palmitoyl-sn-glycero-3-phosphocholine (18:1-16:0 PC, OPPC),</li>    <li id="ul0004-0018" num="0402">1-oleoyl-2-stearoyl-sn-glycero-3-phosphocholine (18:1-18:0 PC, OSPC),</li>    <li id="ul0004-0019" num="0403">1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (16:0-18:1 PE, POPE),</li>    <li id="ul0004-0020" num="0404">1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphoethanolamine (16:0-18:2 PE),</li>    <li id="ul0004-0021" num="0405">1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine (16:0-20:4 PE),</li>    <li id="ul0004-0022" num="0406">1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine (16:0-22:6 PE),</li>    <li id="ul0004-0023" num="0407">1-stearoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (18:0-18:1 PE),</li>    <li id="ul0004-0024" num="0408">1-stearoyl-2-linoleoyl-sn-glycero-3-phosphoethanolamine (18:0-18:2 PE),</li>    <li id="ul0004-0025" num="0409">1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine (18:0-20:4 PE),</li>    <li id="ul0004-0026" num="0410">1-stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine (18:0-22:6 PE),</li>    <li id="ul0004-0027" num="0411">1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), and<br/>any combination thereof.</li></ul></p><p id="p-0337" num="0412">To provide more remarkable nuclease resistance, cellular uptake efficiency, and a more remarkable RNA interference effect, phosphatidylethanolamines may be used as anchoring moieties, for example, dimyristoylpbosphatidyl ethanolamine, dipalmitoylphosphatidyl ethanolamine, 1-palmitoyl-2-oleyl-phosphatidyl ethanolamine, and dioleoylphosphatidyl ethanolamine.</p><p id="p-0338" num="0413">The binding site of lipid (e.g., a phospholipid) and a linker combination or BAM, e.g., an ASO, may be suitably selected according to the types of lipid and linker or ASO. Any position other than hydrophobic groups of the lipid may be linked to the linker or ASO by a chemical bond. For example, when using a phosphatidylethanolamine, the linkage may be made by forming an amide bond, etc. between the amino group of phosphatidylethanolamine and the linker or ASO. When using a phosphatidylglycerol, the linkage may be made by forming an ester bond, an ether bond, etc. between the hydroxyl group of the glycerol residue and the linker or ASO. When using a phosphatidylserine, the linkage may be made by forming an amide bond or an ester bond, etc. between the amino group or carboxyl group of the serine residue and the linker or ASO. When using a phosphatidic acid, the linkage may be made by forming a phosphoester bond, etc. between the phosphate residue and the linker or ASO. When using a phosphatidylinositol, the linkage may be made by forming an ester bond, an ether bond, etc. between the hydroxyl group of the mositol residue and the linker or ASO.</p><heading id="h-0029" level="1">III.A.1.d. Lysolipids (e.g., Lysophospholipids)</heading><p id="p-0339" num="0414">In some aspects, the anchoring moiety comprises a lysolipid, e.g., a lysophospholipid. Lysolipids are derivatives of a lipid in which one or both fatty acyl chains have been removed, generally by hydrolysis. Lysophospholipids are derivatives of a phospholipid in which one or both fatty acyl chains have been removed by hydrolysis</p><p id="p-0340" num="0415">In some aspects, the anchoring moiety comprises any of the phospholipids disclosed above, in which one or both acyl chains have been removed via hydrolysis, and therefore the resulting lysophospholipid comprises one or no fatty acid acyl chain.</p><p id="p-0341" num="0416">In some aspects, the anchoring moiety comprises a lysoglycerophospholipid, a lysoglycosphingoliopid, a lysophosphatidylcholine, a lysophosphatidylethanolamine, a lysophosphatidylinositol, or a lysophosphatidylserine.</p><p id="p-0342" num="0417">In some aspect, the anchoring moiety comprises a lysolipid selected from the non-limiting group consisting of<ul id="ul0005" list-style="none">    <li id="ul0005-0001" num="0418">1-hexanoyl-2-hydroxy-sn-glycero-3-phosphocholine (06:0 Lyso PC),</li>    <li id="ul0005-0002" num="0419">1-heptanoyl-2-hydroxy-sn-glycero-3-phosphocholine (07:0 Lyso PC),</li>    <li id="ul0005-0003" num="0420">1-octanoyl-2-hydroxy-sn-glycero-3-phosphocholine (08:0 Lyso PC),</li>    <li id="ul0005-0004" num="0421">1-nonanoyl-2-hydroxy-sn-glycero-3-phosphocholine (09:0 Lyso PC),</li>    <li id="ul0005-0005" num="0422">1-decanoyl-2-hydroxy-sn-glycero-3-phosphocholine (10:0 Lyso PC),</li>    <li id="ul0005-0006" num="0423">1-undecanoyl-2-hydroxy-sn-glycero-3-phosphocholine (11:0 Lyso PC),</li>    <li id="ul0005-0007" num="0424">1-lauroyl-2-hydroxy-sn-glycero-3-phosphocholine (12:0 Lyso PC),</li>    <li id="ul0005-0008" num="0425">1-tridecanoyl-2-hydroxy-sn-glycero-3-phosphocholine (13:0 Lyso PC),</li>    <li id="ul0005-0009" num="0426">1-myristoyl-2-hydroxy-sn-glycero-3-phosphocholine (14:0 Lyso PC),</li>    <li id="ul0005-0010" num="0427">1-pentadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine (15:0 Lyso PC),</li>    <li id="ul0005-0011" num="0428">1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine (16:0 Lyso PC),</li>    <li id="ul0005-0012" num="0429">1-heptadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine (17:0 Lyso PC),</li>    <li id="ul0005-0013" num="0430">1-stearoyl-2-hydroxy-sn-glycero-3-phosphocholine (18:0 Lyso PC),</li>    <li id="ul0005-0014" num="0431">1-oleoyl-2-hydroxy-sn-glycero-3-phosphocholine (18:1 Lyso PC),</li>    <li id="ul0005-0015" num="0432">1-nonadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine (19:0 Lyso PC),</li>    <li id="ul0005-0016" num="0433">1-arachidoyl-2-hydroxy-sn-glycero-3-phosphocholine (20:0 Lyso PC),</li>    <li id="ul0005-0017" num="0434">1-behenoyl-2-hydroxy-sn-glycero-3-phosphocholine (22:0 Lyso PC),</li>    <li id="ul0005-0018" num="0435">1-lignoceroyl-2-hydroxy-sn-glycero-3-phosphocholine (24:0 Lyso PC),</li>    <li id="ul0005-0019" num="0436">1-hexacosanoyl-2-hydroxy-sn-glycero-3-phosphocholine (26:0 Lyso PC),</li>    <li id="ul0005-0020" num="0437">1-myristoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine (14:0 Lyso PE),</li>    <li id="ul0005-0021" num="0438">1-palmitoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine (16:0 Lyso PE),</li>    <li id="ul0005-0022" num="0439">1-stearoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine (18:0 Lyso PE),</li>    <li id="ul0005-0023" num="0440">1-oleoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine (18:1 Lyso PE),</li>    <li id="ul0005-0024" num="0441">1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), and<br/>any combination thereof.</li></ul></p><heading id="h-0030" level="1">III.A.1.e. Vitamins</heading><p id="p-0343" num="0442">In some aspects, the anchoring moiety comprises a lipophilic vitamin, e.g., folic acid, vitamin A, vitamin E, or vitamin K</p><p id="p-0344" num="0443">In some aspects, the anchoring moiety comprises vitamin A. Vitamin A is a group of unsaturated nutritional organic compounds that includes retinol, retinal, retinoic acid, and several provitamin A carotenoids (most notably beta-carotene). In some aspects, the anchoring moiety comprises retinol. In some aspects, the anchoring moiety comprises a retinoid. Retinoids are a class of chemical compounds that are vitamers of vitamin A or are chemically related to it. In some aspects, the anchoring moiety comprises a first generation retinoid (e.g., retinol, tretinoin, isotreatinoin, or alitretinoin), a second-generation retinoid (e.g., etretinate or acitretin), a third-generation retinoid (e.g., adapalene, bexarotene, or tazarotene), or any combination thereof.</p><p id="p-0345" num="0000"><chemistry id="CHEM-US-00015" num="00015"><img id="EMI-C00015" he="334.09mm" wi="74.59mm" file="US20230002764A1-20230105-C00015.TIF" alt="text missing or illegible when filed" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0346" num="0444">In some aspects, the anchoring moiety comprises vitamin E. Tocopherols are a class of methylated phenols many of which have vitamin E activity. Thus, in some aspects, the anchoring moiety comprises alpha-tocopherol, gamma-tocopherol, delta-tocopherol, or a combination thereof.</p><p id="p-0347" num="0000"><chemistry id="CHEM-US-00016" num="00016"><img id="EMI-C00016" he="104.73mm" wi="74.34mm" file="US20230002764A1-20230105-C00016.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0348" num="0445">Tocotrienols also have vitamin E activity. The critical chemical structural difference between tocotrienols and tocopherols is that tocotrienols have unsaturated isoprenoid side chain with three carbon-carbon double bonds versus saturated side chains for tocopherols. In some aspects, the anchoring moiety comprises alpha-tocotrienol, beta-tocotrienol, gamma-tocotrienol, delta-tocotrienol, or a combination thereof. Tocotrienols can be represented by the formula below</p><p id="p-0349" num="0000"><chemistry id="CHEM-US-00017" num="00017"><img id="EMI-C00017" he="20.24mm" wi="72.56mm" file="US20230002764A1-20230105-C00017.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0350" num="0000">alpha(&#x3b1;)-Tocotrienol: R1=Me, R2=Me, R3=Me;<br/>beta(&#x3b2;)-Tocotrienol: R1=Me, R2=H, R3=Me;<br/>gamma(&#x3b3;)-Tocotrienol: R1=H, R2=Me, R3=Me;<br/>delta(&#x3b4;)-Tocotrienol: R1=H, R2=H, R3=Me.</p><p id="p-0351" num="0446">In some aspects, the anchoring moiety comprises vitamin K. Chemically, the vitamin K family comprises 2-methyl-1.4-naphthoquinone (3-) derivatives. Vitamin K includes two natural vitamers: vitamin K, and vitamin K<sub>2</sub>. The structure of vitamin K, (also known as phytonadione, phylloquinone, or (E)-phytonadione) is marked by the presence of a phytyl group. The structures of vitamin K<sub>2 </sub>(menaquinones) are marked by the polyisoprenyl side chain present in the molecule that can contain six to 13 isoprenyl units. Thus, vitamin K<sub>2 </sub>consists of a number of related chemical subtypes, with differing lengths of carbon side chains made of isoprenoid groups of atoms. MK-4 is the most common form of vitamin K<sub>2</sub>. Long chain forms, such as MK-7, MK-8 and MK-9 are predominant in fermented foods. Longer chain forms of vitamin K<sub>2 </sub>such as MK-10 to MK-13 are synthesized by bacteria, but they are not well absorbed and have little biological function. In addition to the natural forms of vitamin K, there is a number of synthetic forms of vitamin K such as vitamin K<sub>3 </sub>(menadione; 2-methylnaphthalene-1,4-dione), vitamin K<sub>4</sub>, and vitamin K<sub>5</sub>.</p><p id="p-0352" num="0447">Accordingly, in some aspects, the anchoring moiety comprises vitamin K<sub>1</sub>, K<sub>2 </sub>(e.g., MK-4, MK-5, MK-6, MK-7, MK-8, MK-9, MK-10, MK-11, MK-12, or MK-13), K<sub>3</sub>, K<sub>4</sub>, K<sub>5</sub>, or any combination thereof.</p><p id="p-0353" num="0000"><chemistry id="CHEM-US-00018" num="00018"><img id="EMI-C00018" he="107.36mm" wi="152.40mm" file="US20230002764A1-20230105-C00018.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><heading id="h-0031" level="1">III.A.2. Linker Combinations</heading><p id="p-0354" num="0448">In some aspects, an ASO is linked to a hydrophobic membrane anchoring moiety disclosed herein via a linker combination, which can comprise any combination of cleavable and/or non-cleavable linkers. The main function of a linker combination is to provide the optimal spacing between the anchoring moiety or moieties and the BAM target. For example, in the case of an ASO, the linker combination should reduce steric hindrances and position the ASO so it can interact with a target nucleic acid, e.g., a mRNA or a miRNA.</p><p id="p-0355" num="0449">Linkers may be susceptible to cleavage (&#x201c;cleavable linker&#x201d;) thereby facilitating release of the biologically active molecule. Thus, in some aspects, a linker combination disclosed herein can comprise a cleavable linker. Such cleavable linkers may be susceptible, for example, to acid-induced cleavage, photo-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage, at conditions under which the biologically active molecule remains active. Alternatively, linkers may be substantially resistant to cleavage (&#x201c;non-cleavable linker&#x201d;). In some aspects, the cleavable linker comprises a spacer. In some aspects the spacer is PEG.</p><p id="p-0356" num="0450">In some aspects, a linker combination comprises at least 2, at least 3, at least 4, at least 5, or at least 6 or more different linkers disclosed herein. In some aspects, linkers in a linker combination can be linked by an ester linkage (e.g., phosphodiester or phosphorothioate ester).</p><p id="p-0357" num="0451">In some aspects, the linker is direct bond between an anchoring moiety and a BAM, e.g., an ASO.</p><heading id="h-0032" level="1">III.A.2.a. Non-Cleavable Linkers</heading><p id="p-0358" num="0452">In some aspects, the linker combination comprises a &#x201c;non-cleavable liker.&#x201d; Non-cleavable linkers are any chemical moiety capable of linking two or more components of a modified biologically active molecule of the present disclosure (e.g., a biologically active molecule and an anchoring moiety; a biologically active molecule and a cleavable linker; an anchoring moiety and a cleavable linker) in a stable, covalent manner and does not fall off under the categories listed above for cleavable linkers. Thus, non-cleavable linkers are substantially resistant to acid-induced cleavage, photo-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage and disulfide bond cleavage.</p><p id="p-0359" num="0453">Furthermore, non-cleavable refers to the ability of the chemical bond in the linker or adjoining to the linker to withstand cleavage induced by an acid, photolabile-cleaving agent, a peptidase, an esterase, or a chemical or physiological compound that cleaves a disulfide bond, at conditions under which a cyclic dinucleotide and/or the antibody does not lose its activity. In some aspects, the biologically active molecule is attached to the linker via another linker, e.g., a self-immolative linker.</p><p id="p-0360" num="0454">In some aspects, the linker combination comprises a non-cleavable linker comprising, e.g., tetraethylene glycol (TEG), hexaethylene glycol (HEG), polyethylene glycol (PEG), succinimide, or any combination thereof. In some aspects, the non-cleavable linker comprises a spacer unit to link the biologically active molecule to the non-cleavable linker.</p><p id="p-0361" num="0455">In some aspects, one or more non-cleavable linkers comprise smaller units (e.g., HEG, TEG, glycerol, C2 to C12 alkyl, and the like) linked together. In one aspect, the linkage is an ester linkage (e.g., phosphodiester or phosphorothioate ester) or other linkage.</p><heading id="h-0033" level="1">III.A.2.b. Ethylene Glycols (HEG, TEG, PEG)</heading><p id="p-0362" num="0456">In some aspects, the linker combination comprises a non-cleavable linker, wherein the non-cleavable linker comprises a polyethylene glycol (PEG) characterized by a formula R<sup>3</sup>&#x2014;(O&#x2014;CH<sub>2</sub>&#x2014;CH<sub>2</sub>)<sub>n</sub>&#x2014; or R<sup>3</sup>&#x2014;(O&#x2014;CH<sub>2</sub>&#x2014;CH<sub>2</sub>)<sub>n</sub>&#x2014;O&#x2014; with R<sup>3 </sup>being hydrogen, methyl or ethyl and n having a value from 2 to 200. In some aspects, the linker comprises a spacer, wherein the spacer is PEG.</p><p id="p-0363" num="0457">In some aspects, the PEG linker is an oligo-ethylene glycol, e.g., diethylene glycol, triethylene glycol, tetra ethylene glycol (TEG), pentaethylene glycol, or a hexaethylene glycol (HEG) linker.</p><p id="p-0364" num="0458">In some aspects, n has a value of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,18,19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 189, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, or 200.</p><p id="p-0365" num="0459">In some aspects, n is between 2 and 10, between 10 and 20, between 20 and 30, between 30 and 40, between 40 and 50, between 50 and 60, between 60 and 70, between 70 and 80, between 80 and 90, between 90 and 100, between 100 and 110, between 110 and 120, between 120 and 130, between 130 and 140, between 140 and 150, between 150 and 160, between 160 and 170, between 170 and 180, between 180 and 190, or between 190 and 200.</p><p id="p-0366" num="0460">In some specific aspects, n has a value from 3 to 200, from 3 to 20, from 10 to 30, or from 9 to 45.</p><p id="p-0367" num="0461">In some aspects, the PEG is a branched PEG. Branched PEGs have three to ten PEG chains emanating from a central core group.</p><p id="p-0368" num="0462">In certain embodiments, the PEG moiety is a monodisperse polyethylene glycol. In the context of the present disclosure, a monodisperse polyethylene glycol (mdPEG) is a PEG that has a single, defined chain length and molecular weight, mdPEGs are typically generated by separation from the polymerization mixture by chromatography. In certain formulae, a monodisperse PEG moiety is assigned the abbreviation mdPEG.</p><p id="p-0369" num="0463">In some aspects, the PEG is a Star PEG. Star PEGs have 10 to 100 PEG chains emanating from a central core group.</p><p id="p-0370" num="0464">In some aspects, the PEG is a Comb PEGs. Comb PEGs have multiple PEG chains normally grafted onto a polymer backbone.</p><p id="p-0371" num="0465">In certain aspects, the PEG has a molar mass between 100 g/mol and 3000 g/mol, particularly between 100 g/mol and 2500 g/mol, more particularly of approx. 100 g/mol to 2000 g/mol. In certain aspects, the PEG has a molar mass between 200 g/mol and 3000 g/mol, particularly between 300 g/mol and 2500 g/mol, more particularly of approx. 400 g/mol to 2000 g/mol.</p><p id="p-0372" num="0466">In some aspects, the PEG is PEG<sub>100</sub>, PEG<sub>200</sub>, PEG<sub>300</sub>, PEG<sub>400</sub>, PEG<sub>500</sub>, PEG<sub>600</sub>, PEG<sub>700</sub>, PEG<sub>800</sub>, PEG<sub>900</sub>, PEG<sub>1000</sub>, PEG<sub>1100</sub>, PEG<sub>1200</sub>, PEG<sub>1300</sub>, PEG<sub>1400</sub>, PEG<sub>1500</sub>, PEG<sub>1600</sub>, PEG<sub>1700</sub>, PEG<sub>1800</sub>, PEG<sub>1900</sub>, PEG<sub>2000</sub>, PEG<sub>2100</sub>, PEG<sub>2200</sub>, PEG<sub>2300</sub>, PEG<sub>2400</sub>, PEG<sub>2500</sub>, PEG<sub>1600</sub>, PEG<sub>1700</sub>, PEG<sub>1800</sub>, PEG<sub>1900</sub>, PEG<sub>2000</sub>, PEG<sub>2100</sub>, PEG<sub>2200</sub>, PEG<sub>2300</sub>, PEG<sub>2400</sub>, PEG<sub>2500</sub>, PEG<sub>2600</sub>, PEG<sub>2700</sub>, PEG<sub>2800</sub>, PEG<sub>2900</sub>, or PEG<sub>3000</sub>. In one particular aspect, the PEG is PEG<sub>400</sub>. In another particular aspect, the PEG is PEG<sub>2000</sub>.</p><p id="p-0373" num="0467">In some aspects, a linker combination of the present disclosure can comprise several PEG linkers, e.g., a cleavable linker flanked by PEG, HEG, or TEG linkers.</p><p id="p-0374" num="0468">In some aspects, the linker combination comprises (HEG)n and/or (TEG)n, wherein n is an integer between 1 and 50, and each unit is connected, e.g., via a phosphate ester linker, a phosphorothioate ester linkage, or a combination thereof.</p><heading id="h-0034" level="1">III.A.2.c. Glycerol and Polyglycerols (PG)</heading><p id="p-0375" num="0469">In some aspects, the linker combination comprises a non-cleavable linker comprising a glycerol unit or a polyglycerol (PG) described by the formula ((R<sub>3</sub>&#x2014;O&#x2014;(CH<sub>2</sub>&#x2014;CHOH&#x2014;CH<sub>2</sub>O)<sub>n</sub>&#x2014;) with R3 being hydrogen, methyl or ethyl, and n having a value from 3 to 200. In some aspects, n has a value from 3 to 20. In some aspects, n has a value from 10 to 30.</p><p id="p-0376" num="0470">In some aspects, the PG linker is a diglycerol, triglycerol, tetraglycerol (TG), pentaglycerol, or a hexaglycerol (HG) linker.</p><p id="p-0377" num="0471">In some aspects, n has a value of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 189, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, or 200.</p><p id="p-0378" num="0472">In some aspects, n is between 2 and 10, between 10 and 20, between 20 and 30, between 30 and 40, between 40 and 50, between 50 and 60, between 60 and 70, between 70 and 80, between 80 and 90, between 90 and 100, between 100 and 110, between 110 and 120, between 120 and 130, between 130 and 140, between 140 and 150, between 150 and 160, between 160 and 170, between 170 and 180, between 180 and 190, or between 190 and 200.</p><p id="p-0379" num="0473">In some alternatives of these embodiments, n has a value from 9 to 45. In some aspects, the heterologous moiety is a branched polyglycerol described by the formula (R<sup>3</sup>&#x2014;O&#x2014;(CH<sub>2</sub>&#x2014;CHOR&#x2014;CH<sub>2</sub>&#x2014;O<sub>n</sub>&#x2014;) with R<sup>5 </sup>being hydrogen or a linear glycerol chain described by the formula (R<sup>3</sup>&#x2014;O&#x2014;(CH<sub>2</sub>&#x2014;CHOH&#x2014;CH<sub>2</sub>&#x2014;O)<sub>n</sub>&#x2014;) and R<sup>3 </sup>being hydrogen, methyl or ethyl. In some aspects, the heterologous moiety is a hyperbranched polyglycerol described by the formula (R<sup>3</sup>&#x2014;O&#x2014;(CH<sub>2</sub>&#x2014;CHOR<sup>5</sup>&#x2014;CH<sub>2</sub>&#x2014;O<sub>n</sub>&#x2014;) with R<sup>5</sup>being hydrogen or a glycerol chain described by the formula (R<sup>3</sup>&#x2014;O&#x2014;(CH<sub>2</sub>&#x2014;CHOR<sup>6</sup>&#x2014;CH<sub>2</sub>&#x2014;O)<sub>n</sub>&#x2014;), with R<sup>6 </sup>being hydrogen or a glycerol chain described by the formula (R<sup>3</sup>&#x2014;O&#x2014;(CH<sub>2</sub>&#x2014;CHOR<sup>7</sup>&#x2014;CH<sub>2</sub>&#x2014;O)<sub>n</sub>&#x2014;), with R<sup>7 </sup>being hydrogen or a linear glycerol chain described by the formula (R<sup>3</sup>&#x2014;O&#x2014;(CH<sub>2</sub>&#x2014;CHOH&#x2014;CH<sub>2</sub>&#x2014;O)<sub>n</sub>&#x2014;) and R<sup>3 </sup>being hydrogen, methyl or ethyl. Hyperbranched glycerol and methods for its synthesis are described in Oudshom et al. (2006) Biomaterials 27:5471-5479; Wilms et al. (20100 Acc. Chem. Res. 43, 129-41, and references cited therein.</p><p id="p-0380" num="0474">In certain aspects, the PG has a molar mass between 100 g/mol and 3000 g/mol, particularly between 100 g/mol and 2500 g/mol, more particularly of approx. 100 g/mol to 2000 g/mol. In certain aspects, the PG has a molar mass between 200 g/mol and 3000 g/mol, particularly between 300 g/mol and 2500 g/mol, more particularly of approx. 400 g/mol to 2000 g/mol.</p><p id="p-0381" num="0475">In some aspects, the PG is PG<sub>100</sub>, PG<sub>200</sub>, PG<sub>300</sub>, PG<sub>400</sub>, PG<sub>500</sub>, PG<sub>600</sub>, PG<sub>700</sub>, PGa<sub>800</sub>, PG<sub>900</sub>, PG<sub>1000</sub>, PG<sub>1100</sub>, PG<sub>1200</sub>, PG<sub>1300</sub>, PGP<sub>1400</sub>, PG<sub>1500</sub>, PG<sub>1600</sub>, PG<sub>1700</sub>, PG<sub>1800</sub>, PG<sub>1900</sub>, PG<sub>200</sub>, PG<sub>2100</sub>, PG<sub>2200</sub>, PG<sub>2300</sub>, PG<sub>2400</sub>, PG<sub>2500</sub>, PG<sub>1600</sub>, PG<sub>1700</sub>, PG<sub>1800</sub>, PG<sub>1900</sub>, PG<sub>2000</sub>, PG<sub>2100</sub>, PG<sub>2200</sub>, PG<sub>2300</sub>, PG<sub>2400</sub>, PG<sub>2500</sub>, PG<sub>2600</sub>, PG<sub>2700</sub>, PG<sub>2800</sub>, PG<sub>2900</sub>, or PG<sub>3000</sub>. In one particular aspect, the PG is PG<sub>400</sub>. In another particular aspect, the PG is PG<sub>2000</sub>.</p><p id="p-0382" num="0476">In some aspects, the linker combination comprises (glycerol)n, and/or (HG)n and/or (TG)n, wherein n is an integer between 1 and 50, and each unit is connected, e.g., via a phosphate ester linker, a phosphorothioate ester linkage, or a combination thereof.</p><heading id="h-0035" level="1">III.A.2.d. Aliphatic (Alkyl) Linkers</heading><p id="p-0383" num="0477">In some aspects, the linker combination comprises at least one aliphatic (alkyl) linker, e.g., propyl, butyl, hexyl, or C2-C12 alkyl, such as C2-C10 alkyl or C2-C6 alkyl.</p><p id="p-0384" num="0478">In some aspects, the linker combination comprises an alkyl chain, e.g., an unsubstituted alkyl. In some aspects, the linker combination comprises an substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, Aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl, alkenylarylalkyl, alkenyl Reyl alkenyl, alkenyl aryl alkynyl, alkynyl aryl alkyl, alkynyl aryl alkenyl, alkynyl aryl alkynyl, alkyl heteroaryl alkyl, alkyl heteroaryl alkyl, alkyl heteroaryl alkenyl, alkyl heteroaryl alkynyl, alkenyl heteroaryl alkyl, alkenyl heteroaryl alkenyl, alkenyl heteroaryl alkynyl, alkynyl Heteroarylalkyl, alkynylheteroarylalkenyl, alkynylheteroarylalkynyl, alkylheterocyclylalkyl, alkylheterocyclylalkenyl, alkylheterocyclylalkynyl, alkenylheterocyclylalkyl, alkenylheterocyclylalkenyl, or alkenylheterocyclylalkynyl.</p><p id="p-0385" num="0479">Optionally these components are substituted. Substituents include alcohol, alkoxy (such as methoxy, ethoxy, and propoxy), straight or branched chain alkyl (such as C1-C12 alkyl), amine, aminoalkyl (such as amino C1-C12 alkyl), phosphoramidite, phosphate, phosphoramidate, phosphorodithioate, thiophosphate, hydrazide, hydrazine, halogen, (such as F, Cl, Br, or I), amide, alkylamide (such as amide C1-C12 alkyl), carboxylic acid, carboxylic ester, carboxylic anhydride, carboxylic acid halide, ether, sulfonyl halide, imidate ester, isocyanate, isothiocyanate, haloformate, carboduimide adduct, aldehydes, ketone, sulfhydryl, haloacetyl, alkyl halide, alkyl sulfonate, C(&#x2550;O)CH&#x2550;CHC(&#x2550;O) (maleimide), thioether, cyano, sugar (such as mannose, galactose, and glucose), &#x3b1;,&#x3b2;-unsaturated carbonyl, alkyl mercurial, or &#x3b1;,&#x3c1;-unsaturated sulfone.</p><p id="p-0386" num="0480">The term &#x201c;alkyl,&#x201d; by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain hydrocarbon radical having the number of carbon atoms designated (e.g., C<sub>1</sub>-C<sub>10 </sub>means one to ten carbon atoms). Typically, an alkyl group will have from 1 to 24 carbon atoms, for example having from 1 to 10 carbon atoms, from 1 to 8 carbon atoms or from 1 to 6 carbon atoms. A &#x201c;lower alkyl&#x201d; group is an alkyl group having from 1 to 4 carbon atoms. The term &#x201c;alkyl&#x201d; includes di- and multivalent radicals. For example, the term &#x201c;alkyl&#x201d; includes &#x201c;alkylene&#x201d; wherever appropriate, e.g., when the formula indicates that the alkyl group is divalent or when substituents are joined to form a ring. Examples of alkyl radicals include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, tert-butyl, iso-butyl, sec-butyl, as well as homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl and n-octyl.</p><p id="p-0387" num="0481">The term &#x201c;alkylene&#x201d; by itself or as part of another substituent means a divalent (diradical) alkyl group, wherein alkyl is defined herein. &#x201c;Alkylene&#x201d; is exemplified, but not limited, by &#x2014;CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>&#x2014;. Typically, an &#x201c;alkylene&#x201d; group will have from 1 to 24 carbon atoms, for example, having 10 or fewer carbon atoms (e.g., 1 to 8 or 1 to 6 carbon atoms). A &#x201c;lower alkylene&#x201d; group is an alkylene group having from 1 to 4 carbon atoms.</p><p id="p-0388" num="0482">The term &#x201c;alkenyl&#x201d; by itself or as part of another substituent refers to a straight or branched chain hydrocarbon radical having from 2 to 24 carbon atoms and at least one double bond. A typical alkenyl group has from 2 to 10 carbon atoms and at least one double bond. In one embodiment, alkenyl groups have from 2 to 8 carbon atoms or from 2 to 6 carbon atoms and from 1 to 3 double bonds. Exemplary alkenyl groups include vinyl, 2-propenyl, 1-but-3-enyl, crotyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), 2-isopentenyl, 1-pent-3-enyl, 1-hex-5-enyl and the like.</p><p id="p-0389" num="0483">The term &#x201c;alkynyl&#x201d; by itself or as part of another substituent refers to a straight or branched chain, unsaturated or polyunsaturated hydrocarbon radical having from 2 to 24 carbon atoms and at least one triple bond. A typical &#x201c;alkynyl&#x201d; group has from 2 to 10 carbon atoms and at least one triple bond. In one aspect of the disclosure, alkynyl groups have from 2 to 6 carbon atoms and at least one triple bond. Exemplary alkynyl groups include prop-1-ynyl, prop-2-ynyl (i.e., propargyl), ethynyl and 3-butynyl.</p><p id="p-0390" num="0484">The terms &#x201c;alkoxy,&#x201d; &#x201c;alkylamino&#x201d; and &#x201c;alkylthio&#x201d; (or thioalkoxy) are used in their conventional sense, and refer to alkyl groups that are attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively.</p><p id="p-0391" num="0485">The term &#x201c;heteroalkyl,&#x201d; by itself or in combination with another term, means a stable, straight or branched chain hydrocarbon radical consisting of the stated number of carbon atoms (e.g., C<sub>2</sub>-C<sub>10</sub>, or C<sub>2</sub>-C<sub>8</sub>) and at least one heteroatom chosen, e.g., from N, O, S, Si, B and P (in one embodiment, N, O and S), wherein the nitrogen, sulfur and phosphorus atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. The heteroatom(s) is/are placed at any interior position of the heteroalkyl group. Examples of heteroalkyl groups include, but are not limited to, &#x2014;CH<sub>2</sub>&#x2014;CH<sub>2</sub>&#x2014;O&#x2014;CH<sub>3</sub>, &#x2014;CH<sub>2</sub>&#x2014;CH<sub>2</sub>&#x2014;NH&#x2014;CH<sub>3</sub>, &#x2014;CH<sub>2</sub>&#x2014;CH<sub>2</sub>&#x2014;N(CH<sub>3</sub>)&#x2014;CH<sub>3</sub>, &#x2014;CH<sub>2</sub>&#x2014;S&#x2014;CH<sub>2</sub>&#x2014;CH<sub>3</sub>, &#x2014;CH<sub>2</sub>&#x2014;CH<sub>2</sub>&#x2014;S(O)&#x2014;CH<sub>3</sub>, &#x2014;CH<sub>2</sub>&#x2014;CH<sub>2</sub>&#x2014;S(O)<sub>2</sub>&#x2014;CH<sub>3</sub>, &#x2014;CH&#x2550;CHO&#x2014;CH<sub>3</sub>, &#x2014;CH<sub>2</sub>&#x2014;Si(CH<sub>3</sub>)<sub>3</sub>, &#x2014;CH<sub>2</sub>&#x2014;CH&#x2550;N&#x2014;OCH<sub>3</sub>, and &#x2014;CH&#x2550;CH&#x2014;N(CH<sub>3</sub>)&#x2014;CH<sub>3</sub>. Up to two heteroatoms can be consecutive, such as, for example, &#x2014;CH<sub>2</sub>&#x2014;NH&#x2014;OCH<sub>3 </sub>and &#x2014;CH<sub>2</sub>&#x2014;O&#x2014;Si(CH<sub>3</sub>)<sub>3</sub>.</p><p id="p-0392" num="0486">Similarly, the term &#x201c;heteroalkylene&#x201d; by itself or as part of another substituent means a divalent radical derived from heteroalkyl, as exemplified, but not limited by, &#x2014;CH<sub>2</sub>&#x2014;CH<sub>2</sub>&#x2014;S&#x2014;CH<sub>2</sub>&#x2014;CH<sub>2</sub>&#x2014; and &#x2014;CH<sub>2</sub>&#x2014;S&#x2014;CH<sub>2</sub>&#x2014;CH<sub>2</sub>&#x2014;NH&#x2014;CH<sub>2</sub>&#x2014;. Typically, a heteroalkyl group will have from 3 to 24 atoms (carbon and heteroatoms, excluding hydrogen) (3- to 24-membered heteroalkyl). In another example, the heteroalkyl group has a total of 3 to 10 atoms (3- to 10-membered heteroalkyl) or from 3 to 8 atoms (3- to 8-membered heteroalkyl). The term &#x201c;heteroalkyl&#x201d; includes &#x201c;heteroalkylene&#x201d; wherever appropriate, e.g., when the formula indicates that the heteroalkyl group is divalent or when substituents are joined to form a ring.</p><p id="p-0393" num="0487">The term &#x201c;cycloalkyl&#x201d; by itself or in combination with other terms, represents a saturated or unsaturated, non-aromatic carbocyclic radical having from 3 to 24 carbon atoms, for example, having from 3 to 12 carbon atoms (e.g., C<sub>3</sub>-C<sub>8 </sub>cycloalkyl or C<sub>3</sub>-C<sub>6 </sub>cycloalkyl). Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl and the like. The term &#x201c;cycloalkyl&#x201d; also includes bridged, polycyclic (e.g., bicyclic) structures, such as norbornyl, adamantyl and bicyclo[2.2.1]heptyl. The &#x201c;cycloalkyl&#x201d; group can be fused to at least one (e.g., 1 to 3) other ring selected from aryl (e.g., phenyl), heteroaryl (e.g., pyridyl) and non-aromatic (e.g., carbocyclic or heterocyclic) rings. When the &#x201c;cycloalkyl&#x201d; group includes a fused aryl, heteroaryl or heterocyclic ring, then the &#x201c;cycloalkyl&#x201d; group is attached to the remainder of the molecule via the carbocyclic ring.</p><p id="p-0394" num="0488">The term &#x201c;heterocycloalkyl,&#x201d; &#x201c;heterocyclic,&#x201d; &#x201c;heterocycle,&#x201d; or &#x201c;heterocyclyl,&#x201d; by itself or in combination with other terms, represents a carbocyclic, non-aromatic ring (e.g., 3- to 8-membered ring and for example, 4-, 5-, 6- or 7-membered ring) containing at least one and up to 5 heteroatoms selected from, e.g., N, O, S, Si, B and P (for example, N, O and S), wherein the nitrogen, sulfur and phosphorus atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized (e.g., from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur), or a fused ring system of 4- to 8-membered rings, containing at least one and up to 10 heteroatoms (e.g., from 1 to 5 heteroatoms selected from N, O and S) in stable combinations known to those of skill in the art. Exemplary heterocycloalkyl groups include a fused phenyl ring. When the &#x201c;heterocyclic&#x201d; group includes a fused aryl, heteroaryl or cycloalkyl ring, then the &#x201c;heterocyclic&#x201d; group is attached to the remainder of the molecule via a heterocycle. A heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule.</p><p id="p-0395" num="0489">Exemplary heterocycloalkyl or heterocyclic groups of the present disclosure include morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S,S-dioxide, piperazinyl, homopiperazinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, tetrahydropyranyl, piperidinyl, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, homopiperidinyl, homomorpholinyl, homothiomorpholinyl, homothiomorpholinyl S,S-dioxide, oxazolidinonyl, dihydropyrazolyl, dihydropyrrolyl, dihydropyrazolyl, dihydropyridyl, dihydropyrimidinyl, dihydrofuryl, dihydropyranyl, tetrahydrothienyl S-oxide, tetrahydrothienyl S,S-dioxide, homothiomorpholinyl S-oxide, 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like.</p><p id="p-0396" num="0490">By &#x201c;aryl&#x201d; is meant a 5-, 6- or 7-membered, aromatic carbocyclic group having a single ring (e.g., phenyl) or being fused to other aromatic or non-aromatic rings (e.g., from 1 to 3 other rings). When the &#x201c;aryl&#x201d; group includes a non-aromatic ring (such as in 1,2,3,4-tetrahydronaphthyl) or heteroaryl group then the &#x201c;aryl&#x201d; group is bonded to the remainder of the molecule via an aryl ring (e.g., a phenyl ring). The aryl group is optionally substituted (e.g., with 1 to 5 substituents described herein). In one example, the aryl group has from 6 to 10 carbon atoms. Non-limiting examples of aryl groups include phenyl, 1-naphthyl, 2-naphthyl, quinoline, indanyl, indenyl, dihydronaphthyl, fluorenyl, tetralinyl, benzo[d][1,3]dioxolyl or 6,7,8,9-tetrahydro-5H-benzo[a]cycloheptenyl. In one embodiment, the aryl group is selected from phenyl, benzo[d][1,3]dioxolyl and naphthyl. The aryl group, in yet another embodiment, is phenyl.</p><p id="p-0397" num="0491">The term &#x201c;arylalkyl&#x201d; or &#x201c;aralkyl&#x201d; is meant to include those radicals in which an aryl group or heteroaryl group is attached to an alkyl group to create the radicals -alkyl-aryl and -alkyl-heteroaryl, wherein alkyl, aryl and heteroaryl are defined herein. Exemplary &#x201c;arylalkyl&#x201d; or &#x201c;aralkyl&#x201d; groups include benzyl, phenethyl, pyridylmethyl and the like.</p><p id="p-0398" num="0492">By &#x201c;aryloxy&#x201d; is meant the group &#x2014;O-aryl, where aryl is as defined herein. In one example, the aryl portion of the aryloxy group is phenyl or naphthyl. The aryl portion of the aryloxy group, in one embodiment, is phenyl.</p><p id="p-0399" num="0493">The term &#x201c;heteroaryl&#x201d; or &#x201c;heteroaromatic&#x201d; refers to a polyunsaturated, 5-, 6- or 7-membered aromatic moiety containing at least one heteroatom (e.g., 1 to 5 heteroatoms, such as 1-3 heteroatoms) selected from N, O, S, Si and B (for example, N, O and S), wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. The &#x201c;heteroaryl&#x201d; group can be a single ring or be fused to other aryl, heteroaryl, cycloalkyl or heterocycloalkyl rings (e.g., from 1 to 3 other rings). When the &#x201c;heteroaryl&#x201d; group includes a fused aryl, cycloalkyl or heterocycloalkyl ring, then the &#x201c;heteroaryl&#x201d; group is attached to the remainder of the molecule via the heteroaryl ring. A heteroaryl group can be attached to the remainder of the molecule through a carbon- or heteroatom.</p><p id="p-0400" num="0494">In one example, the heteroaryl group has from 4 to 10 carbon atoms and from 1 to 5 heteroatoms selected from O, S and N. Non-limiting examples of heteroaryl groups include pyridyl, pyrimidinyl, quinolinyl, benzothienyl, indolyl, indolinyl, pyridazinyl, pyrazinyl, isoindolyl, isoquinolyl, quinazolinyl, quinoxalinyl, phthalazinyl, imidazolyl, isoxazolyl, pyrazolyl, oxazolyl, thiazolyl, indolizinyl, indazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, furanyl, thienyl, pyrrolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, isothiazolyl, naphthyridinyl, isochromanyl, chromanyl, tetrahydroisoquinolinyl, isoindolinyl, isobenzotetrahydrofuranyl, isobenzotetrahydrothienyl, isobenzothienyl, benzoxazolyl, pyridopyridyl, benzotetrahydrofuranyl, benzotetrahydrothienyl, purinyl, benzodioxolyl, triazinyl, pteridinyl, benzothiazolyl, imidazopyridyl, imidazothiazolyl, dihydrobenzisoxazinyl, benzisoxazinyl, benzoxazinyl, dihydrobenzisothiazinyl, benzopyranyl, benzothiopyranyl, chromonyl, chromanonyl, pyridyl-N-oxide, tetrahydroquinolinyl, dihydroquinolinyl, dihydroquinolinonyl, dihydroisoquinolinonyl, dihydrocoumarinyl, dihydroisocoumarinyl, isoindolinonyl, benzodioxanyl, benzoxazolinonyl, pyrrolyl N-oxide, pyrimidinyl N-oxide, pyridazinyl N-oxide, pyrazinyl N-oxide, quinolinyl N-oxide, indolyl N-oxide, indolinyl N-oxide, isoquinolyl N-oxide, quinazolinyl N-oxide, quinoxalinyl N-oxide, phthalazinyl N-oxide, imidazolyl N-oxide, isoxazolyl N-oxide, oxazolyl N-oxide, thiazolyl N-oxide, indolizinyl N-oxide, indazolyl N-oxide, benzothiazolyl N-oxide, benzimidazolyl N-oxide, pyrrolyl N-oxide, oxadiazolyl N-oxide, thiadiazolyl N-oxide, triazolyl N-oxide, tetrazolyl N-oxide, benzothiopyranyl S-oxide, benzothiopyranyl S,S-dioxide. Exemplary heteroaryl groups include imidazolyl, pyrazolyl, thiadiazolyl, triazolyl, isoxazolyl, isothiazolyl, imidazolyl, thiazolyl, oxadiazolyl, and pyridyl. Other exemplary heteroaryl groups include 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, pyridin-4-yl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl. Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable aryl group substituents described below.</p><p id="p-0401" num="0495">Examples of aliphatic linkers include the following structures:</p><heading id="h-0036" level="2">&#x2014;O&#x2014;CO&#x2014;O&#x2014;</heading><heading id="h-0037" level="2">&#x2014;NH&#x2014;CO&#x2014;O&#x2014;</heading><heading id="h-0038" level="2">&#x2014;NH&#x2014;CO&#x2014;NH&#x2014;</heading><p id="p-0402" num="0496">&#x2014;NH&#x2014;(CH<sub>2</sub>)<sub>n1</sub>&#x2014;<br/>&#x2014;S&#x2014;(CH<sub>2</sub>)<sub>n1</sub>&#x2014;<br/>&#x2014;CO&#x2014;(CH<sub>2</sub>)<sub>n1</sub>&#x2014;CO&#x2014;<br/>&#x2014;CO&#x2014;(CH<sub>2</sub>)<sub>n1</sub>&#x2014;NH&#x2014;<br/>&#x2014;NH&#x2014;(CH<sub>2</sub>)<sub>n1</sub>&#x2014;NH&#x2014;<br/>&#x2014;CO&#x2014;NH&#x2014;(CH<sub>2</sub>)<sub>n1</sub>&#x2014;NH&#x2014;CO&#x2014;<br/>&#x2014;C(&#x2550;S)&#x2014;NH&#x2014;(CH<sub>2</sub>)<sub>n1</sub>&#x2014;NH&#x2014;CO&#x2014;<br/>&#x2014;C(&#x2550;S)&#x2014;NH&#x2014;CH<sub>2</sub>)<sub>n1</sub>&#x2014;NH&#x2014;C&#x2014;(&#x2550;S)&#x2014;<br/>&#x2014;CO&#x2014;O&#x2014;(CH<sub>2</sub>)<sub>n1</sub>&#x2014;O&#x2014;CO&#x2014;<br/>&#x2014;C(&#x2550;S)&#x2014;O&#x2014;(CH<sub>2</sub>)<sub>n1</sub>&#x2014;O&#x2014;CO&#x2014;<br/>&#x2014;C(&#x2550;S)&#x2014;O&#x2014;(CH<sub>2</sub>)<sub>n1</sub>&#x2014;O&#x2014;C&#x2014;(&#x2550;S)&#x2014;<br/>&#x2014;CO&#x2014;NH&#x2014;(CH<sub>2</sub>)<sub>n1</sub>&#x2014;O&#x2014;CO&#x2014;<br/>&#x2014;C(&#x2550;S)&#x2014;NH&#x2014;(CH<sub>2</sub>)<sub>n1</sub>&#x2014;O&#x2014;CO&#x2014;<br/>&#x2014;C(&#x2550;S)&#x2014;NH&#x2014;(CH<sub>2</sub>)<sub>n1</sub>&#x2014;O&#x2014;C&#x2014;(&#x2550;S)&#x2014;<br/>&#x2014;CO&#x2014;NH&#x2014;(CH<sub>2</sub>)<sub>n1</sub>&#x2014;O&#x2014;CO&#x2014;<br/>&#x2014;C(&#x2550;S)&#x2014;NH&#x2014;(CH<sub>2</sub>)<sub>n1</sub>&#x2014;CO&#x2014;<br/>&#x2014;C(&#x2550;S)&#x2014;O&#x2014;(CH<sub>2</sub>)<sub>n1</sub>&#x2014;NH&#x2014;CO&#x2014;<br/>&#x2014;C(&#x2550;S)&#x2014;NH&#x2014;(CH<sub>2</sub>)<sub>n1</sub>&#x2014;O&#x2014;C&#x2014;(&#x2550;S)&#x2014;<br/>&#x2014;NH&#x2014;(CH<sub>2</sub>CH<sub>2</sub>O)<sub>n2</sub>&#x2014;CH(CH<sub>2</sub>OH)&#x2014;<br/>&#x2014;NH&#x2014;(CH<sub>2</sub>CH<sub>2</sub>O)<sub>n2</sub>&#x2014;CH<sub>2</sub>&#x2014;<br/>&#x2014;NH&#x2014;(CH<sub>2</sub>CH<sub>2</sub>O)<sub>n2</sub>&#x2014;CH<sub>2</sub>&#x2014;CO&#x2014;<br/>&#x2014;O&#x2014;(CH<sub>2</sub>)<sub>n3</sub>&#x2014;S&#x2014;S&#x2014;(CH<sub>2</sub>)<sub>n4</sub>&#x2014;O&#x2014;P(&#x2550;O)<sub>2</sub>&#x2014;<br/>&#x2014;CO&#x2014;(CH<sub>2</sub>)<sub>n3</sub>&#x2014;O&#x2014;CO&#x2014;NH&#x2014;(CH<sub>2</sub>)<sub>n4</sub>&#x2014;<br/>&#x2014;CO&#x2014;(CH<sub>2</sub>)<sub>n3</sub>&#x2014;CO&#x2014;NH&#x2014;(CH<sub>2</sub>)<sub>n4</sub>&#x2014;</p><heading id="h-0039" level="2">&#x2014;(CH2)<sub>n1</sub>NH&#x2014;</heading><heading id="h-0040" level="2">&#x2014;C(O)(CH2)<sub>n1</sub>NH&#x2014;</heading><heading id="h-0041" level="2">&#x2014;C(O)&#x2014;(CH2)<sub>n1</sub>&#x2014;C(O)&#x2014;</heading><heading id="h-0042" level="2">&#x2014;C(O)&#x2014;(CH2)<sub>n1</sub>&#x2014;C(O)O&#x2014;</heading><heading id="h-0043" level="2">&#x2014;C(O)&#x2014;</heading><heading id="h-0044" level="2">&#x2014;C(O)&#x2014;(CH2)<sub>n1</sub>&#x2014;NH&#x2014;C(O)&#x2014;</heading><heading id="h-0045" level="2">&#x2014;C(O)&#x2014;CH2)<sub>n1</sub>&#x2014;</heading><heading id="h-0046" level="2">&#x2014;C(O)&#x2014;NH&#x2014;</heading><heading id="h-0047" level="2">&#x2014;C(O)&#x2014;</heading><heading id="h-0048" level="2">&#x2014;(CH2)<sub>n1</sub>&#x2014;C(O)&#x2014;</heading><heading id="h-0049" level="2">&#x2014;(CH2)<sub>n1</sub>&#x2014;C(O)O&#x2014;</heading><heading id="h-0050" level="2">&#x2014;(CH2)<sub>n1</sub>&#x2014;</heading><heading id="h-0051" level="2">&#x2014;(CH2)<sub>n1</sub>&#x2014;NH&#x2014;C(O)&#x2014;</heading><p id="p-0403" num="0497">n1 is an integer between 1 and 40 (e.g., 2 to 20, or 2 to 12); n2 is an integer between 1 and 20 (e.g., 1 to 10, or 1 to 6); n3 and n4 may be the same or different, and are an integer between 1 and 20 (e.g., 1 to 10, or 1 to 6).</p><p id="p-0404" num="0498">In some aspects, the linker combination comprises (C3)n, (C4)n, (C5)n, (C6)n, (C7)n, or (C8)n, or a combination thereof, wherein n is an integer between 1 and 50, and each unit is connected, e.g., via a phosphate ester linker, a phosphorothioate ester linkage, or a combination thereof.</p><heading id="h-0052" level="1">III.A.3. Cleavable Linkers</heading><p id="p-0405" num="0499">In some aspects, different components of an ASO disclosed herein can be linker by a cleavable linker. The term cleavable linker refers to a linker comprising at least one linkage or chemical bond that can be broken or cleaved. As used herein, the term cleave refers to the breaking of one or more chemical bonds in a relatively large molecule in a manner that produces two or more relatively smaller molecules. Cleavage may be mediated, e.g., by a nuclease, peptidase, protease, phosphatase, oxidase, or reductase, for example, or by specific physicochemical conditions, e.g., redox environment, pH, presence of reactive oxygen species, or specific wavelengths of light.</p><p id="p-0406" num="0500">In some aspects, the term &#x201c;cleavable,&#x201d; as used herein, refers, e.g., to rapidly degradable linkers, such as, e.g., phosphodiester and disulfides, while the term &#x201c;non-cleavable&#x201d; refers, e.g., to more stable linkages, such as, e.g., nuclease-resistant phosphorothioates.</p><p id="p-0407" num="0501">In some aspects, the cleavable linker is a dinucleotide or trinucleotide linker, a disulfide, an imine, a thioketal, a val-cit dipeptide, or any combination thereof.</p><p id="p-0408" num="0502">In some aspects, the cleavable linker comprises valine-alanine-p-aminobenzylcarbamate or valine-citrulline-p-aminobenzylcarbamate.</p><heading id="h-0053" level="1">III.A.3.a. Redox Cleavable Linkers</heading><p id="p-0409" num="0503">In some aspects, the linker combination comprises a redox cleavable linker. As a non-limiting example, one type of cleavable linker is a redox cleavable linking group that is cleaved upon reduction or upon oxidation.</p><p id="p-0410" num="0504">In some aspects, the redox cleavable linker contains a disulfide bond, i.e., it is a disulfide cleavable linker.</p><p id="p-0411" num="0505">Redox cleavable linkers can be reduced, e.g., by intracellular mercaptans, oxidases, or reductases.</p><heading id="h-0054" level="1">III.A.3.b. Reactive Oxygen Species (ROS) Cleavable Linkers</heading><p id="p-0412" num="0506">In some aspects, the linker combination can comprise a cleavable linker which may be cleaved by a reactive oxygen species (ROS), such as superoxide (Of) or hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), generated, e.g., by inflammation processes such as activated neutrophils. In some aspects, the ROS cleavable linker is a thioketal cleavable linker. See, e.g., U.S. Pat. No. 8,354,455B2, which is herein incorporated by reference in its entirety.</p><heading id="h-0055" level="1">III.A.3.c, pH Dependent Cleavable Linkers</heading><p id="p-0413" num="0507">In some aspects, the linker is an &#x201c;acid labile linker&#x201d; comprising an acid cleavable linking group, which is a linking group that is selectively cleaved under acidic conditions (pH&#x3c;7).</p><p id="p-0414" num="0508">As a non-limiting example, the acid cleavable linking group is cleaved in an acidic environment, e.g., about 6.0, 5.5, 5.0 or less. In some aspects, the pH is about 6.5 or less. In some aspects, the linker is cleaved by an agent such as an enzyme that can act as a general acid, e.g., a peptidase (which may be substrate specific) or a phosphatase. Within cells, certain low pH organelles, such as endosomes and lysosomes, can provide a cleaving environment to the acid cleavable linking group. Although the pH of human serum is 7.4, the average pH in cells is slightly lower, ranging from about 7.1 to 7.3. Endosomes also have an acidic pH, ranging from 5.5 to 6.0, and lysosomes are about 5.0 at an even more acidic pH. Accordingly, pH dependent cleavable linkers are sometimes called endosomically labile linkers in the art.</p><p id="p-0415" num="0509">The acid cleavable group may have the general formula &#x2014;C&#x2550;NN&#x2014;, C(O)O, or &#x2014;OC(O). In another non-limiting example, when the carbon attached to the ester oxygen (alkoxy group) is attached to an aryl group, a substituted alkyl group, or a tertiary alkyl group such as dimethyl pentyl or t-butyl, for example. Examples of acid cleavable linking groups include, but are not limited to amine, imine, amino ester, benzoic imine, diortho ester, polyphosphoester, polyphosphazene, acetal, vinyl ether, hydrazone, cis-aconitate, hydrazide, thiocarbamoyl, imizine, azidomethyl-methylmaleic anhydride, thiopropionate, a masked endosomolytic agent, a citraconyl group, or any combination thereof. Disulfide linkages are also susceptible to pH.</p><p id="p-0416" num="0510">In some aspects, the linker comprises a low pH-labile hydrazone bond. Such acid-labile bonds have been extensively used in the field of conjugates, e.g., antibody-drug conjugates. See, for example, Zhou et al, Biomacromolecules 2011, 12, 1460-7; Yuan et al, Acta Biomater. 2008, 4, 1024-37; Zhang et al, Acta Biomater. 2007, 6, 838-50; Yang et al, J. Pharmacol. Exp. Ther. 2007, 321, 462-8; Reddy et al, Cancer Chemother. Pharmacol. 2006, 58, 229-36; Doronina et al, Nature Biotechnol. 2003, 21, 778-84.</p><p id="p-0417" num="0511">In certain embodiments, the linker comprises a low pH-labile bond selected from the following: ketals that are labile in acidic environments (e.g., pH less than 7, greater than about 4) to form a diol and a ketone; acetals that are labile in acidic environments (e.g., pH less than 7, greater than about 4) to form a diol and an aldehyde; imines or iminiums that are labile in acidic environments (e.g., pH less than 7, greater than about 4) to form an amine and an aldehyde or a ketone; silicon-oxygen-carbon linkages that are labile under acidic condition; silicon-nitrogen (silazane) linkages; silicon-carbon linkages (e.g., arylsilanes, vinylsilanes, and allylsilanes); maleamates (amide bonds synthesized from maleic anhydride derivatives and amines); ortho esters; hydrazones; activated carboxylic acid derivatives (e.g., esters, amides) designed to undergo acid catalyzed hydrolysis); or vinyl ethers.</p><p id="p-0418" num="0512">Further examples may be found in U.S. Pat. Nos. 9,790,494B2 and 8,137,695B2, the contents of which are incorporated herein by reference in their entireties.</p><heading id="h-0056" level="1">III.A.3.d. Enzymatic Cleavable Linkers</heading><p id="p-0419" num="0513">In some aspects, the linker combination can comprise a linker cleavable by intracellular or extracellular enzymes, e.g., proteases, esterases, nucleases, amidases. The range of enzymes that can cleave a specific linker in a linker combination depends on the specific bonds and chemical structure of the linker. Accordingly, peptidic linkers can be cleaved, e.g., by peptidases, linkers containing ester linkages can be cleaved, e.g., by esterases; linkers containing amide linkages can be cleaved, e.g., by amidases; etc.</p><heading id="h-0057" level="1">III.A.3.e. Protease Cleavable Linkers</heading><p id="p-0420" num="0514">In some aspects, the linker combination comprises a protease cleavable linker, i.e., a linker that can be cleaved by an endogenous protease. Only certain peptides are readily cleaved inside or outside cells. See, e.g., Trout et al., 79 Proc. Natl. Acad. Sci. USA, 626-629 (1982) and Umemoto et al. 43 Int. J. Cancer, 677-684 (1989). Cleavable linkers can contain cleavable sites composed of &#x3b1;-amino acid units and peptidic bonds, which chemically are amide bonds between the carboxylate of one amino acid and the amino group of a second amino acid. Other amide bonds, such as the bond between a carboxylate and the &#x3b1;-amino acid group of lysine, are understood not to be peptidic bonds and are considered non-cleavable.</p><p id="p-0421" num="0515">In some aspects, the protease-cleavable linker comprises a cleavage site for a protease, e.g., neprilysin (CALLA or CDlO), thimet oligopeptidase (TOP), leukotriene A4 hydrolase, endothelin converting enzymes, ste24 protease, neurolysin, mitochondrial intermediate peptidase, interstitial collagenases, collagenases, stromelysins, macrophage elastase, matrilysin, gelatinases, meprins, procollagen C-endopeptidases, procollagen N-endopeptidases, ADAMs and ADAMTs metalloproteinases, myelin associated metalloproteinases, enamelysin, tumor necrosis factor &#x3b1;-converting enzyme, insulysin, nardilysin, mitochondrial processing peptidase, magnolysin, dactylysin-like metalloproteases, neutrophil collagenase, matrix metallopeptidases, membrane-type matrix metalloproteinases, SP2 endopeptidase, prostate specific antigen (PSA), plasmin, urokinase, human fibroblast activation protein (FAP&#x3b1;), trypsin, chymotrypsins, caldecrin, pancreatic elastases, pancreatic endopeptidase, enteropeptidase, leukocyte elastase, myeloblasts, chymases, tryptase, granzyme, stratum corneum chymotryptic enzyme, acrosin, kallikreins, complement components and factors, alternative-complement pathway c3/c5 convertase, mannose-binding protein-associated serine protease, coagulation factors, thrombin, protein c, u and t-type plasminogen activator, cathepsin G, hepsin, prostasin, hepatocyte growth factor-activating endopeptidase, subtilisin/kexin type proprotein convertases, furin, proprotein convertases, prolyl peptidases, acylaminoacyl peptidase, peptidyl-glycaminase, signal peptidase, n-terminal nucleophile aminohydrolases, 20s proteasome, &#x3b3;-glutamyl transpeptidase, mitochondrial endopeptidase, mitochondrial endopeptidase Ia, htra2 peptidase, matriptase, site 1 protease, legumain, cathepsins, cysteine cathepsins, calpains, ubiquitin isopeptidase T, caspases, glycosylphosphatidylinositoliprotein transamidase, cancer procoagulant, prohormone thiol protease, &#x3b3;-Glutamyl hydrolase, bleomycin hydrolase, seprase, cathepsin B, cathepsin D, cathepsin L, cathepsin M, proteinase K, pepsins, chymosyn, gastricsin, renin, yapsin and/or mapsins, Prostate-Specific antigen (PSA), or any Asp-N, Glu-C, Lys-C or Arg-C proteases in general. See, e.g., Cancer Res. 77(24):7027-7037 (2017), which is herein incorporated by reference in its entirety.</p><p id="p-0422" num="0516">In some aspects, the cleavable linker component comprises a peptide comprising one to ten amino acid residues. In these aspects, the peptide allows for cleavage of the linker by a protease, thereby facilitating release of the biologically active molecule upon exposure to intracellular proteases, such as lysosomal enzymes (Doronina et al. (2003) Nat. Biotechnol. 21:778-784). Exemplary peptides include, but are not limited to, dipeptides, tripeptides, tetrapeptides, pentapeptides, and hexapeptides.</p><p id="p-0423" num="0517">A peptide may comprise naturally-occurring and/or non-natural amino acid residues. The term &#x201c;naturally-occurring amino acid&#x201d; refer to Ala, Asp, Cys, Glu, Phe, Gly, His, He, Lys, Leu, Met, Asn, Pro, Gin, Arg, Ser, Thr, Val, Trp, and Tyr. &#x201c;Non-natural amino acids&#x201d; (i.e., amino acids do not occur naturally) include, by way of non-limiting example, homoserine, homoarginine, citrulline, phenylglycine, taurine, iodotyrosine, seleno-cysteine, norleucine (&#x201c;Nle&#x201d;), norvaline (&#x201c;Nva&#x201d;), beta-alanine, L- or D-naphthalanine, omithine (&#x201c;Om&#x201d;), and the like. Peptides can be designed and optimized for enzymatic cleavage by a particular enzyme, for example, a tumor-associated protease, cathepsin B, C and D, or a plasmin protease.</p><p id="p-0424" num="0518">Amino acids also include the D-forms of natural and non-natural amino acids. &#x201c;D-&#x201d; designates an amino acid having the &#x201c;D&#x201d; (dextrorotary) configuration, as opposed to the configuration in the naturally occurring (&#x201c;L-&#x201d;) amino acids. Natural and non-natural amino acids can be purchased commercially (Sigma Chemical Co., Advanced Chemtech) or synthesized using methods known in the art.</p><p id="p-0425" num="0519">Exemplary dipeptides include, but are not limited to, valine-alanine, valine-citrulline, phenylalanine-lysine, N-methyl-valine-citrulline, cyclohexylalanine-lysine, and beta-alanine-lysine. Exemplary tripeptides include, but are not limited to, glycine-valine-citrulline (gly-val-cit) and glycine-glycine-glycine (gly-gly-gly).</p><heading id="h-0058" level="1">III.A.3.f. Esterase Cleavable Linkers</heading><p id="p-0426" num="0520">Some linkers are cleaved by esterases (&#x201c;esterase cleavable linkers&#x201d;). Only certain esters can be cleaved by esterases and amidases present inside or outside of cells. Esters are formed by the condensation of a carboxylic acid and an alcohol. Simple esters are esters produced with simple alcohols, such as aliphatic alcohols, and small cyclic and small aromatic alcohols. Examples of ester-based cleavable linking groups include, but are not limited to, esters of alkylene, alkenylene and alkynylene groups. The ester cleavable linking group has the general formula &#x2014;C(O)O&#x2014; or &#x2014;OC(O)&#x2014;.</p><heading id="h-0059" level="1">III.A.3.g. Phosphatase Cleavable Linkers</heading><p id="p-0427" num="0521">In some aspects, a linker combination can includes a phosphate-based cleavable linking group is cleaved by an agent that degrades or hydrolyzes phosphate groups. An example of an agent that cleaves intracellular phosphate groups is an enzyme such as intracellular phosphatase. Examples of phosphate-based linking groups are &#x2014;O&#x2014;P(O)(OR k)&#x2014;O&#x2014;, &#x2014;O&#x2014;P(S)(OR<sub>k</sub>)&#x2014;O&#x2014;, &#x2014;O&#x2014;P(S)(SR<sub>k</sub>)&#x2014;O&#x2014;, &#x2014;S&#x2014;P (O)(OR<sub>k</sub>)&#x2014;O&#x2014;, &#x2014;O&#x2014;P(O)(OR<sub>k</sub>)&#x2014;S&#x2014;, &#x2014;S&#x2014;P(O)(OR<sub>k</sub>) &#x2014;S&#x2014;, &#x2014;O&#x2014;P(S)(OR<sub>k</sub>)&#x2014;S&#x2014;, &#x2014;SP(S)(OR<sub>k</sub>)&#x2014;O&#x2014;, &#x2014;OP (O)(R<sub>k</sub>)&#x2014;O&#x2014;, &#x2014;OP(S)(R<sub>k</sub>)&#x2014;O&#x2014;, &#x2014;SP(O)(R<sub>k</sub>)&#x2014;O&#x2014;, &#x2014;SP(S)(R)&#x2014;O&#x2014;, &#x2014;SP(O)(R)&#x2014;S&#x2014;, or &#x2014;OP(S)(R)&#x2014;S&#x2014;.</p><p id="p-0428" num="0522">In various aspects, R<sub>k </sub>is any of the following: NH<sub>2</sub>, BH<sub>3</sub>, CH<sub>3</sub>, C<sub>1-6 </sub>alkyl, C<sub>6-10 </sub>aryl, C<sub>1-6 </sub>alkoxy and C<sub>6-10 </sub>aryl-oxy. In some aspects, C<sub>1-6 </sub>alkyl and C<sub>6-10 </sub>aryl are unsubstituted. Further non-limiting examples are &#x2014;O&#x2014;P(O)(OH)&#x2014;O&#x2014;, &#x2014;O&#x2014;P(S)(OH)&#x2014;O&#x2014;, &#x2014;O&#x2014;P(S)(SH)&#x2014;O&#x2014;, &#x2014;S&#x2014;P(O)(OH)&#x2014;O&#x2014;, &#x2014;O&#x2014;P(O) (OH)&#x2014;S&#x2014;, &#x2014;S&#x2014;P(O)(OH)&#x2014;S&#x2014;, &#x2014;O&#x2014;P(S)(OH)&#x2014;S&#x2014;, &#x2014;S&#x2014;P(S)(OH)&#x2014;O&#x2014;, &#x2014;O&#x2014;P(O)(H)&#x2014;O&#x2014;, &#x2014;O&#x2014;P(S)(H)&#x2014;O&#x2014;, &#x2014;S&#x2014;P(O)(H)&#x2014;O&#x2014;, &#x2014;SP(S)(H)&#x2014;O&#x2014;, &#x2014;SP(O)(H)&#x2014;S&#x2014;, &#x2014;OP(S)(H)&#x2014;S&#x2014;, or &#x2014;O&#x2014;P(O)(OH)&#x2014;O&#x2014;.</p><heading id="h-0060" level="1">II.A.3.h. Photoactivated Cleavable Linkers</heading><p id="p-0429" num="0523">In some aspects, the combination linker comprises a photoactivated cleavable linker, e.g., a nitrobenzyl linker or a linker comprising a nitrobenzyl reactive group.</p><heading id="h-0061" level="1">III.A.3.i. Self-Immolative Linker</heading><p id="p-0430" num="0524">In some aspects, the linker combination comprises a self-immolative linker In some aspects, the self-immolative linker in the EV (e.g., exosome) of the present disclosure undergoes 1,4 elimination after the enzymatic cleavage of the protease-cleavable linker. In some aspects, the self-immolative linker in the EV (e.g., exosome) of the present disclosure undergoes 1,6 elimination after the enzymatic cleavage of the protease-cleavable linker. In some aspects, the self-immolative linker is, e.g., a p-aminobenzyl (pAB) derivative, such as a p-aminobenzyl carbamate (pABC), a p-amino benzyl ether (PABE), a p-amino benzyl carbonate, or a combination thereof.</p><p id="p-0431" num="0525">In certain aspects, the self-immolative linker comprises an aromatic group. In some aspects, the aromatic group is selected from the group consisting of benzyl, cinnamyl, naphthyl, and biphenyl. In some aspects, the aromatic group is heterocyclic. In other aspects, the aromatic group comprises at least one substituent. In some aspects, the at least one substituent is selected from the group consisting of F, Cl, I, Br, OH, methyl, methoxy, NO<sub>2</sub>, NH<sub>2</sub>, NO<sup>3+</sup>, NHCOCH<sub>3</sub>, N(CH<sub>3</sub>)<sub>2</sub>, NHCOCF<sub>3</sub>, alkyl, haloalkyl, C<sub>1</sub>-C<sub>8 </sub>alkylhalide, carboxylate, sulfate, sulfamate, and sulfonate. In other aspects, at least one C in the aromatic group is substituted with N, O, or C&#x2014;R*, wherein R* is independently selected from H, F, Cl, I, Br, OH, methyl, methoxy, NO<sub>2</sub>, NH<sub>2</sub>, NO<sup>3+</sup>, NHCOCH<sub>3</sub>, N(CH<sub>3</sub>)<sub>2</sub>, NHCOCF<sub>3</sub>, alkyl, haloalkyl, C<sub>1</sub>-C<sub>8 </sub>alkylhalide, carboxylate, sulfate, sulfamate, and sulfonate.</p><p id="p-0432" num="0526">In some aspects, the self-immolative linker comprises an aminobenzyl carbamate group (e.g., para-aminobenzyl carbamate), an aminobenzyl ether group, or an aminobenzyl carbonate group. In one aspect, the self-immolative linker is p-amino benzyl carbamate (pABC).</p><p id="p-0433" num="0527">pABC is the most efficient and most widespread connector linkage for self-immolative site-specific prodrug activation (see, e.g., Carl et al. J Med. Chem. 24:479-480 (1981); WO 1981/001145; Rautio et la, Nature Reviews Drug Discovery 7:255-270 (2008); Simplicio et al., Molecules 13:519-547 (2008)).</p><p id="p-0434" num="0528">In some aspects, the self-immolative linker connects a biologically active molecule (e.g., an ASO) to a protease-cleavable substrate (e.g, Val-Cit). In specific aspects, the carbamate group of a pABC self-immolative linker is connected to an amino group of a biologically active molecule (e.g., ASO), and the amino group of the pABC self-immolative linker is connected to a protease-cleavable substrate.</p><p id="p-0435" num="0529">The aromatic ring of the aminobenzyl group can optionally be substituted with one or more (e.g., R, and/or R<sub>2</sub>) substituents on the aromatic ring, which replace a hydrogen that is otherwise attached to one of the four non-substituted carbons that form the ring. As used herein, the symbol &#x201c;R.&#x201d; (e.g., R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>) is a general abbreviation that represents a substituent group as described herein.</p><p id="p-0436" num="0530">Substituent groups can improve the self-immolative ability of the p-aminobenzyl group (Hay et al., J. Chem Soc., Perkin Trans. 1:2759-2770 (1999); see also, Sykes et al. J. Chem. Soc., Perkin Trans. 1:1601-1608 (2000)).</p><p id="p-0437" num="0531">Self-immolative elimination can take place, e.g., via 1,4 elimination, 1,6 elimination (e.g., pABC), 1,8 elimination (e.g., p-amino-cinnamyl alcohol), &#x3b2;-elimination, cyclisation-elimination (e.g., 4-aminobutanol ester and ethylenediamines), cyclization/lactonization, cyclization/lactolization, etc. See, e.g., Singh et al. Curr. Med. Chem. 15:1802-1826 (2008); Greenwald et al. J. Med. Chem. 43:475-487 (2000).</p><p id="p-0438" num="0532">In some aspects, the self-immolative linker can comprise, e.g., cinnamyl, naphthyl, or biphenyl groups (see, e.g., Blencowe et al. Polym. Chem. 2:773-790 (2011)). In some aspects, the self-immolative linker comprises a heterocyclic ring (see., e.g., U.S. Pat. Nos. 7,375,078; 7,754,681). Numerous homoaromatic (see, e.g., Carl et al. J. Med. Chem. 24:479 (1981); Senter et al. J. Org. Chem. 55:2975 (1990); Taylor et al. J. Org. Chem. 43:1197 (1978); Andrianomenjanahary et al. Bioorg. Med. Chem. Lett. 2:1903 (1992)), and coumarin (see, e.g., Weinstein et al. Chem. Commun. 46:553 (2010)), furan, thiophene, thiazole, oxazole, isoxazole, pyrrole, pyrazole (see, e.g., Hay et al. J. Med. Chem. 46:5533 (2003)), pyridine (see, e.g., Perry-Feigenbaum et al. Org. Biomol. Chem. 7:4825 (2009)), imidazone (see, e.g., Nailor et al. Bioorg. Med. Chem. Lett. Z:1267 (1999); Hay and Denny, Tetrahedron Lett. 38:8425 (1997)), and triazole (see, e.g., Bertrand and Gesson, J. Org. Chem. 72:3596 (2007)) based heteroaromatic groups that are self-immolative under both aqueous and physiological conditions are known in the art. See also, U.S. Pat. Nos. 7,691,962; 7,091,186; U.S. Pat. Publ. Nos. US2006/0269480; US2010/0092496; US2010/0145036; US2003/0130189; US2005/0256030)</p><p id="p-0439" num="0533">In some aspects, a linker combination disclosed herein comprises more than one self-immolative linker in tandem, e.g., two or more pABC units. See, e.g., de Groot et al. J. Org. Chem. 66:8815-8830 (2001). In some aspects, a linker combination disclosed herein can comprise a self-immolative linker (e.g., a p-aminobenzylalcohol or a hemithioaminal derivative of p-carboxybenzaldehyde or glyoxilic acid) linked to a fluorigenic probe (see, e.g., Meyer et al. Org. Biomol. Chem. 8:1777-1780 (2010)).</p><p id="p-0440" num="0534">Where substituent groups in the self-immolative linker s are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents, which would result from writing the structure from right to left. For example, &#x201c;&#x2014;CH<sub>2</sub>O&#x2014;&#x201d; is intended to also recite &#x201c;&#x2014;OCH<sub>2</sub>&#x2014;&#x201d;.</p><p id="p-0441" num="0535">Substituent groups in self-immolative, for example, R, and/or R<sub>2 </sub>substituents in a p-aminobenzyl self-immolative linker as discuss above can include, e.g., alkyl, alkylene, alkenyl, alkynyl, alkoxy, alkylamino, alkylthio, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, aryloxy, heteroaryl, etc. When a compound of the present disclosure includes more than one substituent, then each of the substituents is independently chosen.</p><p id="p-0442" num="0536">In some specific aspects, the self-immolative linker is attached to cleavable peptide linker has the following formula, the combination having the following formula:</p><p id="p-0443" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>-Aa-Yy-<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0444" num="0000">wherein each -A- is independently an amino acid unit, a is independently an integer from 1 to 12; and &#x2014;Y&#x2014; is a self-immolative spacer, and y is 1, or 2. In some aspects, -A<sub>a</sub>- is a dipeptide, a tripeptide, a tetrapeptide, a pentapeptide, or a hexapeptide. In some aspects, -A<sub>a</sub>- is selected from the group consisting of valine-alanine, valine-citrulline, phenylalanine-lysine, N-methylvaline-citrulline, cyclohexylalanine-lysine, and beta-alanine-lysine. In some aspects, -A<sub>a</sub>- is valine-alanine or valine-citrulline.</p><p id="p-0445" num="0537">In some aspects, the self-immolative linker &#x2014;Y<sub>y</sub>&#x2014; has the following formula:</p><p id="p-0446" num="0000"><chemistry id="CHEM-US-00019" num="00019"><img id="EMI-C00019" he="22.10mm" wi="45.97mm" file="US20230002764A1-20230105-C00019.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0447" num="0000">wherein each R<sup>2 </sup>is independently C<sub>1-8 </sub>alkyl, &#x2014;O&#x2014;(C<sub>1-8 </sub>alkyl), halogen, nitro, or cyano; and m is an integer from 0 to 4. In some aspects, m is 0, 1, or 2. In some aspects, m is 0.</p><p id="p-0448" num="0538">In some aspects, the cleavable linker is valine-alanine-p-aminobenzylcarbamate or valine-citrulline-p-aminobenzylcarbamate.</p><heading id="h-0062" level="1">III.A.4. Reactive Moieties (RM)</heading><p id="p-0449" num="0539">The ASOs of the present disclosure are generated either via chemical synthesis or via chemical reaction between their components. For example, in some aspects, an anchoring moiety comprising a reactive group (e.g., maleimide) can react with an ASO comprising a maleimide-reacting group, to yield a hydrophobically modified ASO of the present disclosure, where the anchoring moiety may insert into the lipid bilayer of the membrane of an exosome, thereby attaching the ASO to the surface of the exosome.</p><p id="p-0450" num="0540">Any component or group of components of a hydrophobically modified ASO of the present disclosure can comprise at least a RG and/or an RM, which would allow the attachment of the components through one reaction or series of reactions, to yield a hydrophobically modified ASO of the present disclosure. Exemplary synthesis schemas for the production of hydrophobically modified ASOs include:</p><heading id="h-0063" level="2">[AM]&#x2212;/RG/+/RM/&#x2212;[ASO]&#x2192;[AM]&#x2212;[ASO]</heading><heading id="h-0064" level="2">[AM]&#x2212;/RM/+/RG/&#x2212;[ASO]&#x2192;[AM]&#x2212;[ASO]</heading><heading id="h-0065" level="2">[AM]&#x2212;[L]&#x2212;/RM/+/RG/&#x2212;[ASO]&#x2192;[AM]&#x2212;[L]&#x2212;[ASO]</heading><heading id="h-0066" level="2">[AM]&#x2212;[L]&#x2212;/RG/+/RM/&#x2212;[ASO]&#x2192;[AM]&#x2212;[L]&#x2212;[ASO]</heading><heading id="h-0067" level="2">[AM]&#x2212;/RM/+/RG/&#x2212;[L]&#x2212;[ASO]&#x2192;[AM]&#x2212;[L]&#x2212;[ASO]</heading><heading id="h-0068" level="2">[AM]&#x2212;/RG/+/RM/&#x2212;[L]&#x2212;[ASO]&#x2192;[AM]&#x2212;[L]&#x2212;[ASO]</heading><heading id="h-0069" level="2">[AM]&#x2212;[L]&#x2212;/RM/+/RG/&#x2212;[L]&#x2212;[ASO]&#x2192;[AM]&#x2212;[L]&#x2212;[L]&#x2212;[ASO]</heading><heading id="h-0070" level="2">[AM]&#x2212;[L]&#x2212;/RG/+/RM/&#x2212;[L]&#x2212;[ASO]&#x2192;[AM]&#x2212;[L]&#x2212;[L]&#x2212;[ASO]</heading><p id="p-0451" num="0541">wherein [AM] is an anchoring moiety, [ASO] is an antisense oligonucleotide, [L] is a linker or linker combination, /RM/ is a reactive moiety, and /RG/ is a reactive group. In any of the schematic representations provided, the ASO can be attached, e.g., via its 5&#x2032; end or 3&#x2032; end.</p><p id="p-0452" num="0542">Exemplary synthesis schemas for the production of intermediates in the synthesis of ASOs include:</p><heading id="h-0071" level="2">[AM]&#x2212;/RM/+/RG/&#x2212;[L]&#x2192;[AM]&#x2212;[L]</heading><heading id="h-0072" level="2">[AM]&#x2212;/RG/+/RM/&#x2212;[L]&#x2192;[AM]&#x2212;[L]</heading><heading id="h-0073" level="2">[L]&#x2212;/RM/+/RG/&#x2212;[L]&#x2192;[L]&#x2212;[L]</heading><heading id="h-0074" level="2">[L]&#x2212;/RG/+/RM/&#x2212;[L]&#x2192;[L]&#x2212;[L]</heading><heading id="h-0075" level="2">[L]&#x2212;/RM/+/RG/&#x2212;[ASO]&#x2192;[L]&#x2212;[ASO]</heading><heading id="h-0076" level="2">[L]&#x2212;/RG/+/RM/&#x2212;[ASO]&#x2192;[L]&#x2212;[ASO]</heading><p id="p-0453" num="0543">wherein [AM] is an anchoring moiety, [ASO] is an antisense oligonucleotide, [L] is a linker or linker combination, /RM/ is a reactive moiety, and /RG/ is a reactive group. In any of the schematic representations provided, the ASO can be attached, e.g., via its 5&#x2032; end or 3&#x2032; end.</p><p id="p-0454" num="0544">In some aspects, the reactive group &#x201c;/RG/&#x201d; can be, e.g., an amino group, a thiol group, a hydroxyl group, a carboxylic acid group, or an azide group. Specific reactive moieties &#x201c;/RM/&#x201d; that can react with these reactive groups are described in more detail below.</p><p id="p-0455" num="0545">[AM]&#x2212;(/RM/)n+(/RG/&#x2212;[L]&#x2212;[ASO])n&#x2192;[AM]&#x2212;[L]&#x2212;[ASO]</p><p id="p-0456" num="0546">Any of the anchoring moieties, linker or linker combinations, or ASO disclosed herein can be conjugated to a reactive moiety, e.g., an amino reactive moiety (e.g., NHS-ester, p-nitrophenol, isothiocyanate, isocyanate, or aldehyde), a thiol reactive moiety (e.g., acrylate, maleimide, or pyridyl disulfide), a hydroxy reactive moiety (e.g., isothiocyanate or isocyanate), a carboxylic acid reactive moiety (e.g., epoxide), or an azide reactive moiety (e.g., alkyne).</p><p id="p-0457" num="0547">Exemplary reactive moieties that can be used to covalent bind two components disclosed herein (e.g., an anchoring moiety and an ASO, or an anchoring moiety and a linker, or an anchoring moiety and a linker, or two linkers, or a linker and an ASO, or a two anchoring moieties) include, e.g., N-succinimidyl-3-(2-pyridyldithio)propionate, N-4-maleimide butyric acid, S&#x2014;(2-pyridyldithio)cysteamine, iodoacetoxysuccinimide, N-(4-maleimidebutyryl oxy)succinimide, N-[5-(3&#x2032;-maleimide propylamide)-1-carboxypentyl]iminodiacetic acid, N-(5-aminopentyl)iminodiacetic acid, and 1&#x2032;-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite). Bifunctional linkers (linkers containing two functional groups) are also usable.</p><p id="p-0458" num="0548">In some aspects, an anchoring moiety, linker, or ASO can comprise a terminal oxyamino group, e.g., &#x2014;ONH2, an hydrazino group, &#x2014;NHNH2, a mercapto group (i.e., SH or thiol), or an olefin (e.g., CH&#x2550;CH2). In some aspects, an anchoring moiety, linker, or ASO can comprise an electrophilic moiety, e.g., at a terminal position, e.g., an aldehyde, alkyl halide, mesylate, tosylate, nosylate, or brosylate, or an activated carboxylic acid ester, e.g, an NHS ester, a phosphoramidite, or a pentafluorophenyl ester. In some aspects, a covalent bond can be formed by coupling a nucleophilic group of a ligand, e.g., a hydroxyl, a thiol or amino group, with an electrophilic group.</p><p id="p-0459" num="0549">The present invention is amenable to all manner of reactive groups and reactive moieties including but not limited to those known in the art</p><p id="p-0460" num="0550">The term &#x201c;protecting group,&#x201d; as used herein, refers to a labile chemical moiety which is known in the art to protect reactive groups including without limitation, hydroxyl, amino and thiol groups, against undesired reactions during synthetic procedures. Protecting groups are typically used selectively and/or orthogonally to protect sites during reactions at other reactive sites and can then be removed to leave the unprotected group as is or available for further reactions. Protecting groups as known in the art are described generally in Greene and Wuts, <i>Protective Groups in Organic Synthesis, </i>3rd edition. John Wiley &#x26; Sons, New York (1999).</p><p id="p-0461" num="0551">Additionally, the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the compounds described herein are known in the art and include, for example, those such as described in R Larock. Comprehensive Organic Transformations, VCH Publishers (1989); T. W. Greene and P. G. M. Wuts. Protective Groups in Organic Synthesis. 2d. Ed., John Wiley and Sons (1991), L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof.</p><p id="p-0462" num="0552">Solid phase synthesis known in the art may additionally or alternatively be employed. Suitable solid phase techniques, including automated synthesis techniques, are described in F. Eckstein (ed.), Oligonucleotides and Analogues, a Practical Approach. Oxford University Press, New York (1991) and Toy, P. H.; Lam, Y (ed.), Solid-Phase Organic synthesis, concepts, Strategies, and Applications, John Wiley &#x26; Sons. Inc. New Jersey (2012).</p><p id="p-0463" num="0553">In some aspects, the reactive group can alternatively react with more than one of the reactive moieties described below.</p><heading id="h-0077" level="1">III.A.4.a. Amine Reactive Moieties</heading><p id="p-0464" num="0554">In some aspects, the reactive moiety is an amine reactive moiety. As used herein the term &#x201c;amine reactive moiety&#x201d; refers to a chemical groups which can react with a reactive group having an amino moiety, e.g., primary amines. Exemplary amine reactive moieties are N-hydroxysuccinimide esters (NHS-ester), p-nitrophenol, isothiocyanate, isocyanate, and aldehyde. Alternative reactive moieties that react with primary amines are also well known in the art. In some aspects, an amine reactive moiety can be attached to a terminal position of an anchoring moiety, linker combination, or ASO of the present disclosure.</p><p id="p-0465" num="0555">In some aspects, the amine reactive moiety is a NHS-ester. Typically, a NHS-ester reactive moiety reacts with a primary amine of a reactive group to yield a stable amide bond and N-hydroxysuccinimide (NHS).</p><p id="p-0466" num="0556">In some aspects, the amine reactive moiety is a p-nitrophenol group. Typically, a p-nitrophenol reactive moiety is an activated carbamate that reacts with a primary amine of a reactive group to yield a stable carbamate moiety and p-nitrophenol.</p><p id="p-0467" num="0557">In some aspects, the amine reactive moiety is an isothiocyanate. Typically, a isothiocyanate reacts with a primary amine of a reactive group to yield a stable thiourea moiety.</p><p id="p-0468" num="0558">In some aspects, the amine reactive moiety is an isocyanate. Typically, a isocyanate reacts with a primary amine of a reactive group to yield a stable urea moiety.</p><p id="p-0469" num="0559">In some aspects, amine the reactive moiety is an aldehyde. Typically, aldehydes react with primary amines to form Schiff bases which can be further reduced to form a covalent bond through reductive amination.</p><heading id="h-0078" level="1">III.A.4.b. Thiol Reactive Moieties</heading><p id="p-0470" num="0560">In some aspects, the reactive moiety is a thiol reactive moiety. As used herein the term &#x201c;thiol reactive moiety&#x201d; refers to a chemical groups which can react with a reactive group having a thiol moiety (or mercapto group). Exemplary thiol reactive moieties are acrylates, maleimides, and pyridyl disulfides. Alternative reactive moieties that react with thiols are also well known in the art. In some aspects, a thiol reactive moiety can be attached to a terminal position of an anchoring moiety, linker combination, or ASO of the present disclosure.</p><p id="p-0471" num="0561">In some aspects, the thiol reactive moiety is an acrylate. Typically, acrylates react with thiols at the carbon p to the carbonyl of the acrylate to form a stable sulfide bond.</p><p id="p-0472" num="0562">In some aspects, the thiol reactive moiety is a maleimide. Typically, maleimides react with thiols at either of at the carbon p the to the carbonyls to form a stable sulfide bond.</p><p id="p-0473" num="0563">In some aspects, the thiol reactive moiety is a pyridyl disulfide. Typically, pyridyl disulfides react with thiols at the sulfur atom p to the pyridyl to form a stable disulfide bond and pyridine-2-thione.</p><heading id="h-0079" level="1">III.A.4.c. Hydroxy Reactive Moieties</heading><p id="p-0474" num="0564">In some aspects, the reactive moiety is a hydroxyl reactive moiety. As used herein the term &#x201c;hydroxyl reactive moiety&#x201d; refers to a chemical group which can react with a reactive group having an hydroxyl moiety. Exemplary hydroxyl reactive moieties are isothiocyanates and isocyanates. Alternative reactive moieties that react with hydroxyl moieties are also well known in the art. In some aspects, a hydroxyl reactive moiety can be attached to a terminal position of an anchoring moiety, linker combination, or ASO of the present disclosure.</p><p id="p-0475" num="0565">In some aspects, the hydroxyl reactive moiety is an isothiocyanate. Typically, an isothiocyanate reacts with a hydroxyl of a reactive group to yield a stable carbamothioate moiety.</p><p id="p-0476" num="0566">In some aspects, amine the reactive moiety is a isocyanate. Typically, an isocyante reacts with a hydroxyl of a reactive group to yield a stable carbamate moiety.</p><heading id="h-0080" level="1">III.A.4.d. Carboxylic Acid Reactive Moieties</heading><p id="p-0477" num="0567">In some aspects, the reactive moiety is a carboxylic acid reactive moiety. As used herein the term &#x201c;carboxylic acid reactive moiety&#x201d; refers to a chemical groups which can react with a reactive group having an carboxylic acid moiety. An exemplary carboxylic acid reactive moieties is an epoxide. Alternative reactive moieties that react with carboxylic acid moieties are also well known in the art. In some aspects, an carboxylic acid reactive moiety can be attached to a terminal position of an anchoring moiety, linker combination, or ASO of the present disclosure.</p><p id="p-0478" num="0568">In some aspects, the carboxylic acid reactive moiety is an epoxide. Typically, an epoxide reacts with the carboxylic acid of a reactive group at either of the carbon atoms of the epoxide to form a 2-hydroxyethyl acetate moiety.</p><heading id="h-0081" level="1">III.A.4.e. Azide Reactive Moieties</heading><p id="p-0479" num="0569">In some aspects, the reactive moiety is an azide reactive moiety. As used herein the term &#x201c;azide reactive moiety&#x201d; refers to a chemical groups which can react with a reactive group having an azide moiety. An exemplary azide reactive moieties is an alkyne. Alternative reactive moieties that react with azide moieties are also well known in the art. In some aspects, a carboxylic acid reactive moiety can be attached to a terminal position of an anchoring moiety, linker combination, or ASO of the present disclosure.</p><p id="p-0480" num="0570">In some aspects, the azide reactive moiety is an alkyne. Typically, an alkyne reacts with the azide of a reactive group through a 1,3-dipolar cycloaddition reaction, also referred to &#x201c;click chemistry,&#x201d; to form a 1,2,3-triazole moiety.</p><heading id="h-0082" level="1">III.A.5.Specific Examples and Topologies</heading><p id="p-0481" num="0571">In specific aspects of the present disclosure, the linker combination consists of a linker of formula</p><p id="p-0482" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>[Alkyl linker]m-[PEG1]n-[PEG2]o<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0483" num="0000">wherein m, n, and o are 0 or 1, and at least one of m, n, or o is not zero. Exemplary linker combinations according to such formula are C6-TEG-HEG, C6-HEG, C6-TEG, C6, TEG-HEG, TEG, C8-TEG-HEG, C8-HEG, C8-TEG, and C8.</p><p id="p-0484" num="0572">In some aspects, the linker combination comprises a non-cleavable linker (e.g., TEG or HEG) in combination with one or more cleavable linkers, e.g., an enzymatic cleavable linker and a self immolative linker.</p><p id="p-0485" num="0573">In a specific aspect, the linker combination the linker combination comprises the linker combination TEG (non-cleavable linker)-Val-Cit(cleavable linker)-pAB(self-immolative linker), as shown below</p><p id="p-0486" num="0000"><chemistry id="CHEM-US-00020" num="00020"><img id="EMI-C00020" he="48.43mm" wi="148.59mm" file="US20230002764A1-20230105-C00020.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0487" num="0574">Specific combinations of anchoring moieties and linker combinations are illustrated in the tables below.</p><p id="p-0488" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="35pt" align="left"/><colspec colname="2" colwidth="161pt" align="center"/><thead><row><entry/><entry namest="offset" nameend="2" rowsep="1">TABLE 2</entry></row></thead><tbody valign="top"><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row><row><entry/><entry>Anchoring </entry><entry>Linker combination</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="35pt" align="left"/><colspec colname="2" colwidth="63pt" align="center"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="63pt" align="center"/><tbody valign="top"><row><entry/><entry>moiety</entry><entry>1<sup>st </sup>Linker</entry><entry>2<sup>nd </sup>Linker</entry><entry>3<sup>rd </sup>Linker</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row><row><entry/><entry>Cholesterol</entry><entry>C6</entry><entry>TEG</entry><entry>HEG</entry></row><row><entry/><entry>Cholesterol</entry><entry>C6</entry><entry>HEG</entry><entry>No</entry></row><row><entry/><entry>Cholesterol</entry><entry>C6</entry><entry>TEG</entry><entry>No</entry></row><row><entry/><entry>Cholesterol</entry><entry>C6</entry><entry>No</entry><entry>No</entry></row><row><entry/><entry>Cholesterol</entry><entry>TEG</entry><entry>HEG</entry><entry>No</entry></row><row><entry/><entry>Cholesterol</entry><entry>TEG</entry><entry>No</entry><entry>No</entry></row><row><entry/><entry>Tocopherol</entry><entry>C8</entry><entry>TEG</entry><entry>HEG</entry></row><row><entry/><entry>Tocopherol</entry><entry>C8</entry><entry>HEG</entry><entry>No</entry></row><row><entry/><entry>Tocopherol</entry><entry>C8</entry><entry>TEG</entry><entry>No</entry></row><row><entry/><entry>Tocopherol</entry><entry>C8</entry><entry>No</entry><entry>No</entry></row><row><entry/><entry>Tocopherol</entry><entry>TEG</entry><entry>HEG</entry><entry>No</entry></row><row><entry/><entry>Tocopherol</entry><entry>HEG</entry><entry>No</entry><entry>No</entry></row><row><entry/><entry>Tocopherol</entry><entry>TEG</entry><entry>No</entry><entry>No</entry></row><row><entry/><entry>Tocopherol</entry><entry>No</entry><entry>No</entry><entry>No</entry></row><row><entry/><entry>Palmitate</entry><entry>C6</entry><entry>TEG</entry><entry>HEG</entry></row><row><entry/><entry>Palmitate</entry><entry>C6</entry><entry>HEG</entry><entry>No</entry></row><row><entry/><entry>Palmitate</entry><entry>C6</entry><entry>TEG</entry><entry>No</entry></row><row><entry/><entry>Palmitate</entry><entry>C6</entry><entry>No</entry><entry>No</entry></row><row><entry/><entry>Cholesterol</entry><entry>TEG</entry><entry>Glycerol</entry><entry>HEG</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0489" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 3</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Linker Combination</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="77pt" align="center"/><colspec colname="2" colwidth="56pt" align="center"/><colspec colname="3" colwidth="84pt" align="center"/><tbody valign="top"><row><entry>Linker 1</entry><entry>Cleavable Linker 2</entry><entry>Linker 3</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>C6</entry><entry>Disulfide</entry><entry>C6</entry></row><row><entry>None</entry><entry>Imine</entry><entry>None</entry></row><row><entry>TEG</entry><entry>Thioketal</entry><entry>TEG</entry></row><row><entry>HEG</entry><entry>Tri/Dinucleotide</entry><entry>HEG</entry></row><row><entry>TEG-HEG</entry><entry>Val-Cit</entry><entry>TEG-HEG</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0490" num="0575">Specific oligonucleotides such as ASOs of the present disclosure are exemplified below</p><p id="p-0491" num="0000"><chemistry id="CHEM-US-00021" num="00021"><img id="EMI-C00021" he="234.95mm" wi="155.02mm" file="US20230002764A1-20230105-C00021.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0492" num="0000">wherein [Cholesterol] is a cholesterol anchoring moiety, [TEG] is a TEG non-cleavable linker, [HEG] is a HEG non-cleavable linker, [SS] is a disulfide redox cleavable linker, [C6] is an alkyl non-cleavable linker, [SMal] is S-maleimide, [Val-Cit] is a valine-citrulline cleavable linker, [pAB] is a pAB self-immolative linker. In some aspects, an ASO of the present disclosure has a structure according to the exemplary structures provided above, in which one or more components has been replaced by a component in the same class as those depicted in the example. For example, the [cholesterol] anchoring moiety can be substituted by another anchoring moiety disclosed herein, a [TEG] can be substituted by another polymeric non-cleavable linker disclosed herein (e.g., HEG, PEG, PG), [Val-Cit] can be replaced by another peptidase cleavable linker, or [pAB] can be substituted by another self-immolative linker.</p><heading id="h-0083" level="1">III.B. Scaffold Moieties</heading><p id="p-0493" num="0576">One or more scaffold moieties can be expressed in the EVs. In some aspects, one or more scaffold moieties are used to anchor an ASO to the EV of the present disclosure. In other aspects, one or more scaffold moieties are used to anchor a protein or a molecule to the EVs in addition to the ASOs. Therefore, an EV of the present disclosure comprises an anchoring moiety linking an ASO and a scaffold moiety linking a protein or a molecule, e.g., a targeting moiety. In some aspects, the ASO is linked to the scaffold moiety. In some aspects, the EV comprises more than one scaffold moiety. In some aspects, a first ASO is linked to a first scaffold moiety and a second ASO is linked to a second scaffold moiety. In some aspects, the first scaffold moiety and the second scaffold moiety are the same type of scaffold moiety, e.g., the first and second scaffold moieties are both a Scaffold X protein. In some aspects, the first scaffold moiety and the second scaffold moiety are different types of scaffold moiety, e.g., the first scaffold moiety is a Scaffold Y protein and the second scaffold moiety is a Scaffold X protein. In some aspects, the first scaffold moiety is a Scaffold Y, disclosed herein. In some aspects, the first scaffold moiety is a Scaffold X, disclosed herein. In some aspects, the second scaffold moiety is a Scaffold Y, disclosed herein. In some aspects, the second scaffold moiety is a Scaffold X, disclosed herein.</p><p id="p-0494" num="0577">In some aspects, the EV comprises one or more scaffold moieties, which are capable of anchoring an ASO to the EV, e.g., exosome, (e.g., either on the luminal surface or on the exterior surface). In certain aspects, the scaffold moiety is a polypeptide (&#x201c;scaffold protein&#x201d;). In certain aspects, the scaffold protein comprises an exosome protein or a fragment thereof. In other aspects, scaffold moieties are non-polypeptide moieties. In some aspects, scaffold proteins include various membrane proteins, such as transmembrane proteins, integral proteins and peripheral proteins, enriched on the exosome membranes. They can include various CD proteins, transporters, integrins, lectins, and cadherins. In certain aspects, a scaffold moiety (e.g., scaffold protein) comprises Scaffold X. In other aspects, a scaffold moiety (e.g., exosome protein) comprises Scaffold Y. In further aspects, a scaffold moiety (e.g., exosome protein) comprises both a Scaffold X and a Scaffold Y.</p><heading id="h-0084" level="1">III.B.1. Scaffold X-Engineered EVs, e.g., Exosomes</heading><p id="p-0495" num="0578">In some aspects, EVs, e.g., exosomes, of the present disclosure comprise a membrane modified in its composition. For example, their membrane compositions can be modified by changing the protein, lipid, or glycan content of the membrane.</p><p id="p-0496" num="0579">In some aspects, the surface-engineered EVs, e.g., exosomes, are generated by chemical and/or physical methods, such as PEG-induced fusion and/or ultrasonic fusion. In other aspects, the surface-engineered EVs, e.g., exosomes, are generated by genetic engineering. EVs, e.g., exosomes, produced from a genetically-modified producer cell or a progeny of the genetically-modified cell can contain modified membrane compositions. In some aspects, surface-engineered EVs, e.g., exosomes, have scaffold moiety (e.g., exosome protein, e.g., Scaffold X) at a higher or lower density (e.g., higher number) or include a variant or a fragment of the scaffold moiety.</p><p id="p-0497" num="0580">For example, surface (e.g., Scaffold X)-engineered EVs, can be produced from a cell (e.g., HEK293 cells) transformed with an exogenous sequence encoding a scaffold moiety (e.g., exosome proteins, e.g., Scaffold X) or a variant or a fragment thereof. EVs including scaffold moiety expressed from the exogenous sequence can include modified membrane compositions.</p><p id="p-0498" num="0581">Various modifications or fragments of the scaffold moiety can be used for the aspects of the present disclosure. For example, scaffold moiety modified to have enhanced affinity to a binding agent can be used for generating surface-engineered EV that can be purified using the binding agent. Scaffold moieties modified to be more effectively targeted to EVs and/or membranes can be used. Scaffold moieties modified to comprise a minimal fragment required for specific and effective targeting to exosome membranes can be also used.</p><p id="p-0499" num="0582">Scaffold moieties can be engineered to be expressed as a fusion molecule, e.g., fusion molecule of Scaffold X to an ASO. For example, the fusion molecule can comprise a scaffold moiety disclosed herein (e.g., Scaffold X, e.g., PTGFRN, BSG, IGSF2, IGSF3, IGSF8, ITGB1, ITGA4, SLC3A2, ATP transporter, or a fragment or a variant thereof) linked to an ASO.</p><p id="p-0500" num="0583">In some aspects, the surface (e.g., Scaffold X)-engineered EVs described herein demonstrate superior characteristics compared to EVs known in the art. For example, surface (e.g., Scaffold X)-engineered contain modified proteins more highly enriched on their surface than naturally occurring EVs or the EVs produced using conventional exosome proteins. Moreover, the surface (e.g., Scaffold X)-engineered EVs of the present disclosure can have greater, more specific, or more controlled biological activity compared to naturally occurring EVs or the EVs produced using conventional exosome proteins.</p><p id="p-0501" num="0584">In some aspects, the Scaffold X comprises Prostaglandin F2 receptor negative regulator (the PTGFRN polypeptide). The PTGFRN protein can be also referred to as CD9 partner 1 (CD9P-1), Glu-Trp-Ile EWI motif-containing protein F (EWI-F), Prostaglandin F2-alpha receptor regulatory protein, Prostaglandin F2-alpha receptor-associated protein, or CD315. The full length amino acid sequence of the human PTGFRN protein (Uniprot Accession No. Q9P2B2) is shown at Table 4 as SEQ ID NO: 301. The PTGFRN polypeptide contains a signal peptide (amino acids 1 to 25 of SEQ ID NO: 301), the extracellular domain (amino acids 26 to 832 of SEQ ID NO: 301), a transmembrane domain (amino acids 833 to 853 of SEQ ID NO: 301), and a cytoplasmic domain (amino acids 854 to 879 of SEQ ID NO: 301). The mature PTGFRN polypeptide consists of SEQ ID NO: 301 without the signal peptide, i.e., amino acids 26 to 879 of SEQ ID NO: 301. In some aspects, a PTGFRN polypeptide fragment useful for the present disclosure comprises a transmembrane domain of the PTGFRN polypeptide. In other aspects, a PTGFRN polypeptide fragment useful for the present disclosure comprises the transmembrane domain of the PTGFRN polypeptide and (i) at least five, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150 amino acids at the N terminus of the transmembrane domain, (ii) at least five, at least 10, at least 15, at least 20, or at least 25 amino acids at the C terminus of the transmembrane domain, or both (i) and (ii).</p><p id="p-0502" num="0585">In some aspects, the fragments of PTGFRN polypeptide lack one or more functional or structural domains, such as IgV.</p><p id="p-0503" num="0586">In other aspects, the Scaffold X comprises an amino acid sequence at least about 70/a, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to amino acids 26 to 879 of SEQ ID NO: 301. In other aspects, the Scaffold X comprises an amino acid sequence at least about at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO: 302. In other aspects, the Scaffold X comprises the amino acid sequence of SEQ ID NO: 302, except one amino acid mutation, two amino acid mutations, three amino acid mutations, four amino acid mutations, five amino acid mutations, six amino acid mutations, or seven amino acid mutations. The mutations can be a substitution, an insertion, a deletion, or any combination thereof. In some aspects, the Scaffold X comprises the amino acid sequence of SEQ ID NO: 302 and 1 amino acid, two amino acids, three amino acids, four amino acids, five amino acids, six amino acids, seven amino acids, eight amino acids, nine amino acids, ten amino acids, 11 amino acids, 12 amino acids, 13 amino acids, 14 amino acids, 15 amino acids, 16 amino acids, 17 amino acids, 18 amino acids, 19 amino acids, or 20 amino acids or longer at the N terminus and/or C terminus of SEQ ID NO: 302.</p><p id="p-0504" num="0587">In other aspects, the Scaffold X comprises an amino acid sequence at least about at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO: 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, or 318. In other aspects, the Scaffold X comprises the amino acid sequence of SEQ ID NO: 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, or 318, except one amino acid mutation, two amino acid mutations, three amino acid mutations, four amino acid mutations, five amino acid mutations, six amino acid mutations, or seven amino acid mutations. The mutations can be a substitution, an insertion, a deletion, or any combination thereof. In some aspects, the Scaffold X comprises the amino acid sequence of SEQ ID NO: 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, or 318 and 1 amino acid, two amino acids, three amino acids, four amino acids, five amino acids, six amino acids, seven amino acids, eight amino acids, nine amino acids, ten amino acids, 11 amino acids, 12 amino acids, 13 amino acids, 14 amino acids, 15 amino acids, 16 amino acids, 17 amino acids, 18 amino acids, 19 amino acids, or 20 amino acids or longer at the N terminus and/or C terminus of SEQ ID NO: 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, or 318.</p><p id="p-0505" num="0000"><tables id="TABLE-US-00005" num="00005"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;4</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Exemplary&#x2003;Scaffold&#x2003;X&#x2003;Protein&#x2003;Sequences</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="140pt" align="left"/><tbody valign="top"><row><entry/><entry>Protein</entry><entry>Sequence</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row><row><entry/><entry>The</entry><entry>MGRLASRPLLLALLSLALCR</entry></row><row><entry/><entry>PTGFRN</entry><entry>GRVVRVPTATLVRVVGTELV</entry></row><row><entry/><entry>Protein</entry><entry>IPCNVSDYDGPSEQNFDWSF</entry></row><row><entry/><entry>(SEQ&#x2003;ID</entry><entry>SSLGSSFVELASTWEVGFPA</entry></row><row><entry/><entry>NO:&#x2003;301)</entry><entry>QLYQERLQRGEILLRRTAND</entry></row><row><entry/><entry/><entry>AVELHIKNVQPSDQGHYKCS</entry></row><row><entry/><entry/><entry>TPSTDATVQGNYEDTVQVKV</entry></row><row><entry/><entry/><entry>LADSLHVGPSARPPPSLSLR</entry></row><row><entry/><entry/><entry>EGEPFELRCTAASASPLHTH</entry></row><row><entry/><entry/><entry>LALLWEVHRGPARRSVLALT</entry></row><row><entry/><entry/><entry>HEGRFHPGLGYEQRYHSGDV</entry></row><row><entry/><entry/><entry>RLDTVGSDAYRLSVSRALSA</entry></row><row><entry/><entry/><entry>DQGSYRCIVSEWIAEQGNWQ</entry></row><row><entry/><entry/><entry>EIQEKAVEVATVVIQPSVLR</entry></row><row><entry/><entry/><entry>AAVPKNVSVAEGKELDLTCN</entry></row><row><entry/><entry/><entry>ITTDRADDVRPEVTWSFSRM</entry></row><row><entry/><entry/><entry>PDSTLPGSRVLARLDRDSLV</entry></row><row><entry/><entry/><entry>HSSPHVALSHVDARSYHLLV</entry></row><row><entry/><entry/><entry>RDVSKENSGYYYCHVSLWAP</entry></row><row><entry/><entry/><entry>GHNRSWHKVAEAVSSPAGVG</entry></row><row><entry/><entry/><entry>VTWLEPDYQVYLNASKVPGF</entry></row><row><entry/><entry/><entry>ADDPTELACRVVDTKSGEAN</entry></row><row><entry/><entry/><entry>VRFTVSWYYRMNRRSDNVVT</entry></row><row><entry/><entry/><entry>SELLAVMDGDWTLKYGERSK</entry></row><row><entry/><entry/><entry>QRAQDGDFIFSKEHTDTFNF</entry></row><row><entry/><entry/><entry>RIQRTTEEDRGNYYCVVSAW</entry></row><row><entry/><entry/><entry>TKQRNNSWVKSKDVFSKPVN</entry></row><row><entry/><entry/><entry>IFWALEDSVLVVKARQPKPF</entry></row><row><entry/><entry/><entry>FAAGNTFEMTCKVSSKNIKS</entry></row><row><entry/><entry/><entry>PRYSVLIMAEKPVGDLSSPN</entry></row><row><entry/><entry/><entry>ETKYIISLDQDSWKLENWTD</entry></row><row><entry/><entry/><entry>ASRVDGVVLEKVQEDEFRYR</entry></row><row><entry/><entry/><entry>MYQTQVSDAGLYRCMVTAWS</entry></row><row><entry/><entry/><entry>PVRGSLWREAATSLSNPIEI</entry></row><row><entry/><entry/><entry>DFQTSGPIFNASVHSDTPSV</entry></row><row><entry/><entry/><entry>IRGDLIKLFCIITVEGAALD</entry></row><row><entry/><entry/><entry>PDDMAFDVSWFAVHSFGLDK</entry></row><row><entry/><entry/><entry>APVLLSSLDRKGIVTTSRRD</entry></row><row><entry/><entry/><entry>WKSDLSLERVSVLEFLLQVH</entry></row><row><entry/><entry/><entry>GSEDQDFGNYYCSVTPWVKS</entry></row><row><entry/><entry/><entry>PTGSWQKEAEIHSKPVFITV</entry></row><row><entry/><entry/><entry>KMDVLNAFKYPLLIGVGLST</entry></row><row><entry/><entry/><entry>VIGLLSCLIGYCSSHWCCKK</entry></row><row><entry/><entry/><entry>EVQETRRERRRLMSMEMD</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>The</entry><entry>GPIFNASVHSDTPSVIRGDL</entry></row><row><entry/><entry>PTGFRN</entry><entry>IKLFCIITVEGAALDPDDMA</entry></row><row><entry/><entry>protein</entry><entry>FDVSWFAVHSFGLDKAPVLL</entry></row><row><entry/><entry>Fragment</entry><entry>SSLDRKGIVTTSRRDWKSDL</entry></row><row><entry/><entry>(SEQ&#x2003;ID</entry><entry>SLERVSVLEFLLQVHGSEDQ</entry></row><row><entry/><entry>NO:&#x2003;302)</entry><entry>DFGNYYCSVTPWVKSPTGSW</entry></row><row><entry/><entry/><entry>QKEAEIHSKPVFITVKMDVL</entry></row><row><entry/><entry/><entry>NAFKYPLLIGVGLSTVIGLL</entry></row><row><entry/><entry/><entry>SCLIGYCSSHWCCKKEVQET</entry></row><row><entry/><entry/><entry>RRERRRLMSMEM</entry></row><row><entry/><entry/><entry>687-878&#x2003;of&#x2003;SEQ&#x2003;ID&#x2003;NO:&#x2003;301</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0506" num="0588">In other aspects, the Scaffold X comprises an amino acid sequence at least about at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO: 319, 320, 321, 322, 323, 323, or 325. In other aspects, the Scaffold X comprises the amino acid sequence of SEQ ID NO: 319, 320, 321, 322, 323, 323, or 325, except one amino acid mutation, two amino acid mutations, three amino acid mutations, four amino acid mutations, five amino acid mutations, six amino acid mutations, or seven amino acid mutations. The mutations can be a substitution, an insertion, a deletion, or any combination thereof. In some aspects, the Scaffold X comprises the amino acid sequence of SEQ ID NO: 319, 320, 321, 322, 323, 323, or 325 and 1 amino acid, two amino acids, three amino acids, four amino acids, five amino acids, six amino acids, seven amino acids, eight amino acids, nine amino acids, ten amino acids, 11 amino acids, 12 amino acids, 13 amino acids, 14 amino acids, 15 amino acids, 16 amino acids, 17 amino acids, 18 amino acids, 19 amino acids, or 20 amino acids or longer at the N terminus and/or C terminus of SEQ ID NO: 319, 320, 321, 322, 323, 323, or 325.</p><p id="p-0507" num="0589">In some aspects, a Scaffold X comprises Basigin (the BSG protein), represented by SEQ ID NO: 303. The BSG protein is also known as 5F7, Collagenase stimulatory factor, Extracellular matrix metalloproteinase inducer (EMMPRIN), Leukocyte activation antigen M6, OK blood group antigen, Tumor cell-derived collagenase stimulatory factor (TCSF), or CD147. The Uniprot number for the human BSG protein is P35613. The signal peptide of the BSG protein is amino acid 1 to 21 of SEQ ID NO: 303. Amino acids 138-323 of SEQ ID NO: 303 is the extracellular domain, amino acids 324 to 344 is the transmembrane domain, and amino acids 345 to 385 of SEQ ID NO: 303 is the cytoplasmic domain.</p><p id="p-0508" num="0590">In other aspects, the Scaffold X comprises an amino acid sequence at least about 70/a, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to amino acids 22 to 385 of SEQ ID NO: 303. In some aspects, the fragments of BSG polypeptide lack one or more functional or structural domains, such as IgV, e.g., amino acids 221 to 315 of SEQ ID NO: 303. In other aspects, the Scaffold X comprises an amino acid sequence at least about at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO: 326, 327, or 328. In other aspects, the Scaffold X comprises the amino acid sequence of SEQ ID NO: 326, 327, or 328, except one amino acid mutation, two amino acid mutations, three amino acid mutations, four amino acid mutations, five amino acid mutations, six amino acid mutations, or seven amino acid mutations. The mutations can be a substitution, an insertion, a deletion, or any combination thereof. In some aspects, the Scaffold X comprises the amino acid sequence of SEQ ID NO: 326, 327, or 328 and 1 amino acid, two amino acids, three amino acids, four amino acids, five amino acids, six amino acids, seven amino acids, eight amino acids, nine amino acids, ten amino acids, 11 amino acids, 12 amino acids, 13 amino acids, 14 amino acids, 15 amino acids, 16 amino acids, 17 amino acids, 18 amino acids, 19 amino acids, or 20 amino acids or longer at the N terminus and/or C terminus of SEQ ID NO: 326, 327, or 328.</p><p id="p-0509" num="0591">In some aspects, a Scaffold X comprises Immunoglobulin superfamily member 8 (IgSF8 or the IGSF8 protein), which is also known as CD81 partner 3, Glu-Trp-Ile EWI motif-containing protein 2 (EWI-2), Keratinocytes-associated transmembrane protein 4 (KCT-4), LIR-D1, Prostaglandin regulatory-like protein (PGRL) or CD316. The full length human IGSF8 protein is accession no. Q969P0 in Uniprot and is shown as SEQ ID NO: 304 herein. The human IGSF8 protein has a signal peptide (amino acids 1 to 27 of SEQ ID NO: 304), an extracellular domain (amino acids 28 to 579 of SEQ ID NO: 304), a transmembrane domain (amino acids 580 to 600 of SEQ ID NO: 304), and a cytoplasmic domain (amino acids 601 to 613 of SEQ ID NO: 304).</p><p id="p-0510" num="0592">In other aspects, the Scaffold X comprises an amino acid sequence at least about 700/a, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to amino acids 28 to 613 of SEQ ID NO: 304. In some aspects, the IGSF8 protein lack one or more functional or structural domains, such as IgV. In other aspects, the Scaffold X comprises an amino acid sequence at least about at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO: 330, 331, 332, or 333. In other aspects, the Scaffold X comprises the amino acid sequence of SEQ ID NO: 330, 331, 332, or 333, except one amino acid mutation, two amino acid mutations, three amino acid mutations, four amino acid mutations, five amino acid mutations, six amino acid mutations, or seven amino acid mutations. The mutations can be a substitution, an insertion, a deletion, or any combination thereof. In some aspects, the Scaffold X comprises the amino acid sequence of SEQ ID NO: 330, 331, 332, or 333 and 1 amino acid, two amino acids, three amino acids, four amino acids, five amino acids, six amino acids, seven amino acids, eight amino acids, nine amino acids, ten amino acids, 11 amino acids, 12 amino acids, 13 amino acids, 14 amino acids, 15 amino acids, 16 amino acids, 17 amino acids, 18 amino acids, 19 amino acids, or 20 amino acids or longer at the N terminus and/or C terminus of SEQ ID NO: 330, 331, 332, or 333.</p><p id="p-0511" num="0593">Non-limiting examples of other Scaffold X proteins can be found at U.S. Ser. No. 10/195,290B1, issued Feb. 5, 2019, which is incorporated by reference in its entireties.</p><p id="p-0512" num="0594">In some aspects, the sequence encodes a fragment of the scaffold moiety lacking at least 5, 10, 50, 100, 200, 300, 400, 500, 600, 700, or 800 amino acids from the N-terminus of the native protein. In some aspects, the sequence encodes a fragment of the scaffold moiety lacking at least 5, 10, 50, 100, 200, 300, 400, 500, 600, 700, or 800 amino acids from the C-terminus of the native protein. In some aspects, the sequence encodes a fragment of the scaffold moiety lacking at least 5, 10, 50, 100, 200, 300, 400, 500, 600, 700, or 800 amino acids from both the N-terminus and C-terminus of the native protein. In some aspects, the sequence encodes a fragment of the scaffold moiety lacking one or more functional or structural domains of the native protein.</p><p id="p-0513" num="0595">In some aspects, the scaffold moieties, e.g., Scaffold X, e.g., a PTGFRN protein, are linked to one or more heterologous proteins. The one or more heterologous proteins can be linked to the N-terminus of the scaffold moieties. The one or more heterologous proteins can be linked to the C-terminus of the scaffold moieties. In some aspects, the one or more heterologous proteins are linked to both the N-terminus and the C-terminus of the scaffold moieties. In some aspects, the heterologous protein is a mammalian protein. In some aspects, the heterologous protein is a human protein.</p><p id="p-0514" num="0596">In some aspects, Scaffold X can be used to link any moiety, e.g., an ASO, to the luminal surface and on the exterior surface of the EV, e.g., exosome, at the same time. For example, the PTGFRN polypeptide can be used to link an ASO inside the lumen (e.g., on the luminal surface) in addition to the exterior surface of the EV, e.g., exosome. Therefore, in certain aspects, Scaffold X can be used for dual purposes, e.g., an ASO on the luminal surface and an ASO on the exterior surface of the EV, e.g., exosome. In some aspects, Scaffold X is a scaffold protein that is capable of anchoring the ASO on the luminal surface of the EV and/or on the exterior surface of the EV.</p><heading id="h-0085" level="1">III.B.2. Scaffold Y-Engineered EVs, e.g., Exosomes</heading><p id="p-0515" num="0597">In some aspects, EVs, e.g., exosomes, of the present disclosure comprise an internal space (i.e., lumen) that is different from that of the naturally occurring EVs. For example, the EV can be changed such that the composition in the luminal surface of the EV, e.g., exosome has the protein, lipid, or glycan content different from that of the naturally-occurring exosomes.</p><p id="p-0516" num="0598">In some aspects, engineered EVs, e.g., exosomes, can be produced from a cell transformed with an exogenous sequence encoding a scaffold moiety (e.g., exosome proteins, e.g., Scaffold Y) or a modification or a fragment of the scaffold moiety that changes the composition or content of the luminal surface of the EV, e.g., exosome. Various modifications or fragments of the exosome protein that can be expressed on the luminal surface of the EV, e.g., exosome, can be used for the aspects of the present disclosure.</p><p id="p-0517" num="0599">In some aspects, the exosome proteins that can change the luminal surface of the EVs, e.g., exosomes, include, but are not limited to, the myristoylated alanine rich Protein Kinase C substrate (MARCKS) protein, the myristoylated alanine rich Protein Kinase C substrate like 1 (MARCKSL1) protein, the brain acid soluble protein 1 (BASP1) protein, or any combination thereof.</p><p id="p-0518" num="0600">In some aspects, Scaffold Y comprises the MARCKS protein (Uniprot accession no. P29966). The MARCKS protein is also known as protein kinase C substrate, 80 kDa protein, light chain. The full-length human MARCKS protein is 332 amino acids in length and comprises a calmodulin-binding domain at amino acid residues 152-176. In some aspects, Scaffold Y comprises the MARCKSL1 protein (Uniprot accession no. P49006). The MARCKSL1 protein is also known as MARCKS-like protein 1, and macrophage myristoylated alanine-rich C kinase substrate. The full-length human MARCKSL1 protein is 195 amino acids in length. The MARCKSL1 protein has an effector domain involved in lipid-binding and calmodulin-binding at amino acid residues 87-110. In some aspects, the Scaffold Y comprises the BASP1 protein (Uniprot accession number P80723). The BASP1 protein is also known as 22 kDa neuronal tissue-enriched acidic protein or neuronal axonal membrane protein NAP-22. The full-length human BASP1 protein sequence (isomer 1) is 227 amino acids in length. An isomer produced by an alternative splicing is missing amino acids 88 to 141 from SEQ ID NO: 403 (isomer 1). Table 5 provides the full-length sequences for the exemplary Scaffold Y disclosed herein (i.e., the MARCKS, MARCKSL1, and BASP1 proteins).</p><p id="p-0519" num="0000"><tables id="TABLE-US-00006" num="00006"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;5</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Exemplary&#x2003;Scaffold&#x2003;Y&#x2003;Protein&#x2003;Sequences</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="98pt" align="left"/><colspec colname="2" colwidth="105pt" align="left"/><tbody valign="top"><row><entry/><entry>Protein</entry><entry>Sequence</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row><row><entry/><entry>The&#x2003;MARCKS</entry><entry>MGAQFSKTAAKGEAAAERPG</entry></row><row><entry/><entry>protein</entry><entry>EAAVASSPSKANGQENGHVK</entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;401)</entry><entry>VNGDASPAAAESGAKEELQA</entry></row><row><entry/><entry/><entry>NGSAPAADKEEPAAAGSGAA</entry></row><row><entry/><entry/><entry>SPSAAEKGEPAAAAAPEAGA</entry></row><row><entry/><entry/><entry>SPVEKEAPAEGEAAEPGSPT</entry></row><row><entry/><entry/><entry>AAEGEAASAASSTSSPKAED</entry></row><row><entry/><entry/><entry>GATPSPSNETPKKKKKRFSF</entry></row><row><entry/><entry/><entry>KKSFKLSGFSFKKNKKEAGE</entry></row><row><entry/><entry/><entry>GGEAEAPAAEGGKDEAAGGA</entry></row><row><entry/><entry/><entry>AAAAAEAGAASGEQAAAPGE</entry></row><row><entry/><entry/><entry>EAAAGEEGAAGGDPQEAKPQ</entry></row><row><entry/><entry/><entry>EAAVAPEKPPASDETKAAEE</entry></row><row><entry/><entry/><entry>PSKVEEKKAEEAGASAAACE</entry></row><row><entry/><entry/><entry>APSAAGPGAPPEQEAAPAEE</entry></row><row><entry/><entry/><entry>PAAAAASSACAAPSQEAQPE</entry></row><row><entry/><entry/><entry>CSPEAPPAEAAE</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>The&#x2003;MARCKSL1</entry><entry>MGSQSSKAPRGDVTAEEAAG</entry></row><row><entry/><entry>protein</entry><entry>ASPAKANGQENGHVKSNGDL</entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;402)</entry><entry>SPKGEGESPPVNGTDEAAGA</entry></row><row><entry/><entry/><entry>TGDAIEPAPPSQGAEAKGEV</entry></row><row><entry/><entry/><entry>PPKETPKKKKKFSFKKPFKL</entry></row><row><entry/><entry/><entry>SGLSFKRNRKEGGGDSSASS</entry></row><row><entry/><entry/><entry>PTEEEQEQGEIGACSDEGTA</entry></row><row><entry/><entry/><entry>QEGKAAATPESQEPQAKGAE</entry></row><row><entry/><entry/><entry>ASAASEEEAGPQATEPSTPS</entry></row><row><entry/><entry/><entry>GPESGPTPASAEQNE</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>The&#x2003;BASP1&#x2003;protein</entry><entry>MGGKLSKKKKGYNVNDEKAK</entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;403)</entry><entry>EKDKKAEGAATEEEGTPKES</entry></row><row><entry/><entry/><entry>EPQAAAEPAEAKEGKEKPDQ</entry></row><row><entry/><entry/><entry>DAEGKAEEKEGEKDAAAAKE</entry></row><row><entry/><entry/><entry>EAPKAEPEKTEGAAEAKAEP</entry></row><row><entry/><entry/><entry>PKAPEQEQAAPGPAAGGEAP</entry></row><row><entry/><entry/><entry>KAAEAAAAPAESAAPAAGEE</entry></row><row><entry/><entry/><entry>PSKEEGEPKKTEAPAAPAAQ</entry></row><row><entry/><entry/><entry>ETKSDGAPASDSKPGSSEAA</entry></row><row><entry/><entry/><entry>PSSKETPAATEAPSSTPKAQ</entry></row><row><entry/><entry/><entry>GPAASAEEPKPVEAPAANSD</entry></row><row><entry/><entry/><entry>QTVTVKE</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0520" num="0601">In other aspects, Scaffold Y useful for the present disclosure comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to amino acids 2 to 227 of SEQ ID NO: 403. In other aspects, the Scaffold Y comprises an amino acid sequence at least about at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to any one of SEQ ID NOs: 404-567. In other aspects, a Scaffold Y useful for the present disclosure comprises the amino acid sequence of SEQ ID NO: 403, except one amino acid mutation, two amino acid mutations, three amino acid mutations, four amino acid mutations, five amino acid mutations, six amino acid mutations, or seven amino acid mutations. In other aspects, a Scaffold Y useful for the present disclosure comprises the amino acid sequence of SEQ ID NO: 403 without Met at amino acid residue 1 of the SEQ ID NO: 403, except one amino acid mutation, two amino acid mutations, three amino acid mutations, four amino acid mutations, five amino acid mutations, six amino acid mutations, or seven amino acid mutations. The mutations can be a substitution, an insertion, a deletion, or any combination thereof. In some aspects, a Scaffold Y useful for the present disclosure comprises the amino acid sequence of any one of SEQ ID NOs: 404-567 and 1 amino acid, two amino acids, three amino acids, four amino acids, five amino acids, six amino acids, seven amino acids, eight amino acids, nine amino acids, ten amino acids, 11 amino acids, 12 amino acids, 13 amino acids, 14 amino acids, 15 amino acids, 16 amino acids, 17 amino acids, 18 amino acids, 19 amino acids, or 20 amino acids or longer at the N terminus and/or C terminus of SEQ ID NOs: 404-567.</p><p id="p-0521" num="0602">In some aspects, the protein sequence of any of SEQ ID NOs: 404-567 is sufficient to be a Scaffold Y for the present disclosure (e.g., scaffold moiety linked to an ASO).</p><p id="p-0522" num="0603">In some aspects, a Scaffold Y useful for the present disclosure comprises a peptide with the GXKLSKKK, where X is alanine or any other amino acid (SEQ ID NO: 404). In some aspects, an EV, e.g., exosome, comprises a peptide with sequence of (G)(&#x3c0;)(&#x3be;)(&#x3a6;/&#x3c0;)(S/A/G/N)(+)(+), wherein each parenthetical position represents an amino acid, and wherein a is any amino acid selected from the group consisting of (Pro, Gly, Ala, Ser), &#x3be; is any amino acid selected from the group consisting of (Asn, Gln, Ser, Thr, Asp, Glu, Lys, His, Arg), &#x3a6; is any amino acid selected from the group consisting of (Val, Ile, Leu, Phe, Trp, Tyr, Met), and (+) is any amino acid selected from the group consisting of (Lys, Arg, His); and wherein position five is not (+) and position six is neither (+) nor (Asp or Glu). In further aspects, an exosome described herein (e.g., engineered exosome) comprises a peptide with sequence of (G)(&#x3c0;)(X)(&#x3a6;/&#x3c0;)(&#x3c0;)(+x+), wherein each parenthetical position represents an amino acid, and wherein &#x3c0; is any amino acid selected from the group consisting of (Pro, Gly, Ala, Ser), X is any amino acid, &#x3a6; is any amino acid selected from the group consisting of (Val, Ile, Leu, Phe, Trp, Tyr, Met), and (+) is any amino acid selected from the group consisting of (Lys, Arg, His); and wherein position five is not (+) and position six is neither (+) nor (Asp or Glu). See Aasland et al., FEBS Letters 513 (2002) 141-144 for amino acid nomenclature.</p><p id="p-0523" num="0604">In other aspects, the Scaffold X comprises an amino acid sequence at least about 70/a, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to any one of SEQ ID NO: 404-567.</p><p id="p-0524" num="0605">Scaffold Y-engineered EVs, e.g., exosomes described herein can be produced from a cell transformed with a sequence set forth in SEQ ID NOs: 404-567.</p><p id="p-0525" num="0606">In some aspects, the Scaffold Y protein useful for the present disclosure comprises an &#x201c;N-terminus domain&#x201d; (ND) and an &#x201c;effector domain&#x201d; (ED), wherein the ND and/or the ED are associated with the luminal surface of the EV, e.g., an exosome. In some aspects, the Scaffold Y protein useful for the present disclosure comprises an intracellular domain, a transmembrane domain, and an extracellular domain; wherein the intracellular domain comprises an &#x201c;N-terminus domain&#x201d; (ND) and an &#x201c;effector domain&#x201d; (ED), wherein the ND and/or the ED are associated with the luminal surface of the EV, e.g., an exosome. As used herein the term &#x201c;associated with&#x201d; refers to the interaction between a scaffold protein with the luminal surface of the EV, e.g., and exosome, that does not involve covalent linking to a membrane component. For example, the scaffolds useful for the present disclosure can be associated with the luminal surface of the EV, e.g., via a lipid anchor (e.g., myristic acid), and/or a polybasic domain that interacts electrostatically with the negatively charged head of membrane phospholipids. In other aspects, the Scaffold Y protein comprises an N-terminus domain (ND) and an effector domain (ED), wherein the ND is associated with the luminal surface of the EV and the ED are associated with the luminal surface of the EV by an ionic interaction, wherein the ED comprises at least two, at least three, at least four, at least five, at least six, or at least seven contiguous basic amino acids, e.g., lysines (Lys), in sequence.</p><p id="p-0526" num="0607">In other aspects, the Scaffold Y protein comprises an N-terminus domain (ND) and an effector domain (ED), wherein the ND is associated with the luminal surface of the EV, e.g., exosome, and the ED is associated with the luminal surface of the EV by an ionic interaction, wherein the ED comprises at least two, at least three, at least four, at least five, at least six, or at least seven contiguous basic amino acids, e.g., lysines (Lys), in sequence.</p><p id="p-0527" num="0608">In some aspects, the ND is associated with the luminal surface of the EV, e.g., an exosome, via lipidation, e.g., via myristoylation. In some aspects, the ND has Gly at the N terminus. In some aspects, the N-terminal Gly is myristoylated.</p><p id="p-0528" num="0609">In some aspects, the ED is associated with the luminal surface of the EV, e.g., an exosome, by an ionic interaction. In some aspects, the ED is associated with the luminal surface of the EV, e.g., an exosome, by an electrostatic interaction, in particular, an attractive electrostatic interaction.</p><p id="p-0529" num="0610">In some aspects, the ED comprises (i) a basic amino acid (e.g., lysine), or (ii) two or more basic amino acids (e.g., lysine) next to each other in a polypeptide sequence. In some aspects, the basic amino acid is lysine (Lys; K), arginine (Arg, R), or Histidine (His, H). In some aspects, the basic amino acid is (Lys)n, wherein n is an integer between 1 and 10.</p><p id="p-0530" num="0611">In other aspects, the ED comprises at least a lysine and the ND comprises a lysine at the C terminus if the N terminus of the ED is directly linked to lysine at the C terminus of the ND, i.e., the lysine is in the N terminus of the ED and is fused to the lysine in the C terminus of the ND. In other aspects, the ED comprises at least two lysines, at least three lysines, at least four lysines, at least five lysines, at least six lysines, or at least seven lysines when the N terminus of the ED is linked to the C terminus of the ND by a linker, e.g., one or more amino acids.</p><p id="p-0531" num="0612">In some aspects, the ED comprises K, KK, KKK, KKKK (SEQ ID NO: 405), KKKKK (SEQ ID NO: 406), R, RR, RRR, RRRR (SEQ ID NO: 407); RRRRR (SEQ ID NO: 408), KR, RK, KKR, KRK, RKK, KRR, RRK, (K/R)(K/R)(K/R)(K/R) (SEQ ID NO: 409), (K/R)(K/R)(K/R)(K/R)(K/R) (SEQ ID NO: 410), or any combination thereof. In some aspects, the ED comprises KK, KKK, KKKK (SEQ ID NO: 405), KKKKK (SEQ ID NO: 406), or any combination thereof. In some aspects, the ND comprises the amino acid sequence as set forth in G:X2:X3:X4:X5:X6, wherein G represents Gly; wherein &#x201c;:&#x201d; represents a peptide bond; wherein each of the X2 to the X6 independently represents an amino acid; and wherein the X6 represents a basic amino acid. In some aspects, the X6 amino acid is selected is selected from the group consisting of Lys, Arg, and His. In some aspects, the X5 amino acid is selected from the group consisting of Pro, Gly, Ala, and Ser. In some aspects, the X2 amino acid is selected from the group consisting of Pro, Gly, Ala, and Ser. In some aspects, the X4 is selected from the group consisting of Pro, Gly, Ala, Ser, Val, Ile, Leu, Phe, Trp, Tyr, Gln, and Met.</p><p id="p-0532" num="0613">In some aspects, the Scaffold Y protein comprises an N-terminus domain (ND) and an effector domain (ED), wherein the ND comprises the amino acid sequence as set forth in G:X2:X3:X4:X5:X6, wherein G represents Gly; wherein &#x201c;:&#x201d; represents a peptide bond; wherein each of the X2 to the X6 is independently an amino acid; wherein the X6 comprises a basic amino acid, and wherein the ED is linked to X6 by a peptide bond and comprises at least one lysine at the N terminus of the ED.</p><p id="p-0533" num="0614">In some aspects, the ND of the Scaffold Y protein comprises the amino acid sequence of G:X2:X3:X4:X5:X6, wherein G represents Gly; &#x201c;:&#x201d; represents a peptide bond; the X2 represents an amino acid selected from the group consisting of Pro, Gly, Ala, and Ser; the X3 represents any amino acid; the X4 represents an amino acid selected from the group consisting of Pro, Gly, Ala, Ser, Val, Ile, Leu, Phe, Trp, Tyr, Gln, and Met; the X5 represents an amino acid selected from the group consisting of Pro, Gly, Ala, and Ser; and the X6 represents an amino acid selected from the group consisting of Lys, Arg, and His.</p><p id="p-0534" num="0615">In some aspects, the X3 amino acid is selected from the group consisting of Asn, Gln, Ser, Thr, Asp, Glu, Lys, His, and Arg.</p><p id="p-0535" num="0616">In some aspects, the ND and ED are joined by a linker. In some aspects, the linker comprises one or more amino acids. In some aspects, the term &#x201c;linker&#x201d; refers to a peptide or polypeptide sequence (e.g., a synthetic peptide or polypeptide sequence) or to a non-polypeptide, e.g., an alkyl chain. In some aspects, two or more linkers can be linked in tandem. Generally, linkers provide flexibility or prevent/ameliorate steric hindrances. Linkers are not typically cleaved; however, in certain aspects, such cleavage can be desirable. Accordingly, in some aspects a linker can comprise one or more protease-cleavable sites, which can be located within the sequence of the linker or flanking the linker at either end of the linker sequence. When the ND and ED are joined by a linker, the ED comprise at least two lysines, at least three lysines, at least four lysines, at least five lysines, at least six lysines, or at least seven lysines.</p><p id="p-0536" num="0617">In some aspects, the linker is a peptide linker. In some aspects, the peptide linker can comprise at least about two, at least about three, at least about four, at least about five, at least about 10, at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 55, at least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least about 85, at least about 90, at least about 95, or at least about 100 amino acids.</p><p id="p-0537" num="0618">In some aspects, the linker is a glycine/serine linker. In some aspects, the peptide linker is glycine/serine linker according to the formula [(Gly)n-Ser]m where n is any integer from 1 to 100 and m is any integer from 1 to 100. In other aspects, the glycine/serine linker is according to the formula [(Gly)x-Sery]z wherein x in an integer from 1 to 4, y is 0 or 1, and z is an integer from 1 to 50. In some aspects, the peptide linker comprises the sequence Gn, where n can be an integer from 1 to 100. In some aspects, the peptide linker can comprise the sequence (GlyAla)n, wherein n is an integer between 1 and 100. In other aspects, the peptide linker can comprise the sequence (GlyGlySer)n, wherein n is an integer between 1 and 100.</p><p id="p-0538" num="0619">In some aspects, the peptide linker is synthetic, i.e., non-naturally occurring. In one aspect, a peptide linker includes peptides (or polypeptides) (e.g., natural or non-naturally occurring peptides) which comprise an amino acid sequence that links or genetically fuses a first linear sequence of amino acids to a second linear sequence of amino acids to which it is not naturally linked or genetically fused in nature. For example, in one aspect the peptide linker can comprise non-naturally occurring polypeptides which are modified forms of naturally occurring polypeptides (e.g., comprising a mutation such as an addition, substitution or deletion).</p><p id="p-0539" num="0620">In other aspects, the peptide linker can comprise non-naturally occurring amino acids. In yet other aspects, the peptide linker can comprise naturally occurring amino acids occurring in a linear sequence that does not occur in nature. In still other aspects, the peptide linker can comprise a naturally occurring polypeptide sequence.</p><p id="p-0540" num="0621">The present disclosure also provides an isolated extracellular vesicle (EV), e.g., an exosome, comprising an ASO linked to a Scaffold Y protein, wherein the Scaffold Y protein comprises ND-ED, wherein: ND comprises G:X2:X3:X4:X5:X6; wherein: G represents Gly; &#x201c;:&#x201d; represents a peptide bond; X2 represents an amino acid selected from the group consisting of Pro, Gly, Ala, and Ser; X3 represents any amino acid; X4 represents an amino acid selected from the group consisting of Pro, Gly, Ala, Ser, Val, Ile, Leu, Phe, Trp, Tyr, Glu, and Met; X5 represents an amino acid selected from the group consisting of Pro, Gly, Ala, and Ser; X6 represents an amino acid selected from the group consisting of Lys, Arg, and His; &#x201c;&#x2212;&#x201d; represents an optional linker; and ED is an effector domain comprising (i) at least two contiguous lysines (Lys), which is linked to the X6 by a peptide bond or one or more amino acids or (ii) at least one lysine, which is directly linked to the X6 by a peptide bond.</p><p id="p-0541" num="0622">In some aspects, the X2 amino acid is selected from the group consisting of Gly and Ala. In some aspects, the X3 amino acid is Lys. In some aspects, the X4 amino acid is Leu or Glu. In some aspects, the X5 amino acid is selected from the group consisting of Ser and Ala. In some aspects, the X6 amino acid is Lys. In some aspects, the X2 amino acid is Gly, Ala, or Ser; the X3 amino acid is Lys or Glu; the X4 amino acid is Leu, Phe, Ser, or Glu; the X5 amino acid is Ser or Ala; and X6 amino acid is Lys. In some aspects, the &#x201c;&#x2212;&#x201d; linker comprises a peptide bond or one or more amino acids.</p><p id="p-0542" num="0623">In some aspects, the ED in the scaffold protein comprises Lys (K), KK, KKK, KKKK (SEQ ID NO: 405), KKKKK (SEQ ID NO: 406), Arg (R), RR, RRR, RRRR (SEQ ID NO: 407); RRRRR (SEQ ID NO: 408), KR, RK, KKR, KRK, RKK, KRR, RRK, (K/R)(K/R)(K/R)(K/R) (SEQ ID NO: 409), (K/R)(K/R)(K/R)(K/R)(K/R) (SEQ ID NO: 410), or any combination thereof.</p><p id="p-0543" num="0624">In some aspects, the Scaffold Y protein comprises an amino acid sequence selected from the group consisting of (i) GGKLSKK (SEQ ID NO: 411), (ii) GAKLSKK (SEQ ID NO: 412), (iii) GGKQSKK (SEQ ID NO: 413), (iv) GGKLAKK (SEQ ID NO: 414), or (v) any combination thereof.</p><p id="p-0544" num="0625">In some aspects, the ND in the Scaffold Y protein comprises an amino acid sequence selected from the group consisting of (i) GGKLSK (SEQ ID NO: 415), (ii) GAKLSK (SEQ ID NO: 416), (iii) GGKQSK (SEQ ID NO: 417), (iv) GGKLAK (SEQ ID NO: 418), or (v) any combination thereof and the ED in the scaffold protein comprises K, KK, KKK, KKKG (SEQ ID NO: 419), KKKGY (SEQ ID NO: 420), KKKGYN (SEQ ID NO: 421), KKKGYNV (SEQ ID NO: 422), KKKGYNVN (SEQ ID NO: 423), KKKGYS (SEQ ID NO: 424), KKKGYG (SEQ ID NO: 425), KKKGYGG (SEQ ID NO: 426), KKKGS (SEQ ID NO: 427), KKKGSG (SEQ ID NO: 428), KKKGSGS (SEQ ID NO: 429), KKKS (SEQ ID NO: 430), KKKSG (SEQ ID NO: 431), KKKSGG (SEQ ID NO: 432), KKKSGGS (SEQ ID NO: 433), KKKSGGSG (SEQ ID NO: 434), KKSGGSGG (SEQ ID NO: 435), KKKSGGSGGS (SEQ ID NO: 436), KRFSFKKS (SEQ ID NO: 437).</p><p id="p-0545" num="0626">In some aspects, the polypeptide sequence of a Scaffold Y protein useful for the present disclosure consists of an amino acid sequence selected from the group consisting of (i) GGKLSKK (SEQ ID NO: 411), (ii) GAKLSKK (SEQ ID NO: 412), (iii) GGKQSKK (SEQ ID NO: 413), (iv) GGKLAKK (SEQ ID NO: 414), or (v) any combination thereof.</p><p id="p-0546" num="0627">In some aspects, the Scaffold Y protein comprises an amino acid sequence selected from the group consisting of (i) GGKLSKKK (SEQ ID NO: 438), (ii) GGKLSKKS (SEQ ID NO: 439), (iii) GAKLSKKK (SEQ ID NO: 440), (iv) GAKLSKKS (SEQ ID NO: 441), (v) GGKQSKKK (SEQ ID NO: 442), (vi) GGKQSKKS (SEQ ID NO: 443), (vii) GGKLAKKK (SEQ ID NO: 444), (viii) GGKLAKKS (SEQ ID NO: 445), and (ix) any combination thereof.</p><p id="p-0547" num="0628">In some aspects, the polypeptide sequence of a Scaffold Y protein useful for the present disclosure consists of an amino acid sequence selected from the group consisting of (i) GGKLSKKK (SEQ ID NO: 438), (ii) GGKLSKKS (SEQ ID NO: 439), (iii) GAKLSKKK (SEQ ID NO: 440), (iv) GAKLSKKS (SEQ ID NO: 441), (v) GGKQSKKK (SEQ ID NO: 442), (vi) GGKQSKKS (SEQ ID NO: 443), (vii) GGKLAKKK (SEQ ID NO: 444), (viii) GGKLAKKS (SEQ ID NO: 445), and (ix) any combination thereof.</p><p id="p-0548" num="0629">In some aspects, the Scaffold Y protein is at least about 8, at least about 9, at least about 10, at least about 11, at least about 12, at least about 13, at least about 14, at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, at least about 20, at least about 21, at least about 22, at least about 23, at least about 24, at least about 25, at least about 26, at least about 27, at least about 28, at least about 29, at least about 30, at least 31, at least about 32, at least about 33, at least about 34, at least about 35, at least about 36, at least about 37, at least about 38, at least about 39, at least about 39, at least about 40, at least about 41, at least about 42, at least about 43, at least about 44, at least about 50, at least about 46, at least about 47, at least about 48, at least about 49, at least about 50, at least about 55, at least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least 85, at least about 90, at least about 95, at least about 100, at least about 105, at least about 110, at least about 115, at least about 120, at least about 125, at least about 130, at least about 135, at least about 140, at least about 145, at least about 150, at least about 155, at least about 160, at least about 165, at least about 170, at least about 175, at least about 180, at least about 185, at least about 190, at least about 195, at least about 200, at least about 205, at least about 210, at least about 215, at least about 220, at least about 225, at least about 230, at least about 235, at least about 240, at least about 245, at least about 250, at least about 255, at least about 260, at least about 265, at least about 270, at least about 275, at least about 280, at least about 285, at least about 290, at least about 295, at least about 300, at least about 305, at least about 310, at least about 315, at least about 320, at least about 325, at least about 330, at least about 335, at least about 340, at least about 345, or at least about 350 amino acids in length.</p><p id="p-0549" num="0630">In some aspects, the Scaffold Y protein is between about 5 and about 10, between about 10 and about 20, between about 20 and about 30, between about 30 and about 40, between about 40 and about 50, between about 50 and about 60, between about 60 and about 70, between about 70 and about 80, between about 80 and about 90, between about 90 and about 100, between about 100 and about 110, between about 110 and about 120, between about 120 and about 130, between about 130 and about 140, between about 140 and about 150, between about 150 and about 160, between about 160 and about 170, between about 170 and about 180, between about 180 and about 190, between about 190 and about 200, between about 200 and about 210, between about 210 and about 220, between about 220 and about 230, between about 230 and about 240, between about 240 and about 250, between about 250 and about 260, between about 260 and about 270, between about 270 and about 280, between about 280 and about 290, between about 290 and about 300, between about 300 and about 310, between about 310 and about 320, between about 320 and about 330, between about 330 and about 340, or between about 340 and about 350 amino acids in length.</p><p id="p-0550" num="0631">In some aspects, the Scaffold Y protein comprises (i) GGKLSKKKKGYNVN (SEQ ID NO: 446), (ii) GAKLSKKKKGYNVN (SEQ ID NO: 447), (iii) GGKQSKKKKGYNVN (SEQ ID NO: 448), (iv) GGKLAKKKKGYNVN (SEQ ID NO: 449), (v) GGKLSKKKKGYSGG (SEQ ID NO: 450), (vi) GGKLSKKKKGSGGS (SEQ ID NO: 451), (vii) GGKLSKKKKSGGSG (SEQ ID NO: 452), (viii) GGKLSKKKSGGSGG (SEQ ID NO: 853), (ix) GGKLSKKSGGSGGS (SEQ ID NO: 484), (x) GGKLSKSGGSGGSV (SEQ ID NO: 855), or (xi) GAKKSKKRFSFKKS (SEQ ID NO: 456).</p><p id="p-0551" num="0632">In some aspects, the polypeptide sequence of a Scaffold Y protein useful for the present disclosure consists of (i) GGKLSKKKKGYNVN (SEQ ID NO: 446), (ii) GAKLSKKKKGYNVN (SEQ ID NO: 447), (iii) GGKQSKKKKGYNVN (SEQ ID NO: 448), (iv) GGKLAKKKKGYNVN (SEQ ID NO: 449), (v) GGKLSKKKKGYSGG (SEQ ID NO: 450), (vi) GGKLSKKKKGSGGS (SEQ ID NO: 451), (vii) GGKLSKKKKSGGSG (SEQ ID NO: 452), (viii) GGKLSKKKSGGSGG (SEQ ID NO: 453), (ix) GGKLSKKSGGSGGS (SEQ ID NO: 454), (x) GGKLSKSGGSGGSV (SEQ ID NO: 455), or (xi) GAKKSKKRFSFKKS (SEQ ID NO: 456).</p><p id="p-0552" num="0633">In some aspects, the Scaffold Y protein useful for the present disclosure does not contain an N-terminal Met. In some aspects, the Scaffold Y protein comprises a lipidated amino acid, e.g., a myristoylated amino acid, at the N-terminus of the scaffold protein, which functions as a lipid anchor. In some aspects, the amino acid residue at the N-terminus of the scaffold protein is Gly. The presence of an N-terminal Gly is an absolute requirement for N-myristoylation. In some aspects, the amino acid residue at the N-terminus of the scaffold protein is synthetic. In some aspects, the amino acid residue at the N-terminus of the scaffold protein is a glycine analog, e.g., allylglycine, butylglycine, or propargylglycine.</p><p id="p-0553" num="0634">Non-limiting examples of scaffold proteins can be found at WO/2019/099942, published May 23, 2019 and WO/2020/101740, published May 22, 2020, which are incorporated by reference in their entireties.</p><heading id="h-0086" level="1">III.C. Targeting Moiety</heading><p id="p-0554" num="0635">In some aspects, the EV, e.g., exosome, comprises a targeting moiety, e.g., an exogenous targeting moiety. In some aspects, the exogenous targeting moiety comprises a peptide, an antibody or an antigen-binding fragment thereof, a chemical compound, an RNA aptamer, or any combination thereof. In some aspects, the targeting moiety comprises a microprotein, a designed ankyrin repeat protein (darpin), an anticalin, an adnectin, an aptamer, a peptide mimetic molecule, a natural ligand for a receptor, a camelid nanobody, or any combination thereof. In some aspects, the exogenous targeting moiety comprises a full-length antibody, a single domain antibody, a heavy chain only antibody (VHH), a single chain antibody, a shark heavy chain only antibody (VNAR), an scFv, a Fv, a Fab, a Fab&#x2032;, a F(ab&#x2032;)2, or any combination thereof. In some aspects, the antibody is a single chain antibody.</p><p id="p-0555" num="0636">In some aspects, the targeting moiety targets the exosome to the liver, heart, lungs, brain, kidneys, central nervous system, peripheral nervous system, muscle, bone, joint, skin, intestine, bladder, pancreas, lymph nodes, spleen, blood, bone marrow, or any combination thereof. In some aspects, the targeting moiety targets the exosome to a tumor cell, dendritic cell, T cell, B cell, macrophage, neuron, hepatocyte, Kupffer cell, a myeloid-lineage cell (e.g., neutrophil, maonocyte, macrophage, or an MDSC (e.g., a monocytic MDSC or a granulocytic MDSC)), hematopoietic stem cell, or any combination thereof.</p><p id="p-0556" num="0637">In some aspects, the targeting moiety is linked to the EV, e.g., the exosome, by a scaffold protein. In some aspects, the scaffold protein is any scaffold protein disclosed herein. In some aspects, the scaffold protein is a Scaffold X. In some aspects, the scaffold protein is a Scaffold Y.</p><heading id="h-0087" level="1">III.D. Linkers</heading><p id="p-0557" num="0638">As described supra, extracellular vesicles (EVs) of the present disclosure (e.g., exosomes and nanovesicles) can comprises one or more linkers that link a molecule of interest (e.g., an ASO) to the EVs (e.g., to the exterior surface or on the luminal surface). In some aspects, an ASO is linked to the EVs directly or via a scaffold moiety (e.g., Scaffold X or Scaffold Y). In certain aspects, the ASO is linked to the scaffold moiety by a linker. In certain aspects, the ASO is linked to the second scaffold moiety by a linker.</p><p id="p-0558" num="0639">In certain aspects, an ASO is linked to the exterior surface of an exosome via Scaffold X. In further aspects, an ASO is linked to the luminal surface of an exosome via Scaffold X or Scaffold Y. The linker can be any chemical moiety known in the art.</p><p id="p-0559" num="0640">As used herein, the term &#x201c;linker&#x201d; refers to a peptide or polypeptide sequence (e.g., a synthetic peptide or polypeptide sequence) or to a non-polypeptide, e.g., an alkyl chain. In some aspects, two or more linkers can be linked in tandem. When multiple linkers are present, each of the linkers can be the same or different. Generally, linkers provide flexibility or prevent/ameliorate steric hindrances. Linkers are not typically cleaved; however, in certain aspects, such cleavage can be desirable. Accordingly, in some aspects, a linker can comprise one or more protease-cleavable sites, which can be located within the sequence of the linker or flanking the linker at either end of the linker sequence.</p><p id="p-0560" num="0641">In some aspects, the linker is a peptide linker. In some aspects, the peptide linker can comprise at least about two, at least about three, at least about four, at least about five, at least about 10, at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 55, at least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least about 85, at least about 90, at least about 95, or at least about 100 amino acids, v</p><p id="p-0561" num="0642">In some aspects, the peptide linker is synthetic, i.e., non-naturally occurring. In one aspect, a peptide linker includes peptides (or polypeptides) (e.g., natural or non-naturally occurring peptides) which comprise an amino acid sequence that links or genetically fuses a first linear sequence of amino acids to a second linear sequence of amino acids to which it is not naturally linked or genetically fused in nature. For example, in one aspect the peptide linker can comprise non-naturally occurring polypeptides which are modified forms of naturally occurring polypeptides (e.g., comprising a mutation such as an addition, substitution or deletion).</p><p id="p-0562" num="0643">Linkers can be susceptible to cleavage (&#x201c;cleavable linker&#x201d;) thereby facilitating release of the biologically active molecule (e.g., an ASO).</p><p id="p-0563" num="0644">In some aspects, the linker is a &#x201c;reduction-sensitive linker.&#x201d; In some aspects, the reduction-sensitive linker contains a disulfide bond. In some aspects, the linker is an &#x201c;acid labile linker.&#x201d; In some aspects, the acid labile linker contains hydrazone. Suitable acid labile linkers also include, for example, a cis-aconitic linker, a hydrazide linker, a thiocarbamoyl linker, or any combination thereof.</p><p id="p-0564" num="0645">In some aspects, the linker comprises a non-cleavable linker.</p><p id="p-0565" num="0646">In some aspects, the linker comprises acrylic phosphoramidite (e.g., ACRYDITE&#x2122;), adenylation, azide (NHS Ester), digoxigenin (NHS Ester), cholesterol-TEG, I-LINKER&#x2122;, an amino modifier (e.g., amino modifier C6, amino modifier C12, amino modifier C6 dT, or Uni-Link&#x2122; amino modifier), alkyne, 5&#x2032; Hexynyl, 5-Octadiynyl dU, biotinylation (e.g., biotin, biotin (Azide), biotin dT, biotin-TEG, dual biotin, PC biotin, or desthiobiotin), thiol modification (thiol modifier C3 S&#x2014;S, dithiol or thiol modifier C6 S&#x2014;S), or any combination thereof.</p><p id="p-0566" num="0647">In some aspects, the linker comprises a terpene such as nerolidol, famesol, limonene, linalool, geraniol, carvone, fenchone, or menthol; a lipid such as palmitic acid or myristic acid; cholesterol; oleyl; retinyl; cholesteryl residues; cholic acid; adamantane acetic acid; 1-pyrene butyric acid; dihydrotestosterone; 1,3-Bis-O(hexadecyl)glycerol; geranyloxyhexyl group; hexadecylglycerol; borneol; 1,3-propanediol; heptadecyl group; 03-(oleoyl)lithocholic acid; O3-(oleoyl)cholenic acid; dimethoxytrityl; phenoxazine, a maleimide moiety, a glucorinidase type, a CL2A-SN38 type, folic acid; a carbohydrate; vitamin A; vitamin E; vitamin K, or any combination thereof.</p><heading id="h-0088" level="1">III.E. Modified EVs Comprising Tropism Moieties</heading><p id="p-0567" num="0648">In some aspects, an EV, e.g., exosome, disclosed herein can be engineered to adjust its properties, e.g., biodistribution, e.g., via incorporation of immuno-affinity ligands or cognate receptor ligands. For example, EV, e.g., exosomes, disclosed herein can be engineered to direct them to a specific cellular type, e.g., Schwann cells, sensory neurons, motor neurons, meningeal macrophages, or a tumor cell, or can be engineered to enhance their migration to a specific compartment, e.g., to the CNS (in order to improve intrathecal compartment retention) or to a tumor microenvironment.</p><p id="p-0568" num="0649">In some aspects, an EV, e.g., exosome, comprises (i) an ASO disclosed herein and (ii) a bio-distribution modifying agent or targeting moiety. In some aspects, the bio-distribution modifying agent or targeting moiety comprises a single-domain antigen-biding moiety, e.g., a VHH and/or a vNAR. As used here, the terms &#x201c;bio-distribution modifying agent&#x201d; and &#x201c;targeting moiety&#x201d; are used interchangeably and refer to an agent that can modify the distribution of extracellular vesicles (e.g., exosomes, nanovesicles) in vivo or in vitro (e.g., in a mixed culture of cells of different varieties). In some aspects, the targeting moiety alters the tropism of the EV (e.g., exosome), i.e., the target moiety is a &#x201c;tropism moiety&#x201d;. As used herein, the term &#x201c;tropism moiety&#x201d; refers to a targeting moiety that when expressed on an EV (e.g., exosome) alters and/or enhances the natural movement of the EV. For example, in some aspects, a tropism moiety can promote the EV (e.g., exosome) to be taken up by a particular cell, tissue, or organ.</p><p id="p-0569" num="0650">EVs, e.g., exosomes, exhibit preferential uptake in discrete cell types and tissues, and their tropism can be directed by adding proteins to their surface that interact with receptors on the surface of target cells. The tropism moiety can comprise a biological molecule, such as a protein, a peptide, a lipid, or a carbohydrate, or a synthetic molecule. For example, in some aspects the tropism moiety can comprise an affinity ligand, e.g., an antibody (such as an anti-CD19 nanobody, an anti-CD22 nanobody, an anti-CLEC9A nanobody, or an anti-CD3 nanobody), a VHH domain, a phage display peptide, a fibronectin domain, a camelid nanobody, and/or a vNAR. In some aspects, the tropism moiety can comprise, e.g., a synthetic polymer (e.g., PEG), a natural ligand/molecule (e.g., CD40L, albumin, CD47, CD24, CD55, CD59), and/or a recombinant protein (e.g., XTEN).</p><p id="p-0570" num="0651">In some aspects, a tropism moiety can increase uptake of the EV, e.g., an exosome, by a cell. In some aspects, the tropism moiety that can increase uptake of the EV, e.g., an exosome, by a cell comprises a lymphocyte antigen 75 (also known as DEC205 or CD205), C-type lectin domain family 9 member A (CLEC9A), C-type lectin domain family 6 (CLEC6), C-type lectin domain family 4 member A (also known as DCIR or CLEC4A), Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (also known as DC-SIGN or CD209), lectin-type oxidized LDL receptor 1 (LOX-1), macrophage receptor with collagenous structure (MARCO), C-type lectin domain family 12 member A (CLEC12A), C-type lectin domain family 10 member A (CLEC10A), DC-asialoglycoprotein receptor (DC-ASGPR), DC immunoreceptor 2 (DCIR2), Dectin-1, macrophage mannose receptor (MMR), BDCA-2 (CD303, CLEC4C), Dectin-2, BST-2 (CD317), Langerin, CD206, CD11b, CD11c, CD123, CD304, XCR1, AXL, SIGLEC 6, CD209, SIRPA, CX3CR1, GPR182, CD14, CD16, CD32, CD34, CD38, CD10, anti-CD3 antibody, or any combination thereof.</p><p id="p-0571" num="0652">In some aspects, when tropism to the central nervous system is desired, an EV, e.g., exosome, of the present disclosure can comprise a tissue or cell-specific target ligand, which increases EV, e.g., exosome, tropism to a specific central nervous system tissue or cell. In some aspects, the cell is a glial cell. In some aspects, the glial cell is an oligodendrocyte, an astrocyte, an ependymal cell, a microglia cell, a Schwann cell, a satellite glial cell, an olfactory ensheathing cell, or a combination thereof. In some aspects, the cell is a neural stem cell. In some aspects, the cell-specific target ligand, which increases EV, e.g., exosome, tropism to a Schwann cells binds to a Schwann cell surface marker such as Myelin Basic Protein (MBP), Myelin Protein Zero (P0), P75NTR, NCAM, PMP22, or any combination thereof. In some aspects, the cell-specific tropism moiety comprises an antibody or an antigen-binding portion thereof, an aptamer, or an agonist or antagonist of a receptor expressed on the surface of the Schwann cell.</p><p id="p-0572" num="0653">In some aspects, the bio-distribution modifying agent or targeting moiety comprises an antigen-binding moiety that binds an antigen expressed on a tumor cell. In some aspects, the bio-distribution modifying agent or targeting moiety comprises an antigen-binding moiety that binds an antigen expressed in a tumor microenvironment. In some aspects, the bio-distribution modifying agent or targeting moiety comprises an antigen-binding moiety that binds mesothelin. Any antigen-binding moiety known in the art that is capable of binding mesothelin can be used in the EVs disclosed herein. In some aspects, bio-distribution modifying agent or targeting moiety comprises an antigen-binding moiety that binds CD33. Any antigen-binding moiety known in the art that is capable of binding CD33 can be used in the EVs disclosed herein. In certain aspects, the antigen-binding moiety that binds CD33 is selected from the anti-CD33 binding moieties disclosed in U.S. Pat. No. 5,877,296, which is incorporated by reference herein in its entirety.</p><p id="p-0573" num="0654">In principle, the EVs, e.g., exosomes of the present disclosure comprising at least one tropism moiety that can direct the EV, e.g., exosome, to a specific target cell or tissue (e.g., a cell in the CNS or a Schwann cell in peripheral nerves) can be administered using any suitable administration method known in the art (e.g., intravenous injection or infusion) since the presence of the tropism moiety (alone or in combination with the presence of an antiphagocytic signal such as CD47 and the use of a specific administration route) will induce a tropism of the EVs, e.g., exosomes, towards the desired target cell or tissue.</p><p id="p-0574" num="0655">In certain aspects, the tropism moiety is linked, e.g., chemically linked via a maleimide moiety, to a scaffold moiety, e.g., a Scaffold X protein or a fragment thereof, on the exterior surface of the EV, e.g., exosome. Tropism can be further improved by the attachment of an anti-phagocytic signal (e.g., CD47 and/or CD24), a half-life extension moiety (e.g., albumin or PEG), or any combination thereof to the external surface of an EV, e.g., exosome of the present disclosure. In certain aspects, the anti-phagocytic signal is linked, e.g., chemically linked via a maleimide moiety, to a scaffold moiety, e.g., a Scaffold X protein or a fragment thereof, on the exterior surface of the EV, e.g., exosome.</p><p id="p-0575" num="0656">Pharmacokinetics, biodistribution, and in particular tropism and retention in the desired tissue or anatomical location can also be accomplished by selecting the appropriate administration route (e.g., intrathecal administration or intraocular administration to improve tropism to the central nervous system).</p><p id="p-0576" num="0657">In some aspects, the EV, e.g., exosome, comprises at least two different tropism moieties. In some aspects, the EV, e.g., exosome, comprises three different tropism moieties. In some aspects, the EV, e.g., exosome, comprises four different tropism moieties. In some aspects, the EV, e.g., exosome, comprises five or more different tropism moieties. In some aspects, one or more of the tropism moieties increases uptake of the EV, e.g., exosome, by a cell. In some aspects, each tropism moiety is attached to a scaffold moiety, e.g., a Scaffold X protein or a fragment thereof. In some aspects, multiple tropism moieties can be attached to the same scaffold moiety, e.g., a Scaffold X protein or a fragment thereof. In some aspects, several tropism moieties can be attached in tandem to a scaffold moiety, e.g., a Scaffold X protein or a fragment thereof. In some aspects, a tropism moiety disclosed herein or a combination thereof is attached to a scaffold moiety, e.g., a Scaffold X protein or a fragment thereof, via a linker or spacer. In some aspects, a linker or spacer or a combination thereof is interposed between two tropism moieties disclosed herein.</p><p id="p-0577" num="0658">Non-limiting examples of tropism moieties capable of directing EVs, e.g., exosomes, of the present disclosure to different nervous system cell types are disclosed below.</p><heading id="h-0089" level="1">III.E.1. Tropism Moieties Targeting Schwann Cells</heading><p id="p-0578" num="0659">In some aspects, a tropism moiety can target a Schwann cell. In some aspects, the tropism moiety that directs an EV, e.g., exosome, disclosed herein to a Schwann cell targets, e.g., a transferrin receptor (TfR), apolipoprotein D (ApoD), Galectin 1 (LGALS1), Myelin proteolipid protein (PLP), Glypican 1, or Syndecan 3. In some aspects, the tropism moiety directing an EV, e.g., exosome, of the present disclosure to a Schwann cell is a transferrin, or a fragment, variant or derivative thereof.</p><p id="p-0579" num="0660">In some aspects, a tropism moiety of the present disclosure targets a transferrin receptor (TfR). Transferrin receptors, e.g., TfR1 or TfR2, are carrier proteins for transferrin. Transferrin receptors import iron by internalizing the transferrin-ion complex through receptor-mediated endocytosis.</p><p id="p-0580" num="0661">TfR1 (see, e.g., UniProt P02786 TFR1_Human) or transferrin receptor 1 (also known as cluster of differentiation 71 or CD71) is expressed on the endothelial cells of the blood-brain barrier (BBB). TfR1 is known to be expressed in a variety of cells such as red blood cells, monocytes, hepatocytes, intestinal cells, and erythroid cells, and is upregulated in rapidly dividing cells such as tumor cells (non small cell lung cancer, colon cancer, and leukemia) as well as in tissue affected by disorders such as acute respiratory distress syndrome (ARDS). TfR2 is primarily expressed in liver and erythroid cells, is found to a lesser extent in lung, spleen and muscle, and has a 45% identity and 66% similarity with TfR1. TfR1 is a transmembrane receptor that forms a homodimer of 760 residues with disulfide bonds and a molecular weight of 90 kDa. Affinity for transferrin varies between the two receptor types, with the affinity for TfR1 being at least 25-30 fold higher than that of TfR2.</p><p id="p-0581" num="0662">Binding to TfR1 allows the transit of large molecules, e.g., antibodies, into the brain. Some TfR1-targeting antibodies have been shown to cross the blood-brain barrier, without interfering with the uptake of iron. Amongst those are the mouse anti rat-TfR antibody OX26 and the rat anti mouse-TfR antibody 8D3. The affinity of the antibody-TfR interaction is important to determine the success of transcytotic transport over endothelial cells of the BBB. Monovalent TfR interaction favors BBB transport due to altered intracellular sorting pathways. Avidity effects of bivalent interactions redirecting transport to the lysosome. Also, reducing TfR binding affinity directly promote dissociation from the TfR which increase brain parenchymal exposure of the TfR binding antibody. See, e g., U.S. Pat. No. 8,821,943, which is herein incorporated by reference in its entirety. Accordingly, in some aspects, a tropism moiety of the present disclosure can comprise a ligand that can target TfR, e.g., target TfR1, such as transferrin, or an antibody or other binding molecule capable of specifically binding to TfR. In some aspects, the antibody targeting a transferrin receptor is a low affinity anti-transferring receptor antibody (see, e.g., US20190202936A1 which is herein incorporated by reference in its entirety).</p><p id="p-0582" num="0663">In some aspects, the tropism moiety comprises all or a portion (e.g., a binding portion) of a ligand for a transferrin receptor, for example a human transferrin available in GenBank as Accession numbers NM001063, XM002793, XM039847, NM002343 or NM013900, among others, or a variant, fragment, or derivative thereof.</p><p id="p-0583" num="0664">In some aspects, the tropism moiety comprises a transferrin-receptor-targeting moiety, i.e., a targeting moiety directed to a transferrin receptor. Suitable transferrin-receptor-targeting moieties include a transferrin or transferrin variant, such as, but not limited to, a serum transferrin, lacto transferrin (lactoferrin) ovotransferrin, or melanotransferrin. Transferrins are a family of nonheme iron-binding proteins found in vertebrates, including serum transferrins, lacto transferrins (lactoferrins), ovotransferrins, and melanotransferrins. Serum transferrin is a glycoprotein with a molecular weight of about 80 kDa, comprising a single polypeptide chain with two N-linked polysaccharide chains that are branched and terminate in multiple antennae, each with terminal sialic acid residues. There are two main domains, the N domain of about 330 amino acids, and the C domain of about 340 amino acids, each of which is divided into two subdomains, N1 and N2, and C1 and C2. Receptor binding of transferrin occurs through the C domain, regardless of glycosylation.</p><p id="p-0584" num="0665">In some aspects, the tropism moiety is a serum transferrin or transferrin variant such as, but not limited to a hexasialo transferrin, a pentasialo transferrin, a tetrasialo transferrin, a trisialo transferrin, a disialo transferrin, a monosialo transferrin, or an asialo transferrin, or a carbohydrate-deficient transferrin (CDT) such as an asialo, monosialo or disialo transferrin, or a carbohydrate-free transferrin (CFT) such as an asialo transferrin. In some aspects, the tropism moiety is a transferrin variant having the N-terminal domain of transferrin, the C-terminal domain of transferrin, the glycosylation of native transferrin, reduced glycosylation as compared to native (wild-type) transferrin, no glycosylation, at least two N terminal lobes of transferrin, at least two C terminal lobes of transferrin, at least one mutation in the N domain, at least one mutation in the C domain, a mutation wherein the mutant has a weaker binding avidity for transferrin receptor than native transferrin, and/or a mutation wherein the mutant has a stronger binding avidity for transferrin receptor than native transferrin, or any combination of the foregoing.</p><p id="p-0585" num="0666">In some aspects, the tropism moiety targeting a transferrin receptor comprises an anti-trasferrin receptor variable new antigen receptor (vNAR), e.g., a binding domain with a general motif structure (FW1-CDR1-FW2-3-CDR3-FW4). See, e.g., U.S. 2017-0348416, which is herein incorporated by reference in its entirety, vNARs are key component of the adaptive immune system of sharks. At only 11 kDa, these single-domain structures are the smallest IgG-like proteins in the animal kingdom and provide an excellent platform for molecular engineering and biologics drug discovery, vNAR attributes include high affinity for target, ease of expression, stability, solubility, multi-specificity, and increased potential for solid tissue penetration. See Ubah et al. Biochem. Soc. Trans. (2018) 46(6):1559-1565.</p><p id="p-0586" num="0667">In some aspects, the tropism moiety comprises a vNAR domain capable of specifically binding to TfR1, wherein the vNAR domain comprises or consists essentially of a vNAR scaffold with any one CDR1 peptide in Table 1 of U.S. 2017-0348416 in combination with any one CDR3 peptide in Table 1 of U.S. 2017-0348416.</p><p id="p-0587" num="0668">In some aspects, a tropism moiety of the present disclosure targets ApoD. Unlike other lipoproteins, which are mainly produced in the liver, apolipoprotein D is mainly produced in the brain, cerebellum, and peripheral nerves. ApoD is 169 amino acids long, including a secretion peptide signal of 20 amino acids. It contains two glycosylation sites (aspargines 45 and 78) and the molecular weight of the mature protein varies from 20 to 32 kDa. ApoD binds steroid hormones such as progesterone and pregnenolone with a relatively strong affinity, and to estrogen with a weaker affinity. Arachidonic acid (AA) is an ApoD ligand with a much better affinity than that of progesterone or pregnenolone. Other ApoD ligands include E-3-methyl-2-hexenoic acid, retinoic acid, sphingomyelin and sphingolipids. Accordingly, in some aspects, a tropism moiety of the present disclosure comprises a ligand that can target ApoD, e.g., an antibody or other binding molecule capable of specifically binding to ApoD.</p><p id="p-0588" num="0669">In some aspects, a tropism moiety of the present disclosure targets Galectin 1. The galectin-1 protein is 135 amino acids in length. Accordingly, in some aspects, a tropism moiety of the present disclosure comprises a ligand that can target Galectin 1, e.g., an antibody or other binding molecule capable of specifically binding to Galectin 1.</p><p id="p-0589" num="0670">In some aspects, a tropism moiety of the present disclosure targets PLP. PLP is the major myelin protein from the CNS. It plays an important role in the formation or maintenance of the multilamellar structure of myelin. The myelin sheath is a multi-layered membrane, unique to the nervous system that functions as an insulator to greatly increase the efficiency of axonal impulse conduction. PLP is a highly conserved hydrophobic protein of 276 to 280 amino acids which contains four transmembrane segments, two disulfide bonds and which covalently binds lipids (at least six palmitate groups in mammals). Accordingly, in some aspects, a tropism moiety of the present disclosure comprises a ligand that can target PLP, e.g., an antibody or other binding molecule capable of specifically binding to PLP.</p><p id="p-0590" num="0671">In some aspects, a tropism moiety of the present disclosure targets Glypican 1. Accordingly, in some aspects, a tropism moiety of the present disclosure comprises a ligand that can target Glypican 1, e.g, an antibody or other binding molecule capable of specifically binding to Glypican 1. In some aspects, a tropism moiety of the present disclosure targets Syndecan 3. Accordingly, in some aspects, a tropism moiety of the present disclosure comprises a ligand that can target Syndecan 3, e.g., an antibody or other binding molecule capable of specifically binding to Syndecan 3.</p><heading id="h-0090" level="1">III.E.2. Tropism Moieties Targeting Sensory Neurons</heading><p id="p-0591" num="0672">In some aspects, a tropism moiety disclosed herein can direct an EV, e.g, exosome, disclosed herein to a sensory neuron. In some aspects, the tropism moiety that directs an EV, e.g, exosome, disclosed herein to a sensory neuron targets a Trk receptor, e.g., TrkA, TrkB, TrkC, or a combination thereof.</p><p id="p-0592" num="0673">Trk (tropomyosin receptor kinase) receptors are a family of tyrosine kinases that regulates synaptic strength and plasticity in the mammalian nervous system. The common ligands of Trk receptors are neurotrophins, a family of growth factors critical to the functioning of the nervous system. The binding of these molecules is highly specific. Each type of neurotrophin has different binding affinity toward its corresponding Trk receptor. Accordingly, in some aspects, the tropism moiety directing an EV, e.g, exosome, disclosed herein to a sensory neuron, comprises a neurotrophin.</p><p id="p-0593" num="0674">Neurotrophins bind to Trk receptors as homodimers. Accordingly, in some aspects, the tropism moiety comprises at least two neurotrophins disclosed herein, e.g., in tandem. In some aspects, the tropism moiety comprises at least two neurotrophins disclosed herein, e.g., in tandem, that are attached to a scaffold protein, for example, Protein X, via a linker. In some aspects, the linker connecting the scaffold protein, e.g., Protein X, to the neurotrophin (e.g., a neurotrophin homodimer) has a length of at least 10 amino acids. In some aspects, the linker connecting the scaffold protein, e.g., Protein X, to the neurotrophin (e.g., a neurotrophin homodimer) has a length of at least about 25 amino acids, about 30 amino acids, about 35 amino acids, about 40 amino acids, about 45 amino acids, or about 50 amino acids.</p><p id="p-0594" num="0675">In some aspects, the neurotrophin is a neurotrophin precursor, i.e., a proneurotrophin, which is later cleaved to produce a mature protein.</p><p id="p-0595" num="0676">Nerve growth factor (NGF) is the first identified and probably the best characterized member of the neurotrophin family. It has prominent effects on developing sensory and sympathetic neurons of the peripheral nervous system. Brain-derived neurotrophic factor (BDNF) has neurotrophic activities similar to NGF, and is expressed mainly in the CNS and has been detected in the heart, lung, skeletal muscle and sciatic nerve in the periphery (Leibrock, J, et al., Nature, 341:149-152 (1989)). Neurotrophin-3 (NT-3) is the third member of the NGF family and is expressed predominantly in a subset of pyramidal and granular neurons of the hippocampus, and has been detected in the cerebellum, cerebral cortex and peripheral tissues such as liver and skeletal muscles (Emfors, P, et al., Neuron 1: 983-996 (1990)). Neurotrophin-4 (also called NT-415) is the most variable member of the neurotrophin family. Neurotrophin-6 (NT-5) was found in teleost fish and binds to p75 receptor.</p><p id="p-0596" num="0677">In some aspects, the neurotrophin targeting TrkB comprises, e.g., NT-4 or BDNF, or a fragment, variant, or derivative thereof. In some aspects, the neurotrophin targeting TrkA comprises, e.g., NGF or a fragment, variant, or derivative thereof. In some aspects, the neurotrophin targeting TrkC comprises, e.g., NT-3 or a fragment, variant, or derivative thereof.</p><p id="p-0597" num="0678">In some aspects, the tropism moiety comprises brain derived neurotrophic factor (BDNF). In some aspects, the BDNF is a variant of native BDNF, such as a two amino acid carboxyl-truncated variant. In some aspects, the tropism moiety comprises the full-length 119 amino acid sequence of BDNF (HSDPARRCELSVCDSISEWVTAADKKTAVDMSCGTVTVLEKVPVSKGQLKQYFYETKCNPMG YTKEGCRGIDKRHWNSQCRTTQSYVRALTMDSKKRIGWRFIRIDTSCVCTLTIKRGR; SEQ ID NO: 161). In some aspects, a one amino-acid carboxy-truncated variant of BDNF is utilized (amino acids 1-118 of SEQ ID NO: 161)</p><p id="p-0598" num="0679">In some aspects, the tropism moiety comprises a carboxy-truncated variant of the native BDNF, e.g., a variant in which 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 amino acids are absent from the carboxy-terminus of the BDNF. BDNF variants include the complete 119 amino acid BDNF, the 117 or 118 amino acid variant with a truncated carboxyl terminus, variants with a truncated amino terminus, or variants with up to about 20%, about 30, or about 40% change in amino acid composition, as long as the protein variant still binds to the TrkB receptor with high affinity.</p><p id="p-0599" num="0680">In some aspects, the tropism moiety comprises a two amino-acid carboxy-truncated variant of BDNF (amino acids 1-117 of SEQ ID NO: 161). In some aspects, the tropism moiety comprises a three amino-acid carboxy-truncated variant of BDNF (amino acids 1-116 of SEQ ID NO: 161). In some aspects, the tropism moiety comprises a four amino-acid carboxy-truncated variant of BDNF (amino acids 1-115 of SEQ ID NO: 161). In some aspects, the tropism moiety comprises a five amino-acid carboxy-truncated variant of BDNF (amino acids 1-114 of SEQ ID NO: 161). In some aspects, the tropism moiety comprises a BDNF that is at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or about 100% identical with the sequence of SEQ ID NO: 161, or a truncated version thereof, e.g., the 117 or 118 amino acid variant with a one- or two-amino acid truncated carboxyl terminus, or variants with a truncated amino terminus. See, e.g., U.S. Pat. No. 8,053,569B2, which is herein incorporated by reference in its entirety.</p><p id="p-0600" num="0681">In some aspects, the tropism moiety comprises nerve growth factor (NGF). In some aspects, the NGF is a variant of native NGF, such as a truncated variant. In some aspects, the tropism moiety comprises the 26-kDa beta subunit of protein, the only component of the 7S NGF complex that is biologically active. In some aspects, the tropism moiety comprises the full-length 120 amino acid sequence of beta NGF (SSSHPIFHRGEFSVCDSVSVWVGDKTTATDIKGKEVMVLGEVNINNSVFKQYFFETKCRDPNPV DSGCRGIDSKHWNSYCITHTFVKALTMDGKQAAWRFIRIDTACVCVLSRKAVRRA; SEQ ID NO: 162). In some aspects, the tropism moiety comprises a carboxy-truncated variant of the native NGF, e.g., a variant in which 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 amino acids are absent from the carboxy-terminus of NGF. NGF variants include the complete 120 amino acid NGF, the shorter amino acid variants with a truncated carboxyl terminus, variants with a truncated amino terminus, or variants with up to about 20%, about 30%, or about 40% change in amino acid composition, as long as the tropism moiety still binds to the TrkB receptor with high affinity. In some aspects, the tropism moiety comprises an NGF that is at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or about 100% identical with the sequence of SEQ ID NO: 162, or a truncated version thereof.</p><p id="p-0601" num="0682">In some aspects, the tropism moiety comprises neurotrophin-3 (NT-3). In some aspects, the NT-3 is a variant of native NT-3, such as a truncated variant. In some aspects, the tropism moiety comprises the full-length 119 amino acid sequence of NT-3 (YAEHKSHRGEYSVCDSESLWVTDKSSAIDIRGHQVTVLGEIKTGNSPVKQYFYETRCKEARPVK NGCRGIDDKHWNSQCKTSQTYVRALTSENNKLVGWRWIRIDTSCVCALSRKIGRT; SEQ ID NO: 163). In some aspects, the tropism moiety comprises a carboxy-truncated variant of the native NT-3, e.g., a variant in which 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 amino acids are absent from the carboxy-terminus of NT-3. NT-3 variants include the complete 119 amino acid NT-3, the shorter amino acid variants with a truncated carboxyl terminus, variants with a truncated amino terminus, or variants with up to about 20%, about 30%, or about 40% change in amino acid composition, as long as the tropism moiety still binds to the TrkC receptor with high affinity. In some aspects, the tropism moiety comprises an NT-3 that is at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or about 100% identical with the sequence of SEQ ID NO: 163, or a truncated version thereof.</p><p id="p-0602" num="0683">In some aspects, the tropism moiety comprises neurotrophin-4 (NT-4). In some aspects, the NT-4 is a variant of native NT-4, such as a truncated variant. In some aspects, the tropism moiety comprises the full-length 130 amino acid sequence of NT-4 (GVSETAPASRRGELAVCDAVSGWVTDRRTAVDLRGREVEVLGEVPAAGGSPLRQYFFETRCKA DNAEEGGPGAGGGGCRGVDRRHWVSECKAKQSYVRALTADAQGRVGWRWIRIDTACVCTLLS RTGRA; SEQ ID NO: 164). In some aspects, the tropism moiety comprises a carboxy-truncated variant of the native NT-4, e.g., a variant in which 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 amino acids are absent from the carboxy-terminus of NT-4. NT-4 variants include the complete 130 amino acid NT-4, the shorter amino acid variants with a truncated carboxyl terminus, variants with a truncated amino terminus, or variants with up to about 20%, about 30%, or about 40% change in amino acid composition, as long as the tropism moiety still binds to the TrkB receptor with high affinity. In some aspects, the tropism moiety comprises an NT-4 that is at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or about 100% identical with the sequence of SEQ ID NO: 164, or a truncated version thereof.</p><p id="p-0603" num="0684">Structure/function relationship studies of NGF and NGF-related recombinant molecules demonstrated that mutations in NGF region 25-36, along with other &#x3b2;-hairpin loop and non-loop regions, significantly influenced NGF/NGF-receptor interactions (Ibanez et al., EMBO J., 10, 2105-2110, (1991)). Small peptides derived from this region have been demonstrated to mimic NGF in binding to Mock receptor and affecting biological responses (LeSauteur et al. J. Biol. Chem. 270, 6564-6569, 1995). Dimers of cyclized peptides corresponding to &#x3b2;-loop regions of NGF were found to act as partial NGF agonists in that they had both survival-promoting and NGF-inhibiting activity while monomer and linear peptides were inactive (Longo et al., J. Neurosci. Res., 48, 1-17, 1997). Accordingly, in some aspects, a tropism moiety of the present disclosure comprises such peptides.</p><p id="p-0604" num="0685">Cyclic peptides have also been designed and synthesized to mimic the &#x3b2;-loop regions of NGF, BDNF, NT3 and NT-4/5. Certain monomers, dimers or polymers of these cyclic peptides can have a three-dimensional structure, which binds to neurotrophin receptors under physiological conditions. All of these structural analogs of neurotrophins that bind to nerve cell surface receptors and are internalized can serve as the binding agent B of the compound according to the present disclosure to deliver the conjugated therapeutic moiety TM to the nervous system. Accordingly, in some aspects, a tropism moiety of the present disclosure comprises such cyclic peptides or combinations thereof.</p><p id="p-0605" num="0686">In some aspects, antibodies against nerve cell surface receptors that are capable of binding to the receptors and being internalized can also serve as tropism moieties binding to a Trk receptor. For example, monoclonal antibody (MAb) 5C3 is specific for the NGF docking site of the human p140 TrkA receptor, with no cross-reactivity with human TrkB receptor. MAb 5C3 and its Fab mimic the effects of NGF in vitro, and image human Trk-A positive tumors in vivo (Kramer et al., Eur. J. Cancer, 33, 2090-2091, (1997)). Molecular cloning, recombination, mutagenesis and modeling studies of Mab 5C3 variable region indicated that three or less of its complementarity determining regions (CDRs) are relevant for binding to TrkA. Assays with recombinant CDRs and CDR-like synthetic polypeptides demonstrated that they had agonistic bioactivities similar to intact Mab 5C3. Monoclonal antibody MC192 against p75 receptor has also been demonstrated to have neurotrophic effects. Therefore, these antibodies and their functionally equivalent fragments can also serve as tropism moieties of the present disclosure.</p><p id="p-0606" num="0687">In some aspects, peptidomimetics that are synthesized by incorporating unnatural amino acids or other organic molecules can also serve tropism moieties of the present disclosure.</p><p id="p-0607" num="0688">Other neurotrophins are known in the art. Accordingly, in some aspects, the target moiety comprises a neurotrophin selected from the group consisting of fibroblast growth factor (FGF)-2 and other FGFs, erythropoietin (EPO), hepatocyte growth factor (HGF), epidermal growth factor (EGF), transforming growth factor (TGF)-a, TGF-(3, vascular endothelial growth factor (VEGF), interleukin-1 receptor antagonist (IL-Ira), ciliary neurotrophic factor (CNTF), glial-derived neurotrophic factor (GDNF), neurturin, platelet-derived growth factor (PDGF), heregulin, neuregulin, artemin, persephin, interleukins, granulocyte-colony stimulating factor (CSF), granulocyte-macrophage-CSF, netrins, cardiotrophin-1, hedgehogs, leukemia inhibitory factor (LIF), midlcine, pleiotrophin, bone morphogenetic proteins (BMPs), netrins, saposins, semaphorins, and stem cell factor (SCF).</p><p id="p-0608" num="0689">In some aspects, the tropism moiety directing an EV, e.g, exosome, disclosed herein to a sensory neuron, comprises a varicella zoster virus (VZV) peptide.</p><heading id="h-0091" level="1">III.E.3. Tropism Moieties Targeting Motor Neurons</heading><p id="p-0609" num="0690">In some aspects, a tropism moiety disclosed herein can direct an EV, e.g, exosome, disclosed herein to a motor neuron. In some aspects, the tropism moiety that directs an EV, e.g, exosome, disclosed herein to a motor comprises a Rabies Virus Glycoprotein (RVG) peptide, a Targeted Axonal Import (TAxI) peptide, a P75R peptide, or a Tet-C peptide.</p><p id="p-0610" num="0691">In some aspects, the tropism moiety comprises a Rabies Virus Glycoprotein (RVG) peptide. See, e.g., U.S. Pat. App. Publ. 2014-00294727, which is herein incorporated by reference in its entirety. In some aspects, the RVG peptide comprises amino acid residues 173-202 of the RVG (YTIWMPENPRPGTPCDIFTNSRGKRASNG; SEQ ID NO: 601) or a variant, fragment, or derivative thereof. In some aspects, the tropism moiety is a fragment of SEQ ID NO: 601. Such a fragment of SEQ ID NO: 601 can have, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids deleted from the N-terminal and/or the C-terminal of SEQ ID NO: 601. A functional fragment derived from SEQ ID NO: 601 can be identified by sequentially deleting N- and/or C-terminal amino acids from SEQ ID NO: 601 and assessing the function of the resulting peptide fragment, such as function of the peptide fragment to bind acetylcholine receptor and/or ability to transmit through the blood brain barrier. In some aspects, the tropism moiety comprises a fragment of SEQ ID NO: 601 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16 or 15 amino acids in length. In some aspects, the tropism moiety comprises a fragment of SEQ ID NO: 601 less than 15 peptides in length.</p><p id="p-0611" num="0692">A &#x201c;variant&#x201d; of a RGV peptide, for example SEQ ID NO: 601, is meant to refer to a molecule substantially similar in structure and function, i.e., where the function is the ability to pass or transit through the BBB, to either the entire molecule, or to a fragment thereof. A variant of an RVG peptide can contain a mutation or modification that differs from a reference amino acid in SEQ ID NO: 601. In some aspects, a variant of SEQ ID NO: 601 is a fragment of SEQ ID NO: 601 as disclosed herein. In some aspects, an RVG variant can be a different isoform of SEQ ID NO: 601 or can comprise different isomer amino acids. Variants can be naturally-occurring, synthetic, recombinant, or chemically modified polynucleotides or polypeptides isolated or generated using methods well known in the art. RVG variants can include conservative or non-conservative amino acid changes. See, e.g., U.S. Pat. No. 9,757,470, which is herein incorporated by reference in its entirety.</p><p id="p-0612" num="0693">In some aspects, the tropism moiety comprises a Targeted Axonal Import (TAxI) peptide. In some aspects, the TAxI peptide is cyclized TAxI peptide of sequence SACQSQSQMRCGGG (SEQ ID NO: 602). See, e.g., Sellers et al. (2016) Proc. Natl. Acad. Sci. USA 113:2514-2519, and U.S. Pat. No. 9,056,892, which are herein incorporated by reference in their entireties. TAxI transport peptides as described herein may be of any length. Typically, the transport peptide will be between 6 and 50 amino acids in length, more typically between 10 and 20 amino acids in length. In some aspects, the TAxI transport peptide comprises the amino acid sequence QSQSQMR (SEQ ID NO. 603). ASGAQAR (SEQ ID NO: 604), PF, or TSTAPHLRLRLTSR (SEQ ID NO: 605). Optionally, the TAxI transport peptide further includes a flanking sequence to facilitate incorporation into a delivery construct or carrier, e.g., a linker. In one aspect, the peptide is flanked with cysteines. In some aspects, the TAxI transport peptide further comprises additional sequence selected to facilitate delivery into nuclei. For example, a peptide that facilitates nuclear delivery is a nuclear localizing signal (NLS). Typically, this signal consists of a few short sequences of positively charged lysines or arginines, such as PPKKRKV (SEQ ID NO: 606). In one aspect, the NLS has the amino acid sequence PKKRKV (SEQ ID NO: 607).</p><p id="p-0613" num="0694">In some aspects, a tropism moiety of the present disclosure comprises a peptide BBB shuttle disclosed in the table below. See, e.g., Oller-Salvia et al. (2016) Chem. Soc. Rev. 45, 4690-4707, and Jafari et al. (2019) Expert Opinion on Drug Delivery 16:583-605 which are herein incorporated by reference in their entireties.</p><p id="p-0614" num="0000"><tables id="TABLE-US-00007" num="00007"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="21pt" align="left"/><colspec colname="2" colwidth="77pt" align="left"/><colspec colname="3" colwidth="105pt" align="left"/><thead><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row><row><entry/><entry>SEQ</entry><entry/><entry/></row><row><entry/><entry>ID</entry><entry/><entry/></row><row><entry/><entry>NO</entry><entry>Peptide</entry><entry>Sequence</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/><entry>608</entry><entry>Angiopep-2</entry><entry>TFFYGGSRGKRNNFKTEEY-<i>OH</i></entry></row><row><entry/><entry> </entry></row><row><entry/><entry>609</entry><entry>ApoB&#x2003;(3371-3409)</entry><entry>SSVIDALQYKLEGTTRLTRK-</entry></row><row><entry/><entry/><entry/><entry>RGLKLATALSLSNKFVEGS</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>610</entry><entry>ApoE&#x2003;(159-167)2</entry><entry>(LRKLRKRLL)<sub>2</sub></entry></row><row><entry/><entry> </entry></row><row><entry/><entry>611</entry><entry>Peptide-22</entry><entry><i>Ac</i>-C(&#x26;)MPRLRGC(&#x26;)-<i>NH</i><sub>2</sub></entry></row><row><entry/><entry> </entry></row><row><entry/><entry>612</entry><entry>THR</entry><entry>THRPPMWSPVWP-<i>NH</i><sub>2</sub></entry></row><row><entry/><entry> </entry></row><row><entry/><entry>613</entry><entry>THR&#x2003;retro-enantio</entry><entry>pwvpswmpprht-<i>NH</i><sub>2</sub></entry></row><row><entry/><entry> </entry></row><row><entry/><entry>614</entry><entry>CRT</entry><entry>C(&#x26;)RTIGPSVC(&#x26;)</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>615</entry><entry>Leptin30</entry><entry>YQQILTSMPSRNVIQISND-</entry></row><row><entry/><entry/><entry/><entry>LENLRDLLHVL</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>616</entry><entry>RVG29</entry><entry>YTIWMPENPRPGTPCDIFT-</entry></row><row><entry/><entry/><entry/><entry>NSRGKRASNG-<i>OH</i></entry></row><row><entry/><entry> </entry></row><row><entry/><entry>617</entry><entry><sup>D</sup>CDX</entry><entry>GreirtGraerwsekf-<i>OH</i></entry></row><row><entry/><entry> </entry></row><row><entry/><entry>618</entry><entry>Apamin</entry><entry>C(&#x26;<sub>1</sub>)NC(&#x26;<sub>2</sub>)KAPETALC(&#x26;<sub>1</sub>)-</entry></row><row><entry/><entry/><entry/><entry>AR-RC(&#x26;<sub>2</sub>)QQH-<i>NH</i><sub>2</sub></entry></row><row><entry/><entry> </entry></row><row><entry/><entry>619</entry><entry>MiniAp-4</entry><entry>[Dap](&#x26;)KAPETALD(&#x26;)</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>620</entry><entry>GSH</entry><entry>&#x3b3;-L-glutamyl-CG-<i>OH</i></entry></row><row><entry/><entry> </entry></row><row><entry/><entry>621</entry><entry>G23</entry><entry>HLNILSTLWKYRC</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>622</entry><entry>87</entry><entry>GFtGFLS(<i>O</i>-&#x3b2;-Glc)-<i>NH</i><sub>2</sub></entry></row><row><entry/><entry> </entry></row><row><entry/><entry>623</entry><entry>TGN</entry><entry>TGNYKALHPHNG</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>624</entry><entry>TAT&#x2003;(47-57)</entry><entry>YGRKKRRQRRR-<i>NH</i><sub>2</sub></entry></row><row><entry/><entry> </entry></row><row><entry/><entry>625</entry><entry>SynBI</entry><entry>RGGRLSYSRRRFSTSTGR</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>626</entry><entry>Diketopiperazines</entry><entry>&#x26;(<i>N</i>-MePhe)-(<i>N</i>-MePhe)</entry></row><row><entry/><entry/><entry/><entry>Diketo-piperazines</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>627</entry><entry>PhPro</entry><entry>(Phenylproline)<sub>4</sub>-<i>NH</i><sub>2</sub></entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables><br/>Nomenclature for cyclic peptides (&#x26;) is adapted to the 3-letter amino acid code from the one described by Spengler et al-. <i>Pept. Res., </i>2005, 65, 550-555 [Dap] stands for diaminopropionic acid.</p><heading id="h-0092" level="1">III.F. Anti-Phagocytic Signal</heading><p id="p-0615" num="0695">Clearance of administered EVs, e.g., exosomes, by the body's immune system can reduce the efficacy of an administered EV, e.g., exosome, therapy. In some aspects, the surface of the EV, e.g., exosome, is modified to limit or block uptake of the EV, e.g., exosome, by cells of the immune system, e.g., macrophages. In some aspects, the surface of the EV, e.g., exosome, is modified to express one or more surface antigen that inhibits uptake of the EV, e.g., exosome, by a macrophage. In some aspects, the surface antigen is associated with the exterior surface of the EV, (e.g., exosome).</p><p id="p-0616" num="0696">Surface antigens useful in the present disclosure include, but are not limited to, antigens that label a cell as a &#x201c;self&#x201d; cell. In some aspects, the surface antigen comprises an anti-phagocytic signal. In some aspects, the anti-phagocytic signal is selected from CD47, CD24, a fragment thereof, and any combination thereof. In certain aspects, the anti-phagocytic signal comprises CD24, e.g., human CD24. In some aspects, the anti-phagocytic signal comprises a fragment of CD24, e.g., human CD24. In certain aspects, the EV, e.g., exosome, is modified to express CD47 or a fragment thereof on the exterior surface of the EV, e.g., exosome.</p><p id="p-0617" num="0697">CD47, also referred to as leukocyte surface antigen CD47 and integrin associated protein (IAP), as used herein, is a transmembrane protein that is found on many cells in the body. CD47 is often referred to as the &#x201c;don't eat me&#x201d; signal, as it signals to immune cells, in particular myeloid cells, that a particular cell expressing CD47 is not a foreign cell. CD47 is the receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction of CD47 with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. CD47 is also known to have a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. CD47 also plays an important role in memory formation and synaptic plasticity in the hippocampus (by similarity). In addition, CD47 can play a role in membrane transport and/or integrin dependent signal transduction, prevent premature elimination of red blood cells, and be involved in membrane permeability changes induced following virus infection.</p><p id="p-0618" num="0698">In some aspects, an EV, e.g., exosome, disclosed herein is modified to express a human CD47 on the surface of the EV, e.g., exosome. The canonical amino acid sequence for human CD47 and various known isoforms are disclosed herein (UniProtKB-Q08722) as SEQ ID NOs: 629-632. In some aspects, the EV, e.g., exosome, is modified to express a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 629 or a fragment thereof. In some aspects, the EV, e.g., exosome, is modified to express a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 630 or a fragment thereof. In some aspects, the EV, e.g., exosome, is modified to express a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 631 or a fragment thereof. In some aspects, the EV, e.g., exosome, is modified to express a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 632 or a fragment thereof.</p><p id="p-0619" num="0699">In some aspects, the EV, e.g., exosome, is modified to express full length CD47 on the surface of the EV, e.g., exosome. In some aspects, the EV, e.g., exosome, is modified to express a fragment of CD47 on the surface of the EV, e.g., exosome, wherein the fragment comprises the extracellular domain of CD47, e.g., human CD47. Any fragment of CD47 that retains an ability to block and/or inhibit phagocytosis by a macrophage can be used in the EVs, e.g., exosomes, disclosed herein. In some aspects, the fragment comprises amino acids 19 to about 141 of the canonical human CD47 sequence (e.g., amino acids 19-141 of SEQ ID NO 629). In some aspects, the fragment comprises amino acids 19 to about 135 of the canonical human CD47 sequence (e.g., amino acids 19-135 of SEQ ID NO 629). In some aspects, the fragment comprises amino acids 19 to about 130 of the canonical human CD47 sequence (e.g., amino acids 19-130 of SEQ ID NO 629). In some aspects, the fragment comprises amino acids 19 to about 125 of the canonical human CD47 sequence (e.g., amino acids 19-125 of SEQ ID NO 629).</p><p id="p-0620" num="0700">In some aspects, the EV, e.g., exosome, is modified to express a polypeptide having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to amino acids 19 to about 141 of the canonical human CD47 sequence (e.g., amino acids 19-141 of SEQ ID NO 629). In some aspects, the EV, e.g., exosome, is modified to express a polypeptide having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to amino acids 19 to about 135 of the canonical human CD47 sequence (e.g., amino acids 19-135 of SEQ ID NO 629). In some aspects, the EV, e.g., exosome, is modified to express a polypeptide having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to amino acids 19 to about 130 of the canonical human CD47 sequence (e.g., amino acids 19-130 of SEQ ID NO 629). In some aspects, the EV, e.g., exosome, is modified to express a polypeptide having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to amino acids 19 to about 125 of the canonical human CD47 sequence (e.g., amino acids 19-125 of SEQ ID NO 629).</p><p id="p-0621" num="0701">In some aspects, the CD47 or the fragment thereof is modified to increase the affinity of CD47 and its ligand SIRP&#x3b1;. In some aspects, the fragment of CD47 comprises a Velcro-CD47 (see, e.g., Ho et al., JBC 290:12650-63 (2015), which is incorporated by reference herein in its entirety). In some aspects, the Velcro-CD47 comprises a C15S substitution relative to the wild-type human CD47 sequence (SEQ ID NO: 629).</p><p id="p-0622" num="0702">In some aspects, the EV, e.g., exosome, comprises a CD47 or a fragment thereof expressed on the surface of the EV, e.g., exosome, at a level that is higher than an unmodified EV, e.g., exosome. In some aspects, the CD47 or the fragment thereof is fused with a scaffold protein. Any scaffold protein disclosed herein can be used to express the CD47 or the fragment thereof on the surface of the EV, e.g., exosome. In some aspects, the EV, e.g., exosome, is modified to express a fragment of CD47 fused to the N-terminus of a Scaffold X protein. In some aspects, the EV, e.g., exosome, is modified to express a fragment of CD47 fused to the N-terminus of PTGFRN.</p><p id="p-0623" num="0703">In some aspects, the EV, e.g., exosome, comprises at least about 20 molecules, at least about 30 molecules, at least about 40, at least about 50, at least about 75, at least about 100, at least about 125, at least about 150, at least about 200, at least about 250, at least about 300, at least about 350, at least about 400, at least about 450, at least about 500, at least about 750, or at least about 1000 molecules of CD47 on the surface of the EV, e.g., exosome. In some aspects, the EV, e.g., exosome, comprises at least about 20 molecules of CD47 on the surface of the EV, e.g., exosome. In some aspects, the EV, e.g., exosome, comprises at least about 30 molecules of CD47 on the surface of the EV, e.g., exosome. In some aspects, the EV, e.g., exosome, comprises at least about 40 molecules of CD47 on the surface of the EV, e.g., exosome. In some aspects, the EV, e.g., exosome, comprises at least about 50 molecules of CD47 on the surface of the EV, e.g., exosome. In some aspects, the EV, e.g., exosome, comprises at least about 100 molecules of CD47 on the surface of the EV, e.g., exosome. In some aspects, the EV, e.g., exosome, comprises at least about 200 molecules of CD47 on the surface of the EV, e.g., exosome. In some aspects, the EV, e.g., exosome, comprises at least about 300 molecules of CD47 on the surface of the EV, e.g., exosome. In some aspects, the EV, e.g., exosome, comprises at least about 400 molecules of CD47 on the surface of the EV, e.g., exosome. In some aspects, the EV, e.g., exosome, comprises at least about 500 molecules of CD47 on the surface of the EV, e.g., exosome. In some aspects, the EV, e.g., exosome, comprises at least about 1000 molecules of CD47 on the surface of the EV, e.g., exosome.</p><p id="p-0624" num="0704">In some aspects, expression CD47 or a fragment thereof on the surface of the EV, e.g., exosome, results in decreased uptake of the EV, e.g., exosome, by myeloid cells as compared to an EV, e.g., exosome, not expressing CD47 or a fragment thereof. In some aspects, uptake by myeloid cells of the EV, e.g., exosome, expressing CD47 or a fragment thereof is decreased by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95%, relative to uptake by myeloid cells of EVs, e.g., exosomes, that do not express CD47 or a fragment thereof.</p><p id="p-0625" num="0705">In some aspects, expression CD47 or a fragment thereof on the surface of the EV, e.g., exosome, results in decreased localization of the EV, e.g., exosome, to the liver, as compared to an EV, e.g., exosome, not expressing CD47 or a fragment thereof. In some aspects, localization to the liver of EVs, e.g., exosomes, expressing CD47 or a fragment thereof is decreased by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95%, relative to the localization to the liver of EVs, e.g., exosomes, not expressing CD47 or a fragment thereof.</p><p id="p-0626" num="0706">In some aspects, the in vivo half-life of an EV, e.g., exosome, expressing CD47 or a fragment thereof is increased relative to the in vivo half-life of an EV, e.g., exosome, that does not express CD47 or a fragment thereof. In some aspects, the in vivo half-life of an EV, e.g., exosome, expressing CD47 or a fragment thereof is increased by at least about 1.5-fold, at least about 2-fold, at least about 2.5-fold, at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 4.5-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, or at least about 10-fold, relative to the in vivo half-life of an EV, e.g., exosome, that does not express CD47 or a fragment thereof.</p><p id="p-0627" num="0707">In some aspects, an EV, e.g., exosome, expressing CD47 or a fragment thereof has an increased retention in circulation, e.g., plasma, relative to the retention of an EV, e.g., exosome, that does not express CD47 or a fragment thereof in circulation, e.g., plasma. In some aspects, retention in circulation, e.g., plasma, of an EV, e.g., exosome, expressing CD47 or a fragment thereof is increased by at least about 1.5-fold, at least about 2-fold, at least about 2.5-fold, at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 4.5-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, or at least about 10-fold, relative to the retention in circulation, e.g., plasma, of an EV, e.g., exosome, that does not express CD47 or a fragment thereof.</p><p id="p-0628" num="0708">In some aspects, an EV, e.g., exosome, expressing CD47 or a fragment thereof has an altered biodistribution when compared with an exosome that does not express CD47 or a fragment. In some aspects, the altered biodistribution leads to increased uptake into endothelial cells, T cells, or increased accumulation in various tissues, including, but not limited to skeletal muscle, cardiac muscle, diaphragm, kidney, bone marrow, central nervous system, lungs, cerebral spinal fluid (CSF), or any combination thereof.</p><heading id="h-0093" level="1">IV. Producer Cell for Production of Engineered Exosomes</heading><p id="p-0629" num="0709">EVs, e.g., exosomes, of the present disclosure can be produced from a cell grown in vitro or a body fluid of a subject. When exosomes are produced from in vitro cell culture, various producer cells, e.g., HEK293 cells, CHO cells, and MSCs, can be used. In certain aspects, a producer cell is not a dendritic cell, macrophage, B cell, mast cell, neutrophil, Kupffer-Browicz cell, cell derived from any of these cells, or any combination thereof.</p><p id="p-0630" num="0710">Human embryonic kidney 293 cells, also often referred to as HEK 293, HEK-293, 293 cells, or less precisely as HEK cells, are a specific cell line originally derived from human embryonic kidney cells grown in tissue culture.</p><p id="p-0631" num="0711">HEK 293 cells were generated in 1973 by transfection of cultures of normal human embryonic kidney cells with sheared adenovirus 5 DNA in Alex van der Eb's laboratory in Leiden, the Netherlands. The cells were cultured and transfected by adenovirus. Subsequent analysis has shown that the transformation was brought about by inserting &#x2dc;4.5 kilobases from the left arm of the viral genome, which became incorporated into human chromosome 19.</p><p id="p-0632" num="0712">A comprehensive study of the genomes and transcriptomes of HEK 293 and five derivative cell lines compared the HEK 293 transcriptome with that of human kidney, adrenal, pituitary and central nervous tissue. The HEK 293 pattern most closely resembled that of adrenal cells, which have many neuronal properties.</p><p id="p-0633" num="0713">HEK 293 cells have a complex karyotype, exhibiting two or more copies of each chromosome and with a modal chromosome number of 64. They are described as hypotriploid, containing less than three times the number of chromosomes of a haploid human gamete. Chromosomal abnormalities include a total of three copies of the X chromosome and four copies of chromosome 17 and chromosome 22.</p><p id="p-0634" num="0714">Variants of HEK293 cells useful to produce EVs include, but are not limited to, HEK 293F, HEK 293FT, and HEK 293T.</p><p id="p-0635" num="0715">The producer cell can be genetically modified to comprise exogenous sequences encoding an ASO to produce EVs described herein. The genetically-modified producer cell can contain the exogenous sequence by transient or stable transformation. The exogenous sequence can be transformed as a plasmid. In some aspects, the exogenous sequence is a vector. The exogenous sequences can be stably integrated into a genomic sequence of the producer cell, at a targeted site or in a random site. In some aspects, a stable cell line is generated for production of lumen-engineered exosomes.</p><p id="p-0636" num="0716">The exogenous sequences can be inserted into a genomic sequence of the producer cell, located within, upstream (5&#x2032;-end) or downstream (3&#x2032;-end) of an endogenous sequence encoding an exosome protein. Various methods known in the art can be used for the introduction of the exogenous sequences into the producer cell. For example, cells modified using various gene editing methods (e.g., methods using a homologous recombination, transposon-mediated system, loxP-Cre system, CRISPR/Cas9 or TALEN) are within the scope of the present disclosure.</p><p id="p-0637" num="0717">The exogenous sequences can comprise a sequence encoding a scaffold moiety disclosed herein or a fragment or variant thereof. An extra copy of the sequence encoding a scaffold moiety can be introduced to produce an exosome described herein (e.g., having a higher density of a scaffold moiety on the surface or on the luminal surface of the EV, e.g., exosome). An exogenous sequence encoding a modification or a fragment of a scaffold moiety can be introduced to produce a lumen-engineered and/or surface-engineered exosome containing the modification or the fragment of the scaffold moiety.</p><p id="p-0638" num="0718">In some aspects, a producer cell can be modified, e.g., transfected, with one or more vectors encoding a scaffold moiety linked to an ASO.</p><p id="p-0639" num="0719">In some aspects, EVs, e.g., exosomes, of the present disclosure (e.g., surface-engineered and/or lumen-engineered exosomes) can be produced from a cell transformed with a sequence encoding a full-length, mature scaffold moiety disclosed herein or a scaffold moiety linked to an ASO. Any of the scaffold moieties described herein can be expressed from a plasmid, an exogenous sequence inserted into the genome or other exogenous nucleic acid, such as a synthetic messenger RNA (mRNA).</p><heading id="h-0094" level="1">V. Pharmaceutical Compositions</heading><p id="p-0640" num="0720">Provided herein are pharmaceutical compositions comprising an EV, e.g., exosome, of the present disclosure having the desired degree of purity, and a pharmaceutically acceptable carrier or excipient, in a form suitable for administration to a subject. Pharmaceutically acceptable excipients or carriers can be determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions comprising a plurality of extracellular vesicles. (See, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa. 21st ed. (2005)). The pharmaceutical compositions are generally formulated sterile and in full compliance with all Good Manufacturing Practice (GMP) regulations of the U.S. Food and Drug Administration.</p><p id="p-0641" num="0721">In some aspects, a pharmaceutical composition comprises one or more therapeutic agents and an exosome described herein. In certain aspects, the EVs, e.g., exosomes, are co-administered with one or more additional therapeutic agents in a pharmaceutically acceptable carrier. In some aspects, the ASO and the one or more additional therapeutic agents for the present disclosure can be administered in the same EV. In other aspects, the ASO and the one or more additional therapeutic agents for the present disclosure are administered in different EVs. For example, the present disclosure includes a pharmaceutical composition comprising an EV comprising an ASO and an EV comprising an additional therapeutic agent. In some aspects, the pharmaceutical composition comprising the EV, e.g., exosome, is administered prior to administration of the additional therapeutic agent(s). In other aspects, the pharmaceutical composition comprising the EV, e.g., exosome, is administered after the administration of the additional therapeutic agent(s). In further aspects, the pharmaceutical composition comprising the EV, e.g., exosome, is administered concurrently with the additional therapeutic agent(s).</p><p id="p-0642" num="0722">Acceptable carriers, excipients, or stabilizers are nontoxic to recipients (e.g., animals or humans) at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and/or non-ionic surfactants such as TWEEN&#x2122;, PLURONICS&#x2122; or polyethylene glycol (PEG).</p><p id="p-0643" num="0723">Examples of carriers or diluents include, but are not limited to, water, saline, Ringer's solutions, dextrose solution, and 5% human serum albumin. The use of such media and compounds for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or compound is incompatible with the extracellular vesicles described herein, use thereof in the compositions is contemplated. Supplementary therapeutic agents can also be incorporated into the compositions. Typically, a pharmaceutical composition is formulated to be compatible with its intended route of administration. The EVs, e.g., exosomes, can be administered by parenteral, topical, intravenous, oral, subcutaneous, intra-arterial, intradermal, transdermal, rectal, intracranial, intraperitoneal, intranasal, intratumoral, intramuscular route or as inhalants. In certain aspects, the pharmaceutical composition comprising exosomes is administered intravenously, e.g. by injection. The EVs, e.g., exosomes, can optionally be administered in combination with other therapeutic agents that are at least partly effective in treating the disease, disorder or condition for which the EVs, e.g., exosomes, are intended.</p><p id="p-0644" num="0724">Solutions or suspensions can include the following components: a sterile diluent such as water, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial compounds such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating compounds such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and compounds for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.</p><p id="p-0645" num="0725">Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (if water soluble) or dispersions and sterile powders. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL&#x2122; (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). The composition is generally sterile and fluid to the extent that easy syringeability exists. The carrier can be a solvent or dispersion medium containing, e.g., water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, e.g., by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal compounds, e.g., parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. If desired, isotonic compounds, e.g., sugars, polyalcohols such as manitol, sorbitol, and sodium chloride can be added to the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition a compound which delays absorption, e.g., aluminum monostearate and gelatin.</p><p id="p-0646" num="0726">Sterile injectable solutions can be prepared by incorporating the EVs, e.g., exosomes, in an effective amount and in an appropriate solvent with one or more ingredients enumerated herein or known in the art, as desired. Generally, dispersions are prepared by incorporating the EVs, e.g., exosomes, into a sterile vehicle that contains a basic dispersion medium and any desired other ingredients. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The EVs, e.g., exosomes, can be administered in the form of a depot injection or implant preparation which can be formulated in such a manner to permit a sustained or pulsatile release of the EV, e.g., exosome.</p><p id="p-0647" num="0727">Systemic administration of compositions comprising exosomes can also be by transmucosal means. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, e.g., for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of, e.g., nasal sprays.</p><p id="p-0648" num="0728">In certain aspects the pharmaceutical composition comprising EVs, e.g., exosomes is administered intravenously into a subject that would benefit from the pharmaceutical composition. In certain other aspects, the composition is administered to the lymphatic system, e.g., by intralymphatic injection or by intranodal injection (see e.g., Senti et al., PNAS 105(46): 17908 (2008)), or by intramuscular injection, by subcutaneous administration, by intratumoral injection, by direct injection into the thymus, or into the liver.</p><p id="p-0649" num="0729">In certain aspects, the pharmaceutical composition comprising exosomes is administered as a liquid suspension. In certain aspects, the pharmaceutical composition is administered as a formulation that is capable of forming a depot following administration. In certain preferred aspects, the depot slowly releases the EVs, e.g., exosomes, into circulation, or remains in depot form.</p><p id="p-0650" num="0730">Typically, pharmaceutically-acceptable compositions are highly purified to be free of contaminants, are biocompatible and not toxic, and are suited to administration to a subject. If water is a constituent of the carrier, the water is highly purified and processed to be free of contaminants, e.g., endotoxins.</p><p id="p-0651" num="0731">The pharmaceutically-acceptable carrier can be lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginates, gelatin, calcium silicate, micro-crystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate, and/or mineral oil, but is not limited thereto. The pharmaceutical composition can further include a lubricant, a wetting agent, a sweetener, a flavor enhancer, an emulsifying agent, a suspension agent, and/or a preservative.</p><p id="p-0652" num="0732">In some aspects, the pharmaceutical compositions described herein comprise a pharmaceutically acceptable salt. In some aspects, the pharmaceutically acceptable salt comprises a sodium salt, a potassium salt, an ammonium salt, or any combination thereof.</p><p id="p-0653" num="0733">The pharmaceutical compositions described herein comprise the EVs, e.g., exosomes, described herein and optionally an additional pharmaceutically active or therapeutic agent. The additional therapeutic agent can be a biological agent, a small molecule agent, or a nucleic acid agent. In some aspects, the additional therapeutic agent is an additional CEBP/&#x3b2; antagonist. In some aspects, the CEBP/&#x3b2; antagonist is any CEBP/&#x3b2; antagonist disclosed herein. In some aspects, the additional CEBP/&#x3b2; antagonist is an anti-CEBP/&#x3b2; antibody. In some aspects, the additional CEBP/&#x3b2; antagonist is a small molecule. In some aspects, the additional CEBP/&#x3b2; antagonist is a small molecule.</p><p id="p-0654" num="0734">In some aspects, the additional CEBP/&#x3b2; antagonist comprises an ASO. In some aspects, the additional CEBP/&#x3b2; antagonist comprises any ASO described herein.</p><p id="p-0655" num="0735">Dosage forms are provided that comprise a pharmaceutical composition comprising the EVs, e.g., exosomes, described herein. In some aspects, the dosage form is formulated as a liquid suspension for intravenous injection. In some aspects, the dosage form is formulated as a liquid suspension for intratumoral injection.</p><p id="p-0656" num="0736">In certain aspects, the preparation of exosomes is subjected to radiation, e.g., X rays, gamma rays, beta particles, alpha particles, neutrons, protons, elemental nuclei, UV rays in order to damage residual replication-competent nucleic acids.</p><p id="p-0657" num="0737">In certain aspects, the preparation of exosomes is subjected to gamma irradiation using an irradiation dose of more than 1, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, or more than 100 kGy.</p><p id="p-0658" num="0738">In certain aspects, the preparation of exosomes is subjected to X-ray irradiation using an irradiation dose of more than 0.1, 0.5, 1, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, or greater than 10000 mSv.</p><heading id="h-0095" level="1">VI. Kits</heading><p id="p-0659" num="0739">Also provided herein are kits comprising one or more exosomes described herein. In some aspects, provided herein is a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions described herein, such as one or more exosomes provided herein, optional an instruction for use. In some aspects, the kits contain a pharmaceutical composition described herein and any prophylactic or therapeutic agent, such as those described herein. In some aspects, the kit further comprises instructions to administer the EV according to any method disclosed herein. In some aspects, the kit is for use in the treatment of a disease or condition associated with hematopoiesis. In some aspects, the kit is a diagnostic kit.</p><heading id="h-0096" level="1">VII. Methods of Producing EVs</heading><p id="p-0660" num="0740">In some aspects, the present disclosure is also directed to methods of producing EVs described herein. In some aspects, the method comprises: obtaining the EV, e.g., exosome from a producer cell, wherein the producer cell contains one or more components of the EV, e.g., exosome (e.g., an ASO); and optionally isolating the obtained EV, e.g., exosome. In some aspects, the method comprises: modifying a producer cell by introducing one or more components of an EV disclosed herein (e.g., an ASO); obtaining the EV, e.g., exosome, from the modified producer cell; and optionally isolating the obtained EV, e.g., exosome. In further aspects, the method comprises: obtaining an EV from a producer cell; isolating the obtained EV; and modifying the isolated EV. In certain aspects, the method further comprises formulating the isolated EV into a pharmaceutical composition.</p><heading id="h-0097" level="1">VII.A. Methods of Modifying a Producer Cell</heading><p id="p-0661" num="0741">As described supra, in some aspects, a method of producing an EV comprises modifying a producer cell with one or more moieties (e.g., an ASO). In certain aspects, the one or more moieties comprise an ASO. In some aspects, the one or more moieties further comprise a scaffold moiety disclosed herein (e.g., Scaffold X or Scaffold Y).</p><p id="p-0662" num="0742">In some aspects, the producer cell can be a mammalian cell line, a plant cell line, an insect cell line, a fungi cell line, or a prokaryotic cell line. In certain aspects, the producer cell is a mammalian cell line. Non-limiting examples of mammalian cell lines include: a human embryonic kidney (HEK) cell line, a Chinese hamster ovary (CHO) cell line, an HT-1080 cell line, a HeLa cell line, a PERC-6 cell line, a CEVEC cell line, a fibroblast cell line, an amniocyte cell line, an epithelial cell line, a mesenchymal stem cell (MSC) cell line, and combinations thereof. In certain aspects, the mammalian cell line comprises HEK-293 cells, BJ human foreskin fibroblast cells, fHDF fibroblast cells, AGE.HN&#xae; neuronal precursor cells, CAP&#xae; amniocyte cells, adipose mesenchymal stem cells, RPTEC/TERT1 cells, or combinations thereof. In some aspects, the producer cell is a primary cell. In certain aspects, the primary cell can be a primary mammalian cell, a primary plant cell, a primary insect cell, a primary fungi cell, or a primary prokaryotic cell.</p><p id="p-0663" num="0743">In some aspects, the producer cell is not an immune cell, such as an antigen presenting cell, a T cell, a B cell, a natural killer cell (NK cell), a macrophage, a T helper cell, or a regulatory T cell (Treg cell). In other aspects, the producer cell is not an antigen presenting cell (e.g., dendritic cells, macrophages, B cells, mast cells, neutrophils, Kupffer-Browicz cell, or a cell derived from any such cells).</p><p id="p-0664" num="0744">In some aspects, the one or more moieties can be a transgene or mRNA, and introduced into the producer cell by transfection, viral transduction, electroporation, extrusion, sonication, cell fusion, or other methods that are known to the skilled in the art.</p><p id="p-0665" num="0745">In some aspects, the one or more moieties is introduced to the producer cell by transfection. In some aspects, the one or more moieties can be introduced into suitable producer cells using synthetic macromolecules, such as cationic lipids and polymers (Papapetrou et al., <i>Gene Therapy </i>12: S118&#x2014;S130 (2005)). In some aspects, the cationic lipids form complexes with the one or more moieties through charge interactions. In some of these aspects, the positively charged complexes bind to the negatively charged cell surface and are taken up by the cell by endocytosis. In some other aspects, a cationic polymer can be used to transfect producer cells. In some of these aspects, the cationic polymer is polyethylenimine (PEI). In certain aspects, chemicals such as calcium phosphate, cyclodextrin, or polybrene, can be used to introduce the one or more moieties to the producer cells. The one or more moieties can also be introduced into a producer cell using a physical method such as particle-mediated transfection, &#x201c;gene gun&#x201d;, biolistics, or particle bombardment technology (Papapetrou et al., <i>Gene Therapy </i>12: S118&#x2014;S130 (2005)). A reporter gene such as, for example, beta-galactosidase, chloramphenicol acetyltransferase, luciferase, or green fluorescent protein can be used to assess the transfection efficiency of the producer cell.</p><p id="p-0666" num="0746">In certain aspects, the one or more moieties are introduced to the producer cell by viral transduction. A number of viruses can be used as gene transfer vehicles, including moloney murine leukemia virus (MMLV), adenovirus, adeno-associated virus (AAV), herpes simplex virus (HSV), lentiviruses, and spumaviruses. The viral mediated gene transfer vehicles comprise vectors based on DNA viruses, such as adenovirus, adeno-associated virus and herpes virus, as well as retroviral based vectors.</p><p id="p-0667" num="0747">In certain aspects, the one or more moieties are introduced to the producer cell by electroporation. Electroporation creates transient pores in the cell membrane, allowing for the introduction of various molecules into the cell. In some aspects, DNA and RNA as well as polypeptides and non-polypeptide therapeutic agents can be introduced into the producer cell by electroporation.</p><p id="p-0668" num="0748">In certain aspects, the one or more moieties introduced to the producer cell by microinjection. In some aspects, a glass micropipette can be used to inject the one or more moieties into the producer cell at the microscopic level.</p><p id="p-0669" num="0749">In certain aspects, the one or more moieties are introduced to the producer cell by extrusion.</p><p id="p-0670" num="0750">In certain aspects, the one or more moieties are introduced to the producer cell by sonication. In some aspects, the producer cell is exposed to high intensity sound waves, causing transient disruption of the cell membrane allowing loading of the one or more moieties.</p><p id="p-0671" num="0751">In certain aspects, the one or more moieties are introduced to the producer cell by cell fusion. In some aspects, the one or more moieties are introduced by electrical cell fusion. In other aspects, polyethylene glycol (PEG) is used to fuse the producer cells. In further aspects, sendai virus is used to fuse the producer cells.</p><p id="p-0672" num="0752">In some aspects, the one or more moieties are introduced to the producer cell by hypotonic lysis. In such aspects, the producer cell can be exposed to low ionic strength buffer causing them to burst allowing loading of the one or more moieties. In other aspects, controlled dialysis against a hypotonic solution can be used to swell the producer cell and to create pores in the producer cell membrane. The producer cell is subsequently exposed to conditions that allow resealing of the membrane.</p><p id="p-0673" num="0753">In some aspects, the one or more moieties are introduced to the producer cell by detergent treatment. In certain aspects, producer cell is treated with a mild detergent which transiently compromises the producer cell membrane by creating pores allowing loading of the one or more moieties. After producer cells are loaded, the detergent is washed away thereby resealing the membrane.</p><p id="p-0674" num="0754">In some aspects, the one or more moieties introduced to the producer cell by receptor mediated endocytosis. In certain aspects, producer cells have a surface receptor which upon binding of the one or more moieties induces internalization of the receptor and the associated moieties.</p><p id="p-0675" num="0755">In some aspects, the one or more moieties are introduced to the producer cell by filtration. In certain aspects, the producer cells and the one or more moieties can be forced through a filter of pore size smaller than the producer cell causing transient disruption of the producer cell membrane and allowing the one or more moieties to enter the producer cell.</p><p id="p-0676" num="0756">In some aspects, the producer cell is subjected to several freeze thaw cycles, resulting in cell membrane disruption allowing loading of the one or more moieties.</p><heading id="h-0098" level="1">VII.B. Methods of Modifying EV, e.g., Exosome</heading><p id="p-0677" num="0757">In some aspects, a method of producing an EV, e.g., exosome, comprises modifying the isolated EV by directly introducing one or more moieties into the EVs. In certain aspects, the one or more moieties comprise an ASO. In some aspects, the one or more moieties comprise a scaffold moiety disclosed herein (e.g., Scaffold X or Scaffold Y).</p><p id="p-0678" num="0758">In certain aspects, the one or more moieties are introduced to the EV by transfection. In some aspects, the one or more moieties can be introduced into the EV using synthetic macromolecules such as cationic lipids and polymers (Papapetrou et al., Gene Therapy 12: S118&#x2014;S130 (2005)). In certain aspects, chemicals such as calcium phosphate, cyclodextrin, or polybrene, can be used to introduce the one or more moieties to the EV.</p><p id="p-0679" num="0759">In certain aspects, the one or more moieties are introduced to the EV by electroporation. In some aspects, EVs are exposed to an electrical field which causes transient holes in the EV membrane, allowing loading of the one or more moieties.</p><p id="p-0680" num="0760">In certain aspects, the one or more moieties are introduced to the EV by microinjection. In some aspects, a glass micropipette can be used to inject the one or more moieties directly into the EV at the microscopic level.</p><p id="p-0681" num="0761">In certain aspects, the one or more moieties are introduced to the EV by extrusion.</p><p id="p-0682" num="0762">In certain aspects, the one or more moieties are introduced to the EV by sonication. In some aspects, EVs are exposed to high intensity sound waves, causing transient disruption of the EV membrane allowing loading of the one or more moieties.</p><p id="p-0683" num="0763">In some aspects, one or more moieties can be conjugated to the surface of the EV. Conjugation can be achieved chemically or enzymatically, by methods known in the art.</p><p id="p-0684" num="0764">In some aspects, the EV comprises one or more moieties that are chemically conjugated.</p><p id="p-0685" num="0765">Chemical conjugation can be accomplished by covalent bonding of the one or more moieties to another molecule, with or without use of a linker. The formation of such conjugates is within the skill of artisans and various techniques are known for accomplishing the conjugation, with the choice of the particular technique being guided by the materials to be conjugated. In certain aspects, polypeptides are conjugated to the EV. In some aspects, non-polypeptides, such as lipids, carbohydrates, nucleic acids, and small molecules, are conjugated to the EV.</p><p id="p-0686" num="0766">In some aspects, the one or more moieties are introduced to the EV by hypotonic lysis. In such aspects, the EVs can be exposed to low ionic strength buffer causing them to burst allowing loading of the one or more moieties. In other aspects, controlled dialysis against a hypotonic solution can be used to swell the EV and to create pores in the EV membrane. The EV is subsequently exposed to conditions that allow resealing of the membrane.</p><p id="p-0687" num="0767">In some aspects, the one or more moieties are introduced to the EV by detergent treatment. In certain aspects, extracellular vesicles are treated with a mild detergent which transiently compromises the EV membrane by creating pores allowing loading of the one or more moieties. After EVs are loaded, the detergent is washed away thereby resealing the membrane.</p><p id="p-0688" num="0768">In some aspects, the one or more moieties are introduced to the EV by receptor mediated endocytosis. In certain aspects, EVs have a surface receptor which upon binding of the one or more moieties induces internalization of the receptor and the associated moieties.</p><p id="p-0689" num="0769">In some aspects, the one or more moieties are introduced to the EV by mechanical firing. In certain aspects, extracellular vesicles can be bombarded with one or more moieties attached to a heavy or charged particle such as gold microcarriers. In some of these aspects, the particle can be mechanically or electrically accelerated such that it traverses the EV membrane.</p><p id="p-0690" num="0770">In some aspects, extracellular vesicles are subjected to several freeze thaw cycles, resulting in EV membrane disruption allowing loading of the one or more moieties.</p><heading id="h-0099" level="1">VII.C. Methods of Isolating EV, e.g., Exosome</heading><p id="p-0691" num="0771">In some aspects, methods of producing EVs disclosed herein comprises isolating the EV from the producer cells. In certain aspects, the EVs released by the producer cell into the cell culture medium. It is contemplated that all known manners of isolation of EVs are deemed suitable for use herein. For example, physical properties of EVs can be employed to separate them from a medium or other source material, including separation on the basis of electrical charge (e.g., electrophoretic separation), size (e.g., filtration, molecular sieving, etc.), density (e.g., regular or gradient centrifugation), Svedberg constant (e.g., sedimentation with or without external force, etc.). Alternatively, or additionally, isolation can be based on one or more biological properties, and include methods that can employ surface markers (e.g., for precipitation, reversible binding to solid phase, FACS separation, specific ligand binding, non-specific ligand binding, affinity purification etc.).</p><p id="p-0692" num="0772">Isolation and enrichment can be done in a general and non-selective manner, typically including serial centrifugation. Alternatively, isolation and enrichment can be done in a more specific and selective manner, such as using EV or producer cell-specific surface markers. For example, specific surface markers can be used in immunoprecipitation, FACS sorting, affinity purification, and magnetic separation with bead-bound ligands.</p><p id="p-0693" num="0773">In some aspects, size exclusion chromatography can be utilized to isolate the EVs. Size exclusion chromatography techniques are known in the art. Exemplary, non-limiting techniques are provided herein. In some aspects, a void volume fraction is isolated and comprises the EVs of interest. Further, in some aspects, the EVs can be further isolated after chromatographic separation by centrifugation techniques (of one or more chromatography fractions), as is generally known in the art. In some aspects, for example, density gradient centrifugation can be utilized to further isolate the extracellular vesicles. In certain aspects, it can be desirable to further separate the producer cell-derived EVs from EVs of other origin. For example, the producer cell-derived EVs can be separated from non-producer cell-derived EVs by immunosorbent capture using an antigen antibody specific for the producer cell.</p><p id="p-0694" num="0774">In some aspects, the isolation of EVs can involve combinations of methods that include, but are not limited to, differential centrifugation, size-based membrane filtration, immunoprecipitation, FACS sorting, and magnetic separation.</p><p id="p-0695" num="0775">The practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, for example, Sambrook et al., ed. (1989) Molecular Cloning A Laboratory Manual (2nd ed.; Cold Spring Harbor Laboratory Press); Sambrook et al., ed. (1992) Molecular Cloning: A Laboratory Manual, (Cold Springs Harbor Laboratory, NY); D. N. Glover ed., (1985) DNA Cloning, Volumes I and II; Gait, ed. (1984) Oligonucleotide Synthesis; Mullis et al. U.S. Pat. No. 4,683,195; Hames and Higgins, eds. (1984) Nucleic Acid Hybridization; Hames and Higgins, eds. (1984) Transcription And Translation; Freshney (1987) Culture Of Animal Cells (Alan R. Liss, Inc.); Immobilized Cells And Enzymes (IRL Press) (1986); Perbal (1984) A Practical Guide To Molecular Cloning; the treatise, Methods In Enzymology (Academic Press, Inc., N.Y.); Miller and Calos eds. (1987) Gene Transfer Vectors For Mammalian Cells, (Cold Spring Harbor Laboratory); Wu et al., eds., Methods In Enzymology, Vols. 154 and 155; Mayer and Walker, eds. (1987) Immunochemical Methods In Cell And Molecular Biology (Academic Press, London); Weir and Blackwell, eds., (1986) Handbook Of Experimental Immunology, Volumes I-IV; Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1986); Crooke, Antisense drug Technology: Principles, Strategies and Applications, 2<sup>nd</sup>Ed. CRC Press (2007) and in Ausubel et al. (1989) Current Protocols in Molecular Biology (John Wiley and Sons, Baltimore, Md.).</p><heading id="h-0100" level="1">VIII. Methods of Use</heading><p id="p-0696" num="0776">In certain aspects, the present disclosure provides methods of preventing and/or treating a disease or disorder in a subject in need thereof, comprising administering an EV (e.g., exosome) disclosed herein (e.g., comprising an ASO of the present disclosure) to the subject. As described herein, ASOs useful for the present disclosure can specifically hybridize to one or more regions of a CEBP/&#x3b2; transcript (e.g., pre-mRNA or mRNA), resulting in reduction and/or inhibition of CEBP/&#x3b2;1 protein expression in a cell. Accordingly, EVs (e.g., exosomes) comprising such an ASO (e.g., EVs disclosed herein) can be useful for preventing and/or treating any disease or disorder associated with increased expression of a CEBP/&#x3b2; protein.</p><p id="p-0697" num="0777">In some aspects, a disease or disorder that can be treated with the present methods comprises a cancer. In certain aspects, the cancer is associated with increased expression of a CEBP/&#x3b2; protein. Non-limiting examples of cancers that can be treated with the present disclosure include a colorectal cancer, lung cancer (e.g., non-small cell lung cancer (NSCLC)), pancreatic cancer, leukemia, uterine cancer, ovarian cancer, bladder cancer, bile duct cancer, gastric cancer, or any combination thereof.</p><p id="p-0698" num="0778">When administered to a subject with a cancer, in certain aspects, EVs (e.g., exosome) of the present disclosure can up-regulate an immune response and enhance the tumor targeting of the subject's immune system. In some aspects, the cancer being treated is characterized by infiltration of leukocytes (T-cells, B-cells, macrophages, dendritic cells, monocytes) into the tumor microenvironment, or so-called &#x201c;hot tumors&#x201d; or &#x201c;inflammatory tumors&#x201d;. In some aspects, the cancer being treated is characterized by low levels or undetectable levels of leukocyte infiltration into the tumor microenvironment, or so-called &#x201c;cold tumors&#x201d; or &#x201c;non-inflammatory tumors&#x201d;. In some aspects, an EV is administered in an amount and for a time sufficient to convert a &#x201c;cold tumor&#x201d; into a &#x201c;hot tumor&#x201d;, i.e., said administering results in the infiltration of leukocytes (such as T-cells) into the tumor microenvironment. In certain aspects, cancer comprises bladder cancer, cervical cancer, renal cell cancer, testicular cancer, colorectal cancer, lung cancer, head and neck cancer, and ovarian, lymphoma, liver cancer, glioblastoma, melanoma, myeloma, leukemia, pancreatic cancers, or combinations thereof. In other term, &#x201c;distal tumor&#x201d; or &#x201c;distant tumor&#x201d; refers to a tumor that has spread from the original (or primary) tumor to distant organs or distant tissues, e.g., lymph nodes. In some aspects, the EVs of the disclosure treats a tumor after the metastatic spread.</p><p id="p-0699" num="0779">In some aspects, the EVs (e.g., exosomes) are administered intravenously to the circulatory system of the subject. In some aspects, the EVs are infused in suitable liquid and administered into a vein of the subject.</p><p id="p-0700" num="0780">In some aspects, the EVs (e.g., exosomes) are administered intra-arterially to the circulatory system of the subject. In some aspects, the EVs are infused in suitable liquid and administered into an artery of the subject.</p><p id="p-0701" num="0781">In some aspects, the EVs (e.g., exosomes) are administered to the subject by intrathecal administration. In some aspects, the EVs (e.g., exosomes) are administered by intrathecal administration, followed by application of a mechanical convective force to the torso. See, e.g., Verma et al., <i>Alzheimer's Dement. </i>12:e02030 (2020); which is incorporated by reference herein in its entirety). As such, certain aspects of the present disclosure are directed to methods of administering an EV, e.g., an exosome, to a subject in need thereof, comprising administering the EV, e.g., exosome, to the subject by intrathecal injection, followed by applying a mechanical convective force to the torso of the subject. In some aspects, the mechanical convective force is achieved using a high frequency chest wall or lumbothoracic oscillating respiratory clearance device (e.g., a Smart Vest or Smart Wrap, ELECTROMED INC, New Prague, Minn., USA). In some aspects, the mechanical convective force, e.g., the oscillating vest, facilitates spread of the intrathecally dosed EVs, e.g., exosomes, further down the nerve thus allowing for better EV, e.g., exosome, delivery to nerves.</p><p id="p-0702" num="0782">In some aspects, the intra- and trans-compartmental biodistribution of exosomes can be manipulated by exogenous extracorporeal forces acting upon a subject after compartmental delivery of exosomes. This includes the application of mechanical convection, for example by way of applying percussion, vibration, shaking, or massaging of a body compartment or the entire body. Following intrathecal dosing for example, the application of chest wall vibrations by several means including an oscillating mechanical jacket can spread the biodistribution of exosomes along the neuraxis or along cranial and spinal nerves, which can be helpful in the treatment of nerve disorders by drug carrying exosomes.</p><p id="p-0703" num="0783">In some aspects, the application of external mechanical convective forces via an oscillating jacket or other similar means can be used to remove exosomes and other material from the cerebrospinal fluid of the intrathecal space and out to the peripheral circulation. This aspect can help remove endogenous toxic exosomes and other deleterious macromolecules such as beta-amyloid, tau, alpha-synuclein, TDP43, neurofilament and excessive cerebrospinal fluid from the intrathecal space to the periphery for elimination.</p><p id="p-0704" num="0784">In some aspects, exosomes delivered via the intracebroventricular route can be made to translocate throughout the neuraxis by simultaneously incorporating a lumbar puncture and allowing for ventriculo-lumbar perfusion wherein additional fluid is infused into the ventricles after exosome dosing, while allowing the existing neuraxial column of CSF to exit is the lumbar puncture. Ventriculo-lumbar perfusion can allow ICV dosed exosome to spread along the entire neuraxis and completely cover the subarachoid space in order to treat leptomeningeal cancer and other diseases.</p><p id="p-0705" num="0785">In some aspects, the application of external extracorporeal focused ultrasound, thermal energy (heat) or cold may be used to manipulate the compartmental pharmacokinetics and drug release properties of exosomes engineered to be sensitive to these phenomena.</p><p id="p-0706" num="0786">In some aspects, the intracompartmental behavior and biodistribution of exosomes engineered to contain paramagnetic material can be manipulated by the external application of magnets or a magnetic field.</p><p id="p-0707" num="0787">In some aspects, the EVs are administered via an injection into the spinal canal, or into the subarachnoid space so that it reaches the cerebrospinal fluid (CSF).</p><p id="p-0708" num="0788">In some aspects, the EVs (e.g., exosomes) are administered intratumorally into one or more tumors of the subject.</p><p id="p-0709" num="0789">In some aspects, the EVs (e.g., exosomes) are administered to the subject by intranasal administration. In some aspects, the EVs can be insufflated through the nose in a form of either topical administration or systemic administration. In certain aspects, the EVs are administered as nasal spray.</p><p id="p-0710" num="0790">In some aspects, the EVs (e.g., exosomes) are administered to the subject by intraperitoneal administration. In some aspects, the EVs are infused in suitable liquid and injected into the peritoneum of the subject. In some aspects, the intraperitoneal administration results in distribution of the EVs to the lymphatics. In some aspects, the intraperitoneal administration results in distribution of the EVs to the thymus, spleen, and/or bone marrow. In some aspects, the intraperitoneal administration results in distribution of the EVs to one or more lymph nodes. In some aspects, the intraperitoneal administration results in distribution of the EVs to one or more of the cervical lymph node, the inguinal lymph node, the mediastinal lymph node, or the sternal lymph node. In some aspects, the intraperitoneal administration results in distribution of the EVs to the pancreas.</p><p id="p-0711" num="0791">In some aspects, the EVs, e.g., exosomes, are administered to the subject by periocular administration. In some aspects, the s are injected into the periocular tissues. Periocular drug administration includes the routes of subconjunctival, anterior sub-Tenon's, posterior sub-Tenon's, and retrobulbar administration.</p><p id="p-0712" num="0792">All of the references cited above, as well as all references cited herein, are incorporated herein by reference in their entireties.</p><p id="p-0713" num="0793">The following examples are offered by way of illustration and not by way of limitation.</p><heading id="h-0101" level="1">VIII.A. Methods of Treating a Brain Cancer</heading><p id="p-0714" num="0794">Certain aspects of the present disclosure are directed to methods of treating a brain cancer in a subject in need thereof. In some aspects, the method comprises administering to the subject a therapeutically effective amount of an EV, e.g., exosome, comprising an ASO, as disclosed herein. In some aspects, the EV, e.g., exosome, is capable of targeted delivery of a therapeutic agent, e.g., an ASO, as disclosed herein, to the CNS to treat the brain cancer. In some aspects, the EV, e.g., exosome, is capable of up-regulating an immune response in the subject, thereby enhancing the subject's immune response against the neuroimmunological disorder. In some aspects, the composition is administered intratumorally or intrathecally to the subject.</p><p id="p-0715" num="0795">Also provided herein are methods of preventing metastasis of a brain tumor in a subject. The method comprises administering to the subject a therapeutically effective amount of the compositions disclosed herein, wherein the composition is capable of preventing a brain tumor at one location in the subject from promoting the growth of one or more tumors at another location in the subject. In some aspects, the composition is administered intratumorally or intrathecally in a first tumor in one location, and the composition administered in a first tumor prevents metastasis of one or more tumors at a second location.</p><p id="p-0716" num="0796">In some aspects, administering an EV, e.g., exosome, disclosed herein inhibits and/or reduces growth of a brain tumor in a subject. In some aspects, the growth of a brain tumor (e.g., tumor volume or weight) is reduced by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% compared to a reference (e.g., tumor volume in a corresponding subject after administration of an EV, e.g., exosome, without the ASO).</p><p id="p-0717" num="0797">As used herein, the term &#x201c;brain tumor&#x201d; refers to an abnormal growth of cells within the brain (e.g., within the meninges). Brain tumors can be categorized as primary or secondary brain tumor. &#x201c;Primary brain tumor&#x201d; refers to brain tumors that originate within the brain. &#x201c;Secondary brain tumor&#x201d; refers to brain tumors that are the result of cancer cells originating at primary sites outside the brain that have metastasized (i.e., spread) to the brain. Unless specified otherwise, the term brain tumor can refer to both primary and secondary brain tumors.</p><p id="p-0718" num="0798">In some aspects, a brain tumor that can be treated with the present disclosure comprises an acoustic neuroma, choroid plexus carcinoma, craniopharyngioma, embryonal tumor, glioma, medulloblastoma, meningioma, pediatric brain tumor, pineoblastoma, pituitary tumor, or combinations thereof.</p><p id="p-0719" num="0799">In certain aspects, a brain tumor that can be treated with the present disclosure comprises a glioma. As used herein, the term &#x201c;glioma&#x201d; refers to a type of tumor that starts in the glial cells of the brain or the spine. In some aspects, a glioma can be classified by specific type of cells with which they share histological features. Accordingly, a glioma that can be treated with EVs (e.g., exosomes) disclosed herein can be classified as an ependymoma (ependymal cells), astrocytoma (astrocytes), oligodendroglioma (oligodendrocytes), brainstem glioma (e.g., diffuse intrinsic pontine glioma), optic nerve glioma, mixed glioma, oligoastrocytoma, or any combination thereof. In certain aspects, an astrocytoma comprises glioblastoma multiforme (GBM).</p><p id="p-0720" num="0800">Gliomas disclosed herein can be further categorized according to their grade, which is determined by pathologic evaluation of the tumor. In some aspects, the neuropathological evaluation and diagnostics of brain tumor specimens is performed according to WHO Classification of Tumours of the Central Nervous System. In some aspects, a glioma that can be treated with the present disclosure comprises a low-grade glioma. A &#x201c;low-grade glioma&#x201d; [WHO grade II] are well-differentiated (not anaplastic) and tend to exhibit benign tendencies and portend a better prognosis for the patient. However, in some aspects, low-grade gliomas can have a uniform rate of recurrence and increase in grade over time, so should be classified as malignant. In some aspects, a glioma that can be treated comprises a high grade glioma. A &#x201c;high-grade glioma&#x201d; [WHO grades III-IV] gliomas are undifferentiated or anaplastic and are malignant and carry a worse prognosis. Of numerous grading systems in use, the most common is the World Health Organization (WHO) grading system for astrocytoma, under which tumors are graded from I (least advanced disease-best prognosis) to IV (most advanced disease-worst prognosis). Non-limiting examples of high-grade gliomas include anaplastic astrocytomas and glioblastoma multiforme.</p><p id="p-0721" num="0801">In some aspects, an EV (e.g., exosome) disclosed herein can be used to treat a glioma grade I, grade II, grade III, grade IV, or combinations thereof, as determined under the WHO grading system. In certain aspects, an EV (e.g., exosome) disclosed herein can be used to treat any type of gliomas.</p><p id="p-0722" num="0802">In some aspects, the glioma treatable by the present methods is a diffuse intrinsic pontine glioma (DIPG), a type of brainstem glioma. Diffuse intrinsic pontine glioma primarily affects children, usually between the ages of 5 and 7. The median survival time with DIPG is under 12 months. Surgery to attempt tumor removal is usually not possible or advisable for DIPG. By their very nature, these tumors invade diffusely throughout the brain stem, growing between normal nerve cells.</p><p id="p-0723" num="0803">In other aspects, the glioma treatable by the present methods is an IDH1 and IDH2-mutated glioma. Patients with glioma carrying mutations in either IDH1 or IDH2 have a relatively favorable survival, compared with patients with glioma with wild-type IDH1/2 genes. In WHO grade III glioma, IDH1/2-mutated glioma have a median prognosis of &#x2dc;3.5 years, whereas IDH1/2 wild-type glioma perform poor with a median overall survival of 1.5 years. In glioblastoma, the difference is larger.</p><p id="p-0724" num="0804">In some aspects, a neuroimmunological disorder that can be treated with the present disclosure comprises a neoplastic meningitis. As used herein, &#x201c;neoplastic meningitis&#x201d; refers to a tumor which has spread from the original tumor site into the dural and leptomeninges, which are thin tissue membranes covering the brain and spinal cord. In some aspects, connective tissue nerve sheaths that extend from the meninges onto and into nerves can also become involved. Neoplastic meningitis is also known as carcinomatous meningitis, leptomeningeal carcinoma, leptomeningeal carcinomatosis, leptomeningeal metastasis, leptomeningeal disease (LMD), leptomeningeal cancer, meningeal carcinomatosis, and meningeal metastasis. In certain aspects, a neoplastic meningitis is caused by leukemia. In some aspects, a neoplastic meningitis is caused by melanoma, breast, lung, gastrointestinal cancer, or combinations thereof. In certain aspects, a neoplastic meningitis is caused by a glioma.</p><p id="p-0725" num="0805">In some aspects, an EV (e.g., exosome) disclosed herein can re-activate macrophages (e.g., within the nervous system) and/or reverse nervous system anergy. In certain aspects, re-activating macrophages (e.g., within the nervous system) and/or reversing nervous system anergy can help treat a neuroimmunological disorder (e.g., by eradicating neoplastic or infectious lesions within the nervous system).</p><heading id="h-0102" level="1">EXAMPLES</heading><heading id="h-0103" level="1">Example 1: In Vitro Analysis of mRNA and/or Protein Reduction</heading><p id="p-0726" num="0806">Exemplary ASOs disclosed herein were designed to specifically target the CEBP/&#x3b2; transcript (<figref idref="DRAWINGS">FIG. <b>1</b></figref>). The disclosed ASOs will be tested for their ability to knockdown CEBP/&#x3b2; mRNA and/or CEBP/&#x3b2;1 protein expression in reporter cell lines containing a human CEBP/&#x3b2; coding sequence upstream of reporter. CEBP/&#x3b2;-specific siRNA will be used as positive control.</p><p id="p-0727" num="0807">Briefly, the reporter cell lines expressing CEBP/&#x3b2;1 will be grown in cell culture media and seeded onto a 96 well plate. Then, the cells will be treated with different concentrations of EVs (e.g., exosomes) comprising one or more ASOs disclosed herein (&#x201c;EV-ASO&#x201d;). Methods for producing such EVs are provided elsewhere in the present disclosure. Approximately 3 days after EV-ASO treatment, the cells will be harvested and RNA and/or protein will be purified from the cells. Then, the CEBP/&#x3b2; mRNA and/or CEBP/&#x3b2;1 proteinexpression levels in the cells will be quantified using assays such as, qPCR and Western blot.</p><p id="p-0728" num="0808">A lead ASO will be selected first by using in silico selection based on alternative transcript cross reactivity, species cross reactivity, specificity for gene of interest, presence of SNPs within ASO, length of ASO, location diversity, toxic motifs, and predicted binding affinity. Next, the ASOs will be screened for the ability to knock down (by at least 50% at 2 nM, and less than 20% knock down of GAPDH at 20 nM) target gene expression in cell lines transfected with the target sequence (CEBP/&#x3b2; mRNA). ASOs will then be assayed for target gene knock down potency in primary macrophages from at least two donors. Housekeeping gene expression stability, diversity of sequence location, and expression of predicted off-targets after treatment will also be observed. Optimal ASOs having the highest reprogramming activity (gene expression changes, cytokine production, T cell suppression) in primary macrophages will be selected as the lead ASOs.</p><heading id="h-0104" level="1">Example 2: Construction of an Exosome</heading><p id="p-0729" num="0809">To generate exosomes described herein, human embryonic kidney (HEK) cell line (e.g., HEK293SF) will be used. The cells will be stably transfected with Scaffold X, Scaffold Y, and/or anchoring moiety linked to an agent of interest.</p><p id="p-0730" num="0810">Upon transfection, HEK cells will be grown to high density in chemically defined medium for 7 days. Conditioned cell culture media will be then collected and centrifuged at 300-800&#xd7;g for 5 minutes at room temperature to remove cells and large debris. Media supernatant will be supplemented with 1000 U/L BENZONASE&#xae; and incubated at 37&#xb0; C. for 1 hour in a water bath. Supernatant will be collected and centrifuged at 16,000&#xd7;g for 30 minutes at 4&#xb0; C., to remove residual cell debris and other large contaminants. Supernatant will then be ultracentrifuged at 133,900&#xd7;g for 3 hours at 4&#xb0; C., to pellet the exosomes. Supernatant will be discarded and any residual media will be aspirated from the bottom of the tube. The pellet will be resuspended in 200-1000 &#x3bc;L PBS (&#x2014;Ca &#x2014;Mg).</p><p id="p-0731" num="0811">To further enrich exosome populations, the pellet will be processed via density gradient purification (sucrose or OPTIPREP&#x2122;).</p><p id="p-0732" num="0812">The gradient will be spun at 200,000&#xd7;g for 16 hours at 4&#xb0; C. in a 12 mL Ultra-Clear (344059) tube placed in a SW 41 Ti rotor to separate the exosome fraction.</p><p id="p-0733" num="0813">The exosome layer will then be gently removed from the top layer and diluted in &#x2dc;32.5 mL PBS in a 38.5 mL Ultra-Clear (344058) tube and ultracentrifuged again at 133,900&#xd7;g for 3 hours at 4&#xb0; C., to pellet the purified exosomes. The resulting pellet will be resuspended in a minimal volume of PBS (&#x2dc;200 &#x3bc;L) and stored at 4&#xb0; C.</p><p id="p-0734" num="0814">For OPTIPREP&#x2122; gradient, a 3-tier sterile gradient will be prepared with equal volumes of 10%, 30%, and 45% OPTIPREP&#x2122; in a 12 mL Ultra-Clear (344059) tube for a SW 41 Ti rotor. The pellet will be added to the OPTIPREP&#x2122; gradient and ultracentrifuged at 200,000&#xd7;g for 16 hours at 4&#xb0; C., to separate the exosome fraction. The exosome layer will then be gently collected from the top &#x2dc;3 mL of the tube.</p><p id="p-0735" num="0815">The exosome fraction will be diluted in &#x2dc;32 mL PBS in a 38.5 mL Ultra-Clear (344058) tube and ultracentrifuged at 133,900&#xd7;g for 3 hours at 4&#xb0; C., to pellet the purified exosomes. The pelleted exosomes will then be resuspended in a minimal volume of PBS (&#x2dc;200 &#x3bc;L) and stored at 4&#xb0; C. until ready to be used.</p><heading id="h-0105" level="1">Example 3: ASO Design</heading><p id="p-0736" num="0816">Mouse and human ASOs were designed to target CEBP/&#x3b2; (Gene ID No. 1051) expression. Target sequences were selected using the reference sequences NM_001285878.1 for human CEBP/&#x3b2; # and NM_009883.4 for mouse CEBP/&#x3b2;. A list of possible ASOs were generated for each gene by tilling of ASOs across the entire length of the nascent transcript. ASOs having 15, 16, 17, 18, 19, or 20 nucleobases in length were generated.</p><p id="p-0737" num="0817">ASOs were prioritized based on the following properties: must hit all splice forms; low self-dimerization energy (on-target activity); no GGGG motif (can cause synthesis issues); less than 3 CpG dinucleotides in the oligo (potential immunostimulation); less than 8 bases of palindromic sequence (potential dimerization &#x26; immunostimulation); more than 2 mismatch and no more than 17 contiguous bases in an off-target hit to any gene, including known miRNA and lncRNA, and both nascent and mature transcripts; no overlap with repetitive sequences; and no overlap with SNPs of greater than or equal to 0.01 MAF in the general population. Additional criteria included Predicted species cross reactivity (e.g., human, cyno, rhesus, rat, mouse transcripts); and an off target (OT) filter less than or equal to 3 mismatch (mm) in mature transcripts, less than or equal to 3 mm in Inc transcripts, less than or equal to 3 mm in miRNAs, and less than or equal to 3 mm in nascent transcripts.</p><heading id="h-0106" level="1">Example 4: ASO Loading on Exosomes</heading><p id="p-0738" num="0818">BALB/c mice bearing CT26 subcutaneous (sc) tumors were treated intravenously with a single dose of 2E11 exosomes loaded with a reporter ASO (&#x201c;exo ASO&#x201d;; 8 &#x3bc;g of fluorescently labeled Cy5 exoASO) or with a single dose (8 &#x3bc;g) of free reporter ASO (&#x201c;free ASO&#x201d;). One hour following administration, increased exo ASO uptake was observed in CD11b<sup>+</sup> dendritic cells, monocytes, and mMDSCs in the blood (<figref idref="DRAWINGS">FIG. <b>2</b>A</figref>); Kupffer cells in the liver (<figref idref="DRAWINGS">FIG. <b>2</b>B</figref>); red pulp macs, monocytes, and mMDSCs in the spleen (<figref idref="DRAWINGS">FIG. <b>2</b>C</figref>); and dendritic cells and mMDSCs in tumor tissue (<figref idref="DRAWINGS">FIGS. <b>2</b>D-<b>2</b>E</figref>), as evidenced by MFI, relative to the localization of free ASO. Uptake of exo ASO was also higher in bone marrow (<figref idref="DRAWINGS">FIGS. <b>2</b>F-<b>2</b>G</figref>) as compared to uptake of free ASO and negative controls (<figref idref="DRAWINGS">FIGS. <b>2</b>H-<b>2</b>K</figref>), shows expression of PTGFRN cognate receptors in glioblastoma (GBM) in various cell types across five targets, with the highest expression present in myeloid cells.</p><p id="p-0739" num="0819">BALB/c mice bearing CT26 subcutaneous tumors were treated with a single intratumoral dose (4 &#x3bc;g) of either exo ASO or free ASO. One hour following administration, tumors were dissected and enzymatically digested, and tumor cell suspensions analyzed by flow cytometry. Exo ASO uptake was observed in tumor cells, macrophages, myeloid-derived suppressor cells, and dendritic cells (<figref idref="DRAWINGS">FIGS. <b>2</b>L-<b>2</b>M</figref>; MDSC: myeloid-derived suppressor cells; mMDSC: monocytic MDSC; gMDSC: granulocytic MDSC; cDC2=type 2 conventional dendritic cells; cDC1=type 1 conventional dendritic cells).</p><heading id="h-0107" level="1">Example 5: Exo-CEBP/&#x3b2;-ASO Are Capable of Repolarizing M2 Macrophages</heading><p id="p-0740" num="0820">Primary human macrophages were polarized with IL4/IL10/TGF&#x3b2; treatment and treated with increasing concentrations of Exo-CEBP/&#x3b2;-ASO. Human primary M2 macrophages were incubated for 48 hours with equivalent doses of exoASO and free ASO targeting CEBP/&#x3b2;, along with an exoASO scramble control. Gene expression analysis was performed by Nanostring using the nCounter Human Myeloid Innate Immunity Panel v2 or by LEGENDPLEX multiplex flow cytometry. In vitro treatment of primary human macrophages with Exo-CEBP/&#x3b2;-ASO induces dose-dependent knockdown of CEBP/&#x3b2; (<figref idref="DRAWINGS">FIG. <b>3</b>A</figref>), respectively, as well as the downregulation of an M2 macrophage gene, CD163 (<figref idref="DRAWINGS">FIG. <b>3</b>B</figref>). Potency was found to be slightly higher using the Exo-ASOs as compared to the free ASOs. Various M2 genes were downregulated and various M1 genes were upregulated following treatment with Exo-CEBP/&#x3b2;-ASO (<figref idref="DRAWINGS">FIGS. <b>4</b>A-<b>4</b>J and <b>4</b>O</figref>). In addition, cytokine production was upregulated and downregulated after lipopolysaccharide (LPS) stimulation and treatment with Exo-CEBP/&#x3b2;-ASO (<figref idref="DRAWINGS">FIGS. <b>4</b>K-<b>4</b>N</figref>).</p><heading id="h-0108" level="1">Example 6: Exo-CEBP/&#x3b2;-ASO Target Gene Knockdown in CD11b Cells</heading><p id="p-0741" num="0821">In vivo, the primary recipient cell for Exo-CEBP/P-ASO is CD11b cells. To further measure the uptake and known-down efficiency of the Exo-ASOs, mice bearing CT26 tumors were treated by intratumoral (IT) injection with 4 &#x3bc;g Exo-CEBP/&#x3b2;-ASO or exoASO scramble, 3 injections (q.o.d.), and sacrificed. CD11b<sup>+</sup> cells were then isolated and enriched (<figref idref="DRAWINGS">FIGS. <b>5</b>A-<b>5</b>F</figref>). CT26 tumors were treated intratumoral (IT) with 4 &#x3bc;g of exoASO C/EBPs or exoASO Scramble, 3 injections (q.o.d.). After treatment, tumor-associated myeloid cells were isolated using CD11b-positive selection magnetic bead isolation (80% enrichment). Gene expression analysis in CD11b+ enriched tumor associated myeloid cells was performed by Nanostring using the nCounter Human Myeloid Innate Immunity Panel v2.</p><p id="p-0742" num="0822">Though not the endpoint, tumor volume was significantly lower in Exo-CEBP/P-ASO treated mice relative to mice treated with a scramble Exo-ASO control, and mice treated with Exo-CEBP/3-ASO tended to have smaller tumors than mice treated with a free ASO control (<figref idref="DRAWINGS">FIG. <b>5</b>G</figref>). Exo-ASO target gene knockdown was more pronounced in the CD11b-enriched cells than non-enriched cells following treatment with Exo-CEBP/&#x3b2;-ASO (<figref idref="DRAWINGS">FIG. <b>6</b>A</figref>). In addition, the Exo-ASOs were effective at reducing Arg1 expression to a greater extent in CD11b-enriched cells than non-enriched cells, as measured using qPCR (<figref idref="DRAWINGS">FIG. <b>6</b>B</figref>).</p><p id="p-0743" num="0823">CD11b-enriched cells treated with either Exo-CEBP/&#x3b2;-ASO also showed macrophage reprogramming as evidenced by upregulation of various M1 genes and downregulation of various M2 genes (<figref idref="DRAWINGS">FIGS. <b>7</b>A-<b>7</b>W</figref>).</p><heading id="h-0109" level="1">Example 7: Treatment of Fibrosis Using Exo-CEBP/&#x3b2;-ASO</heading><p id="p-0744" num="0824">Excessive M2 macrophage activation leads to the continuous production of TGF&#x3b2; and growth factors that promote proliferation of myofibroblasts, activation of EMT/EndoMT, and extracellular matrix deposition. M2 macrophages represent a break point between wound healing and exacerbation of pro-fibrotic process. To test whether Exo-CEBP/&#x3b2;-ASO could be used to treat fibrosis in a subject, primary human M2 macrophages were polarized with IL-13/TGF&#x3b2; treatment, which are drivers of fibrosis. Cells were then exposed to increasing concentrations of free CEBP/&#x3b2; ASO (<figref idref="DRAWINGS">FIGS. <b>8</b>A and <b>8</b>B</figref>) or Exo-CEBP/&#x3b2;-ASO (<figref idref="DRAWINGS">FIGS. <b>8</b>A and <b>8</b>B</figref>); and assayed for expression of CEBP/&#x3b2; (<figref idref="DRAWINGS">FIG. <b>8</b>B</figref>) or expression of TGF&#x3b2;1 (<figref idref="DRAWINGS">FIG. <b>8</b>B</figref>).</p><p id="p-0745" num="0825">To test the feasibility of Exo-ASO delivery in vivo using intra-nasal administration, 6-weak old mice were treated with bleomycin to induce pulmonary fibrosis. Two weeks later, mice were administered Exo-ASO-Cy5 intranasally, and the mice were sacrificed 4 hours post-administration. Bleomycin induced mice administered Exo-ASO-Cy5 showed increased total flux of Cy5 relative to na&#xef;ve mice administered Exo-ASO-Cy5 (&#x201c;IN na&#xef;ve&#x201d;) and relative to na&#xef;ve and treated mice administered a PBS negative control (&#x201c;&#x2014;C&#x201d;) (<figref idref="DRAWINGS">FIG. <b>9</b></figref>).</p><p id="p-0746" num="0826">Exosome uptake was observed by lung macrophages and lung capillary endothelial cells in both normal lung and induced-pulmonary fibrosis lungs tissue (<figref idref="DRAWINGS">FIGS. <b>10</b>A-<b>10</b>H and <b>11</b>A-<b>11</b>H</figref>).</p><heading id="h-0110" level="1">Example 8: Treatment of a Hepatocarcinoma Mouse-Model Using Exo-CEBP/&#x3b2;-ASO</heading><p id="p-0747" num="0827">Hepa1-6 mice will be used to test the in vivo efficacy of Exo-CEBP/&#x3b2;-ASO for treating a tumor. The Hepa1-6 line is an orthotopic mouse model of hepatocarcinoma. Samples were obtained from CRO and analyzed by in situ hybridization for expression of CEBP/&#x3b2; (<figref idref="DRAWINGS">FIGS. <b>12</b>A-<b>12</b>B</figref>).</p><heading id="h-0111" level="1">Example 9: Treatment of a Colon Carcinoma Mouse-Model Using Exo-CEBP/&#x3b2;-ASO</heading><p id="p-0748" num="0828">CT26 tumor cells were implanted subcutaneously into the flanks of BALB/c mice (n=10 for each group). Eight days after implantation mice were treated intratumorally with exoASO-CEBP/&#x3b2; or free CEBP/&#x3b2; ASO or intraperitoneally with anti-PD1 antibodies or anti-CSF1R antibodies (n=10 mice per group). As controls, two groups of mice were treated with either exoASO-scramble or PBS. Analysis of the geometric means of the tumor volumes shows that mice treated with exoASO-CEBP/&#x3b2; had very little tumor growth through 30 days post-implantation (<figref idref="DRAWINGS">FIG. <b>13</b>B</figref>). Mice treated with free CEBP/&#x3b2; ASO had reduced tumor growth compared to mice treated with anti-CSFIR antibodies. Six out of 10 mice treated with exo-ASO CEBP/&#x3b2; had complete responses while none of the mice in the other groups did (<figref idref="DRAWINGS">FIGS. <b>13</b>C-<b>13</b>H</figref>).</p><heading id="h-0112" level="1">Example 10: Treatment of Hepatocellular Carcinoma (HCC) in a Mouse-Model Using Exo-CEBP/8</heading><p id="p-0749" num="0829">Exo ASO 2 and Free ASO 2 was administered by intravenous injection (IV) into the caudal vein of healthy female C57Bl/6J (C57Bl/6Jrj) mice. The treatment schedule is summarized in Table 7 below:</p><p id="p-0750" num="0000"><tables id="TABLE-US-00008" num="00008"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="28pt" align="left"/><colspec colname="2" colwidth="28pt" align="left"/><colspec colname="3" colwidth="63pt" align="left"/><colspec colname="4" colwidth="49pt" align="left"/><colspec colname="5" colwidth="35pt" align="left"/><thead><row><entry/><entry namest="offset" nameend="5" rowsep="1">TABLE 7</entry></row><row><entry/><entry namest="offset" nameend="5" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/><entry>1</entry><entry>8</entry><entry>Untreated</entry><entry>&#x2014;</entry><entry>&#x2014;</entry></row><row><entry/><entry>2</entry><entry>8</entry><entry>Exo ASO 2</entry><entry>Dose #1</entry><entry>IV</entry></row><row><entry/><entry>3</entry><entry>8</entry><entry>Anti-PD-1</entry><entry>10</entry><entry>IP</entry></row><row><entry/><entry>4</entry><entry>8</entry><entry>Free ASO 2</entry><entry>Dose #2</entry><entry>IV</entry></row><row><entry/><entry>5</entry><entry>8</entry><entry>Anti-CSF1R</entry><entry>10</entry><entry>IP</entry></row><row><entry/><entry namest="offset" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0751" num="0830">At the time of termination, the liver was collected, weighed and macroscopically observed and scored for visible lesions. One lobe was collected in RNAlater (5 volumes of RNAlater per 1 volume (g) of tissue) then frozen for internal gene expression analysis, and 2 lobes for IHC per animal (collected in 10% NBF for 24 hours, room temperature, then transferred to PBS at 4&#xb0; C.). Animal viability and behavior was observed daily, and a daily clinical follow-up was conducted during the critical experimental period. Body weights were measured a minimum of twice a week.</p><p id="p-0752" num="0831">ExoASO C/EBPs induced dose-dependent knockdown (KD) of target genes in primary human M2 macrophages with greater potency (IC50) than free ASO. We evaluated efficacy of exoASO C/EBPs alone or in combination with anti-PD1 therapy, as shown in <figref idref="DRAWINGS">FIGS. <b>15</b>A-<b>15</b>H</figref>. ExoASO C/EBP3 was as efficacious as monotherapies (60% complete responses (CR)) whereas anti-PD1 or anti-CSFR1 mAb were not effective (0% CR, <figref idref="DRAWINGS">FIGS. <b>15</b>A-<b>15</b>H</figref>). ExoASO C/EBP3 in combination with anti-PD-1 mAb resulted in greater efficacy (80% CR), and enhanced survival (70% at day 55) compared to exoASO-C/EBPs monotherapy (50% survival at day 50) (<figref idref="DRAWINGS">FIG. <b>16</b></figref>). Durable anti-tumor responses were observed with the exoASO therapies as there was no tumor growth upon re-challenge in mice that achieved CRs against the primary tumor. (<figref idref="DRAWINGS">FIG. <b>17</b></figref>)</p><p id="p-0753" num="0832">We evaluated anti-tumor efficacy using an orthotopic hepatocellular carcinoma (HCC) model. Mice were dosed IV using: exoASO-C/EBPs; free C/EBP3 ASO; anti-PD1 or; anti-CSF1R mAbs. exoASO-C/EBPs treatment attenuated HCC-mediated increase in liver to body weight ratios (S 10%) (<figref idref="DRAWINGS">FIGS. <b>18</b>A-<b>18</b>H</figref>) and resulted in little to no observable tumor lesions in 50% of treated mice (<figref idref="DRAWINGS">FIG. <b>19</b>A-<b>19</b>E</figref>). Tumor reduction was further amplified when the exoASO-C/EBPs was combined with an anti-PD-1 antibody, resulting in further attenuation of HCC-mediated increase in liver size (<figref idref="DRAWINGS">FIG. <b>18</b>H</figref>) and in the percent of scored lesions (<figref idref="DRAWINGS">FIG. <b>19</b>B</figref>).</p><p id="p-0754" num="0833">In contrast, increased liver to body weight ratios (L 10%) and observable tumor lesions occurred in all mice (100%) treated with either free C/EBPs ASO or anti-CSF1R mAb. ExoASO CEBP&#x3b2; is as efficacious as monotherapies in TAM-rich tumors when administered locally or systemically (<figref idref="DRAWINGS">FIG. <b>20</b></figref>). ExoASO-CEBPs has increased potency when administered in combination with checkpoint antibodies.</p><heading id="h-0113" level="1">Example 11: Treatment of a Glioblastoma Multiforme Mouse Model Using Exo-C/EBP&#x3b2;-ASO</heading><p id="p-0755" num="0834">Glioblastoma Multiforme (GBM) carrying mice will be treated intratumorally with exo-C/EBP&#x3b2;-ASO or free C/EBPs ASO. As controls, two groups of mice will be treated with either exoASO-scramble or PBS. The geometric means of the tumor volumes will be measured through at least 30 days post-implantation. Macrophage localization and marker gene expression will be monitored, including the occurrence of tumor-infiltrating macrophages.</p><heading id="h-0114" level="1">Example 12: Treatment of a Leptomeningeal Cancer Disease (IMD) Mouse Model Using Exo-C/EBP&#x3b2;-ASO</heading><p id="p-0756" num="0835">Leptomeningeal Cancer Disease (LMD) mice will be treated intratumorally with exo-C/EBP&#x3b2;-ASO or free C/EBPs ASO. As controls, two groups of mice will be treated with either exoASO-scramble or PBS. The geometric means of the tumor volumes will be measured through at least 30 days post-implantation. Macrophage localization and marker gene expression will be monitored, including the occurrence of tumor-infiltrating macrophages.</p><heading id="h-0115" level="1">Example 13: Administration of exoCEBP/&#x3b2;-ASO by CIVO&#xae;</heading><p id="p-0757" num="0836">YUMM1.7 cells were implanted in the flanks of C57bl/6J mice, followed by intratumoral microinjections of exoCEBP/&#x3b2; ASO, Free C/EBPs ASO, or exoASO Scramble using the Comparative In Vivo Oncology (CIVO&#xae;) Platform by Presage Biosciences (<figref idref="DRAWINGS">FIGS. <b>21</b>A-<b>21</b>G</figref>). Mice were euthanized 24 hours after one single dose, (n=6 mice per group). Expression of TNFa, CD11b, iNOS and F4/80 by In situ hybridization (ISH), twenty-four hours post dosing is shown in <figref idref="DRAWINGS">FIGS. <b>21</b>A-<b>21</b>L</figref>, wherein each panel is a different injection site on the same tumor. A potent induction of the expression of M1 macrophage markers TNFa (<figref idref="DRAWINGS">FIG. <b>21</b>I</figref>) and iNOS (<figref idref="DRAWINGS">FIG. <b>21</b>K</figref>) and the monocyte marker CD11b (<figref idref="DRAWINGS">FIG. <b>21</b>J</figref>) was observed after treatment with CEBPB exoASOs, as compared to free ASO (<figref idref="DRAWINGS">FIGS. <b>21</b>E-<b>21</b>H</figref>) or a scramble exoASO control (<figref idref="DRAWINGS">FIGS. <b>21</b>A-<b>21</b>D</figref>). These PD readouts reveal a polarization to a pro inflammatory M1 phenotype by CEBP/&#x3b2;-targeting exoASOs</p><heading id="h-0116" level="1">INCORPORATION BY REFERENCE</heading><p id="p-0758" num="0837">All publications, patents, patent applications and other documents cited in this application are hereby incorporated by reference in their entireties for all purposes to the same extent as if each individual publication, patent, patent application or other document were individually indicated to be incorporated by reference for all purposes.</p><heading id="h-0117" level="1">EQUIVALENTS</heading><p id="p-0759" num="0838">While various specific aspects have been illustrated and described, the above specification is not restrictive. It will be appreciated that various changes can be made without departing from the spirit and scope of the invention(s). Many variations will become apparent to those skilled in the art upon review of this specification.</p><?detailed-description description="Detailed Description" end="tail"?></description><us-sequence-list-doc id="SEQLST-0"><sequence-list file="US20230002764A1-20230105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.25"/></us-sequence-list-doc><us-chemistry idref="CHEM-US-00001" cdx-file="US20230002764A1-20230105-C00001.CDX" mol-file="US20230002764A1-20230105-C00001.MOL"/><us-chemistry idref="CHEM-US-00002" cdx-file="US20230002764A1-20230105-C00002.CDX" mol-file="US20230002764A1-20230105-C00002.MOL"/><us-chemistry idref="CHEM-US-00003" cdx-file="US20230002764A1-20230105-C00003.CDX" mol-file="US20230002764A1-20230105-C00003.MOL"/><us-chemistry idref="CHEM-US-00004" cdx-file="US20230002764A1-20230105-C00004.CDX" mol-file="US20230002764A1-20230105-C00004.MOL"/><us-chemistry idref="CHEM-US-00005" cdx-file="US20230002764A1-20230105-C00005.CDX" mol-file="US20230002764A1-20230105-C00005.MOL"/><us-chemistry idref="CHEM-US-00006" cdx-file="US20230002764A1-20230105-C00006.CDX" mol-file="US20230002764A1-20230105-C00006.MOL"/><us-chemistry idref="CHEM-US-00007" cdx-file="US20230002764A1-20230105-C00007.CDX" mol-file="US20230002764A1-20230105-C00007.MOL"/><us-chemistry idref="CHEM-US-00008" cdx-file="US20230002764A1-20230105-C00008.CDX" mol-file="US20230002764A1-20230105-C00008.MOL"/><us-chemistry idref="CHEM-US-00009" cdx-file="US20230002764A1-20230105-C00009.CDX" mol-file="US20230002764A1-20230105-C00009.MOL"/><us-chemistry idref="CHEM-US-00010" cdx-file="US20230002764A1-20230105-C00010.CDX" mol-file="US20230002764A1-20230105-C00010.MOL"/><us-chemistry idref="CHEM-US-00011" cdx-file="US20230002764A1-20230105-C00011.CDX" mol-file="US20230002764A1-20230105-C00011.MOL"/><us-chemistry idref="CHEM-US-00012" cdx-file="US20230002764A1-20230105-C00012.CDX" mol-file="US20230002764A1-20230105-C00012.MOL"/><us-chemistry idref="CHEM-US-00013" cdx-file="US20230002764A1-20230105-C00013.CDX" mol-file="US20230002764A1-20230105-C00013.MOL"/><us-chemistry idref="CHEM-US-00014" cdx-file="US20230002764A1-20230105-C00014.CDX" mol-file="US20230002764A1-20230105-C00014.MOL"/><us-chemistry idref="CHEM-US-00015" cdx-file="US20230002764A1-20230105-C00015.CDX" mol-file="US20230002764A1-20230105-C00015.MOL"/><us-chemistry idref="CHEM-US-00016" cdx-file="US20230002764A1-20230105-C00016.CDX" mol-file="US20230002764A1-20230105-C00016.MOL"/><us-chemistry idref="CHEM-US-00017" cdx-file="US20230002764A1-20230105-C00017.CDX" mol-file="US20230002764A1-20230105-C00017.MOL"/><us-chemistry idref="CHEM-US-00018" cdx-file="US20230002764A1-20230105-C00018.CDX" mol-file="US20230002764A1-20230105-C00018.MOL"/><us-chemistry idref="CHEM-US-00019" cdx-file="US20230002764A1-20230105-C00019.CDX" mol-file="US20230002764A1-20230105-C00019.MOL"/><us-chemistry idref="CHEM-US-00020" cdx-file="US20230002764A1-20230105-C00020.CDX" mol-file="US20230002764A1-20230105-C00020.MOL"/><us-chemistry idref="CHEM-US-00021" cdx-file="US20230002764A1-20230105-C00021.CDX" mol-file="US20230002764A1-20230105-C00021.MOL"/><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. An extracellular vesicle comprising an antisense oligonucleotide (ASO) which comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within a CEBP/&#x3b2; transcript (SEQ ID NO: 11 or SEQ ID NO: 13).</claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. The extracellular vesicle of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the ASO is not TGGATTTAAAGGCAGGCGGC (SEQ ID NO: 90).</claim-text></claim><claim id="CLM-003-9" num="003-9"><claim-text><b>3</b>-<b>9</b>. (canceled)</claim-text></claim><claim id="CLM-00010" num="00010"><claim-text><b>10</b>. The extracellular vesicle of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the ASO is a gapmer, a mixmer, or a totalmer.</claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. The extracellular vesicle of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the ASO comprises one or more nucleoside analogs.</claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. (canceled)</claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. The extracellular vesicle of <claim-ref idref="CLM-00011">claim 11</claim-ref>, wherein one or more of the nucleoside analogs is a sugar modified nucleoside.</claim-text></claim><claim id="CLM-14-21" num="14-21"><claim-text><b>14</b>-<b>21</b>. (canceled)</claim-text></claim><claim id="CLM-00022" num="00022"><claim-text><b>22</b>. The extracellular vesicle of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the contiguous nucleotide sequence comprises a nucleotide sequence complementary to a sequence selected from the sequences in <figref idref="DRAWINGS">FIG. <b>1</b></figref>: or wherein the ASO comprises a nucleotide sequence selected from SEO ID NOs: 194-296, with one or two mismatches.</claim-text></claim><claim id="CLM-23-24" num="23-24"><claim-text><b>23</b>-<b>24</b>. (canceled)</claim-text></claim><claim id="CLM-00025" num="00025"><claim-text><b>25</b>. The extracellular vesicle of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the ASO has a design selected from the group consisting of the designs in <figref idref="DRAWINGS">FIG. <b>1</b></figref>, wherein the upper letter is a sugar modified nucleoside and the lower case letter is DNA.</claim-text></claim><claim id="CLM-26-30" num="26-30"><claim-text><b>26</b>-<b>30</b>. (canceled)</claim-text></claim><claim id="CLM-00031" num="00031"><claim-text><b>31</b>. The extracellular vesicle of <claim-ref idref="CLM-00001">claim 1</claim-ref>, which further comprises<claim-text>(i) an anchoring moiety, wherein the ASO is linked to the anchoring moiety;</claim-text><claim-text>(ii) an exogenous targeting moiety: or</claim-text><claim-text>(iii) both (i) and (ii).</claim-text></claim-text></claim><claim id="CLM-32-74" num="32-74"><claim-text><b>32</b>-<b>74</b>. (canceled)</claim-text></claim><claim id="CLM-00075" num="00075"><claim-text><b>75</b>. The extracellular vesicle of <claim-ref idref="CLM-00031">claim 31</claim-ref>, wherein the anchoring moiety comprises sterol, GM1, a lipid, a vitamin, a small molecule, a peptide, or a combination thereof.</claim-text></claim><claim id="CLM-76-77" num="76-77"><claim-text><b>76</b>-<b>77</b>. (canceled)</claim-text></claim><claim id="CLM-00078" num="00078"><claim-text><b>78</b>. The extracellular vesicle of <claim-ref idref="CLM-00031">claim 31</claim-ref>, wherein the ASO is linked to the anchoring moiety by a linker.</claim-text></claim><claim id="CLM-00079" num="00079"><claim-text><b>79</b>. (canceled)</claim-text></claim><claim id="CLM-00080" num="00080"><claim-text><b>80</b>. The extracellular vesicle of <claim-ref idref="CLM-00078">claim 78</claim-ref>, wherein the linker;<claim-text>(i) is a polypeptide;</claim-text><claim-text>(ii) is a non-polypeptide moiety;</claim-text><claim-text>(iii) comprises ethylene glycol;</claim-text><claim-text>(iv) comprises acrylic phosphoramidite (e.g., Acrydite&#x2122;), adenylation, azide (NS Ester), digoxigenin (NHS Ester), cholesterol-TEG, I-LINKER&#x2122;, an amino modifier (e.g., amino modifier C6, amino modifier C12, amino modifier C6 dT, or Uni-Link&#x2122; amino modifier), alkyne, 5&#x2032; Hexynyl, 5-Octadiynyl dU, biotinylation (e.g., biotin, biotin (Azide), biotin dT, biotin-TEG, dual biotin, PC biotin, or desthiobiotin), thiol modification (thiol modifier C3 S&#x2014;S, dithiol or thiol modifier C6 S&#x2014;S), or any combination thereof;</claim-text><claim-text>(v) comprises valine-alanine-p-aminobenzylcarbamate or valine-citrulline-p-aminobenzylcarbamate; or</claim-text><claim-text>(vi) any combination thereof.</claim-text></claim-text></claim><claim id="CLM-81-87" num="81-87"><claim-text><b>81</b>-<b>87</b>. (canceled)</claim-text></claim><claim id="CLM-00088" num="00088"><claim-text><b>88</b>. The extracellular vesicle of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the EV is an exosome.</claim-text></claim><claim id="CLM-00089" num="00089"><claim-text><b>89</b>. An antisense oligonucleotide (ASO) comprising comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within a CEBP/&#x3b2; transcript (SEQ ID NO: 11 or SEQ ID NO: 13).</claim-text></claim><claim id="CLM-90-112" num="90-112"><claim-text><b>90</b>-<b>112</b>. (canceled)</claim-text></claim><claim id="CLM-00113" num="00113"><claim-text><b>113</b>. A conjugate comprising the ASO of <claim-ref idref="CLM-00089">claim 89</claim-ref>, wherein the ASO is covalently attached to at least one non-nucleotide or non-polynucleotide moiety.</claim-text></claim><claim id="CLM-114-115" num="114-115"><claim-text><b>114</b>-<b>115</b>. (canceled)</claim-text></claim><claim id="CLM-00116" num="00116"><claim-text><b>116</b>. A pharmaceutical composition comprising the extracellular vesicle of <claim-ref idref="CLM-00001">claim 1</claim-ref>, and a pharmaceutically acceptable diluent, carrier, salt, or adjuvant.</claim-text></claim><claim id="CLM-117-122" num="117-122"><claim-text><b>117</b>-<b>122</b>. (canceled)</claim-text></claim><claim id="CLM-00123" num="00123"><claim-text><b>123</b>. A kit comprising the extracellular vesicle of <claim-ref idref="CLM-00001">claim 1</claim-ref>, and instructions for use.</claim-text></claim><claim id="CLM-00124" num="00124"><claim-text><b>124</b>. (canceled)</claim-text></claim><claim id="CLM-00125" num="00125"><claim-text><b>125</b>. A method of inhibiting or reducing CEBP/&#x3b2; protein expression in a cell, comprising administering the extracellular vesicle of <claim-ref idref="CLM-00001">claim 1</claim-ref> to the cell expressing CEBP/&#x3b2; protein, wherein the CEBP/&#x3b2; protein expression in the cell is inhibited or reduced after the administration.</claim-text></claim><claim id="CLM-00126" num="00126"><claim-text><b>126</b>. A method of treating a cancer in a subject in need thereof, comprising administering an effective amount of the extracellular vesicle of <claim-ref idref="CLM-00001">claim 1</claim-ref> to the subject.</claim-text></claim><claim id="CLM-127-128" num="127-128"><claim-text><b>127</b>-<b>128</b>. (canceled)</claim-text></claim><claim id="CLM-00129" num="00129"><claim-text><b>129</b>. A method of treating a disease or disorder in a subject in need thereof, comprising administering an effective amount of the extracellular vesicle of <claim-ref idref="CLM-00001">claim 1</claim-ref> to the subject, wherein the disease or disorder is selected from a fibrosis, an inflammation, a neurodegenerative disease, a metabolic disorder/CVD, and any combination thereof.</claim-text></claim><claim id="CLM-130-138" num="130-138"><claim-text><b>130</b>-<b>138</b>. (canceled)</claim-text></claim><claim id="CLM-00139" num="00139"><claim-text><b>139</b>. A method of activating meningeal macrophages, inducing M1 polarization of meningeal macrophages, or inducing meningeal macrophage infiltration of a tumor in a subject in need thereof, comprising administering the extracellular vesicle of <claim-ref idref="CLM-00001">claim 1</claim-ref> to the subject.</claim-text></claim><claim id="CLM-140-142" num="140-142"><claim-text><b>140</b>-<b>142</b>. (canceled)</claim-text></claim></claims></us-patent-application>